assay_id,assay_tissue,variant_id,src_assay_id,assay_cell_type,chembl_id,assay_type,bao_format,assay_strain,assay_category,confidence_score,doc_id,description,assay_test_type,assay_organism,assay_tax_id,assay_subcellular_fraction
1,,,,,CHEMBL615117,B,BAO_0000019,,,8,11087,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,,,
2,,,,,CHEMBL615118,F,BAO_0000219,,,0,684,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,,,
3,,,,,CHEMBL615119,B,BAO_0000019,,,0,15453,,,,,
4,,,,,CHEMBL615120,B,BAO_0000249,,,4,17841,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,Bos taurus,9913.0,
5,,,,143B,CHEMBL615121,F,BAO_0000219,,,1,17430,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,Homo sapiens,9606.0,
6,,,,143B,CHEMBL615122,F,BAO_0000219,,,1,17430,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,Homo sapiens,9606.0,
7,,,,143B,CHEMBL615123,F,BAO_0000219,,,1,13799,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,Mus musculus,10090.0,
8,,,,143B,CHEMBL615124,F,BAO_0000219,,,1,17774,In vitro cell cytotoxicity was determined against 143B cell line,,Homo sapiens,9606.0,
9,,,,143B,CHEMBL615125,F,BAO_0000219,,,1,3801,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,Homo sapiens,9606.0,
10,,,,143B,CHEMBL615126,F,BAO_0000219,,,1,17430,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,Homo sapiens,9606.0,
11,,,,143B,CHEMBL615127,F,BAO_0000219,,,1,17430,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,Homo sapiens,9606.0,
12,,,,143B,CHEMBL615128,F,BAO_0000219,,,1,17774,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,Homo sapiens,9606.0,
13,,,,,CHEMBL857900,F,BAO_0000218,,,1,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,Staphylococcus aureus,1280.0,
14,,,,,CHEMBL615129,F,BAO_0000218,,,1,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,Staphylococcus aureus,1280.0,
15,,,,,CHEMBL615130,F,BAO_0000218,,,1,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,Staphylococcus aureus,1280.0,
16,,,,,CHEMBL615131,F,BAO_0000218,,,1,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,Staphylococcus aureus,1280.0,
17,,,,,CHEMBL884521,A,BAO_0000357,,,9,11347,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,Rattus norvegicus,10116.0,
18,,,,,CHEMBL615132,B,BAO_0000357,,,8,16474,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,,,
19,,,,,CHEMBL615133,B,BAO_0000019,,,8,10091,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,,,
20,,,,,CHEMBL615134,B,BAO_0000357,,,8,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,,,
21,,,,,CHEMBL615135,B,BAO_0000357,,,8,16474,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,,,
22,,,,,CHEMBL615136,B,BAO_0000357,,,8,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,,,
23,,,,,CHEMBL615137,B,BAO_0000357,,,8,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,,,
24,,,,,CHEMBL615138,B,BAO_0000357,,,8,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,,,
25,,,,,CHEMBL836324,B,BAO_0000219,,,0,14352,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,,,
26,,,,,CHEMBL615139,B,BAO_0000357,,,8,5646,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,Oryctolagus cuniculus,9986.0,
27,,,,,CHEMBL615140,B,BAO_0000357,,,8,5646,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,Oryctolagus cuniculus,9986.0,
28,,,,,CHEMBL615141,B,BAO_0000219,,,8,10997,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,,,
29,,,,,CHEMBL615142,B,BAO_0000357,,,8,6309,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,soya bean,3847.0,
30,,,,,CHEMBL615143,B,BAO_0000357,,,8,167,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,Glycine max,3847.0,
31,,,,,CHEMBL615144,B,BAO_0000357,,,8,167,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,Glycine max,3847.0,
32,,,,,CHEMBL872867,B,BAO_0000357,,,8,11087,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,Glycine max,3847.0,
33,,,,,CHEMBL615145,B,BAO_0000357,,,8,11087,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,Glycine max,3847.0,
34,,,,,CHEMBL615146,B,BAO_0000357,,,8,13622,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,Glycine max,3847.0,
35,,,,,CHEMBL615147,B,BAO_0000357,,,8,13622,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,Glycine max,3847.0,
36,,,,,CHEMBL615148,A,BAO_0000019,,,0,11347,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,Rattus norvegicus,10116.0,
37,,,,,CHEMBL615149,B,BAO_0000019,,,0,5926,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,Escherichia coli,562.0,
38,,,,,CHEMBL615150,B,BAO_0000019,,,0,4567,Dissociation constant with dimeric 16S rRNA RNA construct B,,,,
39,,,,,CHEMBL615151,B,BAO_0000225,,,3,3782,Dissociation constant towards 16S rRNA construct A,,,,
40,,,,,CHEMBL615152,B,BAO_0000225,,,3,3782,Dissociation constant towards 16S rRNA construct B,,,,
41,,,,,CHEMBL615153,B,BAO_0000225,,,3,4466,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,Escherichia coli,562.0,
42,,,,,CHEMBL615154,B,BAO_0000225,,,3,6592,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,Escherichia coli,562.0,
43,,,,,CHEMBL615155,B,BAO_0000019,,,8,898,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,,
44,,,,,CHEMBL615156,B,BAO_0000019,,,8,898,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,,
45,,,,,CHEMBL615157,B,BAO_0000019,,,8,13163,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,Homo sapiens,9606.0,
46,,,,,CHEMBL615158,B,BAO_0000019,,,8,13163,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,Homo sapiens,9606.0,
47,,,,,CHEMBL615159,B,BAO_0000019,,,9,10691,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,Rattus norvegicus,10116.0,
48,,,,,CHEMBL615172,B,BAO_0000019,,,9,10691,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,Rattus norvegicus,10116.0,
49,,,,,CHEMBL615173,B,BAO_0000019,,,9,10691,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,Rattus norvegicus,10116.0,
50,,,,,CHEMBL615174,B,BAO_0000019,,,9,10691,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,Rattus norvegicus,10116.0,
51,,,,,CHEMBL884518,B,BAO_0000019,,,8,898,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,,
52,,,,,CHEMBL615175,B,BAO_0000357,,,8,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,,,
53,,,,,CHEMBL615176,B,BAO_0000357,,,8,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,,,
54,,,,,CHEMBL615177,B,BAO_0000357,,,8,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,,,
55,,,,,CHEMBL615178,B,BAO_0000249,,,5,15103,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,,Rattus norvegicus,10116.0,Membranes
56,,,,1A9,CHEMBL615179,F,BAO_0000219,,,1,5116,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,Homo sapiens,9606.0,
57,,,,Oocytes,CHEMBL615180,F,BAO_0000219,,,7,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,Rattus norvegicus,10116.0,
58,,,,Oocytes,CHEMBL615181,F,BAO_0000219,,,7,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,Rattus norvegicus,10116.0,
59,,,,Oocytes,CHEMBL615182,F,BAO_0000219,,,7,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,Rattus norvegicus,10116.0,
60,,,,1A9,CHEMBL615183,F,BAO_0000219,,,1,4787,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,Homo sapiens,9606.0,
61,,,,1A9,CHEMBL615184,F,BAO_0000219,,,1,4787,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,Homo sapiens,9606.0,
62,,,,1A9,CHEMBL615185,F,BAO_0000219,,,1,3547,Cytotoxic activity against human ovarian cancer (1A9) cell line,,Homo sapiens,9606.0,
63,,,,1A9,CHEMBL615186,F,BAO_0000219,,,1,3547,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,Homo sapiens,9606.0,
64,,,,1A9,CHEMBL615187,F,BAO_0000219,,,1,6726,Effective dose of compound against replication of 1A9 cell line was evaluated,,Homo sapiens,9606.0,
65,,,,1A9,CHEMBL885343,F,BAO_0000219,,,1,3455,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,Homo sapiens,9606.0,
66,,,,1A9,CHEMBL615188,F,BAO_0000219,,,1,5726,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,Homo sapiens,9606.0,
67,,,,1A9,CHEMBL615189,F,BAO_0000219,,,1,5726,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,Homo sapiens,9606.0,
68,,,,1A9,CHEMBL615190,F,BAO_0000219,,,1,5726,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,Homo sapiens,9606.0,
69,,,,1A9,CHEMBL615191,F,BAO_0000219,,,1,3395,Inhibitory activity against Taxol resistant 1A9 cell lines,,Homo sapiens,9606.0,
70,,,,1A9,CHEMBL615192,F,BAO_0000219,,,1,3415,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,Homo sapiens,9606.0,
71,,,,1A9,CHEMBL827083,F,BAO_0000219,,,1,3415,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,Homo sapiens,9606.0,
72,,,,1A9,CHEMBL615193,F,BAO_0000219,,,1,17099,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,Homo sapiens,9606.0,
73,,,,1A9,CHEMBL615194,F,BAO_0000219,,,1,17099,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,Homo sapiens,9606.0,
74,,,,1A9,CHEMBL615195,F,BAO_0000219,,,1,17099,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,Homo sapiens,9606.0,
75,,,,1A9,CHEMBL615196,F,BAO_0000219,,,1,17099,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,Homo sapiens,9606.0,
76,,,,Jurkat,CHEMBL615197,F,BAO_0000219,,,1,17721,Inhibitory concentration against Jurkat cells,,Homo sapiens,9606.0,
77,,,,,CHEMBL615198,F,BAO_0000019,,,0,1229,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,,,
78,,,,,CHEMBL615199,A,BAO_0000357,,,9,11347,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,Rattus norvegicus,10116.0,
79,,,,,CHEMBL615200,B,BAO_0000357,,,8,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,,,
80,,,,,CHEMBL615201,B,BAO_0000357,,,8,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,,,
81,,,,,CHEMBL615202,B,BAO_0000357,,,8,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,,,
82,,,,,CHEMBL615203,B,BAO_0000251,,,8,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",,Candida albicans,5476.0,Microsomes
83,,,,,CHEMBL615204,B,BAO_0000251,,,8,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",,Candida albicans,5476.0,Microsomes
84,,,,,CHEMBL615205,B,BAO_0000251,,,8,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",,Saccharomyces cerevisiae,4932.0,Microsomes
85,,,,,CHEMBL615206,B,BAO_0000251,,,8,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",,Saccharomyces cerevisiae,4932.0,Microsomes
86,Liver,,,,CHEMBL615207,B,BAO_0000251,,,8,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",,Sus scrofa,9823.0,Microsomes
87,,,,,CHEMBL827084,B,BAO_0000019,,,8,791,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,Rattus norvegicus,10116.0,
88,,,,,CHEMBL615208,B,BAO_0000019,,,8,791,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,Rattus norvegicus,10116.0,
89,,,,,CHEMBL615209,B,BAO_0000019,,,8,791,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,Rattus norvegicus,10116.0,
90,Liver,,,,CHEMBL615210,B,BAO_0000251,,,9,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",,Rattus norvegicus,10116.0,Microsomes
91,Liver,,,,CHEMBL615211,B,BAO_0000251,,,9,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,Rattus norvegicus,10116.0,Microsomes
92,Liver,,,,CHEMBL615212,B,BAO_0000251,,,9,153,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,Rattus norvegicus,10116.0,Microsomes
93,,,,,CHEMBL615213,B,BAO_0000357,,,8,8269,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,,,
94,,,,,CHEMBL615273,B,BAO_0000357,,,8,8269,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,,,
95,,,,HepG2,CHEMBL615274,F,BAO_0000219,,,1,17653,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,Homo sapiens,9606.0,
96,,,,HepG2,CHEMBL615275,F,BAO_0000219,,,1,14277,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,Homo sapiens,9606.0,
97,,,,HepG2,CHEMBL615276,F,BAO_0000219,,,1,1717,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,Homo sapiens,9606.0,
98,,,,HepG2,CHEMBL615277,F,BAO_0000219,,,1,14091,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,Homo sapiens,9606.0,
99,,,,HepG2,CHEMBL615326,F,BAO_0000219,,,1,14091,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,Homo sapiens,9606.0,
100,,,,,CHEMBL883130,F,BAO_0000218,,,1,17653,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,Hepatitis B virus,10407.0,
101,,,,HepG2,CHEMBL884519,F,BAO_0000219,,,1,13105,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,Homo sapiens,9606.0,
102,,,,HepG2,CHEMBL615327,F,BAO_0000219,,,1,1717,Concentration required to inhibit 50% of 2.2.15 cell line,,Homo sapiens,9606.0,
103,,,,HepG2,CHEMBL615328,A,BAO_0000219,,,1,13105,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,Homo sapiens,9606.0,
104,,,,2.2.15,CHEMBL615329,F,BAO_0000218,,,1,13600,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,Homo sapiens,9606.0,
105,,,,2.2.15,CHEMBL615330,F,BAO_0000218,,,1,13467,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,Homo sapiens,9606.0,
106,,,,2.2.15,CHEMBL615331,F,BAO_0000218,,,1,17477,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,Hepatitis B virus,10407.0,
107,,,,2.2.15,CHEMBL615332,F,BAO_0000218,,,1,1593,In vitro anti-HBV activity in 2.2.15 cells,,Homo sapiens,9606.0,
108,,,,2.2.15,CHEMBL615333,F,BAO_0000218,,,1,1593,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,Homo sapiens,9606.0,
109,,,,2.2.15,CHEMBL615334,F,BAO_0000218,,,1,15089,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,Homo sapiens,9606.0,
110,,,,2.2.15,CHEMBL615335,F,BAO_0000218,,,1,15089,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,Homo sapiens,9606.0,
111,,,,2.2.15,CHEMBL615336,F,BAO_0000218,,,1,1593,Cytotoxicity in 2.2.15 cells,,Homo sapiens,9606.0,
112,,,,2.2.15,CHEMBL615337,F,BAO_0000218,,,1,1593,Cytotoxicity in 2.2.15 cells; Not determined,,Homo sapiens,9606.0,
113,,,,2.2.15,CHEMBL615338,F,BAO_0000218,,,1,13600,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,Homo sapiens,9606.0,
114,,,,2.2.15,CHEMBL615339,F,BAO_0000218,,,1,13467,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,Homo sapiens,9606.0,
115,,,,2.2.15,CHEMBL615340,F,BAO_0000218,,,1,13467,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,Homo sapiens,9606.0,
116,,,,HepG2,CHEMBL615341,F,BAO_0000219,,,1,14764,Antiviral activity against HBV was determined in 2.215 cell line,,Homo sapiens,9606.0,
117,,,,,CHEMBL615342,B,BAO_0000251,,,0,6531,Inhibition of 20-HETE synthesis in human renal microsomes,,Homo sapiens,9606.0,Microsomes
118,,,,,CHEMBL615343,B,BAO_0000019,,,0,17322,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,,,
119,,,,2008,CHEMBL615344,F,BAO_0000219,,,1,17072,Inhibitory concentration against 2008 (ovarian) cells,,Homo sapiens,9606.0,
120,,,,2008,CHEMBL615345,F,BAO_0000219,,,1,16936,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,Homo sapiens,9606.0,
121,,,,2008,CHEMBL615346,F,BAO_0000219,,,1,16936,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,Homo sapiens,9606.0,
122,,,,2008,CHEMBL615347,F,BAO_0000219,,,1,17146,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,Homo sapiens,9606.0,
123,,,,2008,CHEMBL615348,F,BAO_0000219,,,1,17146,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,Homo sapiens,9606.0,
124,,,,2008/R,CHEMBL827085,F,BAO_0000219,,,1,10797,In vitro inhibition of 2008/R ovarian cancer cell line,,Homo sapiens,9606.0,
125,,,,2008/R,CHEMBL615349,F,BAO_0000219,,,1,10797,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,Homo sapiens,9606.0,
126,,,,2008/S,CHEMBL615350,F,BAO_0000219,,,1,10797,In vitro inhibition of 2008/S ovarian cancer cell line,,Homo sapiens,9606.0,
127,,,,2008/S,CHEMBL615351,F,BAO_0000219,,,1,10797,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,Homo sapiens,9606.0,
128,,,,,CHEMBL615352,B,BAO_0000220,,,2,4823,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,Homo sapiens,9606.0,
129,,,,,CHEMBL615353,B,BAO_0000220,,,2,12912,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,Homo sapiens,9606.0,
130,,,,,CHEMBL615354,B,BAO_0000220,,,2,2957,Inhibition of chymotrypsin-like activity of 20S proteasome,,,,
131,,,,,CHEMBL615355,B,BAO_0000220,,,2,2957,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,,,
132,,,,,CHEMBL615356,B,BAO_0000220,,,2,3260,Inhibitory activity against 20S proteosome,,,,
133,,,,,CHEMBL615357,B,BAO_0000019,,,0,3451,Compound was tested for inhibitory activity against tryptase,,Homo sapiens,9606.0,
134,,,,HepG2,CHEMBL615358,F,BAO_0000219,,,1,13885,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,Homo sapiens,9606.0,
135,,,,HepG2,CHEMBL827086,F,BAO_0000219,,,1,13885,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,Homo sapiens,9606.0,
136,,,,,CHEMBL615359,B,BAO_0000019,,,0,3676,Compound was tested for the inhibition of Alpha-glucosidase,,,,
137,,,,,CHEMBL615360,B,BAO_0000357,,,8,6043,Inhibitory concentration against human neutrophil elastase (HNE),,,,
138,Heart,,,,CHEMBL615361,F,BAO_0000218,,,0,11140,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,,Rattus norvegicus,10116.0,
139,,,,,CHEMBL615362,F,BAO_0000019,,,8,10543,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,,,
140,,,,,CHEMBL615363,F,BAO_0000019,,,8,10543,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,,,
141,,,,,CHEMBL615364,B,BAO_0000357,,,8,10543,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,,,
142,,,,,CHEMBL615365,F,BAO_0000019,,,8,10543,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,,,
143,,,,P338,CHEMBL615366,F,BAO_0000219,,,1,11365,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,Mus musculus,10090.0,
144,,,,P338,CHEMBL615367,F,BAO_0000219,,,1,11365,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,Mus musculus,10090.0,
145,,,,PBL,CHEMBL615368,F,BAO_0000219,,,1,11803,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,Homo sapiens,9606.0,
146,,,,,CHEMBL615369,F,BAO_0000019,,,0,11803,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,Ovis aries,9940.0,
147,,,,,CHEMBL615370,F,BAO_0000019,,,0,11803,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,Ovis aries,9940.0,
148,,,,,CHEMBL615673,B,BAO_0000357,,,8,12278,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,,,
149,,,,,CHEMBL615674,F,BAO_0000019,,,0,8249,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,Homo sapiens,9606.0,
150,,,,,CHEMBL615675,F,BAO_0000019,,,0,8249,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,Homo sapiens,9606.0,
151,,,,CCRF-CEM,CHEMBL615676,F,BAO_0000219,,,0,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,Homo sapiens,9606.0,
152,,,,CCRF-CEM,CHEMBL615677,F,BAO_0000219,,,0,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,Homo sapiens,9606.0,
153,,,,CCRF-CEM,CHEMBL615678,F,BAO_0000219,,,0,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,Homo sapiens,9606.0,
154,,,,CCRF-CEM,CHEMBL615679,F,BAO_0000219,,,0,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,Homo sapiens,9606.0,
155,,,,,CHEMBL615680,F,BAO_0000019,,,0,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,Homo sapiens,9606.0,
156,,,,,CHEMBL615681,F,BAO_0000019,,,0,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,Homo sapiens,9606.0,
157,,,,,CHEMBL857972,B,BAO_0000249,,,6,16992,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,,,
158,,,,,CHEMBL857899,F,BAO_0000218,,,1,10543,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,Streptococcus pyogenes,1314.0,
159,,,,,CHEMBL615371,F,BAO_0000218,,,1,17833,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,Human herpesvirus 3,10335.0,
160,,,,HEL,CHEMBL615372,F,BAO_0000218,,,1,17290,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,vericilla zoster virus,10335.0,
161,,,,,CHEMBL615373,F,BAO_0000218,,,1,17290,Antiviral activity against 07/1 strain of VZV; ND: No data,,vericilla zoster virus,10335.0,
162,,,,,CHEMBL615374,F,BAO_0000218,,,1,17290,Antiviral activity against 07/1 strain of VZV; ND=No data,,vericilla zoster virus,10335.0,
163,,,,,CHEMBL615375,F,BAO_0000218,,,1,10932,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,escherichia cloac,561.0,
164,,,,,CHEMBL615376,B,BAO_0000019,,,0,9707,Ratio of Ki at A2 to Ki at A1 receptors,,,,
165,,,,,CHEMBL615377,B,BAO_0000249,,,8,2346,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,Candida albicans,5476.0,
166,,,,,CHEMBL615378,B,BAO_0000357,,,8,2205,"Inhibition of 1,3-beta-glucan synthase",,Candida glabrata CBS 138,284593.0,
167,,,,1-87 tumor cell line,CHEMBL615379,F,BAO_0000219,,,1,11900,Inhibition of growth of 1-87 human tumor cell line,,Homo sapiens,9606.0,
168,,,,,CHEMBL615380,B,BAO_0000219,,,9,14864,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,Rattus norvegicus,10116.0,
169,,,,,CHEMBL615381,B,BAO_0000357,,,9,16474,Inhibitory activity against soybean 1-lipoxygenase (SLO),,Glycine max,3847.0,
170,,,,,CHEMBL615382,B,BAO_0000357,,,9,16474,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,Glycine max,3847.0,
171,,,,,CHEMBL615383,B,BAO_0000357,,,9,16474,% inhibition against soybean 1-lipoxygenase (SLO),,Glycine max,3847.0,
172,,,,,CHEMBL615384,B,BAO_0000357,,,9,16474,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,Glycine max,3847.0,
173,,,,,CHEMBL615385,B,BAO_0000357,,,9,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,Glycine max,3847.0,
174,,,,,CHEMBL615386,B,BAO_0000357,,,9,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,Glycine max,3847.0,
175,,,,,CHEMBL615387,B,BAO_0000357,,,9,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,Glycine max,3847.0,
176,,,,,CHEMBL615388,B,BAO_0000357,,,9,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,Glycine max,3847.0,
177,,,,,CHEMBL615214,B,BAO_0000357,,,9,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,Glycine max,3847.0,
178,,,,,CHEMBL827087,B,BAO_0000357,,,9,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,Glycine max,3847.0,
179,,,,,CHEMBL615215,B,BAO_0000357,,,9,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,Glycine max,3847.0,
180,,,,,CHEMBL615216,B,BAO_0000357,,,9,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,Glycine max,3847.0,
181,,,,,CHEMBL615217,B,BAO_0000357,,,9,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,Glycine max,3847.0,
182,,,,,CHEMBL615218,B,BAO_0000357,,,9,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,Glycine max,3847.0,
183,,,,,CHEMBL615219,B,BAO_0000357,,,9,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,Glycine max,3847.0,
184,,,,,CHEMBL615220,B,BAO_0000019,,,0,10413,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,Mus musculus,10090.0,
185,,,,C3H 10T1/2,CHEMBL615221,F,BAO_0000219,,,1,16929,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,Mus musculus,10090.0,
186,,,,,CHEMBL615222,F,BAO_0000019,,,0,1229,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,,,
187,,,,,CHEMBL615223,B,BAO_0000357,,,8,16587,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,,,
188,,,,,CHEMBL615224,B,BAO_0000357,,,8,16587,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,,,
189,,,,,CHEMBL615225,B,BAO_0000357,,,8,16587,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,,,
190,,,,,CHEMBL615226,B,BAO_0000357,,,8,16587,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,,,
191,,,,,CHEMBL615227,B,BAO_0000357,,,8,16587,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,,,
192,,,,,CHEMBL615228,F,BAO_0000019,,,9,8058,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,Bos taurus,9913.0,
193,,,,,CHEMBL615229,B,BAO_0000357,,,9,9065,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,Rattus norvegicus,10116.0,
194,Adrenal gland,,,,CHEMBL615230,B,BAO_0000357,,,9,8865,Inhibition of 11 beta-hydroxylase from rat adrenal gland,,Rattus norvegicus,10116.0,
195,,,,,CHEMBL615231,B,BAO_0000357,,,9,9066,Inhibition of rat adrenal 11-beta-hydroxylase,,Rattus norvegicus,10116.0,
196,,,,,CHEMBL884520,B,BAO_0000357,,,9,8394,Inhibition of rat adrenal 11-beta-hydroxylase,,Rattus norvegicus,10116.0,
197,,,,,CHEMBL615232,B,BAO_0000357,,,9,8394,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,Rattus norvegicus,10116.0,
198,,,,,CHEMBL615233,B,BAO_0000019,,,8,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,,,
199,,,,,CHEMBL827088,B,BAO_0000357,,,8,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,,,
200,,,,,CHEMBL615234,B,BAO_0000357,,,8,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,,,
201,,,,,CHEMBL615235,F,BAO_0000019,,,8,9295,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,,,
202,,,,,CHEMBL615236,B,BAO_0000019,,,8,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,,
203,,,,,CHEMBL615237,B,BAO_0000019,,,8,13622,Compound was tested in vitro for inhibition of 12-LO human platelet,,,,
204,,,,,CHEMBL615238,F,BAO_0000019,,,8,12079,Inhibitory concentration against human platelet 12-lipoxygenase,,,,
205,,,,,CHEMBL615239,B,BAO_0000019,,,8,13622,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,,,
206,,,,,CHEMBL615240,F,BAO_0000019,,,9,12079,Inhibitory concentration against human platelet 12-lipoxygenase,,Homo sapiens,9606.0,
207,,,,,CHEMBL615241,B,BAO_0000019,,,8,13500,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,,,
208,,,,,CHEMBL615242,B,BAO_0000357,,,8,13723,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,,,
209,,,,,CHEMBL615243,B,BAO_0000019,,,8,16474,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,,,
210,,,,,CHEMBL615244,B,BAO_0000019,,,8,1630,Inhibitory activity against human platelet 12-lipoxygenase,,,,
211,,,,,CHEMBL615245,B,BAO_0000019,,,8,167,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,,,
212,,,,,CHEMBL615246,B,BAO_0000019,,,8,16474,% inhibition against human platelet 12-lipoxygenase (12-HLO),,,,
213,,,,,CHEMBL615247,B,BAO_0000019,,,8,167,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,,,
214,,,,,CHEMBL615248,B,BAO_0000019,,,8,16474,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,,,
215,,,,,CHEMBL615249,B,BAO_0000357,,,8,10091,Inhibitory activity towards porcine 12-lipoxygenase,,,,
216,,,,,CHEMBL615250,B,BAO_0000357,,,8,11966,Tested for inhibition against porcine 12-LO,,,,
217,,,,,CHEMBL615251,B,BAO_0000019,,,8,951,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,,,
218,,,,,CHEMBL615252,B,BAO_0000019,,,8,10997,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,,,
219,,,,,CHEMBL828340,B,BAO_0000019,,,8,10193,In vitro inhibition of rat platelet 12-lipoxygenase,,,,
220,,,,,CHEMBL615253,B,BAO_0000019,,,8,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,,
221,,,,,CHEMBL615254,B,BAO_0000019,,,8,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,,,
222,,,,,CHEMBL615255,B,BAO_0000019,,,8,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,,,
223,,,,,CHEMBL615256,B,BAO_0000019,,,8,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,,
224,,,,,CHEMBL615257,B,BAO_0000019,,,8,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,,,
225,,,,,CHEMBL615258,B,BAO_0000019,,,8,11087,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,,,
226,,,,41M,CHEMBL615259,F,BAO_0000219,,,1,15569,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,Homo sapiens,9606.0,
227,,,,41M,CHEMBL615260,F,BAO_0000219,,,1,12989,In vitro antitumor activity against 41M cell line.,,Homo sapiens,9606.0,
228,,,,41M,CHEMBL615261,F,BAO_0000219,,,1,16745,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,Homo sapiens,9606.0,
229,,,,41M,CHEMBL615262,F,BAO_0000219,,,1,15569,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,Homo sapiens,9606.0,
230,,,,41M,CHEMBL615263,F,BAO_0000219,,,1,12989,In vitro antitumor activity against 41McisR cell line.,,Homo sapiens,9606.0,
231,,,,41M,CHEMBL838393,F,BAO_0000219,,,1,12989,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,Homo sapiens,9606.0,
232,,,,41M,CHEMBL615264,F,BAO_0000219,,,1,16745,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,Homo sapiens,9606.0,
233,,,,,CHEMBL615265,B,BAO_0000357,,,9,6210,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,Homo sapiens,9606.0,
234,,,,,CHEMBL615266,B,BAO_0000357,,,9,6210,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,Homo sapiens,9606.0,
235,,,,,CHEMBL615267,B,BAO_0000357,,,8,6226,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,,,
236,,,,,CHEMBL615268,B,BAO_0000357,,,8,17855,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,,,
237,,,,,CHEMBL615269,B,BAO_0000357,,,8,17855,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,,,
238,,,,,CHEMBL615270,B,BAO_0000357,,,8,17855,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,,,
239,,,,,CHEMBL615271,B,BAO_0000357,,,8,10413,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,,,
240,,,,,CHEMBL615272,B,BAO_0000357,,,8,10413,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,Escherichia coli,562.0,
241,,,,,CHEMBL615103,B,BAO_0000357,,,8,10413,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,Escherichia coli,562.0,
242,,,,,CHEMBL615104,B,BAO_0000357,,,8,10413,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,Escherichia coli,562.0,
243,,,,,CHEMBL615105,B,BAO_0000357,,,8,10413,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,,,
244,,,,,CHEMBL872866,B,BAO_0000357,,,8,10413,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,,,
245,,,,,CHEMBL615106,B,BAO_0000357,,,8,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,Sus scrofa,9823.0,
246,,,,,CHEMBL615107,B,BAO_0000019,,,8,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,Sus scrofa,9823.0,
247,,,,,CHEMBL615108,B,BAO_0000357,,,8,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,Sus scrofa,9823.0,
248,,,,,CHEMBL615109,B,BAO_0000357,,,8,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,Sus scrofa,9823.0,
249,,,,,CHEMBL615110,B,BAO_0000357,,,8,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,Sus scrofa,9823.0,
250,,,,,CHEMBL840105,B,BAO_0000019,,,8,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,Sus scrofa,9823.0,
251,,,,,CHEMBL615111,B,BAO_0000019,,,8,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,Sus scrofa,9823.0,
252,,,,,CHEMBL615112,B,BAO_0000019,,,8,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,Sus scrofa,9823.0,
253,,,,,CHEMBL615113,B,BAO_0000019,,,8,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,Sus scrofa,9823.0,
254,,,,,CHEMBL615114,B,BAO_0000019,,,8,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,Sus scrofa,9823.0,
255,,,,,CHEMBL615115,B,BAO_0000357,,,8,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,Sus scrofa,9823.0,
256,,,,,CHEMBL615116,B,BAO_0000019,,,8,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,Sus scrofa,9823.0,
257,,,,,CHEMBL615698,B,BAO_0000357,,,8,7323,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,,,
258,,,,,CHEMBL615699,B,BAO_0000019,,,0,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,Sus scrofa,9823.0,
259,,,,,CHEMBL615700,B,BAO_0000019,,,0,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,Sus scrofa,9823.0,
260,,,,,CHEMBL615701,B,BAO_0000357,,,8,13750,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,Saccharomyces cerevisiae,4932.0,
261,,,,,CHEMBL615702,B,BAO_0000019,,,0,7662,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,Rattus norvegicus,10116.0,
262,,,,,CHEMBL615703,B,BAO_0000019,,,0,7662,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,Rattus norvegicus,10116.0,
263,,,,,CHEMBL615704,B,BAO_0000019,,,0,7662,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,Rattus norvegicus,10116.0,
264,,,,,CHEMBL615705,F,BAO_0000019,,,6,12211,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,,,
265,,,,,CHEMBL615706,F,BAO_0000019,,,6,12211,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,,,
266,Ileum,,,,CHEMBL615707,F,BAO_0000221,,,9,12211,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,,Cavia porcellus,10141.0,
267,,,,,CHEMBL615708,F,BAO_0000019,,,8,12211,Stimulatory activity of intragastric pressure was tested in the rat,,,,
268,,,,,CHEMBL615709,B,BAO_0000357,,,8,15453,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,,,
269,,,,,CHEMBL615710,F,BAO_0000218,,,0,11884,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,Rattus norvegicus,10116.0,
270,,,,,CHEMBL615711,F,BAO_0000019,,,8,7185,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,,,
271,,,,,CHEMBL615712,B,BAO_0000357,,,9,6876,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,Homo sapiens,9606.0,
272,,,,,CHEMBL836325,B,BAO_0000357,,,9,6876,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,Homo sapiens,9606.0,
273,,,,,CHEMBL615713,F,BAO_0000019,,,8,11863,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,,,
274,,,,,CHEMBL615714,B,BAO_0000357,,,8,11863,Inhibition constant of high-affinity 5-HT uptake,,,,
275,,,,,CHEMBL615715,F,BAO_0000019,,,8,11863,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,,,
276,,,,,CHEMBL615716,F,BAO_0000019,,,8,11863,Maximum rate was determined for high affinity transport of 5-HT,,,,
277,,,,,CHEMBL615717,F,BAO_0000019,,,4,4639,Compound was tested for agonistic activity against 5-HT uptake,,,,
278,,,,,CHEMBL881818,B,BAO_0000019,,,8,15796,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,,,
279,,,,,CHEMBL884540,B,BAO_0000357,,,8,15796,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,Bos taurus,9913.0,
280,,,,,CHEMBL615718,B,BAO_0000224,,,5,12801,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,Rattus norvegicus,10116.0,
281,,,,,CHEMBL615719,B,BAO_0000224,,,4,12801,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,,,
282,,,,,CHEMBL615720,B,BAO_0000249,,,4,12120,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,,,Membranes
283,,,,,CHEMBL615721,B,BAO_0000249,,,4,12120,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,,,Membranes
284,,,,,CHEMBL615722,B,BAO_0000019,,,4,11963,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,,
285,,,,,CHEMBL615723,F,BAO_0000019,,,8,11701,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,,,
286,Hippocampus,,,,CHEMBL615724,B,BAO_0000221,,,8,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,
287,Hippocampus,,,,CHEMBL615725,B,BAO_0000221,,,8,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,
288,Hippocampus,,,,CHEMBL615726,B,BAO_0000221,,,8,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,
289,,,,,CHEMBL615727,F,BAO_0000218,,,8,16394,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),In vivo,,,
290,,,,,CHEMBL615728,F,BAO_0000019,,,9,11574,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,Cavia porcellus,10141.0,
291,,,,CHO,CHEMBL857971,B,BAO_0000219,,,8,15779,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,,
292,,,,,CHEMBL615729,B,BAO_0000357,,,8,15363,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,,,
293,,,,,CHEMBL615730,F,BAO_0000019,,,9,15363,Efficacy against 5-hydroxytryptamine 2A receptor,,Rattus norvegicus,10116.0,
294,,,,,CHEMBL615731,F,BAO_0000019,,,8,15329,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,,,
295,,,,,CHEMBL615732,F,BAO_0000019,,,8,15329,Relative potency towards 5-HT2A receptor of rat tail artery,,,,
296,,,,,CHEMBL615733,F,BAO_0000019,,,8,15329,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,,,
297,,,,,CHEMBL615734,F,BAO_0000019,,,8,15329,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,,,
298,,,,,CHEMBL615735,F,BAO_0000019,,,8,15329,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,,,
299,,,,,CHEMBL615736,F,BAO_0000019,,,8,15329,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,,,
300,Ileum,,,,CHEMBL615737,F,BAO_0000221,,,9,273,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,Cavia porcellus,10141.0,
301,Ileum,,,,CHEMBL615738,F,BAO_0000221,,,9,273,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),,Cavia porcellus,10141.0,
302,Ileum,,,,CHEMBL615739,F,BAO_0000221,,,9,273,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,Cavia porcellus,10141.0,
303,,,,,CHEMBL615278,B,BAO_0000357,,,8,12092,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,,,
304,,,,,CHEMBL615279,F,BAO_0000019,,,9,1317,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,Rattus norvegicus,10116.0,
305,,,,,CHEMBL615280,B,BAO_0000357,,,8,12409,Binding affinity against 5-hydroxytryptamine 4 receptor,,,,
306,,,,,CHEMBL615281,B,BAO_0000019,,,0,11126,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,Gallus gallus,9031.0,
307,,,,,CHEMBL615282,F,BAO_0000019,,,0,11126,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,Homo sapiens,9606.0,
308,,,,,CHEMBL615283,F,BAO_0000019,,,0,11126,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,Homo sapiens,9606.0,
309,,,,HL-60,CHEMBL615284,B,BAO_0000219,,,1,11126,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,Homo sapiens,9606.0,
310,,,,,CHEMBL615285,B,BAO_0000019,,,0,11126,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,Homo sapiens,9606.0,
311,,,,,CHEMBL615286,B,BAO_0000019,,,0,11126,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,Homo sapiens,9606.0,
312,,,,Oocytes,CHEMBL615287,B,BAO_0000219,,,7,17807,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,Homo sapiens,9606.0,
313,,,,,CHEMBL615288,F,BAO_0000220,,,2,16575,Chymotryptic inhibitory activity against 26S proteasome,,,,
314,,,,,CHEMBL615289,B,BAO_0000220,,,2,15407,Inhibitory activity against 26S proteasome degradation of IkB,,,,
315,,,,A2780,CHEMBL615290,F,BAO_0000219,,,1,10797,In vitro inhibition of 2780/DOX ovarian cancer cell line,,Homo sapiens,9606.0,
316,,,,A2780,CHEMBL884522,F,BAO_0000219,,,1,10797,In vitro inhibition of 2780/S ovarian cancer cell line,,Homo sapiens,9606.0,
317,,,,,CHEMBL615291,F,BAO_0000019,,,0,3469,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,Homo sapiens,9606.0,
318,,,,,CHEMBL615292,B,BAO_0000225,,,3,16037,Association constant for binding to AATT 28-mer AATT hairpin,,,,
319,,,,,CHEMBL615293,B,BAO_0000225,,,3,16037,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,,,
320,,,,,CHEMBL615294,B,BAO_0000225,,,3,16037,Reaction Rate Parameter for 28-mer AATT hairpin,,,,
321,,,,,CHEMBL615295,B,BAO_0000225,,,3,16037,Reaction Rate Parameter for 28-mer AATT hairpin,,,,
322,,,,,CHEMBL825021,F,BAO_0000019,,,0,16524,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,Homo sapiens,9606.0,
323,,,,,CHEMBL615296,F,BAO_0000019,,,0,16524,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,Homo sapiens,9606.0,
324,,,,,CHEMBL615297,F,BAO_0000019,,,0,16524,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,Homo sapiens,9606.0,
325,,,,,CHEMBL615298,F,BAO_0000019,,,0,16758,Cytotoxicity against cell line 2SC/20 determined by MTT test,,Cricetulus griseus,10029.0,
326,,,,,CHEMBL615299,F,BAO_0000019,,,0,16758,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,Cricetulus griseus,10029.0,
327,,,,,CHEMBL615300,F,BAO_0000019,,,0,16758,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,Cricetulus griseus,10029.0,
328,,,,,CHEMBL615301,B,BAO_0000357,,,8,14360,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,,,
329,,,,,CHEMBL615302,B,BAO_0000357,,,9,14360,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,Homo sapiens,9606.0,
330,,,,,CHEMBL615303,B,BAO_0000019,,,0,9964,Selectivity ratio of ID50 in liver and heart,,Rattus norvegicus,10116.0,
331,,,,,CHEMBL615304,B,BAO_0000019,,,8,9964,"Selectivity, ratio of relative ID50 in liver and heart",,,,
332,,,,,CHEMBL615305,B,BAO_0000019,,,8,9964,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,,,
333,,,,,CHEMBL615306,B,BAO_0000218,,,8,9964,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,,
334,,,,,CHEMBL615307,B,BAO_0000218,,,8,9964,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,,
335,,,,,CHEMBL615308,B,BAO_0000218,,,8,9964,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",In vivo,,,
336,,,,,CHEMBL615309,F,BAO_0000218,,,8,9964,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",In vivo,,,
337,,,,,CHEMBL615310,B,BAO_0000019,,,0,9964,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,,,
338,,,,,CHEMBL615311,B,BAO_0000019,,,8,9964,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,,,
339,,,,,CHEMBL615312,B,BAO_0000019,,,0,9964,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,Homo sapiens,9606.0,
340,,,,,CHEMBL615313,B,BAO_0000019,,,8,9964,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,,,
341,,,,,CHEMBL615314,F,BAO_0000019,,,8,9964,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,,,
342,,,,,CHEMBL615315,B,BAO_0000019,,,8,9964,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,,,
343,,,,,CHEMBL615316,B,BAO_0000218,,,0,9964,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,Rattus norvegicus,10116.0,
344,,,,,CHEMBL615317,B,BAO_0000218,,,8,9964,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,In vivo,,,
345,,,,,CHEMBL615318,B,BAO_0000218,,,8,9964,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,,
346,,,,,CHEMBL615319,B,BAO_0000218,,,0,9964,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,Rattus norvegicus,10116.0,
347,,,,,CHEMBL615320,B,BAO_0000019,,,8,9964,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,,,
348,,,,,CHEMBL615321,F,BAO_0000019,,,8,9964,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,,,
349,,,,,CHEMBL615322,B,BAO_0000019,,,0,3796,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,Rattus norvegicus,10116.0,
350,,,,,CHEMBL615323,B,BAO_0000357,,,8,4251,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,Escherichia coli,562.0,
351,,,,,CHEMBL615407,B,BAO_0000357,,,8,4251,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,Escherichia coli,562.0,
352,,,,,CHEMBL857267,B,BAO_0000357,,,8,4251,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,Escherichia coli,562.0,
353,,,,,CHEMBL615408,B,BAO_0000357,,,8,4251,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,Escherichia coli,562.0,
354,,,,,CHEMBL615409,B,BAO_0000357,,,8,166,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,,,
355,,,,,CHEMBL615410,B,BAO_0000357,,,8,17861,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,,,
356,,,,,CHEMBL615411,B,BAO_0000357,,,8,166,Inhibition constant against 3-dehydroquinate synthase,,,,
357,,,,,CHEMBL615412,B,BAO_0000357,,,8,166,Association rate constant against 3-dehydroquinate synthase,,,,
358,,,,,CHEMBL615413,B,BAO_0000357,,,8,166,Rate constant against 3-dehydroquinate synthase,,,,
359,,,,,CHEMBL615414,B,BAO_0000019,,,0,3548,Inhibitory activity against fuc-TVII,,,,
360,Liver,,,,CHEMBL615415,B,BAO_0000251,,,9,9877,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,Rattus norvegicus,10116.0,Microsomes
361,Liver,,,,CHEMBL615416,B,BAO_0000251,,,9,9877,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,Rattus norvegicus,10116.0,Microsomes
362,Liver,,,,CHEMBL615417,B,BAO_0000251,,,9,9877,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,Rattus norvegicus,10116.0,Microsomes
363,Liver,,,,CHEMBL615418,B,BAO_0000251,,,9,9877,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,Rattus norvegicus,10116.0,Microsomes
364,Liver,,,,CHEMBL615419,B,BAO_0000251,,,9,9877,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,Rattus norvegicus,10116.0,Microsomes
365,Liver,,,,CHEMBL615420,B,BAO_0000251,,,9,9877,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,,Rattus norvegicus,10116.0,Microsomes
366,Liver,,,,CHEMBL615421,B,BAO_0000251,,,9,9877,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,,Rattus norvegicus,10116.0,Microsomes
367,Liver,,,,CHEMBL615422,B,BAO_0000251,,,9,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,,Rattus norvegicus,10116.0,Microsomes
368,Liver,,,,CHEMBL615423,B,BAO_0000251,,,9,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,,Rattus norvegicus,10116.0,Microsomes
369,Liver,,,,CHEMBL872868,B,BAO_0000251,,,9,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,,Rattus norvegicus,10116.0,Microsomes
370,Liver,,,,CHEMBL615424,B,BAO_0000251,,,9,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,,Rattus norvegicus,10116.0,Microsomes
371,,,,,CHEMBL825022,B,BAO_0000224,,,4,3003,Inhibitory activity against 3-phosphoglycerate kinase.,,,,
372,,,,,CHEMBL615425,B,BAO_0000224,,,4,3003,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,,,
373,,,,,CHEMBL615426,B,BAO_0000224,,,4,3003,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,,,
374,,,,,CHEMBL615427,B,BAO_0000357,,,9,17185,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,Homo sapiens,9606.0,
375,,,,3677 melanoma cell line,CHEMBL615428,F,BAO_0000219,,,1,6072,Cytotoxicity on 3677 melanoma cells,,Homo sapiens,9606.0,
376,,,,3677 melanoma cell line,CHEMBL615429,F,BAO_0000219,,,1,6072,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,Homo sapiens,9606.0,
377,,,,MC-38,CHEMBL615430,F,BAO_0000219,,,1,5018,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,Mus musculus,10090.0,
378,,,,,CHEMBL615431,F,BAO_0000019,,,0,2852,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,Homo sapiens,9606.0,
379,,,,B16,CHEMBL615432,F,BAO_0000218,,,0,8663,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,,,
380,,,,B16,CHEMBL615433,F,BAO_0000218,,,0,8663,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,,,
381,,,,,CHEMBL615434,F,BAO_0000019,,,9,3245,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,Human rhinovirus 14,12131.0,
382,,,,,CHEMBL615435,F,BAO_0000218,,,1,3245,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,Human rhinovirus sp.,169066.0,
383,,,,,CHEMBL615436,F,BAO_0000218,,,1,3877,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,human rhinovirus type 14,169066.0,
384,,,,,CHEMBL615437,F,BAO_0000218,,,1,3877,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,human rhinovirus type 14,169066.0,
385,,,,,CHEMBL615438,F,BAO_0000019,,,9,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,Human rhinovirus 14,12131.0,
386,,,,,CHEMBL615439,F,BAO_0000019,,,9,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,Human rhinovirus 14,12131.0,
387,,,,,CHEMBL615440,F,BAO_0000019,,,9,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,Human rhinovirus 14,12131.0,
388,,,,,CHEMBL615441,F,BAO_0000019,,,9,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,Human rhinovirus 14,12131.0,
389,,,,,CHEMBL615641,F,BAO_0000218,,,1,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,Enterovirus,12059.0,
390,,,,,CHEMBL872065,F,BAO_0000218,,,1,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,Enterovirus,12059.0,
391,,,,,CHEMBL825023,F,BAO_0000218,,,1,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,Enterovirus,12059.0,
392,,,,,CHEMBL615642,F,BAO_0000218,,,1,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,Enterovirus,12059.0,
393,,,,,CHEMBL615643,B,BAO_0000357,,,8,13748,Inhibition of human rhinovirus 3C protease,,Human rhinovirus B,147712.0,
394,,,,,CHEMBL615644,B,BAO_0000019,,,0,17699,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,Homo sapiens,9606.0,
395,,,,3EM 37,CHEMBL615645,F,BAO_0000218,,,1,7145,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,Mus musculus,10090.0,
396,,,,3EM 37,CHEMBL615646,F,BAO_0000218,,,1,7145,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,Mus musculus,10090.0,
397,,,,3EM 37,CHEMBL615647,F,BAO_0000218,,,1,7145,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,Mus musculus,10090.0,
398,,,,3EM 37,CHEMBL615648,F,BAO_0000218,,,1,7145,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,Mus musculus,10090.0,
399,,,,3EM 37,CHEMBL615649,F,BAO_0000218,,,1,7145,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,Mus musculus,10090.0,
400,,,,3EM 37,CHEMBL615650,F,BAO_0000218,,,1,7145,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,Mus musculus,10090.0,
401,,,,3LL cell line,CHEMBL615651,F,BAO_0000218,,,1,5325,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,Mus musculus,10090.0,
402,,,,3LL cell line,CHEMBL615652,F,BAO_0000218,,,1,5325,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,Mus musculus,10090.0,
403,,,,3LL cell line,CHEMBL615653,F,BAO_0000218,,,1,5325,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,Mus musculus,10090.0,
404,,,,3LL cell line,CHEMBL615654,F,BAO_0000219,,,1,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,Mus musculus,10090.0,
405,,,,3LL cell line,CHEMBL615655,F,BAO_0000219,,,1,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,Mus musculus,10090.0,
406,,,,3LL cell line,CHEMBL825024,F,BAO_0000219,,,1,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,Mus musculus,10090.0,
407,,,,3LL cell line,CHEMBL615656,F,BAO_0000219,,,1,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,Mus musculus,10090.0,
408,,,,3LL cell line,CHEMBL615657,F,BAO_0000219,,,1,16169,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,Mus musculus,10090.0,
409,,,,3LL cell line,CHEMBL615658,F,BAO_0000219,,,1,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,Mus musculus,10090.0,
410,,,,3LL cell line,CHEMBL615659,F,BAO_0000219,,,1,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,Mus musculus,10090.0,
411,,,,3LL cell line,CHEMBL615660,F,BAO_0000219,,,1,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,Mus musculus,10090.0,
412,,,,3LL cell line,CHEMBL615661,F,BAO_0000219,,,1,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,Mus musculus,10090.0,
413,,,,3LL cell line,CHEMBL615662,F,BAO_0000219,,,1,16169,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,Mus musculus,10090.0,
414,,,,3LL cell line,CHEMBL615663,F,BAO_0000219,,,1,16169,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,Mus musculus,10090.0,
415,,,,3LL cell line,CHEMBL615664,F,BAO_0000219,,,1,16169,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,Mus musculus,10090.0,
416,,,,3LL cell line,CHEMBL615665,F,BAO_0000219,,,1,16169,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,Mus musculus,10090.0,
417,,,,3LL cell line,CHEMBL615666,F,BAO_0000219,,,1,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,Mus musculus,10090.0,
418,,,,3LL cell line,CHEMBL615667,F,BAO_0000219,,,1,16169,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,Mus musculus,10090.0,
419,,,,3LL cell line,CHEMBL615668,F,BAO_0000219,,,1,16169,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,Mus musculus,10090.0,
420,,,,3LL cell line,CHEMBL615669,F,BAO_0000219,,,1,16169,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,Mus musculus,10090.0,
421,,,,3LL cell line,CHEMBL615670,F,BAO_0000219,,,1,16169,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,Mus musculus,10090.0,
422,,,,3LL cell line,CHEMBL836739,F,BAO_0000219,,,1,16169,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,Mus musculus,10090.0,
423,,,,3LL cell line,CHEMBL615671,F,BAO_0000219,,,1,16169,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,Mus musculus,10090.0,
424,,,,3LL cell line,CHEMBL615672,F,BAO_0000219,,,1,16169,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,Mus musculus,10090.0,
425,,,,3LL cell line,CHEMBL615791,F,BAO_0000219,,,1,16169,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,Mus musculus,10090.0,
426,,,,3LL cell line,CHEMBL615792,F,BAO_0000219,,,1,16169,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,Mus musculus,10090.0,
427,,,,3LL cell line,CHEMBL615793,F,BAO_0000219,,,1,16169,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,Mus musculus,10090.0,
428,,,,3LL cell line,CHEMBL615794,F,BAO_0000219,,,1,16169,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,Mus musculus,10090.0,
429,,,,3LL cell line,CHEMBL615795,F,BAO_0000219,,,1,16169,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,Mus musculus,10090.0,
430,,,,3LLD122,CHEMBL615590,F,BAO_0000219,,,1,15547,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,Homo sapiens,9606.0,
431,,,,,CHEMBL615591,F,BAO_0000218,,,0,8663,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,,,
432,,,,,CHEMBL615592,F,BAO_0000218,,,0,8663,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,,,
433,,,,,CHEMBL615593,F,BAO_0000218,,,0,8663,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,,,
434,,,,,CHEMBL615594,F,BAO_0000218,,,0,8663,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,,,
435,,,,NIH3T3,CHEMBL615595,F,BAO_0000219,,,1,4504,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,Mus musculus,10090.0,
436,,,,NIH3T3,CHEMBL615596,F,BAO_0000219,,,1,4504,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,Mus musculus,10090.0,
437,,,,NIH3T3,CHEMBL615597,F,BAO_0000219,,,8,12695,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,,,
438,,,,NIH3T3,CHEMBL615598,F,BAO_0000219,,,1,12695,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,Mus musculus,10090.0,
439,,,,NIH3T3,CHEMBL615599,F,BAO_0000219,,,1,12695,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,Mus musculus,10090.0,
440,,,,NIH3T3,CHEMBL615600,F,BAO_0000219,,,1,17642,Effective dose against murine 3T3 fibroblasts cells,,Mus musculus,10090.0,
441,,,,NIH3T3,CHEMBL615601,F,BAO_0000219,,,1,17642,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,Mus musculus,10090.0,
442,,,,NIH3T3,CHEMBL615602,F,BAO_0000219,,,1,12340,Cytotoxic effect on 3T3 cells,,Mus musculus,10090.0,
443,,,,NIH3T3,CHEMBL615603,F,BAO_0000219,,,1,12340,Cytotoxic effect on 3T3 cells,,Mus musculus,10090.0,
444,,,,NIH3T3,CHEMBL615604,F,BAO_0000219,,,1,12716,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,Mus musculus,10090.0,
445,,,,NIH3T3,CHEMBL615605,F,BAO_0000219,,,1,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,Mus musculus,10090.0,
446,,,,NIH3T3,CHEMBL615606,F,BAO_0000219,,,1,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,Mus musculus,10090.0,
447,,,,NIH3T3,CHEMBL884526,F,BAO_0000219,,,1,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,Mus musculus,10090.0,
448,,,,NIH3T3,CHEMBL615607,F,BAO_0000219,,,1,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,Mus musculus,10090.0,
449,,,,NIH3T3,CHEMBL615608,F,BAO_0000219,,,1,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,Mus musculus,10090.0,
450,,,,NIH3T3,CHEMBL615609,F,BAO_0000219,,,1,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,Mus musculus,10090.0,
451,,,,NIH3T3,CHEMBL615682,F,BAO_0000219,,,1,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,Mus musculus,10090.0,
452,,,,NIH3T3,CHEMBL615683,F,BAO_0000219,,,1,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,Mus musculus,10090.0,
453,,,,NIH3T3,CHEMBL615684,F,BAO_0000218,,,1,17780,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,Mus musculus,10090.0,
454,,,,,CHEMBL615685,F,BAO_0000219,,,7,12751,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,Mus musculus,10090.0,
455,,,,NIH3T3,CHEMBL615686,F,BAO_0000219,,,1,12380,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,Mus musculus,10090.0,
456,,,,NIH3T3,CHEMBL615687,F,BAO_0000219,,,1,14892,Inhibitory activity against 3T3 cell line,,Mus musculus,10090.0,
457,,,,NIH3T3,CHEMBL884523,F,BAO_0000219,,,1,12695,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,Mus musculus,10090.0,
458,,,,,CHEMBL615688,F,BAO_0000019,,,8,12695,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,,,
459,,,,NIH3T3,CHEMBL615689,F,BAO_0000219,,,1,12695,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,Mus musculus,10090.0,
460,,,,NIH3T3,CHEMBL615690,F,BAO_0000219,,,1,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,Mus musculus,10090.0,
461,,,,,CHEMBL615691,F,BAO_0000019,,,8,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,,,
462,,,,,CHEMBL615692,F,BAO_0000019,,,8,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,,,
463,,,,NIH3T3,CHEMBL615693,F,BAO_0000219,,,1,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,Mus musculus,10090.0,
464,,,,NIH3T3,CHEMBL615324,F,BAO_0000219,,,1,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,Mus musculus,10090.0,
465,,,,NIH3T3,CHEMBL615325,F,BAO_0000219,,,9,4959,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,Homo sapiens,9606.0,
466,,,,NIH3T3,CHEMBL615490,F,BAO_0000219,,,9,4959,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,Homo sapiens,9606.0,
467,,,,NIH3T3,CHEMBL615491,F,BAO_0000219,,,9,4959,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,Homo sapiens,9606.0,
468,,,,NIH3T3,CHEMBL615492,F,BAO_0000219,,,9,4959,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,Homo sapiens,9606.0,
469,,,,NIH3T3,CHEMBL615493,F,BAO_0000219,,,1,12082,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,Mus musculus,10090.0,
470,,,,NIH3T3,CHEMBL615494,F,BAO_0000219,,,1,12082,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,Mus musculus,10090.0,
471,,,,NIH3T3,CHEMBL615495,F,BAO_0000219,,,1,12082,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,Mus musculus,10090.0,
472,,,,NIH3T3,CHEMBL615496,F,BAO_0000219,,,1,12082,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,Mus musculus,10090.0,
473,,,,NIH3T3,CHEMBL615497,F,BAO_0000219,,,1,2643,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,Mus musculus,10090.0,
474,,,,NIH3T3,CHEMBL615498,F,BAO_0000219,,,1,11926,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,Mus musculus,10090.0,
475,,,,NIH3T3,CHEMBL615499,A,BAO_0000219,,,1,15204,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,Mus musculus,10090.0,
476,,,,NIH3T3,CHEMBL835522,F,BAO_0000219,,,1,15992,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,Mus musculus,10090.0,
477,,,,NIH3T3,CHEMBL615500,F,BAO_0000219,,,1,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,Mus musculus,10090.0,
478,,,,NIH3T3,CHEMBL615501,F,BAO_0000219,,,1,16279,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,Mus musculus,10090.0,
479,,,,NIH3T3,CHEMBL615502,F,BAO_0000219,,,1,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,Mus musculus,10090.0,
480,,,,NIH3T3,CHEMBL615503,F,BAO_0000219,,,1,16279,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,Mus musculus,10090.0,
481,,,,NIH3T3,CHEMBL615504,F,BAO_0000219,,,1,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,Mus musculus,10090.0,
482,,,,NIH3T3,CHEMBL615505,F,BAO_0000219,,,1,16279,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,Mus musculus,10090.0,
483,,,,NIH3T3,CHEMBL615506,F,BAO_0000219,,,1,12831,Inhibition of swiss 3T3 mouse fibroblast proliferation,,Mus musculus,10090.0,
484,,,,NIH3T3,CHEMBL615507,F,BAO_0000219,,,1,13497,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,Mus musculus,10090.0,
485,,,,3T3-L1,CHEMBL615508,F,BAO_0000218,,,1,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,,
486,,,,3T3-L1,CHEMBL615509,F,BAO_0000219,,,1,13618,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,Mus musculus,10090.0,
487,,,,3T3-L1,CHEMBL615510,F,BAO_0000219,,,1,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,Mus musculus,10090.0,
488,,,,3T3-L1,CHEMBL615511,F,BAO_0000219,,,1,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,Mus musculus,10090.0,
489,,,,3T3-L1,CHEMBL615512,F,BAO_0000219,,,1,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,Mus musculus,10090.0,
490,,,,3T3-L1,CHEMBL615513,F,BAO_0000218,,,1,14840,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,Mus musculus,10090.0,
491,,,,3T3-L1,CHEMBL615514,F,BAO_0000218,,,1,14840,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,Mus musculus,10090.0,
492,,,,3T3-L1,CHEMBL615515,F,BAO_0000219,,,1,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,,,
493,,,,3T3-L1,CHEMBL615516,F,BAO_0000219,,,1,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,,,
494,,,,3T3-L1,CHEMBL615517,F,BAO_0000219,,,1,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,,
495,,,,3T3-L1,CHEMBL615518,F,BAO_0000219,,,1,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,,,
496,,,,3T3-L1,CHEMBL615519,F,BAO_0000219,,,1,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,,
497,,,,3T3-L1,CHEMBL615520,F,BAO_0000218,,,1,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,,,
498,,,,3T3-L1,CHEMBL615521,F,BAO_0000218,,,1,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,,,
499,,,,3T3-L1,CHEMBL615522,F,BAO_0000218,,,1,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,,,
500,,,,3T3-L1,CHEMBL615523,F,BAO_0000218,,,1,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,,
501,,,,3T3-L1,CHEMBL615524,F,BAO_0000218,,,1,13715,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,,,
502,,,,3T3-L1,CHEMBL615525,F,BAO_0000218,,,1,13715,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,,
503,,,,3T3-L1,CHEMBL615526,F,BAO_0000218,,,1,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,,,
504,,,,3T3-L1,CHEMBL615527,F,BAO_0000218,,,1,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,,
505,,,,3T3-L1,CHEMBL615528,F,BAO_0000218,,,1,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,,,
506,,,,3T3-L1,CHEMBL615529,F,BAO_0000218,,,1,13715,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,,
507,,,,3T3-L1,CHEMBL615530,F,BAO_0000218,,,1,13715,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,,
508,,,,3T3-L1,CHEMBL615531,F,BAO_0000218,,,1,13715,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,,,
509,,,,3T3-L1,CHEMBL615532,F,BAO_0000219,,,1,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,,,
510,,,,3T3-L1,CHEMBL615533,F,BAO_0000219,,,1,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,,
511,,,,3T3-L1,CHEMBL615534,F,BAO_0000219,,,1,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,,,
512,,,,3T3-L1,CHEMBL615535,F,BAO_0000218,,,1,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,,,
513,,,,3T3-L1,CHEMBL615536,F,BAO_0000218,,,1,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,,
514,,,,3T3-L1,CHEMBL615537,F,BAO_0000218,,,1,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,,
515,,,,3T3-L1,CHEMBL615538,F,BAO_0000218,,,1,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,,
516,,,,3T3-L1,CHEMBL836166,F,BAO_0000218,,,1,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,,,
517,,,,3T3-L1,CHEMBL615539,F,BAO_0000219,,,8,6411,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,,,
518,,,,3T3-L1,CHEMBL615540,F,BAO_0000219,,,1,6411,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,Mus musculus,10090.0,
519,,,,3T3-L1,CHEMBL615541,F,BAO_0000219,,,8,6411,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,,,
520,,,,3T3-L1,CHEMBL615542,F,BAO_0000219,,,1,3966,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,Mus musculus,10090.0,
521,,,,3T3-L1,CHEMBL615543,F,BAO_0000219,,,1,3966,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,Mus musculus,10090.0,
522,,,,3T3-L1,CHEMBL615544,F,BAO_0000219,,,1,15556,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,Mus musculus,10090.0,
523,,,,3T3-L1,CHEMBL615545,F,BAO_0000219,,,1,5845,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,Mus musculus,10090.0,
524,,,,3T3-L1,CHEMBL615546,F,BAO_0000219,,,1,14422,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,Mus musculus,10090.0,
525,,,,3T3-L1,CHEMBL615547,F,BAO_0000219,,,1,5845,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,Mus musculus,10090.0,
526,,,,3T3-L1,CHEMBL615548,F,BAO_0000219,,,1,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,Mus musculus,10090.0,
527,,,,3T3-L1,CHEMBL615549,F,BAO_0000219,,,1,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,Mus musculus,10090.0,
528,,,,3T3-L1,CHEMBL615550,F,BAO_0000219,,,1,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,Mus musculus,10090.0,
529,,,,3Y1 cell line,CHEMBL615551,F,BAO_0000219,,,1,6349,Inhibitory activity against rat fibroblast (3Y1) cell line,,Rattus norvegicus,10116.0,
530,,,,3Y1 cell line,CHEMBL615552,F,BAO_0000219,,,1,15899,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,Rattus norvegicus,10116.0,
531,,,,3Y1 cell line,CHEMBL615553,F,BAO_0000219,,,1,15899,Cytotoxicity in 3Y1 cells.,,Rattus norvegicus,10116.0,
532,,,,3Y1 cell line,CHEMBL615554,F,BAO_0000219,,,1,15899,Cytostatic effect in 3Y1 cells.,,Rattus norvegicus,10116.0,
533,,,,3Y1 cell line,CHEMBL615555,F,BAO_0000219,,,1,15899,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,Rattus norvegicus,10116.0,
534,,,,3Y1 cell line,CHEMBL615556,F,BAO_0000219,,,1,17038,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,Rattus norvegicus,10116.0,
535,,,,,CHEMBL615557,B,BAO_0000019,,,0,12421,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,,,
536,,,,,CHEMBL615558,B,BAO_0000019,,,0,12947,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,,,
537,,,,,CHEMBL872066,B,BAO_0000019,,,0,12947,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,,,
538,,,,,CHEMBL615559,B,BAO_0000019,,,9,4896,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,Sus scrofa,9823.0,
539,,,,,CHEMBL615560,B,BAO_0000019,,,8,6148,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,,,
540,,,,,CHEMBL615561,B,BAO_0000019,,,8,16432,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,,,
541,,,,,CHEMBL857062,B,BAO_0000019,,,8,4978,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,,,
542,,,,,CHEMBL615562,B,BAO_0000019,,,8,4978,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,,,
543,,,,,CHEMBL615563,B,BAO_0000019,,,8,3723,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,,,
544,,,,,CHEMBL615564,B,BAO_0000357,,,8,3518,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,,,
545,,,,,CHEMBL615565,B,BAO_0000019,,,8,4164,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,,,
546,,,,,CHEMBL615566,B,BAO_0000019,,,8,3518,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,,,
547,,,,,CHEMBL615567,B,BAO_0000019,,,9,4164,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,Sus scrofa,9823.0,
548,,,,,CHEMBL615568,B,BAO_0000019,,,8,3518,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,,,
549,,,,,CHEMBL615569,B,BAO_0000357,,,8,3518,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,,,
550,,,,,CHEMBL615570,B,BAO_0000019,,,8,4978,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,,,
551,,,,,CHEMBL615571,B,BAO_0000019,,,8,4978,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,,,
552,,,,,CHEMBL615572,B,BAO_0000224,,,4,6455,Binding affinity against melatonin (MT1) receptor (pC1),,,,
553,,,,,CHEMBL615573,B,BAO_0000019,,,0,2222,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,,,
554,,,,,CHEMBL615574,B,BAO_0000019,,,0,13020,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,,,
555,,,,,CHEMBL615575,B,BAO_0000019,,,0,13021,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,,,
556,,,,,CHEMBL615576,B,BAO_0000357,,,8,14532,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,,,
557,,,,,CHEMBL615577,B,BAO_0000357,,,8,14118,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,,,
558,Hippocampus,,,,CHEMBL615578,B,BAO_0000221,,,8,11884,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,,,
559,,,,,CHEMBL615579,B,BAO_0000357,,,8,13969,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,,,
560,,,,,CHEMBL615580,B,BAO_0000357,,,8,13392,Binding affinity for 5-hydroxytryptamine 1A receptor,,,,
561,,,,,CHEMBL615581,B,BAO_0000019,,,8,14430,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,,,
562,Hippocampus,,,,CHEMBL615582,B,BAO_0000221,,,8,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,,
563,Hippocampus,,,,CHEMBL615583,B,BAO_0000221,,,8,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,,
564,Hippocampus,,,,CHEMBL615584,B,BAO_0000221,,,8,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,
565,Hippocampus,,,,CHEMBL833691,B,BAO_0000221,,,8,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,
566,Hippocampus,,,,CHEMBL615585,B,BAO_0000221,,,8,9995,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,
567,Hippocampus,,,,CHEMBL615586,B,BAO_0000221,,,8,9995,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,
568,Hippocampus,,,,CHEMBL884524,B,BAO_0000221,,,8,9995,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,
569,Hippocampus,,,,CHEMBL615587,B,BAO_0000221,,,8,12249,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,,
570,Hippocampus,,,,CHEMBL615588,B,BAO_0000221,,,8,11799,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,,,
571,,,,,CHEMBL615589,B,BAO_0000249,,,9,14331,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,,Rattus norvegicus,10116.0,Membranes
572,Hippocampus,,,,CHEMBL615442,B,BAO_0000221,,,8,11884,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,,Bos taurus,9913.0,
573,Hippocampus,,,,CHEMBL615443,B,BAO_0000221,,,8,14331,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,,,
574,Hippocampus,,,,CHEMBL615444,B,BAO_0000221,,,8,11701,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,,,
575,Hippocampus,,,,CHEMBL615445,B,BAO_0000221,,,8,11701,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,,,
576,Hippocampus,,,,CHEMBL615446,B,BAO_0000221,,,8,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,,,
577,,,,CHO,CHEMBL615447,B,BAO_0000219,,,8,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,,,
578,Hippocampus,,,,CHEMBL615448,B,BAO_0000221,,,8,12248,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,,
579,Hippocampus,,,,CHEMBL615449,B,BAO_0000221,,,8,12249,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,,
580,,,,CHO,CHEMBL615450,B,BAO_0000219,,,8,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,
581,Hippocampus,,,,CHEMBL615451,B,BAO_0000221,,,8,11799,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,,,
582,,,,,CHEMBL615452,B,BAO_0000357,,,8,634,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,,,
583,Hippocampus,,,,CHEMBL615453,B,BAO_0000221,,,8,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,
584,Hippocampus,,,,CHEMBL615454,B,BAO_0000221,,,8,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,
585,Hippocampus,,,,CHEMBL615455,B,BAO_0000221,,,8,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,
586,Hippocampus,,,,CHEMBL615456,B,BAO_0000221,,,8,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,
587,Hippocampus,,,,CHEMBL615457,B,BAO_0000221,,,8,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,
588,Hippocampus,,,,CHEMBL615458,B,BAO_0000218,,,8,12210,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,,,
589,Hippocampus,,,,CHEMBL615459,B,BAO_0000221,,,8,13311,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,
590,,,,CHO,CHEMBL615460,B,BAO_0000219,,,9,2331,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,Homo sapiens,9606.0,
591,,,,,CHEMBL615461,F,BAO_0000019,,,8,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,Cavia porcellus,10141.0,
592,,,,,CHEMBL615462,F,BAO_0000019,,,8,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,Cavia porcellus,10141.0,
593,Hippocampus,,,,CHEMBL615463,F,BAO_0000221,,,8,11574,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,,Cavia porcellus,10141.0,
594,Ileum,,,,CHEMBL615464,B,BAO_0000221,,,8,12867,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,Cavia porcellus,10141.0,
595,Ileum,,,,CHEMBL615465,B,BAO_0000221,,,8,12867,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,Cavia porcellus,10141.0,
596,Ileum,,,,CHEMBL615466,B,BAO_0000221,,,8,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,Cavia porcellus,10141.0,
597,Ileum,,,,CHEMBL615467,B,BAO_0000221,,,8,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,Cavia porcellus,10141.0,
598,Ileum,,,,CHEMBL615468,B,BAO_0000221,,,8,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,Cavia porcellus,10141.0,
599,Ileum,,,,CHEMBL615469,B,BAO_0000221,,,8,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,,Cavia porcellus,10141.0,
600,,,,,CHEMBL615470,B,BAO_0000357,,,8,11574,Binding affinity against 5-hydroxytryptamine 1A receptor,,Cavia porcellus,10141.0,
601,,,,,CHEMBL615471,B,BAO_0000357,,,8,13114,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,Cavia porcellus,10141.0,
602,,,,,CHEMBL615472,B,BAO_0000357,,,8,13181,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,Cavia porcellus,10141.0,
603,Hippocampus,,,,CHEMBL883242,B,BAO_0000221,,,8,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,Cavia porcellus,10141.0,
604,Hippocampus,,,,CHEMBL615473,F,BAO_0000221,,,8,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,Cavia porcellus,10141.0,
605,,,,CHO,CHEMBL615474,B,BAO_0000218,,,8,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,Cricetulus griseus,10029.0,
606,,,,,CHEMBL615475,B,BAO_0000357,,,8,17785,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,,,
607,,,,HeLa,CHEMBL615476,F,BAO_0000219,,,8,1558,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,,,
608,,,,HeLa,CHEMBL615477,F,BAO_0000219,,,8,1558,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,,,
609,,,,,CHEMBL615478,F,BAO_0000019,,,8,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,,,
610,,,,CHO,CHEMBL615160,F,BAO_0000219,,,8,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,,,
611,,,,CHO,CHEMBL615161,F,BAO_0000219,,,8,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,,,
612,,,,CHO,CHEMBL615162,F,BAO_0000219,,,8,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,,,
613,,,,CHO,CHEMBL615163,F,BAO_0000219,,,8,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,,,
614,,,,CHO,CHEMBL615164,B,BAO_0000219,,,8,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,
615,,,,CHO,CHEMBL615165,B,BAO_0000219,,,8,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,
616,,,,CHO,CHEMBL615166,B,BAO_0000219,,,8,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,,,
617,,,,,CHEMBL615167,F,BAO_0000219,,,8,14256,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,,,
618,,,,HeLa,CHEMBL615168,B,BAO_0000219,,,9,3445,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,Homo sapiens,9606.0,
619,,,,HeLa,CHEMBL615169,B,BAO_0000219,,,9,3445,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,Homo sapiens,9606.0,
620,,,,CHO,CHEMBL615170,B,BAO_0000219,,,9,17200,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,Homo sapiens,9606.0,
621,,,,CHO,CHEMBL615171,B,BAO_0000219,,,9,17200,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,Homo sapiens,9606.0,
622,,,,,CHEMBL615694,F,BAO_0000019,,,8,15180,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,,,
623,,,,,CHEMBL615695,F,BAO_0000019,,,8,15180,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,,,
624,,,,,CHEMBL615696,F,BAO_0000019,,,8,16026,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,,
625,,,,CHO,CHEMBL615697,F,BAO_0000219,,,8,2759,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,,
626,,,,CHO,CHEMBL859410,F,BAO_0000219,,,9,2759,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,Homo sapiens,9606.0,
627,,,,CHO,CHEMBL615841,F,BAO_0000219,,,8,2759,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,,,
628,,,,CHO,CHEMBL615842,F,BAO_0000219,,,9,2759,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,Homo sapiens,9606.0,
629,,,,CHO,CHEMBL835003,F,BAO_0000219,,,8,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,,
630,,,,CHO,CHEMBL615843,F,BAO_0000219,,,8,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,,,
631,,,,CHO,CHEMBL615979,F,BAO_0000219,,,9,2759,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,Homo sapiens,9606.0,
632,,,,CHO,CHEMBL615980,F,BAO_0000219,,,8,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,,,
633,,,,CHO,CHEMBL615981,F,BAO_0000219,,,9,2759,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,Homo sapiens,9606.0,
634,,,,,CHEMBL615982,F,BAO_0000019,,,9,3445,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,Homo sapiens,9606.0,
635,,,,,CHEMBL615983,F,BAO_0000019,,,9,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,Homo sapiens,9606.0,
636,,,,,CHEMBL615984,F,BAO_0000019,,,9,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,Homo sapiens,9606.0,
637,,,,,CHEMBL615985,F,BAO_0000019,,,9,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,Homo sapiens,9606.0,
638,,,,CHO,CHEMBL615986,F,BAO_0000219,,,8,17624,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,,
639,,,,CHO,CHEMBL615987,F,BAO_0000219,,,8,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,,
640,,,,CHO,CHEMBL615988,F,BAO_0000219,,,8,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,,,
641,,,,CHO,CHEMBL615989,F,BAO_0000219,,,8,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,,
642,,,,CHO,CHEMBL615990,F,BAO_0000219,,,8,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,,,
643,,,,CHO,CHEMBL615991,F,BAO_0000219,,,8,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,,,
644,,,,CHO,CHEMBL615992,F,BAO_0000219,,,8,17624,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,,
645,,,,CHO,CHEMBL615993,F,BAO_0000219,,,8,17624,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,,,
646,,,,CHO,CHEMBL615994,F,BAO_0000219,,,8,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,,
647,,,,CHO,CHEMBL615995,F,BAO_0000219,,,8,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,,,
648,,,,CHO,CHEMBL615996,F,BAO_0000219,,,8,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,,
649,,,,CHO,CHEMBL615997,F,BAO_0000219,,,8,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,,,
650,,,,,CHEMBL615998,F,BAO_0000019,,,8,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,
651,,,,,CHEMBL615999,F,BAO_0000019,,,8,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,
652,,,,,CHEMBL616000,F,BAO_0000019,,,8,6563,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,,,
653,,,,HEK293,CHEMBL616001,F,BAO_0000219,,,8,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,,
654,,,,,CHEMBL616002,F,BAO_0000019,,,9,6876,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,Homo sapiens,9606.0,
655,,,,,CHEMBL616003,F,BAO_0000019,,,8,6876,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,,,
656,,,,,CHEMBL616004,F,BAO_0000019,,,9,5272,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,Homo sapiens,9606.0,
657,,,,,CHEMBL616005,F,BAO_0000019,,,9,5272,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,Homo sapiens,9606.0,
658,,,,,CHEMBL616006,F,BAO_0000019,,,8,5548,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,,
659,,,,,CHEMBL616007,F,BAO_0000019,,,8,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,,,
660,,,,,CHEMBL616008,F,BAO_0000019,,,8,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,,
661,,,,,CHEMBL616009,F,BAO_0000019,,,8,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,,
662,,,,,CHEMBL616010,F,BAO_0000019,,,8,5929,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,,,
663,,,,,CHEMBL616011,F,BAO_0000019,,,9,5929,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,Homo sapiens,9606.0,
664,,,,,CHEMBL615740,F,BAO_0000019,,,9,5929,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,Homo sapiens,9606.0,
665,,,,,CHEMBL615741,F,BAO_0000019,,,8,16245,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,,,
666,,,,,CHEMBL615742,F,BAO_0000019,,,8,5640,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,,,
667,,,,,CHEMBL615743,F,BAO_0000019,,,8,5640,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,,,
668,,,,CHO,CHEMBL615744,F,BAO_0000219,,,8,14509,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,,,
669,,,,CHO,CHEMBL615745,F,BAO_0000219,,,8,14509,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,,,
670,,,,,CHEMBL615746,B,BAO_0000357,,,8,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,,
671,,,,,CHEMBL615747,B,BAO_0000357,,,8,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,,
672,,,,,CHEMBL615748,F,BAO_0000019,,,8,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,
673,,,,,CHEMBL615749,F,BAO_0000019,,,8,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,,,
674,,,,,CHEMBL615750,F,BAO_0000019,,,8,6563,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,,,
675,,,,,CHEMBL616259,F,BAO_0000019,,,9,6563,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,Homo sapiens,9606.0,
676,,,,,CHEMBL616260,F,BAO_0000019,,,8,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,
677,,,,,CHEMBL616261,F,BAO_0000019,,,9,5272,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,Homo sapiens,9606.0,
678,,,,,CHEMBL616262,F,BAO_0000019,,,9,5272,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,Homo sapiens,9606.0,
679,,,,,CHEMBL616263,F,BAO_0000019,,,9,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,Homo sapiens,9606.0,
680,,,,,CHEMBL616264,F,BAO_0000019,,,9,5272,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,Homo sapiens,9606.0,
681,,,,,CHEMBL616265,F,BAO_0000019,,,9,5272,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,Homo sapiens,9606.0,
682,,,,,CHEMBL616266,F,BAO_0000019,,,9,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,Homo sapiens,9606.0,
683,,,,,CHEMBL616267,F,BAO_0000019,,,9,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,Homo sapiens,9606.0,
684,,,,,CHEMBL616268,F,BAO_0000019,,,9,5272,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,Homo sapiens,9606.0,
685,,,,,CHEMBL616269,B,BAO_0000357,,,9,16146,Inhibition of human 5-hydroxytryptamine 1A receptor,,Homo sapiens,9606.0,
686,,,,CHO,CHEMBL884528,B,BAO_0000219,,,8,17624,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,
687,,,,HEK293,CHEMBL616270,B,BAO_0000219,,,9,13706,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,,,
688,,,,CHO,CHEMBL616271,B,BAO_0000219,,,8,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,,,
689,,,,CHO,CHEMBL616272,F,BAO_0000219,,,8,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,,
690,,,,,CHEMBL616273,B,BAO_0000357,,,8,6861,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,,,
691,,,,,CHEMBL616274,B,BAO_0000357,,,9,17200,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,Homo sapiens,9606.0,
692,,,,CHO,CHEMBL616275,B,BAO_0000219,,,8,17624,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,,,
693,,,,CHO,CHEMBL616276,B,BAO_0000219,,,8,17624,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,
694,,,,,CHEMBL616277,F,BAO_0000218,,,0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,In vivo,Rattus norvegicus,10116.0,
695,,,,,CHEMBL616278,F,BAO_0000218,,,0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,In vivo,Rattus norvegicus,10116.0,
696,,,,,CHEMBL616279,F,BAO_0000218,,,0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,In vivo,Rattus norvegicus,10116.0,
697,,,,,CHEMBL616280,F,BAO_0000218,,,0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,In vivo,Rattus norvegicus,10116.0,
698,,,,,CHEMBL616281,F,BAO_0000218,,,0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,In vivo,Rattus norvegicus,10116.0,
699,,,,,CHEMBL616282,F,BAO_0000218,,,0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,In vivo,Rattus norvegicus,10116.0,
700,,,,,CHEMBL616283,F,BAO_0000218,,,0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,In vivo,Rattus norvegicus,10116.0,
701,,,,,CHEMBL616284,F,BAO_0000218,,,0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,In vivo,Rattus norvegicus,10116.0,
702,,,,,CHEMBL616285,F,BAO_0000218,,,0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,In vivo,Rattus norvegicus,10116.0,
703,,,,,CHEMBL616286,F,BAO_0000218,,,0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,In vivo,Rattus norvegicus,10116.0,
704,,,,,CHEMBL616287,F,BAO_0000218,,,0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,In vivo,Rattus norvegicus,10116.0,
705,,,,,CHEMBL616288,F,BAO_0000218,,,0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,In vivo,Rattus norvegicus,10116.0,
706,,,,,CHEMBL616289,F,BAO_0000218,,,0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,In vivo,Rattus norvegicus,10116.0,
707,,,,,CHEMBL615610,F,BAO_0000218,,,0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,In vivo,Rattus norvegicus,10116.0,
708,,,,,CHEMBL615611,F,BAO_0000218,,,0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,In vivo,Rattus norvegicus,10116.0,
709,,,,,CHEMBL615612,F,BAO_0000218,,,0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,In vivo,Rattus norvegicus,10116.0,
710,,,,,CHEMBL615613,F,BAO_0000218,,,0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,In vivo,Rattus norvegicus,10116.0,
711,,,,,CHEMBL615614,F,BAO_0000218,,,0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,In vivo,Rattus norvegicus,10116.0,
712,,,,,CHEMBL615615,F,BAO_0000218,,,0,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,In vivo,Rattus norvegicus,10116.0,
713,,,,,CHEMBL615616,B,BAO_0000019,,,4,11440,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,,,
714,Hypothalamus,,,,CHEMBL615617,B,BAO_0000249,,,8,6238,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,,,
715,,,,,CHEMBL615618,B,BAO_0000019,,,8,10046,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,,,
716,,,,,CHEMBL615619,B,BAO_0000019,,,8,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,,,
717,,,,,CHEMBL615620,B,BAO_0000019,,,8,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,,,
718,,,,,CHEMBL615621,B,BAO_0000357,,,8,167,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,,,
719,,,,,CHEMBL615622,B,BAO_0000357,,,8,167,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,,,
720,,,,,CHEMBL615623,F,BAO_0000019,,,8,11520,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,,,
721,,,,,CHEMBL615624,F,BAO_0000019,,,8,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,,
722,,,,,CHEMBL615625,F,BAO_0000019,,,8,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,,
723,,,,,CHEMBL767045,F,BAO_0000019,,,8,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,,
724,,,,,CHEMBL615626,F,BAO_0000019,,,8,135,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,Cavia porcellus,10141.0,
725,,,,,CHEMBL615627,F,BAO_0000019,,,8,135,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,Cavia porcellus,10141.0,
726,,,,,CHEMBL615628,B,BAO_0000019,,,8,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,Cavia porcellus,10141.0,
727,,,,,CHEMBL615629,B,BAO_0000357,,,8,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,Cavia porcellus,10141.0,
728,,,,,CHEMBL615630,B,BAO_0000357,,,9,12281,Inhibitory concentration against 5-lipoxygenase from human whole blood,,Homo sapiens,9606.0,
729,,,,,CHEMBL615631,B,BAO_0000219,,,8,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,,,
730,,,,,CHEMBL615632,F,BAO_0000218,,,8,12576,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,,,
731,,,,,CHEMBL615633,B,BAO_0000357,,,8,12281,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,,,
732,,,,,CHEMBL615634,F,BAO_0000218,,,8,12576,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,,,
733,,,,,CHEMBL615635,B,BAO_0000019,,,8,11089,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,Sus scrofa,9823.0,
734,,,,,CHEMBL615636,B,BAO_0000357,,,8,11006,In vitro inhibition of rat 5-Lipoxygenase,,,,
735,,,,,CHEMBL615637,B,BAO_0000357,,,9,11481,Inhibitory activity against 5-Lipoxygenase,,Rattus norvegicus,10116.0,
736,,,,RBL-1,CHEMBL615638,B,BAO_0000219,,,8,10864,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,,,
737,,,,RBL-1,CHEMBL615639,B,BAO_0000219,,,8,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,,,
738,,,,RBL-1,CHEMBL615640,B,BAO_0000219,,,8,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,,,
739,,,,,CHEMBL615796,B,BAO_0000019,,,8,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,,,
740,,,,,CHEMBL615845,B,BAO_0000219,,,8,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,,,
741,,,,,CHEMBL615846,B,BAO_0000357,,,8,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,,,
742,,,,RBL-1,CHEMBL615847,B,BAO_0000219,,,8,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,,,
743,,,,,CHEMBL615848,B,BAO_0000357,,,8,11311,The compound was tested for inhibition of isolated 5-Lipoxygenase,,,,
744,,,,,CHEMBL615849,B,BAO_0000019,,,0,11481,Ratio of IC50 against 5-LO and COX,,Rattus norvegicus,10116.0,
745,,,,,CHEMBL615850,B,BAO_0000357,,,8,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,,,
746,,,,,CHEMBL615851,B,BAO_0000357,,,8,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,,,
747,,,,,CHEMBL615852,B,BAO_0000219,,,8,11311,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,,,
748,,,,,CHEMBL615853,F,BAO_0000019,,,8,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,,,
749,Prostate gland,,,,CHEMBL884527,B,BAO_0000357,,,8,4288,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,,,
750,,,,,CHEMBL872871,B,BAO_0000019,,,0,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,Columba livia,8932.0,
751,,,,,CHEMBL615854,B,BAO_0000019,,,0,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,Columba livia,8932.0,
752,,,,,CHEMBL767046,B,BAO_0000019,,,0,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,Columba livia,8932.0,
753,,,,,CHEMBL615855,B,BAO_0000357,,,8,11249,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,,,
754,,,,,CHEMBL615856,F,BAO_0000019,,,9,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,Rattus norvegicus,10116.0,
755,,,,,CHEMBL615857,F,BAO_0000019,,,9,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,Rattus norvegicus,10116.0,
756,,,,,CHEMBL615858,F,BAO_0000019,,,9,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,Rattus norvegicus,10116.0,
757,Hippocampus,,,,CHEMBL615859,B,BAO_0000221,,,8,12416,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,,,
758,,,,,CHEMBL615860,B,BAO_0000357,,,8,16293,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,,,
759,,,,,CHEMBL615861,B,BAO_0000019,,,0,13047,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,Oryctolagus cuniculus,9986.0,
760,,,,,CHEMBL615862,B,BAO_0000019,,,0,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,Oryctolagus cuniculus,9986.0,
761,,,,,CHEMBL615863,B,BAO_0000019,,,0,13047,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,Oryctolagus cuniculus,9986.0,
762,,,,,CHEMBL615864,B,BAO_0000019,,,0,13047,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,Oryctolagus cuniculus,9986.0,
763,Hippocampus,,,,CHEMBL615865,B,BAO_0000221,,,4,10085,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,,
764,Hippocampus,,,,CHEMBL615866,B,BAO_0000221,,,4,10085,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,,
765,Hippocampus,,,,CHEMBL615867,B,BAO_0000221,,,4,10085,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,,
766,,,,,CHEMBL615868,B,BAO_0000249,,,4,9841,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,,,Membranes
767,,,,,CHEMBL615869,B,BAO_0000249,,,5,8822,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,Rattus norvegicus,10116.0,
768,,,,,CHEMBL615870,B,BAO_0000019,,,5,9806,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,Rattus norvegicus,10116.0,
769,,,,,CHEMBL615871,B,BAO_0000019,,,5,9806,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,Rattus norvegicus,10116.0,
770,,,,,CHEMBL615872,B,BAO_0000224,,,4,8868,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,,,
771,Hippocampus,,,,CHEMBL833492,B,BAO_0000221,,,4,9036,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,,,
772,Hippocampus,,,,CHEMBL615873,B,BAO_0000221,,,4,11374,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,,,
773,,,,,CHEMBL615479,B,BAO_0000224,,,4,10881,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,,,
774,,,,,CHEMBL615480,B,BAO_0000019,,,4,8822,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,,,
775,,,,,CHEMBL615481,B,BAO_0000249,,,5,9806,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,Rattus norvegicus,10116.0,
776,,,,,CHEMBL872869,B,BAO_0000019,,,4,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,,
777,,,,,CHEMBL615482,B,BAO_0000019,,,4,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,,
778,Brain,,,,CHEMBL615483,B,BAO_0000221,,,4,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,,
779,Brain,,,,CHEMBL615484,B,BAO_0000221,,,4,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,,
780,,,,,CHEMBL615485,B,BAO_0000019,,,4,8569,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,,,
781,,,,,CHEMBL615486,B,BAO_0000224,,,5,10062,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,Rattus norvegicus,10116.0,
782,,,,,CHEMBL615487,B,BAO_0000224,,,4,4771,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,,,
783,,,,,CHEMBL615488,B,BAO_0000224,,,4,10062,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,,
784,,,,,CHEMBL615489,B,BAO_0000224,,,4,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,,
785,,,,,CHEMBL615389,B,BAO_0000224,,,4,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,,
786,,,,,CHEMBL615390,B,BAO_0000019,,,4,15463,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,,,
787,,,,,CHEMBL615391,B,BAO_0000019,,,4,15463,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,,,
788,,,,,CHEMBL615392,B,BAO_0000224,,,4,9098,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,,,
789,,,,,CHEMBL615393,B,BAO_0000019,,,0,3070,Affinity for 5-hydroxytryptamine 1 receptor,,Rattus norvegicus,10116.0,
790,Brain,,,,CHEMBL615394,B,BAO_0000221,,,4,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,,,
791,Brain,,,,CHEMBL615395,B,BAO_0000221,,,4,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,,
792,,,,,CHEMBL615396,B,BAO_0000224,,,4,6398,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,,,
793,Brain,,,,CHEMBL615397,B,BAO_0000221,,,4,1344,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,,,
794,,,,,CHEMBL615398,B,BAO_0000019,,,4,11963,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,,
795,,,,,CHEMBL615399,B,BAO_0000019,,,0,8908,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,Rattus norvegicus,10116.0,
796,,,,,CHEMBL615400,B,BAO_0000019,,,4,9098,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,,,
797,,,,,CHEMBL615401,B,BAO_0000019,,,5,8841,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,Rattus norvegicus,10116.0,
798,,,,,CHEMBL615402,B,BAO_0000019,,,0,8814,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,Rattus norvegicus,10116.0,
799,,,,,CHEMBL615403,B,BAO_0000019,,,4,11752,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,,,
800,Brain,,,,CHEMBL615404,B,BAO_0000221,,,4,11642,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,,,
801,,,,,CHEMBL615781,B,BAO_0000019,,,4,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,,,
802,Brain,,,,CHEMBL615782,B,BAO_0000220,,,4,9231,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,,,
803,Brain,,,,CHEMBL615783,B,BAO_0000221,,,4,11351,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,,,
804,,,,,CHEMBL873481,B,BAO_0000019,,,0,4639,Compound was tested for binding affinity against 5-HT1 receptor,,,,
805,,,,,CHEMBL615784,B,BAO_0000019,,,0,1205,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,,,
806,,,,,CHEMBL615785,B,BAO_0000357,,,8,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,,,
807,,,,,CHEMBL615786,F,BAO_0000249,,,8,13241,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,,,
808,,,,,CHEMBL615787,F,BAO_0000218,,,8,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,In vivo,,,
809,,,,,CHEMBL615788,F,BAO_0000218,,,8,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,In vivo,,,
810,,,,,CHEMBL767044,F,BAO_0000019,,,8,12438,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,,,
811,,,,,CHEMBL615789,F,BAO_0000218,,,8,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,In vivo,,,
812,,,,,CHEMBL615790,F,BAO_0000218,,,8,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,In vivo,,,
813,,,,,CHEMBL615813,F,BAO_0000019,,,8,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,,,
814,,,,,CHEMBL615814,F,BAO_0000219,,,8,15535,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,,,
815,,,,,CHEMBL615815,F,BAO_0000219,,,8,15535,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,,,
816,,,,,CHEMBL615816,F,BAO_0000219,,,8,15535,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,,,
817,,,,,CHEMBL615817,B,BAO_0000249,,,8,9888,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,,,
818,Hippocampus,,,,CHEMBL615818,B,BAO_0000221,,,8,10085,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,,,
819,Hippocampus,,,,CHEMBL615819,B,BAO_0000221,,,8,10085,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,,,
820,,,,,CHEMBL615820,B,BAO_0000249,,,8,17331,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,,,Membranes
821,Hippocampus,,,,CHEMBL615821,B,BAO_0000221,,,9,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,,Rattus norvegicus,10116.0,
822,Hippocampus,,,,CHEMBL615822,B,BAO_0000221,,,9,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,Rattus norvegicus,10116.0,
823,Hippocampus,,,,CHEMBL615823,B,BAO_0000221,,,8,10845,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,,,
824,Hippocampus,,,,CHEMBL615824,B,BAO_0000221,,,9,10845,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,,Rattus norvegicus,10116.0,
825,Hippocampus,,,,CHEMBL615825,B,BAO_0000221,,,9,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,Rattus norvegicus,10116.0,
826,,,,,CHEMBL615826,B,BAO_0000357,,,8,13730,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,,,
827,,,,,CHEMBL615827,B,BAO_0000249,,,8,13508,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,,,
828,Hippocampus,,,,CHEMBL615828,B,BAO_0000249,,,8,13508,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,,,
829,Hippocampus,,,,CHEMBL615829,B,BAO_0000221,,,8,12073,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,
830,Hippocampus,,,,CHEMBL615830,B,BAO_0000221,,,8,4671,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,,,
831,Hippocampus,,,,CHEMBL615831,B,BAO_0000221,,,8,13631,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,,,
832,,,,,CHEMBL615832,B,BAO_0000357,,,8,12438,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,,,
833,,,,,CHEMBL615833,B,BAO_0000019,,,8,10483,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,,,
834,Hippocampus,,,,CHEMBL615834,B,BAO_0000221,,,8,10483,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,,,
835,,,,,CHEMBL615835,B,BAO_0000249,,,8,12352,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,,,
836,Hippocampus,,,,CHEMBL615836,B,BAO_0000249,,,8,14732,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,,,
837,,,,,CHEMBL615837,B,BAO_0000019,,,9,11049,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,Rattus norvegicus,10116.0,
838,,,,,CHEMBL615838,B,BAO_0000019,,,9,11049,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,Rattus norvegicus,10116.0,
839,,,,,CHEMBL615839,B,BAO_0000249,,,8,13657,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,,,
840,,,,,CHEMBL884525,B,BAO_0000019,,,8,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,,,
841,,,,,CHEMBL615840,B,BAO_0000249,,,8,2014,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,,,
842,Hippocampus,,,,CHEMBL615405,B,BAO_0000221,,,8,3086,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,
843,,,,,CHEMBL615406,B,BAO_0000019,,,8,15854,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,,
844,Hippocampus,,,,CHEMBL615900,B,BAO_0000221,,,8,10922,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,,,
845,Hippocampus,,,,CHEMBL615901,B,BAO_0000221,,,8,13346,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,,,
846,,,,,CHEMBL615902,B,BAO_0000357,,,8,15311,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,,,
847,Hippocampus,,,,CHEMBL615903,B,BAO_0000221,,,8,10922,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,,,
848,,,,,CHEMBL615904,B,BAO_0000357,,,8,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,,,
849,,,,,CHEMBL615905,B,BAO_0000357,,,8,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,,,
850,,,,,CHEMBL615906,B,BAO_0000019,,,8,9742,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,,,
851,,,,,CHEMBL615907,F,BAO_0000019,,,8,9742,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,,,
852,,,,,CHEMBL615908,B,BAO_0000019,,,8,12304,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,,
853,Hippocampus,,,,CHEMBL615909,B,BAO_0000221,,,8,15789,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,,,
854,,,,,CHEMBL615910,B,BAO_0000019,,,8,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,,,
855,,,,,CHEMBL615911,B,BAO_0000019,,,8,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,,,
856,,,,,CHEMBL615912,B,BAO_0000019,,,8,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,,,
857,,,,,CHEMBL615913,B,BAO_0000019,,,8,16693,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,,,
858,,,,,CHEMBL615914,B,BAO_0000357,,,8,13276,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,,
859,Hippocampus,,,,CHEMBL615915,B,BAO_0000221,,,8,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,,,
860,,,,,CHEMBL615916,B,BAO_0000357,,,8,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,,,
861,,,,,CHEMBL615917,B,BAO_0000357,,,8,12443,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,,,
862,,,,,CHEMBL615918,B,BAO_0000357,,,8,13830,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,,
863,Hippocampus,,,,CHEMBL615919,B,BAO_0000249,,,8,14286,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,,,
864,Hippocampus,,,,CHEMBL615920,B,BAO_0000221,,,9,14356,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,Rattus norvegicus,10116.0,
865,,,,,CHEMBL615921,B,BAO_0000357,,,8,15306,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,,,
866,,,,,CHEMBL615922,B,BAO_0000357,,,8,15306,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,,,
867,,,,,CHEMBL881290,F,BAO_0000249,,,9,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,Rattus norvegicus,10116.0,
868,Hippocampus,,,,CHEMBL615923,B,BAO_0000221,,,8,3651,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,,,
869,Hippocampus,,,,CHEMBL615924,F,BAO_0000221,,,8,14331,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,
870,Hippocampus,,,,CHEMBL615925,F,BAO_0000221,,,8,14331,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,
871,,,,,CHEMBL615926,B,BAO_0000357,,,9,14178,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,Rattus norvegicus,10116.0,
872,,,,,CHEMBL615927,B,BAO_0000019,,,9,10639,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,Rattus norvegicus,10116.0,
873,Hippocampus,,,,CHEMBL615928,B,BAO_0000221,,,8,12306,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,,
874,,,,,CHEMBL615929,B,BAO_0000357,,,9,1348,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,Rattus norvegicus,10116.0,
875,Hippocampus,,,,CHEMBL615930,B,BAO_0000221,,,8,13605,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,,,
876,,,,CHO,CHEMBL615931,B,BAO_0000219,,,8,17624,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,
877,,,,CHO,CHEMBL615932,F,BAO_0000219,,,8,17624,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,,
878,,,,CHO,CHEMBL615933,F,BAO_0000219,,,8,17624,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,,
879,,,,,CHEMBL615934,B,BAO_0000357,,,8,15267,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,,,
880,,,,,CHEMBL615935,B,BAO_0000357,,,8,16532,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,,,
881,,,,,CHEMBL615936,F,BAO_0000019,,,8,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,
882,,,,CHO,CHEMBL615937,B,BAO_0000219,,,8,4751,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,,,
883,,,,,CHEMBL615938,B,BAO_0000357,,,8,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,,,
884,,,,,CHEMBL615797,B,BAO_0000357,,,8,3805,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,,,
885,,,,,CHEMBL615798,B,BAO_0000357,,,8,5640,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,
886,,,,,CHEMBL872870,B,BAO_0000357,,,8,6563,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,,,
887,,,,,CHEMBL615799,B,BAO_0000357,,,8,5548,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,,,
888,,,,,CHEMBL615800,B,BAO_0000357,,,8,6347,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,,,
889,,,,HEK293,CHEMBL615801,F,BAO_0000219,,,8,17296,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,,
890,,,,,CHEMBL615802,B,BAO_0000019,,,8,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,,,
891,,,,,CHEMBL615803,B,BAO_0000357,,,8,15740,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,,,
892,,,,,CHEMBL835002,F,BAO_0000019,,,8,5640,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,,,
893,,,,,CHEMBL615804,F,BAO_0000019,,,8,5640,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,,,
894,,,,HeLa,CHEMBL615805,B,BAO_0000219,,,8,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,,,
895,,,,CHO,CHEMBL615806,B,BAO_0000219,,,8,4751,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,,,
896,,,,,CHEMBL615807,B,BAO_0000357,,,9,6491,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,Homo sapiens,9606.0,
897,,,,,CHEMBL615808,B,BAO_0000357,,,8,4707,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,,,
898,,,,,CHEMBL615809,B,BAO_0000357,,,9,13910,Binding affinity against 5-hydroxytryptamine 1A receptor,,Homo sapiens,9606.0,
899,,,,HeLa,CHEMBL615810,B,BAO_0000219,,,8,16190,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,,,
900,,,,,CHEMBL615811,B,BAO_0000357,,,8,16633,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,
901,,,,CHO,CHEMBL615812,B,BAO_0000219,,,8,11898,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,,,
902,,,,CHO,CHEMBL615751,B,BAO_0000219,,,8,11898,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,
903,,,,,CHEMBL615752,B,BAO_0000357,,,8,14331,Binding affinity against human 5-hydroxytryptamine 1A receptor,,,,
904,,,,CHO,CHEMBL615753,B,BAO_0000219,,,8,17624,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,,,
905,,,,CHO,CHEMBL615754,B,BAO_0000219,,,8,17624,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,,,
906,,,,,CHEMBL615755,B,BAO_0000357,,,8,3307,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,,,
907,,,,CHO,CHEMBL615756,B,BAO_0000219,,,9,6563,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,Homo sapiens,9606.0,
908,,,,,CHEMBL615757,B,BAO_0000019,,,8,14165,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,,,
909,,,,,CHEMBL615758,B,BAO_0000357,,,8,5732,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,,,
910,,,,,CHEMBL615759,B,BAO_0000357,,,8,13366,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,,,
911,,,,,CHEMBL615760,B,BAO_0000357,,,8,17626,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,,,
912,,,,HeLa,CHEMBL615761,B,BAO_0000219,,,8,6588,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,,,
913,,,,,CHEMBL872104,B,BAO_0000357,,,8,16209,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,,,
914,,,,,CHEMBL615762,B,BAO_0000357,,,8,15463,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,,
915,,,,,CHEMBL615763,B,BAO_0000357,,,8,15463,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,,
916,,,,,CHEMBL615764,B,BAO_0000357,,,8,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,,,
917,,,,Cell line,CHEMBL615765,B,BAO_0000219,,,8,16245,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,,,
918,,,,,CHEMBL615766,B,BAO_0000019,,,8,16245,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,,,
919,,,,,CHEMBL615767,B,BAO_0000357,,,8,5548,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,,,
920,,,,,CHEMBL615768,B,BAO_0000357,,,8,5548,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,
921,,,,,CHEMBL615769,B,BAO_0000357,,,8,5548,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,
922,,,,,CHEMBL615770,B,BAO_0000357,,,8,6876,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,,,
923,,,,,CHEMBL615771,B,BAO_0000357,,,8,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,
924,,,,,CHEMBL615772,B,BAO_0000357,,,8,17785,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,,,
925,,,,,CHEMBL615773,B,BAO_0000357,,,8,6013,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,
926,,,,,CHEMBL615774,B,BAO_0000357,,,8,5929,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,,,
927,,,,,CHEMBL615775,B,BAO_0000357,,,8,16633,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,
928,,,,,CHEMBL615776,B,BAO_0000357,,,8,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,,,
929,,,,,CHEMBL615777,B,BAO_0000357,,,8,16026,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,
930,,,,,CHEMBL615778,B,BAO_0000219,,,8,12469,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,,,
931,,,,,CHEMBL615779,B,BAO_0000357,,,9,15874,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,Homo sapiens,9606.0,
932,,,,,CHEMBL615780,B,BAO_0000357,,,8,15874,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,,
933,,,,,CHEMBL616298,B,BAO_0000357,,,8,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,,,
934,,,,,CHEMBL616299,B,BAO_0000357,,,8,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,,,
935,,,,CHO-K1,CHEMBL616300,B,BAO_0000219,,,8,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,,,
936,,,,CHO-K1,CHEMBL616301,F,BAO_0000219,,,8,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,,,
937,,,,,CHEMBL616302,B,BAO_0000019,,,8,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,,,
938,,,,,CHEMBL616117,B,BAO_0000019,,,8,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,,,
939,,,,,CHEMBL616118,B,BAO_0000019,,,8,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,,,
940,,,,,CHEMBL616119,B,BAO_0000019,,,8,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,,,
941,,,,HeLa,CHEMBL616120,B,BAO_0000219,,,9,3445,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,Homo sapiens,9606.0,
942,,,,,CHEMBL616121,B,BAO_0000357,,,8,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,,,
943,,,,,CHEMBL616122,B,BAO_0000357,,,8,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,,,
944,,,,,CHEMBL616123,B,BAO_0000357,,,8,17626,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,,,
945,,,,,CHEMBL616124,B,BAO_0000357,,,9,4234,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,Homo sapiens,9606.0,
946,,,,,CHEMBL616125,B,BAO_0000357,,,8,5640,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,,,
947,,,,,CHEMBL616126,B,BAO_0000357,,,8,5272,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,Rattus norvegicus,10116.0,
948,,,,CHO,CHEMBL616127,B,BAO_0000219,,,8,4622,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,,,
949,,,,,CHEMBL616128,B,BAO_0000019,,,8,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,,,
950,,,,,CHEMBL616129,B,BAO_0000357,,,8,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,,,
951,,,,,CHEMBL616130,B,BAO_0000357,,,8,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,,,
952,,,,,CHEMBL616131,B,BAO_0000357,,,8,15267,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,,,
953,,,,HeLa,CHEMBL616132,B,BAO_0000219,,,8,17158,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,,,
954,,,,HeLa,CHEMBL616133,B,BAO_0000219,,,9,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,Homo sapiens,9606.0,
955,,,,,CHEMBL616134,B,BAO_0000357,,,8,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,
956,,,,,CHEMBL616135,B,BAO_0000357,,,8,16532,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,,,
957,,,,,CHEMBL616136,B,BAO_0000357,,,9,2391,Affinity for 5-hydroxytryptamine 1A receptor subtype,,Homo sapiens,9606.0,
958,,,,,CHEMBL616137,B,BAO_0000019,,,8,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,,,
959,,,,,CHEMBL872105,B,BAO_0000019,,,8,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,,,
960,,,,,CHEMBL616138,B,BAO_0000357,,,8,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,,,
961,,,,,CHEMBL616139,B,BAO_0000357,,,9,13051,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,Homo sapiens,9606.0,
962,,,,,CHEMBL616140,F,BAO_0000019,,,8,16026,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,,,
963,,,,,CHEMBL616141,B,BAO_0000019,,,8,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,,,
964,,,,,CHEMBL616142,B,BAO_0000357,,,8,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,
965,,,,,CHEMBL616143,B,BAO_0000357,,,8,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,,,
966,,,,HeLa,CHEMBL616144,B,BAO_0000219,,,8,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,,
967,,,,HeLa,CHEMBL616145,B,BAO_0000219,,,8,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,,,
968,,,,HeLa,CHEMBL616012,B,BAO_0000219,,,8,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,,
969,,,,HeLa,CHEMBL616013,B,BAO_0000219,,,8,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,,
970,,,,,CHEMBL616014,F,BAO_0000019,,,8,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,,
971,,,,,CHEMBL616015,F,BAO_0000019,,,8,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,,
972,,,,,CHEMBL616016,F,BAO_0000019,,,8,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,,
973,,,,,CHEMBL616017,F,BAO_0000218,,,8,16394,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,In vivo,,,
974,,,,,CHEMBL616018,B,BAO_0000019,,,8,16394,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,,,
975,,,,,CHEMBL616019,F,BAO_0000019,,,8,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,,,
976,,,,,CHEMBL616020,F,BAO_0000019,,,8,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,,,
977,,,,,CHEMBL858018,B,BAO_0000357,,,8,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,,,
978,,,,HEK293,CHEMBL616021,F,BAO_0000219,,,8,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,,
979,,,,,CHEMBL616022,F,BAO_0000019,,,8,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,,,
980,,,,,CHEMBL616023,F,BAO_0000019,,,8,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,,,
981,,,,,CHEMBL616024,F,BAO_0000019,,,8,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,,,
982,,,,,CHEMBL616025,F,BAO_0000019,,,8,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,,,
983,,,,CHO,CHEMBL616026,F,BAO_0000219,,,8,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,,
984,,,,,CHEMBL616027,F,BAO_0000019,,,8,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,,,
985,,,,,CHEMBL616028,F,BAO_0000019,,,9,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,Homo sapiens,9606.0,
986,,,,,CHEMBL616029,F,BAO_0000019,,,9,3445,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,Homo sapiens,9606.0,
987,,,,CHO,CHEMBL616030,B,BAO_0000219,,,8,4316,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,,,
988,,,,,CHEMBL616031,B,BAO_0000019,,,8,4316,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,,,
989,,,,,CHEMBL616032,F,BAO_0000019,,,9,15180,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,Homo sapiens,9606.0,
990,,,,,CHEMBL616033,F,BAO_0000019,,,9,15180,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,Homo sapiens,9606.0,
991,,,,,CHEMBL616034,F,BAO_0000019,,,8,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,
992,,,,,CHEMBL616035,F,BAO_0000019,,,8,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,
993,,,,,CHEMBL616036,F,BAO_0000019,,,8,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,,,
994,,,,,CHEMBL616037,F,BAO_0000019,,,8,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,
995,,,,,CHEMBL616038,F,BAO_0000019,,,8,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,
996,,,,,CHEMBL616039,F,BAO_0000019,,,8,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,
997,,,,,CHEMBL616040,F,BAO_0000019,,,8,15042,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,,,
998,,,,HeLa,CHEMBL616041,F,BAO_0000219,,,9,15180,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,Homo sapiens,9606.0,
999,,,,HeLa,CHEMBL616042,F,BAO_0000219,,,9,15180,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,Homo sapiens,9606.0,
1000,,,,HeLa,CHEMBL616043,F,BAO_0000219,,,9,15180,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,Homo sapiens,9606.0,
1001,,,,,CHEMBL616044,F,BAO_0000019,,,8,16245,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,,,
1002,,,,,CHEMBL616045,F,BAO_0000019,,,8,16026,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,,
1003,,,,HEK293,CHEMBL616046,F,BAO_0000219,,,8,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,,
1004,,,,CHO,CHEMBL616047,F,BAO_0000219,,,8,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,,,
1005,,,,CHO,CHEMBL616048,F,BAO_0000219,,,8,2759,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,,,
1006,,,,CHO,CHEMBL616049,F,BAO_0000219,,,9,2759,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,Homo sapiens,9606.0,
1007,,,,CHO,CHEMBL616050,F,BAO_0000219,,,8,2759,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,,,
1008,,,,,CHEMBL616051,F,BAO_0000219,,,8,15419,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,,,
1009,,,,,CHEMBL616212,F,BAO_0000219,,,8,15419,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,,,
1010,,,,,CHEMBL616213,F,BAO_0000019,,,8,16026,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,,
1011,,,,,CHEMBL616214,B,BAO_0000219,,,8,1414,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,In vitro,,,
1012,,,,,CHEMBL616215,B,BAO_0000219,,,8,1414,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,In vitro,,,
1013,,,,,CHEMBL616216,B,BAO_0000357,,,8,12861,Binding activity radioligand.,,,,
1014,,,,,CHEMBL616217,B,BAO_0000019,,,8,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,,
1015,,,,,CHEMBL616218,B,BAO_0000357,,,8,5104,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,,,
1016,,,,,CHEMBL616219,B,BAO_0000357,,,8,5105,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,,,
1017,,,,,CHEMBL616220,B,BAO_0000357,,,8,16312,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,,,
1018,,,,,CHEMBL833493,B,BAO_0000357,,,9,15180,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,Homo sapiens,9606.0,
1019,,,,,CHEMBL616221,B,BAO_0000357,,,8,5033,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,,,
1020,,,,CHO,CHEMBL616222,B,BAO_0000219,,,9,16909,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,Homo sapiens,9606.0,
1021,,,,,CHEMBL616223,F,BAO_0000019,,,8,2590,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,,,
1022,,,,,CHEMBL616224,F,BAO_0000019,,,8,2590,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,,,
1023,,,,,CHEMBL616225,B,BAO_0000019,,,8,16394,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,,,
1024,,,,HEK293,CHEMBL616226,B,BAO_0000219,,,9,4540,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,Homo sapiens,9606.0,
1025,,,,HEK293,CHEMBL616227,B,BAO_0000219,,,8,17296,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,,,
1026,,,,HEK293,CHEMBL616228,B,BAO_0000219,,,8,17296,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,,,
1027,,,,HEK293,CHEMBL616229,B,BAO_0000219,,,8,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,,,
1028,,,,HEK293,CHEMBL616230,B,BAO_0000219,,,8,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,,,
1029,,,,HEK293,CHEMBL616231,B,BAO_0000219,,,8,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,,,
1030,,,,,CHEMBL616232,B,BAO_0000357,,,8,6166,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,,,
1031,,,,HEK293,CHEMBL616233,B,BAO_0000219,,,8,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,,,
1032,,,,HEK293,CHEMBL857973,B,BAO_0000219,,,8,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,,,
1033,,,,,CHEMBL616234,B,BAO_0000219,,,8,15316,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,,,
1034,,,,,CHEMBL616235,B,BAO_0000357,,,8,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,,,
1035,,,,HeLa,CHEMBL616236,B,BAO_0000219,,,8,14727,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,,,
1036,,,,,CHEMBL616237,B,BAO_0000019,,,8,14727,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,,,
1037,,,,HEK293,CHEMBL616238,B,BAO_0000219,,,8,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,,,
1038,,,,HEK293,CHEMBL616239,B,BAO_0000219,,,8,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,,,
1039,,,,,CHEMBL616240,B,BAO_0000219,,,8,16429,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,,,
1040,,,,HeLa,CHEMBL616241,B,BAO_0000219,,,9,15042,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,Homo sapiens,9606.0,
1041,,,,HEK293,CHEMBL616242,B,BAO_0000219,,,8,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,,,
1042,,,,HEK293,CHEMBL616243,B,BAO_0000219,,,8,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,,,
1043,,,,,CHEMBL616244,B,BAO_0000357,,,9,17200,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,,,
1044,,,,,CHEMBL616245,B,BAO_0000357,,,9,13051,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,Homo sapiens,9606.0,
1045,,,,,CHEMBL616246,B,BAO_0000357,,,8,5486,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,,,
1046,,,,,CHEMBL616247,B,BAO_0000357,,,8,5254,Binding affinity against 5-HT1D receptor,,,,
1047,,,,,CHEMBL616248,B,BAO_0000357,,,8,5254,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,
1048,,,,,CHEMBL616249,B,BAO_0000357,,,8,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,,
1049,,,,,CHEMBL616250,B,BAO_0000357,,,8,13506,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,Homo sapiens,9606.0,
1050,,,,,CHEMBL616251,B,BAO_0000357,,,8,15267,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,,,
1051,,,,,CHEMBL616252,F,BAO_0000218,,,8,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,In vivo,,,
1052,,,,,CHEMBL616253,F,BAO_0000218,,,8,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,In vivo,,,
1053,,,,,CHEMBL616254,F,BAO_0000218,,,8,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,In vivo,,,
1054,,,,,CHEMBL616255,F,BAO_0000218,,,9,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,Mus musculus,10090.0,
1055,,,,,CHEMBL832872,F,BAO_0000218,,,9,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,Mus musculus,10090.0,
1056,,,,,CHEMBL616256,F,BAO_0000218,,,9,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,Mus musculus,10090.0,
1057,,,,,CHEMBL616257,F,BAO_0000218,,,9,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,Mus musculus,10090.0,
1058,,,,,CHEMBL616258,F,BAO_0000218,,,9,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,Mus musculus,10090.0,
1059,,,,,CHEMBL616384,F,BAO_0000218,,,9,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,Mus musculus,10090.0,
1060,Hippocampus,,,,CHEMBL616385,B,BAO_0000221,,,8,10297,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,,,
1061,,,,,CHEMBL616386,B,BAO_0000357,,,8,13704,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,,,
1062,Hippocampus,,,,CHEMBL616387,B,BAO_0000221,,,9,10297,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,Mus musculus,10090.0,
1063,Hippocampus,,,,CHEMBL616388,B,BAO_0000221,,,8,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,,,
1064,Hippocampus,,,,CHEMBL616389,B,BAO_0000221,,,9,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,Mus musculus,10090.0,
1065,Hippocampus,,,,CHEMBL616390,B,BAO_0000221,,,8,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,,,
1066,,,,,CHEMBL616391,B,BAO_0000357,,,8,217,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,,,
1067,Hippocampus,,,,CHEMBL616392,B,BAO_0000221,,,9,10297,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,Mus musculus,10090.0,
1068,,,,,CHEMBL616393,B,BAO_0000357,,,8,4921,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,Sus scrofa,9823.0,
1069,,,,,CHEMBL616394,B,BAO_0000357,,,8,4921,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,Sus scrofa,9823.0,
1070,,,,,CHEMBL616395,B,BAO_0000019,,,8,4996,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,Sus scrofa,9823.0,
1071,,,,,CHEMBL616396,B,BAO_0000357,,,8,12918,Compound was evaluated for the binding affinity at 5- HT1A receptor,,Sus scrofa,9823.0,
1072,,,,,CHEMBL872907,B,BAO_0000019,,,8,5333,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,Sus scrofa,9823.0,
1073,,,,,CHEMBL616397,B,BAO_0000019,,,8,4437,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,Sus scrofa,9823.0,
1074,,,,,CHEMBL616398,B,BAO_0000019,,,8,1742,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,Sus scrofa,9823.0,
1075,,,,,CHEMBL616399,B,BAO_0000357,,,8,16688,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,Sus scrofa,9823.0,
1076,,,,,CHEMBL857065,B,BAO_0000357,,,8,12861,Binding activity radioligand.,,Sus scrofa,9823.0,
1077,,,,,CHEMBL616400,B,BAO_0000019,,,8,12861,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,Sus scrofa,9823.0,
1078,,,,,CHEMBL616401,B,BAO_0000019,,,8,12861,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,Sus scrofa,9823.0,
1079,,,,,CHEMBL616402,B,BAO_0000019,,,8,12490,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,,,
1080,,,,,CHEMBL616403,B,BAO_0000019,,,8,11828,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,Sus scrofa,9823.0,
1081,Hippocampus,,,,CHEMBL616404,B,BAO_0000221,,,8,11866,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,,Sus scrofa,9823.0,
1082,,,,,CHEMBL616405,B,BAO_0000249,,,8,12827,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,Sus scrofa,9823.0,
1083,,,,,CHEMBL616406,B,BAO_0000019,,,8,12918,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,Sus scrofa,9823.0,
1084,,,,,CHEMBL616407,F,BAO_0000019,,,8,12919,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,Sus scrofa,9823.0,
1085,,,,,CHEMBL616408,B,BAO_0000019,,,8,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,Oryctolagus cuniculus,9986.0,
1086,,,,,CHEMBL616409,B,BAO_0000249,,,9,15796,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,Rattus norvegicus,10116.0,
1087,Hippocampus,,,,CHEMBL616410,B,BAO_0000221,,,9,3651,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",,Rattus norvegicus,10116.0,
1088,,,,,CHEMBL616411,B,BAO_0000357,,,8,188,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,,,
1089,,,,,CHEMBL616412,F,BAO_0000249,,,9,16616,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,Rattus norvegicus,10116.0,Membranes
1090,Hippocampus,,,,CHEMBL616413,F,BAO_0000249,,,9,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,Rattus norvegicus,10116.0,Membranes
1091,Hippocampus,,,,CHEMBL616414,B,BAO_0000221,,,8,12306,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,,
1092,Hippocampus,,,,CHEMBL616415,B,BAO_0000221,,,9,17167,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,,Rattus norvegicus,10116.0,
1093,,,,,CHEMBL616416,B,BAO_0000019,,,8,14776,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,,,
1094,,,,,CHEMBL616417,B,BAO_0000357,,,8,12158,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,,,
1095,,,,,CHEMBL616418,B,BAO_0000357,,,8,13481,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,,,
1096,,,,,CHEMBL616419,B,BAO_0000219,,,8,13427,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,In vitro,,,
1097,,,,,CHEMBL616420,B,BAO_0000357,,,8,10210,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,,,
1098,,,,,CHEMBL616421,B,BAO_0000249,,,8,10205,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,,,Membranes
1099,,,,,CHEMBL616422,B,BAO_0000249,,,8,10205,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,,,Membranes
1100,,,,,CHEMBL616423,B,BAO_0000249,,,8,10205,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,,,Membranes
1101,,,,,CHEMBL616424,B,BAO_0000357,,,9,12280,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,Rattus norvegicus,10116.0,
1102,,,,,CHEMBL616425,B,BAO_0000357,,,8,17386,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,,,
1103,,,,,CHEMBL616426,B,BAO_0000357,,,8,13654,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,,,
1104,Hippocampus,,,,CHEMBL616427,B,BAO_0000221,,,8,14423,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,,,
1105,Hippocampus,,,,CHEMBL616428,B,BAO_0000221,,,8,15412,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,,,
1106,Hippocampus,,,,CHEMBL616290,B,BAO_0000221,,,8,12073,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,
1107,,,,,CHEMBL616052,B,BAO_0000357,,,9,4101,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,Rattus norvegicus,10116.0,
1108,,,,,CHEMBL616053,B,BAO_0000357,,,8,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,,,
1109,,,,,CHEMBL616054,B,BAO_0000249,,,8,6238,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,,,
1110,,,,,CHEMBL616055,B,BAO_0000357,,,8,16273,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,
1111,,,,,CHEMBL616056,B,BAO_0000357,,,8,11139,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,,,
1112,,,,,CHEMBL616057,B,BAO_0000019,,,8,16796,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,,,
1113,Brain,,,,CHEMBL616058,B,BAO_0000221,,,9,9548,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,Rattus norvegicus,10116.0,
1114,Brain,,,,CHEMBL616059,B,BAO_0000221,,,8,10381,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,,
1115,,,,,CHEMBL616060,B,BAO_0000249,,,8,13408,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,,,
1116,Hippocampus,,,,CHEMBL616061,B,BAO_0000221,,,9,13825,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,,Rattus norvegicus,10116.0,
1117,Hippocampus,,,,CHEMBL616062,B,BAO_0000221,,,8,11147,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,,,
1118,,,,,CHEMBL616063,B,BAO_0000249,,,8,10552,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,,,
1119,Striatum,,,,CHEMBL616064,B,BAO_0000249,,,8,10552,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,,,
1120,,,,,CHEMBL616065,B,BAO_0000249,,,9,17136,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,,Rattus norvegicus,10116.0,Membranes
1121,,,,,CHEMBL616066,B,BAO_0000249,,,9,5778,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,,Rattus norvegicus,10116.0,Membranes
1122,Hippocampus,,,,CHEMBL616067,B,BAO_0000221,,,8,13481,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,
1123,Hippocampus,,,,CHEMBL616068,B,BAO_0000221,,,8,13481,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,,,
1124,Hippocampus,,,,CHEMBL616069,B,BAO_0000221,,,8,13630,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,,,
1125,,,,,CHEMBL616070,B,BAO_0000249,,,8,16245,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,,
1126,Hippocampus,,,,CHEMBL616071,B,BAO_0000221,,,8,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,,,
1127,Hippocampus,,,,CHEMBL616072,B,BAO_0000221,,,8,14509,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,,,
1128,Hippocampus,,,,CHEMBL616073,B,BAO_0000221,,,8,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,,,
1129,Hippocampus,,,,CHEMBL616074,B,BAO_0000221,,,8,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,,,
1130,,,,,CHEMBL616075,B,BAO_0000019,,,8,14256,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,,,
1131,,,,,CHEMBL616076,B,BAO_0000357,,,8,11139,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,,,
1132,,,,,CHEMBL616077,B,BAO_0000019,,,9,11047,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,Rattus norvegicus,10116.0,
1133,,,,,CHEMBL616078,B,BAO_0000019,,,9,11047,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,Rattus norvegicus,10116.0,
1134,,,,,CHEMBL616079,B,BAO_0000019,,,9,11047,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,Rattus norvegicus,10116.0,
1135,,,,CHO-K1,CHEMBL616080,B,BAO_0000219,,,9,2395,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,Rattus norvegicus,10116.0,
1136,,,,,CHEMBL616081,B,BAO_0000357,,,8,9699,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,
1137,Hippocampus,,,,CHEMBL616082,B,BAO_0000221,,,9,12028,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,,Rattus norvegicus,10116.0,
1138,Hippocampus,,,,CHEMBL616083,B,BAO_0000221,,,8,12028,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,,,
1139,,,,,CHEMBL616084,B,BAO_0000019,,,8,5815,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,,
1140,,,,,CHEMBL616085,B,BAO_0000019,,,8,16616,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,,,
1141,,,,,CHEMBL616086,B,BAO_0000019,,,8,5815,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,,,
1142,Hippocampus,,,,CHEMBL616087,B,BAO_0000221,,,8,2761,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,,,
1143,,,,,CHEMBL616088,B,BAO_0000357,,,8,13133,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,,,
1144,,,,,CHEMBL616089,B,BAO_0000019,,,8,10444,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,,,
1145,,,,,CHEMBL616090,B,BAO_0000357,,,9,13278,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,Rattus norvegicus,10116.0,
1146,,,,,CHEMBL616091,B,BAO_0000357,,,8,15874,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,,
1147,Striatum,,,,CHEMBL616092,B,BAO_0000249,,,8,10552,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,,,Membranes
1148,,,,,CHEMBL616093,B,BAO_0000357,,,8,11130,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,,,
1149,,,,,CHEMBL616094,B,BAO_0000218,,,8,11130,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),In vivo,,,
1150,Brain,,,,CHEMBL616095,B,BAO_0000221,,,8,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,,,
1151,,,,,CHEMBL616096,B,BAO_0000357,,,9,13670,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,Rattus norvegicus,10116.0,
1152,,,,,CHEMBL616097,B,BAO_0000249,,,8,9888,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,,,
1153,,,,,CHEMBL616098,B,BAO_0000249,,,9,3678,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,,Rattus norvegicus,10116.0,Membranes
1154,Hippocampus,,,,CHEMBL616099,B,BAO_0000221,,,8,11332,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,,,
1155,Hippocampus,,,,CHEMBL616100,B,BAO_0000221,,,8,11332,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,,,
1156,,,,,CHEMBL616101,B,BAO_0000357,,,8,1185,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,,,
1157,,,,,CHEMBL616102,B,BAO_0000249,,,8,2014,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,,,
1158,,,,,CHEMBL616103,B,BAO_0000357,,,8,1185,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,,,
1159,,,,,CHEMBL616104,B,BAO_0000019,,,8,14429,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,,,
1160,,,,,CHEMBL616105,B,BAO_0000019,,,8,16288,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,,,
1161,,,,,CHEMBL616106,B,BAO_0000019,,,9,5432,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,Rattus norvegicus,10116.0,
1162,,,,,CHEMBL616107,B,BAO_0000019,,,8,14429,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,,,
1163,,,,,CHEMBL616108,B,BAO_0000357,,,8,13672,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,,,
1164,Hippocampus,,,,CHEMBL616109,B,BAO_0000221,,,8,11296,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,,
1165,,,,,CHEMBL616110,B,BAO_0000357,,,8,11296,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,,,
1166,,,,CHO,CHEMBL616111,B,BAO_0000219,,,8,14749,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,,,
1167,,,,,CHEMBL616112,B,BAO_0000019,,,8,15086,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,,,
1168,Hippocampus,,,,CHEMBL616113,B,BAO_0000221,,,8,13462,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,,,
1169,,,,,CHEMBL616114,B,BAO_0000019,,,8,15363,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,,,
1170,,,,,CHEMBL616115,B,BAO_0000019,,,8,15363,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,,,
1171,,,,,CHEMBL616116,B,BAO_0000357,,,8,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,,,
1172,Brain,,,,CHEMBL615844,B,BAO_0000221,,,8,12816,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,,,
1173,Hippocampus,,,,CHEMBL615939,B,BAO_0000221,,,8,13542,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,,
1174,,,,,CHEMBL615940,B,BAO_0000019,,,8,13308,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,,,
1175,Hippocampus,,,,CHEMBL615941,B,BAO_0000221,,,8,13541,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,,,
1176,Hippocampus,,,,CHEMBL615942,B,BAO_0000221,,,8,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,,,
1177,Hippocampus,,,,CHEMBL615943,B,BAO_0000221,,,8,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,,,
1178,Hippocampus,,,,CHEMBL615944,B,BAO_0000221,,,8,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,,,
1179,Hippocampus,,,,CHEMBL615945,B,BAO_0000221,,,8,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,,,
1180,Hippocampus,,,,CHEMBL615946,B,BAO_0000221,,,8,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,,,
1181,Hippocampus,,,,CHEMBL615947,B,BAO_0000221,,,8,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,,,
1182,Hippocampus,,,,CHEMBL615948,B,BAO_0000221,,,8,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,,,
1183,Hippocampus,,,,CHEMBL615949,B,BAO_0000221,,,8,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,,,
1184,Hippocampus,,,,CHEMBL615950,B,BAO_0000221,,,8,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,,,
1185,Hippocampus,,,,CHEMBL615951,B,BAO_0000221,,,8,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,,,
1186,Hippocampus,,,,CHEMBL615952,B,BAO_0000221,,,8,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,,,
1187,Hippocampus,,,,CHEMBL615953,B,BAO_0000221,,,8,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,,,
1188,Hippocampus,,,,CHEMBL615954,B,BAO_0000221,,,8,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,,,
1189,Hippocampus,,,,CHEMBL615955,B,BAO_0000221,,,9,10058,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,Rattus norvegicus,10116.0,
1190,Hippocampus,,,,CHEMBL615956,B,BAO_0000221,,,8,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,,,
1191,Hippocampus,,,,CHEMBL615957,B,BAO_0000221,,,8,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,,,
1192,,,,,CHEMBL615958,B,BAO_0000019,,,8,12879,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,,,
1193,,,,,CHEMBL615959,B,BAO_0000019,,,8,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,,,
1194,,,,,CHEMBL615960,B,BAO_0000019,,,8,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,,,
1195,,,,,CHEMBL615961,B,BAO_0000019,,,8,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,,,
1196,Brain,,,,CHEMBL615962,B,BAO_0000221,,,8,9548,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,,
1197,,,,,CHEMBL615963,B,BAO_0000019,,,8,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,,,
1198,,,,,CHEMBL615964,B,BAO_0000019,,,8,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,,,
1199,,,,,CHEMBL615965,B,BAO_0000019,,,8,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,,,
1200,,,,CHO,CHEMBL615966,B,BAO_0000219,,,8,13248,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,,,
1201,,,,,CHEMBL615967,B,BAO_0000249,,,8,3147,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,,,
1202,,,,,CHEMBL615968,B,BAO_0000019,,,8,13949,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,,,
1203,,,,CHO,CHEMBL615969,B,BAO_0000218,,,8,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,,,
1204,,,,,CHEMBL615970,B,BAO_0000218,,,8,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,,,
1205,,,,,CHEMBL615971,B,BAO_0000357,,,9,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,Rattus norvegicus,10116.0,
1206,,,,,CHEMBL615972,B,BAO_0000249,,,8,15535,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,,Membranes
1207,,,,,CHEMBL615973,B,BAO_0000249,,,8,15535,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,,,
1208,,,,,CHEMBL615974,B,BAO_0000249,,,8,15535,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,,,
1209,,,,CHO,CHEMBL615975,B,BAO_0000219,,,9,16372,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,Homo sapiens,9606.0,
1210,,,,,CHEMBL615976,B,BAO_0000249,,,8,14608,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,,,
1211,Hippocampus,,,,CHEMBL872106,B,BAO_0000221,,,9,4795,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,,Rattus norvegicus,10116.0,
1212,,,,,CHEMBL615977,B,BAO_0000357,,,8,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,,
1213,,,,,CHEMBL615978,B,BAO_0000357,,,8,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,,,
1214,,,,,CHEMBL616166,B,BAO_0000357,,,8,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,,,
1215,,,,,CHEMBL616167,B,BAO_0000357,,,8,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,,,
1216,,,,,CHEMBL616168,B,BAO_0000357,,,8,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,,,
1217,,,,,CHEMBL616169,B,BAO_0000357,,,8,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,,,
1218,,,,,CHEMBL616170,B,BAO_0000357,,,8,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,,,
1219,,,,,CHEMBL616171,B,BAO_0000357,,,8,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,,,
1220,,,,,CHEMBL616172,B,BAO_0000357,,,8,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,,,
1221,,,,,CHEMBL616173,B,BAO_0000357,,,8,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,,,
1222,,,,,CHEMBL616174,B,BAO_0000357,,,8,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,,,
1223,,,,,CHEMBL616175,B,BAO_0000357,,,8,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,,,
1224,,,,,CHEMBL616176,B,BAO_0000357,,,8,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,,,
1225,,,,,CHEMBL616177,B,BAO_0000357,,,8,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,,,
1226,,,,,CHEMBL616178,B,BAO_0000357,,,8,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,,,
1227,,,,,CHEMBL616179,B,BAO_0000019,,,8,9742,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,,,
1228,,,,,CHEMBL616180,B,BAO_0000357,,,8,12073,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,,,
1229,,,,,CHEMBL616181,B,BAO_0000357,,,8,4101,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,,,
1230,,,,,CHEMBL616182,B,BAO_0000019,,,8,15360,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,,,
1231,Hippocampus,,,,CHEMBL616183,B,BAO_0000221,,,8,11576,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,,
1232,,,,,CHEMBL615874,B,BAO_0000019,,,8,5834,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,,,
1233,,,,CHO-K1,CHEMBL615875,B,BAO_0000219,,,9,2395,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,Rattus norvegicus,10116.0,
1234,,,,,CHEMBL615876,B,BAO_0000019,,,8,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,,,
1235,,,,,CHEMBL615877,B,BAO_0000019,,,8,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,,,
1236,,,,,CHEMBL615878,B,BAO_0000357,,,8,3967,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,,,
1237,,,,,CHEMBL615879,B,BAO_0000357,,,8,12884,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,,,
1238,,,,,CHEMBL615880,B,BAO_0000357,,,8,2343,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,,,
1239,,,,,CHEMBL615881,B,BAO_0000019,,,8,11511,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,,,
1240,,,,,CHEMBL615882,B,BAO_0000019,,,9,11511,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,Rattus norvegicus,10116.0,
1241,,,,,CHEMBL615883,F,BAO_0000218,,,8,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,In vivo,,,
1242,,,,,CHEMBL615884,F,BAO_0000218,,,8,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),In vivo,,,
1243,,,,,CHEMBL615885,F,BAO_0000218,,,8,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),In vivo,,,
1244,,,,,CHEMBL615886,F,BAO_0000218,,,8,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),In vivo,,,
1245,,,,,CHEMBL615887,F,BAO_0000218,,,8,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),In vivo,,,
1246,,,,,CHEMBL615888,F,BAO_0000218,,,8,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),In vivo,,,
1247,,,,,CHEMBL615889,F,BAO_0000218,,,8,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),In vivo,,,
1248,,,,,CHEMBL615890,F,BAO_0000218,,,8,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),In vivo,,,
1249,,,,,CHEMBL615891,F,BAO_0000218,,,8,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),In vivo,,,
1250,,,,,CHEMBL615892,F,BAO_0000218,,,8,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),In vivo,,,
1251,,,,,CHEMBL615893,F,BAO_0000218,,,8,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),In vivo,,,
1252,,,,,CHEMBL615894,F,BAO_0000218,,,8,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),In vivo,,,
1253,,,,,CHEMBL615895,F,BAO_0000218,,,8,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),In vivo,,,
1254,,,,,CHEMBL615896,F,BAO_0000218,,,8,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),In vivo,,,
1255,,,,,CHEMBL615897,F,BAO_0000218,,,8,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,In vivo,,,
1256,,,,,CHEMBL615898,F,BAO_0000249,,,9,16616,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,Rattus norvegicus,10116.0,Membranes
1257,,,,,CHEMBL615899,B,BAO_0000019,,,8,16796,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,,,
1258,,,,,CHEMBL616291,B,BAO_0000019,,,8,16796,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,,,
1259,,,,,CHEMBL616292,B,BAO_0000357,,,8,15629,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,,,
1260,,,,,CHEMBL616293,F,BAO_0000249,,,8,13241,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,,,
1261,Hippocampus,,,,CHEMBL616294,B,BAO_0000221,,,8,12073,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,
1262,Hippocampus,,,,CHEMBL616295,B,BAO_0000249,,,8,14286,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,,,
1263,Brain,,,,CHEMBL616296,B,BAO_0000221,,,8,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,,,
1264,,,,,CHEMBL616297,F,BAO_0000019,,,8,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,,,
1265,,,,,CHEMBL616605,F,BAO_0000019,,,8,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,,,
1266,,,,,CHEMBL616606,F,BAO_0000019,,,8,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,,,
1267,,,,,CHEMBL616607,F,BAO_0000019,,,8,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,,,
1268,,,,,CHEMBL616608,F,BAO_0000019,,,8,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,,,
1269,,,,,CHEMBL616609,F,BAO_0000019,,,8,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,,,
1270,,,,,CHEMBL616610,F,BAO_0000019,,,9,13630,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,Rattus norvegicus,10116.0,
1271,,,,,CHEMBL616611,F,BAO_0000019,,,8,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,,,
1272,,,,,CHEMBL616612,F,BAO_0000019,,,8,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,,,
1273,,,,,CHEMBL616613,F,BAO_0000019,,,8,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,,,
1274,,,,,CHEMBL616614,F,BAO_0000019,,,8,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,,,
1275,,,,,CHEMBL616615,F,BAO_0000019,,,8,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,,,
1276,,,,,CHEMBL616616,F,BAO_0000019,,,8,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,,,
1277,,,,,CHEMBL616617,F,BAO_0000019,,,8,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,,,
1278,,,,,CHEMBL616618,F,BAO_0000019,,,8,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,,,
1279,,,,,CHEMBL616619,F,BAO_0000019,,,8,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,,,
1280,,,,,CHEMBL616620,F,BAO_0000019,,,8,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,,,
1281,,,,,CHEMBL616621,F,BAO_0000019,,,8,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,,,
1282,,,,,CHEMBL616622,F,BAO_0000019,,,8,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,,,
1283,,,,,CHEMBL616146,F,BAO_0000019,,,8,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,,,
1284,,,,,CHEMBL832873,F,BAO_0000019,,,8,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,,,
1285,,,,,CHEMBL616147,F,BAO_0000019,,,8,13630,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,,,
1286,,,,,CHEMBL872872,F,BAO_0000019,,,8,13630,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,,,
1287,,,,,CHEMBL616148,F,BAO_0000019,,,8,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,,,
1288,Hippocampus,,,,CHEMBL616149,B,BAO_0000221,,,8,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,,,
1289,Hippocampus,,,,CHEMBL616150,B,BAO_0000221,,,8,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,,,
1290,,,,,CHEMBL616151,B,BAO_0000249,,,9,14331,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,,Rattus norvegicus,10116.0,Membranes
1291,Hippocampus,,,,CHEMBL872873,B,BAO_0000221,,,8,15260,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,,,
1292,Hippocampus,,,,CHEMBL616670,B,BAO_0000221,,,8,15260,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,,,
1293,Hippocampus,,,,CHEMBL616671,B,BAO_0000221,,,8,15260,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,,,
1294,,,,,CHEMBL884861,F,BAO_0000249,,,9,16616,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,Rattus norvegicus,10116.0,
1295,,,,,CHEMBL616672,B,BAO_0000357,,,8,15629,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,,,
1296,,,,,CHEMBL616673,B,BAO_0000019,,,8,15086,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,,,
1297,,,,,CHEMBL616674,F,BAO_0000019,,,8,5717,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,,,
1298,,,,,CHEMBL616675,B,BAO_0000357,,,8,12652,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,,,
1299,Hippocampus,,,,CHEMBL616676,B,BAO_0000221,,,8,14608,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,,,
1300,Hippocampus,,,,CHEMBL616677,B,BAO_0000221,,,8,12306,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,,
1301,Hippocampus,,,,CHEMBL616678,B,BAO_0000221,,,8,12306,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,,
1302,,,,,CHEMBL616679,B,BAO_0000357,,,9,15247,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,Rattus norvegicus,10116.0,
1303,Hippocampus,,,,CHEMBL616680,B,BAO_0000221,,,8,17529,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,,,
1304,Hippocampus,,,,CHEMBL616681,B,BAO_0000221,,,8,14826,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,
1305,Hippocampus,,,,CHEMBL616682,B,BAO_0000221,,,8,14826,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,
1306,Hippocampus,,,,CHEMBL616683,B,BAO_0000221,,,8,13241,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,,
1307,Hippocampus,,,,CHEMBL616684,B,BAO_0000221,,,8,14093,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,,,
1308,Hippocampus,,,,CHEMBL616685,B,BAO_0000221,,,8,14093,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,,,
1309,Brain,,,,CHEMBL616686,B,BAO_0000221,,,8,14442,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,,,
1310,,,,,CHEMBL616687,B,BAO_0000357,,,8,9919,Affinity for 5-hydroxytryptamine 1A receptor site,,,,
1311,,,,,CHEMBL616688,B,BAO_0000357,,,8,9919,Affinity for 5-hydroxytryptamine 1A receptor site,,,,
1312,Hippocampus,,,,CHEMBL616689,B,BAO_0000221,,,8,11440,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,,,
1313,,,,,CHEMBL616690,B,BAO_0000357,,,8,11257,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,,,
1314,,,,,CHEMBL616691,B,BAO_0000357,,,8,10330,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,,,
1315,Hippocampus,,,,CHEMBL616692,B,BAO_0000221,,,9,17331,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,,Rattus norvegicus,10116.0,
1316,,,,,CHEMBL616693,B,BAO_0000249,,,8,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,,,
1317,,,,,CHEMBL616694,B,BAO_0000019,,,9,12058,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,Rattus norvegicus,10116.0,
1318,Hippocampus,,,,CHEMBL616695,B,BAO_0000221,,,8,9699,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,,,
1319,,,,,CHEMBL616696,B,BAO_0000357,,,8,9547,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,,,
1320,,,,,CHEMBL616697,B,BAO_0000357,,,8,10330,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,,,
1321,,,,,CHEMBL616698,B,BAO_0000357,,,8,14331,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,,,
1322,,,,,CHEMBL616949,B,BAO_0000019,,,9,14060,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,Rattus norvegicus,10116.0,
1323,Hippocampus,,,,CHEMBL616950,B,BAO_0000221,,,8,14744,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,,,
1324,,,,,CHEMBL832875,B,BAO_0000357,,,8,13506,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,,,
1325,Brain,,,,CHEMBL616951,B,BAO_0000221,,,8,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,,
1326,Brain,,,,CHEMBL616952,B,BAO_0000221,,,8,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,,
1327,,,,,CHEMBL616953,B,BAO_0000357,,,8,10062,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,,,
1328,,,,,CHEMBL616954,B,BAO_0000357,,,8,12073,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,,,
1329,,,,,CHEMBL616955,B,BAO_0000357,,,8,14875,GTPgammaS radioligand binding assay,,,,
1330,,,,,CHEMBL616956,B,BAO_0000357,,,8,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,,,
1331,,,,,CHEMBL616957,F,BAO_0000019,,,8,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,,,
1332,,,,,CHEMBL616958,F,BAO_0000019,,,8,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,,,
1333,,,,,CHEMBL616959,B,BAO_0000357,,,8,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,,,
1334,,,,,CHEMBL616960,B,BAO_0000357,,,8,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,,,
1335,,,,,CHEMBL616961,F,BAO_0000019,,,8,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,,,
1336,,,,HeLa,CHEMBL616962,B,BAO_0000219,,,8,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,,,
1337,,,,HeLa,CHEMBL616963,B,BAO_0000219,,,8,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,,,
1338,,,,,CHEMBL616524,B,BAO_0000357,,,9,6491,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,Homo sapiens,9606.0,
1339,,,,CHO,CHEMBL616525,B,BAO_0000219,,,8,16190,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,,,
1340,,,,,CHEMBL872908,B,BAO_0000019,,,8,14165,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,,,
1341,,,,,CHEMBL616526,B,BAO_0000019,,,8,14165,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,,,
1342,,,,,CHEMBL616527,B,BAO_0000357,,,9,4234,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,Homo sapiens,9606.0,
1343,,,,,CHEMBL616528,B,BAO_0000219,,,8,6328,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,,,
1344,,,,,CHEMBL616529,B,BAO_0000357,,,8,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,,
1345,,,,,CHEMBL616530,B,BAO_0000357,,,8,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,,,
1346,,,,,CHEMBL616531,B,BAO_0000357,,,8,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,,,
1347,,,,,CHEMBL616532,B,BAO_0000357,,,8,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,,,
1348,,,,,CHEMBL616533,B,BAO_0000357,,,8,6013,Binding affinity towards 5-hydroxytryptamine 1B receptor,,,,
1349,,,,,CHEMBL616534,B,BAO_0000357,,,8,5843,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,,,
1350,,,,,CHEMBL616535,B,BAO_0000357,,,8,14454,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,,,
1351,,,,,CHEMBL616536,B,BAO_0000357,,,8,16209,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,,,
1352,,,,,CHEMBL616537,B,BAO_0000357,,,8,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,,,
1353,,,,CHO-K1,CHEMBL616538,F,BAO_0000219,,,8,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,,,
1354,,,,,CHEMBL616539,F,BAO_0000019,,,8,14251,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,,,
1355,,,,,CHEMBL616540,B,BAO_0000019,,,8,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,,,
1356,,,,,CHEMBL616429,B,BAO_0000357,,,8,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,,,
1357,,,,,CHEMBL616430,B,BAO_0000357,,,8,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,,,
1358,,,,,CHEMBL616431,B,BAO_0000219,,,9,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,Homo sapiens,9606.0,
1359,,,,,CHEMBL616432,B,BAO_0000357,,,9,3804,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,Homo sapiens,9606.0,
1360,,,,,CHEMBL616433,B,BAO_0000357,,,9,2391,Affinity for 5-hydroxytryptamine 1B receptor subtype,,Homo sapiens,9606.0,
1361,,,,,CHEMBL616434,B,BAO_0000357,,,9,4175,Binding affinity for human 5-hydroxytryptamine 1B receptor,,Homo sapiens,9606.0,
1362,,,,CHO,CHEMBL616435,B,BAO_0000219,,,8,17296,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,,,
1363,,,,,CHEMBL616436,B,BAO_0000019,,,8,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,,,
1364,,,,HeLa,CHEMBL616437,B,BAO_0000219,,,8,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,,,
1365,,,,HeLa,CHEMBL616438,B,BAO_0000219,,,8,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,,,
1366,,,,HeLa,CHEMBL616439,B,BAO_0000219,,,8,17211,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,,,
1367,,,,,CHEMBL616440,B,BAO_0000357,,,9,15926,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,Homo sapiens,9606.0,
1368,,,,CHO-K1,CHEMBL616441,B,BAO_0000219,,,8,16312,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,,,
1369,,,,,CHEMBL616442,B,BAO_0000357,,,8,5843,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,,,
1370,,,,,CHEMBL616443,B,BAO_0000357,,,8,5843,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,,,
1371,,,,CHO-K1,CHEMBL616444,B,BAO_0000219,,,8,16312,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,,,
1372,,,,,CHEMBL616445,B,BAO_0000357,,,9,15926,Binding activity against human 5-hydroxytryptamine 1B receptor,,Homo sapiens,9606.0,
1373,,,,,CHEMBL616446,B,BAO_0000357,,,9,15926,Binding activity against human 5-hydroxytryptamine 1B receptor,,Homo sapiens,9606.0,
1374,,,,CHO,CHEMBL616447,B,BAO_0000219,,,9,4540,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,Homo sapiens,9606.0,
1375,,,,,CHEMBL616448,B,BAO_0000357,,,8,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,,,
1376,,,,CHO,CHEMBL616449,B,BAO_0000219,,,8,17296,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,,,
1377,,,,CHO,CHEMBL616450,B,BAO_0000219,,,8,17296,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,,,
1378,,,,CHO,CHEMBL857974,B,BAO_0000219,,,8,17296,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,,,
1379,,,,CHO,CHEMBL616451,B,BAO_0000219,,,8,15779,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,,
1380,,,,CHO,CHEMBL616452,B,BAO_0000219,,,8,15779,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,,
1381,,,,CHO,CHEMBL616453,B,BAO_0000219,,,8,15779,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,,,
1382,,,,CHO,CHEMBL616454,B,BAO_0000219,,,8,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,,,
1383,,,,,CHEMBL616455,B,BAO_0000357,,,9,14875,Binding affinity for human 5-hydroxytryptamine 1B receptor,,Homo sapiens,9606.0,
1384,,,,CHO,CHEMBL616456,B,BAO_0000219,,,8,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,,,
1385,,,,,CHEMBL616457,B,BAO_0000357,,,8,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,,,
1386,,,,CHO,CHEMBL616458,B,BAO_0000219,,,8,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,,,
1387,,,,CHO,CHEMBL616459,B,BAO_0000219,,,8,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,,,
1388,,,,,CHEMBL616460,F,BAO_0000019,,,8,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,,,
1389,,,,,CHEMBL616461,F,BAO_0000019,,,8,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,,,
1390,,,,CHO,CHEMBL616462,F,BAO_0000219,,,8,14875,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,,,
1391,,,,CHO,CHEMBL616463,F,BAO_0000219,,,8,14875,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,,,
1392,,,,,CHEMBL616464,F,BAO_0000019,,,8,15250,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,,,
1393,,,,CHO,CHEMBL616465,B,BAO_0000219,,,8,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,,,
1394,,,,,CHEMBL832874,B,BAO_0000357,,,8,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,,,
1395,,,,,CHEMBL616184,F,BAO_0000019,,,8,3025,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,Oryctolagus cuniculus,9986.0,
1396,,,,,CHEMBL616185,B,BAO_0000019,,,8,14998,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,Oryctolagus cuniculus,9986.0,
1397,,,,,CHEMBL616186,B,BAO_0000019,,,8,14998,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,Oryctolagus cuniculus,9986.0,
1398,,,,,CHEMBL616187,B,BAO_0000019,,,8,14998,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,Oryctolagus cuniculus,9986.0,
1399,,,,,CHEMBL616188,B,BAO_0000357,,,8,13969,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,,,
1400,,,,,CHEMBL873475,B,BAO_0000357,,,9,13392,Binding affinity for 5-hydroxytryptamine 1B receptor,,,,
1401,Striatum,,,,CHEMBL616189,B,BAO_0000019,,,9,3651,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,,Rattus norvegicus,10116.0,
1402,,,,,CHEMBL616190,B,BAO_0000357,,,8,10025,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,,,
1403,,,,,CHEMBL616191,B,BAO_0000357,,,8,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,,,
1404,,,,,CHEMBL616192,B,BAO_0000357,,,8,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,,,
1405,,,,,CHEMBL616193,B,BAO_0000357,,,8,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,,,
1406,,,,,CHEMBL616194,B,BAO_0000357,,,8,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,,,
1407,,,,,CHEMBL616195,B,BAO_0000357,,,8,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,,,
1408,,,,,CHEMBL616196,B,BAO_0000357,,,8,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,,,
1409,Hippocampus,,,,CHEMBL616197,B,BAO_0000249,,,8,4622,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,,,
1410,,,,,CHEMBL616198,B,BAO_0000019,,,8,14911,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,,,
1411,Hippocampus,,,,CHEMBL616199,B,BAO_0000221,,,8,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,,,
1412,Hippocampus,,,,CHEMBL616200,B,BAO_0000221,,,8,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,,,
1413,Hippocampus,,,,CHEMBL616201,B,BAO_0000221,,,8,14235,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,,
1414,Hippocampus,,,,CHEMBL616202,B,BAO_0000221,,,8,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,,,
1415,Hippocampus,,,,CHEMBL616203,B,BAO_0000221,,,8,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,,,
1416,Hippocampus,,,,CHEMBL616204,B,BAO_0000221,,,8,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,,,
1417,Hippocampus,,,,CHEMBL616205,B,BAO_0000221,,,8,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,,,
1418,Hippocampus,,,,CHEMBL616206,B,BAO_0000221,,,8,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,,,
1419,,,,,CHEMBL616207,B,BAO_0000249,,,8,16118,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,,,
1420,,,,,CHEMBL616208,B,BAO_0000249,,,8,3268,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,,,
1421,,,,,CHEMBL616209,B,BAO_0000249,,,8,3268,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,,,
1422,,,,,CHEMBL616210,B,BAO_0000357,,,8,16117,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,,,
1423,Hippocampus,,,,CHEMBL616211,B,BAO_0000221,,,8,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,,,
1424,Hippocampus,,,,CHEMBL616504,B,BAO_0000221,,,8,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,,,
1425,Hippocampus,,,,CHEMBL616505,B,BAO_0000221,,,9,14356,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,Rattus norvegicus,10116.0,
1426,,,,,CHEMBL616506,F,BAO_0000019,,,8,15740,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,,,
1427,Hippocampus,,,,CHEMBL872107,B,BAO_0000221,,,8,12306,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,,
1428,Hippocampus,,,,CHEMBL616507,B,BAO_0000221,,,9,13348,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,,Rattus norvegicus,10116.0,
1429,,,,,CHEMBL616303,B,BAO_0000249,,,8,10394,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,,,
1430,Hippocampus,,,,CHEMBL616304,B,BAO_0000221,,,8,15260,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,,,
1431,Hippocampus,,,,CHEMBL616305,B,BAO_0000221,,,8,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,,
1432,Hippocampus,,,,CHEMBL616306,F,BAO_0000221,,,8,15260,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,,,
1433,,,,,CHEMBL616307,B,BAO_0000357,,,8,12851,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,,,
1434,Hippocampus,,,,CHEMBL881829,B,BAO_0000221,,,9,2148,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,,Rattus norvegicus,10116.0,
1435,,,,,CHEMBL616308,B,BAO_0000357,,,8,13134,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,,,
1436,,,,,CHEMBL616309,B,BAO_0000019,,,8,12462,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,,,
1437,,,,,CHEMBL616310,B,BAO_0000019,,,8,12462,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,,,
1438,,,,CHO,CHEMBL616311,B,BAO_0000219,,,8,12462,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,,,
1439,,,,,CHEMBL616312,B,BAO_0000357,,,8,11933,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,,,
1440,,,,,CHEMBL616313,B,BAO_0000357,,,8,11933,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,,,
1441,Hippocampus,,,,CHEMBL616314,B,BAO_0000221,,,9,403,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,Rattus norvegicus,10116.0,
1442,Hippocampus,,,,CHEMBL616315,B,BAO_0000221,,,8,15538,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,
1443,Hippocampus,,,,CHEMBL616567,B,BAO_0000221,,,8,15538,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,,,
1444,Hippocampus,,,,CHEMBL616568,B,BAO_0000221,,,8,15538,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,,,
1445,,,,,CHEMBL616569,B,BAO_0000019,,,8,12464,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,,,
1446,,,,,CHEMBL616570,B,BAO_0000357,,,8,1455,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,,,
1447,,,,,CHEMBL616571,B,BAO_0000357,,,8,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,,,
1448,Hippocampus,,,,CHEMBL616572,B,BAO_0000221,,,8,12639,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,,,
1449,,,,,CHEMBL616573,B,BAO_0000249,,,8,13949,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,,,
1450,,,,,CHEMBL616574,B,BAO_0000357,,,9,12463,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,Rattus norvegicus,10116.0,
1451,Hippocampus,,,,CHEMBL616575,B,BAO_0000221,,,8,14829,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,,,
1452,Hippocampus,,,,CHEMBL872108,B,BAO_0000221,,,8,14829,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,,,
1453,,,,,CHEMBL616576,B,BAO_0000357,,,8,12092,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,,,
1454,,,,,CHEMBL616577,B,BAO_0000249,,,8,403,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,,,
1455,,,,,CHEMBL616578,B,BAO_0000249,,,8,403,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,,,
1456,,,,,CHEMBL616579,B,BAO_0000357,,,8,3967,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,,,
1457,,,,,CHEMBL616580,B,BAO_0000019,,,9,12771,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,Rattus norvegicus,10116.0,
1458,,,,,CHEMBL616581,B,BAO_0000019,,,8,15086,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,,,
1459,Hippocampus,,,,CHEMBL616582,B,BAO_0000221,,,8,14909,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,
1460,Hippocampus,,,,CHEMBL616583,B,BAO_0000221,,,8,14949,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,
1461,Hippocampus,,,,CHEMBL616584,B,BAO_0000221,,,9,2309,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,,Rattus norvegicus,10116.0,
1462,,,,,CHEMBL616585,B,BAO_0000357,,,8,4170,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,
1463,Hippocampus,,,,CHEMBL616586,B,BAO_0000221,,,9,11642,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,,Rattus norvegicus,10116.0,
1464,Hippocampus,,,,CHEMBL616587,B,BAO_0000221,,,8,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,,,
1465,Hippocampus,,,,CHEMBL616588,B,BAO_0000221,,,8,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,,,
1466,Hippocampus,,,,CHEMBL616589,B,BAO_0000221,,,8,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,,,
1467,Hippocampus,,,,CHEMBL616590,B,BAO_0000221,,,8,12953,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,,,
1468,,,,CHO,CHEMBL616591,B,BAO_0000219,,,8,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,,,
1469,,,,,CHEMBL616592,B,BAO_0000357,,,8,12536,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,,
1470,,,,,CHEMBL616593,B,BAO_0000357,,,8,10058,The inhibition activity of 5-HT1A at 1 uM,,,,
1471,,,,CHO-K1,CHEMBL616594,B,BAO_0000219,,,8,12902,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,,,
1472,,,,,CHEMBL616595,B,BAO_0000249,,,8,14057,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,,,
1473,,,,,CHEMBL616596,B,BAO_0000357,,,8,11296,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,,,
1474,Hippocampus,,,,CHEMBL616597,B,BAO_0000221,,,8,11296,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,,
1475,Hippocampus,,,,CHEMBL616598,B,BAO_0000221,,,8,11296,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,,
1476,,,,,CHEMBL616599,F,BAO_0000249,,,9,16616,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,,Rattus norvegicus,10116.0,Membranes
1477,Hippocampus,,,,CHEMBL616600,F,BAO_0000249,,,9,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,Rattus norvegicus,10116.0,Membranes
1478,,,,,CHEMBL616601,B,BAO_0000019,,,8,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,,,
1479,,,,,CHEMBL616602,B,BAO_0000019,,,8,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,,,
1480,,,,,CHEMBL616603,B,BAO_0000019,,,8,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,,,
1481,,,,,CHEMBL616604,B,BAO_0000019,,,8,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,,,
1482,,,,,CHEMBL616316,B,BAO_0000249,,,8,17136,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,,,
1483,,,,,CHEMBL616317,B,BAO_0000249,,,8,17136,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,,,
1484,,,,,CHEMBL616318,B,BAO_0000019,,,9,16616,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,Rattus norvegicus,10116.0,
1485,Hippocampus,,,,CHEMBL616319,B,BAO_0000221,,,8,17331,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,,,
1486,Hippocampus,,,,CHEMBL616320,B,BAO_0000221,,,8,17331,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,,,
1487,Hippocampus,,,,CHEMBL616321,B,BAO_0000221,,,9,17167,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,,Rattus norvegicus,10116.0,
1488,,,,,CHEMBL616322,F,BAO_0000019,,,8,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,,,
1489,,,,,CHEMBL616323,F,BAO_0000019,,,8,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,,,
1490,,,,,CHEMBL616324,B,BAO_0000357,,,8,4671,Ratio of binding affinity to 5-HT 1A and D2 receptor,,,,
1491,Hippocampus,,,,CHEMBL616325,B,BAO_0000221,,,8,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,,,
1492,Hippocampus,,,,CHEMBL616326,B,BAO_0000221,,,8,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,,,
1493,Hippocampus,,,,CHEMBL616327,B,BAO_0000221,,,8,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,,,
1494,,,,,CHEMBL616328,B,BAO_0000357,,,8,12073,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,,,
1495,,,,,CHEMBL858110,B,BAO_0000249,,,8,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,,,
1496,,,,,CHEMBL616329,F,BAO_0000249,,,8,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,,,
1497,,,,,CHEMBL616330,B,BAO_0000249,,,8,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,,,
1498,,,,,CHEMBL616331,F,BAO_0000249,,,8,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,,,
1499,,,,,CHEMBL616332,F,BAO_0000249,,,8,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,,,
1500,Brain,,,,CHEMBL857063,B,BAO_0000249,,,8,9737,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,,
1501,,,,,CHEMBL616333,B,BAO_0000019,,,8,9737,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,,,
1502,,,,,CHEMBL616334,F,BAO_0000019,,,8,5717,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,,,
1503,Hippocampus,,,,CHEMBL616335,B,BAO_0000221,,,8,12253,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,,
1504,,,,,CHEMBL616336,B,BAO_0000019,,,8,14025,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,,,
1505,,,,,CHEMBL616337,B,BAO_0000249,,,8,10425,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,,,
1506,,,,,CHEMBL616338,B,BAO_0000019,,,8,14998,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,,,
1507,Hippocampus,,,,CHEMBL616339,B,BAO_0000221,,,8,13694,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,,,
1508,Hippocampus,,,,CHEMBL616340,B,BAO_0000221,,,8,13694,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,,,
1509,,,,,CHEMBL616341,B,BAO_0000357,,,8,4342,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,,,
1510,,,,,CHEMBL616342,B,BAO_0000357,,,9,12936,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,Rattus norvegicus,10116.0,
1511,,,,,CHEMBL616343,B,BAO_0000019,,,9,13144,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,Rattus norvegicus,10116.0,
1512,,,,,CHEMBL616344,B,BAO_0000019,,,8,13343,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,,,
1513,,,,,CHEMBL616345,B,BAO_0000357,,,8,12132,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,,
1514,,,,,CHEMBL616346,B,BAO_0000019,,,8,15419,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,,,
1515,Hippocampus,,,,CHEMBL616347,B,BAO_0000221,,,8,1479,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,,
1516,,,,,CHEMBL616348,B,BAO_0000019,,,8,14287,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,,,
1517,,,,,CHEMBL616349,B,BAO_0000357,,,8,13116,Binding affinity at 5-hydroxytryptamine 1A receptor,,,,
1518,,,,,CHEMBL616152,B,BAO_0000249,,,9,2759,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,,Rattus norvegicus,10116.0,Membranes
1519,,,,,CHEMBL616153,B,BAO_0000249,,,8,2759,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,,,
1520,,,,,CHEMBL616154,B,BAO_0000019,,,8,14748,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,,,
1521,,,,,CHEMBL616155,B,BAO_0000019,,,8,12304,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,,
1522,Hippocampus,,,,CHEMBL616156,B,BAO_0000221,,,9,12409,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,,Rattus norvegicus,10116.0,
1523,Hippocampus,,,,CHEMBL616157,B,BAO_0000221,,,9,12409,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,,Rattus norvegicus,10116.0,
1524,Hippocampus,,,,CHEMBL616158,B,BAO_0000221,,,8,13267,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,,,
1525,,,,,CHEMBL616159,B,BAO_0000357,,,8,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,,
1526,,,,,CHEMBL616160,B,BAO_0000357,,,8,14256,pKi value against rat 5-hydroxytryptamine 1A receptor.,,,,
1527,,,,,CHEMBL616161,B,BAO_0000019,,,8,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,,,
1528,,,,,CHEMBL616162,F,BAO_0000019,,,8,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,,,
1529,,,,,CHEMBL616163,B,BAO_0000357,,,9,13278,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,Rattus norvegicus,10116.0,
1530,,,,,CHEMBL616164,B,BAO_0000249,,,8,1970,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,,Membranes
1531,Brain,,,,CHEMBL616165,B,BAO_0000221,,,8,10034,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,,,
1532,,,,,CHEMBL616355,B,BAO_0000019,,,8,13348,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,Rattus norvegicus,10116.0,
1533,,,,,CHEMBL616356,F,BAO_0000019,,,8,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,,,
1534,Brain,,,,CHEMBL616357,B,BAO_0000221,,,8,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,,
1535,,,,,CHEMBL616358,B,BAO_0000019,,,8,12058,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,,,
1536,,,,,CHEMBL616359,B,BAO_0000357,,,8,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,,,
1537,,,,,CHEMBL616360,B,BAO_0000357,,,8,15453,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,,,
1538,,,,,CHEMBL616361,B,BAO_0000357,,,8,4820,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,
1539,,,,,CHEMBL616362,B,BAO_0000357,,,8,1089,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,,,
1540,,,,,CHEMBL616363,B,BAO_0000249,,,8,386,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,,,Brain membranes
1541,,,,,CHEMBL616364,B,BAO_0000357,,,8,6011,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,,,
1542,,,,,CHEMBL616365,B,BAO_0000357,,,8,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,,,
1543,,,,,CHEMBL616366,B,BAO_0000357,,,8,4402,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,,,
1544,,,,,CHEMBL872906,B,BAO_0000357,,,8,17066,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,
1545,,,,,CHEMBL616367,B,BAO_0000357,,,8,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,,,
1546,,,,,CHEMBL616368,B,BAO_0000357,,,8,2474,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,
1547,,,,,CHEMBL616369,B,BAO_0000357,,,8,4775,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,,,
1548,,,,,CHEMBL616370,B,BAO_0000357,,,9,14294,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,Homo sapiens,9606.0,
1549,,,,,CHEMBL616371,B,BAO_0000357,,,9,14294,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,Homo sapiens,9606.0,
1550,,,,CHO,CHEMBL616372,B,BAO_0000219,,,8,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,
1551,,,,,CHEMBL616373,B,BAO_0000219,,,8,11376,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,,,
1552,,,,,CHEMBL616374,B,BAO_0000218,,,8,2474,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,In vivo,,,
1553,Hippocampus,,,,CHEMBL616375,B,BAO_0000221,,,8,13311,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,
1554,,,,,CHEMBL616376,B,BAO_0000357,,,8,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,,,
1555,,,,,CHEMBL857064,B,BAO_0000357,,,8,1633,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,,,
1556,,,,,CHEMBL616377,B,BAO_0000357,,,8,11866,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,,,
1557,,,,,CHEMBL616378,B,BAO_0000357,,,8,4373,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,,,
1558,,,,,CHEMBL616379,B,BAO_0000357,,,8,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,,,
1559,,,,,CHEMBL616380,B,BAO_0000357,,,8,16946,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,,
1560,,,,,CHEMBL616381,B,BAO_0000357,,,8,13291,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,,,
1561,,,,,CHEMBL616382,B,BAO_0000357,,,8,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,,,
1562,,,,,CHEMBL616383,B,BAO_0000357,,,8,10812,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,,,
1563,,,,CHO,CHEMBL616350,B,BAO_0000219,,,9,3032,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,Mus musculus,10090.0,
1564,,,,,CHEMBL616351,B,BAO_0000357,,,8,16655,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,,
1565,,,,,CHEMBL616352,B,BAO_0000357,,,8,14532,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,,,
1566,,,,,CHEMBL616353,B,BAO_0000357,,,8,13944,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,
1567,,,,,CHEMBL616354,B,BAO_0000357,,,8,13033,Binding affinity against serotonergic 5-HT1a receptor,,,,
1568,,,,,CHEMBL616508,B,BAO_0000357,,,8,10321,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,,,
1569,,,,,CHEMBL616559,B,BAO_0000357,,,9,2968,Binding affinity for 5-hydroxytryptamine 1A receptor,,Mus musculus,10090.0,
1570,,,,,CHEMBL616560,B,BAO_0000357,,,8,13964,Binding affinity at 5-hydroxytryptamine 1A receptor,,,,
1571,,,,,CHEMBL616561,B,BAO_0000357,,,8,15527,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,,,
1572,,,,CHO,CHEMBL616562,B,BAO_0000219,,,8,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,
1573,,,,CHO,CHEMBL616563,B,BAO_0000219,,,8,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,
1574,,,,,CHEMBL616564,B,BAO_0000357,,,8,15120,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,,,
1575,,,,,CHEMBL616565,B,BAO_0000357,,,8,13313,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,,,
1576,,,,,CHEMBL616566,B,BAO_0000218,,,8,2613,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,,,
1577,,,,,CHEMBL616989,B,BAO_0000357,,,8,16700,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,,,
1578,,,,,CHEMBL857975,B,BAO_0000357,,,8,2201,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,,,
1579,,,,,CHEMBL616990,B,BAO_0000357,,,9,1274,Binding affinity against 5-hydroxytryptamine 1A receptor,,Mus musculus,10090.0,
1580,,,,,CHEMBL616991,B,BAO_0000357,,,8,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,,,
1581,,,,,CHEMBL616992,B,BAO_0000357,,,8,12146,Tested against 5-hydroxytryptamine 1A receptor,,,,
1582,,,,,CHEMBL616993,B,BAO_0000357,,,8,14059,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,,,
1583,,,,,CHEMBL616994,B,BAO_0000019,,,8,14025,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,Oryctolagus cuniculus,9986.0,
1584,,,,,CHEMBL616995,B,BAO_0000019,,,8,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,Oryctolagus cuniculus,9986.0,
1585,,,,HEK293,CHEMBL616996,B,BAO_0000219,,,9,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,Gorilla gorilla,9593.0,
1586,,,,,CHEMBL616997,F,BAO_0000218,,,8,3025,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,In vivo,Cavia porcellus,10141.0,
1587,,,,,CHEMBL616998,F,BAO_0000218,,,8,3025,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,In vivo,Cavia porcellus,10141.0,
1588,,,,,CHEMBL616999,F,BAO_0000019,,,8,15329,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,Cavia porcellus,10141.0,
1589,,,,,CHEMBL617000,F,BAO_0000019,,,8,15329,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,Cavia porcellus,10141.0,
1590,,,,,CHEMBL617001,F,BAO_0000019,,,8,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,Cavia porcellus,10141.0,
1591,,,,,CHEMBL858111,F,BAO_0000019,,,8,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,Cavia porcellus,10141.0,
1592,,,,,CHEMBL617002,F,BAO_0000019,,,8,14165,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,,,
1593,,,,,CHEMBL617003,F,BAO_0000019,,,8,14214,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,,,
1594,,,,,CHEMBL617004,F,BAO_0000019,,,8,14214,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,,,
1595,,,,,CHEMBL617005,F,BAO_0000019,,,9,14214,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,Homo sapiens,9606.0,
1596,,,,CHO-K1,CHEMBL616623,F,BAO_0000219,,,9,13729,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,Homo sapiens,9606.0,
1597,,,,CHO,CHEMBL616624,F,BAO_0000219,,,8,3025,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,,,
1598,,,,,CHEMBL883243,B,BAO_0000357,,,8,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,,,
1599,,,,,CHEMBL616625,F,BAO_0000019,,,8,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,,,
1600,,,,CHO,CHEMBL616626,F,BAO_0000219,,,8,14956,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,,,
1601,,,,CHO,CHEMBL616627,F,BAO_0000219,,,8,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,,,
1602,,,,CHO,CHEMBL616628,F,BAO_0000219,,,8,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,,,
1603,,,,CHO,CHEMBL616629,F,BAO_0000219,,,8,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,,,
1604,,,,CHO,CHEMBL616630,F,BAO_0000219,,,8,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,,,
1605,,,,,CHEMBL616631,F,BAO_0000019,,,8,14956,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,,,
1606,,,,,CHEMBL616632,F,BAO_0000019,,,8,14956,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,,,
1607,,,,,CHEMBL616633,B,BAO_0000357,,,9,14214,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,Homo sapiens,9606.0,
1608,,,,CHO,CHEMBL616634,B,BAO_0000219,,,8,3463,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,,,
1609,,,,,CHEMBL616635,B,BAO_0000357,,,8,15331,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,,,
1610,,,,,CHEMBL885358,B,BAO_0000357,,,9,16146,Binding affinity against 5-hydroxytryptamine 1B receptor,,Homo sapiens,9606.0,
1611,,,,CHO,CHEMBL616636,B,BAO_0000219,,,9,14159,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,Homo sapiens,9606.0,
1612,,,,CHO,CHEMBL616637,B,BAO_0000219,,,8,14158,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,,,
1613,,,,,CHEMBL616638,B,BAO_0000357,,,8,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,,,
1614,,,,CHO,CHEMBL616639,B,BAO_0000219,,,8,15250,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,,,
1615,,,,CHO,CHEMBL616640,B,BAO_0000219,,,8,15250,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,,,
1616,,,,CHO,CHEMBL616641,B,BAO_0000219,,,8,15331,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,,,
1617,,,,CHO,CHEMBL616642,B,BAO_0000219,,,8,15332,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,,,
1618,,,,CHO,CHEMBL616643,B,BAO_0000219,,,8,14956,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,,,
1619,,,,,CHEMBL616644,B,BAO_0000357,,,8,3805,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,,,
1620,,,,,CHEMBL616645,B,BAO_0000357,,,8,14875,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,,,
1621,,,,,CHEMBL616646,F,BAO_0000019,,,8,14454,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,Oryctolagus cuniculus,9986.0,
1622,,,,,CHEMBL616647,F,BAO_0000019,,,8,14454,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,Oryctolagus cuniculus,9986.0,
1623,,,,,CHEMBL616509,B,BAO_0000357,,,8,16288,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,,,
1624,,,,,CHEMBL616510,B,BAO_0000357,,,8,16288,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,,,
1625,,,,,CHEMBL616511,B,BAO_0000357,,,8,16312,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,,,
1626,,,,,CHEMBL616512,B,BAO_0000357,,,8,1348,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,Bos taurus,9913.0,
1627,,,,,CHEMBL616513,B,BAO_0000357,,,8,5834,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,Bos taurus,9913.0,
1628,Striatum,,,,CHEMBL616514,B,BAO_0000019,,,8,13366,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,Bos taurus,9913.0,
1629,,,,,CHEMBL616515,B,BAO_0000357,,,8,1414,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,Bos taurus,9913.0,
1630,,,,,CHEMBL616516,B,BAO_0000019,,,8,14998,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,Bos taurus,9913.0,
1631,,,,,CHEMBL616517,B,BAO_0000357,,,8,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,Bos taurus,9913.0,
1632,,,,,CHEMBL616518,B,BAO_0000357,,,8,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,Bos taurus,9913.0,
1633,,,,,CHEMBL616519,B,BAO_0000357,,,8,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,Bos taurus,9913.0,
1634,,,,,CHEMBL616520,B,BAO_0000357,,,8,10639,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,Bos taurus,9913.0,
1635,,,,,CHEMBL616521,B,BAO_0000357,,,8,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,Bos taurus,9913.0,
1636,,,,,CHEMBL616522,B,BAO_0000357,,,8,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,Bos taurus,9913.0,
1637,,,,,CHEMBL884531,B,BAO_0000357,,,8,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,Bos taurus,9913.0,
1638,,,,,CHEMBL616523,B,BAO_0000357,,,8,11147,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,Bos taurus,9913.0,
1639,Striatum,,,,CHEMBL616731,B,BAO_0000019,,,8,13366,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,Bos taurus,9913.0,
1640,,,,,CHEMBL616732,B,BAO_0000019,,,8,10444,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,Bos taurus,9913.0,
1641,,,,,CHEMBL616733,B,BAO_0000357,,,8,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,Bos taurus,9913.0,
1642,,,,,CHEMBL616734,B,BAO_0000357,,,8,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,Bos taurus,9913.0,
1643,,,,,CHEMBL616735,B,BAO_0000249,,,8,12827,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,Bos taurus,9913.0,
1644,,,,,CHEMBL616736,B,BAO_0000249,,,8,12827,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,Bos taurus,9913.0,
1645,,,,,CHEMBL616737,F,BAO_0000019,,,8,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,Bos taurus,9913.0,
1646,,,,,CHEMBL616738,B,BAO_0000019,,,8,14025,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,Bos taurus,9913.0,
1647,,,,,CHEMBL616739,F,BAO_0000019,,,8,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,Bos taurus,9913.0,
1648,,,,,CHEMBL616740,F,BAO_0000019,,,8,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,Bos taurus,9913.0,
1649,,,,,CHEMBL616741,F,BAO_0000019,,,8,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,Bos taurus,9913.0,
1650,,,,HEK293,CHEMBL616742,B,BAO_0000219,,,8,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,Gorilla gorilla,9593.0,
1651,,,,,CHEMBL616743,B,BAO_0000019,,,9,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,Cavia porcellus,10141.0,
1652,,,,,CHEMBL616744,B,BAO_0000019,,,9,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,Cavia porcellus,10141.0,
1653,,,,,CHEMBL616745,F,BAO_0000019,,,9,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,Cavia porcellus,10141.0,
1654,,,,,CHEMBL616746,F,BAO_0000019,,,9,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,Cavia porcellus,10141.0,
1655,,,,,CHEMBL616747,F,BAO_0000019,,,9,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,Cavia porcellus,10141.0,
1656,,,,,CHEMBL616748,F,BAO_0000019,,,9,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,Cavia porcellus,10141.0,
1657,,,,,CHEMBL616648,F,BAO_0000019,,,9,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,Cavia porcellus,10141.0,
1658,,,,,CHEMBL616649,B,BAO_0000357,,,9,11574,Binding affinity against 5-hydroxytryptamine 1D receptor,,Cavia porcellus,10141.0,
1659,,,,,CHEMBL616650,B,BAO_0000357,,,9,1558,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,Cavia porcellus,10141.0,
1660,,,,,CHEMBL616651,F,BAO_0000218,,,9,12409,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,Cavia porcellus,10141.0,
1661,,,,,CHEMBL616652,F,BAO_0000218,,,9,12409,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,Cavia porcellus,10141.0,
1662,,,,,CHEMBL616653,F,BAO_0000218,,,9,12409,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,Cavia porcellus,10141.0,
1663,,,,,CHEMBL616654,F,BAO_0000218,,,9,12409,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,Cavia porcellus,10141.0,
1664,,,,,CHEMBL616655,B,BAO_0000019,,,9,12253,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,Cavia porcellus,10141.0,
1665,,,,,CHEMBL616656,B,BAO_0000357,,,9,12936,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,Cavia porcellus,10141.0,
1666,,,,,CHEMBL616657,B,BAO_0000019,,,8,13181,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,Cavia porcellus,10141.0,
1667,Striatum,,,,CHEMBL616658,B,BAO_0000357,,,9,12409,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,,Cavia porcellus,10141.0,
1668,,,,,CHEMBL616659,B,BAO_0000357,,,9,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,Cavia porcellus,10141.0,
1669,,,,,CHEMBL616660,B,BAO_0000357,,,8,5254,Binding affinity against 5-hydroxytryptamine 1D receptor,,,,
1670,,,,,CHEMBL616661,B,BAO_0000357,,,8,13051,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,,,
1671,,,,,CHEMBL616662,F,BAO_0000019,,,8,3463,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,,,
1672,,,,,CHEMBL616663,F,BAO_0000019,,,8,15315,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,,,
1673,,,,,CHEMBL616664,F,BAO_0000019,,,8,6011,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,,,
1674,,,,CHO,CHEMBL881820,F,BAO_0000219,,,9,14159,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,Homo sapiens,9606.0,
1675,,,,CHO,CHEMBL616665,F,BAO_0000219,,,8,14159,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,,,
1676,,,,CHO,CHEMBL616666,B,BAO_0000219,,,8,15250,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,,,
1677,,,,CHO,CHEMBL616667,B,BAO_0000219,,,8,15250,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,,,
1678,,,,CHO,CHEMBL616668,F,BAO_0000219,,,8,15331,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,,,
1679,,,,CHO,CHEMBL616669,F,BAO_0000219,,,9,15332,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,Homo sapiens,9606.0,
1680,,,,CHO,CHEMBL617040,F,BAO_0000219,,,8,15332,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,,,
1681,,,,CHO,CHEMBL617041,F,BAO_0000219,,,8,3294,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,,,
1682,,,,CHO,CHEMBL617042,F,BAO_0000219,,,8,14158,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,,,
1683,,,,CHO,CHEMBL617043,F,BAO_0000219,,,8,14956,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,,,
1684,,,,,CHEMBL617044,F,BAO_0000019,,,8,12469,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,,,
1685,,,,CHO,CHEMBL617045,F,BAO_0000219,,,8,3463,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,,,
1686,,,,CHO,CHEMBL617046,F,BAO_0000219,,,9,15250,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,Homo sapiens,9606.0,
1687,,,,CHO,CHEMBL617047,F,BAO_0000219,,,9,15250,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,Homo sapiens,9606.0,
1688,,,,,CHEMBL617048,F,BAO_0000019,,,8,14956,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,,,
1689,,,,,CHEMBL616897,F,BAO_0000019,,,8,14159,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,,,
1690,,,,,CHEMBL616898,F,BAO_0000019,,,9,14159,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,Homo sapiens,9606.0,
1691,,,,CHO,CHEMBL858201,F,BAO_0000219,,,9,14499,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,Homo sapiens,9606.0,
1692,,,,,CHEMBL616899,F,BAO_0000019,,,8,15315,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,,,
1693,,,,,CHEMBL616900,B,BAO_0000219,,,8,3294,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),In vitro,,,
1694,,,,CHO,CHEMBL616901,B,BAO_0000219,,,8,3463,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,,,
1695,,,,,CHEMBL616902,B,BAO_0000357,,,8,15331,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,,,
1696,,,,CHO,CHEMBL616903,B,BAO_0000219,,,9,14159,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,Homo sapiens,9606.0,
1697,,,,CHO,CHEMBL616904,B,BAO_0000219,,,8,14158,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,,,
1698,,,,,CHEMBL616905,B,BAO_0000357,,,8,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,,,
1699,,,,CHO,CHEMBL616906,B,BAO_0000219,,,8,15250,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,,,
1700,,,,CHO,CHEMBL616907,B,BAO_0000219,,,8,15250,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,,
1701,,,,CHO,CHEMBL616908,B,BAO_0000219,,,8,15331,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,,
1702,,,,CHO,CHEMBL616909,B,BAO_0000219,,,9,15332,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,Homo sapiens,9606.0,
1703,,,,CHO,CHEMBL616910,B,BAO_0000219,,,9,14499,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,Homo sapiens,9606.0,
1704,,,,CHO,CHEMBL616911,B,BAO_0000219,,,8,15332,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,,
1705,,,,CHO,CHEMBL616912,B,BAO_0000219,,,8,14956,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,,,
1706,,,,,CHEMBL616913,B,BAO_0000357,,,8,3805,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,,,
1707,,,,CHO,CHEMBL616914,B,BAO_0000219,,,9,6011,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,Homo sapiens,9606.0,
1708,,,,CHO,CHEMBL616915,B,BAO_0000219,,,8,16190,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,,,
1709,,,,,CHEMBL616916,B,BAO_0000019,,,8,14165,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,,,
1710,,,,,CHEMBL616917,B,BAO_0000357,,,9,4234,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,Homo sapiens,9606.0,
1711,,,,,CHEMBL616918,B,BAO_0000357,,,8,15527,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,,,
1712,,,,,CHEMBL616919,B,BAO_0000219,,,8,6328,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,,,
1713,,,,,CHEMBL616920,B,BAO_0000357,,,8,16209,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,,,
1714,,,,,CHEMBL872914,B,BAO_0000357,,,8,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,,,
1715,,,,,CHEMBL616921,B,BAO_0000357,,,8,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,,,
1716,,,,,CHEMBL616922,B,BAO_0000357,,,8,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,,,
1717,,,,,CHEMBL616923,B,BAO_0000357,,,8,6013,Binding affinity towards 5-hydroxytryptamine 1D receptor,,,,
1718,,,,,CHEMBL616924,B,BAO_0000357,,,8,5843,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,,,
1719,,,,,CHEMBL875909,B,BAO_0000357,,,8,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,,,
1720,,,,,CHEMBL616925,B,BAO_0000357,,,8,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,,,
1721,,,,,CHEMBL616926,B,BAO_0000357,,,8,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,,,
1722,,,,,CHEMBL616927,B,BAO_0000357,,,8,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,,,
1723,,,,CHO-K1,CHEMBL616928,F,BAO_0000219,,,8,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,,,
1724,,,,,CHEMBL616929,B,BAO_0000219,,,9,6011,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),In vitro,Homo sapiens,9606.0,
1725,,,,,CHEMBL616930,B,BAO_0000357,,,9,4234,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,Homo sapiens,9606.0,
1726,,,,,CHEMBL616931,B,BAO_0000019,,,8,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,,,
1727,,,,,CHEMBL616932,B,BAO_0000357,,,8,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,,,
1728,,,,,CHEMBL616933,B,BAO_0000357,,,8,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,,,
1729,,,,,CHEMBL616934,B,BAO_0000219,,,9,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,Homo sapiens,9606.0,
1730,,,,,CHEMBL616935,B,BAO_0000357,,,9,3804,Binding affinity for human 5-hydroxytryptamine 1D receptor,,Homo sapiens,9606.0,
1731,,,,,CHEMBL616936,B,BAO_0000357,,,8,16700,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,,,
1732,,,,,CHEMBL616937,B,BAO_0000357,,,9,2391,Affinity for 5-hydroxytryptamine 1D receptor subtype,,Homo sapiens,9606.0,
1733,,,,,CHEMBL616938,B,BAO_0000357,,,9,4175,Binding affinity for human 5-hydroxytryptamine 1D receptor,,Homo sapiens,9606.0,
1734,,,,,CHEMBL616939,B,BAO_0000019,,,8,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,,,
1735,,,,,CHEMBL616940,B,BAO_0000019,,,8,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,,,
1736,,,,,CHEMBL616941,B,BAO_0000357,,,9,15926,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,Homo sapiens,9606.0,
1737,,,,CHO-K1,CHEMBL616942,B,BAO_0000219,,,8,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,,,
1738,,,,CHO-K1,CHEMBL616943,B,BAO_0000219,,,8,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,,,
1739,,,,CHO,CHEMBL616944,B,BAO_0000219,,,4,14956,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,,,
1740,,,,,CHEMBL616945,F,BAO_0000019,,,8,3294,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,,,
1741,,,,,CHEMBL616946,B,BAO_0000357,,,8,12861,Binding activity radioligand.,,,,
1742,,,,,CHEMBL616947,B,BAO_0000019,,,8,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,,
1743,,,,CHO-K1,CHEMBL616948,B,BAO_0000219,,,8,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,,,
1744,,,,,CHEMBL616851,B,BAO_0000357,,,8,5104,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,,,
1745,,,,,CHEMBL616852,B,BAO_0000357,,,8,5105,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,,,
1746,,,,,CHEMBL616853,B,BAO_0000357,,,8,14499,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,,,
1747,,,,,CHEMBL616854,B,BAO_0000357,,,9,15926,Binding activity against human 5-hydroxytryptamine 1D receptor,,Homo sapiens,9606.0,
1748,,,,CHO,CHEMBL616855,B,BAO_0000219,,,9,4540,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,Homo sapiens,9606.0,
1749,,,,CHO,CHEMBL616856,B,BAO_0000219,,,8,15779,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,,,
1750,,,,CHO,CHEMBL616857,B,BAO_0000219,,,8,15779,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,,
1751,,,,,CHEMBL616858,B,BAO_0000357,,,8,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,,,
1752,,,,CHO,CHEMBL616859,B,BAO_0000219,,,8,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,,,
1753,,,,CHO,CHEMBL616860,B,BAO_0000219,,,8,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,,,
1754,,,,HEK293,CHEMBL616861,B,BAO_0000219,,,8,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,,,
1755,,,,HEK293,CHEMBL616541,B,BAO_0000219,,,8,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,,,
1756,,,,HEK293,CHEMBL616542,B,BAO_0000219,,,8,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,,,
1757,,,,CHO,CHEMBL616543,B,BAO_0000219,,,8,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,,,
1758,,,,,CHEMBL616544,B,BAO_0000357,,,9,14875,Binding affinity for human 5-hydroxytryptamine 1D receptor,,Homo sapiens,9606.0,
1759,,,,CHO,CHEMBL616545,B,BAO_0000219,,,8,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,,,
1760,,,,,CHEMBL616546,B,BAO_0000357,,,8,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,,,
1761,,,,CHO,CHEMBL616547,B,BAO_0000219,,,8,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,,,
1762,,,,CHO,CHEMBL616548,B,BAO_0000219,,,8,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,,,
1763,,,,,CHEMBL616549,F,BAO_0000019,,,8,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,,,
1764,,,,,CHEMBL616550,F,BAO_0000019,,,8,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,,,
1765,,,,,CHEMBL857066,B,BAO_0000357,,,8,5254,Binding affinity against 5-HT2C receptor,,,,
1766,,,,,CHEMBL616551,B,BAO_0000357,,,8,5254,Binding affinity against 5-hydroxytryptamine 1D receptor,,,,
1767,,,,,CHEMBL616552,B,BAO_0000357,,,8,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,,,
1768,,,,,CHEMBL832876,F,BAO_0000019,,,8,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,,,
1769,,,,,CHEMBL616553,B,BAO_0000019,,,8,12352,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,,,
1770,,,,,CHEMBL616554,B,BAO_0000357,,,8,9098,Binding affinity towards 5-HT1B was determined,,,,
1771,,,,,CHEMBL616555,B,BAO_0000019,,,8,14430,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,,,
1772,,,,,CHEMBL616556,B,BAO_0000019,,,8,13657,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,,,
1773,,,,,CHEMBL616557,B,BAO_0000019,,,8,13657,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,,,
1774,,,,,CHEMBL616558,B,BAO_0000019,,,8,15854,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,,
1775,,,,,CHEMBL616749,B,BAO_0000019,,,9,10639,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,Rattus norvegicus,10116.0,
1776,,,,,CHEMBL616750,B,BAO_0000357,,,8,10025,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,,,
1777,,,,,CHEMBL616751,B,BAO_0000357,,,8,10025,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,,,
1778,,,,,CHEMBL616752,B,BAO_0000249,,,8,14286,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,,,
1779,Striatum,,,,CHEMBL616753,B,BAO_0000019,,,8,3651,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,,,
1780,,,,,CHEMBL616754,B,BAO_0000357,,,9,14178,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,Rattus norvegicus,10116.0,
1781,,,,,CHEMBL616755,B,BAO_0000019,,,8,10639,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,,,
1782,Striatum,,,,CHEMBL616756,B,BAO_0000019,,,8,13605,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,,,
1783,Striatum,,,,CHEMBL616757,B,BAO_0000019,,,8,5834,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,,,
1784,Striatum,,,,CHEMBL616758,B,BAO_0000357,,,8,10922,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,,,
1785,,,,,CHEMBL616759,B,BAO_0000249,,,8,14286,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,,,
1786,,,,,CHEMBL616760,B,BAO_0000357,,,8,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,,,
1787,Striatum,,,,CHEMBL616761,B,BAO_0000019,,,8,14826,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,,,
1788,Striatum,,,,CHEMBL616762,B,BAO_0000019,,,8,9699,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,,,
1789,,,,,CHEMBL616763,B,BAO_0000019,,,8,14423,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,,,
1790,,,,,CHEMBL872909,B,BAO_0000357,,,8,10062,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,,,
1791,,,,,CHEMBL616764,B,BAO_0000357,,,8,10062,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,,,
1792,,,,,CHEMBL616765,B,BAO_0000357,,,9,12280,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,Rattus norvegicus,10116.0,
1793,Striatum,,,,CHEMBL616766,B,BAO_0000357,,,8,15412,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,,,
1794,Striatum,,,,CHEMBL616767,B,BAO_0000357,,,8,15412,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,,,
1795,,,,,CHEMBL616768,B,BAO_0000357,,,8,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,,,
1796,,,,,CHEMBL616769,B,BAO_0000357,,,8,11147,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,,,
1797,,,,,CHEMBL616770,B,BAO_0000019,,,8,9547,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,,,
1798,,,,,CHEMBL616771,B,BAO_0000019,,,8,10444,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,,,
1799,Striatum,,,,CHEMBL616772,B,BAO_0000019,,,8,12469,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,,,
1800,,,,,CHEMBL616773,B,BAO_0000019,,,8,9098,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,,,
1801,,,,,CHEMBL616774,B,BAO_0000019,,,8,9098,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,,,
1802,,,,,CHEMBL616775,B,BAO_0000357,,,8,9699,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,,,
1803,,,,,CHEMBL616776,B,BAO_0000249,,,8,10394,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,,,
1804,,,,,CHEMBL616777,B,BAO_0000357,,,8,12092,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,,,
1805,,,,,CHEMBL616778,B,BAO_0000357,,,8,16700,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,,,
1806,,,,,CHEMBL616779,B,BAO_0000249,,,9,403,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,Rattus norvegicus,10116.0,
1807,,,,,CHEMBL616780,B,BAO_0000357,,,9,12771,Binding affinity towards 5-hydroxytryptamine 1B receptor,,Rattus norvegicus,10116.0,
1808,,,,,CHEMBL616781,B,BAO_0000019,,,8,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,,,
1809,,,,,CHEMBL616782,B,BAO_0000357,,,8,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,,,
1810,,,,,CHEMBL616783,B,BAO_0000357,,,8,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,,,
1811,Striatum,,,,CHEMBL616784,B,BAO_0000019,,,8,12953,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,,,
1812,,,,,CHEMBL616785,B,BAO_0000357,,,8,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,,,
1813,Brain,,,,CHEMBL857067,B,BAO_0000249,,,8,9737,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,,
1814,,,,,CHEMBL616786,B,BAO_0000019,,,8,9737,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,,,
1815,Brain,,,,CHEMBL616787,B,BAO_0000249,,,8,9737,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,,
1816,,,,,CHEMBL616788,B,BAO_0000357,,,8,12827,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,,,
1817,,,,,CHEMBL616789,B,BAO_0000357,,,8,5033,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,,,
1818,,,,,CHEMBL616790,B,BAO_0000019,,,9,9786,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,Rattus norvegicus,10116.0,
1819,,,,,CHEMBL616791,B,BAO_0000357,,,8,13116,Binding affinity at 5-hydroxytryptamine 1B receptor,,,,
1820,,,,,CHEMBL616792,B,BAO_0000019,,,8,16429,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,,,
1821,,,,,CHEMBL616793,B,BAO_0000249,,,9,12409,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,Rattus norvegicus,10116.0,
1822,,,,,CHEMBL616794,B,BAO_0000357,,,8,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,,,
1823,,,,,CHEMBL616795,B,BAO_0000357,,,8,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,,
1824,,,,,CHEMBL616796,B,BAO_0000019,,,4,5486,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,,,
1825,,,,,CHEMBL616797,B,BAO_0000357,,,8,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,,,
1826,,,,,CHEMBL616798,B,BAO_0000249,,,8,386,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,,,Brain membranes
1827,,,,,CHEMBL616799,B,BAO_0000357,,,8,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,,,
1828,,,,,CHEMBL616800,B,BAO_0000357,,,8,6011,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,,,
1829,,,,,CHEMBL616801,B,BAO_0000357,,,8,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,,,
1830,,,,,CHEMBL616802,B,BAO_0000357,,,8,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,,,
1831,,,,,CHEMBL616803,B,BAO_0000357,,,8,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,,,
1832,,,,,CHEMBL857068,B,BAO_0000357,,,8,1633,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,,,
1833,,,,,CHEMBL616804,B,BAO_0000357,,,8,1633,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,,,
1834,,,,,CHEMBL616805,B,BAO_0000357,,,8,4373,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,,,
1835,,,,,CHEMBL616806,B,BAO_0000357,,,8,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,,,
1836,,,,,CHEMBL616807,B,BAO_0000357,,,8,11574,Binding affinity against 5-hydroxytryptamine 1B receptor,,,,
1837,,,,,CHEMBL616808,B,BAO_0000357,,,8,10321,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,,,
1838,,,,,CHEMBL616809,B,BAO_0000357,,,8,15527,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,,
1839,,,,,CHEMBL616810,B,BAO_0000357,,,8,17200,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,,,
1840,,,,,CHEMBL616811,B,BAO_0000224,,,4,14423,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,,,
1841,,,,,CHEMBL616812,B,BAO_0000357,,,8,5834,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,Bos taurus,9913.0,
1842,,,,,CHEMBL616813,B,BAO_0000357,,,8,11473,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,Sus scrofa,9823.0,
1843,,,,,CHEMBL616814,B,BAO_0000357,,,8,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,Sus scrofa,9823.0,
1844,,,,,CHEMBL616815,B,BAO_0000357,,,8,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,Sus scrofa,9823.0,
1845,,,,,CHEMBL616816,B,BAO_0000357,,,8,10639,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,Sus scrofa,9823.0,
1846,,,,,CHEMBL616817,B,BAO_0000357,,,8,14331,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,Sus scrofa,9823.0,
1847,,,,,CHEMBL616818,B,BAO_0000357,,,8,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,Sus scrofa,9823.0,
1848,,,,,CHEMBL616819,B,BAO_0000357,,,8,9098,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,Sus scrofa,9823.0,
1849,,,,,CHEMBL616820,B,BAO_0000357,,,8,14331,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,Sus scrofa,9823.0,
1850,,,,,CHEMBL616821,B,BAO_0000019,,,8,11828,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,Sus scrofa,9823.0,
1851,,,,,CHEMBL616822,B,BAO_0000357,,,8,11866,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,Sus scrofa,9823.0,
1852,,,,,CHEMBL616823,B,BAO_0000019,,,8,13047,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,Oryctolagus cuniculus,9986.0,
1853,,,,,CHEMBL616824,B,BAO_0000357,,,9,188,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,Rattus norvegicus,10116.0,
1854,,,,,CHEMBL616825,B,BAO_0000357,,,9,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,Rattus norvegicus,10116.0,
1855,,,,,CHEMBL616826,B,BAO_0000357,,,9,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,Rattus norvegicus,10116.0,
1856,,,,,CHEMBL616827,B,BAO_0000019,,,9,11624,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,Rattus norvegicus,10116.0,
1857,,,,,CHEMBL616828,B,BAO_0000357,,,9,11139,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,Rattus norvegicus,10116.0,
1858,,,,,CHEMBL616829,B,BAO_0000357,,,9,11147,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,Rattus norvegicus,10116.0,
1859,,,,,CHEMBL616830,B,BAO_0000019,,,9,10444,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,Rattus norvegicus,10116.0,
1860,,,,,CHEMBL616831,B,BAO_0000357,,,9,11624,Binding affinity against 5-hydroxytryptamine 1C receptor,,Rattus norvegicus,10116.0,
1861,,,,,CHEMBL616832,B,BAO_0000019,,,9,11662,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,Rattus norvegicus,10116.0,
1862,,,,,CHEMBL616833,B,BAO_0000019,,,9,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,Rattus norvegicus,10116.0,
1863,,,,,CHEMBL616834,B,BAO_0000019,,,9,11662,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,Rattus norvegicus,10116.0,
1864,,,,,CHEMBL829595,B,BAO_0000019,,,9,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,Rattus norvegicus,10116.0,
1865,,,,,CHEMBL616835,B,BAO_0000357,,,9,9098,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,Rattus norvegicus,10116.0,
1866,,,,,CHEMBL872910,B,BAO_0000249,,,9,10394,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,Rattus norvegicus,10116.0,
1867,,,,,CHEMBL616836,B,BAO_0000357,,,8,11933,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,,,
1868,,,,,CHEMBL616837,B,BAO_0000357,,,9,12092,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,Rattus norvegicus,10116.0,
1869,,,,,CHEMBL616466,B,BAO_0000019,,,9,12253,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,Rattus norvegicus,10116.0,
1870,,,,HEK293,CHEMBL616467,B,BAO_0000219,,,9,12253,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,Rattus norvegicus,10116.0,
1871,,,,,CHEMBL616468,B,BAO_0000357,,,8,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,,,
1872,,,,,CHEMBL616469,B,BAO_0000357,,,8,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,,,
1873,,,,,CHEMBL616470,B,BAO_0000357,,,8,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,,,
1874,,,,,CHEMBL616471,B,BAO_0000357,,,8,11574,Binding affinity against 5-hydroxytryptamine 1C receptor,,,,
1875,,,,,CHEMBL616472,B,BAO_0000357,,,8,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,,,
1876,,,,,CHEMBL616473,B,BAO_0000357,,,8,13944,Binding affinity against 5-hydroxytryptamine 1C receptor,,,,
1877,,,,,CHEMBL616474,B,BAO_0000357,,,8,13033,Binding affinity against serotonergic 5-HT1c receptor,,,,
1878,,,,,CHEMBL616475,B,BAO_0000357,,,8,10321,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,,,
1879,,,,,CHEMBL616476,B,BAO_0000357,,,8,11866,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,,,
1880,,,,,CHEMBL616477,B,BAO_0000019,,,8,14454,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,Oryctolagus cuniculus,9986.0,
1881,,,,,CHEMBL616478,B,BAO_0000224,,,4,11574,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,,,
1882,,,,,CHEMBL616479,B,BAO_0000224,,,4,11574,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,,,
1883,,,,,CHEMBL616480,B,BAO_0000019,,,4,13631,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,,,
1884,,,,,CHEMBL616481,B,BAO_0000019,,,5,9630,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,Rattus norvegicus,10116.0,
1885,,,,,CHEMBL616482,B,BAO_0000249,,,5,8822,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,Rattus norvegicus,10116.0,
1886,Brain,,,,CHEMBL884713,B,BAO_0000221,,,5,9064,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,,Rattus norvegicus,10116.0,
1887,,,,,CHEMBL616483,B,BAO_0000224,,,4,8868,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,,,
1888,,,,,CHEMBL616484,B,BAO_0000224,,,4,9064,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,,,
1889,,,,,CHEMBL616485,B,BAO_0000019,,,4,9806,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,,,
1890,,,,,CHEMBL616486,B,BAO_0000224,,,4,9098,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,,
1891,,,,,CHEMBL616487,B,BAO_0000224,,,4,8868,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,,,
1892,,,,,CHEMBL616488,B,BAO_0000224,,,4,12765,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,,,
1893,,,,,CHEMBL616489,B,BAO_0000019,,,4,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,
1894,,,,,CHEMBL616490,B,BAO_0000019,,,4,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,
1895,,,,,CHEMBL616491,B,BAO_0000019,,,4,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,,,
1896,,,,,CHEMBL616492,B,BAO_0000019,,,4,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,,,
1897,,,,,CHEMBL616493,B,BAO_0000019,,,4,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,
1898,,,,,CHEMBL616494,B,BAO_0000019,,,4,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,,,
1899,,,,,CHEMBL616495,B,BAO_0000019,,,4,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,,,
1900,,,,,CHEMBL616496,B,BAO_0000019,,,4,3086,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,,,
1901,,,,,CHEMBL616497,B,BAO_0000019,,,4,11049,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,
1902,,,,,CHEMBL616498,B,BAO_0000019,,,4,11049,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,
1903,,,,,CHEMBL616499,B,BAO_0000019,,,4,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,,,
1904,,,,,CHEMBL616500,B,BAO_0000019,,,4,10922,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,,,
1905,Brain,,,,CHEMBL616501,B,BAO_0000221,,,5,9064,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,Rattus norvegicus,10116.0,
1906,Brain,,,,CHEMBL616502,B,BAO_0000221,,,4,10748,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,,,
1907,,,,,CHEMBL884529,B,BAO_0000249,,,4,11614,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,,,Membranes
1908,,,,,CHEMBL616503,B,BAO_0000249,,,4,11615,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,,,Membranes
1909,,,,,CHEMBL616964,B,BAO_0000224,,,4,11615,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,,,
1910,,,,,CHEMBL616965,B,BAO_0000249,,,4,11614,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,,,Membranes
1911,,,,,CHEMBL616966,B,BAO_0000224,,,4,11702,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,,,
1912,,,,,CHEMBL616967,B,BAO_0000224,,,4,11702,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,,,
1913,,,,,CHEMBL616968,B,BAO_0000224,,,5,11702,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,Rattus norvegicus,10116.0,
1914,,,,,CHEMBL616969,B,BAO_0000224,,,4,11702,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,,,
1915,,,,,CHEMBL884530,B,BAO_0000019,,,4,13346,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,,,
1916,,,,,CHEMBL616970,B,BAO_0000224,,,4,10025,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,,,
1917,,,,,CHEMBL616971,B,BAO_0000224,,,4,10025,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,,,
1918,,,,,CHEMBL616972,B,BAO_0000224,,,4,10025,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,,,
1919,,,,,CHEMBL616973,B,BAO_0000224,,,4,9036,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,,,
1920,,,,,CHEMBL616974,B,BAO_0000224,,,4,9036,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,,,
1921,,,,,CHEMBL616975,B,BAO_0000019,,,4,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,,,
1922,,,,,CHEMBL616976,B,BAO_0000019,,,4,12304,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,,,
1923,,,,,CHEMBL616977,B,BAO_0000224,,,4,13276,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,,,
1924,,,,,CHEMBL616978,B,BAO_0000224,,,4,11825,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,,,
1925,,,,,CHEMBL616979,B,BAO_0000224,,,4,12443,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,,,
1926,,,,,CHEMBL616980,B,BAO_0000224,,,4,13830,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,,,
1927,,,,,CHEMBL616981,B,BAO_0000249,,,4,9592,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,,,Membranes
1928,,,,,CHEMBL616982,B,BAO_0000249,,,4,9592,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,,,Membranes
1929,,,,,CHEMBL616983,B,BAO_0000224,,,4,10881,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,,,
1930,,,,,CHEMBL616984,B,BAO_0000019,,,4,13605,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,,,
1931,,,,,CHEMBL616985,B,BAO_0000224,,,5,11624,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,Rattus norvegicus,10116.0,
1932,,,,,CHEMBL616986,B,BAO_0000224,,,4,4101,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,,,
1933,,,,,CHEMBL616987,B,BAO_0000224,,,4,4101,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,,,
1934,,,,,CHEMBL616988,B,BAO_0000019,,,4,15360,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,,,
1935,,,,,CHEMBL617243,B,BAO_0000019,,,4,11576,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,,,
1936,,,,,CHEMBL617244,B,BAO_0000019,,,4,5834,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,,,
1937,,,,CHO-K1,CHEMBL617245,B,BAO_0000219,,,5,2395,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,Rattus norvegicus,10116.0,
1938,,,,,CHEMBL617246,B,BAO_0000249,,,4,11965,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,,,Membranes
1939,,,,,CHEMBL617546,B,BAO_0000224,,,4,3967,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,,,
1940,,,,,CHEMBL617547,B,BAO_0000249,,,4,11130,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,,,Brain membranes
1941,,,,,CHEMBL617548,B,BAO_0000219,,,4,13427,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,In vitro,,,
1942,,,,,CHEMBL617549,B,BAO_0000224,,,4,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,
1943,,,,,CHEMBL617550,B,BAO_0000224,,,4,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,,,
1944,,,,,CHEMBL617551,B,BAO_0000224,,,4,11825,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,,,
1945,,,,,CHEMBL617552,B,BAO_0000249,,,4,12120,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,,,Membranes
1946,,,,,CHEMBL617553,B,BAO_0000249,,,4,12120,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,,,Membranes
1947,Thoracic aorta,,,,CHEMBL617554,F,BAO_0000019,,,4,11963,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,,,
1948,,,,,CHEMBL617555,B,BAO_0000019,,,4,9069,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,,,
1949,,,,,CHEMBL617556,B,BAO_0000224,,,4,8868,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,,,
1950,,,,,CHEMBL617557,B,BAO_0000357,,,8,17200,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,,,
1951,,,,,CHEMBL617558,B,BAO_0000357,,,8,17200,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,,,
1952,,,,,CHEMBL617559,B,BAO_0000357,,,8,13969,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,,,
1953,,,,,CHEMBL617560,B,BAO_0000357,,,9,13392,Binding affinity for 5-hydroxytryptamine 1D receptor,,,,
1954,,,,,CHEMBL617561,B,BAO_0000249,,,8,1742,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,,
1955,,,,,CHEMBL617562,B,BAO_0000249,,,8,1742,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,,
1956,Striatum,,,,CHEMBL617563,B,BAO_0000357,,,8,14331,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,,,
1957,,,,,CHEMBL617564,F,BAO_0000019,,,8,12861,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,,,
1958,,,,,CHEMBL617565,B,BAO_0000019,,,8,12861,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,,,
1959,,,,,CHEMBL856076,B,BAO_0000357,,,8,12861,Binding activity radioligand.,,,,
1960,,,,,CHEMBL617566,B,BAO_0000019,,,8,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,,
1961,,,,,CHEMBL875911,B,BAO_0000019,,,8,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,,
1962,,,,,CHEMBL617567,B,BAO_0000019,,,8,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,,,
1963,,,,,CHEMBL617568,B,BAO_0000249,,,8,675,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,,
1964,,,,,CHEMBL617569,B,BAO_0000019,,,8,12490,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,,,
1965,,,,,CHEMBL617570,B,BAO_0000249,,,8,11828,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,,,
1966,,,,,CHEMBL617571,B,BAO_0000357,,,8,11866,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,,,
1967,,,,,CHEMBL617572,B,BAO_0000357,,,8,773,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,Sus scrofa,9823.0,
1968,,,,,CHEMBL617573,B,BAO_0000357,,,8,13047,The compound was tested for intrinsic activity against 5-HT1D receptor,,Oryctolagus cuniculus,9986.0,
1969,,,,,CHEMBL617574,B,BAO_0000019,,,8,13047,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,Oryctolagus cuniculus,9986.0,
1970,,,,,CHEMBL617575,B,BAO_0000357,,,8,13047,The compound was tested for binding affinity against 5-HT1D receptor,,Oryctolagus cuniculus,9986.0,
1971,,,,,CHEMBL617576,B,BAO_0000357,,,8,188,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,,,
1972,,,,,CHEMBL617577,F,BAO_0000019,,,8,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,,,
1973,,,,,CHEMBL617578,F,BAO_0000019,,,8,12438,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,,,
1974,,,,,CHEMBL617579,B,BAO_0000357,,,8,12438,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,,,
1975,,,,,CHEMBL617580,B,BAO_0000019,,,8,15854,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,,
1976,,,,,CHEMBL617581,B,BAO_0000249,,,8,10394,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,,,
1977,,,,,CHEMBL617582,B,BAO_0000357,,,8,12092,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,,,
1978,,,,,CHEMBL617583,B,BAO_0000019,,,8,3389,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,,,
1979,,,,,CHEMBL617584,B,BAO_0000357,,,8,6011,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,,,
1980,,,,,CHEMBL617585,B,BAO_0000357,,,8,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,,,
1981,,,,,CHEMBL875912,B,BAO_0000357,,,8,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,,,
1982,,,,,CHEMBL617586,B,BAO_0000357,,,8,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,,,
1983,,,,,CHEMBL617587,B,BAO_0000357,,,8,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,,,
1984,,,,,CHEMBL617588,B,BAO_0000357,,,8,11866,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,,,
1985,,,,,CHEMBL857980,B,BAO_0000357,,,8,4687,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,,,
1986,,,,,CHEMBL617589,B,BAO_0000357,,,8,12146,Tested against 5-hydroxytryptamine 1D receptor,,,,
1987,,,,,CHEMBL617590,B,BAO_0000357,,,8,10321,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,,,
1988,,,,HEK293,CHEMBL617591,B,BAO_0000219,,,8,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,,,
1989,,,,,CHEMBL617592,B,BAO_0000357,,,9,1274,Binding affinity against 5-Hydroxytryptamine 1D receptor,,Homo sapiens,9606.0,
1990,,,,,CHEMBL617593,B,BAO_0000357,,,8,15250,,,,,
1991,,,,CHO-K1,CHEMBL617594,B,BAO_0000219,,,8,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,,
1992,,,,CHO-K1,CHEMBL617595,B,BAO_0000219,,,8,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,,
1993,,,,HEK293,CHEMBL617596,B,BAO_0000219,,,8,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,,,
1994,,,,HEK293,CHEMBL617597,B,BAO_0000219,,,8,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,,,
1995,,,,,CHEMBL617598,B,BAO_0000019,,,8,13047,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,,,
1996,,,,,CHEMBL872916,B,BAO_0000357,,,8,13366,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,,,
1997,,,,,CHEMBL617599,B,BAO_0000357,,,8,13366,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,,,
1998,,,,,CHEMBL617091,B,BAO_0000357,,,8,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,,,
1999,,,,CHO-K1,CHEMBL617092,B,BAO_0000219,,,8,12902,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,,,
2000,,,,CHO-K1,CHEMBL617093,B,BAO_0000219,,,8,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,,
2001,,,,,CHEMBL617094,F,BAO_0000019,,,8,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,,,
2002,,,,,CHEMBL617095,F,BAO_0000019,,,8,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,,
2003,,,,,CHEMBL617096,F,BAO_0000019,,,8,14251,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,,
2004,,,,,CHEMBL617097,F,BAO_0000019,,,8,14251,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,,
2005,,,,,CHEMBL617098,F,BAO_0000019,,,8,14251,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,,
2006,,,,,CHEMBL617301,B,BAO_0000357,,,8,13313,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,,,
2007,,,,,CHEMBL617302,B,BAO_0000357,,,8,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,,,
2008,,,,,CHEMBL617303,B,BAO_0000357,,,8,13366,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,,,
2009,,,,,CHEMBL617304,B,BAO_0000357,,,8,13051,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,,,
2010,,,,CHO,CHEMBL617305,B,BAO_0000219,,,8,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,,,
2011,,,,,CHEMBL617306,B,BAO_0000219,,,9,12469,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,Homo sapiens,9606.0,
2012,,,,,CHEMBL617307,B,BAO_0000357,,,8,5619,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,,,
2013,,,,,CHEMBL617308,B,BAO_0000019,,,8,13047,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,Oryctolagus cuniculus,9986.0,
2014,,,,,CHEMBL617309,B,BAO_0000357,,,8,16633,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,,,
2015,,,,,CHEMBL617310,B,BAO_0000357,,,8,16633,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,,,
2016,,,,,CHEMBL617311,B,BAO_0000357,,,8,16633,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,,,
2017,,,,,CHEMBL617312,B,BAO_0000357,,,8,16633,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,,,
2018,,,,,CHEMBL617313,B,BAO_0000357,,,8,3269,Affinity against 5-hydroxytryptamine 1D receptor alpha,,,,
2019,,,,,CHEMBL617314,B,BAO_0000357,,,8,12409,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,,,
2020,,,,,CHEMBL617315,F,BAO_0000019,,,8,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,,
2021,,,,HEK293,CHEMBL617316,B,BAO_0000219,,,8,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,,,
2022,,,,HEK293,CHEMBL617317,B,BAO_0000219,,,8,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,,,
2023,,,,CHO,CHEMBL617318,B,BAO_0000219,,,8,12903,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,,,
2024,,,,,CHEMBL617319,B,BAO_0000019,,,8,13047,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,,,
2025,,,,,CHEMBL617320,B,BAO_0000357,,,9,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,,
2026,,,,,CHEMBL617321,B,BAO_0000357,,,9,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,,
2027,,,,,CHEMBL617322,B,BAO_0000357,,,9,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,,
2028,,,,,CHEMBL616862,B,BAO_0000357,,,8,13366,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,,,
2029,,,,,CHEMBL616863,B,BAO_0000357,,,8,13366,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,,,
2030,,,,CHO,CHEMBL616864,B,BAO_0000219,,,8,12469,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,,,
2031,,,,CHO-K1,CHEMBL616865,B,BAO_0000219,,,8,13706,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,,,
2032,,,,CHO-K1,CHEMBL616866,B,BAO_0000219,,,8,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,,,
2033,,,,,CHEMBL616867,F,BAO_0000019,,,8,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,,
2034,,,,CHO-K1,CHEMBL616868,B,BAO_0000219,,,8,12902,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,,,
2035,,,,,CHEMBL616869,B,BAO_0000357,,,8,13051,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,,,
2036,,,,CHO,CHEMBL616870,B,BAO_0000219,,,8,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,,,
2037,,,,CHO-K1,CHEMBL616871,F,BAO_0000219,,,8,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,,,
2038,,,,CHO-K1,CHEMBL616872,F,BAO_0000219,,,8,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,,,
2039,,,,CHO-K1,CHEMBL616873,F,BAO_0000219,,,8,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,,,
2040,,,,CHO-K1,CHEMBL616838,F,BAO_0000219,,,8,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,,,
2041,,,,,CHEMBL616839,B,BAO_0000357,,,8,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,,,
2042,,,,,CHEMBL616840,B,BAO_0000019,,,8,13047,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,Oryctolagus cuniculus,9986.0,
2043,,,,,CHEMBL616841,B,BAO_0000357,,,8,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,,,
2044,,,,,CHEMBL616842,B,BAO_0000357,,,8,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,,,
2045,,,,,CHEMBL857976,B,BAO_0000357,,,8,12409,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,,,
2046,,,,CHO,CHEMBL616843,B,BAO_0000219,,,8,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,,,
2047,,,,,CHEMBL616844,B,BAO_0000357,,,9,1348,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,Homo sapiens,9606.0,
2048,,,,,CHEMBL616845,B,BAO_0000357,,,8,1348,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,,,
2049,,,,,CHEMBL616846,B,BAO_0000357,,,9,4234,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,Homo sapiens,9606.0,
2050,,,,,CHEMBL616847,B,BAO_0000357,,,8,16209,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,,,
2051,,,,,CHEMBL616848,B,BAO_0000019,,,8,10444,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,,,
2052,,,,,CHEMBL616849,B,BAO_0000357,,,8,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,,,
2053,,,,,CHEMBL872911,B,BAO_0000357,,,8,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,,,
2054,,,,,CHEMBL616850,B,BAO_0000019,,,8,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,,,
2055,,,,CHO,CHEMBL616699,B,BAO_0000219,,,9,12936,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,Homo sapiens,9606.0,
2056,,,,,CHEMBL616700,B,BAO_0000357,,,8,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,,,
2057,,,,CHO,CHEMBL616701,B,BAO_0000219,,,8,15779,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,,
2058,,,,CHO,CHEMBL616702,B,BAO_0000219,,,8,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,,,
2059,,,,CHO,CHEMBL616703,B,BAO_0000219,,,8,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,,,
2060,,,,,CHEMBL616704,B,BAO_0000357,,,8,13181,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,,,
2061,,,,CHO,CHEMBL616705,B,BAO_0000219,,,8,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,,,
2062,,,,,CHEMBL616706,B,BAO_0000357,,,8,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,,,
2063,,,,CHO,CHEMBL616707,B,BAO_0000219,,,8,15146,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,,,
2064,,,,,CHEMBL616708,B,BAO_0000357,,,8,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,,,
2065,,,,,CHEMBL616709,B,BAO_0000357,,,8,12146,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,,,
2066,,,,CHO,CHEMBL616710,B,BAO_0000219,,,8,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,,,
2067,,,,CHO,CHEMBL616711,B,BAO_0000219,,,8,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,,,
2068,,,,CHO,CHEMBL616712,B,BAO_0000219,,,8,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,,,
2069,,,,,CHEMBL616713,B,BAO_0000357,,,8,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,,,
2070,,,,,CHEMBL616714,B,BAO_0000357,,,8,4373,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,,,
2071,,,,,CHEMBL616715,B,BAO_0000357,,,8,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,,,
2072,,,,,CHEMBL616716,B,BAO_0000357,,,8,16633,Binding affinity towards 5-hydroxytryptamine 1E receptor,,,,
2073,,,,,CHEMBL616717,F,BAO_0000019,,,8,17085,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,,,
2074,,,,,CHEMBL616718,F,BAO_0000019,,,8,17085,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,,,
2075,,,,,CHEMBL875905,F,BAO_0000019,,,8,16209,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,,,
2076,,,,,CHEMBL616719,F,BAO_0000019,,,8,16209,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,,,
2077,,,,,CHEMBL616720,F,BAO_0000019,,,8,17085,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,,,
2078,,,,,CHEMBL616721,B,BAO_0000357,,,8,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,,,
2079,,,,CHO,CHEMBL616722,B,BAO_0000219,,,8,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,,,
2080,,,,,CHEMBL616723,B,BAO_0000357,,,8,3805,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,,,
2081,,,,CHO,CHEMBL616724,B,BAO_0000219,,,8,16190,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,,,
2082,,,,,CHEMBL616725,B,BAO_0000357,,,8,16190,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,,,
2083,,,,,CHEMBL616726,B,BAO_0000357,,,8,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,,,
2084,,,,,CHEMBL616727,B,BAO_0000357,,,8,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,,,
2085,,,,,CHEMBL616728,B,BAO_0000357,,,8,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,,,
2086,,,,,CHEMBL616729,B,BAO_0000357,,,8,6866,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,,,
2087,,,,,CHEMBL616730,B,BAO_0000019,,,8,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,,,
2088,,,,,CHEMBL617125,B,BAO_0000357,,,8,16312,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,,,
2089,,,,,CHEMBL857977,B,BAO_0000357,,,8,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,,,
2090,,,,CHO,CHEMBL617126,B,BAO_0000219,,,8,15779,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,,
2091,,,,CHO,CHEMBL617127,B,BAO_0000219,,,8,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,,,
2092,,,,,CHEMBL617128,B,BAO_0000357,,,8,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,,,
2093,,,,CHO,CHEMBL617129,B,BAO_0000219,,,8,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,,,
2094,,,,,CHEMBL617130,B,BAO_0000357,,,8,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,,,
2095,,,,CHO,CHEMBL617131,B,BAO_0000219,,,8,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,,,
2096,,,,CHO,CHEMBL617132,B,BAO_0000219,,,8,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,,,
2097,,,,CHO,CHEMBL617133,B,BAO_0000219,,,8,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,,,
2098,,,,,CHEMBL617134,B,BAO_0000357,,,8,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,,,
2099,,,,,CHEMBL617135,B,BAO_0000357,,,8,4373,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,,,
2100,,,,,CHEMBL617136,B,BAO_0000357,,,8,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,,,
2101,,,,,CHEMBL617137,B,BAO_0000019,,,4,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,,,
2102,,,,,CHEMBL617138,B,BAO_0000019,,,4,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,,,
2103,,,,,CHEMBL617139,B,BAO_0000019,,,4,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,,
2104,,,,,CHEMBL617140,B,BAO_0000019,,,8,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,,,
2105,,,,,CHEMBL617141,F,BAO_0000218,,,4,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",In vivo,,,
2106,,,,,CHEMBL858112,F,BAO_0000019,,,4,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,
2107,,,,,CHEMBL617142,B,BAO_0000019,,,8,12352,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,,,
2108,,,,,CHEMBL617143,B,BAO_0000019,,,0,13657,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,Bos taurus,9913.0,
2109,,,,,CHEMBL617144,B,BAO_0000019,,,0,14331,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,Bos taurus,9913.0,
2110,,,,,CHEMBL617145,B,BAO_0000019,,,0,14331,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,Bos taurus,9913.0,
2111,,,,,CHEMBL617146,B,BAO_0000019,,,0,14331,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,,,
2112,,,,,CHEMBL617147,B,BAO_0000019,,,4,12685,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,Cavia porcellus,10141.0,
2113,,,,,CHEMBL617148,B,BAO_0000019,,,4,14389,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,Cavia porcellus,10141.0,
2114,,,,,CHEMBL617149,B,BAO_0000019,,,4,14386,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,Cavia porcellus,10141.0,
2115,,,,,CHEMBL617150,B,BAO_0000224,,,4,5732,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,,,
2116,,,,,CHEMBL617151,B,BAO_0000224,,,4,16293,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,,
2117,,,,,CHEMBL617201,B,BAO_0000224,,,4,2078,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,,,
2118,,,,,CHEMBL617202,B,BAO_0000357,,,8,5486,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,,,
2119,,,,,CHEMBL617203,B,BAO_0000218,,,4,11820,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,In vivo,,,
2120,,,,,CHEMBL617204,B,BAO_0000019,,,4,10297,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,,,
2121,,,,,CHEMBL617205,B,BAO_0000224,,,4,13704,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,,,
2122,,,,,CHEMBL617206,B,BAO_0000019,,,5,10297,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,Mus musculus,10090.0,
2123,,,,,CHEMBL617207,B,BAO_0000218,,,4,11820,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,In vivo,,,
2124,,,,,CHEMBL617208,B,BAO_0000019,,,5,10297,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,Mus musculus,10090.0,
2125,,,,,CHEMBL617209,B,BAO_0000224,,,4,11555,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,,,
2126,,,,,CHEMBL617210,B,BAO_0000224,,,4,11555,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,,,
2127,,,,,CHEMBL617211,B,BAO_0000224,,,4,11555,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,,,
2128,,,,,CHEMBL617212,B,BAO_0000019,,,5,10297,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,Mus musculus,10090.0,
2129,,,,,CHEMBL617213,B,BAO_0000224,,,4,16688,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,Sus scrofa,9823.0,
2130,,,,,CHEMBL617214,B,BAO_0000224,,,4,16688,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,Sus scrofa,9823.0,
2131,,,,,CHEMBL617215,B,BAO_0000221,,,0,5333,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,,,
2132,,,,,CHEMBL617216,B,BAO_0000221,,,0,4437,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,,,
2133,,,,,CHEMBL617217,B,BAO_0000357,,,8,5033,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,Sus scrofa,9823.0,
2134,,,,,CHEMBL617218,B,BAO_0000019,,,4,15267,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,,,
2135,,,,,CHEMBL872913,B,BAO_0000019,,,4,15267,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,,,
2136,,,,,CHEMBL617219,B,BAO_0000019,,,4,11820,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,,,
2137,,,,,CHEMBL873482,B,BAO_0000224,,,4,9069,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,,,
2138,,,,,CHEMBL617220,B,BAO_0000019,,,5,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,Rattus norvegicus,10116.0,
2139,,,,,CHEMBL617221,B,BAO_0000019,,,4,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,,,
2140,,,,,CHEMBL617222,B,BAO_0000019,,,4,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,,,
2141,,,,,CHEMBL875906,F,BAO_0000019,,,4,10428,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,,,
2142,,,,,CHEMBL617223,B,BAO_0000019,,,4,9628,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,,,
2143,,,,,CHEMBL617224,B,BAO_0000224,,,4,12704,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,,,
2144,,,,,CHEMBL617225,B,BAO_0000224,,,5,15453,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,Rattus norvegicus,10116.0,
2145,,,,,CHEMBL617226,B,BAO_0000224,,,4,188,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,,,
2146,,,,,CHEMBL617227,B,BAO_0000224,,,4,10349,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,,,
2147,,,,,CHEMBL617228,B,BAO_0000224,,,4,10349,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,,,
2148,,,,,CHEMBL617229,B,BAO_0000224,,,4,8868,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,,,
2149,,,,,CHEMBL617230,B,BAO_0000224,,,4,10025,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,,,
2150,,,,,CHEMBL617231,B,BAO_0000224,,,4,10025,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,,,
2151,,,,,CHEMBL617232,B,BAO_0000224,,,4,11702,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,,,
2152,,,,,CHEMBL617233,B,BAO_0000224,,,4,11702,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,,,
2153,,,,,CHEMBL617234,B,BAO_0000224,,,4,11702,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,,,
2154,,,,,CHEMBL617235,F,BAO_0000019,,,4,11702,Compound was tested for the inhibition of quipazine induced head twitches in rats,,,,
2155,,,,,CHEMBL617236,F,BAO_0000019,,,4,11702,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,,,
2156,Hippocampus,,,,CHEMBL617237,B,BAO_0000221,,,4,10085,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,,,
2157,Hippocampus,,,,CHEMBL617238,B,BAO_0000221,,,4,10085,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,,,
2158,Brain,,,,CHEMBL617239,B,BAO_0000221,,,5,9630,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,,Rattus norvegicus,10116.0,
2159,,,,,CHEMBL617240,B,BAO_0000019,,,4,11070,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,,,
2160,,,,,CHEMBL617241,B,BAO_0000249,,,4,9841,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,,,Membranes
2161,,,,,CHEMBL875907,B,BAO_0000249,,,4,9841,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,,,Membranes
2162,,,,,CHEMBL617242,B,BAO_0000019,,,4,13291,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,,,
2163,,,,,CHEMBL617152,F,BAO_0000019,,,4,10590,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,,,
2164,Brain,,,,CHEMBL617153,B,BAO_0000221,,,5,9064,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,Rattus norvegicus,10116.0,
2165,,,,,CHEMBL617154,B,BAO_0000249,,,5,12268,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,,Rattus norvegicus,10116.0,Membranes
2166,Brain,,,,CHEMBL617155,B,BAO_0000221,,,4,13508,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,,,
2167,,,,,CHEMBL617156,F,BAO_0000019,,,4,11279,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,,,
2168,,,,,CHEMBL617157,F,BAO_0000019,,,4,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,,,
2169,,,,,CHEMBL617158,F,BAO_0000019,,,4,11200,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,
2170,,,,,CHEMBL617159,F,BAO_0000019,,,4,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,,,
2171,,,,,CHEMBL617160,F,BAO_0000019,,,4,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,,,
2172,,,,,CHEMBL858113,F,BAO_0000019,,,4,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,
2173,Brain,,,,CHEMBL617247,B,BAO_0000220,,,4,9231,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,,,
2174,,,,,CHEMBL617248,B,BAO_0000019,,,4,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,,,
2175,Brain,,,,CHEMBL617249,B,BAO_0000249,,,4,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,,
2176,,,,,CHEMBL617250,B,BAO_0000019,,,4,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,,,
2177,,,,,CHEMBL617251,B,BAO_0000019,,,4,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,,,
2178,,,,,CHEMBL617252,B,BAO_0000019,,,5,11828,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,Rattus norvegicus,10116.0,
2179,,,,,CHEMBL617006,B,BAO_0000019,,,4,12253,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,,,
2180,,,,,CHEMBL617007,B,BAO_0000019,,,4,12253,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,,,
2181,,,,,CHEMBL617008,F,BAO_0000019,,,4,11279,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,,,
2182,,,,,CHEMBL617009,B,BAO_0000019,,,4,11866,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,,,
2183,,,,,CHEMBL617010,B,BAO_0000224,,,5,14424,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,Rattus norvegicus,10116.0,
2184,,,,,CHEMBL857978,B,BAO_0000019,,,5,15180,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,Rattus norvegicus,10116.0,
2185,,,,,CHEMBL617011,B,BAO_0000019,,,5,15180,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,Rattus norvegicus,10116.0,
2186,,,,,CHEMBL617012,B,BAO_0000019,,,5,9786,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,Rattus norvegicus,10116.0,
2187,,,,,CHEMBL617013,B,BAO_0000224,,,4,12132,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,,,
2188,,,,,CHEMBL617014,B,BAO_0000249,,,4,5486,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,,,
2189,,,,,CHEMBL617015,B,BAO_0000019,,,4,15316,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,,,
2190,,,,,CHEMBL617016,B,BAO_0000019,,,4,16429,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,,,
2191,,,,,CHEMBL617017,B,BAO_0000224,,,4,14617,pKi value for 5-hydroxytryptamine 2 receptor binding site,,,,
2192,Brain,,,,CHEMBL617018,B,BAO_0000221,,,4,11351,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,,,
2193,,,,,CHEMBL617019,F,BAO_0000019,,,4,11279,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,,,
2194,,,,,CHEMBL617020,B,BAO_0000019,,,4,9523,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,,
2195,,,,,CHEMBL617021,B,BAO_0000019,,,4,9523,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,,
2196,,,,,CHEMBL617022,B,BAO_0000019,,,4,9523,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,,
2197,,,,,CHEMBL617023,B,BAO_0000019,,,4,9523,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,,
2198,,,,,CHEMBL617024,B,BAO_0000019,,,4,9523,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,,
2199,,,,,CHEMBL617025,B,BAO_0000019,,,4,9523,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,,
2200,,,,,CHEMBL617026,B,BAO_0000224,,,4,9523,Hill coefficient of compound was determined,,,,
2201,,,,,CHEMBL617027,B,BAO_0000019,,,0,4771,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,,,
2202,,,,,CHEMBL617028,B,BAO_0000019,,,5,5033,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,Rattus norvegicus,10116.0,
2203,,,,,CHEMBL617029,B,BAO_0000019,,,8,10845,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,,,
2204,,,,,CHEMBL875908,B,BAO_0000019,,,8,10845,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,,,
2205,,,,,CHEMBL617030,B,BAO_0000357,,,8,16288,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,,,
2206,,,,,CHEMBL617031,B,BAO_0000019,,,8,16288,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,,,
2207,,,,,CHEMBL617032,B,BAO_0000019,,,8,16190,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,,,
2208,,,,,CHEMBL617033,B,BAO_0000224,,,5,12463,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,Rattus norvegicus,10116.0,
2209,,,,,CHEMBL617034,B,BAO_0000224,,,4,9699,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,,,
2210,,,,,CHEMBL617035,B,BAO_0000224,,,4,9699,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,,,
2211,,,,,CHEMBL617036,B,BAO_0000019,,,4,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,,
2212,,,,,CHEMBL617037,B,BAO_0000224,,,4,1205,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,,,
2213,,,,,CHEMBL617038,B,BAO_0000219,,,0,11376,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,,,
2214,,,,,CHEMBL617039,B,BAO_0000219,,,4,11376,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,,,
2215,,,,,CHEMBL617161,B,BAO_0000224,,,4,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,,,
2216,,,,,CHEMBL617162,B,BAO_0000224,,,4,2222,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,,,
2217,,,,,CHEMBL617163,B,BAO_0000224,,,4,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,,,
2218,,,,,CHEMBL617164,B,BAO_0000224,,,4,1089,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,,,
2219,,,,,CHEMBL617165,B,BAO_0000249,,,4,386,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,,,Brain membranes
2220,,,,,CHEMBL617166,B,BAO_0000224,,,4,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,,,
2221,,,,,CHEMBL617167,B,BAO_0000224,,,4,17066,Binding affinity towards 5-HT2 receptor,,,,
2222,,,,,CHEMBL872912,B,BAO_0000224,,,4,959,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,,
2223,,,,,CHEMBL617168,B,BAO_0000224,,,4,6398,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,,,
2224,,,,,CHEMBL617169,B,BAO_0000224,,,4,11889,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,,,
2225,,,,,CHEMBL617170,B,BAO_0000224,,,4,4221,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,,
2226,,,,,CHEMBL617171,B,BAO_0000224,,,4,11026,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,,,
2227,,,,,CHEMBL617172,B,BAO_0000224,,,4,11866,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,,,
2228,,,,,CHEMBL617173,B,BAO_0000224,,,4,4221,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,,
2229,,,,,CHEMBL617174,B,BAO_0000019,,,0,13950,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,,
2230,,,,,CHEMBL617175,B,BAO_0000224,,,4,1263,5-hydroxytryptamine 2 receptor binding affinity,,,,
2231,,,,,CHEMBL617176,B,BAO_0000357,,,8,13291,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,,,
2232,,,,,CHEMBL617177,B,BAO_0000357,,,8,10812,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,,,
2233,,,,,CHEMBL617178,B,BAO_0000224,,,4,13020,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,,,
2234,,,,,CHEMBL617179,B,BAO_0000224,,,4,13021,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,,,
2235,,,,,CHEMBL617180,B,BAO_0000224,,,4,13020,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,,,
2236,,,,,CHEMBL617181,B,BAO_0000357,,,8,14532,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,,,
2237,,,,,CHEMBL617182,B,BAO_0000357,,,8,13944,Binding affinity against 5-hydroxytryptamine 2 receptor,,,,
2238,,,,,CHEMBL617183,B,BAO_0000357,,,8,14331,Binding affinity against 5-hydroxytryptamine 2 receptor,,,,
2239,,,,,CHEMBL617184,B,BAO_0000357,,,8,14118,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,,,
2240,,,,,CHEMBL617185,B,BAO_0000357,,,8,13033,Binding affinity against serotonergic 5-HT2 receptor,,,,
2241,,,,,CHEMBL617186,B,BAO_0000357,,,8,10321,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,,,
2242,,,,,CHEMBL617187,B,BAO_0000357,,,8,12918,Compound was evaluated for the binding affinity at 5- HT2 receptor,,,,
2243,,,,,CHEMBL617188,B,BAO_0000357,,,8,15120,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,,,
2244,,,,,CHEMBL617189,B,BAO_0000218,,,8,2613,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,,,
2245,,,,,CHEMBL617190,B,BAO_0000224,,,5,13378,Inhibitory activity against cloned human 5-HT2 receptor,,Homo sapiens,9606.0,
2246,,,,CHO,CHEMBL617191,B,BAO_0000219,,,5,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,Homo sapiens,9606.0,
2247,,,,CHO,CHEMBL617192,B,BAO_0000219,,,5,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,Homo sapiens,9606.0,
2248,,,,CHO,CHEMBL617193,B,BAO_0000219,,,5,2331,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,Homo sapiens,9606.0,
2249,,,,CHO,CHEMBL617194,B,BAO_0000219,,,5,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,Homo sapiens,9606.0,
2250,,,,,CHEMBL617195,B,BAO_0000224,,,4,4170,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,
2251,,,,,CHEMBL881830,B,BAO_0000224,,,4,15453,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,,,
2252,,,,,CHEMBL617196,B,BAO_0000357,,,8,1479,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,
2253,,,,,CHEMBL617197,B,BAO_0000224,,,4,11139,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,,,
2254,,,,,CHEMBL617198,B,BAO_0000357,,,8,13969,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,,,
2255,,,,,CHEMBL873476,B,BAO_0000357,,,8,13392,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,,
2256,,,,,CHEMBL617199,B,BAO_0000019,,,8,14430,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,,,
2257,,,,,CHEMBL617200,B,BAO_0000357,,,8,13181,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,Cavia porcellus,10141.0,
2258,,,,,CHEMBL617484,B,BAO_0000357,,,8,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,
2259,,,,,CHEMBL617485,B,BAO_0000357,,,8,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,
2260,,,,,CHEMBL617486,B,BAO_0000357,,,8,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,
2261,,,,,CHEMBL858022,B,BAO_0000357,,,8,13463,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,,,
2262,,,,CHO,CHEMBL617049,B,BAO_0000219,,,8,6347,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,,,
2263,,,,CHO,CHEMBL617050,F,BAO_0000219,,,9,6857,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,Homo sapiens,9606.0,
2264,,,,,CHEMBL617051,F,BAO_0000219,,,8,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,,,
2265,,,,,CHEMBL617052,F,BAO_0000219,,,8,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,,,
2266,,,,,CHEMBL617053,F,BAO_0000219,,,8,4176,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,,,
2267,,,,CHO,CHEMBL617054,B,BAO_0000219,,,8,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,,,
2268,,,,CHO,CHEMBL617055,B,BAO_0000219,,,8,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,,,
2269,,,,,CHEMBL882924,B,BAO_0000357,,,8,15331,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,,,
2270,,,,,CHEMBL617056,B,BAO_0000357,,,9,16146,Inhibition of human 5-hydroxytryptamine 2A receptor,,Homo sapiens,9606.0,
2271,,,,CHO,CHEMBL617057,B,BAO_0000219,,,8,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,,
2272,,,,,CHEMBL617058,B,BAO_0000219,,,8,13631,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,,,
2273,,,,,CHEMBL617059,B,BAO_0000357,,,8,3805,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,,,
2274,,,,CHO,CHEMBL617060,B,BAO_0000219,,,8,4011,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,,,
2275,,,,CHO,CHEMBL617061,B,BAO_0000219,,,8,4012,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,,,
2276,,,,L929,CHEMBL617062,B,BAO_0000219,,,8,6366,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,,,
2277,,,,CHO,CHEMBL617063,B,BAO_0000219,,,8,15949,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,,
2278,,,,,CHEMBL617064,F,BAO_0000019,,,8,14093,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,,,
2279,,,,,CHEMBL617065,F,BAO_0000019,,,8,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,,
2280,,,,CHO,CHEMBL617066,B,BAO_0000219,,,8,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,,,
2281,,,,CHO,CHEMBL617067,B,BAO_0000219,,,8,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,,,
2282,,,,,CHEMBL617068,F,BAO_0000019,,,8,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,,,
2283,,,,,CHEMBL617069,F,BAO_0000019,,,8,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,,,
2284,,,,,CHEMBL617070,F,BAO_0000019,,,8,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,
2285,,,,,CHEMBL617071,B,BAO_0000357,,,8,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,,,
2286,,,,,CHEMBL872915,B,BAO_0000357,,,8,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,
2287,,,,,CHEMBL617072,B,BAO_0000357,,,8,14755,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,,,
2288,,,,,CHEMBL617073,B,BAO_0000357,,,8,16441,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,,,
2289,,,,,CHEMBL617074,B,BAO_0000357,,,8,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,,,
2290,,,,CHO,CHEMBL617075,B,BAO_0000219,,,8,16659,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,,
2291,,,,,CHEMBL617076,B,BAO_0000357,,,8,3307,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,,,
2292,,,,,CHEMBL617077,B,BAO_0000019,,,9,6857,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,Homo sapiens,9606.0,
2293,,,,,CHEMBL617078,B,BAO_0000357,,,8,5635,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,,,
2294,,,,,CHEMBL617079,B,BAO_0000357,,,9,4234,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,Homo sapiens,9606.0,
2295,,,,,CHEMBL617080,B,BAO_0000357,,,8,15527,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,,,
2296,,,,CHO,CHEMBL617081,B,BAO_0000219,,,8,6588,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,,,
2297,,,,,CHEMBL617082,B,BAO_0000219,,,8,13631,Binding affinity towards human 5-HT2A receptor in BEK cells,,,,
2298,,,,,CHEMBL617083,B,BAO_0000357,,,8,17723,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,,,
2299,,,,,CHEMBL617084,B,BAO_0000357,,,8,14770,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,,,
2300,,,,,CHEMBL617085,B,BAO_0000357,,,9,16293,Binding affinity for human 5-hydroxytryptamine 2A receptor,,Homo sapiens,9606.0,
2301,,,,,CHEMBL617086,B,BAO_0000357,,,8,16209,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,,
2302,,,,,CHEMBL617087,B,BAO_0000219,,,8,12469,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,,,
2303,,,,,CHEMBL617088,B,BAO_0000357,,,8,15363,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,,,
2304,,,,,CHEMBL617089,B,BAO_0000357,,,8,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,,,
2305,,,,,CHEMBL617090,B,BAO_0000019,,,8,16441,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,,,
2306,,,,,CHEMBL617513,B,BAO_0000357,,,8,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,,,
2307,,,,HEK293,CHEMBL617514,B,BAO_0000219,,,8,4176,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,,,
2308,,,,,CHEMBL617515,B,BAO_0000019,,,8,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,,,
2309,,,,,CHEMBL617516,B,BAO_0000357,,,8,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,
2310,,,,,CHEMBL617517,B,BAO_0000357,,,9,17200,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,Homo sapiens,9606.0,
2311,,,,CHO,CHEMBL617518,B,BAO_0000219,,,9,4013,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,Homo sapiens,9606.0,
2312,,,,,CHEMBL617519,B,BAO_0000357,,,8,5088,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,,,
2313,,,,,CHEMBL617520,B,BAO_0000357,,,9,5088,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,Homo sapiens,9606.0,
2314,,,,,CHEMBL617521,B,BAO_0000357,,,8,5088,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,,,
2315,,,,,CHEMBL617522,B,BAO_0000357,,,9,5088,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,Homo sapiens,9606.0,
2316,,,,,CHEMBL617523,B,BAO_0000357,,,8,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,,,
2317,,,,,CHEMBL617524,B,BAO_0000357,,,8,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,,
2318,,,,,CHEMBL617525,B,BAO_0000019,,,4,9786,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,,,
2319,,,,,CHEMBL617526,B,BAO_0000019,,,5,9205,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,Rattus norvegicus,10116.0,
2320,,,,,CHEMBL617527,B,BAO_0000224,,,4,11257,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,,,
2321,,,,,CHEMBL617528,B,BAO_0000019,,,4,9362,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,,,
2322,,,,,CHEMBL617529,B,BAO_0000019,,,4,9362,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,,,
2323,,,,,CHEMBL617530,B,BAO_0000224,,,4,10590,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,,,
2324,,,,,CHEMBL617531,B,BAO_0000019,,,4,10468,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,,,
2325,,,,,CHEMBL617532,B,BAO_0000019,,,4,13050,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,,,
2326,,,,,CHEMBL617533,B,BAO_0000019,,,4,11624,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,,,
2327,,,,,CHEMBL617534,B,BAO_0000019,,,4,10468,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,,,
2328,,,,,CHEMBL617535,B,BAO_0000224,,,4,10330,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,,,
2329,,,,,CHEMBL617536,B,BAO_0000224,,,4,10062,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,,,
2330,,,,,CHEMBL617537,B,BAO_0000224,,,4,11642,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,,,
2331,,,,,CHEMBL617538,B,BAO_0000224,,,4,10062,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,,,
2332,,,,,CHEMBL617539,B,BAO_0000219,,,4,13427,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,In vitro,,,
2333,,,,,CHEMBL617540,B,BAO_0000224,,,5,12280,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,Rattus norvegicus,10116.0,
2334,,,,,CHEMBL617541,B,BAO_0000224,,,5,4101,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,Rattus norvegicus,10116.0,
2335,,,,,CHEMBL617542,B,BAO_0000224,,,4,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,,,
2336,,,,,CHEMBL617543,B,BAO_0000224,,,4,11147,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,,,
2337,,,,CHO-K1,CHEMBL617544,B,BAO_0000219,,,5,2395,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,Rattus norvegicus,10116.0,
2338,,,,CHO-K1,CHEMBL617545,B,BAO_0000219,,,5,2395,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,Rattus norvegicus,10116.0,
2339,,,,,CHEMBL617413,B,BAO_0000019,,,5,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,Rattus norvegicus,10116.0,
2340,,,,,CHEMBL617414,B,BAO_0000019,,,4,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,,,
2341,,,,,CHEMBL617415,B,BAO_0000019,,,5,9098,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,Rattus norvegicus,10116.0,
2342,,,,,CHEMBL617416,B,BAO_0000224,,,4,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,
2343,,,,,CHEMBL617417,B,BAO_0000224,,,4,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,,,
2344,,,,,CHEMBL617418,B,BAO_0000019,,,4,9699,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,,,
2345,,,,,CHEMBL617419,B,BAO_0000019,,,4,9699,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,,,
2346,,,,,CHEMBL617420,B,BAO_0000224,,,4,9098,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,,
2347,,,,,CHEMBL617421,B,BAO_0000224,,,5,3070,Affinity for 5-hydroxytryptamine 2 receptor,,Rattus norvegicus,10116.0,
2348,,,,,CHEMBL617422,B,BAO_0000224,,,4,9547,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,,,
2349,,,,,CHEMBL617423,B,BAO_0000019,,,4,10444,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,,,
2350,,,,,CHEMBL617424,B,BAO_0000019,,,4,14617,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,,,
2351,,,,,CHEMBL617425,B,BAO_0000019,,,4,14617,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,,,
2352,,,,,CHEMBL617426,B,BAO_0000224,,,4,11130,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,,,
2353,,,,,CHEMBL617427,B,BAO_0000218,,,4,11130,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),In vivo,,,
2354,Brain,,,,CHEMBL617428,B,BAO_0000221,,,4,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,,,
2355,,,,,CHEMBL617429,B,BAO_0000224,,,4,2797,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,,,
2356,,,,,CHEMBL617430,B,BAO_0000019,,,4,11332,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,,,
2357,,,,,CHEMBL617431,B,BAO_0000019,,,4,11332,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,,,
2358,Frontal cortex,,,,CHEMBL617432,B,BAO_0000019,,,4,10752,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,,,
2359,,,,,CHEMBL617433,B,BAO_0000224,,,4,1185,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,,,
2360,,,,,CHEMBL617434,B,BAO_0000224,,,4,1185,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,,,
2361,,,,,CHEMBL617435,B,BAO_0000224,,,5,11624,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,Rattus norvegicus,10116.0,
2362,,,,,CHEMBL617436,B,BAO_0000019,,,4,1344,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,,,
2363,Striatum,,,,CHEMBL617437,B,BAO_0000019,,,5,15453,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,,Rattus norvegicus,10116.0,
2364,,,,,CHEMBL617438,B,BAO_0000019,,,4,11662,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,,,
2365,,,,,CHEMBL617439,B,BAO_0000019,,,4,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,,
2366,,,,,CHEMBL617440,B,BAO_0000224,,,4,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,,,
2367,,,,,CHEMBL617441,B,BAO_0000224,,,4,9069,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,,,
2368,,,,,CHEMBL872918,B,BAO_0000019,,,5,8814,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,Rattus norvegicus,10116.0,
2369,,,,,CHEMBL617442,B,BAO_0000019,,,5,8908,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,Rattus norvegicus,10116.0,
2370,,,,,CHEMBL617443,B,BAO_0000019,,,4,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,,,
2371,,,,,CHEMBL617444,B,BAO_0000019,,,4,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,,,
2372,,,,,CHEMBL617445,B,BAO_0000019,,,4,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,,,
2373,,,,,CHEMBL617446,B,BAO_0000019,,,4,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,,,
2374,,,,,CHEMBL617447,B,BAO_0000249,,,4,9098,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,,,
2375,,,,,CHEMBL617448,B,BAO_0000019,,,4,9098,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,,,
2376,,,,,CHEMBL617449,B,BAO_0000019,,,4,9098,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,,,
2377,,,,,CHEMBL617450,B,BAO_0000019,,,4,9161,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,,,
2378,,,,,CHEMBL617451,B,BAO_0000019,,,4,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,,,
2379,,,,,CHEMBL617452,B,BAO_0000019,,,4,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,,,
2380,,,,,CHEMBL617453,B,BAO_0000019,,,4,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,,,
2381,,,,,CHEMBL617660,B,BAO_0000019,,,4,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,,,
2382,,,,,CHEMBL617661,B,BAO_0000019,,,4,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,,,
2383,,,,,CHEMBL617662,B,BAO_0000019,,,4,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,,,
2384,,,,,CHEMBL872919,B,BAO_0000019,,,4,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,,,
2385,,,,,CHEMBL617663,B,BAO_0000019,,,4,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,,,
2386,,,,,CHEMBL617664,B,BAO_0000019,,,4,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,,,
2387,,,,,CHEMBL617665,B,BAO_0000019,,,4,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,,,
2388,,,,,CHEMBL617666,B,BAO_0000019,,,4,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,,,
2389,,,,,CHEMBL617667,B,BAO_0000019,,,4,12094,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,,,
2390,,,,,CHEMBL617668,B,BAO_0000249,,,4,12018,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,,,
2391,,,,,CHEMBL617669,B,BAO_0000249,,,4,10394,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,,,
2392,,,,,CHEMBL617670,B,BAO_0000224,,,4,15260,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,,,
2393,,,,,CHEMBL617671,B,BAO_0000224,,,5,11624,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,Rattus norvegicus,10116.0,
2394,,,,,CHEMBL617672,B,BAO_0000224,,,4,13654,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,,,
2395,,,,,CHEMBL617673,B,BAO_0000019,,,4,9541,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,,,
2396,,,,,CHEMBL617674,B,BAO_0000224,,,4,11933,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,,,
2397,,,,,CHEMBL617675,B,BAO_0000019,,,4,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,,,
2398,,,,,CHEMBL617676,B,BAO_0000019,,,4,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,,,
2399,,,,,CHEMBL617677,B,BAO_0000019,,,4,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,,,
2400,,,,,CHEMBL617678,B,BAO_0000019,,,5,8841,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,,,
2401,,,,,CHEMBL617679,B,BAO_0000224,,,4,1455,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,,,
2402,,,,,CHEMBL617680,B,BAO_0000224,,,4,1455,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,,,
2403,,,,,CHEMBL617681,B,BAO_0000019,,,4,11752,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,,,
2404,Brain,,,,CHEMBL617682,B,BAO_0000221,,,4,11642,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,,,
2405,,,,,CHEMBL617683,B,BAO_0000224,,,4,12092,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,,,
2406,,,,,CHEMBL617684,B,BAO_0000224,,,4,3967,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,,,
2407,,,,,CHEMBL617685,B,BAO_0000224,,,5,12771,Binding affinity towards 5-hydroxytryptamine 2 receptor,,Rattus norvegicus,10116.0,
2408,,,,,CHEMBL617686,B,BAO_0000019,,,4,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,,,
2409,,,,,CHEMBL617687,B,BAO_0000224,,,4,11628,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,,,
2410,,,,,CHEMBL617688,B,BAO_0000224,,,4,13654,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,,
2411,,,,,CHEMBL617689,F,BAO_0000019,,,4,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,
2412,,,,,CHEMBL617690,F,BAO_0000019,,,4,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,
2413,,,,,CHEMBL617691,F,BAO_0000218,,,4,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",In vivo,,,
2414,,,,,CHEMBL617692,F,BAO_0000218,,,4,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",In vivo,,,
2415,,,,,CHEMBL617693,F,BAO_0000218,,,4,11200,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",In vivo,,,
2416,,,,,CHEMBL617694,F,BAO_0000218,,,4,11200,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",In vivo,,,
2417,Brain,,,,CHEMBL857985,B,BAO_0000221,,,8,15436,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,,,
2418,,,,,CHEMBL617695,B,BAO_0000019,,,9,15436,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,Rattus norvegicus,10116.0,
2419,,,,,CHEMBL617696,B,BAO_0000019,,,8,14025,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,,,
2420,,,,,CHEMBL617697,B,BAO_0000357,,,8,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,,,
2421,,,,,CHEMBL617257,B,BAO_0000019,,,9,13735,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,Rattus norvegicus,10116.0,
2422,,,,,CHEMBL617258,B,BAO_0000357,,,9,5816,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,Rattus norvegicus,10116.0,
2423,,,,,CHEMBL617259,B,BAO_0000019,,,8,14287,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,,,
2424,,,,,CHEMBL617260,B,BAO_0000357,,,8,15738,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,,,
2425,,,,,CHEMBL617261,B,BAO_0000357,,,9,15738,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,Rattus norvegicus,10116.0,
2426,,,,,CHEMBL617262,B,BAO_0000019,,,8,15026,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,,,
2427,,,,,CHEMBL617263,B,BAO_0000019,,,8,16647,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,,,
2428,,,,,CHEMBL617264,B,BAO_0000019,,,8,16647,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,,,
2429,,,,,CHEMBL617265,B,BAO_0000019,,,9,13345,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,Rattus norvegicus,10116.0,
2430,,,,,CHEMBL617266,B,BAO_0000249,,,8,1543,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,,,Membranes
2431,,,,,CHEMBL617267,B,BAO_0000019,,,8,12444,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,,,
2432,,,,,CHEMBL617268,B,BAO_0000019,,,8,16404,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,,,
2433,,,,CHO,CHEMBL617269,B,BAO_0000219,,,8,16404,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,,,
2434,,,,,CHEMBL617323,B,BAO_0000357,,,8,15577,Kinetic inhibition constant evaluated by measuring serotonergic activity,,,,
2435,,,,,CHEMBL617324,B,BAO_0000357,,,8,15577,Serotonergic activity of the compound.,,,,
2436,,,,,CHEMBL617325,B,BAO_0000249,,,8,2495,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,,,
2437,,,,,CHEMBL617326,B,BAO_0000019,,,9,15042,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,Rattus norvegicus,10116.0,
2438,,,,,CHEMBL617327,B,BAO_0000249,,,8,15026,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,,,
2439,,,,,CHEMBL617328,F,BAO_0000019,,,9,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,Rattus norvegicus,10116.0,
2440,,,,,CHEMBL617329,F,BAO_0000019,,,9,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,Rattus norvegicus,10116.0,
2441,,,,,CHEMBL617330,F,BAO_0000019,,,9,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,Rattus norvegicus,10116.0,
2442,,,,,CHEMBL617331,B,BAO_0000357,,,8,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,
2443,,,,,CHEMBL617332,B,BAO_0000357,,,8,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,,,
2444,,,,,CHEMBL617333,B,BAO_0000357,,,8,4820,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,,
2445,,,,,CHEMBL617334,B,BAO_0000357,,,8,6736,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,,,
2446,,,,,CHEMBL617335,B,BAO_0000357,,,8,5163,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,,,
2447,,,,,CHEMBL617336,B,BAO_0000357,,,8,5163,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,,,
2448,,,,,CHEMBL617337,B,BAO_0000357,,,8,6011,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,,,
2449,,,,,CHEMBL617338,B,BAO_0000357,,,9,14294,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,Homo sapiens,9606.0,
2450,,,,,CHEMBL617339,B,BAO_0000357,,,8,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,,,
2451,,,,,CHEMBL617340,B,BAO_0000357,,,8,17066,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,,
2452,,,,,CHEMBL617341,B,BAO_0000357,,,8,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,,,
2453,,,,,CHEMBL617342,B,BAO_0000357,,,8,6736,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,,,
2454,,,,,CHEMBL617343,B,BAO_0000357,,,8,5163,Affinity for 5-hydroxytryptamine 2A receptor,,,,
2455,,,,NIH3T3,CHEMBL617344,B,BAO_0000219,,,8,16911,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,,,
2456,,,,,CHEMBL617345,B,BAO_0000357,,,8,6841,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,,,
2457,,,,,CHEMBL617346,B,BAO_0000357,,,8,6119,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,,,
2458,,,,,CHEMBL617347,B,BAO_0000357,,,8,3962,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,,,
2459,,,,,CHEMBL617348,B,BAO_0000357,,,8,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,,,
2460,,,,,CHEMBL617349,B,BAO_0000357,,,8,4373,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,,,
2461,,,,,CHEMBL617350,F,BAO_0000019,,,8,3962,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,,,
2462,,,,,CHEMBL872339,B,BAO_0000357,,,8,1633,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,,,
2463,,,,,CHEMBL617351,B,BAO_0000357,,,8,4373,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,,,
2464,,,,,CHEMBL617352,B,BAO_0000357,,,8,6576,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,,,
2465,,,,,CHEMBL617353,B,BAO_0000357,,,8,4687,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,,,
2466,,,,,CHEMBL617354,B,BAO_0000357,,,8,16946,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,,,
2467,,,,,CHEMBL617355,B,BAO_0000357,,,8,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,,,
2468,,,,CHO,CHEMBL617356,B,BAO_0000219,,,8,3032,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,Mus musculus,10090.0,
2469,,,,,CHEMBL617357,B,BAO_0000357,,,8,16655,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,,,
2470,,,,,CHEMBL617358,B,BAO_0000357,,,8,13964,Binding affinity at 5-hydroxytryptamine 2A receptor,,,,
2471,,,,,CHEMBL617359,B,BAO_0000357,,,8,16989,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,,,
2472,,,,,CHEMBL617360,B,BAO_0000357,,,8,16117,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,,,
2473,,,,,CHEMBL875913,B,BAO_0000357,,,8,16700,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,,,
2474,,,,,CHEMBL617361,B,BAO_0000357,,,8,3269,Affinity against 5-hydroxytryptamine 2A receptor,,,,
2475,,,,,CHEMBL617362,B,BAO_0000357,,,9,1274,Binding affinity against 5-Hydroxytryptamine 2A receptor,,Homo sapiens,9606.0,
2476,,,,,CHEMBL617363,B,BAO_0000357,,,8,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,,,
2477,,,,,CHEMBL617364,B,BAO_0000357,,,8,12146,Tested against 5-hydroxytryptamine 2A receptor,,,,
2478,,,,,CHEMBL617365,B,BAO_0000224,,,4,12652,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,,,
2479,,,,,CHEMBL617366,B,BAO_0000224,,,4,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,,,
2480,,,,,CHEMBL617367,B,BAO_0000224,,,4,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,,,
2481,,,,,CHEMBL617368,B,BAO_0000224,,,4,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,,,
2482,,,,,CHEMBL617369,B,BAO_0000357,,,8,16647,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,,,
2483,,,,HEK293,CHEMBL617370,B,BAO_0000219,,,9,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,Homo sapiens,9606.0,
2484,,,,CHO,CHEMBL617371,F,BAO_0000219,,,9,6857,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,Homo sapiens,9606.0,
2485,,,,,CHEMBL617372,B,BAO_0000357,,,8,3805,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,,,
2486,,,,,CHEMBL617373,B,BAO_0000357,,,9,6491,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,Homo sapiens,9606.0,
2487,,,,,CHEMBL617374,F,BAO_0000019,,,8,14093,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,,,
2488,,,,,CHEMBL617375,F,BAO_0000019,,,8,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,,,
2489,,,,,CHEMBL617376,F,BAO_0000019,,,8,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,,,
2490,,,,,CHEMBL617377,F,BAO_0000019,,,8,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,,,
2491,,,,,CHEMBL617378,F,BAO_0000019,,,8,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,,,
2492,,,,,CHEMBL617379,F,BAO_0000019,,,8,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,,,
2493,,,,,CHEMBL617380,B,BAO_0000357,,,8,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,,,
2494,,,,,CHEMBL617381,B,BAO_0000357,,,8,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,,,
2495,,,,,CHEMBL617382,B,BAO_0000357,,,8,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,,,
2496,,,,,CHEMBL617383,B,BAO_0000357,,,8,12369,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,,,
2497,,,,,CHEMBL617384,B,BAO_0000357,,,8,12369,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,,,
2498,,,,,CHEMBL617385,B,BAO_0000357,,,8,12369,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,,,
2499,,,,,CHEMBL617386,B,BAO_0000019,,,8,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,,,
2500,,,,,CHEMBL617387,B,BAO_0000019,,,8,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,,,
2501,,,,NIH3T3,CHEMBL617388,B,BAO_0000219,,,8,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,,
2502,,,,CHO,CHEMBL617389,F,BAO_0000219,,,8,6857,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,,
2503,,,,CHO,CHEMBL617390,F,BAO_0000219,,,9,6857,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,Homo sapiens,9606.0,
2504,,,,,CHEMBL617391,B,BAO_0000224,,,4,5635,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,,,
2505,,,,,CHEMBL617392,B,BAO_0000357,,,8,12861,Binding activity radioligand.,,,,
2506,,,,,CHEMBL617393,B,BAO_0000019,,,8,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,,
2507,,,,L929,CHEMBL617394,B,BAO_0000219,,,8,5105,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,,,
2508,,,,L929,CHEMBL617395,B,BAO_0000219,,,8,5104,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,,,
2509,,,,L929,CHEMBL617396,B,BAO_0000219,,,8,5105,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,,,
2510,,,,L929,CHEMBL617397,B,BAO_0000219,,,8,5105,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,,,
2511,,,,,CHEMBL617398,B,BAO_0000357,,,8,5254,Binding affinity against 5-HT2A receptor,,,,
2512,,,,,CHEMBL617399,B,BAO_0000357,,,8,5254,Binding affinity against 5-hydroxytryptamine 2A receptor,,,,
2513,,,,HEK293,CHEMBL617400,B,BAO_0000219,,,8,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,,,
2514,,,,HEK293,CHEMBL617401,B,BAO_0000219,,,8,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,,,
2515,,,,HEK293,CHEMBL617402,B,BAO_0000219,,,9,14157,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,Homo sapiens,9606.0,
2516,,,,HEK293,CHEMBL617403,B,BAO_0000219,,,9,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,Homo sapiens,9606.0,
2517,,,,,CHEMBL617404,B,BAO_0000357,,,8,14068,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,,,
2518,,,,HEK293,CHEMBL857981,B,BAO_0000219,,,9,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,Homo sapiens,9606.0,
2519,,,,HEK293,CHEMBL617405,B,BAO_0000219,,,9,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,Homo sapiens,9606.0,
2520,,,,HEK293,CHEMBL617253,B,BAO_0000219,,,9,4540,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,Homo sapiens,9606.0,
2521,,,,,CHEMBL617254,B,BAO_0000357,,,8,6166,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,,,
2522,,,,HEK293,CHEMBL617255,B,BAO_0000219,,,8,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,,,
2523,,,,HEK293,CHEMBL617256,B,BAO_0000219,,,8,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,,,
2524,,,,HEK293,CHEMBL616874,B,BAO_0000219,,,8,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,,,
2525,,,,HEK293,CHEMBL616875,B,BAO_0000219,,,9,15779,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,Homo sapiens,9606.0,
2526,,,,HEK293,CHEMBL616876,B,BAO_0000219,,,8,14391,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,,,
2527,,,,HEK293,CHEMBL616877,B,BAO_0000219,,,8,15851,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,,,
2528,,,,HEK293,CHEMBL616878,B,BAO_0000219,,,9,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,Homo sapiens,9606.0,
2529,,,,HEK293,CHEMBL616879,B,BAO_0000219,,,8,3832,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,,,
2530,,,,HEK293,CHEMBL616880,B,BAO_0000219,,,8,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,,,
2531,,,,HEK293,CHEMBL616881,B,BAO_0000219,,,9,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,Homo sapiens,9606.0,
2532,,,,NIH3T3,CHEMBL616882,B,BAO_0000219,,,8,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,,,
2533,,,,NIH3T3,CHEMBL616883,B,BAO_0000219,,,8,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,,
2534,,,,NIH3T3,CHEMBL616884,B,BAO_0000219,,,8,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,,
2535,,,,HEK293,CHEMBL616885,B,BAO_0000219,,,8,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,,,
2536,,,,CHO-K1,CHEMBL616886,B,BAO_0000219,,,8,1883,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,,,
2537,,,,CHO-K1,CHEMBL616887,B,BAO_0000219,,,8,1883,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,,,
2538,,,,,CHEMBL616888,B,BAO_0000357,,,9,14875,Binding affinity for human 5-hydroxytryptamine 2A receptor,,Homo sapiens,9606.0,
2539,,,,HEK293,CHEMBL616889,B,BAO_0000219,,,8,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,,,
2540,,,,HEK293,CHEMBL616890,B,BAO_0000219,,,8,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,,,
2541,,,,CHO,CHEMBL616891,B,BAO_0000219,,,9,16404,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,Homo sapiens,9606.0,
2542,,,,HEK293,CHEMBL616892,B,BAO_0000219,,,8,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,,,
2543,,,,HEK293,CHEMBL616893,B,BAO_0000219,,,8,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,,,
2544,,,,NIH3T3,CHEMBL616894,F,BAO_0000219,,,8,12652,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,,,
2545,,,,NIH3T3,CHEMBL616895,B,BAO_0000219,,,8,4682,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,,,
2546,,,,,CHEMBL616896,F,BAO_0000019,,,8,12652,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,,,
2547,,,,,CHEMBL617099,B,BAO_0000357,,,8,4921,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,,,
2548,,,,,CHEMBL617100,B,BAO_0000357,,,8,4921,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,,,
2549,,,,,CHEMBL884532,B,BAO_0000357,,,8,16312,Binding affinity against rabbit aorta 5-HT2A receptor,,Oryctolagus cuniculus,9986.0,
2550,,,,,CHEMBL617101,B,BAO_0000357,,,8,14998,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,Oryctolagus cuniculus,9986.0,
2551,,,,,CHEMBL617102,B,BAO_0000357,,,8,14025,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,Oryctolagus cuniculus,9986.0,
2552,,,,,CHEMBL617103,B,BAO_0000019,,,8,13047,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,Oryctolagus cuniculus,9986.0,
2553,,,,,CHEMBL617104,B,BAO_0000357,,,8,13047,The compound was tested for binding affinity against 5-HT2A receptor,,Oryctolagus cuniculus,9986.0,
2554,,,,CHO-K1,CHEMBL857979,B,BAO_0000219,,,8,1883,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,,,
2555,,,,,CHEMBL857502,B,BAO_0000019,,,8,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,,,
2556,,,,,CHEMBL617105,B,BAO_0000019,,,8,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,,,
2557,Stomach,,,,CHEMBL858021,B,BAO_0000019,,,8,13463,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,,,
2558,Stomach,,,,CHEMBL875910,B,BAO_0000019,,,9,13463,Binding affinity for 5-HT 2A in rat stomach fundus,,Rattus norvegicus,10116.0,
2559,,,,,CHEMBL617106,B,BAO_0000019,,,8,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,,,
2560,,,,NIH3T3,CHEMBL617107,B,BAO_0000219,,,8,16326,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,,,
2561,,,,,CHEMBL617108,F,BAO_0000019,,,8,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,,,
2562,,,,,CHEMBL617109,F,BAO_0000019,,,8,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,,,
2563,,,,,CHEMBL617110,B,BAO_0000357,,,8,15740,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,,,
2564,,,,,CHEMBL617111,B,BAO_0000357,,,8,16633,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,,,
2565,,,,,CHEMBL617112,F,BAO_0000019,,,9,17200,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,Rattus norvegicus,10116.0,
2566,,,,,CHEMBL617113,B,BAO_0000357,,,8,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,,
2567,,,,,CHEMBL617114,B,BAO_0000357,,,8,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,,
2568,,,,,CHEMBL617115,B,BAO_0000357,,,8,17133,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,,
2569,,,,,CHEMBL617116,F,BAO_0000219,,,8,17200,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,,
2570,,,,,CHEMBL617117,F,BAO_0000019,,,8,15363,Efficacy at 5-hydroxytryptamine 2A receptor,,,,
2571,,,,,CHEMBL617118,B,BAO_0000357,,,8,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,,,
2572,,,,,CHEMBL617119,B,BAO_0000357,,,9,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,Rattus norvegicus,10116.0,
2573,,,,,CHEMBL617120,B,BAO_0000357,,,9,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,Rattus norvegicus,10116.0,
2574,,,,,CHEMBL617121,F,BAO_0000219,,,9,17200,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,Rattus norvegicus,10116.0,
2575,,,,,CHEMBL617122,F,BAO_0000219,,,8,17200,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,,
2576,,,,,CHEMBL617123,B,BAO_0000019,,,8,17211,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,,,
2577,,,,,CHEMBL617124,B,BAO_0000019,,,8,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,,,
2578,,,,,CHEMBL617600,B,BAO_0000249,,,8,13565,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,,,
2579,,,,,CHEMBL617601,B,BAO_0000357,,,8,13730,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,,,
2580,,,,,CHEMBL882923,B,BAO_0000019,,,8,12416,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,,,
2581,,,,,CHEMBL617602,B,BAO_0000357,,,8,15295,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,,,
2582,,,,,CHEMBL617603,B,BAO_0000019,,,8,1742,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,,,
2583,,,,,CHEMBL617604,B,BAO_0000357,,,8,15295,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,,,
2584,,,,,CHEMBL617605,B,BAO_0000019,,,8,14970,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,,,
2585,,,,,CHEMBL617606,B,BAO_0000019,,,8,16693,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,,,
2586,,,,,CHEMBL617607,B,BAO_0000019,,,9,14776,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,Rattus norvegicus,10116.0,
2587,,,,,CHEMBL617455,B,BAO_0000249,,,8,14286,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,
2588,,,,,CHEMBL617456,B,BAO_0000019,,,9,17200,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,Rattus norvegicus,10116.0,
2589,,,,,CHEMBL617457,B,BAO_0000357,,,8,15306,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,,,
2590,,,,,CHEMBL617458,B,BAO_0000357,,,9,14178,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,Rattus norvegicus,10116.0,
2591,,,,,CHEMBL617459,B,BAO_0000019,,,9,14229,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,Rattus norvegicus,10116.0,
2592,,,,,CHEMBL617460,B,BAO_0000357,,,8,12884,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,,,
2593,,,,,CHEMBL617461,B,BAO_0000357,,,8,13149,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,,,
2594,,,,,CHEMBL617462,B,BAO_0000019,,,9,15295,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,Rattus norvegicus,10116.0,
2595,,,,,CHEMBL617463,B,BAO_0000357,,,8,15740,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,,,
2596,,,,,CHEMBL617464,B,BAO_0000019,,,8,15185,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,,,
2597,,,,,CHEMBL617465,B,BAO_0000019,,,8,15185,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,,,
2598,,,,,CHEMBL617466,B,BAO_0000019,,,8,17529,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,,,
2599,,,,,CHEMBL617467,B,BAO_0000019,,,8,14826,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,,,
2600,,,,,CHEMBL617468,B,BAO_0000019,,,8,17211,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,,,
2601,,,,,CHEMBL617469,B,BAO_0000019,,,8,14826,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,,,
2602,,,,,CHEMBL617470,B,BAO_0000019,,,8,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,,,
2603,,,,,CHEMBL617471,B,BAO_0000019,,,8,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,,,
2604,,,,NIH3T3,CHEMBL617472,B,BAO_0000219,,,8,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,,,
2605,,,,,CHEMBL617473,B,BAO_0000357,,,8,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,,,
2606,,,,,CHEMBL617474,B,BAO_0000019,,,9,15436,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,Rattus norvegicus,10116.0,
2607,,,,,CHEMBL617475,B,BAO_0000019,,,9,15436,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,Rattus norvegicus,10116.0,
2608,Brain,,,,CHEMBL617476,B,BAO_0000221,,,8,14442,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,,,
2609,,,,,CHEMBL617477,B,BAO_0000357,,,8,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,,,
2610,,,,NIH3T3,CHEMBL617478,B,BAO_0000219,,,8,12457,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,,,
2611,,,,,CHEMBL617479,F,BAO_0000221,,,8,14755,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,,,
2612,,,,,CHEMBL617480,B,BAO_0000357,,,8,4707,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,,,
2613,,,,,CHEMBL617481,B,BAO_0000357,,,8,13297,Binding affinity against 5-hydroxytryptamine 2A receptor,,,,
2614,,,,,CHEMBL617482,B,BAO_0000019,,,8,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,,,
2615,,,,,CHEMBL617483,B,BAO_0000019,,,8,4664,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,,,
2616,,,,,CHEMBL621528,B,BAO_0000357,,,8,16633,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,,
2617,,,,NIH3T3,CHEMBL621529,B,BAO_0000219,,,9,4664,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,Rattus norvegicus,10116.0,
2618,,,,,CHEMBL621530,B,BAO_0000357,,,8,16133,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,,
2619,,,,,CHEMBL621531,B,BAO_0000357,,,8,16133,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,
2620,,,,,CHEMBL621532,B,BAO_0000019,,,9,14060,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,Rattus norvegicus,10116.0,
2621,,,,,CHEMBL621533,B,BAO_0000357,,,8,16326,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,,
2622,,,,CHO,CHEMBL621534,B,BAO_0000219,,,8,16659,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,,
2623,,,,,CHEMBL621535,B,BAO_0000019,,,8,14776,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,,,
2624,,,,,CHEMBL621536,B,BAO_0000357,,,8,13481,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,,,
2625,,,,,CHEMBL621537,B,BAO_0000357,,,8,17386,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,,,
2626,,,,,CHEMBL621538,B,BAO_0000357,,,9,6611,Binding affinity for 5-hydroxytryptamine 2A receptor,,Rattus norvegicus,10116.0,
2627,,,,,CHEMBL621539,B,BAO_0000019,,,8,14423,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,,,
2628,,,,,CHEMBL621540,B,BAO_0000019,,,8,15412,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,,,
2629,,,,,CHEMBL621541,B,BAO_0000019,,,8,15412,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,,,
2630,,,,,CHEMBL621542,B,BAO_0000019,,,8,6238,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,,,
2631,,,,,CHEMBL621543,B,BAO_0000357,,,8,6648,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,,,
2632,,,,,CHEMBL621544,B,BAO_0000357,,,8,5667,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,,,
2633,,,,,CHEMBL621545,B,BAO_0000357,,,9,6611,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,Rattus norvegicus,10116.0,
2634,,,,,CHEMBL621546,B,BAO_0000357,,,8,13481,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,
2635,,,,,CHEMBL621547,B,BAO_0000357,,,8,13481,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,,,
2636,,,,NIH3T3,CHEMBL618692,B,BAO_0000219,,,8,15558,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,,,
2637,,,,,CHEMBL618693,B,BAO_0000357,,,8,6013,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,,
2638,,,,,CHEMBL872922,B,BAO_0000357,,,8,16633,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,,
2639,,,,,CHEMBL618694,B,BAO_0000357,,,8,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,,,
2640,,,,,CHEMBL618695,B,BAO_0000357,,,9,6013,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,Rattus norvegicus,10116.0,
2641,,,,,CHEMBL618696,B,BAO_0000357,,,8,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,,,
2642,,,,,CHEMBL618697,B,BAO_0000357,,,8,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,,,
2643,,,,,CHEMBL618892,B,BAO_0000357,,,8,6013,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,,,
2644,,,,,CHEMBL618893,B,BAO_0000357,,,8,6013,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,,,
2645,,,,,CHEMBL618894,B,BAO_0000357,,,8,16293,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,,,
2646,,,,NIH3T3,CHEMBL618895,B,BAO_0000219,,,8,17175,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,,,
2647,,,,,CHEMBL618896,B,BAO_0000357,,,9,13278,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,Rattus norvegicus,10116.0,
2648,Caudate-putamen,,,,CHEMBL618897,B,BAO_0000019,,,8,3682,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,,,
2649,,,,,CHEMBL618898,B,BAO_0000357,,,8,2014,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,,,
2650,,,,,CHEMBL618899,B,BAO_0000357,,,8,2014,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,,,
2651,,,,,CHEMBL618900,B,BAO_0000357,,,8,4932,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,,,
2652,,,,,CHEMBL618901,B,BAO_0000019,,,8,4932,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,,,
2653,,,,,CHEMBL618902,B,BAO_0000357,,,8,3935,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,,,
2654,Hippocampus,,,,CHEMBL618903,B,BAO_0000221,,,9,5432,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,,Rattus norvegicus,10116.0,
2655,,,,,CHEMBL618904,B,BAO_0000357,,,8,15818,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,,,
2656,,,,,CHEMBL618905,B,BAO_0000357,,,8,13672,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,,,
2657,,,,,CHEMBL618906,B,BAO_0000357,,,8,13672,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,,,
2658,,,,NIH3T3,CHEMBL618907,B,BAO_0000219,,,8,14749,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,,,
2659,,,,,CHEMBL618908,B,BAO_0000019,,,8,13462,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,,,
2660,,,,,CHEMBL617909,B,BAO_0000357,,,8,15740,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,,,
2661,,,,,CHEMBL617910,B,BAO_0000019,,,8,16647,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,,,
2662,Brain,,,,CHEMBL617911,B,BAO_0000221,,,8,13345,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,,,
2663,,,,,CHEMBL872923,B,BAO_0000249,,,8,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,
2664,,,,,CHEMBL617912,B,BAO_0000249,,,8,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,
2665,,,,,CHEMBL617913,B,BAO_0000019,,,9,15535,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,Rattus norvegicus,10116.0,
2666,,,,,CHEMBL617914,B,BAO_0000249,,,8,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,
2667,,,,,CHEMBL617915,B,BAO_0000249,,,8,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,
2668,,,,,CHEMBL617916,B,BAO_0000249,,,8,16740,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,
2669,,,,,CHEMBL617917,B,BAO_0000019,,,9,4795,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,Rattus norvegicus,10116.0,
2670,,,,,CHEMBL617918,B,BAO_0000019,,,8,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,,,
2671,,,,,CHEMBL617919,B,BAO_0000019,,,8,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,,,
2672,,,,,CHEMBL617920,B,BAO_0000019,,,9,17200,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,Rattus norvegicus,10116.0,
2673,,,,,CHEMBL617921,B,BAO_0000019,,,9,2148,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,Rattus norvegicus,10116.0,
2674,,,,,CHEMBL617922,B,BAO_0000224,,,5,13345,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,Rattus norvegicus,10116.0,
2675,,,,,CHEMBL617923,B,BAO_0000357,,,8,5088,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,,
2676,,,,,CHEMBL617924,B,BAO_0000357,,,8,5088,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,
2677,,,,,CHEMBL617925,B,BAO_0000357,,,8,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,,,
2678,,,,,CHEMBL617926,B,BAO_0000357,,,9,17133,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,Rattus norvegicus,10116.0,
2679,,,,,CHEMBL617927,B,BAO_0000357,,,8,16532,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,,,
2680,,,,,CHEMBL617928,B,BAO_0000357,,,8,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,,,
2681,,,,,CHEMBL617929,B,BAO_0000019,,,9,2309,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,Rattus norvegicus,10116.0,
2682,,,,,CHEMBL617930,B,BAO_0000019,,,8,12953,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,,,
2683,,,,,CHEMBL617931,B,BAO_0000019,,,8,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,,,
2684,,,,,CHEMBL617932,B,BAO_0000019,,,8,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,,,
2685,,,,CHO,CHEMBL617933,B,BAO_0000219,,,8,16659,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,,,
2686,,,,,CHEMBL617934,B,BAO_0000019,,,8,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,,,
2687,,,,,CHEMBL617935,B,BAO_0000019,,,8,16740,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,,,
2688,,,,,CHEMBL617936,B,BAO_0000357,,,8,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,,,
2689,,,,,CHEMBL617937,B,BAO_0000019,,,8,17211,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,,,
2690,,,,,CHEMBL617938,B,BAO_0000019,,,8,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,,,
2691,,,,,CHEMBL617939,B,BAO_0000218,,,8,16633,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,,,
2692,,,,,CHEMBL617940,B,BAO_0000218,,,8,16633,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,,,
2693,,,,,CHEMBL617941,B,BAO_0000218,,,8,16633,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,,,
2694,,,,,CHEMBL617942,B,BAO_0000357,,,8,15026,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,,,
2695,,,,,CHEMBL617943,B,BAO_0000357,,,8,15026,Ratio of pKi of 5-HT2A to that of D2 receptor,,,,
2696,,,,,CHEMBL617944,B,BAO_0000224,,,4,16404,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,,,
2697,,,,,CHEMBL617945,B,BAO_0000224,,,4,16404,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,,,
2698,,,,,CHEMBL617946,B,BAO_0000224,,,4,16404,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,,,
2699,,,,,CHEMBL617947,B,BAO_0000357,,,8,16404,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,,,
2700,,,,,CHEMBL617948,B,BAO_0000357,,,8,16326,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,,,
2701,,,,,CHEMBL858116,F,BAO_0000019,,,8,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,,,
2702,,,,,CHEMBL617949,F,BAO_0000019,,,8,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,,,
2703,,,,,CHEMBL617950,F,BAO_0000019,,,8,15329,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,,,
2704,Thoracic aorta,,,,CHEMBL617951,F,BAO_0000019,,,8,16404,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,,,
2705,Thoracic aorta,,,,CHEMBL617952,F,BAO_0000019,,,8,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,,,
2706,Thoracic aorta,,,,CHEMBL617953,F,BAO_0000019,,,8,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,,,
2707,,,,,CHEMBL617954,B,BAO_0000357,,,8,12861,Binding activity radioligand.,,,,
2708,,,,,CHEMBL617955,B,BAO_0000019,,,8,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,,
2709,,,,,CHEMBL857071,B,BAO_0000019,,,8,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,,,
2710,,,,,CHEMBL617270,B,BAO_0000019,,,8,12490,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,,,
2711,,,,N1E-115,CHEMBL617271,B,BAO_0000219,,,8,12827,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,,,
2712,,,,N1E-115,CHEMBL617272,B,BAO_0000219,,,8,12827,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,,,
2713,,,,,CHEMBL617273,B,BAO_0000019,,,8,12918,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,,,
2714,,,,,CHEMBL617274,F,BAO_0000019,,,9,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,Rattus norvegicus,10116.0,
2715,,,,,CHEMBL617275,B,BAO_0000357,,,8,17723,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,,,
2716,,,,,CHEMBL617276,B,BAO_0000357,,,8,6013,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,,
2717,,,,,CHEMBL617277,B,BAO_0000357,,,8,16293,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,,,
2718,,,,,CHEMBL617278,B,BAO_0000019,,,8,3857,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,,,
2719,,,,,CHEMBL617279,B,BAO_0000019,,,8,3857,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,,,
2720,,,,,CHEMBL617280,B,BAO_0000019,,,8,3857,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,,,
2721,,,,,CHEMBL617281,B,BAO_0000357,,,8,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,,,
2722,,,,,CHEMBL617282,B,BAO_0000357,,,8,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,,,
2723,,,,,CHEMBL617283,B,BAO_0000019,,,8,16441,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,,,
2724,,,,,CHEMBL617284,B,BAO_0000019,,,8,16441,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,,,
2725,,,,HEK293,CHEMBL617285,B,BAO_0000219,,,8,4176,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,,,
2726,,,,,CHEMBL617286,B,BAO_0000019,,,8,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,,,
2727,,,,,CHEMBL617287,B,BAO_0000357,,,9,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,Homo sapiens,9606.0,
2728,,,,,CHEMBL617288,B,BAO_0000357,,,8,5088,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,,,
2729,,,,,CHEMBL617289,B,BAO_0000357,,,8,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,,,
2730,,,,,CHEMBL872917,B,BAO_0000357,,,8,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,
2731,,,,,CHEMBL617290,B,BAO_0000357,,,8,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,,,
2732,,,,CHO,CHEMBL617291,B,BAO_0000219,,,8,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,,
2733,,,,CHO,CHEMBL617292,B,BAO_0000219,,,8,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,,,
2734,,,,NIH3T3,CHEMBL617293,B,BAO_0000219,,,8,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,,
2735,,,,CHO,CHEMBL617294,F,BAO_0000219,,,9,6857,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,Homo sapiens,9606.0,
2736,,,,,CHEMBL617295,B,BAO_0000019,,,8,3857,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,,,
2737,,,,,CHEMBL617296,B,BAO_0000357,,,8,12861,Binding activity radioligand.,,,,
2738,,,,,CHEMBL617297,B,BAO_0000019,,,8,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,,
2739,,,,CHO,CHEMBL617298,B,BAO_0000219,,,8,5104,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,,,
2740,,,,CHO,CHEMBL617299,B,BAO_0000219,,,8,5105,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,,,
2741,,,,CHO,CHEMBL617300,B,BAO_0000219,,,8,5105,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,,,
2742,,,,,CHEMBL617454,B,BAO_0000357,,,8,5254,Binding affinity against 5-HT2C receptor,,,,
2743,,,,HEK293,CHEMBL617505,B,BAO_0000219,,,8,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,,,
2744,,,,HEK293,CHEMBL617506,B,BAO_0000219,,,9,14157,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,Homo sapiens,9606.0,
2745,,,,HEK293,CHEMBL617507,B,BAO_0000219,,,9,12936,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,Homo sapiens,9606.0,
2746,,,,,CHEMBL617508,B,BAO_0000357,,,8,14068,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,,,
2747,,,,HEK293,CHEMBL857982,B,BAO_0000219,,,9,12936,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,Homo sapiens,9606.0,
2748,,,,HEK293,CHEMBL617509,B,BAO_0000219,,,9,4540,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,Homo sapiens,9606.0,
2749,,,,HEK293,CHEMBL617510,B,BAO_0000219,,,9,4540,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,Homo sapiens,9606.0,
2750,,,,,CHEMBL617511,B,BAO_0000357,,,8,6166,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,,,
2751,,,,HEK293,CHEMBL617512,B,BAO_0000219,,,8,17296,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,,,
2752,,,,HEK293,CHEMBL617749,B,BAO_0000219,,,8,17296,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,,,
2753,,,,HEK293,CHEMBL617750,B,BAO_0000219,,,8,15779,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,,
2754,,,,HEK293,CHEMBL617751,B,BAO_0000219,,,8,15779,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,,
2755,,,,HEK293,CHEMBL617752,B,BAO_0000219,,,8,14391,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,,,
2756,,,,HEK293,CHEMBL617753,B,BAO_0000219,,,8,15779,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,,,
2757,,,,HEK293,CHEMBL617754,B,BAO_0000219,,,8,15851,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,,,
2758,,,,HEK293,CHEMBL617755,B,BAO_0000219,,,9,15851,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,Homo sapiens,9606.0,
2759,,,,HEK293,CHEMBL617756,B,BAO_0000219,,,8,15779,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,,,
2760,,,,HEK293,CHEMBL617757,B,BAO_0000219,,,8,3832,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,,,
2761,,,,HEK293,CHEMBL617758,B,BAO_0000219,,,8,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,,,
2762,,,,NIH3T3,CHEMBL617759,B,BAO_0000219,,,8,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,,,
2763,,,,HEK293,CHEMBL617760,B,BAO_0000219,,,8,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,,,
2764,,,,CHO-K1,CHEMBL617761,B,BAO_0000219,,,8,1883,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,,,
2765,,,,,CHEMBL617762,B,BAO_0000357,,,9,4321,Binding affinity against 5-hydroxytryptamine 2C receptor,,Homo sapiens,9606.0,
2766,,,,,CHEMBL617763,B,BAO_0000357,,,8,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,,,
2767,,,,HEK293,CHEMBL857983,B,BAO_0000219,,,8,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,,,
2768,,,,HEK293,CHEMBL617764,B,BAO_0000219,,,8,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,,,
2769,,,,HeLa,CHEMBL617765,B,BAO_0000219,,,8,16404,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,,,
2770,,,,,CHEMBL617766,F,BAO_0000019,,,8,13267,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,,,
2771,Hippocampus,,,,CHEMBL617767,F,BAO_0000221,,,8,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,,,
2772,,,,HEK293,CHEMBL617768,B,BAO_0000219,,,8,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,,,
2773,,,,HEK293,CHEMBL617769,B,BAO_0000219,,,8,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,,,
2774,,,,,CHEMBL858023,B,BAO_0000357,,,8,13463,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,,,
2775,Stomach,,,,CHEMBL617770,B,BAO_0000019,,,8,13463,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,,,
2776,Stomach,,,,CHEMBL617771,B,BAO_0000019,,,8,13463,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,,,
2777,,,,A9,CHEMBL617772,F,BAO_0000219,,,8,12652,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,,,
2778,,,,NIH3T3,CHEMBL617773,B,BAO_0000219,,,8,4682,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,,,
2779,,,,NIH3T3,CHEMBL617850,B,BAO_0000219,,,8,4682,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,,,
2780,,,,NIH3T3,CHEMBL617851,B,BAO_0000219,,,8,4682,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,,,
2781,,,,,CHEMBL617852,F,BAO_0000019,,,8,12652,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,,,
2782,Stomach,,,,CHEMBL858024,B,BAO_0000019,,,8,13463,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,,Mus musculus,10090.0,
2783,Stomach,,,,CHEMBL617853,B,BAO_0000019,,,9,13463,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,,Rattus norvegicus,10116.0,
2784,,,,,CHEMBL617854,B,BAO_0000357,,,8,13969,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,,,
2785,,,,,CHEMBL873477,B,BAO_0000357,,,8,13392,Binding affinity for 5-hydroxytryptamine 2C receptor,,Sus scrofa,9823.0,
2786,,,,,CHEMBL617855,B,BAO_0000357,,,8,13392,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,,
2787,,,,,CHEMBL617856,B,BAO_0000019,,,8,14430,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,,,
2788,,,,,CHEMBL617857,B,BAO_0000019,,,8,1742,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,,,
2789,,,,,CHEMBL617858,B,BAO_0000249,,,8,14286,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,,,
2790,,,,,CHEMBL617859,B,BAO_0000357,,,8,5619,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,,,
2791,,,,,CHEMBL617860,B,BAO_0000357,,,8,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,,,
2792,,,,,CHEMBL617861,B,BAO_0000357,,,8,12861,Binding activity radioligand.,,,,
2793,,,,,CHEMBL617862,B,BAO_0000019,,,8,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,,
2794,,,,,CHEMBL617863,B,BAO_0000019,,,8,12861,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,,,
2795,,,,,CHEMBL617864,B,BAO_0000249,,,8,12827,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,,,
2796,,,,,CHEMBL617649,B,BAO_0000249,,,8,12827,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,,,
2797,,,,,CHEMBL617650,F,BAO_0000019,,,8,12919,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,Sus scrofa,9823.0,
2798,,,,,CHEMBL617651,F,BAO_0000019,,,8,12919,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,Sus scrofa,9823.0,
2799,,,,,CHEMBL617652,B,BAO_0000357,,,8,16429,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,Sus scrofa,9823.0,
2800,,,,,CHEMBL857072,B,BAO_0000019,,,8,773,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,Sus scrofa,9823.0,
2801,,,,,CHEMBL617653,B,BAO_0000357,,,8,5033,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,Sus scrofa,9823.0,
2802,,,,,CHEMBL617654,B,BAO_0000019,,,8,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,,
2803,,,,,CHEMBL617655,F,BAO_0000019,,,8,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,,,
2804,,,,,CHEMBL617656,B,BAO_0000357,,,8,14970,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,,,
2805,,,,,CHEMBL617657,B,BAO_0000357,,,8,14970,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,,,
2806,,,,,CHEMBL617658,B,BAO_0000357,,,8,14970,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,,,
2807,,,,,CHEMBL617659,B,BAO_0000357,,,9,14178,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,Rattus norvegicus,10116.0,
2808,,,,,CHEMBL617838,B,BAO_0000357,,,9,14178,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,Rattus norvegicus,10116.0,
2809,,,,,CHEMBL617839,B,BAO_0000249,,,9,14229,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,,Rattus norvegicus,10116.0,Brain membranes
2810,,,,,CHEMBL617840,B,BAO_0000357,,,8,16532,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,,,
2811,,,,,CHEMBL617841,B,BAO_0000019,,,8,14826,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,,,
2812,,,,,CHEMBL875915,B,BAO_0000019,,,8,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,,,
2813,,,,,CHEMBL617842,B,BAO_0000219,,,8,17211,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,In vitro,,,
2814,,,,NIH3T3,CHEMBL617843,B,BAO_0000219,,,8,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,,,
2815,,,,,CHEMBL617844,B,BAO_0000357,,,8,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,,,
2816,,,,,CHEMBL617845,B,BAO_0000357,,,8,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,,,
2817,,,,NIH3T3,CHEMBL617846,B,BAO_0000219,,,8,12457,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,,,
2818,,,,,CHEMBL617847,B,BAO_0000357,,,8,4707,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,,,
2819,,,,,CHEMBL617848,B,BAO_0000357,,,8,13297,Binding affinity against 5-hydroxytryptamine 2C receptor,,,,
2820,,,,,CHEMBL617849,B,BAO_0000357,,,8,16633,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,,
2821,,,,,CHEMBL621507,B,BAO_0000357,,,8,16133,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,
2822,,,,,CHEMBL621508,B,BAO_0000357,,,8,16326,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,,,
2823,,,,,CHEMBL621509,B,BAO_0000019,,,8,14423,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,,,
2824,,,,,CHEMBL621510,B,BAO_0000019,,,8,15412,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,,,
2825,,,,,CHEMBL621511,B,BAO_0000019,,,8,15412,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,,,
2826,,,,A9,CHEMBL621512,B,BAO_0000219,,,8,15558,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,,,
2827,,,,,CHEMBL621513,B,BAO_0000357,,,8,16633,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,,
2828,,,,,CHEMBL621514,B,BAO_0000357,,,8,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,,,
2829,,,,,CHEMBL621515,B,BAO_0000219,,,8,17175,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,In vitro,,,
2830,,,,,CHEMBL621516,B,BAO_0000219,,,8,12469,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,,,
2831,Caudate-putamen,,,,CHEMBL621517,B,BAO_0000019,,,8,3682,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,,,
2832,,,,,CHEMBL621518,B,BAO_0000357,,,8,4932,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,,,
2833,,,,,CHEMBL621519,B,BAO_0000019,,,8,4932,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,,,
2834,,,,,CHEMBL621520,B,BAO_0000357,,,8,3935,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,,,
2835,,,,,CHEMBL621521,B,BAO_0000357,,,8,15818,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,,,
2836,,,,,CHEMBL621522,B,BAO_0000357,,,8,15818,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,,,
2837,,,,,CHEMBL621523,B,BAO_0000219,,,8,14749,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,,,
2838,,,,,CHEMBL621524,B,BAO_0000357,,,8,15740,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,,,
2839,,,,,CHEMBL621525,B,BAO_0000357,,,9,17133,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,Rattus norvegicus,10116.0,
2840,,,,,CHEMBL872921,B,BAO_0000357,,,8,16532,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,,,
2841,,,,,CHEMBL621526,B,BAO_0000357,,,8,12369,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,,,
2842,,,,,CHEMBL621527,B,BAO_0000219,,,8,12369,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,,,
2843,,,,,CHEMBL617865,B,BAO_0000019,,,9,2309,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,Rattus norvegicus,10116.0,
2844,,,,,CHEMBL617866,B,BAO_0000357,,,8,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,,,
2845,,,,,CHEMBL617867,B,BAO_0000019,,,8,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,,,
2846,,,,,CHEMBL617487,B,BAO_0000357,,,8,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,,,
2847,,,,,CHEMBL617488,B,BAO_0000357,,,8,12953,Binding affinity for 5-hydroxytryptamine 2C receptor,,,,
2848,,,,,CHEMBL617489,B,BAO_0000357,,,8,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,,,
2849,,,,,CHEMBL617490,B,BAO_0000019,,,8,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,,,
2850,,,,,CHEMBL617491,B,BAO_0000019,,,8,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,,,
2851,,,,,CHEMBL617492,B,BAO_0000019,,,8,14025,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,,,
2852,,,,,CHEMBL617493,B,BAO_0000019,,,8,14998,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,,,
2853,,,,,CHEMBL617494,B,BAO_0000357,,,8,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,,,
2854,,,,,CHEMBL617495,B,BAO_0000019,,,9,13735,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,Rattus norvegicus,10116.0,
2855,,,,,CHEMBL617496,B,BAO_0000357,,,8,13181,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,,,
2856,,,,CHO-K1,CHEMBL617497,B,BAO_0000219,,,8,1883,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,,,
2857,,,,,CHEMBL617498,B,BAO_0000357,,,8,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,
2858,,,,,CHEMBL617499,B,BAO_0000357,,,8,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,,,
2859,,,,,CHEMBL617500,F,BAO_0000019,,,8,14579,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,,,
2860,,,,,CHEMBL617501,B,BAO_0000357,,,8,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,,,
2861,,,,,CHEMBL617502,B,BAO_0000357,,,8,4820,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,,
2862,,,,,CHEMBL617503,B,BAO_0000357,,,8,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,,,
2863,,,,,CHEMBL617504,B,BAO_0000357,,,8,14755,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,,,
2864,,,,,CHEMBL617406,B,BAO_0000357,,,8,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,,,
2865,,,,,CHEMBL617407,B,BAO_0000019,,,9,6857,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,Homo sapiens,9606.0,
2866,,,,,CHEMBL617408,B,BAO_0000357,,,8,16209,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,,,
2867,,,,,CHEMBL617409,B,BAO_0000357,,,8,15363,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,,,
2868,,,,,CHEMBL617410,B,BAO_0000357,,,8,15363,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,,,
2869,,,,,CHEMBL617411,B,BAO_0000357,,,8,15363,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,,,
2870,,,,,CHEMBL617412,B,BAO_0000019,,,8,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,,,
2871,,,,,CHEMBL617774,B,BAO_0000357,,,9,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,Homo sapiens,9606.0,
2872,,,,HEK293,CHEMBL617775,B,BAO_0000219,,,9,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,Homo sapiens,9606.0,
2873,,,,HEK293,CHEMBL617776,B,BAO_0000219,,,9,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,Homo sapiens,9606.0,
2874,,,,CHO,CHEMBL617777,F,BAO_0000219,,,9,6857,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,Homo sapiens,9606.0,
2875,,,,CHO,CHEMBL617778,F,BAO_0000219,,,9,6857,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,Homo sapiens,9606.0,
2876,,,,HEK293,CHEMBL617779,B,BAO_0000219,,,8,15779,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,,
2877,,,,HEK293,CHEMBL617780,B,BAO_0000219,,,8,15851,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,,,
2878,,,,HEK293,CHEMBL617781,B,BAO_0000219,,,8,15779,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,,,
2879,,,,HEK293,CHEMBL617782,B,BAO_0000219,,,9,14157,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,Homo sapiens,9606.0,
2880,,,,HEK293,CHEMBL617783,B,BAO_0000219,,,9,4540,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,Homo sapiens,9606.0,
2881,,,,,CHEMBL617784,B,BAO_0000357,,,8,6166,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,,,
2882,,,,HEK293,CHEMBL617785,B,BAO_0000219,,,8,15779,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,,,
2883,,,,HEK293,CHEMBL857984,B,BAO_0000219,,,8,14391,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,,,
2884,,,,HEK293,CHEMBL617786,B,BAO_0000219,,,8,3832,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,,,
2885,,,,HEK293,CHEMBL617787,B,BAO_0000219,,,8,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,,,
2886,,,,HEK293,CHEMBL617788,B,BAO_0000219,,,9,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,Homo sapiens,9606.0,
2887,,,,HEK293,CHEMBL617789,B,BAO_0000219,,,9,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,Homo sapiens,9606.0,
2888,,,,HEK293,CHEMBL617790,B,BAO_0000219,,,8,4199,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,,,
2889,,,,CHO-K1,CHEMBL617791,B,BAO_0000219,,,8,1883,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,,,
2890,,,,,CHEMBL617608,B,BAO_0000357,,,8,4321,Binding affinity against 5-hydroxytryptamine 2B receptor,,,,
2891,,,,HEK293,CHEMBL617609,B,BAO_0000219,,,8,15146,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,,,
2892,,,,HEK293,CHEMBL617610,B,BAO_0000219,,,8,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,,,
2893,,,,HEK293,CHEMBL617611,B,BAO_0000219,,,8,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,,,
2894,,,,HEK293,CHEMBL617612,B,BAO_0000219,,,8,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,,
2895,,,,HEK293,CHEMBL617613,B,BAO_0000219,,,8,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,,
2896,,,,,CHEMBL617614,B,BAO_0000019,,,8,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,Oryctolagus cuniculus,9986.0,
2897,Stomach,,,,CHEMBL617615,B,BAO_0000019,,,8,13463,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,,,
2898,Stomach,,,,CHEMBL858114,B,BAO_0000357,,,8,7259,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,,,
2899,Stomach,,,,CHEMBL617616,B,BAO_0000357,,,8,7259,Affinity against serotonergic receptor in the isolated rat stomach fundus,,,,
2900,Stomach,,,,CHEMBL617617,F,BAO_0000019,,,9,7185,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,,Rattus norvegicus,10116.0,
2901,,,,,CHEMBL875914,F,BAO_0000019,,,9,7185,Antagonistic against 5-hydroxytryptamine 2B receptor,,Rattus norvegicus,10116.0,
2902,Stomach,,,,CHEMBL617618,F,BAO_0000019,,,8,13267,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,,,
2903,Stomach,,,,CHEMBL617619,B,BAO_0000357,,,9,13735,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,,Rattus norvegicus,10116.0,
2904,,,,,CHEMBL617620,F,BAO_0000019,,,8,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,,,
2905,,,,,CHEMBL617621,F,BAO_0000019,,,8,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,,,
2906,,,,,CHEMBL617622,F,BAO_0000019,,,8,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,,,
2907,Stomach,,,,CHEMBL617623,B,BAO_0000357,,,9,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,Rattus norvegicus,10116.0,
2908,Stomach,,,,CHEMBL617624,B,BAO_0000357,,,9,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,Rattus norvegicus,10116.0,
2909,Stomach,,,,CHEMBL617625,B,BAO_0000357,,,9,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,Rattus norvegicus,10116.0,
2910,Stomach,,,,CHEMBL617626,B,BAO_0000357,,,9,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,Rattus norvegicus,10116.0,
2911,Stomach,,,,CHEMBL617627,F,BAO_0000019,,,8,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,,
2912,Stomach,,,,CHEMBL617628,F,BAO_0000019,,,8,16404,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,,
2913,Stomach,,,,CHEMBL617629,F,BAO_0000019,,,8,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,,,
2914,Stomach,,,,CHEMBL858115,F,BAO_0000019,,,8,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,,,
2915,Stomach,,,,CHEMBL617630,F,BAO_0000019,,,9,16404,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,,Rattus norvegicus,10116.0,
2916,Thoracic aorta,,,,CHEMBL617631,F,BAO_0000019,,,8,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,,,
2917,,,,,CHEMBL617632,B,BAO_0000357,,,8,7483,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,,,
2918,,,,,CHEMBL617633,B,BAO_0000357,,,8,7483,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,,,
2919,,,,,CHEMBL617634,B,BAO_0000357,,,8,7483,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,,,
2920,,,,,CHEMBL617635,B,BAO_0000357,,,8,7483,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,,,
2922,Stomach,,,,CHEMBL617637,F,BAO_0000019,,,9,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,Rattus norvegicus,10116.0,
2923,,,,,CHEMBL617638,B,BAO_0000357,,,8,6347,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,
2924,,,,,CHEMBL617639,B,BAO_0000357,,,8,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,,,
2925,,,,,CHEMBL617640,B,BAO_0000357,,,8,4373,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,,,
2926,,,,,CHEMBL617641,B,BAO_0000357,,,8,4687,Evaluated for the binding affinity to 5-HT 2B receptor,,,,
2927,,,,,CHEMBL617642,B,BAO_0000357,,,8,16946,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,,,
2928,,,,,CHEMBL617643,B,BAO_0000357,,,8,16633,Binding affinities against 5-hydroxytryptamine 2B receptor,,,,
2929,,,,,CHEMBL617644,B,BAO_0000357,,,8,16633,Binding affinities towards 5-hydroxytryptamine 2B receptor,,,,
2930,,,,,CHEMBL617645,B,BAO_0000357,,,8,16633,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,,,
2931,,,,,CHEMBL617646,B,BAO_0000357,,,8,15026,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,,,
2932,,,,,CHEMBL617647,B,BAO_0000357,,,8,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,Bos taurus,9913.0,
2933,,,,,CHEMBL617648,B,BAO_0000357,,,8,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,Bos taurus,9913.0,
2934,,,,,CHEMBL617875,B,BAO_0000357,,,8,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,Bos taurus,9913.0,
2935,,,,,CHEMBL617876,B,BAO_0000357,,,8,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,Bos taurus,9913.0,
2936,,,,,CHEMBL617877,B,BAO_0000357,,,8,16404,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,Bos taurus,9913.0,
2937,,,,,CHEMBL617878,B,BAO_0000357,,,8,15026,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,Bos taurus,9913.0,
2938,,,,,CHEMBL617879,B,BAO_0000357,,,8,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,Bos taurus,9913.0,
2939,,,,,CHEMBL617880,B,BAO_0000019,,,8,16312,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,Cavia porcellus,10141.0,
2940,Striatum,,,,CHEMBL617881,B,BAO_0000357,,,9,5486,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,,Cavia porcellus,10141.0,
2941,,,,,CHEMBL857073,B,BAO_0000357,,,8,5254,Binding affinity against 5-HT1A receptor,,,,
2942,,,,CHO,CHEMBL617882,F,BAO_0000219,,,8,3857,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,,,
2943,,,,CHO,CHEMBL617883,F,BAO_0000219,,,9,6857,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,Homo sapiens,9606.0,
2944,,,,,CHEMBL617884,F,BAO_0000219,,,8,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,,,
2945,,,,CHO,CHEMBL617885,B,BAO_0000219,,,8,6347,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,,,
2946,,,,CHO,CHEMBL617886,B,BAO_0000219,,,8,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,,,
2947,,,,,CHEMBL617887,B,BAO_0000357,,,9,16146,Inhibition of human 5-hydroxytryptamine 2C receptor,,Homo sapiens,9606.0,
2948,,,,,CHEMBL617888,B,BAO_0000357,,,8,3805,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,,,
2949,,,,,CHEMBL617889,B,BAO_0000019,,,8,3857,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,,,
2950,,,,,CHEMBL617890,B,BAO_0000357,,,8,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,,,
2951,,,,,CHEMBL617891,B,BAO_0000357,,,8,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,,,
2952,,,,,CHEMBL617892,B,BAO_0000357,,,8,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,,,
2953,,,,CHO,CHEMBL617893,B,BAO_0000219,,,8,4012,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,,,
2954,,,,CHO,CHEMBL617894,B,BAO_0000219,,,8,6366,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,,,
2955,,,,CHO,CHEMBL617895,B,BAO_0000219,,,8,15949,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,,
2956,,,,CHO,CHEMBL617896,B,BAO_0000219,,,8,17211,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,,,
2957,,,,,CHEMBL617897,B,BAO_0000357,,,9,6491,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,Homo sapiens,9606.0,
2958,,,,,CHEMBL617898,F,BAO_0000019,,,8,14093,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,,,
2959,,,,,CHEMBL617899,F,BAO_0000019,,,8,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,,
2960,,,,CHO,CHEMBL617900,B,BAO_0000219,,,8,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,Rattus norvegicus,10116.0,
2961,,,,,CHEMBL617901,F,BAO_0000019,,,8,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,,,
2962,,,,,CHEMBL617902,F,BAO_0000019,,,8,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,,,
2963,,,,,CHEMBL617903,F,BAO_0000019,,,8,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,
2964,,,,,CHEMBL617904,B,BAO_0000357,,,8,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,,,
2965,,,,,CHEMBL617905,B,BAO_0000357,,,8,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,,,
2966,,,,,CHEMBL617906,B,BAO_0000357,,,8,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,,,
2967,,,,,CHEMBL617907,B,BAO_0000357,,,8,14755,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,,,
2968,,,,,CHEMBL617908,B,BAO_0000357,,,8,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,,,
2969,,,,CHO,CHEMBL620617,B,BAO_0000219,,,8,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,,
2970,,,,,CHEMBL620618,B,BAO_0000019,,,9,6857,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,Homo sapiens,9606.0,
2971,,,,,CHEMBL620619,B,BAO_0000357,,,8,5635,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,,,
2972,,,,,CHEMBL620620,B,BAO_0000357,,,9,4234,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,Homo sapiens,9606.0,
2973,,,,,CHEMBL620621,B,BAO_0000357,,,8,16209,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,,,
2974,,,,,CHEMBL872920,B,BAO_0000249,,,7,5778,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,,Rattus norvegicus,10116.0,Membranes
2975,,,,,CHEMBL620622,B,BAO_0000223,,,6,5094,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,,,
2976,,,,,CHEMBL620623,B,BAO_0000019,,,7,809,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,Rattus norvegicus,10116.0,
2977,,,,,CHEMBL620624,B,BAO_0000019,,,6,1578,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,,,
2978,,,,,CHEMBL620625,B,BAO_0000019,,,6,809,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,,,
2979,,,,,CHEMBL620626,B,BAO_0000219,,,6,12469,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,,,
2980,,,,,CHEMBL621307,B,BAO_0000019,,,6,14290,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,,,
2981,,,,,CHEMBL621308,B,BAO_0000019,,,6,14290,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,,,
2982,,,,,CHEMBL621309,B,BAO_0000223,,,6,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,,,
2983,,,,,CHEMBL621310,B,BAO_0000223,,,6,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,,,
2984,,,,,CHEMBL621311,B,BAO_0000223,,,6,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,,,
2985,,,,,CHEMBL621502,B,BAO_0000249,,,6,15253,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,,,
2986,,,,,CHEMBL621503,B,BAO_0000249,,,6,15253,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,,,
2987,,,,,CHEMBL621504,B,BAO_0000249,,,6,11683,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,,,Membranes
2988,,,,,CHEMBL621505,B,BAO_0000223,,,6,12092,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,,,
2989,,,,,CHEMBL621506,B,BAO_0000019,,,6,1946,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,,,
2990,,,,,CHEMBL619781,B,BAO_0000223,,,6,11623,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,,,
2991,,,,,CHEMBL619782,B,BAO_0000223,,,6,11623,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,,,
2992,,,,,CHEMBL619783,B,BAO_0000019,,,6,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,,,
2993,,,,,CHEMBL619784,B,BAO_0000019,,,7,5432,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,Rattus norvegicus,10116.0,
2994,,,,,CHEMBL619785,B,BAO_0000249,,,6,14826,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,,
2995,,,,,CHEMBL619786,B,BAO_0000223,,,6,2222,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,,,
2996,,,,,CHEMBL619787,B,BAO_0000019,,,6,11963,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,,,
2997,,,,,CHEMBL872925,B,BAO_0000019,,,6,14145,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,,,
2998,,,,,CHEMBL619788,B,BAO_0000019,,,6,17819,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,,,
2999,,,,,CHEMBL619789,B,BAO_0000249,,,6,10394,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,,,
3000,,,,,CHEMBL619790,B,BAO_0000249,,,6,10394,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,,,
3001,,,,,CHEMBL619791,B,BAO_0000019,,,6,15034,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,,,
3002,,,,,CHEMBL619792,B,BAO_0000019,,,6,691,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,,,
3003,,,,,CHEMBL619793,B,BAO_0000249,,,6,12092,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,,,Membranes
3004,,,,,CHEMBL619794,B,BAO_0000223,,,7,11752,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,10116.0,
3005,Brain,,,,CHEMBL619795,B,BAO_0000221,,,6,11752,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,,,
3006,,,,,CHEMBL619796,B,BAO_0000019,,,6,301,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,,,
3007,,,,,CHEMBL620448,B,BAO_0000223,,,6,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,,,
3008,,,,,CHEMBL620449,B,BAO_0000223,,,6,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,,,
3009,,,,,CHEMBL620450,B,BAO_0000223,,,6,12092,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,,,
3010,,,,,CHEMBL620451,B,BAO_0000223,,,6,11684,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,,,
3011,,,,,CHEMBL620631,B,BAO_0000223,,,6,11684,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,,,
3012,,,,,CHEMBL620632,B,BAO_0000019,,,6,12953,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,,,
3013,,,,,CHEMBL620633,B,BAO_0000019,,,6,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,,,
3014,,,,,CHEMBL620634,B,BAO_0000223,,,6,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,,,
3015,,,,,CHEMBL620635,B,BAO_0000019,,,6,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,,,
3016,,,,,CHEMBL620636,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,In vivo,,,
3017,,,,,CHEMBL620637,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,,,
3018,,,,,CHEMBL620638,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,,,
3019,,,,,CHEMBL620639,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,In vivo,,,
3020,,,,,CHEMBL620640,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,In vivo,,,
3021,,,,,CHEMBL620641,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,,,
3022,,,,,CHEMBL620642,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,In vivo,,,
3023,,,,,CHEMBL620643,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,,,
3024,,,,,CHEMBL620644,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,In vivo,,,
3025,,,,,CHEMBL620645,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,In vivo,,,
3026,,,,,CHEMBL620646,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,,,
3027,,,,,CHEMBL620647,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,,,
3028,,,,,CHEMBL620648,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,In vivo,,,
3029,,,,,CHEMBL620649,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,In vivo,,,
3030,,,,,CHEMBL620650,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,,,
3031,,,,,CHEMBL620651,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,,,
3032,,,,,CHEMBL872875,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,,,
3033,,,,,CHEMBL620652,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,,,
3034,,,,,CHEMBL620653,F,BAO_0000019,,,6,10609,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,,,
3035,,,,,CHEMBL857076,B,BAO_0000019,,,6,12861,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,,,
3036,,,,,CHEMBL620654,B,BAO_0000019,,,7,12861,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,10116.0,
3037,,,,,CHEMBL620655,B,BAO_0000223,,,6,12861,Binding activity radioligand.,,,,
3038,,,,,CHEMBL620656,B,BAO_0000249,,,6,10728,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,,,Brain membranes
3039,,,,,CHEMBL620657,B,BAO_0000249,,,6,10728,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,,,Brain membranes
3040,,,,,CHEMBL620658,B,BAO_0000357,,,8,5163,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,,,
3041,,,,,CHEMBL620659,B,BAO_0000357,,,8,5163,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,,,
3042,,,,,CHEMBL620660,B,BAO_0000357,,,8,6011,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,,,
3043,,,,,CHEMBL620661,B,BAO_0000357,,,8,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,,,
3044,,,,,CHEMBL620662,B,BAO_0000357,,,8,5635,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,,,
3045,,,,,CHEMBL620663,B,BAO_0000357,,,8,5163,Affinity for 5-hydroxytryptamine 2C receptor,,,,
3046,,,,,CHEMBL620664,B,BAO_0000357,,,8,6841,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,
3047,,,,,CHEMBL620665,B,BAO_0000357,,,8,6119,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,,,
3048,,,,,CHEMBL620666,B,BAO_0000357,,,8,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,,,
3049,,,,,CHEMBL620667,B,BAO_0000357,,,8,1633,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,,,
3050,,,,,CHEMBL620668,B,BAO_0000357,,,8,1633,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,,,
3051,,,,,CHEMBL620669,B,BAO_0000357,,,8,4373,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,,,
3052,,,,,CHEMBL620670,B,BAO_0000357,,,8,6576,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,,,
3053,,,,,CHEMBL620671,B,BAO_0000357,,,8,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,,,
3054,,,,,CHEMBL620672,B,BAO_0000357,,,8,12146,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,,,
3055,,,,,CHEMBL620673,B,BAO_0000357,,,8,12146,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,,,
3056,,,,,CHEMBL620674,B,BAO_0000357,,,8,16946,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,,,
3057,,,,,CHEMBL620675,B,BAO_0000357,,,8,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,,,
3058,,,,,CHEMBL620676,B,BAO_0000357,,,8,16700,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,,,
3059,,,,,CHEMBL621382,B,BAO_0000357,,,8,3269,Affinity against 5-hydroxytryptamine 2C receptor,,,,
3060,,,,,CHEMBL621383,B,BAO_0000357,,,9,1274,Binding affinity against 5-hydroxytryptamine 2C receptor,,Homo sapiens,9606.0,
3061,,,,,CHEMBL621384,B,BAO_0000357,,,8,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,,,
3062,,,,,CHEMBL621385,B,BAO_0000357,,,8,5834,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,Bos taurus,9913.0,
3063,,,,,CHEMBL617989,B,BAO_0000357,,,8,11147,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,Bos taurus,9913.0,
3064,,,,,CHEMBL617990,F,BAO_0000019,,,4,14145,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,Cavia porcellus,10141.0,
3065,Ileum,,,,CHEMBL875085,B,BAO_0000221,,,4,10561,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,Cavia porcellus,10141.0,
3066,,,,,CHEMBL617991,F,BAO_0000019,,,4,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,Cavia porcellus,10141.0,
3067,,,,,CHEMBL617992,F,BAO_0000019,,,4,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,Cavia porcellus,10141.0,
3068,Ileum,,,,CHEMBL617993,B,BAO_0000221,,,4,10561,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,Cavia porcellus,10141.0,
3069,Ileum,,,,CHEMBL617994,B,BAO_0000221,,,4,11454,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,,Cavia porcellus,10141.0,
3070,,,,,CHEMBL617995,F,BAO_0000019,,,4,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,Cavia porcellus,10141.0,
3071,,,,,CHEMBL617996,F,BAO_0000019,,,4,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,Cavia porcellus,10141.0,
3072,,,,,CHEMBL617997,F,BAO_0000019,,,4,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,Cavia porcellus,10141.0,
3073,,,,,CHEMBL617998,F,BAO_0000019,,,4,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,Cavia porcellus,10141.0,
3074,,,,,CHEMBL617999,F,BAO_0000019,,,4,4639,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,Cavia porcellus,10141.0,
3075,,,,,CHEMBL618000,F,BAO_0000019,,,4,4639,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,Cavia porcellus,10141.0,
3076,Ileum,,,,CHEMBL617815,F,BAO_0000221,,,4,15253,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",,Cavia porcellus,10141.0,
3077,Ileum,,,,CHEMBL617816,F,BAO_0000221,,,4,15253,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",,Cavia porcellus,10141.0,
3078,Ileum,,,,CHEMBL617817,F,BAO_0000221,,,4,11963,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,,Cavia porcellus,10141.0,
3079,Ileum,,,,CHEMBL617818,B,BAO_0000221,,,4,1946,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,,Cavia porcellus,10141.0,
3080,Ileum,,,,CHEMBL617819,B,BAO_0000221,,,4,1946,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,,Cavia porcellus,10141.0,
3081,,,,,CHEMBL617820,B,BAO_0000223,,,4,12045,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,Cavia porcellus,10141.0,
3082,Ileum,,,,CHEMBL617821,B,BAO_0000221,,,4,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,Cavia porcellus,10141.0,
3083,Ileum,,,,CHEMBL617822,F,BAO_0000221,,,4,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,Cavia porcellus,10141.0,
3084,Ileum,,,,CHEMBL617823,F,BAO_0000221,,,4,273,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),,Cavia porcellus,10141.0,
3085,Ileum,,,,CHEMBL617824,F,BAO_0000221,,,4,188,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,,Cavia porcellus,10141.0,
3086,Ileum,,,,CHEMBL617825,F,BAO_0000221,,,4,12919,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,,Cavia porcellus,10141.0,
3087,Ileum,,,,CHEMBL617826,F,BAO_0000221,,,4,12918,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,,Cavia porcellus,10141.0,
3088,Ileum,,,,CHEMBL617827,B,BAO_0000221,,,4,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,Cavia porcellus,10141.0,
3089,Ileum,,,,CHEMBL617828,F,BAO_0000221,,,4,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,Cavia porcellus,10141.0,
3090,Ileum,,,,CHEMBL617829,B,BAO_0000221,,,4,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,Cavia porcellus,10141.0,
3091,Ileum,,,,CHEMBL617830,B,BAO_0000221,,,4,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,,Cavia porcellus,10141.0,
3092,Ileum,,,,CHEMBL617831,B,BAO_0000221,,,4,1559,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,,Cavia porcellus,10141.0,
3093,Ileum,,,,CHEMBL617832,B,BAO_0000221,,,4,14424,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,,Cavia porcellus,10141.0,
3094,,,,,CHEMBL617833,B,BAO_0000019,,,0,13181,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,Cavia porcellus,10141.0,
3095,,,,,CHEMBL617834,B,BAO_0000357,,,8,5486,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,,,
3096,,,,,CHEMBL617835,B,BAO_0000223,,,5,6491,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,Homo sapiens,9606.0,
3097,,,,,CHEMBL617836,B,BAO_0000223,,,4,6013,Binding affinity towards 5-HT3 receptor,,,,
3098,,,,,CHEMBL617837,B,BAO_0000223,,,4,12861,Binding activity radioligand.,,,,
3099,,,,,CHEMBL620392,B,BAO_0000019,,,4,12861,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,,,
3100,,,,,CHEMBL620393,B,BAO_0000223,,,4,5104,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,,,
3101,,,,,CHEMBL620394,B,BAO_0000223,,,4,5105,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,,,
3102,,,,,CHEMBL620395,B,BAO_0000223,,,4,5104,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,,,
3103,,,,,CHEMBL620396,B,BAO_0000019,,,0,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,,,
3104,,,,NG108-15,CHEMBL620582,B,BAO_0000219,,,4,13657,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,,,
3105,,,,,CHEMBL620583,B,BAO_0000218,,,4,10369,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",In vivo,,,
3106,,,,,CHEMBL620584,B,BAO_0000019,,,4,10369,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,,,
3107,,,,,CHEMBL620585,B,BAO_0000224,,,4,12918,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,,,
3108,,,,,CHEMBL620586,B,BAO_0000224,,,4,12918,Compound was evaluated for the binding affinity at 5- HT3 receptor,,,,
3109,,,,,CHEMBL620587,B,BAO_0000019,,,4,10369,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,,,
3110,,,,,CHEMBL620588,B,BAO_0000019,,,4,773,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,,,
3111,,,,,CHEMBL620589,F,BAO_0000218,,,4,12918,5-hydroxytryptamine 3 receptor agonism in mouse,,,,
3112,,,,,CHEMBL620590,B,BAO_0000219,,,4,10561,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,,,
3113,,,,,CHEMBL617956,B,BAO_0000019,,,4,12827,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,,,
3114,,,,,CHEMBL617957,B,BAO_0000019,,,4,12827,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,,,
3115,,,,,CHEMBL617958,B,BAO_0000224,,,4,12918,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,,,
3116,,,,,CHEMBL617959,B,BAO_0000219,,,4,273,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,,,
3117,,,,,CHEMBL617960,B,BAO_0000219,,,4,273,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,,,
3118,,,,,CHEMBL617961,B,BAO_0000224,,,4,10561,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,,,
3119,,,,,CHEMBL617962,B,BAO_0000219,,,4,5033,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,In vitro,,,
3120,,,,N1E-115,CHEMBL617963,B,BAO_0000219,,,4,16429,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,,,
3121,,,,,CHEMBL617964,B,BAO_0000019,,,8,10322,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,,,
3122,,,,,CHEMBL617965,B,BAO_0000219,,,8,14331,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,,,
3123,,,,,CHEMBL617966,B,BAO_0000357,,,9,13462,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,Mus musculus,10090.0,
3124,,,,,CHEMBL857074,B,BAO_0000019,,,8,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,,
3125,,,,,CHEMBL617967,B,BAO_0000357,,,8,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,Sus scrofa,9823.0,
3126,,,,,CHEMBL617968,B,BAO_0000357,,,8,12861,Binding activity radioligand.,,Sus scrofa,9823.0,
3127,,,,,CHEMBL617969,B,BAO_0000223,,,4,10561,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,Oryctolagus cuniculus,9986.0,
3128,,,,,CHEMBL617970,B,BAO_0000223,,,4,10561,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,Oryctolagus cuniculus,9986.0,
3129,,,,,CHEMBL617971,B,BAO_0000223,,,4,10561,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,Oryctolagus cuniculus,9986.0,
3130,,,,,CHEMBL617972,B,BAO_0000019,,,4,10561,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,Oryctolagus cuniculus,9986.0,
3131,,,,,CHEMBL617973,F,BAO_0000019,,,4,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,Oryctolagus cuniculus,9986.0,
3132,,,,,CHEMBL617974,F,BAO_0000019,,,4,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,Oryctolagus cuniculus,9986.0,
3133,Ileum,,,,CHEMBL617975,F,BAO_0000221,,,4,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,Oryctolagus cuniculus,9986.0,
3134,,,,,CHEMBL617976,F,BAO_0000019,,,4,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,Oryctolagus cuniculus,9986.0,
3135,,,,,CHEMBL617977,F,BAO_0000019,,,4,273,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,Oryctolagus cuniculus,9986.0,
3136,,,,,CHEMBL617978,F,BAO_0000019,,,4,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,Oryctolagus cuniculus,9986.0,
3137,,,,,CHEMBL617979,F,BAO_0000019,,,4,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,Oryctolagus cuniculus,9986.0,
3138,,,,CHO,CHEMBL617980,B,BAO_0000219,,,4,13047,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,Oryctolagus cuniculus,9986.0,
3139,,,,,CHEMBL617981,B,BAO_0000019,,,7,1650,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,10116.0,
3140,,,,,CHEMBL617982,B,BAO_0000019,,,8,16288,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,,,
3141,,,,,CHEMBL617983,B,BAO_0000357,,,8,16288,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,,,
3142,,,,,CHEMBL617984,B,BAO_0000019,,,7,10254,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,Rattus norvegicus,10116.0,
3143,,,,,CHEMBL617985,B,BAO_0000019,,,6,14532,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,,,
3144,Heart,,,,CHEMBL617986,F,BAO_0000218,,,6,13392,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",In vivo,,,
3145,Heart,,,,CHEMBL617987,F,BAO_0000019,,,6,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,,,
3146,Heart,,,,CHEMBL617988,F,BAO_0000019,,,6,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,,,
3147,Heart,,,,CHEMBL617792,F,BAO_0000019,,,6,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,,,
3148,Heart,,,,CHEMBL617793,F,BAO_0000019,,,6,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,,,
3149,,,,,CHEMBL617794,F,BAO_0000019,,,6,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,,,
3150,,,,,CHEMBL617795,F,BAO_0000019,,,6,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,,,
3151,,,,,CHEMBL617796,F,BAO_0000019,,,6,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,,,
3152,,,,,CHEMBL617797,F,BAO_0000019,,,6,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,,,
3153,,,,,CHEMBL617798,F,BAO_0000218,,,7,1089,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),In vivo,Rattus norvegicus,10116.0,
3154,,,,,CHEMBL617799,F,BAO_0000218,,,6,1089,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),In vivo,,,
3155,,,,,CHEMBL617800,F,BAO_0000218,,,7,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,Rattus norvegicus,10116.0,
3156,,,,,CHEMBL617801,F,BAO_0000019,,,7,11454,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,Rattus norvegicus,10116.0,
3157,,,,,CHEMBL617802,F,BAO_0000218,,,7,12205,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,In vivo,Rattus norvegicus,10116.0,
3158,,,,,CHEMBL617803,F,BAO_0000019,,,7,1089,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,Rattus norvegicus,10116.0,
3159,,,,,CHEMBL617804,B,BAO_0000019,,,6,5094,Binding affinity towards 5-HT3 receptor in rat was evaluated,,,,
3160,,,,,CHEMBL617805,B,BAO_0000019,,,7,2622,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,10116.0,
3161,,,,,CHEMBL617806,B,BAO_0000223,,,6,245,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,,,
3162,,,,,CHEMBL617807,B,BAO_0000019,,,6,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,,,
3163,,,,,CHEMBL617808,B,BAO_0000019,,,6,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,,,
3164,,,,,CHEMBL617809,B,BAO_0000249,,,6,3020,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,,,
3165,,,,,CHEMBL617810,B,BAO_0000019,,,6,1742,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,,,
3166,Brain,,,,CHEMBL617811,B,BAO_0000249,,,6,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,,,
3167,Brain,,,,CHEMBL617812,B,BAO_0000221,,,6,17394,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,,,
3168,,,,,CHEMBL617813,B,BAO_0000249,,,6,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,,
3169,,,,,CHEMBL617814,B,BAO_0000249,,,6,14286,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,,
3170,,,,,CHEMBL617698,B,BAO_0000019,,,6,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,,,
3171,,,,,CHEMBL617699,B,BAO_0000019,,,7,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,Rattus norvegicus,10116.0,
3172,,,,,CHEMBL617700,B,BAO_0000019,,,7,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,Rattus norvegicus,10116.0,
3173,,,,,CHEMBL617701,B,BAO_0000223,,,7,14178,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,10116.0,
3174,,,,,CHEMBL617702,B,BAO_0000019,,,6,15034,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,,,
3175,,,,,CHEMBL617703,B,BAO_0000249,,,6,1089,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,,,Membranes
3176,,,,,CHEMBL617704,B,BAO_0000019,,,7,1089,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,Rattus norvegicus,10116.0,
3177,,,,,CHEMBL617705,B,BAO_0000223,,,6,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,,,
3178,,,,,CHEMBL617706,B,BAO_0000223,,,7,12801,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,10116.0,
3179,,,,NG108-15,CHEMBL617707,B,BAO_0000219,,,6,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,,,
3180,,,,NG108-15,CHEMBL617708,B,BAO_0000219,,,6,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,,,
3181,,,,,CHEMBL617709,B,BAO_0000019,,,6,15194,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,,,
3182,,,,,CHEMBL617710,B,BAO_0000019,,,6,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,,,
3183,,,,,CHEMBL882925,B,BAO_0000019,,,6,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,,,
3184,,,,,CHEMBL617711,B,BAO_0000019,,,6,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,,,
3185,,,,,CHEMBL617712,F,BAO_0000019,,,6,10610,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,,,
3186,,,,,CHEMBL617713,F,BAO_0000019,,,7,10355,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,Rattus norvegicus,10116.0,
3187,,,,,CHEMBL617714,F,BAO_0000019,,,6,691,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,,,
3188,,,,,CHEMBL617715,F,BAO_0000218,,,6,10611,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,,,
3189,,,,,CHEMBL617716,F,BAO_0000218,,,6,12801,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,In vivo,,,
3190,,,,,CHEMBL617717,F,BAO_0000218,,,6,10609,Inhibition of 5-HT evoked reflex bradycardia in rat.,,,,
3191,,,,,CHEMBL617718,F,BAO_0000218,,,6,11454,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3192,,,,,CHEMBL617719,F,BAO_0000218,,,6,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3193,,,,,CHEMBL617720,F,BAO_0000218,,,6,11454,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),In vivo,,,
3194,,,,,CHEMBL617721,F,BAO_0000218,,,7,11454,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,In vivo,Rattus norvegicus,10116.0,
3195,,,,,CHEMBL617722,F,BAO_0000218,,,6,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3196,,,,,CHEMBL617723,F,BAO_0000218,,,6,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,In vivo,,,
3197,,,,,CHEMBL617724,F,BAO_0000218,,,6,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3198,,,,,CHEMBL617725,F,BAO_0000218,,,6,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3199,,,,,CHEMBL617726,F,BAO_0000218,,,6,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3200,,,,,CHEMBL617727,F,BAO_0000218,,,6,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3201,,,,,CHEMBL617728,F,BAO_0000218,,,6,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3202,,,,,CHEMBL617729,F,BAO_0000218,,,6,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3203,,,,,CHEMBL617730,F,BAO_0000218,,,6,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,In vivo,,,
3204,,,,,CHEMBL617731,F,BAO_0000218,,,6,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3205,,,,,CHEMBL617732,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3206,,,,,CHEMBL617733,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3207,,,,,CHEMBL617734,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3208,,,,,CHEMBL872874,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,In vivo,,,
3209,,,,,CHEMBL617735,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,In vivo,,,
3210,,,,,CHEMBL617736,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,In vivo,,,
3211,,,,,CHEMBL617737,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,In vivo,,,
3212,,,,,CHEMBL617738,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,In vivo,,,
3213,,,,,CHEMBL617739,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3214,,,,,CHEMBL617740,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3215,,,,,CHEMBL617741,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3216,,,,,CHEMBL617742,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3217,,,,,CHEMBL617743,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3218,,,,,CHEMBL617744,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3219,,,,,CHEMBL617745,F,BAO_0000218,,,6,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3220,,,,,CHEMBL617746,F,BAO_0000218,,,6,670,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,,,
3221,,,,,CHEMBL617747,F,BAO_0000218,,,6,670,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,,,
3222,,,,,CHEMBL617748,F,BAO_0000218,,,6,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,In vivo,,,
3223,,,,,CHEMBL618909,F,BAO_0000218,,,6,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,In vivo,,,
3224,,,,,CHEMBL618910,F,BAO_0000218,,,6,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,In vivo,,,
3225,,,,,CHEMBL618911,F,BAO_0000218,,,6,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,In vivo,,,
3226,,,,,CHEMBL618912,F,BAO_0000218,,,6,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,In vivo,,,
3227,,,,,CHEMBL618913,F,BAO_0000218,,,6,10322,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),In vivo,,,
3228,,,,,CHEMBL618914,F,BAO_0000019,,,6,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,,,
3229,,,,,CHEMBL618915,F,BAO_0000019,,,6,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,,,
3230,,,,,CHEMBL618916,B,BAO_0000223,,,7,15412,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,10116.0,
3231,,,,,CHEMBL618917,F,BAO_0000019,,,6,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,,,
3232,Hippocampus,,,,CHEMBL618918,B,BAO_0000221,,,7,15412,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,,,
3233,,,,,CHEMBL618919,B,BAO_0000019,,,7,15412,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,Rattus norvegicus,10116.0,
3234,,,,,CHEMBL618920,B,BAO_0000019,,,7,17394,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,10116.0,
3235,,,,,CHEMBL618921,B,BAO_0000223,,,6,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,,,
3236,,,,,CHEMBL618922,B,BAO_0000019,,,6,12457,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,,,
3237,,,,,CHEMBL618923,B,BAO_0000019,,,6,12205,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,,,
3238,,,,,CHEMBL618924,B,BAO_0000019,,,6,14532,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,,,
3239,,,,,CHEMBL618925,B,BAO_0000019,,,6,1122,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,,,
3240,,,,,CHEMBL618926,B,BAO_0000019,,,6,5094,Binding affinity towards 5-HT3 receptor in rat was evaluated,,,,
3241,Ileum,,,,CHEMBL618927,F,BAO_0000221,,,9,809,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,,Cavia porcellus,10141.0,
3242,Ileum,,,,CHEMBL618928,F,BAO_0000221,,,9,809,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,,Cavia porcellus,10141.0,
3243,Ileum,,,,CHEMBL618929,F,BAO_0000221,,,9,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",,Cavia porcellus,10141.0,
3244,Ileum,,,,CHEMBL618930,F,BAO_0000221,,,9,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",,Cavia porcellus,10141.0,
3245,Ileum,,,,CHEMBL618931,F,BAO_0000221,,,9,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,Cavia porcellus,10141.0,
3246,Ileum,,,,CHEMBL619594,F,BAO_0000221,,,9,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,Cavia porcellus,10141.0,
3247,Ileum,,,,CHEMBL619595,F,BAO_0000221,,,9,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",,Cavia porcellus,10141.0,
3248,Ileum,,,,CHEMBL619596,F,BAO_0000221,,,9,13961,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,,Cavia porcellus,10141.0,
3249,Ileum,,,,CHEMBL619755,F,BAO_0000221,,,9,13961,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,,Cavia porcellus,10141.0,
3250,Ileum,,,,CHEMBL619756,F,BAO_0000221,,,9,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,,Cavia porcellus,10141.0,
3251,Ileum,,,,CHEMBL619757,F,BAO_0000221,,,9,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,,Cavia porcellus,10141.0,
3252,Ileum,,,,CHEMBL619758,F,BAO_0000221,,,9,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,,Cavia porcellus,10141.0,
3253,Ileum,,,,CHEMBL619759,F,BAO_0000221,,,9,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",,Cavia porcellus,10141.0,
3254,Ileum,,,,CHEMBL619760,F,BAO_0000221,,,9,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",,Cavia porcellus,10141.0,
3255,Ileum,,,,CHEMBL619761,F,BAO_0000221,,,9,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",,Cavia porcellus,10141.0,
3256,Ileum,,,,CHEMBL619762,F,BAO_0000221,,,9,14290,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,,Cavia porcellus,10141.0,
3257,Ileum,,,,CHEMBL619763,F,BAO_0000221,,,9,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,Cavia porcellus,10141.0,
3258,Ileum,,,,CHEMBL617868,F,BAO_0000221,,,9,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,Cavia porcellus,10141.0,
3259,,,,,CHEMBL617869,B,BAO_0000357,,,9,15034,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,Cavia porcellus,10141.0,
3260,Striatum,,,,CHEMBL882926,B,BAO_0000249,,,9,5094,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,Cavia porcellus,10141.0,
3261,Striatum,,,,CHEMBL617870,B,BAO_0000249,,,9,5094,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,Cavia porcellus,10141.0,
3262,Striatum,,,,CHEMBL617871,B,BAO_0000357,,,9,5399,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,,Cavia porcellus,10141.0,
3263,Striatum,,,,CHEMBL617872,B,BAO_0000357,,,9,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,,Cavia porcellus,10141.0,
3264,Striatum,,,,CHEMBL617873,B,BAO_0000357,,,9,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,Cavia porcellus,10141.0,
3265,Striatum,,,,CHEMBL617874,B,BAO_0000357,,,9,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,Cavia porcellus,10141.0,
3266,Ileum,,,,CHEMBL619067,F,BAO_0000221,,,9,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,,Cavia porcellus,10141.0,
3267,Ileum,,,,CHEMBL619068,F,BAO_0000221,,,9,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,,Cavia porcellus,10141.0,
3268,Ileum,,,,CHEMBL619069,F,BAO_0000221,,,9,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,Cavia porcellus,10141.0,
3269,,,,,CHEMBL619070,B,BAO_0000357,,,9,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,Cavia porcellus,10141.0,
3270,,,,,CHEMBL619071,B,BAO_0000357,,,9,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,Cavia porcellus,10141.0,
3271,,,,,CHEMBL619072,F,BAO_0000019,,,9,15034,Agonistic activity against 5-hydroxytryptamine 4 receptor,,Cavia porcellus,10141.0,
3272,,,,,CHEMBL619073,F,BAO_0000019,,,9,15034,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,Cavia porcellus,10141.0,
3273,,,,,CHEMBL619074,F,BAO_0000019,,,9,12918,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,Cavia porcellus,10141.0,
3274,,,,,CHEMBL619075,B,BAO_0000357,,,9,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,Cavia porcellus,10141.0,
3275,Striatum,,,,CHEMBL619076,B,BAO_0000357,,,9,17394,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,,Cavia porcellus,10141.0,
3276,Striatum,,,,CHEMBL619077,B,BAO_0000357,,,9,15034,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,,Cavia porcellus,10141.0,
3277,Striatum,,,,CHEMBL619078,B,BAO_0000249,,,9,5094,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,Cavia porcellus,10141.0,
3278,Striatum,,,,CHEMBL619079,B,BAO_0000249,,,9,5094,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,Cavia porcellus,10141.0,
3279,Ileum,,,,CHEMBL619080,B,BAO_0000221,,,9,17358,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,,Cavia porcellus,10141.0,
3280,,,,,CHEMBL619081,B,BAO_0000357,,,9,12953,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,Cavia porcellus,10141.0,
3281,,,,,CHEMBL619082,B,BAO_0000357,,,9,12953,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,Cavia porcellus,10141.0,
3282,,,,,CHEMBL619083,B,BAO_0000357,,,9,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,Cavia porcellus,10141.0,
3283,,,,,CHEMBL619084,B,BAO_0000357,,,9,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,Cavia porcellus,10141.0,
3284,Ileum,,,,CHEMBL859397,F,BAO_0000221,,,9,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,Cavia porcellus,10141.0,
3285,Ileum,,,,CHEMBL619085,F,BAO_0000221,,,9,12918,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,,Cavia porcellus,10141.0,
3286,Ileum,,,,CHEMBL619086,F,BAO_0000221,,,9,12919,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,,Cavia porcellus,10141.0,
3287,Ileum,,,,CHEMBL619087,F,BAO_0000221,,,9,273,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,,Cavia porcellus,10141.0,
3288,Ileum,,,,CHEMBL619088,F,BAO_0000221,,,9,273,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,Cavia porcellus,10141.0,
3289,,,,,CHEMBL619089,B,BAO_0000357,,,9,13181,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,Cavia porcellus,10141.0,
3290,,,,,CHEMBL619090,B,BAO_0000357,,,8,13181,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,Cavia porcellus,10141.0,
3291,,,,,CHEMBL619091,F,BAO_0000019,,,9,15034,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,Cavia porcellus,10141.0,
3292,,,,,CHEMBL619092,B,BAO_0000357,,,9,5033,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,Cavia porcellus,10141.0,
3293,,,,,CHEMBL619093,B,BAO_0000019,,,9,1980,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,Cavia porcellus,10141.0,
3294,,,,HEK293,CHEMBL619094,B,BAO_0000219,,,8,13181,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,Cavia porcellus,10141.0,
3295,,,,,CHEMBL619095,B,BAO_0000019,,,9,14287,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,Cavia porcellus,10141.0,
3296,,,,,CHEMBL857988,B,BAO_0000357,,,9,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,Cavia porcellus,10141.0,
3297,,,,,CHEMBL619096,B,BAO_0000357,,,9,15316,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,Cavia porcellus,10141.0,
3298,Striatum,,,,CHEMBL619097,B,BAO_0000357,,,9,16429,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,,Cavia porcellus,10141.0,
3299,Hippocampus,,,,CHEMBL619098,B,BAO_0000221,,,9,14818,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,,Cavia porcellus,10141.0,
3300,,,,,CHEMBL619751,B,BAO_0000357,,,9,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,Cavia porcellus,10141.0,
3301,,,,,CHEMBL619752,B,BAO_0000357,,,9,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,Cavia porcellus,10141.0,
3302,Ileum,,,,CHEMBL875096,F,BAO_0000221,,,9,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,Cavia porcellus,10141.0,
3303,,,,,CHEMBL619004,B,BAO_0000357,,,8,5486,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,,,
3304,,,,,CHEMBL619005,B,BAO_0000357,,,8,16209,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,,,
3305,,,,,CHEMBL619006,B,BAO_0000019,,,8,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,,,
3306,,,,HeLa,CHEMBL619007,B,BAO_0000219,,,8,4199,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,,,
3307,,,,,CHEMBL619008,B,BAO_0000357,,,8,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,,,
3308,,,,,CHEMBL619009,B,BAO_0000357,,,8,5213,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,,,
3309,,,,HeLa,CHEMBL619010,B,BAO_0000219,,,8,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,,,
3310,,,,,CHEMBL619011,B,BAO_0000357,,,8,17358,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,,,
3311,,,,,CHEMBL619012,B,BAO_0000357,,,8,17358,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,,,
3312,,,,,CHEMBL619013,B,BAO_0000219,,,8,16946,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,,,
3313,,,,,CHEMBL619014,B,BAO_0000357,,,8,17358,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,,,
3314,Cardiac atrium,,,,CHEMBL857503,F,BAO_0000019,,,8,268,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,,,
3315,Cardiac atrium,,,,CHEMBL619015,F,BAO_0000019,,,8,268,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,,,
3316,,,,,CHEMBL619016,B,BAO_0000357,,,8,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,,,
3317,Hippocampus,,,,CHEMBL619017,B,BAO_0000221,,,8,14875,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,,,
3318,Hippocampus,,,,CHEMBL619018,B,BAO_0000221,,,8,13267,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,,Sus scrofa,9823.0,
3319,,,,,CHEMBL619019,B,BAO_0000019,,,8,13047,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,Oryctolagus cuniculus,9986.0,
3320,,,,,CHEMBL619020,B,BAO_0000357,,,9,1650,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,Rattus norvegicus,10116.0,
3321,,,,,CHEMBL619021,F,BAO_0000019,,,8,567,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,,,
3322,,,,,CHEMBL619022,B,BAO_0000357,,,8,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,,,
3323,,,,,CHEMBL619023,B,BAO_0000357,,,8,188,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,,,
3324,,,,,CHEMBL619024,F,BAO_0000019,,,8,670,lntrinsic activity relative to 5-HT receptor,,,,
3325,,,,,CHEMBL619025,F,BAO_0000019,,,8,204,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,,,
3326,,,,,CHEMBL619026,F,BAO_0000019,,,8,1946,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,,,
3327,,,,,CHEMBL619027,F,BAO_0000019,,,8,6398,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,,,
3328,,,,,CHEMBL619028,F,BAO_0000019,,,8,6398,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,,,
3329,,,,,CHEMBL619029,F,BAO_0000019,,,8,17358,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,,,
3330,,,,,CHEMBL619030,F,BAO_0000019,,,8,6398,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,,,
3331,,,,,CHEMBL619031,B,BAO_0000357,,,8,11752,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,,,
3332,,,,,CHEMBL619032,F,BAO_0000019,,,8,809,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,,,
3333,,,,,CHEMBL619033,B,BAO_0000357,,,9,14178,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,Rattus norvegicus,10116.0,
3334,,,,,CHEMBL619034,B,BAO_0000357,,,8,567,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,,,
3335,,,,,CHEMBL619035,B,BAO_0000357,,,8,1946,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,,,
3336,,,,,CHEMBL619036,B,BAO_0000357,,,8,1946,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,,,
3337,,,,,CHEMBL619037,B,BAO_0000019,,,9,13961,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,Rattus norvegicus,10116.0,
3338,Striatum,,,,CHEMBL619038,B,BAO_0000249,,,8,6238,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,,,
3339,,,,,CHEMBL619039,B,BAO_0000249,,,8,14290,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,,,
3340,,,,,CHEMBL619040,B,BAO_0000249,,,8,14290,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,,,
3341,Striatum,,,,CHEMBL619041,B,BAO_0000019,,,9,809,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,Rattus norvegicus,10116.0,
3342,Striatum,,,,CHEMBL619042,B,BAO_0000019,,,8,1578,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,,,
3343,Striatum,,,,CHEMBL619043,B,BAO_0000249,,,8,16709,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,,,
3344,Striatum,,,,CHEMBL619044,B,BAO_0000019,,,8,1946,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,,,
3345,Striatum,,,,CHEMBL619045,B,BAO_0000249,,,8,15253,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,,,
3346,Striatum,,,,CHEMBL619046,B,BAO_0000249,,,8,4535,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,,,
3347,,,,,CHEMBL619047,B,BAO_0000249,,,8,13961,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,,,
3348,Brain,,,,CHEMBL619048,F,BAO_0000221,,,8,17358,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,,,
3349,,,,,CHEMBL859398,F,BAO_0000019,,,8,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,,,
3350,,,,,CHEMBL619049,F,BAO_0000019,,,8,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,,,
3351,,,,,CHEMBL857886,F,BAO_0000019,,,8,670,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,,,
3352,,,,,CHEMBL619050,F,BAO_0000019,,,8,670,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,,,
3353,,,,,CHEMBL620591,F,BAO_0000019,,,8,1317,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,,,
3354,,,,,CHEMBL620592,B,BAO_0000357,,,9,12936,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,Rattus norvegicus,10116.0,
3355,Striatum,,,,CHEMBL620593,B,BAO_0000249,,,8,4535,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,,,
3356,,,,,CHEMBL620594,F,BAO_0000019,,,9,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,Rattus norvegicus,10116.0,
3357,,,,,CHEMBL875079,F,BAO_0000019,,,8,14424,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,,,
3358,,,,,CHEMBL620595,F,BAO_0000019,,,8,14424,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,,,
3359,,,,,CHEMBL620596,F,BAO_0000019,,,9,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,Rattus norvegicus,10116.0,
3360,,,,,CHEMBL620597,F,BAO_0000019,,,8,14424,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,,,
3361,,,,,CHEMBL620598,F,BAO_0000019,,,8,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,,,
3362,,,,,CHEMBL620599,F,BAO_0000218,,,8,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,,,
3363,,,,,CHEMBL620600,F,BAO_0000019,,,8,14424,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,,,
3364,,,,,CHEMBL620601,F,BAO_0000019,,,8,1980,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,Rattus norvegicus,10116.0,
3365,,,,,CHEMBL620602,F,BAO_0000019,,,8,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,,,
3366,,,,,CHEMBL620603,B,BAO_0000357,,,8,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,,,
3367,,,,,CHEMBL620604,B,BAO_0000357,,,8,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,,,
3368,,,,,CHEMBL620605,B,BAO_0000357,,,8,17358,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,,,
3369,,,,,CHEMBL620606,B,BAO_0000357,,,8,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,,,
3370,,,,,CHEMBL620607,F,BAO_0000019,,,8,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,,
3371,,,,,CHEMBL620608,B,BAO_0000357,,,8,16117,In vitro binding affinity towards 5-HT4 receptor was determined,,,,
3372,,,,,CHEMBL620609,F,BAO_0000019,,,8,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,,
3373,,,,,CHEMBL620610,F,BAO_0000019,,,8,17358,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,,,
3374,,,,,CHEMBL620611,B,BAO_0000357,,,8,17358,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,,,
3375,,,,,CHEMBL620612,B,BAO_0000357,,,8,17358,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,,,
3376,,,,,CHEMBL620613,B,BAO_0000357,,,8,17358,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,,,
3377,,,,,CHEMBL620614,B,BAO_0000357,,,8,17358,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,,,
3378,,,,,CHEMBL620615,B,BAO_0000357,,,8,1274,Binding affinity against 5-Hydroxytryptamine 4 receptor,,,,
3379,,,,,CHEMBL857075,B,BAO_0000249,,,6,10728,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,,,Brain membranes
3380,,,,,CHEMBL620616,B,BAO_0000249,,,6,11695,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,,,Brain membranes
3381,,,,,CHEMBL619411,B,BAO_0000249,,,6,11695,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,,,Brain membranes
3382,,,,,CHEMBL619412,B,BAO_0000019,,,6,12490,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,,,
3383,,,,,CHEMBL619413,B,BAO_0000019,,,7,11828,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,10116.0,
3384,Hippocampus,,,,CHEMBL619414,B,BAO_0000221,,,6,12253,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,,,
3385,,,,,CHEMBL619415,B,BAO_0000019,,,6,10561,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,,,
3386,,,,,CHEMBL619416,B,BAO_0000019,,,6,10561,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,,,
3387,,,,,CHEMBL619417,F,BAO_0000019,,,6,14432,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,,,
3388,,,,,CHEMBL619418,B,BAO_0000223,,,7,12936,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,10116.0,
3389,,,,,CHEMBL619419,B,BAO_0000223,,,7,1274,Binding affinity against 5-Hydroxytryptamine 3 receptor,,Rattus norvegicus,10116.0,
3390,,,,,CHEMBL619420,B,BAO_0000019,,,6,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,,,
3391,,,,,CHEMBL619421,B,BAO_0000249,,,6,670,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,,,
3392,,,,,CHEMBL619422,B,BAO_0000019,,,7,968,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,Rattus norvegicus,10116.0,
3393,,,,,CHEMBL619423,B,BAO_0000019,,,6,14287,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,,,
3394,,,,,CHEMBL875080,B,BAO_0000019,,,6,567,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,,,
3395,,,,,CHEMBL619424,B,BAO_0000019,,,6,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,,,
3396,,,,,CHEMBL619425,B,BAO_0000249,,,6,14826,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,,,
3397,,,,,CHEMBL619426,B,BAO_0000223,,,6,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,,,
3398,,,,,CHEMBL619427,B,BAO_0000223,,,6,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,,,
3399,,,,,CHEMBL619645,B,BAO_0000223,,,7,10394,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,Rattus norvegicus,10116.0,
3400,,,,,CHEMBL619646,B,BAO_0000249,,,9,13657,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,,,
3401,Brain,,,,CHEMBL619647,F,BAO_0000221,,,8,1879,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,,,
3402,,,,,CHEMBL619648,F,BAO_0000019,,,8,1879,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,,,
3403,,,,,CHEMBL619165,F,BAO_0000019,,,8,1879,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,,,
3404,,,,,CHEMBL620719,F,BAO_0000218,,,8,204,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,In vivo,,,
3405,,,,,CHEMBL872924,B,BAO_0000019,,,8,1879,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,,,
3406,,,,,CHEMBL620720,B,BAO_0000357,,,8,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,,
3407,,,,,CHEMBL620721,B,BAO_0000019,,,8,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,,,
3408,,,,,CHEMBL620722,B,BAO_0000019,,,8,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,,,
3409,,,,,CHEMBL620723,B,BAO_0000019,,,6,10641,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,,,
3410,,,,,CHEMBL620724,B,BAO_0000019,,,8,773,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,,,
3411,,,,,CHEMBL620725,B,BAO_0000249,,,6,11952,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,,,
3412,,,,,CHEMBL620726,F,BAO_0000019,,,9,14145,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,Rattus norvegicus,10116.0,
3413,,,,,CHEMBL620727,B,BAO_0000357,,,8,17066,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,
3414,,,,,CHEMBL620728,B,BAO_0000223,,,4,6398,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,,,
3415,,,,,CHEMBL620729,B,BAO_0000019,,,0,10321,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,,,
3416,,,,,CHEMBL858288,F,BAO_0000019,,,4,511,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,,,
3417,,,,,CHEMBL620730,B,BAO_0000223,,,4,4639,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,,,
3418,,,,,CHEMBL620731,B,BAO_0000223,,,4,4639,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,
3419,,,,,CHEMBL620732,F,BAO_0000019,,,4,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,Cavia porcellus,10141.0,
3420,,,,,CHEMBL618042,F,BAO_0000019,,,4,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,Cavia porcellus,10141.0,
3421,,,,,CHEMBL618043,F,BAO_0000019,,,4,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,Cavia porcellus,10141.0,
3422,,,,,CHEMBL618044,B,BAO_0000223,,,4,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,,,
3423,,,,,CHEMBL618045,F,BAO_0000019,,,4,268,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,,,
3424,,,,,CHEMBL618046,B,BAO_0000223,,,4,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,,,
3425,,,,,CHEMBL618047,F,BAO_0000019,,,4,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,,,
3426,,,,,CHEMBL875084,F,BAO_0000019,,,4,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,,,
3427,,,,,CHEMBL618048,F,BAO_0000019,,,4,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,,,
3428,,,,,CHEMBL618049,B,BAO_0000223,,,4,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,,,
3429,,,,,CHEMBL619764,F,BAO_0000019,,,4,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,,,
3430,,,,,CHEMBL619765,F,BAO_0000019,,,4,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,,,
3431,,,,,CHEMBL619766,F,BAO_0000019,,,4,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,,,
3432,,,,,CHEMBL619767,B,BAO_0000223,,,4,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,,,
3433,,,,,CHEMBL619768,B,BAO_0000223,,,4,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,,,
3434,,,,,CHEMBL619769,F,BAO_0000019,,,4,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,,,
3435,,,,,CHEMBL619770,B,BAO_0000223,,,4,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,,,
3436,,,,,CHEMBL619771,B,BAO_0000223,,,4,5067,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,
3437,,,,,CHEMBL619772,B,BAO_0000219,,,4,14331,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,,,
3438,,,,,CHEMBL619773,B,BAO_0000223,,,4,5067,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,,,
3439,,,,NG108-15,CHEMBL619774,B,BAO_0000219,,,4,6179,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,,,
3440,,,,,CHEMBL875083,B,BAO_0000019,,,4,4265,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,,,
3441,,,,NG108-15,CHEMBL620718,B,BAO_0000219,,,4,4265,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,,,
3442,,,,,CHEMBL618127,B,BAO_0000223,,,4,17358,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,,,
3443,,,,,CHEMBL618128,B,BAO_0000223,,,4,17358,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,,,
3444,,,,,CHEMBL618129,B,BAO_0000219,,,4,13628,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,In vitro,,,
3445,,,,,CHEMBL618130,B,BAO_0000223,,,4,4612,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,,,
3446,,,,,CHEMBL618131,F,BAO_0000019,,,4,17358,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,,,
3447,,,,,CHEMBL618132,F,BAO_0000019,,,4,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,Cavia porcellus,10141.0,
3448,,,,,CHEMBL618133,F,BAO_0000019,,,4,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,Cavia porcellus,10141.0,
3449,,,,,CHEMBL618134,F,BAO_0000019,,,4,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,Cavia porcellus,10141.0,
3450,,,,,CHEMBL618135,F,BAO_0000019,,,4,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,Cavia porcellus,10141.0,
3451,,,,,CHEMBL618136,B,BAO_0000223,,,4,511,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,,,
3452,,,,,CHEMBL618137,B,BAO_0000223,,,4,1479,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,
3453,,,,,CHEMBL618138,B,BAO_0000223,,,4,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,,,
3454,,,,,CHEMBL618139,B,BAO_0000223,,,4,12146,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,,,
3455,,,,,CHEMBL618140,B,BAO_0000223,,,4,12146,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,,,
3456,,,,,CHEMBL618141,B,BAO_0000223,,,4,13969,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,,,
3457,,,,,CHEMBL873478,B,BAO_0000357,,,8,13392,Binding affinity for 5-hydroxytryptamine 2C receptor,,,,
3458,,,,,CHEMBL618142,B,BAO_0000223,,,6,13392,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,
3459,,,,,CHEMBL618143,B,BAO_0000357,,,8,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,,,
3460,,,,,CHEMBL618144,B,BAO_0000357,,,8,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,,,
3461,,,,,CHEMBL618145,B,BAO_0000357,,,8,16655,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,,,
3462,,,,,CHEMBL618146,B,BAO_0000223,,,4,13020,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,,,
3463,,,,,CHEMBL618147,B,BAO_0000223,,,4,13021,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,,,
3464,,,,,CHEMBL618148,B,BAO_0000223,,,4,13020,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,,,
3465,,,,,CHEMBL618149,B,BAO_0000019,,,8,10321,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,,,
3466,,,,,CHEMBL872927,B,BAO_0000357,,,8,15818,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,,
3467,,,,,CHEMBL618150,B,BAO_0000357,,,8,15818,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,,
3468,,,,,CHEMBL618151,B,BAO_0000357,,,8,17358,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,,,
3469,,,,,CHEMBL875094,B,BAO_0000357,,,8,2222,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,,,
3470,,,,,CHEMBL618152,B,BAO_0000019,,,8,10322,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,,,
3471,,,,,CHEMBL618153,B,BAO_0000357,,,8,16117,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,,,
3472,,,,,CHEMBL618888,B,BAO_0000357,,,8,17200,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,,,
3473,,,,,CHEMBL618889,F,BAO_0000019,,,8,17358,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,,,
3474,,,,,CHEMBL618890,B,BAO_0000357,,,8,16700,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,,,
3475,,,,,CHEMBL618891,B,BAO_0000019,,,8,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,,,
3476,,,,,CHEMBL619054,B,BAO_0000019,,,8,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,,,
3477,,,,,CHEMBL619055,B,BAO_0000223,,,4,12409,Binding affinity against the 5-hydroxytryptamine 3 receptor,,,,
3478,,,,,CHEMBL619056,B,BAO_0000357,,,8,4365,Binding affinity against human 5-hydroxytryptamine 3A receptor,,,,
3479,,,,,CHEMBL619057,F,BAO_0000019,,,8,4365,Percent efficacy against 5-hydroxytryptamine 3A receptor,,,,
3480,,,,,CHEMBL619058,B,BAO_0000357,,,8,4365,Binding affinity against human 5-hydroxytryptamine 3A receptor,,,,
3481,,,,Oocytes,CHEMBL619059,F,BAO_0000219,,,9,6769,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,Rattus norvegicus,10116.0,
3482,,,,Oocytes,CHEMBL619060,F,BAO_0000219,,,9,6769,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,Rattus norvegicus,10116.0,
3483,,,,Oocytes,CHEMBL875095,F,BAO_0000219,,,9,6769,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,Rattus norvegicus,10116.0,
3484,Ileum,,,,CHEMBL619061,F,BAO_0000221,,,9,809,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,,Cavia porcellus,10141.0,
3485,Ileum,,,,CHEMBL619062,F,BAO_0000221,,,9,809,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,,Cavia porcellus,10141.0,
3486,,,,,CHEMBL619063,F,BAO_0000019,,,9,14290,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,Cavia porcellus,10141.0,
3487,Ileum,,,,CHEMBL619064,B,BAO_0000221,,,9,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,,Cavia porcellus,10141.0,
3488,,,,,CHEMBL619065,B,BAO_0000357,,,9,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,Cavia porcellus,10141.0,
3489,Ileum,,,,CHEMBL619066,B,BAO_0000221,,,9,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,,Cavia porcellus,10141.0,
3490,Ileum,,,,CHEMBL619775,B,BAO_0000221,,,8,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,,,
3491,,,,,CHEMBL619776,B,BAO_0000357,,,8,3269,Affinity against 5-hydroxytryptamine 7 receptor,,,,
3492,,,,,CHEMBL619777,B,BAO_0000224,,,4,7721,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,Cavia porcellus,10141.0,
3493,,,,,CHEMBL619778,B,BAO_0000224,,,4,7721,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,Cavia porcellus,10141.0,
3494,Ileum,,,,CHEMBL619779,B,BAO_0000221,,,4,9117,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,,Cavia porcellus,10141.0,
3495,,,,,CHEMBL619780,B,BAO_0000224,,,4,7721,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,Cavia porcellus,10141.0,
3496,,,,,CHEMBL619166,B,BAO_0000224,,,4,7721,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,Cavia porcellus,10141.0,
3497,,,,,CHEMBL619167,F,BAO_0000019,,,4,15796,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,Cavia porcellus,10141.0,
3498,,,,,CHEMBL619168,F,BAO_0000019,,,4,15796,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,Cavia porcellus,10141.0,
3499,Cardiac atrium,,,,CHEMBL619169,B,BAO_0000219,,,9,15650,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,,Homo sapiens,9606.0,
3500,Cardiac atrium,,,,CHEMBL619170,B,BAO_0000219,,,9,15650,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,,Homo sapiens,9606.0,
3501,,,,,CHEMBL619171,F,BAO_0000019,,,5,6866,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,Homo sapiens,9606.0,
3502,Cardiac atrium,,,,CHEMBL619172,F,BAO_0000219,,,9,15650,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",,Homo sapiens,9606.0,
3503,,,,,CHEMBL619173,B,BAO_0000019,,,0,10063,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,Mus musculus,10090.0,
3504,,,,,CHEMBL619174,B,BAO_0000019,,,0,12665,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,Mus musculus,10090.0,
3505,,,,,CHEMBL619175,B,BAO_0000019,,,4,7504,5-hydroxytryptamine receptor binding affinity was determined in rats,,,,
3506,,,,,CHEMBL619176,B,BAO_0000224,,,4,7504,Binding affinity at rat 5-hydroxytryptamine receptor.,,,,
3507,,,,,CHEMBL619177,B,BAO_0000019,,,4,7038,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,,,
3508,,,,,CHEMBL619178,B,BAO_0000224,,,4,7626,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,,,
3509,,,,,CHEMBL619179,B,BAO_0000224,,,4,7626,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,,,
3510,Stomach,,,,CHEMBL619180,F,BAO_0000019,,,4,7185,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,,,
3511,Stomach,,,,CHEMBL619181,F,BAO_0000019,,,4,7185,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,,,
3512,,,,,CHEMBL619182,F,BAO_0000019,,,4,7185,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,,,
3513,,,,,CHEMBL619183,B,BAO_0000224,,,4,6960,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,,,
3514,,,,,CHEMBL619184,B,BAO_0000224,,,4,6960,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,,,
3515,Hippocampus,,,,CHEMBL619185,B,BAO_0000221,,,8,12416,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,,,
3516,,,,,CHEMBL619186,B,BAO_0000357,,,8,15753,Binding affinity for rat 5-hydroxytryptamine transporter.,,,,
3517,,,,,CHEMBL619187,B,BAO_0000019,,,4,8062,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,,,
3518,,,,,CHEMBL619188,B,BAO_0000019,,,5,9036,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,Rattus norvegicus,10116.0,
3519,,,,,CHEMBL619189,B,BAO_0000224,,,5,15067,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,Rattus norvegicus,10116.0,
3520,Brain,,,,CHEMBL619190,F,BAO_0000019,,,9,15753,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,,Rattus norvegicus,10116.0,
3521,Cerebellum,,,,CHEMBL619191,F,BAO_0000221,,,9,15753,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,,Rattus norvegicus,10116.0,
3522,,,,,CHEMBL619192,B,BAO_0000019,,,5,15295,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,Rattus norvegicus,10116.0,
3523,,,,,CHEMBL619193,B,BAO_0000224,,,5,6347,Percent binding affinity against 5-hydroxytryptamine receptor,,Rattus norvegicus,10116.0,
3524,,,,,CHEMBL619194,B,BAO_0000019,,,0,6763,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,,,
3525,,,,,CHEMBL619195,B,BAO_0000224,,,5,12092,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,Rattus norvegicus,10116.0,
3526,,,,,CHEMBL619196,B,BAO_0000224,,,5,1579,Affinity against 5-hydroxytryptamine receptor was determined,,Rattus norvegicus,10116.0,
3527,Stomach,,,,CHEMBL619197,B,BAO_0000019,,,5,1579,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,,Rattus norvegicus,10116.0,
3528,,,,,CHEMBL619198,B,BAO_0000219,,,9,5963,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,In vitro,Homo sapiens,9606.0,
3529,,,,,CHEMBL875081,B,BAO_0000219,,,9,5963,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,In vitro,Homo sapiens,9606.0,
3530,,,,,CHEMBL884712,B,BAO_0000357,,,8,5030,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,,,
3531,,,,,CHEMBL884710,B,BAO_0000357,,,8,15796,Inhibition of 5-hydroxytryptamine reuptake,,,,
3532,,,,,CHEMBL619199,F,BAO_0000019,,,8,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,,,
3533,,,,,CHEMBL619200,F,BAO_0000019,,,8,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,,,
3534,,,,,CHEMBL619201,F,BAO_0000019,,,8,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,,,
3535,,,,,CHEMBL619202,F,BAO_0000019,,,8,12409,Tested for 5-hydroxytryptamine receptor uptake,,,,
3536,,,,CHO,CHEMBL619203,B,BAO_0000219,,,9,16909,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,Homo sapiens,9606.0,
3537,,,,,CHEMBL619204,F,BAO_0000019,,,9,16909,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,Homo sapiens,9606.0,
3538,,,,,CHEMBL619205,B,BAO_0000249,,,8,15629,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,Homo sapiens,9606.0,
3539,,,,,CHEMBL619206,B,BAO_0000357,,,8,15629,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,,,
3540,,,,,CHEMBL619207,B,BAO_0000249,,,8,15629,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,,,
3541,Striatum,,,,CHEMBL619208,F,BAO_0000019,,,8,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,,,
3542,Striatum,,,,CHEMBL619209,F,BAO_0000019,,,8,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,,,
3543,Striatum,,,,CHEMBL619210,F,BAO_0000019,,,8,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,,,
3544,Striatum,,,,CHEMBL619211,F,BAO_0000019,,,8,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,,,
3545,Striatum,,,,CHEMBL619212,F,BAO_0000019,,,8,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,,,
3546,Striatum,,,,CHEMBL620681,F,BAO_0000019,,,8,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,,,
3547,Striatum,,,,CHEMBL620682,F,BAO_0000019,,,8,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,,,
3548,Striatum,,,,CHEMBL620683,F,BAO_0000019,,,8,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,,,
3549,Striatum,,,,CHEMBL620684,F,BAO_0000019,,,8,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,,,
3550,Striatum,,,,CHEMBL620685,F,BAO_0000019,,,8,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,,,
3551,Striatum,,,,CHEMBL620686,F,BAO_0000019,,,8,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,,,
3552,Limbic system,,,,CHEMBL620687,F,BAO_0000019,,,8,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,,,
3553,Limbic system,,,,CHEMBL620688,F,BAO_0000019,,,8,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,,,
3554,Limbic system,,,,CHEMBL620689,F,BAO_0000019,,,8,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,,,
3555,Limbic system,,,,CHEMBL620690,F,BAO_0000019,,,8,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,,,
3556,Limbic system,,,,CHEMBL620691,F,BAO_0000019,,,8,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,,,
3557,Limbic system,,,,CHEMBL620692,F,BAO_0000019,,,8,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,,,
3558,Limbic system,,,,CHEMBL620693,F,BAO_0000019,,,8,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,,,
3559,,,,,CHEMBL620694,B,BAO_0000357,,,8,1274,Binding affinity against 5-hydroxytryptamine 4 receptor,,,,
3560,,,,,CHEMBL857986,F,BAO_0000019,,,8,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,,
3561,,,,,CHEMBL620695,B,BAO_0000357,,,8,14532,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,,,
3562,,,,,CHEMBL620696,B,BAO_0000357,,,8,16989,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,,,
3563,,,,,CHEMBL620697,B,BAO_0000357,,,8,17200,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,,,
3564,,,,,CHEMBL620698,B,BAO_0000357,,,8,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor,,,,
3565,,,,,CHEMBL620699,B,BAO_0000357,,,8,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,,,
3566,,,,,CHEMBL620700,B,BAO_0000357,,,8,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,,,
3567,,,,COS-7,CHEMBL620701,B,BAO_0000219,,,8,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,,,
3568,,,,COS-7,CHEMBL875082,B,BAO_0000219,,,8,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,,,
3569,,,,COS-7,CHEMBL620702,B,BAO_0000219,,,8,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,,,
3570,,,,COS-7,CHEMBL620703,B,BAO_0000219,,,8,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,,,
3571,,,,C6,CHEMBL620704,B,BAO_0000219,,,8,17046,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,,,
3572,,,,C6,CHEMBL620705,B,BAO_0000219,,,8,17046,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,,,
3573,,,,C6,CHEMBL620706,B,BAO_0000219,,,8,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,,,
3574,,,,C6,CHEMBL620707,B,BAO_0000219,,,8,17046,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,,,
3575,,,,,CHEMBL620708,B,BAO_0000357,,,8,17066,Binding affinity towards 5-hydroxytryptamine 5 receptor,,,,
3576,,,,,CHEMBL620709,B,BAO_0000357,,,8,17200,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,,,
3577,,,,,CHEMBL620710,B,BAO_0000357,,,9,16146,Binding affinity against 5-hydroxytryptamine 5A receptor,,Homo sapiens,9606.0,
3578,,,,CHO,CHEMBL620711,B,BAO_0000219,,,8,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,,,
3579,,,,,CHEMBL620712,B,BAO_0000357,,,9,6491,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,Homo sapiens,9606.0,
3580,,,,,CHEMBL620713,B,BAO_0000357,,,9,17066,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,Homo sapiens,9606.0,
3581,,,,,CHEMBL620714,B,BAO_0000357,,,9,17066,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,Homo sapiens,9606.0,
3582,,,,,CHEMBL620715,B,BAO_0000357,,,9,4234,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,Homo sapiens,9606.0,
3583,,,,,CHEMBL620716,B,BAO_0000357,,,8,6013,Binding affinity towards 5-HT5A receptor,,,,
3584,,,,,CHEMBL620717,B,BAO_0000357,,,8,17175,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,,,
3585,,,,,CHEMBL618072,B,BAO_0000357,,,8,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,,,
3586,,,,,CHEMBL857987,B,BAO_0000357,,,8,6166,Binding affinity towards cloned human 5-HT5A receptor was determined,,,,
3587,,,,HEK293,CHEMBL618073,B,BAO_0000219,,,8,15779,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,,
3588,,,,HEK293,CHEMBL618074,B,BAO_0000219,,,8,15779,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,,,
3589,,,,HEK293,CHEMBL618075,B,BAO_0000219,,,8,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,,,
3590,,,,,CHEMBL618076,B,BAO_0000357,,,9,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,Mus musculus,10090.0,
3591,,,,,CHEMBL618077,B,BAO_0000357,,,9,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,Mus musculus,10090.0,
3592,,,,,CHEMBL618078,B,BAO_0000357,,,9,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,Mus musculus,10090.0,
3593,,,,,CHEMBL881821,B,BAO_0000357,,,9,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,Mus musculus,10090.0,
3594,,,,,CHEMBL618079,B,BAO_0000357,,,9,17066,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,Mus musculus,10090.0,
3595,,,,,CHEMBL618080,B,BAO_0000357,,,8,17175,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,,,
3596,,,,HEK293,CHEMBL618081,B,BAO_0000219,,,8,16190,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,,,
3597,,,,HEK293,CHEMBL618082,B,BAO_0000219,,,8,16190,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,,,
3598,,,,,CHEMBL618083,B,BAO_0000357,,,8,4820,Binding affinity towards 5-HT5a receptor,,,,
3599,,,,,CHEMBL618084,B,BAO_0000357,,,9,17066,Binding affinity towards 5-hydroxytryptamine 5A receptor,,Homo sapiens,9606.0,
3600,,,,,CHEMBL618085,B,BAO_0000357,,,8,17066,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,,,
3601,,,,,CHEMBL618086,B,BAO_0000357,,,8,17175,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,,,
3602,,,,,CHEMBL875092,B,BAO_0000357,,,8,16633,Binding affinities against 5-hydroxytryptamine 5A receptor,,,,
3603,,,,,CHEMBL618087,B,BAO_0000357,,,8,16633,Binding affinities towards 5-hydroxytryptamine 5A receptor,,,,
3604,,,,,CHEMBL872926,B,BAO_0000357,,,8,16700,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,,,
3605,,,,,CHEMBL618088,F,BAO_0000019,,,4,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,Cavia porcellus,10141.0,
3606,,,,,CHEMBL618089,B,BAO_0000223,,,4,5486,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,,,
3607,,,,,CHEMBL618090,B,BAO_0000357,,,9,16146,Inhibition of human 5-hydroxytryptamine 6 receptor,,Homo sapiens,9606.0,
3608,,,,,CHEMBL618091,B,BAO_0000357,,,9,17273,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,Homo sapiens,9606.0,
3609,,,,,CHEMBL618092,B,BAO_0000357,,,8,17687,Inhibition against human 5-hydroxytryptamine 6 receptor,,,,
3610,,,,,CHEMBL618093,B,BAO_0000357,,,9,6491,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,Homo sapiens,9606.0,
3611,,,,HeLa,CHEMBL618094,B,BAO_0000219,,,8,16190,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,,,
3612,,,,,CHEMBL618095,B,BAO_0000357,,,9,17066,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,Homo sapiens,9606.0,
3613,,,,,CHEMBL875093,B,BAO_0000357,,,9,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,Homo sapiens,9606.0,
3614,,,,,CHEMBL618096,B,BAO_0000357,,,9,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,Homo sapiens,9606.0,
3615,,,,,CHEMBL618118,B,BAO_0000357,,,9,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,Homo sapiens,9606.0,
3616,,,,,CHEMBL618119,B,BAO_0000357,,,9,3555,Binding affinity against 5-hydroxytryptamine 6 receptor,,Homo sapiens,9606.0,
3617,,,,,CHEMBL618120,B,BAO_0000357,,,8,5808,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,
3618,,,,,CHEMBL618121,B,BAO_0000357,,,8,6013,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,
3619,,,,HEK293,CHEMBL618122,B,BAO_0000219,,,8,15818,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,,,
3620,,,,,CHEMBL618123,B,BAO_0000357,,,8,16209,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,,,
3621,,,,HEK293,CHEMBL618124,B,BAO_0000219,,,8,3935,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,,,
3622,,,,,CHEMBL618125,B,BAO_0000357,,,8,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,
3623,,,,HEK293,CHEMBL618126,B,BAO_0000219,,,9,3805,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,Homo sapiens,9606.0,
3624,,,,,CHEMBL618236,B,BAO_0000019,,,8,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,,,
3625,,,,,CHEMBL618237,B,BAO_0000019,,,8,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,,,
3626,,,,COS-7,CHEMBL618238,B,BAO_0000219,,,8,6786,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,,,
3627,,,,,CHEMBL618239,B,BAO_0000357,,,9,4234,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,Homo sapiens,9606.0,
3628,,,,,CHEMBL618240,B,BAO_0000019,,,8,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,,,
3629,,,,,CHEMBL618241,B,BAO_0000357,,,8,17200,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,,,
3630,,,,HEK293,CHEMBL859399,B,BAO_0000219,,,8,17451,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,,,
3631,,,,,CHEMBL618242,F,BAO_0000019,,,8,3935,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,,,
3632,,,,,CHEMBL857991,B,BAO_0000357,,,8,5033,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,,,
3633,,,,,CHEMBL619951,B,BAO_0000357,,,8,4540,Binding affinity against human 5-hydroxytryptamine 6 receptor,,,,
3634,,,,HeLa,CHEMBL619952,B,BAO_0000219,,,9,4540,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,Homo sapiens,9606.0,
3635,,,,HeLa,CHEMBL619953,B,BAO_0000219,,,9,4540,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,Homo sapiens,9606.0,
3636,,,,HeLa,CHEMBL619954,B,BAO_0000219,,,8,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,,,
3637,,,,HeLa,CHEMBL619955,B,BAO_0000219,,,8,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,,,
3638,,,,HeLa,CHEMBL619956,B,BAO_0000219,,,8,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,,,
3639,,,,CHO,CHEMBL619957,B,BAO_0000219,,,8,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,,
3640,,,,HEK293,CHEMBL619958,B,BAO_0000219,,,8,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,,
3641,,,,HEK293,CHEMBL620627,B,BAO_0000219,,,8,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,,,
3642,,,,HEK293,CHEMBL620628,B,BAO_0000219,,,8,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,,,
3643,,,,HeLa,CHEMBL620629,B,BAO_0000219,,,8,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,,,
3644,,,,,CHEMBL620630,B,BAO_0000357,,,8,6166,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,
3645,,,,HeLa,CHEMBL620782,B,BAO_0000219,,,8,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,,,
3646,,,,,CHEMBL620783,B,BAO_0000357,,,8,15316,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,,,
3647,,,,,CHEMBL620784,B,BAO_0000357,,,8,4199,Binding affinity against human 5-hydroxytryptamine 6 receptor,,,,
3648,,,,HeLa,CHEMBL620785,B,BAO_0000219,,,8,15146,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,,,
3649,,,,,CHEMBL857992,B,BAO_0000357,,,8,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,,,
3650,,,,,CHEMBL620786,B,BAO_0000219,,,8,16429,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,,,
3651,,,,HeLa,CHEMBL620787,B,BAO_0000219,,,8,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,,,
3652,,,,HeLa,CHEMBL620788,B,BAO_0000219,,,8,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,,,
3653,,,,HeLa,CHEMBL620789,B,BAO_0000219,,,8,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,,,
3654,,,,HeLa,CHEMBL620790,B,BAO_0000219,,,8,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,,,
3655,,,,CHO,CHEMBL620791,B,BAO_0000219,,,8,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,,,
3656,,,,,CHEMBL620792,B,BAO_0000019,,,8,14423,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,,,
3657,,,,,CHEMBL620793,B,BAO_0000357,,,8,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,,,
3658,,,,,CHEMBL620794,B,BAO_0000357,,,8,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,,,
3659,,,,HeLa,CHEMBL620795,B,BAO_0000219,,,9,16190,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,Homo sapiens,9606.0,
3660,,,,,CHEMBL620796,B,BAO_0000357,,,8,4820,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,
3661,,,,,CHEMBL620797,B,BAO_0000357,,,8,4639,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,,,
3662,,,,,CHEMBL620798,F,BAO_0000019,,,9,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,Homo sapiens,9606.0,
3663,,,,,CHEMBL620799,B,BAO_0000357,,,8,6011,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,,,
3664,,,,,CHEMBL620800,B,BAO_0000357,,,8,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,
3665,,,,,CHEMBL620801,B,BAO_0000357,,,8,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,,,
3666,,,,,CHEMBL875100,B,BAO_0000357,,,8,5014,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,,,
3667,,,,,CHEMBL620802,B,BAO_0000357,,,8,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,,,
3668,,,,,CHEMBL620803,F,BAO_0000019,,,8,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,,,
3669,,,,,CHEMBL620804,F,BAO_0000019,,,8,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,,,
3670,,,,,CHEMBL620805,B,BAO_0000357,,,8,4373,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,,,
3671,,,,,CHEMBL620806,B,BAO_0000357,,,8,4687,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,,,
3672,,,,,CHEMBL620807,B,BAO_0000357,,,8,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,,,
3673,,,,,CHEMBL620808,B,BAO_0000357,,,8,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,,,
3674,,,,,CHEMBL620809,B,BAO_0000357,,,8,16633,Binding affinities against 5-hydroxytryptamine 6 receptor,,,,
3675,,,,,CHEMBL620810,B,BAO_0000357,,,8,16633,Binding affinities towards 5-hydroxytryptamine 6 receptor,,,,
3676,,,,,CHEMBL620811,B,BAO_0000357,,,9,17066,Binding affinity towards 5-hydroxytryptamine 6 receptor,,Homo sapiens,9606.0,
3677,,,,,CHEMBL620812,B,BAO_0000357,,,8,16700,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,,,
3678,,,,,CHEMBL620813,B,BAO_0000357,,,8,3269,Affinity against 5-hydroxytryptamine 6 receptor,,,,
3679,,,,,CHEMBL620814,B,BAO_0000357,,,8,5486,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,,,
3680,,,,,CHEMBL620815,B,BAO_0000357,,,9,16146,Inhibition of human 5-hydroxytryptamine 7 receptor,,Homo sapiens,9606.0,
3681,,,,HEK293,CHEMBL620816,B,BAO_0000219,,,8,5014,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,,,
3682,,,,,CHEMBL620817,B,BAO_0000357,,,8,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,,,
3683,,,,,CHEMBL620818,B,BAO_0000357,,,8,3805,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,,,
3684,,,,HEK293,CHEMBL620819,B,BAO_0000219,,,8,5014,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,,,
3685,,,,,CHEMBL620820,B,BAO_0000357,,,9,6491,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,Homo sapiens,9606.0,
3686,,,,CHO,CHEMBL620821,B,BAO_0000219,,,8,16190,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,,,
3687,,,,,CHEMBL620822,B,BAO_0000357,,,9,17066,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,Homo sapiens,9606.0,
3688,,,,,CHEMBL620823,B,BAO_0000357,,,9,17066,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,Homo sapiens,9606.0,
3689,,,,,CHEMBL620824,B,BAO_0000357,,,9,3555,Binding affinity against 5-hydroxytryptamine 7 receptor,,Homo sapiens,9606.0,
3690,,,,CHO,CHEMBL620825,B,BAO_0000219,,,8,6588,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,,,
3691,,,,,CHEMBL872930,B,BAO_0000357,,,8,15463,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,,,
3692,,,,,CHEMBL620826,B,BAO_0000357,,,8,6013,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,,
3693,,,,,CHEMBL620827,B,BAO_0000357,,,8,16209,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,,,
3694,,,,,CHEMBL620828,B,BAO_0000357,,,8,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,,,
3695,,,,,CHEMBL620829,B,BAO_0000357,,,8,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,,,
3696,,,,HEK293,CHEMBL620830,B,BAO_0000219,,,8,5014,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,,,
3697,,,,,CHEMBL620831,B,BAO_0000019,,,8,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,,,
3698,,,,,CHEMBL620832,B,BAO_0000019,,,8,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,,,
3699,,,,,CHEMBL621548,B,BAO_0000357,,,9,4234,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,Homo sapiens,9606.0,
3700,,,,,CHEMBL621549,B,BAO_0000019,,,8,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,,,
3701,,,,,CHEMBL621550,B,BAO_0000357,,,8,17200,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,,,
3702,,,,CHO,CHEMBL621551,B,BAO_0000219,,,8,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,,,
3703,,,,,CHEMBL621552,B,BAO_0000019,,,8,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,,,
3704,,,,,CHEMBL857077,B,BAO_0000357,,,8,5104,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,,,
3705,,,,,CHEMBL618158,B,BAO_0000357,,,8,5104,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,,,
3706,,,,COS-7,CHEMBL618159,B,BAO_0000219,,,9,5033,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,Homo sapiens,9606.0,
3707,,,,COS-7,CHEMBL875101,B,BAO_0000219,,,8,5486,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,,,
3708,,,,HEK293,CHEMBL618160,B,BAO_0000219,,,9,4540,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,Homo sapiens,9606.0,
3709,,,,,CHEMBL618161,B,BAO_0000357,,,8,6166,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,,,
3710,,,,HEK293,CHEMBL618162,B,BAO_0000219,,,8,17342,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,,,
3711,,,,,CHEMBL618163,B,BAO_0000357,,,8,17342,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,,,
3712,,,,,CHEMBL618164,B,BAO_0000357,,,8,17296,Binding affinity against 5-hydroxytryptamine 7 human receptors,,,,
3713,,,,,CHEMBL618165,B,BAO_0000219,,,8,16429,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,,,
3714,,,,HEK293,CHEMBL618166,B,BAO_0000219,,,8,15779,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,,,
3715,,,,HEK293,CHEMBL857989,B,BAO_0000219,,,8,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,,
3716,,,,HEK293,CHEMBL619888,B,BAO_0000219,,,8,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,,
3717,,,,HEK293,CHEMBL619889,B,BAO_0000219,,,8,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,,
3718,,,,HEK293,CHEMBL619890,B,BAO_0000219,,,8,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,,,
3719,,,,CHO,CHEMBL619891,B,BAO_0000219,,,8,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,,,
3720,,,,HEK293,CHEMBL619892,B,BAO_0000219,,,8,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,,,
3721,,,,HEK293,CHEMBL619893,B,BAO_0000219,,,9,4199,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,,,
3722,,,,HEK293,CHEMBL619894,B,BAO_0000219,,,8,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,,,
3723,,,,HEK293,CHEMBL619895,B,BAO_0000219,,,9,3680,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,,,
3724,,,,,CHEMBL619896,B,BAO_0000357,,,9,3680,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,,,
3725,,,,COS-7,CHEMBL619897,B,BAO_0000219,,,8,15316,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,,,
3726,,,,HEK293,CHEMBL619898,B,BAO_0000219,,,8,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,,,
3727,,,,HEK293,CHEMBL619899,B,BAO_0000219,,,8,5213,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,,,
3728,,,,HEK293,CHEMBL619900,B,BAO_0000219,,,8,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,,,
3729,,,,HEK293,CHEMBL619901,B,BAO_0000219,,,9,14818,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,Homo sapiens,9606.0,
3730,,,,HEK293,CHEMBL620580,B,BAO_0000219,,,8,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,,,
3731,,,,HEK293,CHEMBL620581,B,BAO_0000219,,,8,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,,,
3732,,,,HEK293,CHEMBL620733,B,BAO_0000219,,,8,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,,,
3733,,,,,CHEMBL620734,B,BAO_0000357,,,9,17200,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,Homo sapiens,9606.0,
3734,,,,,CHEMBL620735,B,BAO_0000357,,,9,17066,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,Mus musculus,10090.0,
3735,,,,,CHEMBL620736,B,BAO_0000019,,,8,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,Oryctolagus cuniculus,9986.0,
3736,,,,CHO,CHEMBL620737,B,BAO_0000219,,,8,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,,,
3737,,,,CHO,CHEMBL620738,B,BAO_0000219,,,8,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,,,
3738,,,,CHO,CHEMBL620739,B,BAO_0000219,,,8,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,,,
3739,,,,CHO,CHEMBL620740,B,BAO_0000219,,,8,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,,,
3740,,,,CHO,CHEMBL620741,B,BAO_0000219,,,8,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,,,
3741,,,,CHO,CHEMBL620742,B,BAO_0000219,,,8,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,,,
3742,,,,CHO,CHEMBL620743,B,BAO_0000219,,,8,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,,,
3743,,,,CHO,CHEMBL620744,B,BAO_0000219,,,8,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,,,
3744,,,,CHO,CHEMBL620745,B,BAO_0000219,,,8,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,,,
3745,,,,CHO,CHEMBL620746,B,BAO_0000219,,,8,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,,,
3746,,,,CHO,CHEMBL620747,B,BAO_0000219,,,8,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,,,
3747,,,,CHO,CHEMBL620748,B,BAO_0000219,,,8,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,,,
3748,,,,CHO,CHEMBL620749,B,BAO_0000219,,,8,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,,,
3749,,,,,CHEMBL620750,B,BAO_0000357,,,8,17066,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,,,
3750,,,,,CHEMBL620751,B,BAO_0000357,,,9,17066,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,Rattus norvegicus,10116.0,
3751,,,,,CHEMBL620752,B,BAO_0000357,,,8,17386,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,,,
3752,,,,,CHEMBL872929,B,BAO_0000019,,,8,14423,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,,,
3753,,,,,CHEMBL620753,B,BAO_0000357,,,9,15874,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,Rattus norvegicus,10116.0,
3754,,,,,CHEMBL620754,B,BAO_0000357,,,9,15874,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,Rattus norvegicus,10116.0,
3755,,,,CHO,CHEMBL620755,B,BAO_0000219,,,9,16372,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,,Rattus norvegicus,10116.0,
3756,,,,,CHEMBL620756,B,BAO_0000357,,,8,4622,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,,,
3757,,,,,CHEMBL620757,B,BAO_0000357,,,8,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,,,
3758,,,,CHO,CHEMBL620758,B,BAO_0000219,,,8,16372,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,,,
3759,,,,CHO,CHEMBL620759,B,BAO_0000219,,,8,16372,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,,,
3760,,,,CHO,CHEMBL620760,B,BAO_0000219,,,8,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,,,
3761,,,,CHO,CHEMBL620761,B,BAO_0000219,,,8,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,,,
3762,Ileum,,,,CHEMBL620762,F,BAO_0000221,,,8,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,,,
3763,Ileum,,,,CHEMBL620763,F,BAO_0000221,,,8,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,,,
3764,Ileum,,,,CHEMBL620764,F,BAO_0000221,,,8,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,,,,
3765,,,,,CHEMBL857990,B,BAO_0000249,,,9,5831,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,,Rattus norvegicus,10116.0,Membranes
3766,,,,,CHEMBL620765,B,BAO_0000357,,,8,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,,,
3767,,,,,CHEMBL620766,B,BAO_0000357,,,8,17319,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,,,
3768,Hypothalamus,,,,CHEMBL620767,B,BAO_0000019,,,8,17342,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,,,,
3769,,,,,CHEMBL620768,B,BAO_0000357,,,8,17342,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,,,
3770,Hypothalamus,,,,CHEMBL619051,B,BAO_0000249,,,8,3680,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,,,,
3771,,,,,CHEMBL619052,B,BAO_0000357,,,8,3680,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,,
3772,,,,HEK293,CHEMBL619053,F,BAO_0000219,,,9,17319,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,,Rattus norvegicus,10116.0,
3773,,,,HEK293,CHEMBL619703,F,BAO_0000219,,,9,17319,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,,Rattus norvegicus,10116.0,
3774,,,,HEK293,CHEMBL619704,F,BAO_0000219,,,9,17319,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,,Rattus norvegicus,10116.0,
3775,,,,,CHEMBL619851,B,BAO_0000357,,,8,4820,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,,
3776,,,,,CHEMBL619852,B,BAO_0000357,,,8,4639,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,,,
3777,,,,,CHEMBL619853,B,BAO_0000357,,,8,6011,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,,,
3778,,,,,CHEMBL619854,B,BAO_0000357,,,9,17066,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,Homo sapiens,9606.0,
3779,,,,,CHEMBL619855,B,BAO_0000357,,,8,17066,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,,,
3780,,,,,CHEMBL619856,B,BAO_0000357,,,8,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,,,
3781,,,,,CHEMBL619857,B,BAO_0000357,,,8,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,,,
3782,,,,,CHEMBL619858,F,BAO_0000019,,,8,17066,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,,,
3783,,,,,CHEMBL619859,B,BAO_0000357,,,8,4373,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,,,
3784,,,,,CHEMBL619860,B,BAO_0000357,,,8,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,,,
3785,,,,,CHEMBL619861,B,BAO_0000357,,,8,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,,,
3786,,,,,CHEMBL619862,B,BAO_0000357,,,8,17342,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,,,
3787,,,,,CHEMBL619863,B,BAO_0000357,,,8,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,,,
3788,,,,,CHEMBL619864,B,BAO_0000357,,,8,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,,,
3789,,,,,CHEMBL872928,B,BAO_0000357,,,8,16633,Binding affinities against 5-hydroxytryptamine 7 receptor,,,,
3790,,,,,CHEMBL619865,B,BAO_0000357,,,8,16633,Binding affinities towards 5-hydroxytryptamine 7 receptor,,,,
3791,,,,,CHEMBL619866,B,BAO_0000357,,,8,17066,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,,,
3792,,,,,CHEMBL619867,B,BAO_0000357,,,8,16700,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,,,
3793,Ileum,,,,CHEMBL619868,B,BAO_0000221,,,8,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,,,
3794,,,,,CHEMBL619869,F,BAO_0000019,,,8,14080,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,,,
3795,,,,,CHEMBL619870,F,BAO_0000019,,,9,14080,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,Homo sapiens,9606.0,
3796,,,,,CHEMBL619871,B,BAO_0000357,,,8,409,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,,,
3797,,,,,CHEMBL619872,B,BAO_0000357,,,8,409,In vitro inhibition of human recombinant lipoxygenase enzyme,,,,
3798,,,,,CHEMBL619873,B,BAO_0000357,,,8,409,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,,,
3799,Blood,,,,CHEMBL619874,B,BAO_0000357,,,8,11090,Inhibition of 5-lipoxygenase in human whole blood.,,,,
3800,Blood,,,,CHEMBL619875,B,BAO_0000357,,,8,11090,Inhibition of 5-lipoxygenase in human whole blood.,,,,
3801,,,,,CHEMBL619876,B,BAO_0000357,,,8,948,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,,,
3802,,,,,CHEMBL619877,B,BAO_0000357,,,8,948,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,,,
3803,,,,,CHEMBL619878,F,BAO_0000219,,,8,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,,,
3804,Blood,,,,CHEMBL619879,F,BAO_0000019,,,8,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,,,,
3805,,,,,CHEMBL619880,B,BAO_0000357,,,8,9637,In vitro inhibition of 5-lipoxygenase from human polymorphs,,,,
3806,,,,,CHEMBL619881,B,BAO_0000357,,,8,11320,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,,,
3807,,,,,CHEMBL619882,B,BAO_0000357,,,8,11320,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,,,
3808,,,,,CHEMBL619883,B,BAO_0000357,,,8,6838,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,,,
3809,Blood,,,,CHEMBL619884,B,BAO_0000357,,,9,17667,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),,Homo sapiens,9606.0,
3810,,,,,CHEMBL619885,B,BAO_0000357,,,8,12703,In vitro potency against human 5-Lipoxygenase,,,,
3811,,,,,CHEMBL619886,F,BAO_0000019,,,9,14312,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,Homo sapiens,9606.0,
3812,Blood,,,,CHEMBL619887,F,BAO_0000019,,,8,14312,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,,,,
3813,,,,,CHEMBL875097,F,BAO_0000019,,,8,5364,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,,,
3814,,,,,CHEMBL618001,B,BAO_0000219,,,8,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,,,
3815,,,,,CHEMBL618002,B,BAO_0000219,,,8,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,,,
3816,,,,,CHEMBL618003,B,BAO_0000219,,,8,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,,,
3817,,,,,CHEMBL618004,B,BAO_0000219,,,8,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,,,
3818,,,,,CHEMBL618005,B,BAO_0000219,,,8,12365,Inhibition of human 5-lipoxygenase in human cells,,,,
3819,,,,,CHEMBL618006,B,BAO_0000357,,,8,10603,Inhibition of human neutrophil 5-lipoxygenase,,,,
3820,,,,,CHEMBL875086,B,BAO_0000019,,,8,10501,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,,,
3821,Blood,,,,CHEMBL618007,B,BAO_0000357,,,8,12281,Inhibition of 5-lipoxygenase from human whole blood,,,,
3822,,,,,CHEMBL618008,B,BAO_0000357,,,8,2567,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,,,
3823,,,,,CHEMBL618009,B,BAO_0000219,,,8,2567,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,,,
3824,,,,,CHEMBL618010,B,BAO_0000357,,,8,10193,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,,,
3825,,,,,CHEMBL618011,B,BAO_0000357,,,8,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,,
3826,,,,,CHEMBL618012,B,BAO_0000357,,,8,13623,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,,,
3827,,,,,CHEMBL882927,B,BAO_0000357,,,8,12780,Tested against 5-lipoxygenase,,,,
3828,,,,,CHEMBL618013,B,BAO_0000357,,,8,12780,Tested for activity against 5-Lipoxygenase (5-LO),,,,
3829,,,,,CHEMBL618014,B,BAO_0000357,,,8,12780,Tested for activity against 5-lipoxygenase,,,,
3830,,,,,CHEMBL618015,B,BAO_0000357,,,8,11966,Tested for inhibition of 5-HPETE production by human 5-LO,,,,
3831,,,,,CHEMBL618016,F,BAO_0000019,,,8,5364,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,,,
3832,,,,,CHEMBL618017,B,BAO_0000357,,,8,13165,Inhibition of Human 5-lipoxygenase,,,,
3833,,,,,CHEMBL618018,B,BAO_0000019,,,8,5364,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,,,
3834,,,,,CHEMBL875087,B,BAO_0000219,,,8,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,,,
3835,,,,,CHEMBL618019,B,BAO_0000219,,,8,11311,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,,,
3836,,,,,CHEMBL618020,B,BAO_0000019,,,8,14863,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,,,
3837,,,,,CHEMBL618021,B,BAO_0000019,,,8,14863,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,,,
3838,Blood,,,,CHEMBL618022,B,BAO_0000357,,,8,11087,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),,,,
3839,,,,,CHEMBL618023,B,BAO_0000357,,,8,455,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,,,
3840,,,,,CHEMBL618024,B,BAO_0000357,,,8,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,,
3841,,,,,CHEMBL873950,B,BAO_0000019,,,8,10319,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,,,
3842,,,,,CHEMBL618025,B,BAO_0000357,,,8,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,,
3843,,,,,CHEMBL618026,B,BAO_0000219,,,8,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,,,
3844,,,,,CHEMBL618027,B,BAO_0000219,,,8,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,,,
3845,,,,,CHEMBL618028,B,BAO_0000219,,,8,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,,,
3846,,,,,CHEMBL618029,B,BAO_0000219,,,8,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,,,
3847,,,,,CHEMBL618030,B,BAO_0000357,,,8,9859,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,,,
3848,,,,,CHEMBL618031,B,BAO_0000357,,,8,9859,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,,,
3849,,,,,CHEMBL618032,B,BAO_0000357,,,8,9859,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,,,
3850,,,,,CHEMBL618033,B,BAO_0000357,,,8,2567,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,,,
3851,,,,,CHEMBL618034,B,BAO_0000357,,,8,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,,,
3852,,,,,CHEMBL875088,B,BAO_0000357,,,8,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,,
3853,,,,,CHEMBL618035,B,BAO_0000019,,,8,949,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,,,
3854,,,,,CHEMBL618036,B,BAO_0000019,,,8,949,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,,,
3855,,,,,CHEMBL618037,B,BAO_0000357,,,8,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,,,
3856,,,,,CHEMBL618038,B,BAO_0000357,,,8,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,,,
3857,,,,,CHEMBL618761,F,BAO_0000019,,,8,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,,,
3858,,,,,CHEMBL618762,B,BAO_0000357,,,8,10603,Inhibition of lipoxygenase at the concentration of 0.1 uM,,,,
3859,,,,,CHEMBL618763,B,BAO_0000357,,,8,10603,Inhibition of lipoxygenase at the concentration of 1 uM,,,,
3860,,,,,CHEMBL618764,B,BAO_0000357,,,8,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,,,
3861,,,,,CHEMBL618765,B,BAO_0000357,,,9,14580,Inhibition of 5-Lipoxygenase (5-LOX),,Homo sapiens,9606.0,
3862,,,,,CHEMBL618766,B,BAO_0000357,,,8,11090,Inhibition of 5-lipoxygenase in mouse macrophages.,,,,
3863,,,,,CHEMBL618767,B,BAO_0000357,,,8,11090,Inhibition of 5-lipoxygenase in mouse macrophages.,,,,
3864,,,,,CHEMBL619380,B,BAO_0000357,,,8,6339,Inhibitory activity against lipoxygenase-2 in mice,,,,
3865,,,,,CHEMBL619381,B,BAO_0000357,,,8,6339,Inhibitory activity against murine lipoxygenase-2.,,,,
3866,,,,,CHEMBL619382,B,BAO_0000357,,,9,12281,Inhibition of 5-lipoxygenase from mouse macrophage,,Mus musculus,10090.0,
3867,,,,,CHEMBL619383,B,BAO_0000357,,,8,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,,,
3868,,,,,CHEMBL619384,B,BAO_0000019,,,8,11089,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,Sus scrofa,9823.0,
3869,,,,,CHEMBL619385,B,BAO_0000019,,,8,10091,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,Sus scrofa,9823.0,
3870,,,,,CHEMBL882928,B,BAO_0000019,,,8,14352,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,Oryctolagus cuniculus,9986.0,
3871,,,,,CHEMBL619386,B,BAO_0000019,,,9,13329,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,Rattus norvegicus,10116.0,
3872,,,,,CHEMBL619387,B,BAO_0000019,,,8,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,,,
3873,,,,,CHEMBL619388,B,BAO_0000019,,,8,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,,,
3874,,,,,CHEMBL619389,B,BAO_0000019,,,8,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,,,
3875,,,,,CHEMBL619390,B,BAO_0000019,,,8,13329,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,,,
3876,,,,,CHEMBL619391,B,BAO_0000019,,,8,13329,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,,,
3877,,,,,CHEMBL619392,B,BAO_0000019,,,8,13329,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,,,
3878,,,,,CHEMBL619393,B,BAO_0000019,,,8,11311,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,,,
3879,,,,,CHEMBL619394,B,BAO_0000019,,,8,11311,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,,,
3880,,,,RBL-1,CHEMBL619395,B,BAO_0000219,,,8,105,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,,,
3881,,,,RBL-1,CHEMBL619396,B,BAO_0000219,,,8,105,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,,,
3882,,,,,CHEMBL619397,B,BAO_0000357,,,8,9138,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,,,
3883,,,,,CHEMBL619398,B,BAO_0000357,,,8,9138,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,,,
3884,,,,,CHEMBL619399,B,BAO_0000357,,,8,9138,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,,,
3885,,,,,CHEMBL619400,B,BAO_0000357,,,8,14427,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,,,
3886,,,,,CHEMBL619401,B,BAO_0000019,,,8,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,,,
3887,,,,,CHEMBL619402,B,BAO_0000019,,,8,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,,,
3888,,,,RBL-2H3,CHEMBL619403,B,BAO_0000219,,,9,14427,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,,Rattus norvegicus,10116.0,
3889,,,,,CHEMBL619404,B,BAO_0000357,,,8,14427,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,,,
3890,,,,,CHEMBL619405,B,BAO_0000357,,,8,14427,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,,,
3891,,,,RBL-1,CHEMBL619406,B,BAO_0000219,,,8,10293,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,,,
3892,,,,RBL-1,CHEMBL619407,B,BAO_0000219,,,9,338,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,,Rattus norvegicus,10116.0,
3893,,,,,CHEMBL619408,B,BAO_0000357,,,8,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,,,
3894,,,,RBL-1,CHEMBL619409,B,BAO_0000219,,,8,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,,,
3895,,,,RBL-1,CHEMBL619410,B,BAO_0000219,,,8,9247,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,,,
3896,,,,RBL-1,CHEMBL619753,B,BAO_0000219,,,8,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,,,
3897,,,,RBL-1,CHEMBL619754,B,BAO_0000219,,,8,137,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,,,
3898,,,,,CHEMBL619903,B,BAO_0000357,,,8,11481,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,,,
3899,,,,,CHEMBL619904,B,BAO_0000357,,,8,11481,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,,,
3900,,,,,CHEMBL619905,B,BAO_0000357,,,8,9029,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,,,
3901,,,,,CHEMBL619906,B,BAO_0000019,,,8,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,,,
3902,,,,,CHEMBL619907,B,BAO_0000019,,,8,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,,,
3903,,,,,CHEMBL619908,B,BAO_0000019,,,8,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,,,
3904,,,,,CHEMBL619909,B,BAO_0000019,,,8,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,,,
3905,,,,RBL-1,CHEMBL619910,F,BAO_0000219,,,8,13358,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,,,
3906,,,,RBL-1,CHEMBL882929,B,BAO_0000219,,,8,1175,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,,,
3907,,,,RBL-1,CHEMBL619911,B,BAO_0000219,,,8,8797,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,,,
3908,,,,,CHEMBL619912,B,BAO_0000019,,,8,8797,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,,,
3909,,,,,CHEMBL619913,B,BAO_0000357,,,9,577,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,Rattus norvegicus,10116.0,
3910,,,,RBL-1,CHEMBL619914,B,BAO_0000219,,,8,9295,In vitro inhibitory activity against RBL-1 5-LO,,,,
3911,,,,RBL-1,CHEMBL619915,B,BAO_0000219,,,8,9295,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,,,
3912,,,,RBL-1,CHEMBL619916,B,BAO_0000219,,,8,9295,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,,,
3913,,,,,CHEMBL619917,B,BAO_0000218,,,8,9295,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,,,
3914,,,,,CHEMBL619918,B,BAO_0000357,,,8,9295,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,,,
3915,,,,,CHEMBL619919,B,BAO_0000218,,,8,216,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,,,
3916,,,,RBL-1,CHEMBL883710,B,BAO_0000219,,,8,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,,,
3917,Blood,,,,CHEMBL619920,B,BAO_0000019,,,8,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,,,,
3918,,,,,CHEMBL619921,B,BAO_0000357,,,8,10091,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,,,
3919,,,,,CHEMBL619922,F,BAO_0000019,,,8,10274,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,,,
3920,,,,,CHEMBL619923,F,BAO_0000219,,,8,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,,,
3921,,,,RBL-1,CHEMBL619924,B,BAO_0000219,,,8,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,,,
3922,,,,,CHEMBL619925,B,BAO_0000357,,,8,12576,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,,,
3923,,,,RBL-1,CHEMBL619926,B,BAO_0000219,,,8,9546,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,,,
3924,,,,RBL-1,CHEMBL619927,B,BAO_0000219,,,8,9521,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,,,
3925,,,,RBL-1,CHEMBL619928,B,BAO_0000219,,,8,10626,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,,,
3926,,,,RBL-1,CHEMBL619929,B,BAO_0000219,,,8,9225,In vitro inhibition of RBL-1 5-lipoxygenase,,,,
3927,,,,RBL-1,CHEMBL875089,B,BAO_0000219,,,8,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,,,
3928,,,,RBL-1,CHEMBL619930,B,BAO_0000219,,,8,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,,,
3929,,,,RBL-1,CHEMBL619931,B,BAO_0000219,,,8,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,,,
3930,,,,RBL-1,CHEMBL619932,B,BAO_0000219,,,8,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,,,
3931,,,,RBL-1,CHEMBL619933,B,BAO_0000219,,,8,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,,,
3932,,,,RBL-1,CHEMBL619934,B,BAO_0000219,,,8,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,,,
3933,,,,RBL-1,CHEMBL619935,B,BAO_0000219,,,8,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,,,
3934,,,,RBL-1,CHEMBL619936,B,BAO_0000219,,,8,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,,,
3935,,,,RBL-1,CHEMBL619937,B,BAO_0000219,,,8,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,,,
3936,,,,RBL-1,CHEMBL619938,B,BAO_0000219,,,8,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,,,
3937,,,,RBL-1,CHEMBL619939,B,BAO_0000219,,,8,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,,,
3938,,,,RBL-1,CHEMBL619940,B,BAO_0000219,,,8,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,,,
3939,,,,RBL-1,CHEMBL875090,B,BAO_0000219,,,8,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,,,
3940,,,,RBL-1,CHEMBL619941,B,BAO_0000219,,,8,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,,,
3941,,,,RBL-1,CHEMBL619942,B,BAO_0000219,,,8,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,,,
3942,,,,RBL-1,CHEMBL883711,B,BAO_0000219,,,8,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,,,
3943,,,,RBL-1,CHEMBL619943,B,BAO_0000219,,,8,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,,,
3944,,,,RBL-1,CHEMBL619944,B,BAO_0000219,,,8,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,,,
3945,,,,RBL-1,CHEMBL619945,B,BAO_0000219,,,8,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,,,
3946,,,,RBL-1,CHEMBL619946,B,BAO_0000219,,,8,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,,,
3947,,,,RBL-1,CHEMBL619947,B,BAO_0000219,,,8,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,,,
3948,,,,RBL-1,CHEMBL619948,B,BAO_0000219,,,8,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,,,
3949,,,,RBL-1,CHEMBL619949,B,BAO_0000219,,,8,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,,,
3950,,,,,CHEMBL619950,B,BAO_0000019,,,8,9401,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,,,
3951,,,,,CHEMBL618050,B,BAO_0000019,,,8,10325,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,,,
3952,,,,RBL-2H3,CHEMBL875091,F,BAO_0000219,,,8,1556,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,,,
3953,,,,RBL-2H3,CHEMBL618051,F,BAO_0000219,,,8,1556,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,,,
3954,,,,RBL-1,CHEMBL618052,B,BAO_0000219,,,9,961,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,,Rattus norvegicus,10116.0,
3955,,,,,CHEMBL618053,B,BAO_0000019,,,8,6838,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,,,
3956,,,,,CHEMBL618054,B,BAO_0000019,,,8,10325,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,,,
3957,,,,RBL-1,CHEMBL618055,B,BAO_0000219,,,9,9209,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,Rattus norvegicus,10116.0,
3958,,,,RBL-1,CHEMBL618056,B,BAO_0000219,,,8,11520,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,,,
3959,,,,,CHEMBL618057,B,BAO_0000357,,,8,137,In vitro inhibitory activity against 5-lipoxygenase was determined,,,,
3960,,,,RBL-1,CHEMBL618058,B,BAO_0000219,,,8,4717,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,,,
3961,,,,RBL-1,CHEMBL618059,B,BAO_0000219,,,8,10636,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,,,
3962,,,,,CHEMBL618060,F,BAO_0000019,,,9,14312,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,Rattus norvegicus,10116.0,
3963,,,,RBL-1,CHEMBL618061,B,BAO_0000219,,,8,1203,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,,,
3964,,,,,CHEMBL618062,B,BAO_0000019,,,8,1203,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,,,
3965,,,,RBL-1,CHEMBL618063,B,BAO_0000219,,,8,13622,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,,,
3966,,,,,CHEMBL618064,B,BAO_0000357,,,8,9793,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,,,
3967,,,,RBL-1,CHEMBL618065,B,BAO_0000219,,,9,1143,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,,Rattus norvegicus,10116.0,
3968,,,,RBL-1,CHEMBL618066,B,BAO_0000219,,,9,11854,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,,Rattus norvegicus,10116.0,
3969,,,,RBL-1,CHEMBL618067,B,BAO_0000219,,,8,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,,,
3970,,,,RBL-1,CHEMBL618068,B,BAO_0000219,,,8,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,,,
3971,,,,RBL-1,CHEMBL618069,B,BAO_0000219,,,9,10501,Inhibition of 5-lipoxygenase in rat RBL-1 cells,,Rattus norvegicus,10116.0,
3972,,,,RBL-1,CHEMBL618070,B,BAO_0000219,,,8,12526,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,,,
3973,Limbic system,,,,CHEMBL618071,F,BAO_0000019,,,8,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,,,,
3974,Limbic system,,,,CHEMBL619247,F,BAO_0000019,,,8,10034,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,,,
3975,,,,,CHEMBL619248,F,BAO_0000019,,,8,10034,Approximate dose levels for a half maximal reduction of 5-HTP levels,,,,
3976,Hippocampus,,,,CHEMBL619249,B,BAO_0000221,,,8,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,,
3977,Hippocampus,,,,CHEMBL619250,B,BAO_0000221,,,8,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,,
3978,,,,,CHEMBL619251,B,BAO_0000019,,,8,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,,,
3979,Blood,,,,CHEMBL619252,F,BAO_0000019,,,8,12079,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,,Canis lupus familiaris,9615.0,
3980,Blood,,,,CHEMBL619253,F,BAO_0000019,,,8,12079,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,,,,
3981,,,,,CHEMBL619254,B,BAO_0000219,,,8,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,,,
3982,,,,,CHEMBL619255,B,BAO_0000219,,,8,12338,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,,,
3983,,,,,CHEMBL619256,B,BAO_0000219,,,8,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,,,
3984,,,,,CHEMBL875418,B,BAO_0000219,,,8,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,,,
3985,,,,,CHEMBL619257,B,BAO_0000219,,,8,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,,,
3986,,,,,CHEMBL619258,B,BAO_0000219,,,8,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,,,
3987,,,,,CHEMBL619259,B,BAO_0000357,,,8,12365,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,,,
3988,,,,,CHEMBL619260,B,BAO_0000357,,,8,13500,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,,,
3989,Blood,,,,CHEMBL619261,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
3990,Blood,,,,CHEMBL619263,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
3991,Blood,,,,CHEMBL619264,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
3992,Blood,,,,CHEMBL619265,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
3993,Blood,,,,CHEMBL619266,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
3994,Blood,,,,CHEMBL619902,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
3995,Blood,,,,CHEMBL620058,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
3996,Blood,,,,CHEMBL620059,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
3997,Blood,,,,CHEMBL620060,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
3998,Blood,,,,CHEMBL620061,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
3999,Blood,,,,CHEMBL620062,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4000,Blood,,,,CHEMBL620063,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4001,Blood,,,,CHEMBL620064,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4002,Blood,,,,CHEMBL620065,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4003,Blood,,,,CHEMBL620066,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4004,Blood,,,,CHEMBL620067,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4005,Blood,,,,CHEMBL620068,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4006,Blood,,,,CHEMBL620069,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4007,Blood,,,,CHEMBL620070,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4008,Blood,,,,CHEMBL620071,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4009,Blood,,,,CHEMBL620072,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4010,Blood,,,,CHEMBL620036,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4011,Blood,,,,CHEMBL857702,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4012,Blood,,,,CHEMBL620037,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4013,Blood,,,,CHEMBL620038,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4014,Blood,,,,CHEMBL620039,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4015,Blood,,,,CHEMBL620040,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4016,Blood,,,,CHEMBL620041,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4017,Blood,,,,CHEMBL620042,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4018,Blood,,,,CHEMBL620043,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4019,Blood,,,,CHEMBL620044,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4020,Blood,,,,CHEMBL620045,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4021,Blood,,,,CHEMBL620046,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4022,Blood,,,,CHEMBL620047,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4023,Blood,,,,CHEMBL620048,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4024,Blood,,,,CHEMBL857703,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4025,Blood,,,,CHEMBL620049,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4026,Blood,,,,CHEMBL620050,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4027,Blood,,,,CHEMBL620051,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4028,Blood,,,,CHEMBL619213,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4029,Blood,,,,CHEMBL619214,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4030,Blood,,,,CHEMBL619804,F,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4031,Blood,,,,CHEMBL619805,F,BAO_0000218,,,8,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4032,Blood,,,,CHEMBL619806,F,BAO_0000218,,,8,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4033,Blood,,,,CHEMBL619807,F,BAO_0000218,,,8,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4034,Blood,,,,CHEMBL619808,F,BAO_0000218,,,8,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,Canis lupus familiaris,9615.0,
4035,,,,,CHEMBL619809,B,BAO_0000218,,,8,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,Canis lupus familiaris,9615.0,
4036,,,,,CHEMBL619810,B,BAO_0000218,,,8,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,Canis lupus familiaris,9615.0,
4037,,,,,CHEMBL619811,B,BAO_0000218,,,8,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,Canis lupus familiaris,9615.0,
4038,,,,,CHEMBL620769,B,BAO_0000218,,,8,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,Canis lupus familiaris,9615.0,
4039,,,,,CHEMBL620770,B,BAO_0000218,,,8,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,Canis lupus familiaris,9615.0,
4040,,,,,CHEMBL620771,B,BAO_0000218,,,8,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,Canis lupus familiaris,9615.0,
4041,,,,,CHEMBL620772,B,BAO_0000218,,,8,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,Canis lupus familiaris,9615.0,
4042,,,,,CHEMBL620773,B,BAO_0000218,,,8,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,Canis lupus familiaris,9615.0,
4043,,,,,CHEMBL620774,B,BAO_0000357,,,8,9203,Ability to inhibit 5-lipoxygenase in guinea pig,,Cavia porcellus,10141.0,
4044,,,,,CHEMBL620775,B,BAO_0000357,,,8,82,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,Cavia porcellus,10141.0,
4045,,,,,CHEMBL620776,B,BAO_0000357,,,8,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,Cavia porcellus,10141.0,
4046,Blood,,,,CHEMBL620777,B,BAO_0000218,,,8,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",,Cavia porcellus,10141.0,
4047,,,,,CHEMBL620778,B,BAO_0000357,,,8,1065,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,Cavia porcellus,10141.0,
4048,,,,,CHEMBL620779,B,BAO_0000357,,,8,1065,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,Cavia porcellus,10141.0,
4049,,,,,CHEMBL621500,B,BAO_0000019,,,8,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,Cavia porcellus,10141.0,
4050,,,,,CHEMBL621501,B,BAO_0000019,,,8,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,Cavia porcellus,10141.0,
4051,,,,,CHEMBL618098,B,BAO_0000019,,,8,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,Cavia porcellus,10141.0,
4052,,,,,CHEMBL618099,B,BAO_0000019,,,8,10504,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,Cavia porcellus,10141.0,
4053,,,,,CHEMBL618100,B,BAO_0000357,,,8,7788,Inhibitory activity against 5-lipoxygenase,,Cavia porcellus,10141.0,
4054,,,,,CHEMBL618101,B,BAO_0000357,,,8,10001,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,Cavia porcellus,10141.0,
4055,,,,,CHEMBL618102,B,BAO_0000357,,,8,10193,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,Cavia porcellus,10141.0,
4056,,,,,CHEMBL618103,B,BAO_0000357,,,8,13243,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,Cavia porcellus,10141.0,
4057,,,,,CHEMBL618104,B,BAO_0000357,,,8,13243,Inhibitory activity uM,,Cavia porcellus,10141.0,
4058,,,,,CHEMBL883712,B,BAO_0000219,,,8,969,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,Cavia porcellus,10141.0,
4059,,,,,CHEMBL618105,B,BAO_0000357,,,8,10001,Inhibitory activity against 5-lipoxygenase at 10 uM,,Cavia porcellus,10141.0,
4060,,,,,CHEMBL618106,B,BAO_0000357,,,8,7788,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,Cavia porcellus,10141.0,
4061,,,,,CHEMBL618107,B,BAO_0000357,,,8,10001,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,Cavia porcellus,10141.0,
4062,,,,,CHEMBL618108,B,BAO_0000357,,,8,10193,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,Cavia porcellus,10141.0,
4063,,,,,CHEMBL618109,B,BAO_0000357,,,8,13243,Inhibitory activity uM,,Cavia porcellus,10141.0,
4064,,,,,CHEMBL618110,B,BAO_0000357,,,8,13243,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,Cavia porcellus,10141.0,
4065,,,,,CHEMBL618111,B,BAO_0000357,,,8,13243,Inhibitory activity uM,,Cavia porcellus,10141.0,
4066,,,,,CHEMBL618112,F,BAO_0000019,,,8,13243,Inhibitory activity uM,,Cavia porcellus,10141.0,
4067,,,,,CHEMBL618113,B,BAO_0000019,,,8,10504,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,Cavia porcellus,10141.0,
4068,,,,,CHEMBL618114,B,BAO_0000357,,,8,7788,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,Cavia porcellus,10141.0,
4069,Ileum,,,,CHEMBL620871,F,BAO_0000221,,,8,10546,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,,Cavia porcellus,10141.0,
4070,,,,,CHEMBL620872,B,BAO_0000357,,,8,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,,
4071,,,,,CHEMBL620873,B,BAO_0000357,,,8,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,,
4072,,,,,CHEMBL620874,B,BAO_0000357,,,8,2578,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,,,
4073,,,,,CHEMBL620875,B,BAO_0000357,,,8,12780,In vitro inhibition of human 5-Lipoxygenase.,,,,
4074,Liver,,,,CHEMBL620876,B,BAO_0000251,,,0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,Rattus norvegicus,10116.0,Microsomes
4075,Liver,,,,CHEMBL620877,B,BAO_0000251,,,0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,Rattus norvegicus,10116.0,Microsomes
4076,Liver,,,,CHEMBL857854,B,BAO_0000251,,,0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,Rattus norvegicus,10116.0,Microsomes
4077,Liver,,,,CHEMBL620878,B,BAO_0000251,,,0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,,Rattus norvegicus,10116.0,Microsomes
4078,Liver,,,,CHEMBL620879,B,BAO_0000251,,,0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,Rattus norvegicus,10116.0,Microsomes
4079,Liver,,,,CHEMBL620880,B,BAO_0000251,,,0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,Rattus norvegicus,10116.0,Microsomes
4080,Liver,,,,CHEMBL620881,B,BAO_0000251,,,0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,Rattus norvegicus,10116.0,Microsomes
4081,Liver,,,,CHEMBL620882,B,BAO_0000251,,,0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,Rattus norvegicus,10116.0,Microsomes
4082,Liver,,,,CHEMBL620883,B,BAO_0000251,,,0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,Rattus norvegicus,10116.0,Microsomes
4083,Liver,,,,CHEMBL620884,B,BAO_0000251,,,0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,Rattus norvegicus,10116.0,Microsomes
4084,Liver,,,,CHEMBL620885,B,BAO_0000251,,,0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,Rattus norvegicus,10116.0,Microsomes
4085,Liver,,,,CHEMBL620886,B,BAO_0000251,,,0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,,Rattus norvegicus,10116.0,Microsomes
4086,Liver,,,,CHEMBL620887,B,BAO_0000251,,,0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,Rattus norvegicus,10116.0,Microsomes
4087,Liver,,,,CHEMBL618039,B,BAO_0000251,,,0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,Rattus norvegicus,10116.0,Microsomes
4088,Liver,,,,CHEMBL618040,B,BAO_0000251,,,0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,Rattus norvegicus,10116.0,Microsomes
4089,Liver,,,,CHEMBL618041,B,BAO_0000251,,,0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,,Rattus norvegicus,10116.0,Microsomes
4090,Liver,,,,CHEMBL618216,B,BAO_0000251,,,0,7411,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,Rattus norvegicus,10116.0,Microsomes
4091,Liver,,,,CHEMBL618217,B,BAO_0000251,,,0,7411,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,Rattus norvegicus,10116.0,Microsomes
4092,Liver,,,,CHEMBL618218,B,BAO_0000251,,,0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,,Rattus norvegicus,10116.0,Microsomes
4093,Liver,,,,CHEMBL618219,B,BAO_0000251,,,0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,,Rattus norvegicus,10116.0,Microsomes
4094,Liver,,,,CHEMBL618220,B,BAO_0000251,,,0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,,Rattus norvegicus,10116.0,Microsomes
4095,Liver,,,,CHEMBL618221,B,BAO_0000251,,,0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,,Rattus norvegicus,10116.0,Microsomes
4096,Liver,,,,CHEMBL618222,B,BAO_0000251,,,0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,,Rattus norvegicus,10116.0,Microsomes
4097,Liver,,,,CHEMBL618223,B,BAO_0000251,,,0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,Rattus norvegicus,10116.0,Microsomes
4098,Liver,,,,CHEMBL618224,B,BAO_0000251,,,0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,Rattus norvegicus,10116.0,Microsomes
4099,Liver,,,,CHEMBL618225,B,BAO_0000251,,,0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,,Rattus norvegicus,10116.0,Microsomes
4100,Liver,,,,CHEMBL618226,B,BAO_0000251,,,0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,,Rattus norvegicus,10116.0,Microsomes
4101,Liver,,,,CHEMBL618227,B,BAO_0000251,,,0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,Rattus norvegicus,10116.0,Microsomes
4102,Liver,,,,CHEMBL618228,B,BAO_0000251,,,0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,Rattus norvegicus,10116.0,Microsomes
4103,Liver,,,,CHEMBL618229,B,BAO_0000251,,,0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,Rattus norvegicus,10116.0,Microsomes
4104,Liver,,,,CHEMBL618230,B,BAO_0000251,,,0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,Rattus norvegicus,10116.0,Microsomes
4105,Liver,,,,CHEMBL618231,B,BAO_0000251,,,0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,Rattus norvegicus,10116.0,Microsomes
4106,Liver,,,,CHEMBL618232,B,BAO_0000251,,,0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,Rattus norvegicus,10116.0,Microsomes
4107,Liver,,,,CHEMBL618233,B,BAO_0000251,,,0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,Rattus norvegicus,10116.0,Microsomes
4108,Liver,,,,CHEMBL618234,B,BAO_0000251,,,0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,Rattus norvegicus,10116.0,Microsomes
4109,Liver,,,,CHEMBL618235,B,BAO_0000251,,,0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,Rattus norvegicus,10116.0,Microsomes
4110,Liver,,,,CHEMBL618115,B,BAO_0000251,,,0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,Rattus norvegicus,10116.0,Microsomes
4111,Liver,,,,CHEMBL618116,B,BAO_0000251,,,0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,Rattus norvegicus,10116.0,Microsomes
4112,Liver,,,,CHEMBL618117,B,BAO_0000251,,,0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,Rattus norvegicus,10116.0,Microsomes
4113,Liver,,,,CHEMBL619968,B,BAO_0000251,,,0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,Rattus norvegicus,10116.0,Microsomes
4114,Liver,,,,CHEMBL619969,B,BAO_0000251,,,0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,Rattus norvegicus,10116.0,Microsomes
4115,Liver,,,,CHEMBL619970,B,BAO_0000251,,,0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,Rattus norvegicus,10116.0,Microsomes
4116,Liver,,,,CHEMBL619971,B,BAO_0000251,,,0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,,Rattus norvegicus,10116.0,Microsomes
4117,Liver,,,,CHEMBL619972,B,BAO_0000251,,,0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,,Rattus norvegicus,10116.0,Microsomes
4118,Liver,,,,CHEMBL619973,B,BAO_0000251,,,0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,,Rattus norvegicus,10116.0,Microsomes
4119,Liver,,,,CHEMBL619974,B,BAO_0000251,,,0,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,,Rattus norvegicus,10116.0,Microsomes
4120,Liver,,,,CHEMBL619975,B,BAO_0000251,,,0,7411,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,Rattus norvegicus,10116.0,Microsomes
4121,,,,,CHEMBL619976,B,BAO_0000251,,,0,7411,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,,Rattus norvegicus,10116.0,Microsomes
4122,Liver,,,,CHEMBL619977,B,BAO_0000251,,,0,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,Rattus norvegicus,10116.0,Microsomes
4123,Liver,,,,CHEMBL619978,B,BAO_0000251,,,0,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",,Rattus norvegicus,10116.0,Microsomes
4124,Liver,,,,CHEMBL619979,B,BAO_0000251,,,0,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",,Rattus norvegicus,10116.0,Microsomes
4125,Liver,,,,CHEMBL619980,B,BAO_0000251,,,0,7411,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,Rattus norvegicus,10116.0,Microsomes
4126,Liver,,,,CHEMBL619981,B,BAO_0000251,,,0,7411,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,Rattus norvegicus,10116.0,Microsomes
4127,,,,RPMI-8226,CHEMBL619982,F,BAO_0000219,,,1,10797,In vitro inhibition of 7226/S myeloma cancer cell line,,Homo sapiens,9606.0,
4128,,,,BEL-7404 tumor cell line,CHEMBL619983,F,BAO_0000219,,,1,6881,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),,Homo sapiens,9606.0,
4129,,,,786-0,CHEMBL620031,F,BAO_0000219,,,1,3838,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,Homo sapiens,9606.0,
4130,,,,786-0,CHEMBL620032,F,BAO_0000219,,,1,3838,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,Homo sapiens,9606.0,
4131,,,,V79,CHEMBL620033,F,BAO_0000219,,,1,12981,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,,Cricetulus griseus,10029.0,
4132,,,,V79,CHEMBL620034,F,BAO_0000219,,,1,12981,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,,Cricetulus griseus,10029.0,
4133,,,,7800C1 cell line,CHEMBL620035,F,BAO_0000219,,,1,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,,Rattus norvegicus,10116.0,
4134,,,,7800C1 cell line,CHEMBL618318,F,BAO_0000219,,,1,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,,Rattus norvegicus,10116.0,
4135,,,,7800C1 cell line,CHEMBL618319,F,BAO_0000219,,,1,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,,Rattus norvegicus,10116.0,
4136,,,,7800C1 cell line,CHEMBL618320,F,BAO_0000219,,,1,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,,Rattus norvegicus,10116.0,
4137,,,,7800C1 cell line,CHEMBL618321,F,BAO_0000219,,,1,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,,Rattus norvegicus,10116.0,
4138,,,,7800C1 cell line,CHEMBL883118,F,BAO_0000219,,,1,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,,Rattus norvegicus,10116.0,
4139,,,,786-0,CHEMBL883795,F,BAO_0000219,,,1,17229,In vitro antitumor activity against renal 786-0 tumor cell lines,,Homo sapiens,9606.0,
4140,,,,786-0,CHEMBL618322,F,BAO_0000219,,,1,12858,Cytotoxic activity against 786-0 Renal cancer cell line,,Homo sapiens,9606.0,
4141,,,,786-0,CHEMBL618323,F,BAO_0000219,,,1,16325,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,,Homo sapiens,9606.0,
4142,,,,786-0,CHEMBL618324,F,BAO_0000219,,,1,16325,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,,Homo sapiens,9606.0,
4143,,,,786-0,CHEMBL618325,F,BAO_0000219,,,1,5858,In vitro antitumor activity against human renal 786-0 cell line,,Homo sapiens,9606.0,
4144,,,,786-0,CHEMBL875416,F,BAO_0000219,,,1,16325,Inhibition of Renal cancer in 786-0 cancer cell lines,,Homo sapiens,9606.0,
4145,,,,786-0,CHEMBL618326,F,BAO_0000219,,,1,14696,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,,Homo sapiens,9606.0,
4146,,,,786-0,CHEMBL618327,F,BAO_0000219,,,1,3786,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,,Homo sapiens,9606.0,
4147,,,,786-0,CHEMBL619215,F,BAO_0000219,,,1,14696,inhibition of the growth of renal cancer(786-0) cell line,,Homo sapiens,9606.0,
4148,,,,786-0,CHEMBL619216,F,BAO_0000219,,,1,14769,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,Homo sapiens,9606.0,
4149,,,,786-0,CHEMBL619217,F,BAO_0000219,,,1,15354,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,,Homo sapiens,9606.0,
4150,,,,786-0,CHEMBL619218,F,BAO_0000219,,,1,14255,The IC50 value was measured on 786-0 cell line in ovarian tumor,,Homo sapiens,9606.0,
4151,,,,786-0,CHEMBL619219,F,BAO_0000219,,,1,14255,The IC50 value was measured on 786-0 cell line in ovarian tumor t,,Homo sapiens,9606.0,
4152,,,,786-0,CHEMBL619220,F,BAO_0000219,,,1,14255,The IC50 value was measured on 786-0 cell line in renal tumor type.,,Homo sapiens,9606.0,
4153,,,,786-0,CHEMBL619221,F,BAO_0000219,,,1,14696,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,,Homo sapiens,9606.0,
4154,,,,786-0,CHEMBL619222,F,BAO_0000219,,,1,12016,Tested for cytotoxic activity against renal cancer 786-0 cell line,,Homo sapiens,9606.0,
4155,,,,786-0,CHEMBL857454,F,BAO_0000219,,,1,2597,Compound was tested for growth inhibitory activity against 786-0 cell line,,Homo sapiens,9606.0,
4156,,,,RBL-1,CHEMBL619223,B,BAO_0000219,,,8,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,,,
4157,,,,RBL-1,CHEMBL619224,B,BAO_0000219,,,8,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,,,
4158,,,,,CHEMBL619225,B,BAO_0000019,,,8,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,,,
4159,,,,RBL-1,CHEMBL619226,B,BAO_0000219,,,8,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,,,
4160,,,,RBL-1,CHEMBL619227,B,BAO_0000219,,,8,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,,,
4161,,,,,CHEMBL619228,B,BAO_0000357,,,8,12767,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,,,
4162,,,,,CHEMBL619229,B,BAO_0000219,,,8,10997,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,,,
4163,,,,RBL-1,CHEMBL619230,B,BAO_0000219,,,8,11388,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,,,
4164,,,,,CHEMBL619231,B,BAO_0000357,,,8,167,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,,,
4165,,,,,CHEMBL619232,B,BAO_0000357,,,8,167,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,,,
4166,,,,,CHEMBL619233,B,BAO_0000357,,,8,13744,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,,,
4167,,,,,CHEMBL619234,B,BAO_0000357,,,8,1630,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,,,
4168,,,,,CHEMBL619235,B,BAO_0000357,,,8,1630,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,,,
4169,,,,,CHEMBL619236,B,BAO_0000019,,,9,969,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,Rattus norvegicus,10116.0,
4170,,,,RBL-1,CHEMBL619237,B,BAO_0000219,,,8,13621,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,,,
4171,,,,,CHEMBL619238,B,BAO_0000357,,,8,10089,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,,,
4172,,,,,CHEMBL619239,B,BAO_0000357,,,8,10193,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,,,
4173,,,,,CHEMBL619240,B,BAO_0000357,,,8,11966,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,,,
4174,,,,,CHEMBL875417,B,BAO_0000019,,,8,12251,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,,,
4175,,,,RBL-1,CHEMBL619241,B,BAO_0000219,,,8,211,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,,,
4176,,,,,CHEMBL619242,F,BAO_0000019,,,8,12251,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,,,
4177,,,,RBL-1,CHEMBL883796,B,BAO_0000219,,,8,12495,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,,,
4178,,,,,CHEMBL619243,B,BAO_0000357,,,8,414,Tested for its inhibitory activity against 5-lipoxygenase,,,,
4179,,,,,CHEMBL619244,B,BAO_0000357,,,8,414,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,,,
4180,,,,,CHEMBL619245,B,BAO_0000019,,,8,10325,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,,,
4181,,,,,CHEMBL619246,B,BAO_0000019,,,8,11966,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,,,
4182,,,,RBL-1,CHEMBL619984,B,BAO_0000219,,,8,165,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,,,
4183,,,,RBL-1,CHEMBL619985,B,BAO_0000219,,,8,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,,,
4184,,,,RBL-1,CHEMBL619986,B,BAO_0000219,,,8,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,,,
4185,,,,RBL-1,CHEMBL619987,B,BAO_0000219,,,8,165,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,,,
4186,,,,,CHEMBL619988,B,BAO_0000218,,,8,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,,,
4187,,,,RBL-1,CHEMBL619989,B,BAO_0000219,,,8,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,,,
4188,,,,RBL-1,CHEMBL619990,B,BAO_0000219,,,8,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,,,
4189,,,,,CHEMBL619991,B,BAO_0000219,,,8,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,,,
4190,,,,,CHEMBL619992,B,BAO_0000219,,,8,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,,,
4191,,,,,CHEMBL619993,B,BAO_0000218,,,8,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),In vivo,,,
4192,,,,RBL-2H3,CHEMBL619994,F,BAO_0000219,,,8,11311,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,,,
4193,,,,RBL-2H3,CHEMBL619995,F,BAO_0000219,,,8,11311,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,,,
4194,,,,,CHEMBL619996,B,BAO_0000019,,,8,11311,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,,,
4195,,,,,CHEMBL619997,B,BAO_0000019,,,8,11732,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,,,
4196,,,,,CHEMBL619998,B,BAO_0000019,,,8,11732,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,,,
4197,,,,,CHEMBL619999,B,BAO_0000019,,,8,11087,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,,,
4198,,,,,CHEMBL620000,B,BAO_0000019,,,8,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,,,
4199,,,,RBL-1,CHEMBL620001,B,BAO_0000219,,,8,11087,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,,,
4200,,,,,CHEMBL620002,B,BAO_0000357,,,9,11087,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,Rattus norvegicus,10116.0,
4201,,,,RBL-1,CHEMBL620003,B,BAO_0000219,,,8,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,,,
4202,,,,RBL-1,CHEMBL620004,F,BAO_0000219,,,8,13986,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,,,
4203,,,,,CHEMBL874063,B,BAO_0000357,,,8,11520,Compound was evaluated for the inhibition of 5-lipoxygenase,,,,
4204,,,,RBL-1,CHEMBL620005,B,BAO_0000219,,,8,10293,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,,,
4205,,,,RBL-1,CHEMBL620006,B,BAO_0000219,,,8,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,,,
4206,,,,RBL-1,CHEMBL620007,B,BAO_0000219,,,8,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,,,
4207,,,,RBL-1,CHEMBL620008,B,BAO_0000219,,,8,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,,,
4208,,,,RBL-1,CHEMBL620009,B,BAO_0000219,,,9,9247,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,,Rattus norvegicus,10116.0,
4209,,,,RBL-1,CHEMBL620010,B,BAO_0000219,,,8,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,,,
4210,,,,RBL-1,CHEMBL620011,B,BAO_0000219,,,8,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,,,
4211,,,,RBL-1,CHEMBL620677,B,BAO_0000219,,,8,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,,,
4212,,,,RBL-1,CHEMBL620678,B,BAO_0000219,,,8,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,,,
4213,,,,RBL-1,CHEMBL620679,B,BAO_0000219,,,8,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,,,
4214,,,,RBL-1,CHEMBL620680,B,BAO_0000219,,,8,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,,,
4215,,,,,CHEMBL620838,B,BAO_0000357,,,9,11481,Inhibitory activity against 5-lipoxygenase at 10 uM,,Rattus norvegicus,10116.0,
4216,,,,,CHEMBL620839,B,BAO_0000357,,,8,105,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,,,
4217,,,,,CHEMBL620840,B,BAO_0000357,,,8,9029,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,,,
4218,,,,RBL-1,CHEMBL620841,B,BAO_0000219,,,8,1175,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,,,
4219,,,,RBL-1,CHEMBL620842,B,BAO_0000219,,,8,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,,,
4220,,,,RBL-1,CHEMBL620843,B,BAO_0000219,,,8,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,,,
4221,,,,RBL-1,CHEMBL620844,B,BAO_0000219,,,8,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,,,
4222,,,,RBL-1,CHEMBL620845,B,BAO_0000219,,,8,9225,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,,,
4223,,,,,CHEMBL620846,B,BAO_0000019,,,8,9401,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,,,
4224,,,,,CHEMBL873951,B,BAO_0000357,,,8,137,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,,,
4225,,,,,CHEMBL620847,B,BAO_0000357,,,8,137,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,,,
4226,,,,RBL-1,CHEMBL620848,B,BAO_0000219,,,8,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,,,
4227,,,,RBL-1,CHEMBL620849,B,BAO_0000219,,,8,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,,,
4228,,,,RBL-1,CHEMBL620850,B,BAO_0000219,,,8,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,,,
4229,,,,RBL-1,CHEMBL620851,B,BAO_0000219,,,8,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,,,
4230,,,,RBL-1,CHEMBL620852,B,BAO_0000219,,,8,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,,,
4231,,,,RBL-1,CHEMBL875098,B,BAO_0000219,,,8,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,,,
4232,,,,RBL-1,CHEMBL620853,B,BAO_0000219,,,9,14799,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,,Rattus norvegicus,10116.0,
4233,,,,,CHEMBL620854,B,BAO_0000019,,,8,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,,,
4234,,,,RBL-1,CHEMBL620855,B,BAO_0000219,,,8,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,,,
4235,,,,RBL-1,CHEMBL839884,B,BAO_0000219,,,8,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,,,
4236,,,,RBL-1,CHEMBL620856,B,BAO_0000219,,,8,12526,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,,,
4237,,,,RBL-1,CHEMBL620857,B,BAO_0000219,,,8,12526,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,,,
4238,,,,,CHEMBL620858,B,BAO_0000019,,,8,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,,,
4239,,,,,CHEMBL620859,B,BAO_0000019,,,8,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,,,
4240,,,,,CHEMBL620860,B,BAO_0000019,,,8,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,,,
4241,,,,,CHEMBL620861,B,BAO_0000019,,,8,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,,,
4242,,,,,CHEMBL620862,B,BAO_0000357,,,8,9138,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,,,
4243,,,,,CHEMBL620863,B,BAO_0000357,,,8,9138,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,,,
4244,,,,,CHEMBL620864,B,BAO_0000019,,,8,11966,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,,,
4245,,,,RBL-1,CHEMBL620865,B,BAO_0000219,,,8,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,,,
4246,,,,RBL-1,CHEMBL620866,B,BAO_0000219,,,8,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,,,
4247,,,,RBL-2H3,CHEMBL620867,B,BAO_0000219,,,8,11311,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,,,
4248,,,,RBL-2H3,CHEMBL620868,B,BAO_0000219,,,8,11311,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,,,
4249,,,,RBL-2H3,CHEMBL620869,F,BAO_0000219,,,8,11311,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,,,
4250,,,,,CHEMBL873952,F,BAO_0000019,,,8,11311,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,,,
4251,,,,,CHEMBL875099,B,BAO_0000357,,,8,11311,The compound was tested for inhibition of isolated 5-lipoxygenase,,,,
4252,,,,RBL-2H3,CHEMBL620870,F,BAO_0000219,,,8,11311,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,,,
4253,,,,,CHEMBL618261,B,BAO_0000019,,,8,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,,,
4254,,,,,CHEMBL618262,B,BAO_0000019,,,8,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,,,
4255,,,,,CHEMBL619428,B,BAO_0000019,,,8,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,,,
4256,,,,,CHEMBL619429,B,BAO_0000019,,,8,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,,,
4257,,,,,CHEMBL619430,B,BAO_0000019,,,8,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,,,
4258,,,,RBL-1,CHEMBL620017,B,BAO_0000219,,,8,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,,,
4259,,,,RBL-1,CHEMBL620018,B,BAO_0000219,,,8,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,,,
4260,,,,RBL-1,CHEMBL620019,F,BAO_0000219,,,8,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,,,
4261,,,,RBL-1,CHEMBL620020,F,BAO_0000219,,,8,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,,,
4262,,,,RBL-1,CHEMBL620021,F,BAO_0000219,,,8,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,,,
4263,,,,RBL-1,CHEMBL620022,F,BAO_0000219,,,8,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,,,
4264,,,,RBL-1,CHEMBL620023,F,BAO_0000219,,,8,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,,,
4265,,,,RBL-1,CHEMBL620024,F,BAO_0000219,,,8,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,,,
4266,,,,RBL-1,CHEMBL620025,F,BAO_0000219,,,8,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,,,
4267,,,,RBL-1,CHEMBL620026,F,BAO_0000219,,,8,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,,,
4268,,,,RBL-1,CHEMBL620027,F,BAO_0000219,,,8,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,,,
4269,,,,,CHEMBL620028,F,BAO_0000019,,,9,13986,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,Rattus norvegicus,10116.0,
4270,,,,,CHEMBL620029,B,BAO_0000357,,,8,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,,,
4271,,,,,CHEMBL620030,B,BAO_0000357,,,8,9295,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,,,
4272,,,,RBL-1,CHEMBL875415,B,BAO_0000219,,,8,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,,,
4273,,,,RBL-1,CHEMBL618256,B,BAO_0000219,,,8,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,,,
4274,,,,RBL-1,CHEMBL618257,B,BAO_0000219,,,8,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,,,
4275,,,,RBL-1,CHEMBL618258,B,BAO_0000219,,,8,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,,,
4276,,,,RBL-1,CHEMBL618259,B,BAO_0000219,,,8,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,,,
4277,,,,,CHEMBL618260,B,BAO_0000019,,,8,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,,,
4278,,,,RBL-1,CHEMBL618215,B,BAO_0000219,,,8,9295,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,,,
4279,,,,RBL-1,CHEMBL618390,B,BAO_0000219,,,8,9295,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,,,
4280,,,,RBL-1,CHEMBL618391,B,BAO_0000219,,,8,9295,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,,,
4281,,,,RBL-1,CHEMBL618392,B,BAO_0000219,,,8,9295,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,,,
4282,,,,RBL-1,CHEMBL618393,B,BAO_0000219,,,8,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,,,
4283,,,,,CHEMBL618394,B,BAO_0000219,,,8,11311,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,,,
4284,,,,RBL-1,CHEMBL618395,B,BAO_0000219,,,8,10489,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,Homo sapiens,9606.0,
4285,,,,RBL-1,CHEMBL618396,B,BAO_0000219,,,9,10489,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,Rattus norvegicus,10116.0,
4286,,,,RBL-1,CHEMBL858253,B,BAO_0000219,,,9,10489,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),,Rattus norvegicus,10116.0,
4287,,,,,CHEMBL618397,B,BAO_0000019,,,9,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,Rattus norvegicus,10116.0,
4288,,,,,CHEMBL618398,B,BAO_0000357,,,8,9295,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,Glycine max,3847.0,
4289,,,,,CHEMBL618399,B,BAO_0000019,,,0,16811,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,,,
4290,,,,,CHEMBL618400,B,BAO_0000357,,,8,168,In vitro inhibition of 5-Lipoxygenase; Inactive.,,,,
4291,,,,,CHEMBL618401,B,BAO_0000357,,,8,6309,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,,,
4292,,,,,CHEMBL618402,B,BAO_0000357,,,8,6309,Inhibitory concentration against 5-lipoxygenase; No inhibition,,,,
4293,,,,RBL-1,CHEMBL876400,B,BAO_0000219,,,8,3092,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,,,
4294,,,,,CHEMBL618403,B,BAO_0000357,,,8,168,Inhibitory activity against 5-lipoxygenase.,,,,
4295,,,,,CHEMBL618404,B,BAO_0000357,,,8,168,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,,,
4296,,,,,CHEMBL618405,B,BAO_0000357,,,8,168,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,,,
4297,,,,,CHEMBL618406,B,BAO_0000357,,,8,168,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,,,
4298,,,,,CHEMBL618407,F,BAO_0000019,,,8,12338,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,,,
4299,,,,,CHEMBL618408,B,BAO_0000357,,,8,4501,Tested for the inhibitory activity against 5-lipoxygenase,,,,
4300,,,,,CHEMBL618409,B,BAO_0000357,,,8,1132,Compound was tested for its inhibitory activity against 5-lipoxygenase,,,,
4301,,,,,CHEMBL618410,B,BAO_0000357,,,8,2117,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,,,
4302,,,,,CHEMBL618411,B,BAO_0000357,,,8,168,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,,,
4303,,,,,CHEMBL618412,B,BAO_0000357,,,8,168,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,,,
4304,,,,RBL-1,CHEMBL618413,B,BAO_0000219,,,8,13575,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,,,
4305,,,,,CHEMBL618414,B,BAO_0000357,,,8,11089,,,,,
4306,,,,,CHEMBL618415,B,BAO_0000357,,,8,216,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,,,
4307,,,,,CHEMBL618416,B,BAO_0000019,,,8,13165,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,,,
4308,,,,,CHEMBL876401,B,BAO_0000357,,,8,3278,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,,,
4309,,,,,CHEMBL618417,B,BAO_0000357,,,8,3278,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,,,
4310,,,,,CHEMBL618418,B,BAO_0000357,,,8,11966,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,,,
4311,,,,,CHEMBL618419,B,BAO_0000357,,,8,175,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,,,
4312,,,,,CHEMBL618420,B,BAO_0000357,,,8,175,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,,,
4313,,,,,CHEMBL618421,B,BAO_0000357,,,8,13449,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,,,
4314,,,,,CHEMBL618422,B,BAO_0000019,,,8,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,,,
4315,,,,,CHEMBL618423,B,BAO_0000019,,,8,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,,,
4316,,,,,CHEMBL618424,B,BAO_0000019,,,8,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,,,
4317,,,,,CHEMBL618425,B,BAO_0000220,,,2,99,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,,,
4318,,,,,CHEMBL618426,F,BAO_0000019,,,0,4349,The dark toxicity against 543 human galactophore carcinoma cells,,Homo sapiens,9606.0,
4319,,,,Panel (56 tumour cell lines),CHEMBL618427,F,BAO_0000219,,,1,4071,Tested in vitro for cytotoxicity against 56 human tumor cell lines,,Homo sapiens,9606.0,
4320,,,,5637,CHEMBL618428,F,BAO_0000219,,,1,17589,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,,Homo sapiens,9606.0,
4321,,,,5637,CHEMBL618429,F,BAO_0000219,,,1,15002,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,,Homo sapiens,9606.0,
4322,,,,5637,CHEMBL618430,F,BAO_0000219,,,1,13958,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",,Homo sapiens,9606.0,
4323,,,,5637,CHEMBL618431,F,BAO_0000219,,,1,17589,Growth inhibition against human 5637 cell lines,,Homo sapiens,9606.0,
4324,,,,5637,CHEMBL883799,F,BAO_0000219,,,1,16748,Antitumor activity against human bladder carcinoma 5637 cells.,,Homo sapiens,9606.0,
4325,,,,5637,CHEMBL618432,F,BAO_0000219,,,1,16747,Antitumor activity against human bladder carcinoma 5637 cells,,Homo sapiens,9606.0,
4326,,,,5637,CHEMBL618433,F,BAO_0000219,,,1,16747,Antitumor activity against human bladder carcinoma 5637 cells,,Homo sapiens,9606.0,
4327,,,,,CHEMBL618434,B,BAO_0000357,,,9,15285,In vitro inhibition of bovine trypsin(Trp).,,Bos taurus,9913.0,
4328,,,,CV-1,CHEMBL618435,B,BAO_0000219,,,8,3726,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,,Cercopithecidae,9527.0,
4329,,,,,CHEMBL876402,B,BAO_0000357,,,8,5033,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,,,
4330,,,,,CHEMBL618436,F,BAO_0000019,,,6,11756,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,,,
4331,,,,,CHEMBL618437,F,BAO_0000218,,,0,11953,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,In vivo,,,
4332,,,,,CHEMBL618438,B,BAO_0000357,,,9,5033,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,Cavia porcellus,10141.0,
4333,,,,,CHEMBL883800,A,BAO_0000251,,,8,11347,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,Rattus norvegicus,10116.0,Microsomes
4334,,,,,CHEMBL618439,A,BAO_0000251,,,8,11347,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,Rattus norvegicus,10116.0,Microsomes
4335,,,,,CHEMBL618440,F,BAO_0000019,,,0,1229,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,,,
4336,,,,,CHEMBL618441,F,BAO_0000019,,,0,1229,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,,,
4337,,,,,CHEMBL618442,B,BAO_0000019,,,8,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,Trypanosoma brucei,5691.0,
4338,,,,,CHEMBL618443,B,BAO_0000019,,,8,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,Trypanosoma brucei,5691.0,
4339,,,,,CHEMBL619158,B,BAO_0000019,,,8,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,Ovis aries,9940.0,
4340,,,,,CHEMBL620974,B,BAO_0000019,,,8,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,Ovis aries,9940.0,
4341,,,,,CHEMBL620975,B,BAO_0000357,,,8,16485,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,,,
4342,,,,,CHEMBL620976,F,BAO_0000019,,,0,4337,Average inhibitory concentration against 60 human cell lines was reported,,Homo sapiens,9606.0,
4343,,,,,CHEMBL620977,F,BAO_0000019,,,0,4112,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,Homo sapiens,9606.0,
4344,,,,Panel NCI-60 (60 carcinoma cell lines),CHEMBL620978,F,BAO_0000219,,,1,16160,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,,Homo sapiens,9606.0,
4345,,,,Panel NCI-60 (60 carcinoma cell lines),CHEMBL620979,F,BAO_0000219,,,1,16160,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,,Homo sapiens,9606.0,
4346,,,,Panel NCI-60 (60 carcinoma cell lines),CHEMBL620980,F,BAO_0000219,,,1,17376,In vitro mean growth inhibitory activity against 60-cell panel,,,,
4347,,,,Panel NCI-60 (60 carcinoma cell lines),CHEMBL620981,F,BAO_0000219,,,1,17376,In vitro mean growth lethal concentration against 60-cell panel,,,,
4348,,,,Panel NCI-60 (60 carcinoma cell lines),CHEMBL620982,F,BAO_0000219,,,1,17376,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,,,
4349,,,,Panel NCI-60 (60 carcinoma cell lines),CHEMBL620983,F,BAO_0000219,,,1,17376,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,,,
4350,,,,,CHEMBL620984,F,BAO_0000019,,,4,3241,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,,,
4351,,,,,CHEMBL620985,F,BAO_0000019,,,4,3241,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,,,
4352,,,,,CHEMBL620986,B,BAO_0000357,,,8,3725,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,,,
4353,,,,,CHEMBL620987,F,BAO_0000218,,,1,10805,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,Plasmodium falciparum,5833.0,
4354,,,,,CHEMBL620988,F,BAO_0000218,,,1,10805,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,Plasmodium falciparum,5833.0,
4355,,,,,CHEMBL620989,F,BAO_0000218,,,1,10805,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,Plasmodium falciparum,5833.0,
4356,,,,,CHEMBL620990,F,BAO_0000218,,,1,10805,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,Plasmodium falciparum,5833.0,
4357,,,,,CHEMBL620991,F,BAO_0000218,,,1,10805,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,Plasmodium falciparum,5833.0,
4358,,,,6C3HED,CHEMBL620992,F,BAO_0000218,,,1,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,Mus musculus,10090.0,
4359,,,,6C3HED,CHEMBL620993,F,BAO_0000218,,,1,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,Mus musculus,10090.0,
4360,,,,6C3HED,CHEMBL620994,F,BAO_0000218,,,1,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,,Mus musculus,10090.0,
4361,,,,6C3HED,CHEMBL620995,F,BAO_0000218,,,1,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,Mus musculus,10090.0,
4362,,,,6C3HED,CHEMBL620996,F,BAO_0000218,,,1,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,Mus musculus,10090.0,
4363,,,,6C3HED,CHEMBL875581,F,BAO_0000218,,,1,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,,Mus musculus,10090.0,
4364,,,,,CHEMBL620997,F,BAO_0000218,,,0,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,In vivo,Mus musculus,10090.0,
4365,,,,,CHEMBL620998,F,BAO_0000218,,,0,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,In vivo,Mus musculus,10090.0,
4366,,,,,CHEMBL620999,F,BAO_0000218,,,0,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),In vivo,Mus musculus,10090.0,
4367,,,,,CHEMBL621000,F,BAO_0000218,,,0,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,In vivo,Mus musculus,10090.0,
4368,,,,,CHEMBL621001,F,BAO_0000218,,,0,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,In vivo,Mus musculus,10090.0,
4369,,,,,CHEMBL621002,F,BAO_0000218,,,0,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,In vivo,Mus musculus,10090.0,
4370,,,,,CHEMBL621003,F,BAO_0000218,,,0,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,In vivo,Mus musculus,10090.0,
4371,,,,,CHEMBL621004,F,BAO_0000218,,,0,10685,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",In vivo,Mus musculus,10090.0,
4372,,,,,CHEMBL621005,F,BAO_0000218,,,0,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),In vivo,Mus musculus,10090.0,
4373,,,,,CHEMBL621006,F,BAO_0000218,,,0,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),In vivo,Mus musculus,10090.0,
4374,,,,,CHEMBL621007,F,BAO_0000218,,,0,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,In vivo,Mus musculus,10090.0,
4375,,,,,CHEMBL621008,F,BAO_0000218,,,0,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,Mus musculus,10090.0,
4376,,,,,CHEMBL621009,F,BAO_0000218,,,0,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,Mus musculus,10090.0,
4377,,,,,CHEMBL857705,F,BAO_0000218,,,0,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,Mus musculus,10090.0,
4378,,,,,CHEMBL619828,F,BAO_0000218,,,0,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,Mus musculus,10090.0,
4379,,,,,CHEMBL619829,F,BAO_0000218,,,0,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,Mus musculus,10090.0,
4380,,,,,CHEMBL619830,F,BAO_0000218,,,0,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,Mus musculus,10090.0,
4381,,,,,CHEMBL619831,F,BAO_0000218,,,0,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,Mus musculus,10090.0,
4382,,,,,CHEMBL619832,F,BAO_0000218,,,0,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,Mus musculus,10090.0,
4383,,,,,CHEMBL619833,A,BAO_0000218,,,0,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,Mus musculus,10090.0,
4384,,,,,CHEMBL619834,A,BAO_0000218,,,0,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,Mus musculus,10090.0,
4385,,,,,CHEMBL619835,A,BAO_0000218,,,0,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,Mus musculus,10090.0,
4386,,,,,CHEMBL619836,A,BAO_0000218,,,0,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,Mus musculus,10090.0,
4387,,,,6C3HED,CHEMBL619837,F,BAO_0000218,,,1,8831,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",,Mus musculus,10090.0,
4388,,,,,CHEMBL619838,F,BAO_0000218,,,0,11704,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,In vivo,,,
4389,,,,,CHEMBL619839,A,BAO_0000218,,,1,11704,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,Mus musculus,10090.0,
4390,,,,6C3HED,CHEMBL619840,F,BAO_0000218,,,1,10685,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,In vivo,Mus musculus,10090.0,
4391,,,,6C3HED,CHEMBL619841,F,BAO_0000218,,,1,10685,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,In vivo,Mus musculus,10090.0,
4392,,,,6C3HED,CHEMBL857704,F,BAO_0000218,,,1,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),,Mus musculus,10090.0,
4393,,,,6C3HED,CHEMBL619842,F,BAO_0000218,,,1,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),,Mus musculus,10090.0,
4394,,,,6C3HED,CHEMBL619843,F,BAO_0000218,,,1,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),,Mus musculus,10090.0,
4395,,,,,CHEMBL619844,B,BAO_0000019,,,0,17763,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,Staphylococcus aureus,1280.0,
4396,Liver,,,,CHEMBL857855,B,BAO_0000251,,,0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,,Rattus norvegicus,10116.0,Microsomes
4397,Liver,,,,CHEMBL619845,B,BAO_0000251,,,0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,Rattus norvegicus,10116.0,Microsomes
4398,Liver,,,,CHEMBL619846,B,BAO_0000251,,,0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,,Rattus norvegicus,10116.0,Microsomes
4399,Liver,,,,CHEMBL619847,B,BAO_0000251,,,0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,,Rattus norvegicus,10116.0,Microsomes
4400,Liver,,,,CHEMBL619848,B,BAO_0000251,,,0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,,Rattus norvegicus,10116.0,Microsomes
4401,Liver,,,,CHEMBL620893,B,BAO_0000251,,,0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,,Rattus norvegicus,10116.0,Microsomes
4402,Liver,,,,CHEMBL620894,B,BAO_0000251,,,0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,,Rattus norvegicus,10116.0,Microsomes
4403,Liver,,,,CHEMBL620895,B,BAO_0000251,,,0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,,Rattus norvegicus,10116.0,Microsomes
4404,Liver,,,,CHEMBL620896,B,BAO_0000251,,,0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,Rattus norvegicus,10116.0,Microsomes
4405,Liver,,,,CHEMBL620897,B,BAO_0000251,,,0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,Rattus norvegicus,10116.0,Microsomes
4406,Liver,,,,CHEMBL620898,B,BAO_0000251,,,0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,Rattus norvegicus,10116.0,Microsomes
4407,Liver,,,,CHEMBL620899,B,BAO_0000251,,,0,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,Rattus norvegicus,10116.0,Microsomes
4408,Plasma,,,,CHEMBL620900,A,BAO_0000218,,,0,347,The apparent total plasma clearance in monkey,In vivo,Cercopithecidae,9527.0,
4409,,,,,CHEMBL620901,A,BAO_0000218,,,0,3341,Compound was evaluated for Hepatic clearance in monkey,In vivo,Cercopithecidae,9527.0,
4410,,,,,CHEMBL620902,A,BAO_0000218,,,0,17853,Lower clearance in monkey (i.v.) at 0.5 mpk,In vivo,Cercopithecidae,9527.0,
4411,,,,,CHEMBL620903,A,BAO_0000218,,,0,4514,Plasma clearance in rhesus monkey,In vivo,Cercopithecidae,9527.0,
4412,,,,,CHEMBL620904,A,BAO_0000218,,,0,6062,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,In vivo,Cercopithecidae,9527.0,
4413,,,,,CHEMBL620905,A,BAO_0000218,,,0,6821,Plasma clearance of compound was determined in monkey,In vivo,Cercopithecidae,9527.0,
4414,,,,,CHEMBL620906,A,BAO_0000218,,,0,6057,Plasma clearance was calculated in rhesus monkey,In vivo,Cercopithecidae,9527.0,
4415,,,,,CHEMBL875420,A,BAO_0000218,,,0,5145,Plasma clearance in rhesus monkey,In vivo,Cercopithecidae,9527.0,
4416,,,,,CHEMBL620907,A,BAO_0000218,,,0,6641,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,Cercopithecidae,9527.0,
4417,,,,,CHEMBL620908,A,BAO_0000218,,,0,5472,Plasma clearance was evaluated in rhesus,In vivo,Cercopithecidae,9527.0,
4418,,,,,CHEMBL620909,A,BAO_0000218,,,0,4257,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,In vivo,Cercopithecidae,9527.0,
4419,,,,,CHEMBL620910,A,BAO_0000218,,,0,5546,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,In vivo,Cercopithecidae,9527.0,
4420,,,,,CHEMBL620911,A,BAO_0000218,,,0,5334,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),In vivo,Cercopithecidae,9527.0,
4421,,,,,CHEMBL620912,A,BAO_0000218,,,0,5334,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),In vivo,Cercopithecidae,9527.0,
4422,,,,,CHEMBL620913,A,BAO_0000218,,,0,17509,Cmax 24 hr after 2 mg/kg oral administration in monkeys,In vivo,Cercopithecidae,9527.0,
4423,,,,,CHEMBL620914,A,BAO_0000218,,,0,6535,Cmax in monkey after administration of 1 mg/kg iv,In vivo,Cercopithecidae,9527.0,
4424,,,,,CHEMBL620915,A,BAO_0000218,,,0,5668,Cmax was determine after peroral administration at 10 mpk in Rhesus,In vivo,Cercopithecidae,9527.0,
4425,,,,,CHEMBL620916,A,BAO_0000218,,,0,5922,Cmax in cynomolgus monkey by iv administration,In vivo,Cercopithecidae,9527.0,
4426,,,,,CHEMBL620917,A,BAO_0000218,,,0,5922,Cmax in cynomolgus monkey by po administration,In vivo,Cercopithecidae,9527.0,
4427,,,,,CHEMBL620918,A,BAO_0000218,,,0,6078,Cmax value evaluated in monkey,In vivo,Cercopithecidae,9527.0,
4428,,,,,CHEMBL620919,A,BAO_0000218,,,0,2661,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,In vivo,Cercopithecidae,9527.0,
4429,Plasma,,,,CHEMBL620920,A,BAO_0000218,,,0,3249,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,In vivo,Cercopithecidae,9527.0,
4430,Plasma,,,,CHEMBL620921,A,BAO_0000218,,,0,3249,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,In vivo,Cercopithecidae,9527.0,
4431,Plasma,,,,CHEMBL620922,A,BAO_0000218,,,0,5553,Maximal plasma concentration in squirrel monkeys,In vivo,Cercopithecidae,9527.0,
4432,,,,,CHEMBL620923,A,BAO_0000218,,,0,1916,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,In vivo,Cercopithecidae,9527.0,
4433,Plasma,,,,CHEMBL620924,A,BAO_0000218,,,0,6227,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,In vivo,Cercopithecidae,9527.0,
4434,,,,,CHEMBL620925,A,BAO_0000218,,,0,4809,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),In vivo,Cercopithecidae,9527.0,
4435,,,,,CHEMBL620926,A,BAO_0000218,,,0,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,In vivo,Cercopithecidae,9527.0,
4436,,,,,CHEMBL620927,A,BAO_0000218,,,0,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,In vivo,Cercopithecidae,9527.0,
4437,,,,,CHEMBL620928,A,BAO_0000218,,,0,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,In vivo,Cercopithecidae,9527.0,
4438,,,,,CHEMBL620929,A,BAO_0000218,,,0,5355,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,In vivo,Cercopithecidae,9527.0,
4439,Plasma,,,,CHEMBL620930,A,BAO_0000218,,,0,6221,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,In vivo,Cercopithecidae,9527.0,
4440,,,,,CHEMBL620931,A,BAO_0000218,,,0,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,Cercopithecidae,9527.0,
4441,,,,,CHEMBL620932,A,BAO_0000218,,,0,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,Cercopithecidae,9527.0,
4442,,,,,CHEMBL620933,A,BAO_0000218,,,0,4257,Absolute bioavailability was evaluated in monkey,In vivo,monkey,9443.0,
4443,,,,,CHEMBL620934,A,BAO_0000218,,,0,6221,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,In vivo,monkey,9443.0,
4444,,,,,CHEMBL620935,A,BAO_0000218,,,0,17667,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,In vivo,monkey,9443.0,
4445,,,,,CHEMBL620936,A,BAO_0000218,,,0,17267,Bioavailability of compound was determined in rhesus monkey,In vivo,Macaca mulatta,9544.0,
4446,,,,,CHEMBL620937,A,BAO_0000218,,,0,4256,Bioavailability determined after oral administration in marmoset,In vivo,marmosets,38020.0,
4447,,,,,CHEMBL620938,A,BAO_0000218,,,0,4256,Oral bioavailability in cynomolgus monkey,In vivo,Macaca fascicularis,9541.0,
4448,,,,,CHEMBL620939,A,BAO_0000218,,,0,17853,Bioavailability in monkey (p.o.) at 2.0 mpk,In vivo,monkey,9443.0,
4449,,,,,CHEMBL620940,A,BAO_0000218,,,0,16365,Bioavailability was evaluated after oral administration in monkey,In vivo,monkey,9443.0,
4450,,,,,CHEMBL620941,A,BAO_0000218,,,0,1916,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,In vivo,Macaca fascicularis,9541.0,
4451,,,,,CHEMBL620942,A,BAO_0000218,,,0,5334,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),In vivo,Macaca mulatta,9544.0,
4452,,,,,CHEMBL620943,A,BAO_0000218,,,0,5334,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),In vivo,Macaca mulatta,9544.0,
4453,,,,,CHEMBL620944,A,BAO_0000218,,,0,17592,Bioavailability of the compound was determined in monkey,In vivo,monkey,9443.0,
4454,,,,,CHEMBL620945,A,BAO_0000218,,,0,1399,Bioavailability in squirrel monkey (dose 5 mg/kg),In vivo,Saimiri sciureus,9521.0,
4455,,,,,CHEMBL620946,A,BAO_0000218,,,0,4809,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),In vivo,monkey,9443.0,
4456,,,,,CHEMBL620947,A,BAO_0000218,,,0,3341,Oral bioavailability in monkey,In vivo,monkey,9443.0,
4457,,,,,CHEMBL620948,A,BAO_0000218,,,0,64,Compound was tested for bioavailability in squirrel monkey,In vivo,Saimiri sciureus,9521.0,
4458,,,,,CHEMBL620949,A,BAO_0000218,,,0,5005,Oral bioavailability in Rhesus monkey,In vivo,Macaca mulatta,9544.0,
4459,,,,,CHEMBL620950,A,BAO_0000218,,,0,5005,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),In vivo,Macaca mulatta,9544.0,
4460,,,,,CHEMBL620951,A,BAO_0000218,,,0,5237,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,In vivo,Macaca fascicularis,9541.0,
4461,,,,,CHEMBL620952,A,BAO_0000218,,,0,5237,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,In vivo,Macaca fascicularis,9541.0,
4462,,,,,CHEMBL875421,A,BAO_0000218,,,0,5302,Oral bioavailability in monkey (dose 5 mg/kg),In vivo,monkey,9443.0,
4463,,,,,CHEMBL620953,A,BAO_0000218,,,0,17667,Oral bioavailability of compound at 5 mg/kg in monkey,In vivo,monkey,9443.0,
4464,,,,,CHEMBL873491,A,BAO_0000218,,,1,6161,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,In vivo,Canis lupus familiaris,9615.0,
4465,,,,,CHEMBL620954,A,BAO_0000218,,,1,6161,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,In vivo,Canis lupus familiaris,9615.0,
4466,Plasma,,,,CHEMBL620955,A,BAO_0000218,,,1,3854,Plasma half life determined,,Canis lupus familiaris,9615.0,
4467,Plasma,,,,CHEMBL618097,A,BAO_0000218,,,1,993,Plasma half life in dog,,Canis lupus familiaris,9615.0,
4468,Plasma,,,,CHEMBL618268,A,BAO_0000218,,,1,4514,Plasma half-life in Beagle dogs,,Canis lupus familiaris,9615.0,
4469,Plasma,,,,CHEMBL618269,A,BAO_0000218,,,1,5334,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),In vivo,Canis lupus familiaris,9615.0,
4470,Plasma,,,,CHEMBL618270,A,BAO_0000218,,,1,5334,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),In vivo,Canis lupus familiaris,9615.0,
4471,,,,,CHEMBL618271,A,BAO_0000218,,,1,1466,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,In vivo,Canis lupus familiaris,9615.0,
4472,,,,,CHEMBL873493,A,BAO_0000218,,,1,1466,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,In vivo,Canis lupus familiaris,9615.0,
4473,,,,,CHEMBL621031,A,BAO_0000218,,,1,5313,Tested for the half life period in dog,,Canis lupus familiaris,9615.0,
4474,,,,,CHEMBL621032,A,BAO_0000218,,,1,5313,Tested for the half life period in dog at dosage of 10 mpk,In vivo,Canis lupus familiaris,9615.0,
4475,,,,,CHEMBL621033,A,BAO_0000218,,,1,3880,The compound was tested for half life in dog,,Canis lupus familiaris,9615.0,
4476,Plasma,,,,CHEMBL621034,A,BAO_0000218,,,1,3639,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",,Canis lupus familiaris,9615.0,
4477,,,,,CHEMBL621035,A,BAO_0000218,,,1,3880,The half life was determined,,Canis lupus familiaris,9615.0,
4478,Plasma,,,,CHEMBL621036,A,BAO_0000218,,,1,3918,The plasma half-life in dogs,,Canis lupus familiaris,9615.0,
4479,Plasma,,,,CHEMBL621037,A,BAO_0000218,,,1,16452,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,,Canis lupus familiaris,9615.0,
4480,,,,,CHEMBL619812,A,BAO_0000218,,,1,17796,Half life in dog,,Canis lupus familiaris,9615.0,
4481,,,,,CHEMBL619813,A,BAO_0000218,,,1,5983,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,In vivo,Canis lupus familiaris,9615.0,
4482,,,,,CHEMBL873335,A,BAO_0000218,,,1,1466,tmax upon peroral administration of 10.0 mg/Kg dose in dog,In vivo,Canis lupus familiaris,9615.0,
4483,,,,,CHEMBL619814,A,BAO_0000218,,,1,16456,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,In vivo,Canis lupus familiaris,9615.0,
4484,,,,,CHEMBL619815,A,BAO_0000218,,,1,6113,Cmax in ferrets after 30 mg/kg oral dose,In vivo,Mustela putorius furo,9669.0,
4485,,,,,CHEMBL619816,F,BAO_0000218,,,1,6113,Emesis in ferrets at 30 mg/kg oral dose,In vivo,Mustela putorius furo,9669.0,
4486,,,,,CHEMBL619817,A,BAO_0000218,,,0,17796,Bioavailability in cynomolgus monkey,In vivo,Macaca fascicularis,9541.0,
4487,,,,,CHEMBL619818,A,BAO_0000218,,,1,17796,Volume of distribution in cynomolgus,In vivo,Macaca fascicularis,9541.0,
4488,Plasma,,,,CHEMBL619819,A,BAO_0000218,,,0,5308,AUC tested in guinea pig when 3 mg/kg dose was given perorally,,Cavia porcellus,10141.0,
4489,,,,,CHEMBL619820,A,BAO_0000218,,,0,4877,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,Cavia porcellus,10141.0,
4490,,,,,CHEMBL875419,A,BAO_0000218,,,0,4876,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,Cavia porcellus,10141.0,
4491,Plasma,,,,CHEMBL619821,A,BAO_0000218,,,0,4878,AUC in guinea pig after 3mg/kg oral dose,In vivo,Cavia porcellus,10141.0,
4492,,,,,CHEMBL619822,A,BAO_0000218,,,0,5308,Bioavailability in guinea pig was tested,In vivo,Cavia porcellus,10141.0,
4493,,,,,CHEMBL619823,A,BAO_0000218,,,0,4877,Tested for oral bioavailability in guinea pig at 5 mg/kg,In vivo,Cavia porcellus,10141.0,
4494,,,,,CHEMBL619824,A,BAO_0000218,,,0,4876,Tested for the oral bioavailability of the compound,In vivo,Cavia porcellus,10141.0,
4495,,,,,CHEMBL619825,A,BAO_0000218,,,0,4876,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,In vivo,Cavia porcellus,10141.0,
4496,,,,,CHEMBL619826,A,BAO_0000218,,,0,5308,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,In vivo,Cavia porcellus,10141.0,
4497,Lung,,,,CHEMBL619827,A,BAO_0000218,,,0,4877,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,In vivo,Cavia porcellus,10141.0,
4498,,,,,CHEMBL618167,A,BAO_0000218,,,0,4878,Cmax in guinea pig after 3mg/kg oral dose,In vivo,Cavia porcellus,10141.0,
4499,Blood,,,,CHEMBL618168,A,BAO_0000019,,,0,5689,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,,Cavia porcellus,10141.0,
4500,Brain,,,,CHEMBL618169,A,BAO_0000019,,,0,5689,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,,Cavia porcellus,10141.0,
4501,,,,,CHEMBL618170,A,BAO_0000019,,,0,5689,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,Cavia porcellus,10141.0,
4502,Intestine,,,,CHEMBL618171,A,BAO_0000019,,,0,5689,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,,Cavia porcellus,10141.0,
4503,Kidney,,,,CHEMBL618172,A,BAO_0000019,,,0,5689,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,,Cavia porcellus,10141.0,
4504,Liver,,,,CHEMBL618173,A,BAO_0000019,,,0,5689,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,,Cavia porcellus,10141.0,
4505,,,,,CHEMBL618174,A,BAO_0000019,,,0,5689,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,Cavia porcellus,10141.0,
4506,Spleen,,,,CHEMBL875408,A,BAO_0000019,,,0,5689,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,,Cavia porcellus,10141.0,
4507,,,,,CHEMBL839827,A,BAO_0000218,,,0,14465,Elimination T1/2 in Guinea pig (PO dose),In vivo,Cavia porcellus,10141.0,
4508,,,,,CHEMBL618175,A,BAO_0000019,,,0,5689,Partition coefficient was measured as -log (counts per min ),,Cavia porcellus,10141.0,
4509,,,,,CHEMBL618176,A,BAO_0000218,,,0,611,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,In vivo,Cavia porcellus,10141.0,
4510,,,,,CHEMBL618177,A,BAO_0000218,,,0,611,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,In vivo,Cavia porcellus,10141.0,
4511,,,,,CHEMBL618178,A,BAO_0000218,,,0,14465,Elimination T1/2 in Guinea pig (PO dose),In vivo,Cavia porcellus,10141.0,
4512,,,,,CHEMBL618179,A,BAO_0000218,,,0,4876,"Tested for the half life period of the compound, intravenously",In vivo,Cavia porcellus,10141.0,
4513,,,,,CHEMBL873489,A,BAO_0000019,,,0,5689,Half-life was measured,,Cavia porcellus,10141.0,
4514,,,,,CHEMBL618180,A,BAO_0000019,,,0,7515,The time required for onset of inotropy after addition of a single dose of delta F75,,Cavia porcellus,10141.0,
4515,,,,,CHEMBL618181,A,BAO_0000218,,,0,17667,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,In vivo,Cavia porcellus,10141.0,
4516,,,,,CHEMBL618182,A,BAO_0000218,,,0,17667,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,In vivo,Cavia porcellus,10141.0,
4517,,,,,CHEMBL618183,A,BAO_0000218,,,0,4727,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,In vivo,Cricetulus griseus,10029.0,
4518,,,,,CHEMBL618184,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,Mus musculus,10090.0,
4519,,,,,CHEMBL618185,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,Mus musculus,10090.0,
4520,,,,,CHEMBL618186,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,Mus musculus,10090.0,
4521,,,,,CHEMBL618187,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,Mus musculus,10090.0,
4522,,,,,CHEMBL618188,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,In vivo,Mus musculus,10090.0,
4523,,,,,CHEMBL875409,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,Mus musculus,10090.0,
4524,,,,,CHEMBL618189,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,Mus musculus,10090.0,
4525,Blood,,,,CHEMBL618190,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,In vivo,Mus musculus,10090.0,
4526,Blood,,,,CHEMBL618191,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,In vivo,Mus musculus,10090.0,
4527,Blood,,,,CHEMBL618192,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,In vivo,Mus musculus,10090.0,
4528,Bone,,,,CHEMBL618193,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,In vivo,Mus musculus,10090.0,
4529,Bone,,,,CHEMBL618194,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,In vivo,Mus musculus,10090.0,
4530,Bone,,,,CHEMBL618195,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,In vivo,Mus musculus,10090.0,
4531,Brain,,,,CHEMBL618196,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,In vivo,Mus musculus,10090.0,
4532,Brain,,,,CHEMBL618197,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,In vivo,Mus musculus,10090.0,
4533,Brain,,,,CHEMBL618198,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,In vivo,Mus musculus,10090.0,
4534,Heart,,,,CHEMBL618199,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,In vivo,Mus musculus,10090.0,
4535,Heart,,,,CHEMBL618200,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,In vivo,Mus musculus,10090.0,
4536,Heart,,,,CHEMBL618201,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,In vivo,Mus musculus,10090.0,
4537,Intestine,,,,CHEMBL618202,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,In vivo,Mus musculus,10090.0,
4538,Intestine,,,,CHEMBL618203,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,In vivo,Mus musculus,10090.0,
4539,Intestine,,,,CHEMBL618204,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,In vivo,Mus musculus,10090.0,
4540,Kidney,,,,CHEMBL618205,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,In vivo,Mus musculus,10090.0,
4541,Kidney,,,,CHEMBL618206,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,In vivo,Mus musculus,10090.0,
4542,Kidney,,,,CHEMBL618207,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,In vivo,Mus musculus,10090.0,
4543,Liver,,,,CHEMBL618208,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,In vivo,Mus musculus,10090.0,
4544,Liver,,,,CHEMBL618932,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,In vivo,Mus musculus,10090.0,
4545,Liver,,,,CHEMBL618933,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,In vivo,Mus musculus,10090.0,
4546,Lung,,,,CHEMBL618934,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,In vivo,Mus musculus,10090.0,
4547,Lung,,,,CHEMBL618935,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,In vivo,Mus musculus,10090.0,
4548,Lung,,,,CHEMBL618936,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,In vivo,Mus musculus,10090.0,
4549,Muscle tissue,,,,CHEMBL618937,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,In vivo,Mus musculus,10090.0,
4550,Muscle tissue,,,,CHEMBL618938,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,In vivo,Mus musculus,10090.0,
4551,Muscle tissue,,,,CHEMBL619104,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,In vivo,Mus musculus,10090.0,
4552,Spleen,,,,CHEMBL619105,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,In vivo,Mus musculus,10090.0,
4553,Spleen,,,,CHEMBL619106,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,In vivo,Mus musculus,10090.0,
4554,Spleen,,,,CHEMBL619107,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,In vivo,Mus musculus,10090.0,
4555,Stomach,,,,CHEMBL875410,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,In vivo,Mus musculus,10090.0,
4556,Stomach,,,,CHEMBL619108,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,In vivo,Mus musculus,10090.0,
4557,Stomach,,,,CHEMBL619109,A,BAO_0000218,,,1,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,In vivo,Mus musculus,10090.0,
4558,,,,,CHEMBL619110,A,BAO_0000218,,,1,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,In vivo,Mus musculus,10090.0,
4559,,,,,CHEMBL619111,F,BAO_0000218,,,1,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,In vivo,Mus musculus,10090.0,
4560,,,,,CHEMBL619112,A,BAO_0000218,,,1,16597,MRT value at a dose of 10 mg/kg intravenous administration in mice.,In vivo,Mus musculus,10090.0,
4561,,,,,CHEMBL619113,A,BAO_0000218,,,1,16597,MRT value at a dose of 10 mg/kg peroral administration in mice.,In vivo,Mus musculus,10090.0,
4562,,,,,CHEMBL619114,A,BAO_0000218,,,1,17764,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,In vivo,Mus musculus,10090.0,
4563,,,,,CHEMBL619115,F,BAO_0000218,,,1,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,In vivo,Mus musculus,10090.0,
4564,,,,A2780,CHEMBL619116,F,BAO_0000219,,,1,3830,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,,Homo sapiens,9606.0,
4565,,,,A2780,CHEMBL619117,F,BAO_0000219,,,1,3829,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,,Homo sapiens,9606.0,
4566,,,,A2780,CHEMBL619118,F,BAO_0000219,,,1,2040,Compound was evaluated for cytotoxicity against A2780 cell lines.,,Homo sapiens,9606.0,
4567,,,,A2780,CHEMBL619119,F,BAO_0000219,,,1,15684,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,,Homo sapiens,9606.0,
4568,,,,A2780,CHEMBL619120,F,BAO_0000219,,,1,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,Homo sapiens,9606.0,
4569,,,,A2780,CHEMBL619121,F,BAO_0000219,,,1,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,Homo sapiens,9606.0,
4570,,,,A2780,CHEMBL619122,F,BAO_0000219,,,1,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,Homo sapiens,9606.0,
4571,,,,A2780,CHEMBL619123,F,BAO_0000219,,,1,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,Homo sapiens,9606.0,
4572,,,,A2780,CHEMBL619124,F,BAO_0000219,,,1,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,Homo sapiens,9606.0,
4573,,,,A2780,CHEMBL619125,F,BAO_0000219,,,1,2859,Compound was evaluated for cytotoxicity against A2780 cell line,,Homo sapiens,9606.0,
4574,,,,A2780,CHEMBL875411,F,BAO_0000219,,,1,5618,In vitro inhibitory activity against human tumor cell line A2780,,Homo sapiens,9606.0,
4575,,,,A2780,CHEMBL619126,F,BAO_0000219,,,1,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,,Homo sapiens,9606.0,
4576,,,,A2780,CHEMBL619127,F,BAO_0000219,,,1,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,Homo sapiens,9606.0,
4577,,,,A2780,CHEMBL619128,F,BAO_0000219,,,1,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,Homo sapiens,9606.0,
4578,,,,A2780,CHEMBL619129,F,BAO_0000219,,,1,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,Homo sapiens,9606.0,
4579,,,,A2780,CHEMBL619130,F,BAO_0000219,,,1,2113,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,,Homo sapiens,9606.0,
4580,,,,A2780,CHEMBL619131,F,BAO_0000219,,,1,2113,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,,Homo sapiens,9606.0,
4581,,,,A2780,CHEMBL619132,F,BAO_0000219,,,1,16745,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,,Homo sapiens,9606.0,
4582,,,,A2780,CHEMBL619133,F,BAO_0000218,,,1,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,Homo sapiens,9606.0,
4583,,,,A2780,CHEMBL619134,F,BAO_0000219,,,1,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,Homo sapiens,9606.0,
4584,,,,A2780,CHEMBL619135,F,BAO_0000219,,,1,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,Homo sapiens,9606.0,
4585,,,,A2780,CHEMBL619136,F,BAO_0000219,,,1,2040,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,,Homo sapiens,9606.0,
4586,,,,A2780,CHEMBL619137,F,BAO_0000219,,,1,2040,Relative resistance factor in A2780 cisplatin-resistant line,,Homo sapiens,9606.0,
4587,,,,A2780,CHEMBL883713,F,BAO_0000219,,,1,16165,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,,Homo sapiens,9606.0,
4588,,,,A2780,CHEMBL875412,F,BAO_0000219,,,1,16165,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,,Homo sapiens,9606.0,
4589,,,,A2780,CHEMBL619138,F,BAO_0000218,,,1,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,Homo sapiens,9606.0,
4590,,,,A2780,CHEMBL619262,F,BAO_0000218,,,1,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,Homo sapiens,9606.0,
4591,,,,A2780,CHEMBL619139,F,BAO_0000219,,,1,3992,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,,Homo sapiens,9606.0,
4592,,,,A2780,CHEMBL619140,F,BAO_0000219,,,1,10553,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,,Homo sapiens,9606.0,
4593,,,,A2780,CHEMBL619141,F,BAO_0000219,,,1,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,,Homo sapiens,9606.0,
4594,,,,A2780,CHEMBL619142,F,BAO_0000219,,,1,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,,Homo sapiens,9606.0,
4595,,,,A2780,CHEMBL619143,F,BAO_0000219,,,1,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,,Homo sapiens,9606.0,
4596,,,,A2780,CHEMBL619144,F,BAO_0000219,,,1,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,,Homo sapiens,9606.0,
4597,,,,A2780,CHEMBL619145,F,BAO_0000219,,,1,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,,Homo sapiens,9606.0,
4598,,,,A2780,CHEMBL619146,F,BAO_0000219,,,1,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,,Homo sapiens,9606.0,
4599,,,,A2780,CHEMBL619147,F,BAO_0000219,,,1,15569,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,,Homo sapiens,9606.0,
4600,,,,A2780,CHEMBL619148,F,BAO_0000219,,,1,17420,Antiproliferative effect of compound on A2780/DX cell line,,Homo sapiens,9606.0,
4601,,,,A2780,CHEMBL619149,F,BAO_0000219,,,1,17420,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,,Homo sapiens,9606.0,
4602,,,,A2780,CHEMBL619150,F,BAO_0000219,,,1,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),,Homo sapiens,9606.0,
4603,,,,A2780,CHEMBL619151,F,BAO_0000219,,,1,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),,Homo sapiens,9606.0,
4604,,,,A2780,CHEMBL883794,F,BAO_0000219,,,1,17672,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,,Homo sapiens,9606.0,
4605,,,,A2780,CHEMBL619152,F,BAO_0000219,,,1,17672,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,,Homo sapiens,9606.0,
4606,,,,A2780,CHEMBL619153,F,BAO_0000219,,,1,17270,In vitro cytotoxicity against A2780ADR cell line,,Homo sapiens,9606.0,
4607,,,,A2780,CHEMBL619154,F,BAO_0000219,,,1,17270,In vitro cytotoxicity against A2780CIS cell line,,Homo sapiens,9606.0,
4608,,,,A2780,CHEMBL619155,F,BAO_0000219,,,1,5574,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,,Homo sapiens,9606.0,
4609,,,,A2780,CHEMBL619156,F,BAO_0000219,,,1,2113,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,,Homo sapiens,9606.0,
4610,,,,A2780,CHEMBL619157,F,BAO_0000219,,,1,16913,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",,Homo sapiens,9606.0,
4611,,,,A2780,CHEMBL619797,F,BAO_0000219,,,1,16913,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",,Homo sapiens,9606.0,
4612,,,,,CHEMBL619798,A,BAO_0000218,,,0,17839,Oral bioavailability of compound in rhesus macaques,In vivo,Macaca mulatta,9544.0,
4613,,,,,CHEMBL619799,A,BAO_0000218,,,0,6821,Oral bioavailability in monkey,In vivo,monkey,9443.0,
4614,,,,,CHEMBL619800,A,BAO_0000218,,,0,6078,Oral bioavailability evaluated in monkey,In vivo,monkey,9443.0,
4615,,,,,CHEMBL619801,A,BAO_0000218,,,0,6535,Oral bioavailability in monkey (dose 1 mg/kg p.o.),In vivo,monkey,9443.0,
4616,,,,,CHEMBL619802,A,BAO_0000218,,,0,4449,Oral bioavailability in Rhesus monkey,In vivo,Macaca mulatta,9544.0,
4617,,,,,CHEMBL619803,A,BAO_0000218,,,0,6057,Oral bioavailability was calculated in rhesus monkey,In vivo,Macaca mulatta,9544.0,
4618,,,,,CHEMBL619965,A,BAO_0000218,,,0,5922,Oral bioavailability in cynomolgus monkey,In vivo,Macaca fascicularis,9541.0,
4619,,,,,CHEMBL619966,A,BAO_0000218,,,0,5940,Oral bioavailability in monkey,In vivo,monkey,9443.0,
4620,,,,,CHEMBL619967,A,BAO_0000218,,,0,6265,Oral bioavailability in monkey,In vivo,monkey,9443.0,
4621,,,,,CHEMBL620073,A,BAO_0000218,,,0,6265,Oral bioavailability in monkey (dose 1 mg/kg),In vivo,monkey,9443.0,
4622,,,,,CHEMBL620074,A,BAO_0000218,,,0,6265,Oral bioavailability in monkey (dose 5 mg/kg),In vivo,monkey,9443.0,
4623,,,,,CHEMBL620075,A,BAO_0000218,,,0,5940,Oral bioavailability in monkey,In vivo,monkey,9443.0,
4624,,,,,CHEMBL620076,A,BAO_0000218,,,0,5940,Oral bioavailability in monkey,In vivo,monkey,9443.0,
4625,,,,,CHEMBL620077,A,BAO_0000218,,,0,4514,Oral bioavailability in rhesus monkey,In vivo,Macaca mulatta,9544.0,
4626,,,,,CHEMBL620078,A,BAO_0000218,,,0,5546,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,In vivo,Macaca mulatta,9544.0,
4627,,,,,CHEMBL620079,A,BAO_0000218,,,0,5553,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,In vivo,Saimiri sciureus,9521.0,
4628,,,,,CHEMBL620080,A,BAO_0000218,,,0,6641,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,monkey,9443.0,
4629,,,,,CHEMBL620081,A,BAO_0000218,,,0,5472,Oral bioavailability in Rhesus monkey,In vivo,Macaca mulatta,9544.0,
4630,,,,,CHEMBL620082,A,BAO_0000218,,,0,5668,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),In vivo,Macaca mulatta,9544.0,
4631,,,,,CHEMBL620083,A,BAO_0000218,,,0,5711,Oral bioavailability in monkey at 10 mg/kg of the compound,In vivo,monkey,9443.0,
4632,,,,,CHEMBL620084,A,BAO_0000218,,,0,5145,Bioavailability in Rhesus monkey,In vivo,Macaca mulatta,9544.0,
4633,,,,,CHEMBL620085,A,BAO_0000218,,,0,3443,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Cercopithecidae,9527.0,
4634,,,,,CHEMBL874595,A,BAO_0000218,,,0,3443,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Cercopithecidae,9527.0,
4635,,,,,CHEMBL873352,A,BAO_0000218,,,0,3249,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,In vivo,Cercopithecidae,9527.0,
4636,,,,,CHEMBL620086,A,BAO_0000218,,,0,3249,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,In vivo,Cercopithecidae,9527.0,
4637,,,,,CHEMBL620087,A,BAO_0000218,,,0,5355,Mean residence time was determined after intravenous administration in cynomolgus monkeys,In vivo,Cercopithecidae,9527.0,
4638,,,,,CHEMBL620088,A,BAO_0000218,,,0,5355,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,In vivo,Cercopithecidae,9527.0,
4639,,,,,CHEMBL620089,A,BAO_0000218,,,0,5355,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,In vivo,Cercopithecidae,9527.0,
4640,,,,,CHEMBL620090,A,BAO_0000218,,,0,4809,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),In vivo,Cercopithecidae,9527.0,
4641,,,,,CHEMBL620091,A,BAO_0000218,,,0,4809,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),In vivo,Cercopithecidae,9527.0,
4642,,,,,CHEMBL620092,A,BAO_0000251,,,0,14294,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),,Cercopithecidae,9527.0,Microsomes
4643,,,,,CHEMBL620093,A,BAO_0000251,,,0,14294,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),,Cercopithecidae,9527.0,Microsomes
4644,,,,,CHEMBL620094,A,BAO_0000251,,,0,14294,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),,Cercopithecidae,9527.0,Microsomes
4645,,,,,CHEMBL620095,A,BAO_0000251,,,0,14294,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),,Cercopithecidae,9527.0,Microsomes
4646,,,,,CHEMBL620096,A,BAO_0000218,,,0,3443,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,Cercopithecidae,9527.0,
4647,,,,,CHEMBL620097,A,BAO_0000218,,,0,3443,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,Cercopithecidae,9527.0,
4648,,,,,CHEMBL620098,A,BAO_0000019,,,0,11271,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,Cercopithecidae,9527.0,
4649,,,,,CHEMBL620099,A,BAO_0000218,,,0,3443,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Cercopithecidae,9527.0,
4650,,,,,CHEMBL620100,A,BAO_0000218,,,0,3443,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Cercopithecidae,9527.0,
4651,,,,,CHEMBL620101,A,BAO_0000019,,,0,6821,Elimination Half-life of compound was determined in monkey,,Cercopithecidae,9527.0,
4652,,,,,CHEMBL620102,A,BAO_0000019,,,0,17267,Half life of compound was determined in rhesus monkey,,Cercopithecidae,9527.0,
4653,Plasma,,,,CHEMBL620103,A,BAO_0000366,,,0,5819,Half life in monkey plasma,,Cercopithecidae,9527.0,
4654,Plasma,,,,CHEMBL620104,A,BAO_0000366,,,0,5819,Half life in monkey plasma; Not detected,,Cercopithecidae,9527.0,
4655,,,,,CHEMBL874596,A,BAO_0000218,,,0,1916,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,In vivo,Cercopithecidae,9527.0,
4656,,,,,CHEMBL873490,A,BAO_0000218,,,0,17509,Half-life 24 hr after 2 mg/kg iv administration in monkeys,In vivo,Cercopithecidae,9527.0,
4657,,,,,CHEMBL620105,A,BAO_0000019,,,0,1399,Terminal half life of the compound.,,Cercopithecidae,9527.0,
4658,,,,,CHEMBL620780,A,BAO_0000218,,,0,1916,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,In vivo,Cercopithecidae,9527.0,
4659,,,,,CHEMBL620781,A,BAO_0000218,,,0,4809,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),In vivo,Cercopithecidae,9527.0,
4660,,,,,CHEMBL620956,A,BAO_0000218,,,0,5546,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,Cercopithecidae,9527.0,
4661,Urine,,,,CHEMBL620957,A,BAO_0000218,,,0,3443,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Cercopithecidae,9527.0,
4662,Urine,,,,CHEMBL620958,A,BAO_0000218,,,0,3443,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Cercopithecidae,9527.0,
4663,,,,,CHEMBL620959,A,BAO_0000218,,,0,4257,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,In vivo,Cercopithecidae,9527.0,
4664,,,,,CHEMBL620960,A,BAO_0000218,,,0,6221,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,In vivo,Cercopithecidae,9527.0,
4665,,,,,CHEMBL620961,A,BAO_0000218,,,0,5472,Volume of distribution was evaluated in rhesus,In vivo,Cercopithecidae,9527.0,
4666,,,,,CHEMBL620962,A,BAO_0000218,,,0,4727,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,In vivo,Cricetulus griseus,10029.0,
4667,,,,,CHEMBL620963,A,BAO_0000218,,,0,4727,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,In vivo,Cricetulus griseus,10029.0,
4668,,,,,CHEMBL620964,A,BAO_0000218,,,0,4727,Bioavailability in hamster was determined,In vivo,Cricetulus griseus,10029.0,
4669,,,,,CHEMBL620965,A,BAO_0000218,,,0,4727,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,In vivo,Cricetulus griseus,10029.0,
4670,,,,,CHEMBL620966,A,BAO_0000218,,,0,4727,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,In vivo,Cricetulus griseus,10029.0,
4671,Blood,,,,CHEMBL620967,A,BAO_0000221,,,0,4727,Half life of compound was determined in hamster blood,,Cricetulus griseus,10029.0,
4672,,,,,CHEMBL620968,A,BAO_0000019,,,0,1452,Michaelis-Menten constant of the compound.,,Sus scrofa,9823.0,
4673,,,,,CHEMBL874597,A,BAO_0000019,,,0,1452,Vmax value was measured at 0 uM concentration of silyl ether.,,Sus scrofa,9823.0,
4674,,,,,CHEMBL620969,A,BAO_0000019,,,0,1452,Vmax value was measured at 10 uM concentration of silyl ether.,,Sus scrofa,9823.0,
4675,,,,,CHEMBL620970,A,BAO_0000019,,,0,1452,Vmax value was measured at 5 uM concentration of silyl ether.,,Sus scrofa,9823.0,
4676,,,,,CHEMBL620971,B,BAO_0000357,,,9,11706,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,Homo sapiens,9606.0,
4677,,,,,CHEMBL620972,A,BAO_0000218,,,0,1916,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,Homo sapiens,9606.0,
4678,,,,,CHEMBL620973,A,BAO_0000019,,,0,17791,Compound was evaluated for area under the curve expressed as (h*ug/ml),,Homo sapiens,9606.0,
4679,,,,,CHEMBL618243,A,BAO_0000019,,,0,7766,Active metabolite of ifosfamide determined in humans; A-Active,,Homo sapiens,9606.0,
4680,,,,,CHEMBL618244,A,BAO_0000019,,,0,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,Homo sapiens,9606.0,
4681,,,,,CHEMBL618245,A,BAO_0000019,,,0,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,Homo sapiens,9606.0,
4682,,,,,CHEMBL618246,A,BAO_0000019,,,0,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,Homo sapiens,9606.0,
4683,,,,,CHEMBL618247,A,BAO_0000019,,,0,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,Homo sapiens,9606.0,
4684,,,,,CHEMBL618248,A,BAO_0000218,,,0,17791,Compound was evaluated for oral bioavailability in human,,Homo sapiens,9606.0,
4685,Urine,,,,CHEMBL618249,A,BAO_0000019,,,0,7766,Metabolite of ifosfamide determined in urine; NF-Not found,,Homo sapiens,9606.0,
4686,,,,,CHEMBL618250,A,BAO_0000019,,,0,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,Homo sapiens,9606.0,
4687,,,,,CHEMBL874598,A,BAO_0000019,,,0,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,Homo sapiens,9606.0,
4688,,,,,CHEMBL618251,A,BAO_0000019,,,0,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,Homo sapiens,9606.0,
4689,,,,,CHEMBL618252,A,BAO_0000019,,,0,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,Homo sapiens,9606.0,
4690,,,,,CHEMBL618253,A,BAO_0000019,,,0,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,Homo sapiens,9606.0,
4691,,,,,CHEMBL618254,A,BAO_0000019,,,0,6852,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,Homo sapiens,9606.0,
4692,,,,,CHEMBL618255,A,BAO_0000019,,,0,6852,Percent of compound in healthy individuals (Group D),,Homo sapiens,9606.0,
4693,Liver,,,,CHEMBL618983,A,BAO_0000251,,,0,4397,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,Homo sapiens,9606.0,Microsomes
4694,,,,,CHEMBL618984,A,BAO_0000019,,,0,17409,Binding towards human plasma protein at 10 uM,,Homo sapiens,9606.0,
4695,,,,,CHEMBL618985,A,BAO_0000019,,,0,17409,Binding towards human plasma protein at 100 uM,,Homo sapiens,9606.0,
4696,,,,,CHEMBL618986,A,BAO_0000019,,,0,17176,Human plasma protein binding activity was determined,,Homo sapiens,9606.0,
4697,,,,,CHEMBL618987,A,BAO_0000019,,,0,15444,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,Homo sapiens,9606.0,
4698,,,,,CHEMBL618988,A,BAO_0000019,,,0,17267,Percent binding of compound towards human plasma protein was determined,,Homo sapiens,9606.0,
4699,Liver,,,,CHEMBL618989,A,BAO_0000251,,,0,5944,Plasma clearance in human liver microsomes,In vitro,Homo sapiens,9606.0,Microsomes
4700,Liver,,,,CHEMBL618990,A,BAO_0000251,,,0,5668,In vitro intrinsic clearance in human liver microsome,In vitro,Homo sapiens,9606.0,Microsomes
4701,Liver,,,,CHEMBL618991,A,BAO_0000251,,,0,5669,In vitro intrinsic clearance in human liver microsome,In vitro,Homo sapiens,9606.0,Microsomes
4702,,,,,CHEMBL876725,A,BAO_0000251,,,0,5041,In vitro microsome metabolism clearance in human was determined,In vitro,Homo sapiens,9606.0,Microsomes
4703,,,,,CHEMBL618992,A,BAO_0000251,,,0,5041,In vitro microsome metabolism clearance in human was determined; High,In vitro,Homo sapiens,9606.0,Microsomes
4704,,,,,CHEMBL618993,A,BAO_0000251,,,0,5041,In vitro microsome metabolism clearance in human was determined; ND denotes no data,In vitro,Homo sapiens,9606.0,Microsomes
4705,Liver,,,,CHEMBL618994,A,BAO_0000251,,,0,5676,Pharmacokinetic property (clearance) in human liver microsome,In vitro,Homo sapiens,9606.0,Microsomes
4706,Liver,,,,CHEMBL618995,A,BAO_0000251,,,0,5944,Plasma clearance in human liver microsomes,In vitro,Homo sapiens,9606.0,Microsomes
4707,Liver,,,,CHEMBL618996,A,BAO_0000251,,,0,17538,In vitro clearance in human liver microsomes,In vitro,Homo sapiens,9606.0,Microsomes
4708,Liver,,,,CHEMBL618997,A,BAO_0000251,,,0,6331,Intrinsic clearance in human liver microsomes was determined,In vitro,Homo sapiens,9606.0,Microsomes
4709,Liver,,,,CHEMBL618998,A,BAO_0000251,,,0,5948,Intrinsic clearance in human liver microsomes was determined,In vitro,Homo sapiens,9606.0,Microsomes
4710,,,,,CHEMBL618999,A,BAO_0000218,,,0,5965,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,In vivo,Homo sapiens,9606.0,
4711,,,,,CHEMBL620223,A,BAO_0000218,,,0,1916,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,In vivo,Homo sapiens,9606.0,
4712,,,,,CHEMBL620224,A,BAO_0000218,,,0,5965,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,Homo sapiens,9606.0,
4713,,,,,CHEMBL620225,A,BAO_0000019,,,0,1299,Stability in human plasma 2 hr after incubation expressed as percent concentration,,Homo sapiens,9606.0,
4714,,,,,CHEMBL620226,A,BAO_0000019,,,0,1299,Stability in human plasma 4 hr after incubation expressed as percent concentration,,Homo sapiens,9606.0,
4715,Urine,,,,CHEMBL620227,A,BAO_0000019,,,0,7766,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,Homo sapiens,9606.0,
4716,Urine,,,,CHEMBL876726,A,BAO_0000019,,,0,7766,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,Homo sapiens,9606.0,
4717,Urine,,,,CHEMBL620228,A,BAO_0000019,,,0,7766,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,Homo sapiens,9606.0,
4718,Urine,,,,CHEMBL620229,A,BAO_0000019,,,0,7766,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,Homo sapiens,9606.0,
4719,,,,,CHEMBL620230,F,BAO_0000218,,,1,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,In vivo,Mus musculus,10090.0,
4720,,,,,CHEMBL620231,F,BAO_0000218,,,1,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,In vivo,Mus musculus,10090.0,
4721,,,,,CHEMBL620232,F,BAO_0000218,,,1,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,In vivo,Mus musculus,10090.0,
4722,,,,,CHEMBL620233,F,BAO_0000218,,,1,17764,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,In vivo,Mus musculus,10090.0,
4723,,,,,CHEMBL620234,A,BAO_0000218,,,1,14294,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,Mus musculus,10090.0,
4724,,,,,CHEMBL620235,A,BAO_0000218,,,1,14294,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,Mus musculus,10090.0,
4725,,,,,CHEMBL620236,A,BAO_0000218,,,1,14294,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,Mus musculus,10090.0,
4726,Liver,,,,CHEMBL620237,A,BAO_0000218,,,1,6251,In vitro metabolic potential in mouse liver microsomes,,Mus musculus,10090.0,
4727,,,,,CHEMBL620238,A,BAO_0000218,,,1,17582,Ability of compound to bind to plasma protein was evaluated in HSA cells,,Mus musculus,10090.0,
4728,Adrenal gland,,,,CHEMBL620239,A,BAO_0000218,,,1,17811,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),,Mus musculus,10090.0,
4729,Brain,,,,CHEMBL620240,A,BAO_0000218,,,1,17811,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,,Mus musculus,10090.0,
4730,Brain,,,,CHEMBL620241,A,BAO_0000218,,,1,17811,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,,Mus musculus,10090.0,
4731,,,,,CHEMBL876727,A,BAO_0000218,,,1,17811,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,Mus musculus,10090.0,
4732,Kidney,,,,CHEMBL620242,A,BAO_0000218,,,1,17811,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),,Mus musculus,10090.0,
4733,,,,,CHEMBL620243,A,BAO_0000218,,,1,17811,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,Mus musculus,10090.0,
4734,,,,,CHEMBL620244,A,BAO_0000218,,,1,5288,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,Mus musculus,10090.0,
4735,Serum,,,,CHEMBL620245,A,BAO_0000218,,,1,2717,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,,Mus musculus,10090.0,
4736,Serum,,,,CHEMBL620246,A,BAO_0000218,,,1,2717,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,,Mus musculus,10090.0,
4737,Serum,,,,CHEMBL620247,A,BAO_0000218,,,1,2717,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,,Mus musculus,10090.0,
4738,Plasma,,,,CHEMBL620248,A,BAO_0000218,,,1,17753,Half life of compound was determined in plasma of mice at 24 mg/Kg,In vivo,Mus musculus,10090.0,
4739,Plasma,,,,CHEMBL873497,A,BAO_0000218,,,1,17753,Half life of compound was determined in plasma of mice at 40 mg/Kg,In vivo,Mus musculus,10090.0,
4740,Plasma,,,,CHEMBL620249,A,BAO_0000218,,,1,17753,Half life of compound was determined in plasma of mice at 5 mg/Kg,In vivo,Mus musculus,10090.0,
4741,,,,,CHEMBL620250,F,BAO_0000218,,,1,17764,Half life after intraperitoneal administration in mice at 18 uM/kg,In vivo,Mus musculus,10090.0,
4742,,,,,CHEMBL620251,F,BAO_0000218,,,1,17764,Half life after intraperitoneal administration in mice at 23 uM/kg,In vivo,Mus musculus,10090.0,
4743,,,,,CHEMBL620252,F,BAO_0000218,,,1,17764,Half life after intraperitoneal administration in mice at 25 uM/kg,In vivo,Mus musculus,10090.0,
4744,,,,,CHEMBL620253,F,BAO_0000218,,,1,17764,Half life after intraperitoneal administration in mice at 26 uM/kg,In vivo,Mus musculus,10090.0,
4745,,,,,CHEMBL620254,F,BAO_0000218,,,1,17764,Half life after intravenous administration in mice at 23 uM/kg,In vivo,Mus musculus,10090.0,
4746,,,,,CHEMBL620255,A,BAO_0000218,,,1,17764,Half life after intravenous administration in mice at 24 uM/kg,In vivo,Mus musculus,10090.0,
4747,,,,,CHEMBL620256,A,BAO_0000218,,,1,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,In vivo,Mus musculus,10090.0,
4748,,,,,CHEMBL876728,A,BAO_0000218,,,1,2675,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,In vivo,Mus musculus,10090.0,
4749,,,,,CHEMBL620257,A,BAO_0000218,,,1,2675,Maximum time required to reach Cp max was evaluated in mice after oral administration,In vivo,Mus musculus,10090.0,
4750,,,,,CHEMBL620258,A,BAO_0000218,,,1,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),In vivo,Mus musculus,10090.0,
4751,,,,,CHEMBL620259,A,BAO_0000218,,,1,4890,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",In vivo,Mus musculus,10090.0,
4752,,,,,CHEMBL620260,A,BAO_0000218,,,1,429,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,In vivo,Mus musculus,10090.0,
4753,Blood,,,,CHEMBL620261,A,BAO_0000218,,,1,17837,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,In vivo,Mus musculus,10090.0,
4754,,,,,CHEMBL620262,A,BAO_0000218,,,1,16597,Half life at a dose of 10 mg/kg intravenous administration in mice.,In vivo,Mus musculus,10090.0,
4755,,,,,CHEMBL620263,A,BAO_0000218,,,1,16597,Half life at a dose of 10 mg/kg peroral administration in mice.,In vivo,Mus musculus,10090.0,
4756,,,,,CHEMBL620264,A,BAO_0000218,,,1,6619,Half life in ob/ob mice,,Mus musculus,10090.0,
4757,,,,,CHEMBL620265,A,BAO_0000218,,,1,4066,Half-life at a single subcutaneous administration of 40 mg/kg in mice,In vivo,Mus musculus,10090.0,
4758,,,,,CHEMBL620266,A,BAO_0000218,,,1,4239,Half-life was measured in mouse,,Mus musculus,10090.0,
4759,,,,,CHEMBL620267,A,BAO_0000218,,,1,5969,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,In vivo,Mus musculus,10090.0,
4760,,,,,CHEMBL619364,A,BAO_0000218,,,1,8999,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,Mus musculus,10090.0,
4761,,,,,CHEMBL619365,A,BAO_0000218,,,1,8999,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,Mus musculus,10090.0,
4762,Brain,,,,CHEMBL619366,A,BAO_0000218,,,1,17641,T2 in brain of mice at the oral dose of 50 mg/kg,,Mus musculus,10090.0,
4763,Kidney,,,,CHEMBL619367,A,BAO_0000218,,,1,17641,T2 in kidney of mice at the oral dose of 50 mg/kg,,Mus musculus,10090.0,
4764,Liver,,,,CHEMBL619368,A,BAO_0000218,,,1,17641,T2 in liver of mice at the oral dose of 50 mg/kg,,Mus musculus,10090.0,
4765,Lung,,,,CHEMBL619369,A,BAO_0000218,,,1,17641,T2 in lungs of mice at the oral dose of 50 mg/kg,,Mus musculus,10090.0,
4766,Spleen,,,,CHEMBL876729,A,BAO_0000218,,,1,17641,T2 in spleen of mice at the oral dose of 50 mg/kg,,Mus musculus,10090.0,
4767,,,,,CHEMBL619370,A,BAO_0000218,,,1,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,In vivo,Mus musculus,10090.0,
4768,,,,,CHEMBL619371,A,BAO_0000218,,,1,4890,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",In vivo,Mus musculus,10090.0,
4769,,,,,CHEMBL619372,A,BAO_0000218,,,1,429,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,In vivo,Mus musculus,10090.0,
4770,,,,,CHEMBL620012,A,BAO_0000218,,,1,429,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,In vivo,Mus musculus,10090.0,
4771,,,,,CHEMBL620013,A,BAO_0000218,,,1,5969,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,In vivo,Mus musculus,10090.0,
4772,,,,A2780,CHEMBL620014,F,BAO_0000219,,,1,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,Homo sapiens,9606.0,
4773,,,,A2780,CHEMBL620015,F,BAO_0000219,,,1,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,Homo sapiens,9606.0,
4774,,,,A2780,CHEMBL621010,F,BAO_0000219,,,1,16913,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",,Homo sapiens,9606.0,
4775,,,,A2780,CHEMBL621011,F,BAO_0000219,,,1,16913,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",,Homo sapiens,9606.0,
4776,,,,A2780,CHEMBL621012,F,BAO_0000219,,,1,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,Homo sapiens,9606.0,
4777,,,,A2780,CHEMBL621013,F,BAO_0000219,,,1,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,Homo sapiens,9606.0,
4778,,,,A2780,CHEMBL621014,F,BAO_0000219,,,1,17270,In vitro cytotoxicity against A2780TAX cell line,,Homo sapiens,9606.0,
4779,,,,A2780cisR,CHEMBL618154,F,BAO_0000219,,,1,5618,In vitro inhibitory activity against human tumor cell line A2780cis,,Homo sapiens,9606.0,
4780,,,,A2780,CHEMBL618155,F,BAO_0000219,,,1,17777,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,,Homo sapiens,9606.0,
4781,,,,A2780cisR,CHEMBL618156,F,BAO_0000219,,,1,16112,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,,Homo sapiens,9606.0,
4782,,,,A2780cisR,CHEMBL618157,F,BAO_0000219,,,1,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,Homo sapiens,9606.0,
4783,,,,A2780,CHEMBL618328,F,BAO_0000219,,,1,6633,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,,Homo sapiens,9606.0,
4784,,,,A2780,CHEMBL618329,F,BAO_0000219,,,1,16930,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,,Homo sapiens,9606.0,
4785,,,,A2780,CHEMBL618330,F,BAO_0000219,,,1,17496,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,,Homo sapiens,9606.0,
4786,,,,A2780,CHEMBL618331,F,BAO_0000219,,,1,12989,In vitro antitumor activity against A2780cisR cell line.,,Homo sapiens,9606.0,
4787,,,,A2780,CHEMBL618332,F,BAO_0000219,,,1,4840,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),,Homo sapiens,9606.0,
4788,,,,A2780,CHEMBL618333,F,BAO_0000219,,,1,12989,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,,Homo sapiens,9606.0,
4789,,,,A2780cisR,CHEMBL618334,F,BAO_0000219,,,1,16745,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,,Homo sapiens,9606.0,
4790,,,,A2780,CHEMBL618335,F,BAO_0000219,,,1,16597,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,,Homo sapiens,9606.0,
4791,,,,,CHEMBL618336,B,BAO_0000019,,,9,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,Rattus norvegicus,10116.0,
4792,,,,,CHEMBL618337,F,BAO_0000019,,,8,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,,,
4793,,,,,CHEMBL618338,F,BAO_0000019,,,9,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,Rattus norvegicus,10116.0,
4794,,,,HEK293,CHEMBL618339,F,BAO_0000219,,,9,15856,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,,Homo sapiens,9606.0,
4795,,,,HEK293,CHEMBL618340,F,BAO_0000219,,,9,15856,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,,Homo sapiens,9606.0,
4796,,,,,CHEMBL618341,B,BAO_0000019,,,9,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,Mus musculus,10090.0,
4797,,,,,CHEMBL618342,F,BAO_0000019,,,8,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,,,
4798,,,,,CHEMBL618343,F,BAO_0000019,,,9,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,Mus musculus,10090.0,
4799,,,,,CHEMBL621038,B,BAO_0000357,,,8,17402,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,,,
4800,,,,T-cells,CHEMBL621039,F,BAO_0000219,,,0,11746,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),,Homo sapiens,9606.0,
4801,,,,T-cells,CHEMBL621040,F,BAO_0000219,,,0,11746,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,,Homo sapiens,9606.0,
4802,,,,A-375,CHEMBL621041,F,BAO_0000219,,,1,5455,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,,Homo sapiens,9606.0,
4803,,,,A-375,CHEMBL621042,F,BAO_0000219,,,1,2068,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,,Homo sapiens,9606.0,
4804,,,,A-375,CHEMBL621043,F,BAO_0000219,,,1,2683,In vitro antitumor activity against A375cell line extracted form melanoma,,Homo sapiens,9606.0,
4805,,,,A-375,CHEMBL621044,F,BAO_0000219,,,1,15313,Inhibition of cell growth in (A375) melan cell line,,Homo sapiens,9606.0,
4806,,,,A-375,CHEMBL621045,F,BAO_0000219,,,1,13739,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,,Homo sapiens,9606.0,
4807,,,,A-375,CHEMBL621046,F,BAO_0000219,,,1,13739,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,,Homo sapiens,9606.0,
4808,,,,A-375,CHEMBL621047,F,BAO_0000219,,,1,14750,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,,Homo sapiens,9606.0,
4809,,,,A-427,CHEMBL621048,F,BAO_0000219,,,1,14777,Antiproliferative activity measured against A427 human lung carcinoma,,Homo sapiens,9606.0,
4810,,,,A-427,CHEMBL883798,F,BAO_0000219,,,1,14777,Antiproliferative activity measured against A427 human lung carcinoma,,Homo sapiens,9606.0,
4811,,,,A-427,CHEMBL621049,F,BAO_0000219,,,1,17672,Cytotoxicity against lung carcinoma A427 tumor cell lines,,Homo sapiens,9606.0,
4812,,,,A-427,CHEMBL621050,F,BAO_0000219,,,1,14368,Inhibition of large cell lung carcinoma (A427),,Homo sapiens,9606.0,
4813,,,,A-427,CHEMBL621051,F,BAO_0000219,,,1,14368,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,,Homo sapiens,9606.0,
4814,,,,A-427,CHEMBL621052,F,BAO_0000219,,,1,13866,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,Homo sapiens,9606.0,
4815,,,,A-427,CHEMBL621053,F,BAO_0000219,,,1,2545,Inhibitory concentration in human lung carcinoma A427 cell line,,Homo sapiens,9606.0,
4816,,,,A-427,CHEMBL621054,F,BAO_0000219,,,1,2545,Inhibitory concentration in human lung carcinoma A427/VCR cell line,,Homo sapiens,9606.0,
4817,,,,,CHEMBL621055,A,BAO_0000218,,,0,6062,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,In vivo,Cercopithecidae,9527.0,
4818,,,,,CHEMBL876398,A,BAO_0000218,,,0,4578,Tested for volume of distribution upon iv administration to african green monkey,In vivo,Cercopithecidae,9527.0,
4819,,,,,CHEMBL621056,A,BAO_0000218,,,0,17592,Volume of distribution in monkey,In vivo,Cercopithecidae,9527.0,
4820,,,,,CHEMBL621057,A,BAO_0000218,,,0,5005,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,In vivo,Macaca mulatta,9544.0,
4821,,,,,CHEMBL621058,A,BAO_0000218,,,0,5005,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,In vivo,Macaca mulatta,9544.0,
4822,,,,,CHEMBL621059,A,BAO_0000218,,,0,5922,Pharmacokinetic property(Vdss) in cynomolgus monkey,In vivo,Cercopithecidae,9527.0,
4823,,,,,CHEMBL621060,A,BAO_0000218,,,0,5355,The distribution volume after intravenous administration in cynomolgus monkeys,In vivo,Cercopithecidae,9527.0,
4824,,,,,CHEMBL621061,A,BAO_0000218,,,0,5355,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,In vivo,Cercopithecidae,9527.0,
4825,,,,,CHEMBL621062,A,BAO_0000218,,,0,5355,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,In vivo,Cercopithecidae,9527.0,
4826,,,,,CHEMBL621063,A,BAO_0000218,,,0,6057,Volume displacement was calculated in rhesus monkey,In vivo,Cercopithecidae,9527.0,
4827,,,,,CHEMBL621064,A,BAO_0000218,,,0,5145,Volume of distribution in steady state was determined in rhesus monkey,In vivo,Cercopithecidae,9527.0,
4828,,,,,CHEMBL621065,A,BAO_0000218,,,0,6821,Volume of distribution of compound was determined in monkey,In vivo,Cercopithecidae,9527.0,
4829,,,,,CHEMBL621066,A,BAO_0000218,,,0,5334,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),In vivo,Cercopithecidae,9527.0,
4830,,,,,CHEMBL621067,A,BAO_0000218,,,0,5334,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),In vivo,Cercopithecidae,9527.0,
4831,,,,,CHEMBL621068,A,BAO_0000218,,,0,6641,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,Cercopithecidae,9527.0,
4832,,,,,CHEMBL876399,A,BAO_0000218,,,0,2661,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,In vivo,Cercopithecidae,9527.0,
4833,,,,,CHEMBL621069,A,BAO_0000218,,,0,6535,Volume distribution in monkey after administration of 1 mg/kg iv,In vivo,Cercopithecidae,9527.0,
4834,,,,,CHEMBL621070,A,BAO_0000218,,,0,4809,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),In vivo,Cercopithecidae,9527.0,
4835,,,,,CHEMBL621071,A,BAO_0000218,,,0,6062,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,In vivo,Cercopithecidae,9527.0,
4836,,,,,CHEMBL621072,A,BAO_0000218,,,0,3443,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,Cercopithecidae,9527.0,
4837,,,,,CHEMBL618209,A,BAO_0000218,,,0,4578,Oral systemic bioavailability upon iv administration to african green monkey,In vivo,Cercopithecidae,9527.0,
4838,,,,,CHEMBL618210,A,BAO_0000218,,,0,4809,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),In vivo,Cercopithecidae,9527.0,
4839,,,,,CHEMBL618211,A,BAO_0000019,,,0,11271,Baboon plasma free fraction. ,,Cercopithecidae,9527.0,
4840,,,,,CHEMBL618212,A,BAO_0000218,,,0,6057,Area under the curve was calculated in rhesus monkey after iv administration,,Cercopithecidae,9527.0,
4841,,,,,CHEMBL618213,A,BAO_0000019,,,0,6057,Area under the curve was calculated in rhesus monkey after peroral administration,,Cercopithecidae,9527.0,
4842,,,,,CHEMBL618214,A,BAO_0000019,,,0,17853,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,Cercopithecidae,9527.0,
4843,,,,,CHEMBL873492,A,BAO_0000218,,,0,5302,Half life period in monkey after 5 mg/kg dose,In vivo,Cercopithecidae,9527.0,
4844,,,,,CHEMBL618272,A,BAO_0000218,,,0,4257,Half-life was determined in monkey after 3 mg/kg of i.v. dose,In vivo,Cercopithecidae,9527.0,
4845,,,,,CHEMBL618273,A,BAO_0000218,,,0,4257,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,In vivo,Cercopithecidae,9527.0,
4846,Plasma,,,,CHEMBL618274,A,BAO_0000218,,,0,13501,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,In vivo,Cercopithecidae,9527.0,
4847,,,,,CHEMBL618275,A,BAO_0000218,,,0,5394,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,In vivo,Cercopithecidae,9527.0,
4848,,,,,CHEMBL618276,A,BAO_0000218,,,0,2661,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,In vivo,Cercopithecidae,9527.0,
4849,,,,,CHEMBL618277,A,BAO_0000019,,,0,3341,Compound was evaluated for terminal half life in monkey,,Cercopithecidae,9527.0,
4850,,,,,CHEMBL618278,A,BAO_0000218,,,0,3045,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,In vivo,Cercopithecidae,9527.0,
4851,Plasma,,,,CHEMBL618279,A,BAO_0000218,,,0,5005,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,In vivo,Macaca mulatta,9544.0,
4852,,,,,CHEMBL618280,A,BAO_0000019,,,0,4847,Half life of compound was determined in squirrel monkey,,Cercopithecidae,9527.0,
4853,,,,,CHEMBL618281,A,BAO_0000218,,,0,4256,Half life after iv administration in cynomolgus monkey,In vivo,Macaca fascicularis,9541.0,
4854,Plasma,,,,CHEMBL618282,A,BAO_0000218,,,0,6535,Half life in monkey plasma after administration of 1 mg/kg iv,In vivo,Cercopithecidae,9527.0,
4855,,,,,CHEMBL618283,A,BAO_0000019,,,0,6057,Half life was calculated in rhesus monkey,,Cercopithecidae,9527.0,
4856,,,,,CHEMBL618284,A,BAO_0000019,,,0,17592,Half life in monkey,,Cercopithecidae,9527.0,
4857,,,,,CHEMBL618285,A,BAO_0000218,,,0,6641,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,Cercopithecidae,9527.0,
4858,,,,,CHEMBL618286,A,BAO_0000019,,,0,5472,Half life was evaluated in rhesus,,Cercopithecidae,9527.0,
4859,,,,,CHEMBL618287,A,BAO_0000218,,,0,6221,Half life period after oral administration (2.5 mg/kg) in monkey was determined,In vivo,Cercopithecidae,9527.0,
4860,,,,,CHEMBL618288,A,BAO_0000218,,,0,5668,Half life period was determine after peroral administration at 10 mpk in Rhesus,In vivo,Cercopithecidae,9527.0,
4861,,,,,CHEMBL876393,A,BAO_0000218,,,0,4809,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),In vivo,Cercopithecidae,9527.0,
4862,,,,,CHEMBL618289,A,BAO_0000218,,,0,5546,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,In vivo,Cercopithecidae,9527.0,
4863,,,,,CHEMBL618290,A,BAO_0000218,,,0,5553,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,In vivo,Cercopithecidae,9527.0,
4864,,,,,CHEMBL618291,A,BAO_0000019,,,0,6078,Half-life was calculated in monkey,,Cercopithecidae,9527.0,
4865,,,,,CHEMBL618292,A,BAO_0000019,,,0,5147,Half-life in Squirrel monkey,,Cercopithecidae,9527.0,
4866,,,,,CHEMBL618293,A,BAO_0000019,,,0,5145,Half-life in rhesus monkey,,Cercopithecidae,9527.0,
4867,,,,,CHEMBL618294,A,BAO_0000218,,,0,6062,Half-life was measured in monkey after an iv dose of 1 mg/kg,In vivo,Cercopithecidae,9527.0,
4868,,,,,CHEMBL618295,A,BAO_0000218,,,0,5355,Half-life period after intravenous administration in cynomolgus monkeys,In vivo,Cercopithecidae,9527.0,
4869,,,,,CHEMBL618296,A,BAO_0000218,,,0,5355,Half-life period after oral administration in cynomolgus monkeys,In vivo,Cercopithecidae,9527.0,
4870,,,,,CHEMBL618297,A,BAO_0000218,,,0,5355,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,In vivo,Cercopithecidae,9527.0,
4871,Urine,,,,CHEMBL618298,A,BAO_0000019,,,0,7766,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,Homo sapiens,9606.0,
4872,Urine,,,,CHEMBL618299,A,BAO_0000019,,,0,7766,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,Homo sapiens,9606.0,
4873,Urine,,,,CHEMBL618300,A,BAO_0000019,,,0,7766,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,Homo sapiens,9606.0,
4874,Urine,,,,CHEMBL618301,A,BAO_0000019,,,0,7766,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,Homo sapiens,9606.0,
4875,Urine,,,,CHEMBL618302,A,BAO_0000019,,,0,7766,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,Homo sapiens,9606.0,
4876,Urine,,,,CHEMBL876394,A,BAO_0000019,,,0,7766,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,Homo sapiens,9606.0,
4877,Urine,,,,CHEMBL618303,A,BAO_0000019,,,0,7766,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,Homo sapiens,9606.0,
4878,Urine,,,,CHEMBL618304,A,BAO_0000019,,,0,7766,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,Homo sapiens,9606.0,
4879,,,,,CHEMBL618305,A,BAO_0000218,,,0,1916,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,In vivo,Homo sapiens,9606.0,
4880,,,,,CHEMBL618306,A,BAO_0000218,,,0,16643,Oral bioavailability in human,In vivo,Homo sapiens,9606.0,
4881,,,,,CHEMBL618307,A,BAO_0000019,,,0,17248,Compound was tested for human plasma protein binding,,Homo sapiens,9606.0,
4882,,,,,CHEMBL618308,A,BAO_0000019,,,0,17248,Compound was tested for human plasma protein binding; Not determined,,Homo sapiens,9606.0,
4883,,,,,CHEMBL618309,A,BAO_0000019,,,0,6241,Protein binding activity of compound in human plasma; % Free,,Homo sapiens,9606.0,
4884,,,,,CHEMBL618310,A,BAO_0000019,,,0,17716,Unbound fraction (plasma),,Homo sapiens,9606.0,
4885,Plasma,,,,CHEMBL873353,A,BAO_0000366,,,0,17605,Half life for the hydrolysis of compound in human blood serum,,Homo sapiens,9606.0,
4886,Plasma,,,,CHEMBL618311,A,BAO_0000366,,,0,17625,Half life period in human plasma using phosphate buffer (0.08 M),,Homo sapiens,9606.0,
4887,Plasma,,,,CHEMBL618312,A,BAO_0000366,,,0,17625,Half life period in human plasma using phosphate buffer (0.1 M),,Homo sapiens,9606.0,
4888,Plasma,,,,CHEMBL618313,A,BAO_0000366,,,0,17747,Half-life in human plasma was determined,,Homo sapiens,9606.0,
4889,,,,,CHEMBL618314,A,BAO_0000019,,,0,15613,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,Homo sapiens,9606.0,
4890,,,,,CHEMBL618315,A,BAO_0000019,,,0,354,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,Homo sapiens,9606.0,
4891,,,,,CHEMBL618316,A,BAO_0000019,,,0,3741,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,Homo sapiens,9606.0,
4892,,,,,CHEMBL618317,A,BAO_0000019,,,0,3741,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,Homo sapiens,9606.0,
4893,,,,,CHEMBL620138,A,BAO_0000019,,,0,3741,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,Homo sapiens,9606.0,
4894,,,,,CHEMBL858280,A,BAO_0000019,,,0,17599,Partition coefficient (logP),,Homo sapiens,9606.0,
4895,,,,,CHEMBL620139,A,BAO_0000019,,,0,5486,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,Homo sapiens,9606.0,
4896,,,,,CHEMBL620140,A,BAO_0000251,,,0,5600,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,,Homo sapiens,9606.0,Microsomes
4897,,,,,CHEMBL620141,A,BAO_0000019,,,0,14294,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,Homo sapiens,9606.0,
4898,,,,,CHEMBL620142,A,BAO_0000019,,,0,14294,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,Homo sapiens,9606.0,
4899,,,,,CHEMBL620143,A,BAO_0000019,,,0,14294,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,Homo sapiens,9606.0,
4900,,,,,CHEMBL620144,A,BAO_0000251,,,0,14294,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),,Homo sapiens,9606.0,Microsomes
4901,,,,,CHEMBL620145,A,BAO_0000251,,,0,14294,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),,Homo sapiens,9606.0,Microsomes
4902,,,,,CHEMBL620146,A,BAO_0000251,,,0,14294,Metabolism of compound in human microsomes; Trace,,Homo sapiens,9606.0,Microsomes
4903,Liver,,,,CHEMBL620147,A,BAO_0000251,,,0,6260,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,,Homo sapiens,9606.0,Microsomes
4904,,,,,CHEMBL620148,A,BAO_0000251,,,0,6187,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,,Homo sapiens,9606.0,Microsomes
4905,Liver,,,,CHEMBL620149,A,BAO_0000251,,,0,6251,In vitro metabolic potential in human liver microsomes,,Homo sapiens,9606.0,Microsomes
4906,,,,,CHEMBL876412,A,BAO_0000019,,,0,3246,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,Homo sapiens,9606.0,
4907,,,,,CHEMBL619352,A,BAO_0000019,,,0,17313,Tested for human plasma protein binding of the compound; Not tested,,Homo sapiens,9606.0,
4908,,,,,CHEMBL619353,A,BAO_0000019,,,0,6227,Compound was tested for percent protein binding (PB) in human,,Homo sapiens,9606.0,
4909,Plasma,,,,CHEMBL619354,A,BAO_0000019,,,0,5530,Protein binding in human plasma,,Homo sapiens,9606.0,
4910,,,,,CHEMBL619355,A,BAO_0000019,,,0,6108,Permeability coefficient (B to A) in Caco-2 cell,,Homo sapiens,9606.0,
4911,,,,,CHEMBL619356,A,BAO_0000019,,,0,6108,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,Homo sapiens,9606.0,
4912,,,,,CHEMBL619357,A,BAO_0000019,,,0,2774,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,Homo sapiens,9606.0,
4913,,,,,CHEMBL619358,A,BAO_0000019,,,0,16643,In vitro rate of absorption observed as Caco-2 permeability in humans,,Homo sapiens,9606.0,
4914,,,,Caco-2,CHEMBL619359,A,BAO_0000219,,,0,17582,Cellular permeability of compound was determined in Caco-2 cells; High,,Homo sapiens,9606.0,
4915,,,,Caco-2,CHEMBL619360,A,BAO_0000219,,,0,6838,Permeability in Caco-2 cells of compound,,Homo sapiens,9606.0,
4916,,,,,CHEMBL619361,A,BAO_0000019,,,0,6108,Permeability coefficient (A to B) in Caco-2 cell,,Homo sapiens,9606.0,
4917,,,,,CHEMBL619362,A,BAO_0000019,,,0,6108,Permeability coefficient (B to A) in Caco-2 cell,,Homo sapiens,9606.0,
4918,,,,,CHEMBL619363,A,BAO_0000019,,,0,6108,Permeability coefficient (Papp) (Caco-2 cell monolayer),,Homo sapiens,9606.0,
4919,,,,,CHEMBL618942,A,BAO_0000019,,,0,2146,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,Homo sapiens,9606.0,
4920,,,,,CHEMBL618943,A,BAO_0000019,,,0,4514,Compound was tested for protein binding in human plasma,,Homo sapiens,9606.0,
4921,,,,,CHEMBL618944,A,BAO_0000019,,,0,6108,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,Homo sapiens,9606.0,
4922,Urine,,,,CHEMBL618945,A,BAO_0000019,,,0,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,,Homo sapiens,9606.0,
4923,,,,,CHEMBL618946,A,BAO_0000218,,,1,5969,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,In vivo,Mus musculus,10090.0,
4924,,,,,CHEMBL876413,A,BAO_0000218,,,1,3277,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),In vivo,Mus musculus,10090.0,
4925,,,,,CHEMBL618947,A,BAO_0000218,,,1,3802,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,In vivo,Mus musculus,10090.0,
4926,Plasma,,,,CHEMBL618948,A,BAO_0000218,,,1,2862,Time taken to reach maximum concentration in plasma upon oral administration in mouse,In vivo,Mus musculus,10090.0,
4927,Plasma,,,,CHEMBL618949,A,BAO_0000218,,,1,6348,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,Mus musculus,10090.0,
4928,,,,,CHEMBL618950,F,BAO_0000218,,,1,17764,Tmax after intraperitoneal administration in mice at 23 uM/kg,In vivo,Mus musculus,10090.0,
4929,,,,,CHEMBL618951,A,BAO_0000218,,,1,5781,Tmax after oral administration at 30 mg/kg in ICR mouse,In vivo,Mus musculus,10090.0,
4930,,,,,CHEMBL618952,A,BAO_0000218,,,1,17764,Tmax after peroral administration in mice at 2.4 uM/kg,In vivo,Mus musculus,10090.0,
4931,,,,,CHEMBL618953,A,BAO_0000218,,,1,4066,Tmax at a single subcutaneous administration of 40 mg/kg in mice,In vivo,Mus musculus,10090.0,
4932,Brain,,,,CHEMBL618954,A,BAO_0000218,,,1,17641,Tmax in brain of mice at the oral dose of 50 mg/kg,In vivo,Mus musculus,10090.0,
4933,Kidney,,,,CHEMBL618955,A,BAO_0000218,,,1,17641,Tmax in kidney of mice at the oral dose of 50 mg/kg,In vivo,Mus musculus,10090.0,
4934,Liver,,,,CHEMBL618956,A,BAO_0000218,,,1,17641,Tmax in liver of mice at the oral dose of 50 mg/kg,In vivo,Mus musculus,10090.0,
4935,Lung,,,,CHEMBL618957,A,BAO_0000218,,,1,17641,Tmax in lungs of mice at the oral dose of 50 mg/kg,In vivo,Mus musculus,10090.0,
4936,,,,,CHEMBL618958,F,BAO_0000218,,,1,17764,Tmax in mice at 18 uM/kg i.p. administration,In vivo,Mus musculus,10090.0,
4937,,,,,CHEMBL618959,F,BAO_0000218,,,1,17764,Tmax in mice at 23 uM/kg i.v. administration,In vivo,Mus musculus,10090.0,
4938,,,,,CHEMBL618960,F,BAO_0000218,,,1,17764,Tmax in mice at 25 uM/kg i.p. administration,In vivo,Mus musculus,10090.0,
4939,,,,,CHEMBL876723,F,BAO_0000218,,,1,17764,Tmax in mice at 26 uM/kg i.p. administration,In vivo,Mus musculus,10090.0,
4940,Spleen,,,,CHEMBL618961,A,BAO_0000218,,,1,17641,Tmax in spleen of mice at the oral dose of 50 mg/kg,In vivo,Mus musculus,10090.0,
4941,,,,,CHEMBL618962,A,BAO_0000218,,,1,16597,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,In vivo,Mus musculus,10090.0,
4942,,,,,CHEMBL618963,A,BAO_0000218,,,1,16597,Tmax value at a dose of 10 mg/kg peroral administration in mice.,In vivo,Mus musculus,10090.0,
4943,,,,,CHEMBL618964,A,BAO_0000218,,,1,5951,Tmax value in IRC mice,,Mus musculus,10090.0,
4944,,,,,CHEMBL618965,A,BAO_0000218,,,1,5506,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,In vivo,Mus musculus,10090.0,
4945,,,,,CHEMBL618966,A,BAO_0000218,,,1,5506,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,In vivo,Mus musculus,10090.0,
4946,Urine,,,,CHEMBL618967,A,BAO_0000218,,,1,429,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),,Mus musculus,10090.0,
4947,Urine,,,,CHEMBL618968,A,BAO_0000218,,,1,429,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),,Mus musculus,10090.0,
4948,Urine,,,,CHEMBL618969,A,BAO_0000218,,,1,4066,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),,Mus musculus,10090.0,
4949,,,,,CHEMBL618970,A,BAO_0000218,,,1,17734,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,Mus musculus,10090.0,
4950,,,,,CHEMBL618971,A,BAO_0000218,,,1,17734,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,Mus musculus,10090.0,
4951,,,,,CHEMBL618972,A,BAO_0000218,,,1,6062,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,In vivo,Mus musculus,10090.0,
4952,,,,,CHEMBL618973,A,BAO_0000218,,,1,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,In vivo,Mus musculus,10090.0,
4953,,,,,CHEMBL618974,A,BAO_0000218,,,1,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,In vivo,Mus musculus,10090.0,
4954,,,,,CHEMBL618975,A,BAO_0000218,,,1,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,In vivo,Mus musculus,10090.0,
4955,,,,,CHEMBL618976,A,BAO_0000218,,,1,5980,Vd in mice,In vivo,Mus musculus,10090.0,
4956,,,,,CHEMBL618977,A,BAO_0000218,,,1,17592,Volume of distribution in mouse,In vivo,Mus musculus,10090.0,
4957,,,,,CHEMBL876724,A,BAO_0000218,,,1,6348,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,Mus musculus,10090.0,
4958,,,,,CHEMBL618978,A,BAO_0000218,,,1,17753,Volume of distribution of compound in plasma was determined at 24 mg/Kg,In vivo,Mus musculus,10090.0,
4959,,,,,CHEMBL618979,A,BAO_0000218,,,1,17753,Volume of distribution of compound in plasma was determined at 40 mg/Kg,In vivo,Mus musculus,10090.0,
4960,,,,,CHEMBL618980,A,BAO_0000218,,,1,17753,Volume of distribution of compound in plasma was determined at 5 mg/Kg,In vivo,Mus musculus,10090.0,
4961,,,,,CHEMBL618981,A,BAO_0000218,,,1,4239,Pharmacokinetic property (vdss) was measured in mouse,In vivo,Mus musculus,10090.0,
4962,,,,,CHEMBL618982,A,BAO_0000218,,,1,2862,Value distribution upon iv administration in mouse,In vivo,Mus musculus,10090.0,
4963,,,,,CHEMBL620150,A,BAO_0000218,,,1,17734,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,In vivo,Mus musculus,10090.0,
4964,,,,,CHEMBL620151,A,BAO_0000218,,,1,2675,Volume of distribution was evaluated in mice after intravenous administration,In vivo,Mus musculus,10090.0,
4965,,,,,CHEMBL620152,A,BAO_0000218,,,1,2675,Volume of distribution was evaluated in mice after oral administration,In vivo,Mus musculus,10090.0,
4966,,,,,CHEMBL620153,A,BAO_0000218,,,1,17837,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,In vivo,Mus musculus,10090.0,
4967,,,,,CHEMBL876395,A,BAO_0000218,,,1,5727,Steady state volume of distribution was determined in mice,In vivo,Mus musculus,10090.0,
4968,,,,,CHEMBL620154,A,BAO_0000218,,,1,17852,Volume distribution (steady state) of compound was determined in mouse,In vivo,Mus musculus,10090.0,
4969,,,,,CHEMBL620155,A,BAO_0000218,,,1,17764,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,In vivo,Mus musculus,10090.0,
4970,,,,,CHEMBL620156,A,BAO_0000218,,,1,16597,Vss value at a dose of 10 mg/kg intravenous administration in mice.,In vivo,Mus musculus,10090.0,
4971,,,,,CHEMBL620157,A,BAO_0000218,,,1,6062,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,In vivo,Mus musculus,10090.0,
4972,Kidney,,,,CHEMBL620158,A,BAO_0000218,,,1,16438,Biodistribution of compound (oxidized form) in in kidney tissue,In vivo,Mus musculus,10090.0,
4973,Blood,,,,CHEMBL620159,A,BAO_0000218,,,1,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,In vivo,Mus musculus,10090.0,
4974,Blood,,,,CHEMBL620160,A,BAO_0000218,,,1,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",In vivo,Mus musculus,10090.0,
4975,Blood,,,,CHEMBL620161,A,BAO_0000218,,,1,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,Mus musculus,10090.0,
4976,,,,A-427,CHEMBL620162,F,BAO_0000219,,,1,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,,Homo sapiens,9606.0,
4977,,,,A-431,CHEMBL620163,F,BAO_0000219,,,1,16597,Inhibition of A431 human squamous cell carcinoma cell proliferation,,Homo sapiens,9606.0,
4978,,,,A-431,CHEMBL620833,F,BAO_0000219,,,1,16062,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,,Homo sapiens,9606.0,
4979,,,,A-431,CHEMBL876396,F,BAO_0000219,,,1,16062,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,,Homo sapiens,9606.0,
4980,,,,A-431,CHEMBL620834,F,BAO_0000219,,,1,16958,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,,Homo sapiens,9606.0,
4981,,,,A-431,CHEMBL620835,F,BAO_0000219,,,1,6700,Inhibition of A431 human carcinoma cell proliferation,,Homo sapiens,9606.0,
4982,,,,A-431,CHEMBL620836,F,BAO_0000219,,,1,17226,In vitro inhibition of A431 (human carcinoma) cell basal growth.,,Homo sapiens,9606.0,
4983,,,,A-431,CHEMBL620837,F,BAO_0000219,,,1,6828,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,,Homo sapiens,9606.0,
4984,,,,A-431,CHEMBL621017,F,BAO_0000219,,,1,12314,In vitro cytotoxicity against epidermoid carcinoma cell line,,Homo sapiens,9606.0,
4985,,,,A-431,CHEMBL621018,F,BAO_0000218,,,9,13412,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",,Homo sapiens,9606.0,
4986,,,,A-431,CHEMBL621019,F,BAO_0000219,,,1,13299,Antiproliferative activity of compound was measured on human tumor cell line A431.,,Homo sapiens,9606.0,
4987,,,,A-431,CHEMBL621020,F,BAO_0000219,,,1,17420,Antiproliferative effect of compound on A431 cell line expressing mutant p53,,Homo sapiens,9606.0,
4988,,,,A-431,CHEMBL621021,F,BAO_0000219,,,1,13678,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,,Homo sapiens,9606.0,
4989,,,,A-431,CHEMBL621022,F,BAO_0000219,,,8,14171,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,,,
4990,,,,A-431,CHEMBL621023,F,BAO_0000219,,,1,6333,Tested for antiproliferative activity against human A431 cells,,Homo sapiens,9606.0,
4991,,,,A-431,CHEMBL621024,F,BAO_0000219,,,9,2356,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,,Homo sapiens,9606.0,
4992,,,,A-431,CHEMBL621025,F,BAO_0000219,,,1,15578,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,,Homo sapiens,9606.0,
4993,,,,A-431,CHEMBL621026,F,BAO_0000219,,,1,5126,Inhibition of A431 cell proliferation,,Homo sapiens,9606.0,
4994,,,,A-431,CHEMBL621027,F,BAO_0000219,,,1,6844,Cytotoxic effect on A431 human epidermoid carcinoma cells,,Homo sapiens,9606.0,
4995,,,,A-431,CHEMBL876397,F,BAO_0000219,,,1,6844,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),,Homo sapiens,9606.0,
4996,,,,A-431,CHEMBL883797,F,BAO_0000219,,,1,4925,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,,Homo sapiens,9606.0,
4997,,,,A-431,CHEMBL621028,F,BAO_0000219,,,1,4925,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,,Homo sapiens,9606.0,
4998,,,,A-431,CHEMBL621029,F,BAO_0000219,,,1,13978,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,,Homo sapiens,9606.0,
4999,,,,A-431,CHEMBL621030,F,BAO_0000219,,,1,16786,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,,Homo sapiens,9606.0,
5000,,,,A-431,CHEMBL621147,F,BAO_0000219,,,8,13412,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,,,
5001,,,,A-431,CHEMBL621148,F,BAO_0000218,,,1,17824,In vivo antiproliferative activity against A431 cell line,,Homo sapiens,9606.0,
5002,,,,A-431,CHEMBL621149,F,BAO_0000219,,,9,12751,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,,Homo sapiens,9606.0,
5003,,,,A-431,CHEMBL621150,F,BAO_0000219,,,1,12380,Inhibition of A431 human epidermoid carcinoma cell proliferation,,Homo sapiens,9606.0,
5004,,,,A-431,CHEMBL621151,F,BAO_0000219,,,9,4959,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,,Homo sapiens,9606.0,
5005,,,,A-431,CHEMBL621152,F,BAO_0000219,,,1,6333,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),,Homo sapiens,9606.0,
5006,,,,A-431,CHEMBL621153,F,BAO_0000219,,,1,6333,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),,Homo sapiens,9606.0,
5007,,,,A-431,CHEMBL884000,F,BAO_0000219,,,1,6333,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),,Homo sapiens,9606.0,
5008,,,,,CHEMBL621154,F,BAO_0000019,,,9,5296,Inhibition of EGFR overexpressing A431 cell proliferation,,Homo sapiens,9606.0,
5009,,,,A-431,CHEMBL621155,F,BAO_0000219,,,1,12624,Inhibition of A431 cell proliferation,,Homo sapiens,9606.0,
5010,,,,A-431,CHEMBL621156,F,BAO_0000219,,,9,14926,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,,Homo sapiens,9606.0,
5011,,,,A-431,CHEMBL621157,F,BAO_0000219,,,9,14926,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",,Homo sapiens,9606.0,
5012,,,,A-431,CHEMBL621158,F,BAO_0000219,,,8,14926,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,,,
5013,,,,A-431,CHEMBL621159,F,BAO_0000219,,,1,15144,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,Homo sapiens,9606.0,
5014,,,,A-431,CHEMBL621160,F,BAO_0000219,,,1,15144,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,Homo sapiens,9606.0,
5015,,,,A-431,CHEMBL621161,F,BAO_0000219,,,1,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,,Homo sapiens,9606.0,
5016,,,,A-431,CHEMBL621162,F,BAO_0000219,,,1,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,,Homo sapiens,9606.0,
5017,,,,A-431,CHEMBL621163,F,BAO_0000219,,,1,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,Homo sapiens,9606.0,
5018,,,,A-431,CHEMBL621164,F,BAO_0000219,,,1,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,,Homo sapiens,9606.0,
5019,,,,A-431,CHEMBL621165,F,BAO_0000219,,,1,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,,Homo sapiens,9606.0,
5020,,,,,CHEMBL619159,A,BAO_0000019,,,0,5922,Half-life period in cynomolgus monkey,,Cercopithecidae,9527.0,
5021,Plasma,,,,CHEMBL619160,A,BAO_0000366,,,0,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",In vitro,Cercopithecidae,9527.0,
5022,,,,,CHEMBL619161,A,BAO_0000218,,,0,17853,Longer half-life in monkey (i.v.) at 0.5 mpk,In vivo,Cercopithecidae,9527.0,
5023,Plasma,,,,CHEMBL619162,A,BAO_0000366,,,0,993,Plasma half life in monkey,,Cercopithecidae,9527.0,
5024,Plasma,,,,CHEMBL619163,A,BAO_0000366,,,0,4514,Plasma half-life in rhesus monkey,,Cercopithecidae,9527.0,
5025,Plasma,,,,CHEMBL619164,A,BAO_0000218,,,0,5334,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),In vivo,Cercopithecidae,9527.0,
5026,Plasma,,,,CHEMBL619320,A,BAO_0000218,,,0,5334,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),In vivo,Cercopithecidae,9527.0,
5027,,,,,CHEMBL619321,A,BAO_0000218,,,0,4578,Tested for half life upon iv administration to african green monkey,In vivo,Cercopithecidae,9527.0,
5028,,,,,CHEMBL873336,A,BAO_0000218,,,0,2661,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,In vivo,Cercopithecidae,9527.0,
5029,,,,,CHEMBL619322,A,BAO_0000218,,,0,5355,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,In vivo,Cercopithecidae,9527.0,
5030,,,,,CHEMBL619323,A,BAO_0000218,,,0,5355,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,In vivo,Cercopithecidae,9527.0,
5031,,,,,CHEMBL619324,A,BAO_0000218,,,0,5355,The time for peak concentration value after oral administration in cynomolgus monkeys,In vivo,Cercopithecidae,9527.0,
5032,,,,,CHEMBL619325,A,BAO_0000019,,,0,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,Cercopithecidae,9527.0,
5033,,,,,CHEMBL876411,A,BAO_0000019,,,0,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,Cercopithecidae,9527.0,
5034,,,,,CHEMBL619326,A,BAO_0000019,,,0,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,Cercopithecidae,9527.0,
5035,,,,,CHEMBL619327,A,BAO_0000019,,,0,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,Cercopithecidae,9527.0,
5036,,,,,CHEMBL619328,A,BAO_0000019,,,0,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,Cercopithecidae,9527.0,
5037,,,,,CHEMBL619329,A,BAO_0000019,,,0,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,Cercopithecidae,9527.0,
5038,,,,,CHEMBL619330,A,BAO_0000019,,,0,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,Cercopithecidae,9527.0,
5039,,,,,CHEMBL619331,A,BAO_0000019,,,0,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,Cercopithecidae,9527.0,
5040,,,,,CHEMBL619332,A,BAO_0000019,,,0,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,Cercopithecidae,9527.0,
5041,,,,,CHEMBL619333,A,BAO_0000019,,,0,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,Cercopithecidae,9527.0,
5042,,,,,CHEMBL619334,A,BAO_0000019,,,0,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,Cercopithecidae,9527.0,
5043,,,,,CHEMBL619335,A,BAO_0000019,,,0,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,Cercopithecidae,9527.0,
5044,,,,,CHEMBL619336,A,BAO_0000019,,,0,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,Cercopithecidae,9527.0,
5045,,,,,CHEMBL619337,A,BAO_0000019,,,0,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,Cercopithecidae,9527.0,
5046,,,,,CHEMBL619338,A,BAO_0000019,,,0,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,Cercopithecidae,9527.0,
5047,,,,,CHEMBL619339,A,BAO_0000019,,,0,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,Cercopithecidae,9527.0,
5048,,,,,CHEMBL619340,A,BAO_0000218,,,1,5809,Bioavailability in rat (cannulated) (dose 2 mg/kg),In vivo,Rattus norvegicus,10116.0,
5049,Plasma,,,,CHEMBL873496,A,BAO_0000218,,,1,17720,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,In vivo,Rattus norvegicus,10116.0,
5050,Plasma,,,,CHEMBL619341,A,BAO_0000218,,,1,3546,AUC value in rat after IV administration at a dose of 10 mg/kg,,Rattus norvegicus,10116.0,
5051,Plasma,,,,CHEMBL619342,A,BAO_0000218,,,1,3546,AUC value in rat after oral administration at a dose of 10 mg/kg,,Rattus norvegicus,10116.0,
5052,,,,,CHEMBL619343,A,BAO_0000218,,,1,3546,Cmax value in rat after oral administration at a dose of 10 mg/kg,In vivo,Rattus norvegicus,10116.0,
5053,,,,,CHEMBL619344,A,BAO_0000218,,,1,3546,Bioavailability in rat after oral administration at a dose of 10 mg/kg,In vivo,Rattus norvegicus,10116.0,
5054,,,,,CHEMBL619345,A,BAO_0000218,,,1,3546,Tmax value in rat after oral administration at a dose of 10 mg/kg,In vivo,Rattus norvegicus,10116.0,
5055,,,,,CHEMBL619346,A,BAO_0000218,,,1,3546,Vc value in rat after IV administration at a dose of 10 mg/kg,,Rattus norvegicus,10116.0,
5056,,,,,CHEMBL619347,A,BAO_0000218,,,1,3546,Half life period in rat after IV administration at a dose of 10 mg/kg,In vivo,Rattus norvegicus,10116.0,
5057,,,,,CHEMBL619348,A,BAO_0000019,,,0,10625,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,Papio hamadryas,9557.0,
5058,,,,,CHEMBL619349,A,BAO_0000019,,,0,10625,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,Papio hamadryas,9557.0,
5059,,,,,CHEMBL619350,A,BAO_0000019,,,0,10625,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,Papio hamadryas,9557.0,
5060,,,,,CHEMBL619351,A,BAO_0000019,,,0,10625,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,Papio hamadryas,9557.0,
5061,,,,,CHEMBL875953,A,BAO_0000019,,,0,10625,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,Papio hamadryas,9557.0,
5062,,,,,CHEMBL621716,A,BAO_0000019,,,0,10625,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,Papio hamadryas,9557.0,
5063,,,,,CHEMBL621717,A,BAO_0000019,,,0,10625,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,Papio hamadryas,9557.0,
5064,,,,,CHEMBL621718,A,BAO_0000019,,,0,10625,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,Papio hamadryas,9557.0,
5065,,,,,CHEMBL621719,A,BAO_0000019,,,0,3510,Area under curve after 1 mpk peroral administration to beagles,,beagle,9615.0,
5066,,,,,CHEMBL621720,A,BAO_0000019,,,0,3510,Area under curve after 2 mpk peroral administration to beagles,,beagle,9615.0,
5067,,,,,CHEMBL621721,A,BAO_0000218,,,0,3510,Cmax value after 1 mpk peroral administration to beagles,In vivo,beagle,9615.0,
5068,Urine,,,,CHEMBL621722,A,BAO_0000019,,,0,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,,Homo sapiens,9606.0,
5069,Urine,,,,CHEMBL621723,A,BAO_0000019,,,0,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,,Homo sapiens,9606.0,
5070,Urine,,,,CHEMBL621724,A,BAO_0000019,,,0,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,,Homo sapiens,9606.0,
5071,Urine,,,,CHEMBL623443,A,BAO_0000019,,,0,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,,Homo sapiens,9606.0,
5072,Urine,,,,CHEMBL623444,A,BAO_0000019,,,0,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,,Homo sapiens,9606.0,
5073,Urine,,,,CHEMBL623445,A,BAO_0000019,,,0,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,,Homo sapiens,9606.0,
5074,Urine,,,,CHEMBL623446,A,BAO_0000019,,,0,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,,Homo sapiens,9606.0,
5075,Liver,,,,CHEMBL623447,A,BAO_0000251,,,0,16643,Metabolic stability observed at 30 min after administration in human liver microsomes,,Homo sapiens,9606.0,Microsomes
5076,,,,,CHEMBL623448,A,BAO_0000019,,,0,6852,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,Homo sapiens,9606.0,
5077,,,,,CHEMBL623449,A,BAO_0000019,,,0,6852,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,Homo sapiens,9606.0,
5078,,,,,CHEMBL623450,A,BAO_0000019,,,0,6852,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,Homo sapiens,9606.0,
5079,Liver,,,,CHEMBL623451,A,BAO_0000251,,,0,6567,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",,Homo sapiens,9606.0,Microsomes
5080,,,,,CHEMBL623452,A,BAO_0000019,,,0,6570,Metabolic stability (% remaining at 30 mins) in human S9.,,Homo sapiens,9606.0,
5081,,,,,CHEMBL623453,A,BAO_0000019,,,0,6570,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,Homo sapiens,9606.0,
5082,Liver,,,,CHEMBL623454,A,BAO_0000251,,,0,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes,,Homo sapiens,9606.0,Microsomes
5083,Liver,,,,CHEMBL623455,A,BAO_0000251,,,0,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,,Homo sapiens,9606.0,Microsomes
5084,Liver,,,,CHEMBL624371,A,BAO_0000251,,,0,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,,Homo sapiens,9606.0,Microsomes
5085,,,,,CHEMBL624372,A,BAO_0000218,,,0,5202,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,Homo sapiens,9606.0,
5086,,,,,CHEMBL624373,A,BAO_0000019,,,0,5481,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,Homo sapiens,9606.0,
5087,,,,,CHEMBL624374,A,BAO_0000019,,,0,5481,Percent remaining in human plasma after incubation for 60 min at 37 C.,,Homo sapiens,9606.0,
5088,,,,,CHEMBL624556,A,BAO_0000019,,,0,3956,The percent remaining in human plasma after 30 min was determined,,Homo sapiens,9606.0,
5089,Plasma,,,,CHEMBL624557,A,BAO_0000366,,,0,5074,Conversion rate of the prodrug in human plasma,,Homo sapiens,9606.0,
5090,Plasma,,,,CHEMBL624558,A,BAO_0000366,,,0,5074,Conversion rate of the prodrug in human plasma; ND means no data,,Homo sapiens,9606.0,
5091,Blood,,,,CHEMBL624559,A,BAO_0000221,,,0,4727,Half life of compound was determined in human blood,,Homo sapiens,9606.0,
5092,,,,,CHEMBL624560,A,BAO_0000019,,,0,5965,Half life of compound was determined in man with once daily dosing,,Homo sapiens,9606.0,
5093,,,,,CHEMBL624561,A,BAO_0000251,,,0,5732,Half life in human microsomes,In vitro,Homo sapiens,9606.0,Microsomes
5094,Plasma,,,,CHEMBL624562,A,BAO_0000366,,,0,5819,Half life in human plasma,,Homo sapiens,9606.0,
5095,Plasma,,,,CHEMBL624563,A,BAO_0000366,,,0,5819,Half life in human plasma; Not detected,,Homo sapiens,9606.0,
5096,,,,,CHEMBL624564,A,BAO_0000218,,,0,1916,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,In vivo,Homo sapiens,9606.0,
5097,Liver,,,,CHEMBL624565,A,BAO_0000251,,,0,6597,Half-life for oxidative metabolic stability was determined using rat liver microsomes,In vitro,Homo sapiens,9606.0,Microsomes
5098,Plasma,,,,CHEMBL875152,A,BAO_0000366,,,0,5229,Half-life in human plasma,,Homo sapiens,9606.0,
5099,Plasma,,,,CHEMBL624566,A,BAO_0000366,,,0,5229,Half-life of the parent prodrug in plasma,,Homo sapiens,9606.0,
5100,Plasma,,,,CHEMBL873805,A,BAO_0000366,,,0,2192,In vitro half life in human plasma was determined,In vitro,Homo sapiens,9606.0,
5101,Liver,,,,CHEMBL624567,A,BAO_0000251,,,0,3032,The compound was tested In Vitro for half life in human liver microsomes.,In vitro,Homo sapiens,9606.0,Microsomes
5102,,,,,CHEMBL624568,A,BAO_0000218,,,0,1916,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,In vivo,Homo sapiens,9606.0,
5103,,,,,CHEMBL624569,A,BAO_0000218,,,0,17716,Observed volume of distribution,In vivo,Homo sapiens,9606.0,
5104,,,,,CHEMBL624570,A,BAO_0000218,,,0,15778,Oral bioavailability in human,In vivo,Homo sapiens,9606.0,
5105,,,,,CHEMBL624571,A,BAO_0000019,,,0,17313,Tested for human plasma protein binding of the compound,,Homo sapiens,9606.0,
5106,,,,,CHEMBL624572,A,BAO_0000019,,,0,4231,"First order rate constant, k was determined in human plasma",,Homo sapiens,9606.0,
5107,,,,,CHEMBL624573,A,BAO_0000019,,,0,4755,Observed rate constant in 80% human plasma at 37 degree Centigrade,,Homo sapiens,9606.0,
5108,,,,,CHEMBL875153,A,BAO_0000019,,,0,4755,Observed rate constant in 80% human plasma at 37 degree Centigrade,,Homo sapiens,9606.0,
5109,Liver,,,,CHEMBL624574,A,BAO_0000251,,,0,16907,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,Homo sapiens,9606.0,Microsomes
5110,,,,,CHEMBL624575,A,BAO_0000019,,,0,10839,The compound was tested for the plasma binding in human,,Homo sapiens,9606.0,
5111,,,,,CHEMBL624576,A,BAO_0000019,,,0,10839,Plasma protein binding (human),,Homo sapiens,9606.0,
5112,Liver,,,,CHEMBL624577,A,BAO_0000251,,,0,3199,Compound was evaluated for half-life in human liver microsomes,In vitro,Homo sapiens,9606.0,Microsomes
5113,Blood,,,,CHEMBL624578,A,BAO_0000221,,,0,1345,Half life measured in vitro for its stability in human blood,In vitro,Homo sapiens,9606.0,
5114,Serum,,,,CHEMBL622796,A,BAO_0000019,,,0,4297,Half life in human serum,,Homo sapiens,9606.0,
5115,Serum,,,,CHEMBL622797,A,BAO_0000019,,,0,4297,Half life in human serum; ND=not determined,,Homo sapiens,9606.0,
5116,,,,,CHEMBL622798,A,BAO_0000019,,,0,4297,Half life were determined in CEM-SS cell extract in decomposition step 1,,Homo sapiens,9606.0,
5117,,,,,CHEMBL622799,A,BAO_0000019,,,0,4297,Half life were determined in CEM-SS cell extract in decomposition step 2,,Homo sapiens,9606.0,
5118,Plasma,,,,CHEMBL622800,A,BAO_0000366,,,0,4231,Half life of the in human plasma,,Homo sapiens,9606.0,
5119,,,,,CHEMBL622801,A,BAO_0000220,,,0,5633,Half life period in human hepatic S9 fraction was determined,In vitro,Homo sapiens,9606.0,S9
5120,Liver,,,,CHEMBL622802,A,BAO_0000251,,,0,5633,Half life period in human liver microsome was determined,In vitro,Homo sapiens,9606.0,Microsomes
5121,,,,,CHEMBL622803,A,BAO_0000019,,,0,17791,Half life period was determined; 6-7,,Homo sapiens,9606.0,
5122,,,,,CHEMBL875154,A,BAO_0000019,,,0,17791,Half life period was evaluated in human,,Homo sapiens,9606.0,
5123,Plasma,,,,CHEMBL622804,A,BAO_0000366,,,0,3160,Half life time in human plasma,,Homo sapiens,9606.0,
5124,Brain,,,,CHEMBL622805,A,BAO_0000218,,,1,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,Mus musculus,10090.0,
5125,Heart,,,,CHEMBL622611,A,BAO_0000218,,,1,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,Mus musculus,10090.0,
5126,Heart,,,,CHEMBL622612,A,BAO_0000218,,,1,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,Mus musculus,10090.0,
5127,Kidney,,,,CHEMBL875160,A,BAO_0000218,,,1,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,Mus musculus,10090.0,
5128,Kidney,,,,CHEMBL622613,A,BAO_0000218,,,1,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",In vivo,Mus musculus,10090.0,
5129,Kidney,,,,CHEMBL622614,A,BAO_0000218,,,1,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,Mus musculus,10090.0,
5130,Liver,,,,CHEMBL622615,A,BAO_0000218,,,1,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,Mus musculus,10090.0,
5131,Liver,,,,CHEMBL622616,A,BAO_0000218,,,1,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,In vivo,Mus musculus,10090.0,
5132,Liver,,,,CHEMBL622617,A,BAO_0000218,,,1,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,Mus musculus,10090.0,
5133,Spleen,,,,CHEMBL622618,A,BAO_0000218,,,1,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,In vivo,Mus musculus,10090.0,
5134,Spleen,,,,CHEMBL622619,A,BAO_0000218,,,1,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",In vivo,Mus musculus,10090.0,
5135,Spleen,,,,CHEMBL622620,A,BAO_0000218,,,1,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,Mus musculus,10090.0,
5136,Brain,,,,CHEMBL622621,A,BAO_0000218,,,1,16438,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,Mus musculus,10090.0,
5137,Blood,,,,CHEMBL622622,A,BAO_0000218,,,1,16438,Biodistribution of compound (oxidized form) in blood tissue,In vivo,Mus musculus,10090.0,
5138,Blood,,,,CHEMBL622623,A,BAO_0000218,,,1,16438,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,Mus musculus,10090.0,
5139,Blood,,,,CHEMBL622624,A,BAO_0000218,,,1,16438,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",In vivo,Mus musculus,10090.0,
5140,Blood,,,,CHEMBL622625,A,BAO_0000218,,,1,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,Mus musculus,10090.0,
5141,Blood,,,,CHEMBL622626,A,BAO_0000218,,,1,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,Mus musculus,10090.0,
5142,Blood,,,,CHEMBL622627,A,BAO_0000218,,,1,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,Mus musculus,10090.0,
5143,Brain,,,,CHEMBL622628,A,BAO_0000218,,,1,16438,Biodistribution of compound (oxidized form) in brain tissue of mice,In vivo,Mus musculus,10090.0,
5144,Brain,,,,CHEMBL622629,A,BAO_0000218,,,1,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,Mus musculus,10090.0,
5145,Brain,,,,CHEMBL622630,A,BAO_0000218,,,1,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,Mus musculus,10090.0,
5146,Brain,,,,CHEMBL622631,A,BAO_0000218,,,1,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,Mus musculus,10090.0,
5147,Brain,,,,CHEMBL622632,A,BAO_0000218,,,1,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,Mus musculus,10090.0,
5148,Brain,,,,CHEMBL622633,A,BAO_0000218,,,1,16438,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",In vivo,Mus musculus,10090.0,
5149,Heart,,,,CHEMBL622634,A,BAO_0000218,,,1,16438,Biodistribution of compound (oxidized form) in heart tissue of mice,In vivo,Mus musculus,10090.0,
5150,Heart,,,,CHEMBL622635,A,BAO_0000218,,,1,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,Mus musculus,10090.0,
5151,Heart,,,,CHEMBL875161,A,BAO_0000218,,,1,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,Mus musculus,10090.0,
5152,Heart,,,,CHEMBL622636,A,BAO_0000218,,,1,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,Mus musculus,10090.0,
5153,Heart,,,,CHEMBL623335,A,BAO_0000218,,,1,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,Mus musculus,10090.0,
5154,Heart,,,,CHEMBL623336,A,BAO_0000218,,,1,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,Mus musculus,10090.0,
5155,Kidney,,,,CHEMBL623337,A,BAO_0000218,,,1,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,Mus musculus,10090.0,
5156,Kidney,,,,CHEMBL623338,A,BAO_0000218,,,1,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",In vivo,Mus musculus,10090.0,
5157,Kidney,,,,CHEMBL623339,A,BAO_0000218,,,1,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,Mus musculus,10090.0,
5158,Kidney,,,,CHEMBL623524,A,BAO_0000218,,,1,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,Mus musculus,10090.0,
5159,Kidney,,,,CHEMBL623525,A,BAO_0000218,,,1,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,Mus musculus,10090.0,
5160,Liver,,,,CHEMBL623526,A,BAO_0000218,,,1,16438,Biodistribution of compound (oxidized form) in liver tissue,In vivo,Mus musculus,10090.0,
5161,Liver,,,,CHEMBL623527,A,BAO_0000218,,,1,16438,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,Mus musculus,10090.0,
5162,Liver,,,,CHEMBL623528,A,BAO_0000218,,,1,16438,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,Mus musculus,10090.0,
5163,,,,A-431,CHEMBL624615,F,BAO_0000219,,,1,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,,Homo sapiens,9606.0,
5164,,,,A-431,CHEMBL621672,F,BAO_0000219,,,1,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,Homo sapiens,9606.0,
5165,,,,A-431,CHEMBL621673,F,BAO_0000218,,,1,16289,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,,,
5166,,,,A-431,CHEMBL621674,F,BAO_0000218,,,1,16289,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,,,
5167,,,,A-431,CHEMBL884002,F,BAO_0000219,,,9,16093,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,Homo sapiens,9606.0,
5168,,,,A-431,CHEMBL621850,F,BAO_0000219,,,1,16825,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",,Homo sapiens,9606.0,
5169,,,,A-431,CHEMBL621851,F,BAO_0000219,,,1,4848,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,,Homo sapiens,9606.0,
5170,,,,A-431,CHEMBL621852,F,BAO_0000219,,,9,14827,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,,Homo sapiens,9606.0,
5171,,,,A-431,CHEMBL621853,F,BAO_0000219,,,9,14827,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,,Homo sapiens,9606.0,
5172,,,,A-431,CHEMBL621854,F,BAO_0000218,,,1,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,,,
5173,,,,A-431,CHEMBL621855,F,BAO_0000218,,,1,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,,,
5174,,,,A-431,CHEMBL623724,F,BAO_0000218,,,1,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,,,
5175,,,,A-431,CHEMBL623725,F,BAO_0000218,,,1,16289,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,,,
5176,,,,A-431,CHEMBL623726,F,BAO_0000218,,,1,16289,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,,,
5177,,,,A-431,CHEMBL623727,F,BAO_0000219,,,9,16289,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",,Homo sapiens,9606.0,
5178,,,,A-431,CHEMBL623728,F,BAO_0000219,,,8,16289,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,,,
5179,,,,A-431,CHEMBL623729,F,BAO_0000218,,,1,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,,,
5180,,,,A-431,CHEMBL623730,F,BAO_0000218,,,1,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,,,
5181,,,,A-431,CHEMBL623731,F,BAO_0000218,,,1,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,,,
5182,,,,A-431,CHEMBL623732,F,BAO_0000218,,,1,14555,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",,Mus musculus,10090.0,
5183,,,,A-431,CHEMBL623733,F,BAO_0000218,,,1,14555,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",,Mus musculus,10090.0,
5184,,,,A-431,CHEMBL623734,F,BAO_0000218,,,1,14555,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,Mus musculus,10090.0,
5185,,,,A-431,CHEMBL623735,F,BAO_0000218,,,1,14555,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,Mus musculus,10090.0,
5186,,,,A-431,CHEMBL623736,F,BAO_0000219,,,1,1937,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,,Homo sapiens,9606.0,
5187,,,,A-431,CHEMBL623737,F,BAO_0000219,,,1,13739,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,,Homo sapiens,9606.0,
5188,,,,A-431,CHEMBL623738,F,BAO_0000219,,,1,3558,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,,Homo sapiens,9606.0,
5189,,,,A-431,CHEMBL875168,F,BAO_0000219,,,1,3558,Dose giving a 50% decrease in the living cell number (A437 cells),,Homo sapiens,9606.0,
5190,,,,A549,CHEMBL623739,F,BAO_0000219,,,1,17686,In vitro inhibitory concentration against proliferation of A459 cell line.,,Homo sapiens,9606.0,
5191,,,,A549,CHEMBL623740,F,BAO_0000219,,,1,5305,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,,Homo sapiens,9606.0,
5192,,,,A549,CHEMBL624424,F,BAO_0000219,,,1,3614,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,,Homo sapiens,9606.0,
5193,,,,A498,CHEMBL624425,F,BAO_0000219,,,1,17229,In vitro antitumor activity against renal A498 tumor cell lines,,Homo sapiens,9606.0,
5194,,,,A498,CHEMBL624426,F,BAO_0000219,,,1,15935,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",,Homo sapiens,9606.0,
5195,,,,A498,CHEMBL624427,F,BAO_0000219,,,1,15935,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",,Homo sapiens,9606.0,
5196,,,,A498,CHEMBL624428,F,BAO_0000219,,,1,15560,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,,Homo sapiens,9606.0,
5197,,,,A498,CHEMBL624429,F,BAO_0000219,,,1,13891,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,,Homo sapiens,9606.0,
5198,,,,A498,CHEMBL624620,F,BAO_0000219,,,1,13891,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,,Homo sapiens,9606.0,
5199,,,,A498,CHEMBL624621,F,BAO_0000219,,,1,13788,Cytotoxicity on kidney carcinoma (A-498) cell line,,Homo sapiens,9606.0,
5200,,,,A498,CHEMBL624622,F,BAO_0000219,,,1,15403,Compound was evaluated against Human cell line renal A498,,Homo sapiens,9606.0,
5201,,,,A498,CHEMBL624623,F,BAO_0000219,,,1,1009,Compound was tested for inhibition of A498 human renal cancer cell line,,Homo sapiens,9606.0,
5202,,,,A498,CHEMBL874365,F,BAO_0000219,,,1,1043,Growth inhibitory activity against A498 human cancer cell line,,Homo sapiens,9606.0,
5203,,,,A498,CHEMBL624624,F,BAO_0000219,,,1,5858,In vitro antitumor activity against human renal A498 cell line,,Homo sapiens,9606.0,
5204,,,,A498,CHEMBL624625,F,BAO_0000219,,,1,5958,In vitro cytotoxic activity against renal (A498) cell line,,Homo sapiens,9606.0,
5205,,,,A498,CHEMBL624626,F,BAO_0000219,,,1,5506,In vitro cytotoxic activity against human renal cancer (A498) cell line,,Homo sapiens,9606.0,
5206,,,,A498,CHEMBL624627,F,BAO_0000219,,,1,12781,Tested for cytostatic activity against renal A498 cell line,,Homo sapiens,9606.0,
5207,,,,A498,CHEMBL883157,F,BAO_0000219,,,1,14399,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,,Homo sapiens,9606.0,
5208,,,,A498,CHEMBL624628,F,BAO_0000219,,,1,5958,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,,Homo sapiens,9606.0,
5209,,,,,CHEMBL624629,A,BAO_0000218,,,0,3510,Cmax value after 2 mpk peroral administration to beagles,In vivo,beagle,9615.0,
5210,,,,,CHEMBL623551,A,BAO_0000218,beagle,,0,3510,Bioavailability,In vivo,Canis lupus familiaris,9615.0,
5211,,,,,CHEMBL623552,A,BAO_0000218,beagle,,0,3510,Bioavailability after 1 mpk peroral administration to beagles,In vivo,Canis lupus familiaris,9615.0,
5212,,,,,CHEMBL623553,A,BAO_0000218,beagle,,0,3510,Bioavailability after 2 mpk peroral administration to beagles,In vivo,Canis lupus familiaris,9615.0,
5213,,,,,CHEMBL623554,A,BAO_0000019,,,0,3085,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,Bos taurus,9913.0,
5214,,,,,CHEMBL623555,A,BAO_0000019,,,0,3085,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,Bos taurus,9913.0,
5215,,,,,CHEMBL623556,A,BAO_0000019,,,0,3085,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,Bos taurus,9913.0,
5216,,,,,CHEMBL623557,A,BAO_0000019,,,0,9372,Solubility against bovine alpha-chymotrypsin,,Bos taurus,9913.0,
5217,,,,,CHEMBL623558,A,BAO_0000019,,,0,3085,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,Bos taurus,9913.0,
5218,,,,,CHEMBL623559,A,BAO_0000019,,,0,3085,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,Bos taurus,9913.0,
5219,Spleen,,,,CHEMBL623560,A,BAO_0000221,,,0,1469,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,,Bos taurus,9913.0,
5220,,,,,CHEMBL623561,A,BAO_0000019,,,0,4297,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,Bos taurus,9913.0,
5221,,,,,CHEMBL623562,A,BAO_0000019,,,0,4297,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,Bos taurus,9913.0,
5222,,,,,CHEMBL623563,A,BAO_0000019,,,0,17585,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,Bos taurus,9913.0,
5223,Spleen,,,,CHEMBL623564,A,BAO_0000221,,,0,1336,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,,Bos taurus,9913.0,
5224,,,,,CHEMBL873806,A,BAO_0000019,,,0,3085,Half life in presence of 2 mg/mL BSA at pH 8.8,,Bos taurus,9913.0,
5225,,,,,CHEMBL623565,A,BAO_0000019,,,0,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,Bos taurus,9913.0,
5226,,,,,CHEMBL623566,A,BAO_0000019,,,0,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,Bos taurus,9913.0,
5227,,,,,CHEMBL623567,A,BAO_0000019,,,0,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,Bos taurus,9913.0,
5228,,,,,CHEMBL623568,A,BAO_0000019,,,0,1540,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,Bos taurus,9913.0,
5229,Plasma,,,,CHEMBL623569,A,BAO_0000218,,,1,6316,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,,Canis lupus familiaris,9615.0,
5230,Plasma,,,,CHEMBL623570,A,BAO_0000218,,,1,17594,AUC after administration at 100 mg/kg/day in dogs,,Canis lupus familiaris,9615.0,
5231,Plasma,,,,CHEMBL624254,A,BAO_0000218,,,1,4953,AUC in dog at 0-24 hr by peroral administration at 3 mpk,,Canis lupus familiaris,9615.0,
5232,Plasma,,,,CHEMBL624255,A,BAO_0000218,,,1,16907,AUC value after 15 mg/kg iv dose in Dogs,,Canis lupus familiaris,9615.0,
5233,Plasma,,,,CHEMBL624256,A,BAO_0000218,,,1,16907,AUC value after 30 mg/kg po dose in Dogs,,Canis lupus familiaris,9615.0,
5234,Plasma,,,,CHEMBL624257,A,BAO_0000218,,,1,2959,AUC value after administration of 4 mg/Kg oral dose in dog,,Canis lupus familiaris,9615.0,
5235,Plasma,,,,CHEMBL624258,A,BAO_0000218,,,1,17594,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,,Canis lupus familiaris,9615.0,
5236,,,,,CHEMBL875277,A,BAO_0000218,,,1,5356,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,Canis lupus familiaris,9615.0,
5237,,,,,CHEMBL622667,A,BAO_0000218,,,1,16807,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,Canis lupus familiaris,9615.0,
5238,,,,,CHEMBL622668,A,BAO_0000218,,,1,4527,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,Canis lupus familiaris,9615.0,
5239,,,,,CHEMBL622669,A,BAO_0000218,,,1,4527,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,Canis lupus familiaris,9615.0,
5240,,,,,CHEMBL622670,A,BAO_0000218,,,1,15660,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,Canis lupus familiaris,9615.0,
5241,,,,,CHEMBL622671,A,BAO_0000218,,,1,15660,Area under curve determined in dogs after oral administration of 10 mg/kg,,Canis lupus familiaris,9615.0,
5242,,,,,CHEMBL622672,A,BAO_0000218,,,1,5802,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,Canis lupus familiaris,9615.0,
5243,,,,,CHEMBL622673,A,BAO_0000218,,,1,3598,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,Canis lupus familiaris,9615.0,
5244,,,,,CHEMBL622674,A,BAO_0000218,,,1,3598,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,Canis lupus familiaris,9615.0,
5245,,,,,CHEMBL622675,A,BAO_0000218,,,1,5944,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,Canis lupus familiaris,9615.0,
5246,,,,,CHEMBL622676,A,BAO_0000218,,,1,5944,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,Canis lupus familiaris,9615.0,
5247,,,,,CHEMBL622677,A,BAO_0000218,,,1,5944,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,Canis lupus familiaris,9615.0,
5248,,,,,CHEMBL622678,A,BAO_0000218,,,1,5944,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,Canis lupus familiaris,9615.0,
5249,,,,,CHEMBL622679,A,BAO_0000218,,,1,4186,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,Canis lupus familiaris,9615.0,
5250,,,,,CHEMBL622680,A,BAO_0000218,,,1,5007,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,Canis lupus familiaris,9615.0,
5251,,,,,CHEMBL622681,A,BAO_0000218,,,1,5668,Area under curve was determine after peroral administration at 10 mpk in dog,,Canis lupus familiaris,9615.0,
5252,,,,,CHEMBL875278,A,BAO_0000218,,,1,5668,Area under curve was determine after peroral administration at 5 mpk in dog,,Canis lupus familiaris,9615.0,
5253,,,,,CHEMBL622682,A,BAO_0000218,,,1,5006,Area under curve was determined,,Canis lupus familiaris,9615.0,
5254,,,,,CHEMBL622683,A,BAO_0000218,,,1,5006,Area under curve in dogs,,Canis lupus familiaris,9615.0,
5255,,,,,CHEMBL622684,A,BAO_0000218,,,1,3771,Area under curve in dogs at 10 mg/kg dose fo oral administration,,Canis lupus familiaris,9615.0,
5256,,,,,CHEMBL622685,A,BAO_0000218,,,1,3771,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,Canis lupus familiaris,9615.0,
5257,,,,,CHEMBL622686,A,BAO_0000218,,,1,3771,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,Canis lupus familiaris,9615.0,
5258,,,,,CHEMBL618344,A,BAO_0000218,,,1,1916,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,Canis lupus familiaris,9615.0,
5259,,,,,CHEMBL875582,A,BAO_0000218,,,1,5302,Area under curve value in dog at a dose of 5 mg/kg,,Canis lupus familiaris,9615.0,
5260,,,,,CHEMBL618345,A,BAO_0000218,,,1,5600,Area under curve was determined after 0.1 mg/kg iv administration in dog,,Canis lupus familiaris,9615.0,
5261,,,,,CHEMBL618346,A,BAO_0000218,,,1,5600,Area under curve was determined after 0.3 mg/kg po administration in dog,,Canis lupus familiaris,9615.0,
5262,,,,,CHEMBL618347,A,BAO_0000218,,,1,17764,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,Canis lupus familiaris,9615.0,
5263,,,,,CHEMBL618348,A,BAO_0000218,,,1,4368,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,Canis lupus familiaris,9615.0,
5264,,,,,CHEMBL618349,A,BAO_0000019,,,0,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,Homo sapiens,9606.0,
5265,,,,,CHEMBL618350,A,BAO_0000019,,,0,5318,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,Homo sapiens,9606.0,
5266,,,,,CHEMBL618351,A,BAO_0000019,,,0,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,Homo sapiens,9606.0,
5267,,,,,CHEMBL618352,A,BAO_0000019,,,0,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,Homo sapiens,9606.0,
5268,Blood,,,,CHEMBL873494,A,BAO_0000221,,,0,14518,Time taken to reduce 50% of the concentration of compound in blood plasma,,Homo sapiens,9606.0,
5269,Plasma,,,,CHEMBL618353,A,BAO_0000366,,,0,2209,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,Homo sapiens,9606.0,
5270,Plasma,,,,CHEMBL618354,A,BAO_0000366,,,0,6787,Half life in human plasma,,Homo sapiens,9606.0,
5271,Plasma,,,,CHEMBL875583,A,BAO_0000366,,,0,4898,Half life in human plasma was reported,,Homo sapiens,9606.0,
5272,Serum,,,,CHEMBL618355,A,BAO_0000019,,,0,6072,Half life in human serum,,Homo sapiens,9606.0,
5273,Plasma,,,,CHEMBL618356,A,BAO_0000366,,,0,16907,Half life upon exposure to human plasma,,Homo sapiens,9606.0,
5274,,,,,CHEMBL618357,A,BAO_0000251,,,0,5656,t1/2 in human microsomes,In vitro,Homo sapiens,9606.0,Microsomes
5275,Plasma,,,,CHEMBL618358,A,BAO_0000366,,,0,4755,Half life period in 80% human plasma at 37 degree Centigrade,,Homo sapiens,9606.0,
5276,Zone of skin,,,,CHEMBL618359,A,BAO_0000221,,,0,17503,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),,Homo sapiens,9606.0,
5277,Plasma,,,,CHEMBL618360,A,BAO_0000366,,,0,12357,Half-life measured in in vitro Cathepsin B assay in human plasma,In vitro,Homo sapiens,9606.0,
5278,,,,,CHEMBL618361,A,BAO_0000019,,,0,3076,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,Homo sapiens,9606.0,
5279,Liver,,,,CHEMBL618362,A,BAO_0000251,,,0,6410,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,In vitro,Homo sapiens,9606.0,Microsomes
5280,Plasma,,,,CHEMBL618363,A,BAO_0000366,,,0,3741,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,Homo sapiens,9606.0,
5281,Plasma,,,,CHEMBL618364,A,BAO_0000366,,,0,3741,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,Homo sapiens,9606.0,
5282,Plasma,,,,CHEMBL875584,A,BAO_0000366,,,0,3741,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,Homo sapiens,9606.0,
5283,,,,,CHEMBL618365,A,BAO_0000019,,,0,1540,Half-life in the CEM cell extracts,,Homo sapiens,9606.0,
5284,Plasma,,,,CHEMBL873495,A,BAO_0000366,,,0,2905,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,,Homo sapiens,9606.0,
5285,Plasma,,,,CHEMBL618366,A,BAO_0000366,,,0,2905,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,,Homo sapiens,9606.0,
5286,,,,,CHEMBL618367,A,BAO_0000019,,,0,5523,Half-life was determined,,Homo sapiens,9606.0,
5287,Blood,,,,CHEMBL618368,A,BAO_0000221,,,0,1499,Half-life (human blood stability),,Homo sapiens,9606.0,
5288,Blood,,,,CHEMBL618369,A,BAO_0000221,,,0,1499,Half-life (human blood stability); no data,,Homo sapiens,9606.0,
5289,Plasma,,,,CHEMBL618370,A,BAO_0000366,,,0,17065,Half-life in human plasma,,Homo sapiens,9606.0,
5290,,,,,CHEMBL618371,A,BAO_0000019,,,0,6861,CYP3A4 metabolism half-life (t1/2),,Homo sapiens,9606.0,
5291,Blood,,,,CHEMBL618372,A,BAO_0000221,,,0,1499,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),,Homo sapiens,9606.0,
5292,Plasma,,,,CHEMBL618373,A,BAO_0000366,,,0,530,In vitro half life in human plasma,In vitro,Homo sapiens,9606.0,
5293,Plasma,,,,CHEMBL618374,A,BAO_0000366,,,0,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",In vitro,Homo sapiens,9606.0,
5294,Plasma,,,,CHEMBL618375,A,BAO_0000366,,,0,6695,In vitro hydrolysis in human plasma,In vitro,Homo sapiens,9606.0,
5295,Plasma,,,,CHEMBL618376,A,BAO_0000366,,,0,6695,In vitro hydrolysis in human plasma; no data,In vitro,Homo sapiens,9606.0,
5296,Liver,,,,CHEMBL618377,A,BAO_0000251,,,0,10,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,In vitro,Homo sapiens,9606.0,Microsomes
5297,Plasma,,,,CHEMBL618378,A,BAO_0000366,,,0,993,Plasma half life in human,,Homo sapiens,9606.0,
5298,Plasma,,,,CHEMBL618379,A,BAO_0000366,,,0,15429,Stability after incubation with human plasma (at 37 degree C),,Homo sapiens,9606.0,
5299,Plasma,,,,CHEMBL618380,A,BAO_0000366,,,0,1675,T1/2 was evaluated in human plasma,,Homo sapiens,9606.0,
5300,Plasma,,,,CHEMBL618381,A,BAO_0000366,,,0,2209,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,Homo sapiens,9606.0,
5301,Plasma,,,,CHEMBL618382,A,BAO_0000366,,,0,2209,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",,Homo sapiens,9606.0,
5302,,,,,CHEMBL618383,A,BAO_0000019,,,0,5318,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,Homo sapiens,9606.0,
5303,,,,,CHEMBL618384,A,BAO_0000019,,,0,2412,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,In vitro,Homo sapiens,9606.0,
5304,,,,,CHEMBL618385,A,BAO_0000019,,,0,2412,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,In vitro,Homo sapiens,9606.0,
5305,Plasma,,,,CHEMBL619099,A,BAO_0000366,,,0,2906,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,,Homo sapiens,9606.0,
5306,Plasma,,,,CHEMBL619100,A,BAO_0000366,,,0,2906,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,,Homo sapiens,9606.0,
5307,,,,,CHEMBL619101,A,BAO_0000019,,,0,5495,Time taken for 50% to be consumed by serum PON1 was determined,,Homo sapiens,9606.0,
5308,,,,,CHEMBL619102,A,BAO_0000019,,,0,5495,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,Homo sapiens,9606.0,
5309,Liver,,,,CHEMBL619103,A,BAO_0000251,,,0,4397,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,Homo sapiens,9606.0,Microsomes
5310,,,,,CHEMBL619268,A,BAO_0000218,,,0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,Mus sp.,10095.0,
5311,,,,,CHEMBL619269,A,BAO_0000218,,,0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Mus sp.,10095.0,
5312,,,,,CHEMBL619270,A,BAO_0000218,,,0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,Mus sp.,10095.0,
5313,,,,,CHEMBL619271,A,BAO_0000218,,,0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Mus sp.,10095.0,
5314,,,,,CHEMBL875585,A,BAO_0000218,,,0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,Mus sp.,10095.0,
5315,,,,,CHEMBL619272,A,BAO_0000218,,,0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,Mus sp.,10095.0,
5316,,,,786-0,CHEMBL619273,F,BAO_0000219,,,1,6058,Compound tested for growth inhibition of renal cancer cell line 786-0,,Homo sapiens,9606.0,
5317,,,,786-0,CHEMBL619274,F,BAO_0000219,,,1,17708,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,,Homo sapiens,9606.0,
5318,,,,786-0,CHEMBL619275,F,BAO_0000219,,,1,14017,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,,Homo sapiens,9606.0,
5319,,,,786-0,CHEMBL619276,F,BAO_0000219,,,1,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",,Homo sapiens,9606.0,
5320,,,,786-0,CHEMBL619277,F,BAO_0000219,,,1,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",,Homo sapiens,9606.0,
5321,,,,786-0,CHEMBL619278,F,BAO_0000219,,,1,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",,Homo sapiens,9606.0,
5322,,,,786-0,CHEMBL619279,F,BAO_0000219,,,1,11970,Tested for cytotoxicity against 786-0 cell lines in renal cancer,,Homo sapiens,9606.0,
5323,,,,786-0,CHEMBL858458,F,BAO_0000219,,,1,12400,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,,Homo sapiens,9606.0,
5324,,,,786-0,CHEMBL619280,F,BAO_0000219,,,1,12888,Cytotoxic effect on renal cancer line 786-0,,Homo sapiens,9606.0,
5325,,,,786-0,CHEMBL619281,F,BAO_0000219,,,1,15300,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,,Homo sapiens,9606.0,
5326,,,,786-0,CHEMBL619282,F,BAO_0000219,,,1,14769,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,Homo sapiens,9606.0,
5327,,,,786-0,CHEMBL619283,F,BAO_0000219,,,1,15895,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",,Homo sapiens,9606.0,
5328,,,,786-0,CHEMBL619284,F,BAO_0000219,,,1,17376,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,,Homo sapiens,9606.0,
5329,,,,786-0,CHEMBL619285,F,BAO_0000219,,,1,14882,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,Homo sapiens,9606.0,
5330,,,,786-0,CHEMBL619286,F,BAO_0000219,,,1,14882,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),,Homo sapiens,9606.0,
5331,,,,786-0,CHEMBL619287,F,BAO_0000219,,,1,15176,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,,Homo sapiens,9606.0,
5332,,,,786-0,CHEMBL857455,F,BAO_0000219,,,1,12696,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,Homo sapiens,9606.0,
5333,,,,786-0,CHEMBL883801,F,BAO_0000219,,,1,2496,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),,Homo sapiens,9606.0,
5334,,,,791T cell line,CHEMBL619288,F,BAO_0000219,,,1,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,,Homo sapiens,9606.0,
5335,,,,791T cell line,CHEMBL619289,F,BAO_0000219,,,1,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),,Homo sapiens,9606.0,
5336,,,,791T cell line,CHEMBL619290,F,BAO_0000219,,,1,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,,Homo sapiens,9606.0,
5337,,,,791T cell line,CHEMBL619291,F,BAO_0000219,,,1,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),,Homo sapiens,9606.0,
5338,,,,791T cell line,CHEMBL619292,F,BAO_0000219,,,1,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),,Homo sapiens,9606.0,
5339,,,,791T cell line,CHEMBL619293,F,BAO_0000219,,,1,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,,Homo sapiens,9606.0,
5340,,,,791T cell line,CHEMBL619294,F,BAO_0000219,,,1,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),,Homo sapiens,9606.0,
5341,,,,791T cell line,CHEMBL619295,F,BAO_0000219,,,1,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),,Homo sapiens,9606.0,
5342,,,,791T cell line,CHEMBL619296,F,BAO_0000219,,,1,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),,Homo sapiens,9606.0,
5343,,,,791T cell line,CHEMBL619297,F,BAO_0000219,,,1,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,,Homo sapiens,9606.0,
5344,,,,786-0,CHEMBL619298,F,BAO_0000219,,,1,12782,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,,Homo sapiens,9606.0,
5345,,,,,CHEMBL619299,F,BAO_0000019,,,0,1229,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,,,
5346,,,,RPMI-8226,CHEMBL619300,F,BAO_0000219,,,1,15313,Inhibition of cell growth in drug resistant 8226 myeloma cell line,,Homo sapiens,9606.0,
5347,,,,RPMI-8226,CHEMBL619301,F,BAO_0000219,,,1,15313,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,,Homo sapiens,9606.0,
5348,,,,RPMI-8226,CHEMBL619302,F,BAO_0000219,,,1,11544,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,,Homo sapiens,9606.0,
5349,,,,RPMI-8226,CHEMBL619303,F,BAO_0000219,,,1,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,Homo sapiens,9606.0,
5350,,,,RPMI-8226,CHEMBL619304,F,BAO_0000219,,,1,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,Homo sapiens,9606.0,
5351,,,,RPMI-8226,CHEMBL857706,F,BAO_0000219,,,1,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,Homo sapiens,9606.0,
5352,,,,RPMI-8226,CHEMBL619305,F,BAO_0000219,,,1,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,Homo sapiens,9606.0,
5353,,,,RPMI-8226,CHEMBL619306,F,BAO_0000219,,,1,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,Homo sapiens,9606.0,
5354,,,,RPMI-8226,CHEMBL619307,F,BAO_0000219,,,1,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,Homo sapiens,9606.0,
5355,,,,RPMI-8226,CHEMBL619308,F,BAO_0000219,,,1,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,Homo sapiens,9606.0,
5356,,,,RPMI-8226,CHEMBL619309,F,BAO_0000219,,,1,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,Homo sapiens,9606.0,
5357,,,,RPMI-8226,CHEMBL619310,F,BAO_0000219,,,1,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,Homo sapiens,9606.0,
5358,,,,A498,CHEMBL619311,F,BAO_0000219,,,1,14769,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,Homo sapiens,9606.0,
5359,,,,A498,CHEMBL619312,F,BAO_0000219,,,1,15354,Compound was tested for the growth inhibition of A498 renal tumor cell line,,Homo sapiens,9606.0,
5360,,,,A498,CHEMBL619313,F,BAO_0000219,,,1,17445,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),,Homo sapiens,9606.0,
5361,,,,A498,CHEMBL619314,F,BAO_0000219,,,1,4337,In vitro inhibitory concentration against renal cancer cell line A498,,Homo sapiens,9606.0,
5362,,,,A498,CHEMBL619959,F,BAO_0000219,,,1,15277,Cytotoxicity against A 498 tumor cell line,,Homo sapiens,9606.0,
5363,,,,A498,CHEMBL619960,F,BAO_0000219,,,1,4812,In vitro antitumor activity against A498 human cancer cell line,,Homo sapiens,9606.0,
5364,,,,A498,CHEMBL619961,F,BAO_0000219,,,1,4812,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),,Homo sapiens,9606.0,
5365,,,,A498,CHEMBL619962,F,BAO_0000219,,,1,4995,Inhibitory dose required against A498 human tumor cell lines,,Homo sapiens,9606.0,
5366,,,,A498,CHEMBL875586,F,BAO_0000219,,,1,5847,Anticancer activity against one renal cancer (A498 cell line),,Homo sapiens,9606.0,
5367,,,,A498,CHEMBL619963,F,BAO_0000219,,,1,6557,In vitro cytotoxicity against melanoma A498 cell line,,Homo sapiens,9606.0,
5368,,,,A498,CHEMBL619964,F,BAO_0000219,,,1,2597,Compound was tested for growth inhibitory activity against A498 cell line,,Homo sapiens,9606.0,
5369,,,,A498,CHEMBL620108,F,BAO_0000219,,,1,6058,Compound tested for growth inhibition of renal cancer cell line A498,,Homo sapiens,9606.0,
5370,,,,A498,CHEMBL620109,F,BAO_0000219,,,1,17708,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,,Homo sapiens,9606.0,
5371,,,,A498,CHEMBL620110,F,BAO_0000219,,,1,15176,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,,Homo sapiens,9606.0,
5372,,,,A498,CHEMBL620111,F,BAO_0000219,,,1,15300,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,,Homo sapiens,9606.0,
5373,,,,A498,CHEMBL620112,F,BAO_0000219,,,1,11970,Tested for cytotoxicity against A498 cell lines in renal cancer,,Homo sapiens,9606.0,
5374,,,,A498,CHEMBL620113,F,BAO_0000219,,,1,12400,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,,Homo sapiens,9606.0,
5375,,,,A498,CHEMBL620114,F,BAO_0000219,,,1,12888,Cytotoxic effect on renal cancer lines A498,,Homo sapiens,9606.0,
5376,,,,A498,CHEMBL620115,F,BAO_0000219,,,1,3030,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,,Homo sapiens,9606.0,
5377,,,,A498,CHEMBL620116,F,BAO_0000219,,,1,14769,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,Homo sapiens,9606.0,
5378,,,,A498,CHEMBL620117,F,BAO_0000219,,,1,17376,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,,Homo sapiens,9606.0,
5379,,,,A498,CHEMBL620118,F,BAO_0000219,,,1,16558,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,,Homo sapiens,9606.0,
5380,,,,A498,CHEMBL620119,F,BAO_0000219,,,1,5194,Cytotoxicity against human kidney carcinoma cell lines A4982LM,,Homo sapiens,9606.0,
5381,,,,A498,CHEMBL620120,F,BAO_0000219,,,1,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,,Homo sapiens,9606.0,
5382,,,,A549,CHEMBL620121,F,BAO_0000219,,,1,16880,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,,Homo sapiens,9606.0,
5383,,,,A549,CHEMBL620122,F,BAO_0000219,,,1,10196,Antitumor activity against A549 human lung carcinoma cell line,,Homo sapiens,9606.0,
5384,,,,A549,CHEMBL620123,F,BAO_0000219,,,1,10196,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,,Homo sapiens,9606.0,
5385,,,,A549,CHEMBL620124,F,BAO_0000219,,,1,10196,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,,Homo sapiens,9606.0,
5386,,,,A549,CHEMBL620125,F,BAO_0000219,,,1,12083,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",,Homo sapiens,9606.0,
5387,,,,A549,CHEMBL620126,F,BAO_0000219,,,1,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,,Homo sapiens,9606.0,
5388,,,,A549,CHEMBL883027,F,BAO_0000219,,,1,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,Homo sapiens,9606.0,
5389,,,,A549,CHEMBL620127,F,BAO_0000219,,,1,16470,In vitro cytotoxic activity against human lung A549 cell line,,Homo sapiens,9606.0,
5390,,,,A549,CHEMBL620128,F,BAO_0000219,,,1,16470,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),,Homo sapiens,9606.0,
5391,,,,A549,CHEMBL620129,F,BAO_0000219,,,1,16470,In vitro cytotoxic activity against human lung A549 cell line),,Homo sapiens,9606.0,
5392,,,,A549,CHEMBL620130,F,BAO_0000219,,,1,16470,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,,Homo sapiens,9606.0,
5393,,,,A549,CHEMBL620131,F,BAO_0000219,,,1,16582,In vitro cytotoxicity against human non small-cell-lung cell line A549.,,Homo sapiens,9606.0,
5394,,,,A549,CHEMBL620132,F,BAO_0000219,,,1,15935,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",,Homo sapiens,9606.0,
5395,,,,A549,CHEMBL620133,F,BAO_0000219,,,1,15935,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",,Homo sapiens,9606.0,
5396,,,,A549,CHEMBL620134,F,BAO_0000219,,,1,16597,Inhibition of A549 human lung carcinoma cell proliferation,,Homo sapiens,9606.0,
5397,,,,A549,CHEMBL620135,F,BAO_0000219,,,1,17376,Inhibitory activity against A549 lung adenocarcinoma cell line,,Homo sapiens,9606.0,
5398,,,,A549,CHEMBL620136,F,BAO_0000219,,,1,16496,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,,Homo sapiens,9606.0,
5399,,,,A549,CHEMBL620137,F,BAO_0000219,,,1,16152,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,,Homo sapiens,9606.0,
5400,,,,A549,CHEMBL620268,F,BAO_0000219,,,1,16152,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,,Homo sapiens,9606.0,
5401,,,,A549,CHEMBL620269,F,BAO_0000219,,,1,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,Homo sapiens,9606.0,
5402,,,,A549,CHEMBL620270,F,BAO_0000219,,,1,2288,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,,Homo sapiens,9606.0,
5403,,,,A549,CHEMBL620271,F,BAO_0000219,,,1,17350,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,Homo sapiens,9606.0,
5404,,,,A549,CHEMBL620272,F,BAO_0000219,,,1,4090,Inhibition of A549 cancer cell proliferation,,Homo sapiens,9606.0,
5405,,,,A549,CHEMBL620273,F,BAO_0000219,,,1,4090,Inhibition of A549 cancer cell proliferation (Not tested),,Homo sapiens,9606.0,
5406,,,,A549,CHEMBL620274,F,BAO_0000219,,,1,17350,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,Homo sapiens,9606.0,
5407,,,,A549,CHEMBL620275,F,BAO_0000219,,,1,4197,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,,Homo sapiens,9606.0,
5408,,,,A549,CHEMBL620276,F,BAO_0000219,,,1,17072,Antiproliferative potency determined as inhibitory concentration against A549 cells,,Homo sapiens,9606.0,
5409,,,,A549,CHEMBL620277,F,BAO_0000219,,,1,17072,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,,Homo sapiens,9606.0,
5410,,,,A549,CHEMBL620278,F,BAO_0000219,,,1,5194,Cytotoxicity against Renal cell lines A549 was determined,,Homo sapiens,9606.0,
5411,,,,,CHEMBL620279,A,BAO_0000218,,,1,4257,Area under curve was determined in dog after a 3 mg/kg of oral dose,,Canis lupus familiaris,9615.0,
5412,,,,,CHEMBL620280,A,BAO_0000218,,,1,6123,Area under curve was determined in dog after oral administration at 1 mg/kg,,Canis lupus familiaris,9615.0,
5413,,,,,CHEMBL620281,A,BAO_0000218,,,1,1337,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,Canis lupus familiaris,9615.0,
5414,,,,,CHEMBL620282,A,BAO_0000218,,,1,1337,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,Canis lupus familiaris,9615.0,
5415,,,,,CHEMBL621134,A,BAO_0000218,,,1,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,Canis lupus familiaris,9615.0,
5416,,,,,CHEMBL621135,A,BAO_0000218,,,1,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,Canis lupus familiaris,9615.0,
5417,,,,,CHEMBL621136,A,BAO_0000218,,,1,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,Canis lupus familiaris,9615.0,
5418,,,,,CHEMBL621137,A,BAO_0000218,,,1,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,Canis lupus familiaris,9615.0,
5419,Plasma,,,,CHEMBL621138,A,BAO_0000218,,,1,17657,Area under plasma concentration time curve in dog upon oral administration,,Canis lupus familiaris,9615.0,
5420,Plasma,,,,CHEMBL875587,A,BAO_0000218,,,1,17650,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,,Canis lupus familiaris,9615.0,
5421,,,,,CHEMBL621139,A,BAO_0000218,,,1,1977,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,Canis lupus familiaris,9615.0,
5422,,,,,CHEMBL621140,A,BAO_0000218,,,1,1977,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,Canis lupus familiaris,9615.0,
5423,,,,,CHEMBL621141,A,BAO_0000218,,,1,3132,Area under the curve for the compound was obtained when tested in dog,,Canis lupus familiaris,9615.0,
5424,,,,,CHEMBL621142,A,BAO_0000218,,,1,5473,Area under the curve at a dose of 1 mg/kg,,Canis lupus familiaris,9615.0,
5425,,,,,CHEMBL621143,A,BAO_0000218,,,1,5474,Area under the curve at a dose of 1 mg/kg (oral),,Canis lupus familiaris,9615.0,
5426,,,,,CHEMBL621144,A,BAO_0000218,,,1,5474,Area under the curve at i.v. dose of 0.2 mg/kg,,Canis lupus familiaris,9615.0,
5427,,,,,CHEMBL621145,A,BAO_0000218,,,1,6062,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,Canis lupus familiaris,9615.0,
5428,,,,,CHEMBL621146,A,BAO_0000218,,,1,4709,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,Canis lupus familiaris,9615.0,
5429,,,,,CHEMBL622567,A,BAO_0000218,,,1,2652,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,Canis lupus familiaris,9615.0,
5430,,,,,CHEMBL622568,A,BAO_0000218,,,1,2652,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,Canis lupus familiaris,9615.0,
5431,,,,,CHEMBL622569,A,BAO_0000218,,,1,2877,Compound was evaluated for area under the curve in dog blood.,,Canis lupus familiaris,9615.0,
5432,,,,,CHEMBL622570,A,BAO_0000218,,,1,5444,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,Canis lupus familiaris,9615.0,
5433,Plasma,,,,CHEMBL622571,A,BAO_0000218,,,1,5130,AUC in dog after oral dose (1 mg/kg),,Canis lupus familiaris,9615.0,
5434,,,,,CHEMBL622572,A,BAO_0000218,,,1,6265,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,Canis lupus familiaris,9615.0,
5435,,,,,CHEMBL622573,A,BAO_0000218,,,1,4657,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,Canis lupus familiaris,9615.0,
5436,,,,,CHEMBL622574,A,BAO_0000218,,,1,16367,Pharmacokinetic parameter AUC after intravenous administration to dogs,,Canis lupus familiaris,9615.0,
5437,,,,,CHEMBL622575,A,BAO_0000218,,,1,16367,Pharmacokinetic parameter AUC after oral administration to dogs,,Canis lupus familiaris,9615.0,
5438,,,,,CHEMBL622576,A,BAO_0000218,,,1,9579,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,Canis lupus familiaris,9615.0,
5439,,,,,CHEMBL622577,A,BAO_0000218,,,1,9579,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,Canis lupus familiaris,9615.0,
5440,,,,,CHEMBL622578,A,BAO_0000218,,,1,5983,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,Canis lupus familiaris,9615.0,
5441,,,,,CHEMBL622579,A,BAO_0000218,,,1,6241,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,Canis lupus familiaris,9615.0,
5442,,,,,CHEMBL622580,A,BAO_0000218,,,1,5313,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,Canis lupus familiaris,9615.0,
5443,,,,,CHEMBL622581,A,BAO_0000218,,,1,5313,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,Canis lupus familiaris,9615.0,
5444,,,,,CHEMBL622582,A,BAO_0000218,,,1,6642,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,Canis lupus familiaris,9615.0,
5445,,,,,CHEMBL622583,A,BAO_0000218,,,1,6642,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,Canis lupus familiaris,9615.0,
5446,,,,,CHEMBL622584,A,BAO_0000218,,,1,6641,Oral AUCN in dog (dosed at 0.5 mpk iv ),,Canis lupus familiaris,9615.0,
5447,,,,,CHEMBL622585,A,BAO_0000218,,,1,6642,Oral AUCN in dog (dosed at 0.5 mpk iv ),,Canis lupus familiaris,9615.0,
5448,,,,,CHEMBL622586,A,BAO_0000218,,,1,17791,Compound was evaluated for oral bioavailability in dog; 90-100,,Canis lupus familiaris,9615.0,
5449,,,,,CHEMBL623281,A,BAO_0000218,,,1,17655,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,Canis lupus familiaris,9615.0,
5450,,,,,CHEMBL623282,A,BAO_0000218,,,1,17655,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,Canis lupus familiaris,9615.0,
5451,,,,,CHEMBL623283,A,BAO_0000218,,,1,6596,PAPP (membrane permeability) in dog kidney cell monolayer assay,,Canis lupus familiaris,9615.0,
5452,,,,,CHEMBL623284,A,BAO_0000218,,,1,3880,Oral bioavailability in dog,,Canis lupus familiaris,9615.0,
5453,,,,,CHEMBL623285,A,BAO_0000218,,,1,16367,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,Canis lupus familiaris,9615.0,
5454,Plasma,,,,CHEMBL623463,A,BAO_0000218,,,1,17409,Plasma protein binding towards dog plasma at 10 uM,,Canis lupus familiaris,9615.0,
5455,Plasma,,,,CHEMBL875952,A,BAO_0000218,,,1,17409,Plasma protein binding towards dog plasma at 100 uM,,Canis lupus familiaris,9615.0,
5456,,,,,CHEMBL621705,A,BAO_0000218,,,1,2959,Bioavailability in dog (dose 4 mg/kg p.o.),In vivo,Canis lupus familiaris,9615.0,
5457,,,,,CHEMBL621706,A,BAO_0000218,,,1,13501,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,In vivo,Canis lupus familiaris,9615.0,
5458,,,,,CHEMBL621707,A,BAO_0000218,,,1,4527,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,In vivo,Canis lupus familiaris,9615.0,
5459,,,,,CHEMBL621708,A,BAO_0000218,,,1,15145,Bioavailability in dogs,In vivo,Canis lupus familiaris,9615.0,
5460,,,,,CHEMBL621709,A,BAO_0000218,,,1,4219,Bioavailability,In vivo,Canis lupus familiaris,9615.0,
5461,,,,,CHEMBL621710,A,BAO_0000218,,,1,17538,Oral bioavailability in dog (dose 10 mg/kg),In vivo,Canis lupus familiaris,9615.0,
5462,,,,,CHEMBL621711,A,BAO_0000218,,,1,17538,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,In vivo,Canis lupus familiaris,9615.0,
5463,,,,,CHEMBL621712,A,BAO_0000218,,,1,1466,Bioavailability in dog (dose 10.0 mg/kg p.o.),In vivo,Canis lupus familiaris,9615.0,
5464,,,,,CHEMBL621713,A,BAO_0000218,,,1,17650,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,In vivo,Canis lupus familiaris,9615.0,
5465,,,,,CHEMBL621714,A,BAO_0000218,,,1,3132,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,In vivo,Canis lupus familiaris,9615.0,
5466,,,,,CHEMBL621715,A,BAO_0000218,,,0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Mus sp.,10095.0,
5467,Liver,,,,CHEMBL623717,A,BAO_0000218,,,0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,,Mus sp.,10095.0,
5468,Liver,,,,CHEMBL623718,A,BAO_0000218,,,0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,,Mus sp.,10095.0,
5469,Liver,,,,CHEMBL623719,A,BAO_0000218,,,0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Mus sp.,10095.0,
5470,,,,,CHEMBL623720,A,BAO_0000218,,,0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,Mus sp.,10095.0,
5471,,,,,CHEMBL623721,A,BAO_0000218,,,0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Mus sp.,10095.0,
5472,Muscle tissue,,,,CHEMBL623722,A,BAO_0000218,,,0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,,Mus sp.,10095.0,
5473,Muscle tissue,,,,CHEMBL623723,A,BAO_0000218,,,0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,,Mus sp.,10095.0,
5474,Muscle tissue,,,,CHEMBL618543,A,BAO_0000218,,,0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Mus sp.,10095.0,
5475,Spleen,,,,CHEMBL618544,A,BAO_0000218,,,0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,,Mus sp.,10095.0,
5476,Spleen,,,,CHEMBL875155,A,BAO_0000218,,,0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Mus sp.,10095.0,
5477,,,,,CHEMBL618545,A,BAO_0000218,,,0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,Mus sp.,10095.0,
5478,,,,,CHEMBL618546,A,BAO_0000218,,,0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,Mus sp.,10095.0,
5479,,,,,CHEMBL623529,A,BAO_0000218,,,0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Mus sp.,10095.0,
5480,,,,,CHEMBL623530,A,BAO_0000218,,,0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,Mus sp.,10095.0,
5481,,,,,CHEMBL621764,A,BAO_0000218,,,0,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Mus sp.,10095.0,
5482,,,,,CHEMBL621765,A,BAO_0000019,,,0,17827,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,Cercopithecidae,9527.0,
5483,Cerebellum,,,,CHEMBL621766,A,BAO_0000019,,,0,17827,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,Cercopithecidae,9527.0,
5484,Frontal cortex,,,,CHEMBL621767,A,BAO_0000019,,,0,17827,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,Cercopithecidae,9527.0,
5485,,,,,CHEMBL621768,A,BAO_0000019,,,0,17827,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,Cercopithecidae,9527.0,
5486,Striatum,,,,CHEMBL621769,A,BAO_0000019,,,0,17827,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),,Cercopithecidae,9527.0,
5487,,,,,CHEMBL621770,A,BAO_0000019,,,0,17827,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,Cercopithecidae,9527.0,
5488,Cerebellum,,,,CHEMBL621771,A,BAO_0000019,,,0,17827,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,Cercopithecidae,9527.0,
5489,Frontal cortex,,,,CHEMBL621772,A,BAO_0000019,,,0,17827,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,Cercopithecidae,9527.0,
5490,,,,,CHEMBL621773,A,BAO_0000019,,,0,17827,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,Cercopithecidae,9527.0,
5491,Striatum,,,,CHEMBL621774,A,BAO_0000019,,,0,17827,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),,Cercopithecidae,9527.0,
5492,,,,,CHEMBL621775,A,BAO_0000218,,,0,17791,Compound was evaluated for oral bioavailability in rats,,Cercopithecidae,9527.0,
5493,Plasma,,,,CHEMBL621776,A,BAO_0000218,,,0,17667,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,In vivo,Cercopithecidae,9527.0,
5494,,,,,CHEMBL621777,A,BAO_0000019,,,0,17791,Half life period was evaluated in monkey,,Cercopithecidae,9527.0,
5495,,,,,CHEMBL875162,A,BAO_0000218,,,0,110,Half-life in rhesus monkeys by intravenous administration of dose,In vivo,Cercopithecidae,9527.0,
5496,Plasma,,,,CHEMBL621778,A,BAO_0000218,,,1,5781,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,,Mus musculus,10090.0,
5497,Plasma,,,,CHEMBL621779,A,BAO_0000218,,,1,17734,AUC after intraperitoneal administration of 100 mg/kg in mice,,Mus musculus,10090.0,
5498,Plasma,,,,CHEMBL622479,A,BAO_0000218,,,1,17718,AUC value was determined after oral administration,,Mus musculus,10090.0,
5499,,,,,CHEMBL622480,A,BAO_0000218,,,1,4573,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,Mus musculus,10090.0,
5500,,,,,CHEMBL622481,A,BAO_0000218,,,1,3277,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,Mus musculus,10090.0,
5501,,,,,CHEMBL622482,A,BAO_0000218,,,1,2862,Area under curve by ioral administration in mouse,,Mus musculus,10090.0,
5502,,,,,CHEMBL622483,A,BAO_0000218,,,1,2862,Area under curve by iv administration in mouse,,Mus musculus,10090.0,
5503,,,,,CHEMBL622484,A,BAO_0000218,,,1,5951,Area under curve at 0-8 hr in IRC mice after peroral administration,,Mus musculus,10090.0,
5504,,,,,CHEMBL622641,A,BAO_0000218,,,1,17729,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,Mus musculus,10090.0,
5505,,,,,CHEMBL622642,A,BAO_0000218,,,1,17728,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,Mus musculus,10090.0,
5506,,,,,CHEMBL622643,A,BAO_0000218,,,1,17728,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,Mus musculus,10090.0,
5507,,,,,CHEMBL622644,A,BAO_0000218,,,1,17729,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,Mus musculus,10090.0,
5508,,,,RPMI-8226,CHEMBL622645,F,BAO_0000219,,,1,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,Homo sapiens,9606.0,
5509,,,,RPMI-8226,CHEMBL622646,F,BAO_0000219,,,1,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,Homo sapiens,9606.0,
5510,,,,RPMI-8226,CHEMBL621238,F,BAO_0000219,,,1,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,Homo sapiens,9606.0,
5511,,,,RPMI-8226,CHEMBL621239,F,BAO_0000219,,,1,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,Homo sapiens,9606.0,
5512,,,,RPMI-8226,CHEMBL621240,F,BAO_0000219,,,1,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,Homo sapiens,9606.0,
5513,,,,RPMI-8226,CHEMBL621241,F,BAO_0000219,,,1,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,Homo sapiens,9606.0,
5514,,,,RPMI-8226,CHEMBL621242,F,BAO_0000219,,,1,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,Homo sapiens,9606.0,
5515,,,,RPMI-8226,CHEMBL620350,F,BAO_0000219,,,1,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,Homo sapiens,9606.0,
5516,,,,RPMI-8226,CHEMBL620351,F,BAO_0000219,,,1,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,Homo sapiens,9606.0,
5517,,,,RPMI-8226,CHEMBL620352,F,BAO_0000219,,,1,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,Homo sapiens,9606.0,
5518,,,,RPMI-8226,CHEMBL620353,F,BAO_0000219,,,1,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,Homo sapiens,9606.0,
5519,,,,RPMI-8226,CHEMBL620354,F,BAO_0000219,,,1,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,Homo sapiens,9606.0,
5520,,,,RPMI-8226,CHEMBL620355,F,BAO_0000219,,,1,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,Homo sapiens,9606.0,
5521,,,,RPMI-8226,CHEMBL620356,F,BAO_0000219,,,1,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,Homo sapiens,9606.0,
5522,,,,RPMI-8226,CHEMBL620357,F,BAO_0000219,,,1,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,Homo sapiens,9606.0,
5523,,,,RPMI-8226,CHEMBL620358,F,BAO_0000219,,,1,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,Homo sapiens,9606.0,
5524,,,,RPMI-8226,CHEMBL620359,F,BAO_0000219,,,1,9424,In vitro inhibition of human 8226 myeloma tumor cell line growth.,,Homo sapiens,9606.0,
5525,,,,RPMI-8226,CHEMBL620360,F,BAO_0000219,,,1,11544,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,,Homo sapiens,9606.0,
5526,,,,RPMI-8226,CHEMBL620361,F,BAO_0000219,,,1,17378,Cytotoxicity of compound against 8226/DOX1V cells,,Homo sapiens,9606.0,
5527,,,,RPMI-8226,CHEMBL620362,F,BAO_0000219,,,1,17378,Cytotoxicity of compound against 8226/S cells,,Homo sapiens,9606.0,
5528,,,,RPMI-8226,CHEMBL620363,F,BAO_0000219,,,1,17079,Inhibitory concentration against 8226 myeloma cancer cell line,,Homo sapiens,9606.0,
5529,,,,RPMI-8226,CHEMBL620364,F,BAO_0000219,,,1,17079,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,,Homo sapiens,9606.0,
5530,,,,833K,CHEMBL620365,F,BAO_0000219,,,1,13466,Inhibition of cell growth was studied in human teratocarcinoma (833K).,,Homo sapiens,9606.0,
5531,,,,833K,CHEMBL620366,F,BAO_0000219,,,1,13466,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',,Homo sapiens,9606.0,
5532,,,,833K,CHEMBL620367,F,BAO_0000219,,,1,2392,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,,Homo sapiens,9606.0,
5533,,,,833K,CHEMBL620368,F,BAO_0000219,,,1,2392,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,,Homo sapiens,9606.0,
5534,,,,,CHEMBL620369,B,BAO_0000019,,,0,6608,Inhibitory activity against caspase-1,,,,
5535,,,,,CHEMBL620370,B,BAO_0000357,,,8,10199,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,Enterococcus faecalis,1351.0,
5536,,,,8701-BC,CHEMBL620371,F,BAO_0000219,,,1,17749,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,,Homo sapiens,9606.0,
5537,,,,8701-BC,CHEMBL620372,F,BAO_0000219,,,1,17749,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,,Homo sapiens,9606.0,
5538,,,,,CHEMBL876492,F,BAO_0000019,,,0,1229,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,,,
5539,,,,,CHEMBL620373,F,BAO_0000019,,,0,1229,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,,,
5540,,,,,CHEMBL620374,F,BAO_0000019,,,0,1229,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,,,
5541,,,,,CHEMBL620375,B,BAO_0000019,,,0,6390,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,,,
5542,,,,,CHEMBL857902,F,BAO_0000019,,,0,16219,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,Streptococcus pyogenes,1314.0,
5543,,,,,CHEMBL620376,F,BAO_0000019,,,0,16219,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,Streptococcus pyogenes,1314.0,
5544,,,,,CHEMBL620377,B,BAO_0000357,,,8,17043,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,,,
5545,,,,KB ,CHEMBL620378,F,BAO_0000219,,,1,6929,Tested for in vitro cytotoxic potency of compound in 9KB assay,,Homo sapiens,9606.0,
5546,,,,KB ,CHEMBL620379,A,BAO_0000219,,,1,6929,Tested for in vitro cytotoxic potency of compound in 9KB assay,,Homo sapiens,9606.0,
5547,,,,,CHEMBL620380,F,BAO_0000219,,,0,7083,In vitro cytotoxicity of compound was tested against 9KB cells.,,Homo sapiens,9606.0,
5548,,,,9L,CHEMBL884006,F,BAO_0000219,,,1,12446,Cytotoxic concentration against 9L cells was determined on day 3,,Rattus norvegicus,10116.0,
5549,,,,9L,CHEMBL620381,F,BAO_0000219,,,1,15345,Tested in vitro for anticancer activity against 9L cells,,Rattus norvegicus,10116.0,
5550,,,,9L,CHEMBL620382,F,BAO_0000219,,,1,15345,Tested in vitro for anticancer activity against 9L cells; Not determined,,Rattus norvegicus,10116.0,
5551,,,,A549,CHEMBL620383,F,BAO_0000219,,,1,6301,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,,Homo sapiens,9606.0,
5552,,,,A549,CHEMBL876493,F,BAO_0000219,,,1,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,,Homo sapiens,9606.0,
5553,,,,A549,CHEMBL620384,F,BAO_0000219,,,1,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,,Homo sapiens,9606.0,
5554,,,,A549,CHEMBL620385,F,BAO_0000219,,,1,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,,Homo sapiens,9606.0,
5555,,,,A549,CHEMBL620386,F,BAO_0000219,,,1,13330,Cytotoxicity against human lung carcinoma A549 cell line,,Homo sapiens,9606.0,
5556,,,,A549,CHEMBL620387,F,BAO_0000219,,,9,17517,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,,Homo sapiens,9606.0,
5557,,,,A549,CHEMBL621404,F,BAO_0000219,,,9,17517,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",,Homo sapiens,9606.0,
5558,,,,A549,CHEMBL621405,F,BAO_0000219,,,1,14425,"In vitro growth inhibition of A549, lung carcinoma",,Homo sapiens,9606.0,
5559,,,,A549,CHEMBL621406,F,BAO_0000219,,,1,14425,"In vitro growth inhibition of A549, lung carcinoma.",,Homo sapiens,9606.0,
5560,,,,A549,CHEMBL621407,F,BAO_0000219,,,1,5228,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,Homo sapiens,9606.0,
5561,,,,A549,CHEMBL621408,F,BAO_0000219,,,1,5351,Cytotoxic activity against human lung cancer A549 cell line was determined,,Homo sapiens,9606.0,
5562,,,,A549,CHEMBL885345,F,BAO_0000219,,,1,12198,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,,Homo sapiens,9606.0,
5563,,,,A549,CHEMBL621409,F,BAO_0000219,,,1,13891,Cytotoxicity concentration against human lung carcinoma A-549 cell line,,Homo sapiens,9606.0,
5564,,,,A549,CHEMBL876034,F,BAO_0000219,,,1,5677,Cytotoxicity in A549 (human carcinoma) cell line.,,Homo sapiens,9606.0,
5565,,,,A549,CHEMBL621410,F,BAO_0000219,,,1,13788,Cytotoxicity on lung carcinoma (A-549) cell line,,Homo sapiens,9606.0,
5566,,,,A549,CHEMBL621411,F,BAO_0000219,,,1,13384,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,,Homo sapiens,9606.0,
5567,,,,A549,CHEMBL621412,F,BAO_0000219,,,1,6726,Effective dose of compound against replication of A549 cell line was evaluated,,Homo sapiens,9606.0,
5568,,,,A549,CHEMBL621413,F,BAO_0000219,,,1,3455,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,,Homo sapiens,9606.0,
5569,,,,A549,CHEMBL621414,F,BAO_0000219,,,1,5726,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),,Homo sapiens,9606.0,
5570,,,,A549,CHEMBL621415,F,BAO_0000219,,,1,5726,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,,Homo sapiens,9606.0,
5571,,,,A549,CHEMBL621416,F,BAO_0000219,,,1,3936,The compound was evaluated for antiproliferative activity against A549 cell line,,Homo sapiens,9606.0,
5572,,,,A549,CHEMBL621417,F,BAO_0000219,,,1,14991,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,,Homo sapiens,9606.0,
5573,,,,A549,CHEMBL621418,F,BAO_0000219,,,1,5243,Concentration required for growth inhibition of human lung carcinoma cell line A549,,Homo sapiens,9606.0,
5574,,,,A549,CHEMBL621419,F,BAO_0000219,,,1,12858,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,,Homo sapiens,9606.0,
5575,,,,A549,CHEMBL621420,F,BAO_0000219,,,1,6776,Growth inhibition against A549 cell line was evaluated,,Homo sapiens,9606.0,
5576,,,,A549,CHEMBL875823,F,BAO_0000219,,,1,16558,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,,Homo sapiens,9606.0,
5577,,,,A549,CHEMBL621421,F,BAO_0000219,,,1,4583,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,,Homo sapiens,9606.0,
5578,,,,A549,CHEMBL621422,F,BAO_0000219,,,1,13514,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,,Homo sapiens,9606.0,
5579,,,,A549,CHEMBL884014,F,BAO_0000219,,,1,15166,Chemosensitivity against DT-diaphorase rich A549 cell lines,,Homo sapiens,9606.0,
5580,,,,A549,CHEMBL621423,F,BAO_0000219,,,1,13873,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,,Homo sapiens,9606.0,
5581,,,,A549,CHEMBL621424,F,BAO_0000219,,,1,6447,In vitro cytotoxicity against human A549 (lung cancer) cell line.,,Homo sapiens,9606.0,
5582,,,,A549,CHEMBL621425,F,BAO_0000219,,,1,2068,In vitro antitumor activity against A549 (lung) human tumor cell lines.,,Homo sapiens,9606.0,
5583,,,,A549,CHEMBL621426,F,BAO_0000219,,,1,1863,In vitro cytotoxic activity against human lung carcinoma A549 cell line,,Homo sapiens,9606.0,
5584,,,,A549,CHEMBL621427,F,BAO_0000219,,,1,13873,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,,Homo sapiens,9606.0,
5585,,,,A549,CHEMBL621428,F,BAO_0000219,,,1,13873,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,Homo sapiens,9606.0,
5586,,,,A549,CHEMBL621429,F,BAO_0000219,,,1,13873,Tested against A549 lung carcinoma in the sulforhodamine B assay.,,Homo sapiens,9606.0,
5587,,,,A549,CHEMBL621430,F,BAO_0000219,,,1,579,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),,Homo sapiens,9606.0,
5588,,,,A549,CHEMBL621431,F,BAO_0000219,,,1,579,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,,Homo sapiens,9606.0,
5589,,,,A549,CHEMBL621432,F,BAO_0000219,,,1,4584,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,,Homo sapiens,9606.0,
5590,,,,A549,CHEMBL621433,F,BAO_0000219,,,1,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,,Homo sapiens,9606.0,
5591,,,,A549,CHEMBL875824,F,BAO_0000219,,,1,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,Homo sapiens,9606.0,
5592,,,,A549,CHEMBL621434,F,BAO_0000219,,,1,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,Homo sapiens,9606.0,
5593,,,,A549,CHEMBL621435,F,BAO_0000219,,,1,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,,Homo sapiens,9606.0,
5594,,,,A549,CHEMBL621436,F,BAO_0000219,,,1,14188,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,,Homo sapiens,9606.0,
5595,,,,A549,CHEMBL621437,F,BAO_0000219,,,1,14188,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,,Homo sapiens,9606.0,
5596,,,,A549,CHEMBL621438,F,BAO_0000219,,,1,15354,Compound was tested for the growth inhibition of A549 lung tumor cell line,,Homo sapiens,9606.0,
5597,,,,A549,CHEMBL621439,F,BAO_0000219,,,1,14253,Growth inhibition of human non-small-lung carcinoma (A549) cell line,,Homo sapiens,9606.0,
5598,,,,A549,CHEMBL621440,F,BAO_0000219,,,1,13873,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,Homo sapiens,9606.0,
5599,,,,,CHEMBL621441,A,BAO_0000218,,,1,3043,Oral bioavailability in dog (conscious),In vivo,Canis lupus familiaris,9615.0,
5600,,,,,CHEMBL621442,A,BAO_0000218,,,1,3045,Compound was evaluated for the oral bioavailability after oral administration in dog.,In vivo,Canis lupus familiaris,9615.0,
5601,,,,,CHEMBL621443,A,BAO_0000218,,,1,3022,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,In vivo,Canis lupus familiaris,9615.0,
5602,,,,,CHEMBL621444,A,BAO_0000218,,,1,4453,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
5603,,,,,CHEMBL625133,A,BAO_0000218,,,1,1696,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
5604,,,,,CHEMBL625134,A,BAO_0000218,,,1,5045,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
5605,,,,,CHEMBL625135,A,BAO_0000218,,,1,5356,Oral bioavailability in dog (fasted),In vivo,Canis lupus familiaris,9615.0,
5606,,,,,CHEMBL625136,A,BAO_0000218,,,1,17764,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,In vivo,Canis lupus familiaris,9615.0,
5607,,,,,CHEMBL625137,A,BAO_0000218,,,1,6448,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
5608,,,,,CHEMBL625138,A,BAO_0000218,,,1,1475,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
5609,,,,,CHEMBL625139,A,BAO_0000218,,,1,3788,Percent bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
5610,,,,,CHEMBL872264,A,BAO_0000218,,,1,3639,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,In vivo,Canis lupus familiaris,9615.0,
5611,,,,,CHEMBL625140,A,BAO_0000218,,,1,13397,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
5612,,,,,CHEMBL624436,A,BAO_0000218,,,1,2137,The compound was evaluated for bioavailability in dogs; 34-44,In vivo,Canis lupus familiaris,9615.0,
5613,,,,,CHEMBL624437,A,BAO_0000218,,,1,2959,Bioavailability in dog (dose 4 mg/kg p.o.),In vivo,Canis lupus familiaris,9615.0,
5614,,,,,CHEMBL872261,A,BAO_0000218,,,1,6448,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
5615,,,,,CHEMBL624438,A,BAO_0000218,,,1,6084,8 hour trough Blood level in dog was measured after administration of compound,,Canis lupus familiaris,9615.0,
5616,Plasma,,,,CHEMBL624439,A,BAO_0000218,,,1,3639,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,In vivo,Canis lupus familiaris,9615.0,
5617,,,,,CHEMBL624440,A,BAO_0000218,,,1,6316,C24 after oral administration at 5 mg/kg,,Canis lupus familiaris,9615.0,
5618,,,,,CHEMBL624441,A,BAO_0000218,,,1,5238,Clearance after oral and iv dosing in dogs,,Canis lupus familiaris,9615.0,
5619,Plasma,,,,CHEMBL624442,A,BAO_0000218,,,1,17796,Clearance of the drug was measured in the plasma of dog,,Canis lupus familiaris,9615.0,
5620,,,,,CHEMBL624443,A,BAO_0000218,,,1,2652,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,Canis lupus familiaris,9615.0,
5621,,,,,CHEMBL624444,A,BAO_0000218,,,1,5654,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,In vivo,Canis lupus familiaris,9615.0,
5622,,,,,CHEMBL624445,A,BAO_0000218,,,1,6621,Clearance of compound was determined in dogs,In vivo,Canis lupus familiaris,9615.0,
5623,,,,,CHEMBL624446,A,BAO_0000218,,,1,6505,Clearance on i.v. administration of 2 mg/kg was measured in dog,In vivo,Canis lupus familiaris,9615.0,
5624,,,,,CHEMBL624447,A,BAO_0000218,,,1,5802,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,In vivo,Canis lupus familiaris,9615.0,
5625,,,,,CHEMBL624448,A,BAO_0000218,,,1,17267,Plasma clearance in dog was determined,In vivo,Canis lupus familiaris,9615.0,
5626,,,,,CHEMBL624449,A,BAO_0000218,,,1,4521,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,In vivo,Canis lupus familiaris,9615.0,
5627,,,,,CHEMBL624450,A,BAO_0000218,,,1,6535,Plasma clearance in dog after administration of 0.25 mg/kg iv,In vivo,Canis lupus familiaris,9615.0,
5628,,,,,CHEMBL875942,A,BAO_0000218,,,1,6535,Plasma clearance in dog after administration of 1 mg/kg iv,In vivo,Canis lupus familiaris,9615.0,
5629,,,,,CHEMBL624451,A,BAO_0000218,,,1,6535,Plasma clearance in dogs,In vivo,Canis lupus familiaris,9615.0,
5630,,,,,CHEMBL624452,A,BAO_0000218,,,1,5542,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,In vivo,Canis lupus familiaris,9615.0,
5631,,,,,CHEMBL624453,A,BAO_0000218,,,1,5199,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,In vivo,Canis lupus familiaris,9615.0,
5632,,,,,CHEMBL624454,A,BAO_0000218,,,1,16907,Plasma clearance after 15 mg/kg iv dose in Dogs,In vivo,Canis lupus familiaris,9615.0,
5633,,,,,CHEMBL624455,A,BAO_0000218,,,1,16907,Plasma clearance after 30 mg/kg po dose in Dogs,In vivo,Canis lupus familiaris,9615.0,
5634,,,,,CHEMBL624456,A,BAO_0000218,,,1,16367,Plasma administration to dogs,In vivo,Canis lupus familiaris,9615.0,
5635,,,,,CHEMBL624457,A,BAO_0000218,,,1,5505,Plasma clearance was determined,In vivo,Canis lupus familiaris,9615.0,
5636,,,,,CHEMBL624458,A,BAO_0000218,,,1,6215,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,In vivo,Canis lupus familiaris,9615.0,
5637,,,,,CHEMBL624459,A,BAO_0000218,,,1,1466,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,In vivo,Canis lupus familiaris,9615.0,
5638,Liver,,,,CHEMBL624460,A,BAO_0000251,,,2,5007,Intrinsic clearance in human liver microsomes,In vitro,Homo sapiens,9606.0,Microsomes
5639,Liver,,,,CHEMBL624461,A,BAO_0000251,,,2,5007,Intrinsic clearance in human liver microsomes,In vitro,Homo sapiens,9606.0,Microsomes
5640,,,,,CHEMBL875943,A,BAO_0000218,,,1,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,In vivo,Canis lupus familiaris,9615.0,
5641,,,,,CHEMBL624462,A,BAO_0000218,,,1,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,In vivo,Canis lupus familiaris,9615.0,
5642,,,,,CHEMBL624463,A,BAO_0000218,,,1,16452,Clearance in dog (dose 1 mg/kg i.v.),In vivo,Canis lupus familiaris,9615.0,
5643,,,,,CHEMBL624464,A,BAO_0000218,,,1,6221,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,In vivo,Canis lupus familiaris,9615.0,
5644,,,,,CHEMBL624465,A,BAO_0000218,,,1,5007,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),In vivo,Canis lupus familiaris,9615.0,
5645,,,,,CHEMBL624466,A,BAO_0000218,,,1,5668,Plasma clearance after peroral administration at 10 mpk in dog,In vivo,Canis lupus familiaris,9615.0,
5646,,,,,CHEMBL624467,A,BAO_0000218,,,1,5668,Plasma clearance after peroral administration at 5 mpk in dog,In vivo,Canis lupus familiaris,9615.0,
5647,,,,,CHEMBL624468,A,BAO_0000218,,,1,5668,Plasma clearance after peroral administration at 5 mg/kg in dog,In vivo,Canis lupus familiaris,9615.0,
5648,,,,,CHEMBL624469,A,BAO_0000218,,,1,15660,Plasma clearance was measured in dog,In vivo,Canis lupus familiaris,9615.0,
5649,,,,,CHEMBL624470,A,BAO_0000218,,,1,15660,Plasma clearance was measured in dog,In vivo,Canis lupus familiaris,9615.0,
5650,,,,,CHEMBL624471,A,BAO_0000218,,,1,5983,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,In vivo,Canis lupus familiaris,9615.0,
5651,,,,,CHEMBL624472,A,BAO_0000218,,,1,5600,Total clearance was determined after 0.1 mg/kg iv administration in dog,In vivo,Canis lupus familiaris,9615.0,
5652,,,,,CHEMBL622775,A,BAO_0000218,,,1,17764,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,In vivo,Canis lupus familiaris,9615.0,
5653,,,,,CHEMBL622776,A,BAO_0000218,,,1,6039,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,In vivo,Canis lupus familiaris,9615.0,
5654,,,,,CHEMBL622777,A,BAO_0000218,,,1,6039,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,In vivo,Canis lupus familiaris,9615.0,
5655,,,,,CHEMBL622778,A,BAO_0000218,,,1,6039,Clearance after peroral administration of 0.2 mg/kg in dog was determined,In vivo,Canis lupus familiaris,9615.0,
5656,,,,,CHEMBL622779,A,BAO_0000218,,,1,4368,Clearance by intravenous administration of 1.2 mg/kg in dog,In vivo,Canis lupus familiaris,9615.0,
5657,,,,,CHEMBL622780,A,BAO_0000218,,,1,4305,Clearance by iv administration in dogs at a dose of 1 mg/kg,In vivo,Canis lupus familiaris,9615.0,
5658,Plasma,,,,CHEMBL622781,A,BAO_0000218,,,1,1918,Clearance value was evaluated in dog plasma,In vivo,Canis lupus familiaris,9615.0,
5659,,,,,CHEMBL622782,A,BAO_0000218,,,1,6005,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,In vivo,Canis lupus familiaris,9615.0,
5660,Plasma,,,,CHEMBL622783,A,BAO_0000218,,,1,4839,Compound was tested for plasma clearance in dog,In vivo,Canis lupus familiaris,9615.0,
5661,,,,,CHEMBL622784,A,BAO_0000218,,,1,4239,Pharmacokinetic property (Plasma clearance) was measured in dog,In vivo,Canis lupus familiaris,9615.0,
5662,,,,,CHEMBL622785,A,BAO_0000218,,,1,17729,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,Mus musculus,10090.0,
5663,,,,,CHEMBL622786,A,BAO_0000218,,,1,17728,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,Mus musculus,10090.0,
5664,,,,,CHEMBL622787,A,BAO_0000218,,,1,5302,Area under curve value in mouse at a dose of 10 mg/kg,,Mus musculus,10090.0,
5665,,,,,CHEMBL875949,A,BAO_0000218,,,1,5506,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,Mus musculus,10090.0,
5666,,,,,CHEMBL622788,A,BAO_0000218,,,1,5506,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,Mus musculus,10090.0,
5667,,,,,CHEMBL622789,F,BAO_0000218,,,1,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,Mus musculus,10090.0,
5668,,,,,CHEMBL622790,F,BAO_0000218,,,1,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,Mus musculus,10090.0,
5669,,,,,CHEMBL622791,F,BAO_0000218,,,1,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,Mus musculus,10090.0,
5670,,,,,CHEMBL622792,F,BAO_0000218,,,1,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,Mus musculus,10090.0,
5671,,,,,CHEMBL622793,A,BAO_0000218,,,1,17764,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,Mus musculus,10090.0,
5672,,,,,CHEMBL622794,A,BAO_0000218,,,1,17753,Area under curve was determined for the compound at 24 mg/Kg,,Mus musculus,10090.0,
5673,,,,,CHEMBL622795,A,BAO_0000218,,,1,17753,Area under curve was determined for the compound at 40 mg/Kg,,Mus musculus,10090.0,
5674,,,,,CHEMBL621803,A,BAO_0000218,,,1,17753,Area under curve was determined for the compound at 5 mg/Kg,,Mus musculus,10090.0,
5675,,,,,CHEMBL621804,A,BAO_0000218,,,1,3132,Area under the curve for the compound is obtained at dose 25 mg/kg,,Mus musculus,10090.0,
5676,,,,,CHEMBL621805,A,BAO_0000218,,,1,3132,Area under the curve for the compound was obtained when tested in mouse,,Mus musculus,10090.0,
5677,,,,,CHEMBL621806,A,BAO_0000218,,,1,17837,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,Mus musculus,10090.0,
5678,,,,,CHEMBL621807,A,BAO_0000218,,,1,17837,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,Mus musculus,10090.0,
5679,,,,,CHEMBL621808,A,BAO_0000218,,,1,6062,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,Mus musculus,10090.0,
5680,,,,,CHEMBL621809,A,BAO_0000218,,,1,4066,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,Mus musculus,10090.0,
5681,,,,,CHEMBL621810,A,BAO_0000218,,,1,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,Mus musculus,10090.0,
5682,,,,,CHEMBL875164,A,BAO_0000218,,,1,14239,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,Mus musculus,10090.0,
5683,,,,,CHEMBL621811,A,BAO_0000218,,,1,14239,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,Mus musculus,10090.0,
5684,,,,,CHEMBL621812,A,BAO_0000218,,,1,4890,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,Mus musculus,10090.0,
5685,,,,,CHEMBL621813,A,BAO_0000218,,,1,429,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,Mus musculus,10090.0,
5686,,,,,CHEMBL621814,A,BAO_0000218,,,1,429,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,Mus musculus,10090.0,
5687,,,,,CHEMBL621815,A,BAO_0000218,,,1,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,Mus musculus,10090.0,
5688,,,,,CHEMBL621816,A,BAO_0000218,,,1,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,Mus musculus,10090.0,
5689,,,,,CHEMBL621817,A,BAO_0000218,,,1,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,Mus musculus,10090.0,
5690,,,,,CHEMBL621818,A,BAO_0000218,,,1,6091,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,Mus musculus,10090.0,
5691,,,,,CHEMBL621819,A,BAO_0000218,,,1,6091,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,Mus musculus,10090.0,
5692,,,,,CHEMBL621820,A,BAO_0000218,,,1,6091,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,Mus musculus,10090.0,
5693,,,,,CHEMBL621821,A,BAO_0000218,,,1,6091,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,Mus musculus,10090.0,
5694,,,,,CHEMBL621822,A,BAO_0000218,,,1,6178,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,Mus musculus,10090.0,
5695,,,,,CHEMBL619474,A,BAO_0000218,,,1,6178,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,Mus musculus,10090.0,
5696,,,,,CHEMBL619475,A,BAO_0000218,,,1,6619,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,Mus musculus,10090.0,
5697,,,,,CHEMBL619476,A,BAO_0000218,,,1,6619,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,Mus musculus,10090.0,
5698,,,,,CHEMBL619477,A,BAO_0000218,,,1,3760,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,Mus musculus,10090.0,
5699,,,,,CHEMBL619478,A,BAO_0000218,,,1,3760,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,Mus musculus,10090.0,
5700,,,,,CHEMBL619479,A,BAO_0000218,,,1,3760,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,Mus musculus,10090.0,
5701,,,,,CHEMBL619480,A,BAO_0000218,,,1,3760,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,Mus musculus,10090.0,
5702,,,,,CHEMBL619481,A,BAO_0000218,,,1,3192,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,Mus musculus,10090.0,
5703,,,,,CHEMBL619482,A,BAO_0000218,,,1,3192,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,Mus musculus,10090.0,
5704,,,,,CHEMBL619483,A,BAO_0000218,,,1,2675,Area under the curve was evaluated in mice after intravenous administration,,Mus musculus,10090.0,
5705,,,,,CHEMBL619484,A,BAO_0000218,,,1,2675,Area under the curve was evaluated in mice after oral administration,,Mus musculus,10090.0,
5706,Plasma,,,,CHEMBL619485,A,BAO_0000218,,,1,16597,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,,Mus musculus,10090.0,
5707,Plasma,,,,CHEMBL619486,A,BAO_0000218,,,1,16597,AUC total value at a dose of 10 mg/kg peroral administration in mice.,,Mus musculus,10090.0,
5708,,,,,CHEMBL619487,A,BAO_0000218,,,1,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,Mus musculus,10090.0,
5709,,,,,CHEMBL619488,A,BAO_0000218,,,1,17734,AUMC after intraperitoneal administration of 100 mg/kg in mice,,Mus musculus,10090.0,
5710,Blood,,,,CHEMBL620106,A,BAO_0000218,,,1,7767,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5711,,,,9L,CHEMBL620107,F,BAO_0000219,,,1,15345,The compound was tested in vitro for anticancer activity against 9L cells,,,,
5712,,,,,CHEMBL620283,F,BAO_0000019,,,0,2181,Anti proliferation activity determined; Weak effect,,Rattus norvegicus,10116.0,
5713,,,,,CHEMBL875176,F,BAO_0000219,,,0,2181,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,Rattus norvegicus,10116.0,
5714,,,,,CHEMBL620284,F,BAO_0000219,,,0,2181,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,Rattus norvegicus,10116.0,
5715,,,,,CHEMBL623515,F,BAO_0000219,,,0,2181,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,Rattus norvegicus,10116.0,
5716,,,,,CHEMBL623516,F,BAO_0000019,,,0,10486,The cytotoxic activity was in vitro tested by 9PS assay method,,Mus musculus,10090.0,
5717,,,,,CHEMBL623517,F,BAO_0000019,,,0,10486,The cytotoxic activity was in vitro tested by 9PS assay method.,,Mus musculus,10090.0,
5718,,,,,CHEMBL857878,A,BAO_0000019,,,0,15508,Partition coefficient (logD6.5),,,,
5719,,,,A2780,CHEMBL623518,F,BAO_0000219,,,1,5242,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,,Homo sapiens,9606.0,
5720,,,,A-375,CHEMBL624195,F,BAO_0000219,,,1,16167,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),,Homo sapiens,9606.0,
5721,,,,A-431,CHEMBL624196,F,BAO_0000219,,,1,4782,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,,Homo sapiens,9606.0,
5722,,,,A-431,CHEMBL624197,F,BAO_0000219,,,9,16093,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,Homo sapiens,9606.0,
5723,,,,A498,CHEMBL624198,F,BAO_0000219,,,1,2596,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,,Homo sapiens,9606.0,
5724,,,,A498,CHEMBL621287,F,BAO_0000219,,,1,2596,in vitro cytotoxicity against A 498 cancer cell line,,Homo sapiens,9606.0,
5725,,,,A498,CHEMBL621288,F,BAO_0000219,,,1,3239,In vitro cytotoxic activity against renal (A 498) cancer cell line.,,Homo sapiens,9606.0,
5726,,,,A498,CHEMBL876496,F,BAO_0000219,,,1,1847,Cytotoxic activity against A 498 renal cancer cell lines.,,Homo sapiens,9606.0,
5727,,,,A498,CHEMBL621289,F,BAO_0000219,,,1,10553,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,,Homo sapiens,9606.0,
5728,,,,,CHEMBL621290,F,BAO_0000019,,,0,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,Staphylococcus aureus,1280.0,
5729,,,,,CHEMBL621291,F,BAO_0000019,,,0,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,Staphylococcus aureus,1280.0,
5730,,,,,CHEMBL621292,F,BAO_0000019,,,0,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,Staphylococcus aureus,1280.0,
5731,,,,,CHEMBL621293,F,BAO_0000019,,,0,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,Staphylococcus aureus,1280.0,
5732,,,,A549,CHEMBL621294,F,BAO_0000219,,,1,4782,Inhibitory concentration required against A 549 lung cancer cell line,,Homo sapiens,9606.0,
5733,,,,A549,CHEMBL621295,F,BAO_0000219,,,1,11805,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,,Homo sapiens,9606.0,
5734,,,,A549,CHEMBL884007,F,BAO_0000219,,,1,11805,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,,Homo sapiens,9606.0,
5735,,,,A549,CHEMBL621296,F,BAO_0000219,,,1,2007,In vitro cytotoxicity against lung cancer A 549 cell lines,,Homo sapiens,9606.0,
5736,,,,A549,CHEMBL621297,F,BAO_0000219,,,1,4594,Compound was tested for its cytotoxicity against A 549 cell line,,Homo sapiens,9606.0,
5737,,,,A549,CHEMBL839828,F,BAO_0000219,,,1,6018,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",,Homo sapiens,9606.0,
5738,,,,A549,CHEMBL620397,F,BAO_0000219,,,1,6018,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",,Homo sapiens,9606.0,
5739,,,,A549,CHEMBL620398,F,BAO_0000219,,,1,3599,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,,Homo sapiens,9606.0,
5740,,,,A549,CHEMBL620399,F,BAO_0000219,,,1,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,Homo sapiens,9606.0,
5741,,,,A549,CHEMBL620400,F,BAO_0000219,,,1,16132,In vitro inhibition of A549 (human lung cancer) cell growth.,,Homo sapiens,9606.0,
5742,,,,A549,CHEMBL620401,F,BAO_0000219,,,1,16132,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,,Homo sapiens,9606.0,
5743,,,,A549,CHEMBL620402,F,BAO_0000219,,,1,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,Homo sapiens,9606.0,
5744,,,,A549,CHEMBL620403,F,BAO_0000219,,,1,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),,Homo sapiens,9606.0,
5745,,,,,CHEMBL620404,F,BAO_0000218,,,0,11913,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,,,
5746,,,,,CHEMBL620405,F,BAO_0000218,,,4,12621,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,In vivo,,,
5747,,,,,CHEMBL620406,F,BAO_0000218,,,4,12621,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,In vivo,,,
5748,,,,,CHEMBL620407,F,BAO_0000218,,,4,12621,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,In vivo,,,
5749,,,,,CHEMBL620408,F,BAO_0000218,,,4,12621,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,In vivo,,,
5750,,,,,CHEMBL620409,F,BAO_0000218,,,4,12621,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,In vivo,,,
5751,,,,A498,CHEMBL620410,F,BAO_0000219,,,1,3600,Inhibition of A-498 human Renal cell proliferation,,Homo sapiens,9606.0,
5752,,,,,CHEMBL620411,F,BAO_0000019,,,0,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,Rattus norvegicus,10116.0,
5753,,,,,CHEMBL620412,F,BAO_0000019,,,0,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,Rattus norvegicus,10116.0,
5754,,,,,CHEMBL876596,F,BAO_0000019,,,0,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,Rattus norvegicus,10116.0,
5755,,,,A 172,CHEMBL620413,F,BAO_0000219,,,1,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,,Homo sapiens,9606.0,
5756,,,,A 172,CHEMBL620414,F,BAO_0000219,,,1,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,Homo sapiens,9606.0,
5757,,,,A 172,CHEMBL620415,F,BAO_0000219,,,1,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,Homo sapiens,9606.0,
5758,,,,A549,CHEMBL620416,F,BAO_0000219,,,1,13617,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,,Homo sapiens,9606.0,
5759,,,,A549,CHEMBL620417,F,BAO_0000219,,,1,4584,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,,Homo sapiens,9606.0,
5760,,,,A549,CHEMBL620418,F,BAO_0000219,,,1,13799,Cytotoxic activity evaluated against A549 tumor cells,,Homo sapiens,9606.0,
5761,,,,A549,CHEMBL620419,F,BAO_0000219,,,1,16726,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,,Homo sapiens,9606.0,
5762,,,,A549,CHEMBL620420,F,BAO_0000219,,,1,16109,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,,Homo sapiens,9606.0,
5763,,,,A549,CHEMBL620421,F,BAO_0000219,,,1,16109,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,,Homo sapiens,9606.0,
5764,,,,A549,CHEMBL620422,F,BAO_0000219,,,1,15474,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,,Homo sapiens,9606.0,
5765,,,,A549,CHEMBL620423,F,BAO_0000219,,,1,6851,Cytotoxicity of compound against A549 cell line,,Homo sapiens,9606.0,
5766,,,,A549,CHEMBL620424,F,BAO_0000219,,,1,17534,Cytotoxicity against human lung cell carcinoma A549 cell line,,Homo sapiens,9606.0,
5767,,,,A549,CHEMBL620425,F,BAO_0000219,,,1,2621,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,,Homo sapiens,9606.0,
5768,,,,A549,CHEMBL620426,F,BAO_0000219,,,1,830,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,,Homo sapiens,9606.0,
5769,,,,A549,CHEMBL620427,F,BAO_0000219,,,1,14255,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,,Homo sapiens,9606.0,
5770,,,,A549,CHEMBL620428,F,BAO_0000219,,,1,14255,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,,Homo sapiens,9606.0,
5771,,,,A549,CHEMBL620429,F,BAO_0000219,,,1,1590,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,,Homo sapiens,9606.0,
5772,,,,A549,CHEMBL620430,F,BAO_0000219,,,1,6146,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,,Homo sapiens,9606.0,
5773,,,,A549,CHEMBL839887,F,BAO_0000219,,,1,17427,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,Homo sapiens,9606.0,
5774,,,,A549,CHEMBL620431,F,BAO_0000219,,,1,5280,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,,Homo sapiens,9606.0,
5775,,,,A549,CHEMBL884010,F,BAO_0000219,,,1,16786,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,,Homo sapiens,9606.0,
5776,,,,A549,CHEMBL620538,F,BAO_0000219,,,1,5895,In vitro cytotoxicity against A549 (human lung cancer),,Homo sapiens,9606.0,
5777,,,,A549,CHEMBL620539,F,BAO_0000219,,,1,14297,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,Homo sapiens,9606.0,
5778,,,,A549,CHEMBL623373,F,BAO_0000218,,,1,17824,In vivo antiproliferative activity against A549 cell line,,Homo sapiens,9606.0,
5779,,,,A549,CHEMBL623374,F,BAO_0000219,,,1,14368,Inhibition of non-small-cell lung adenocarcinoma (A549),,Homo sapiens,9606.0,
5780,,,,A549,CHEMBL623375,F,BAO_0000219,,,1,14368,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,,Homo sapiens,9606.0,
5781,,,,A549,CHEMBL623376,F,BAO_0000219,,,1,14254,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,,Homo sapiens,9606.0,
5782,,,,A549,CHEMBL623377,F,BAO_0000219,,,1,15897,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),,Homo sapiens,9606.0,
5783,,,,A549,CHEMBL623378,F,BAO_0000219,,,1,13866,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,Homo sapiens,9606.0,
5784,,,,A549,CHEMBL623379,F,BAO_0000219,,,1,13370,Inhibitory activity of compound against human A549 lung carcinoma cell line.,,Homo sapiens,9606.0,
5785,,,,A549,CHEMBL623380,F,BAO_0000219,,,1,4862,Inhibitory activity against A549 lung cancer cell line,,Homo sapiens,9606.0,
5786,,,,A549,CHEMBL623381,F,BAO_0000219,,,1,4862,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,,Homo sapiens,9606.0,
5787,,,,A549,CHEMBL623382,F,BAO_0000219,,,1,4862,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,,Homo sapiens,9606.0,
5788,,,,A549,CHEMBL623383,F,BAO_0000219,,,1,15970,Inhibitory concentration against A549 (lung cancer) cell line,,Homo sapiens,9606.0,
5789,,,,A549,CHEMBL623384,F,BAO_0000219,,,1,17713,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,Homo sapiens,9606.0,
5790,,,,A549,CHEMBL623385,F,BAO_0000219,,,1,4833,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,,Homo sapiens,9606.0,
5791,,,,A549,CHEMBL623386,F,BAO_0000219,,,1,13736,Activity against A549 cancer cell line.,,Homo sapiens,9606.0,
5792,,,,A549,CHEMBL884105,F,BAO_0000219,,,1,4312,The compound was evaluated for cytotoxicity against A549 cell line,,Homo sapiens,9606.0,
5793,,,,A549,CHEMBL623387,F,BAO_0000219,,,1,5421,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,,Homo sapiens,9606.0,
5794,,,,A549,CHEMBL621568,F,BAO_0000219,,,1,5421,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,Homo sapiens,9606.0,
5795,,,,A549,CHEMBL621569,F,BAO_0000219,,,1,14717,Growth inhibitory activity was measured for human A549 tumor cell line.,,Homo sapiens,9606.0,
5796,,,,A549,CHEMBL621570,F,BAO_0000219,,,1,4634,Inhibitory activity against A549 lung cancer cell line,,Homo sapiens,9606.0,
5797,,,,A549,CHEMBL621571,F,BAO_0000219,,,1,1149,Inhibitory activity against A549 cell line; inactive,,Homo sapiens,9606.0,
5798,,,,A549,CHEMBL621572,F,BAO_0000219,,,1,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,Homo sapiens,9606.0,
5799,,,,A549,CHEMBL621573,F,BAO_0000219,,,1,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,Homo sapiens,9606.0,
5800,,,,A549,CHEMBL621574,F,BAO_0000219,,,1,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,Homo sapiens,9606.0,
5801,,,,A549,CHEMBL621575,F,BAO_0000219,,,1,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),,Homo sapiens,9606.0,
5802,,,,A549,CHEMBL621576,F,BAO_0000219,,,1,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),,Homo sapiens,9606.0,
5803,,,,A549,CHEMBL621577,F,BAO_0000219,,,1,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),,Homo sapiens,9606.0,
5804,,,,A549,CHEMBL621578,F,BAO_0000219,,,1,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),,Homo sapiens,9606.0,
5805,,,,A549,CHEMBL621579,F,BAO_0000219,,,1,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),,Homo sapiens,9606.0,
5806,,,,A549,CHEMBL621580,F,BAO_0000219,,,1,5726,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,,Homo sapiens,9606.0,
5807,,,,,CHEMBL621581,A,BAO_0000218,,,1,17800,Plasma clearance (in vivo) in mongrel dogs was determined,In vivo,Canis lupus familiaris,9615.0,
5808,,,,,CHEMBL621582,A,BAO_0000218,,,1,5985,Plasma clearance was measured in dog,In vivo,Canis lupus familiaris,9615.0,
5809,,,,,CHEMBL621583,A,BAO_0000218,,,1,5530,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,In vivo,Canis lupus familiaris,9615.0,
5810,,,,,CHEMBL621584,A,BAO_0000218,,,1,5530,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,In vivo,Canis lupus familiaris,9615.0,
5811,Plasma,,,,CHEMBL621585,A,BAO_0000218,,,1,4839,Tested for plasma clearance in dog,In vivo,Canis lupus familiaris,9615.0,
5812,,,,,CHEMBL621586,A,BAO_0000218,,,1,3639,The compound was tested for clearance in dog plasma.,In vivo,Canis lupus familiaris,9615.0,
5813,,,,,CHEMBL875835,A,BAO_0000218,,,1,4838,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",In vivo,Canis lupus familiaris,9615.0,
5814,,,,,CHEMBL621587,A,BAO_0000218,,,1,4137,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,In vivo,Canis lupus familiaris,9615.0,
5815,Plasma,,,,CHEMBL621588,A,BAO_0000218,,,1,5017,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),In vivo,Canis lupus familiaris,9615.0,
5816,Liver,,,,CHEMBL621589,A,BAO_0000218,,,1,17538,In vitro clearance in dog liver microsomes,In vitro,Canis lupus familiaris,9615.0,Microsomes
5817,,,,,CHEMBL621590,A,BAO_0000218,,,1,6161,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,In vivo,Canis lupus familiaris,9615.0,
5818,,,,,CHEMBL621591,A,BAO_0000218,,,1,6161,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,In vivo,Canis lupus familiaris,9615.0,
5819,,,,,CHEMBL621592,A,BAO_0000218,,,1,1696,Plasma clearance in dog,In vivo,Canis lupus familiaris,9615.0,
5820,,,,,CHEMBL621593,A,BAO_0000218,,,1,6762,Clearance rate in dog,In vivo,Canis lupus familiaris,9615.0,
5821,Plasma,,,,CHEMBL621594,A,BAO_0000218,,,1,5932,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,In vivo,Canis lupus familiaris,9615.0,
5822,,,,,CHEMBL621595,A,BAO_0000218,,,1,6305,Clearance in dogs,In vivo,Canis lupus familiaris,9615.0,
5823,,,,,CHEMBL621596,A,BAO_0000218,,,1,4942,Plasma clearance in dogs,In vivo,Canis lupus familiaris,9615.0,
5824,,,,,CHEMBL621597,A,BAO_0000218,,,1,4219,Plasma clearance was determined,In vivo,Canis lupus familiaris,9615.0,
5825,,,,,CHEMBL621598,A,BAO_0000218,,,1,17853,Lower clearance in dog (i.v.) at 0.5 mpk,In vivo,Canis lupus familiaris,9615.0,
5826,,,,,CHEMBL621599,A,BAO_0000218,,,1,4514,Plasma clearance in Beagle dogs,In vivo,Canis lupus familiaris,9615.0,
5827,,,,,CHEMBL875836,A,BAO_0000218,,,1,6448,Plasma clearance (Clp) in dog,In vivo,Canis lupus familiaris,9615.0,
5828,,,,,CHEMBL621600,A,BAO_0000218,,,1,6227,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,In vivo,Canis lupus familiaris,9615.0,
5829,,,,,CHEMBL621601,A,BAO_0000218,,,1,6227,Plasma clearance (pharmacokinetic parameter) in dog was determined,In vivo,Canis lupus familiaris,9615.0,
5830,,,,,CHEMBL618474,A,BAO_0000218,,,1,6062,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,In vivo,Canis lupus familiaris,9615.0,
5831,,,,,CHEMBL618475,A,BAO_0000218,,,1,6821,Plasma clearance of compound was determined in dog,In vivo,Canis lupus familiaris,9615.0,
5832,,,,,CHEMBL624524,A,BAO_0000218,,,1,4709,Plasma clearance after intravenous administration of 1 mg/kg in dog,In vivo,Canis lupus familiaris,9615.0,
5833,,,,,CHEMBL624525,A,BAO_0000218,,,1,4521,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,In vivo,Canis lupus familiaris,9615.0,
5834,,,,,CHEMBL624526,A,BAO_0000218,,,1,5374,Plasma clearance in dog was determined,In vivo,Canis lupus familiaris,9615.0,
5835,,,,,CHEMBL624527,A,BAO_0000218,,,1,6057,Plasma clearance was calculated in dog,In vivo,Canis lupus familiaris,9615.0,
5836,,,,,CHEMBL624528,A,BAO_0000218,,,1,4727,Plasma clearance at the dose of 2 mg/kg in dog,In vivo,Canis lupus familiaris,9615.0,
5837,,,,,CHEMBL624529,A,BAO_0000218,,,1,5145,Plasma clearance in dog,In vivo,Canis lupus familiaris,9615.0,
5838,,,,,CHEMBL624530,A,BAO_0000218,,,1,17657,Plasma clearance in dog,In vivo,Canis lupus familiaris,9615.0,
5839,,,,,CHEMBL624531,A,BAO_0000218,,,1,17657,Plasma clearance in dog; Unable to calculate,In vivo,Canis lupus familiaris,9615.0,
5840,,,,,CHEMBL624532,A,BAO_0000218,,,1,5145,Plasma clearance in rhesus monkey,In vivo,Canis lupus familiaris,9615.0,
5841,,,,,CHEMBL624533,A,BAO_0000218,,,1,6642,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),In vivo,Canis lupus familiaris,9615.0,
5842,,,,,CHEMBL624534,A,BAO_0000218,,,1,6641,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,Canis lupus familiaris,9615.0,
5843,,,,,CHEMBL624535,A,BAO_0000218,,,1,6642,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,Canis lupus familiaris,9615.0,
5844,,,,,CHEMBL624536,A,BAO_0000218,,,1,5472,Plasma clearance was evaluated in dog,In vivo,Canis lupus familiaris,9615.0,
5845,,,,,CHEMBL624537,A,BAO_0000218,,,1,5472,Plasma clearance was evaluated in dog; Not tested,In vivo,Canis lupus familiaris,9615.0,
5846,,,,,CHEMBL624538,A,BAO_0000218,,,1,5472,Plasma clearance was evaluated in rhesus,In vivo,Canis lupus familiaris,9615.0,
5847,,,,,CHEMBL624539,A,BAO_0000218,,,1,5472,Plasma clearance was evaluated in rhesus; Not tested,In vivo,Canis lupus familiaris,9615.0,
5848,,,,,CHEMBL624540,A,BAO_0000218,,,1,4257,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,In vivo,Canis lupus familiaris,9615.0,
5849,,,,,CHEMBL624541,A,BAO_0000218,,,1,6679,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,Canis lupus familiaris,9615.0,
5850,,,,,CHEMBL624542,A,BAO_0000218,,,1,5546,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,In vivo,Canis lupus familiaris,9615.0,
5851,,,,,CHEMBL624543,A,BAO_0000218,,,1,6348,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,Canis lupus familiaris,9615.0,
5852,,,,,CHEMBL624544,A,BAO_0000218,,,1,5474,Clearance value at a dose of 0.2 mg/kg i.v.,In vivo,Canis lupus familiaris,9615.0,
5853,Plasma,,,,CHEMBL624545,A,BAO_0000218,,,1,6316,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,In vivo,Canis lupus familiaris,9615.0,
5854,,,,,CHEMBL624546,A,BAO_0000218,,,1,17594,Cmax after oral dose of compound at 3 mg/kg in dogs,In vivo,Canis lupus familiaris,9615.0,
5855,,,,,CHEMBL875957,A,BAO_0000218,,,1,17594,Cmax after single intravenous bolus of 1 mg/kg in dogs,In vivo,Canis lupus familiaris,9615.0,
5856,,,,,CHEMBL624547,A,BAO_0000218,,,1,5802,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,In vivo,Canis lupus familiaris,9615.0,
5857,,,,,CHEMBL624548,A,BAO_0000218,,,1,6535,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,In vivo,Canis lupus familiaris,9615.0,
5858,,,,,CHEMBL624549,A,BAO_0000218,,,1,6535,Cmax in dog after administration of 1 mg/kg iv,In vivo,Canis lupus familiaris,9615.0,
5859,Plasma,,,,CHEMBL624550,A,BAO_0000218,,,1,1466,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,In vivo,Canis lupus familiaris,9615.0,
5860,,,,,CHEMBL621613,A,BAO_0000218,,,1,6505,Cmax on p.o. administration of 10 mg/kg was measured in dog,In vivo,Canis lupus familiaris,9615.0,
5861,,,,,CHEMBL621614,A,BAO_0000218,,,1,5668,Cmax was determine after peroral administration at 10 mpk in dog,In vivo,Canis lupus familiaris,9615.0,
5862,,,,,CHEMBL623431,A,BAO_0000218,,,1,5668,Cmax was determine after peroral administration at 5 mpk in dog,In vivo,Canis lupus familiaris,9615.0,
5863,,,,,CHEMBL623432,A,BAO_0000218,,,1,5668,Cmax was determine after peroral administration at 5 mg/kg in dog,In vivo,Canis lupus familiaris,9615.0,
5864,,,,,CHEMBL623433,A,BAO_0000218,,,1,5600,Cmax after 0.3 mg/kg po administration in dog,In vivo,Canis lupus familiaris,9615.0,
5865,,,,,CHEMBL623434,A,BAO_0000218,,,1,17764,Cmax after peroral administration in dogs at 2.4 uM/kg,In vivo,Canis lupus familiaris,9615.0,
5866,,,,,CHEMBL623435,A,BAO_0000218,,,1,6123,Cmax in dog after oral administration at 1 mg/kg,In vivo,Canis lupus familiaris,9615.0,
5867,,,,,CHEMBL623436,A,BAO_0000218,,,1,6123,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,In vivo,Canis lupus familiaris,9615.0,
5868,,,,,CHEMBL875958,A,BAO_0000218,,,1,6757,Cmax upon oral administration in male Beagle dog at 10 mg/kg,In vivo,Canis lupus familiaris,9615.0,
5869,,,,,CHEMBL623437,A,BAO_0000218,,,1,16907,Cmax value after 15 mg/kg iv dose in Dogs,In vivo,Canis lupus familiaris,9615.0,
5870,Blood,,,,CHEMBL623438,A,BAO_0000218,,,1,7767,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5871,Blood,,,,CHEMBL623439,A,BAO_0000218,,,1,7767,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5872,Bone,,,,CHEMBL623440,A,BAO_0000218,,,1,7767,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5873,Bone,,,,CHEMBL623441,A,BAO_0000218,,,1,7767,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5874,Bone,,,,CHEMBL623442,A,BAO_0000218,,,1,7767,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5875,,,,,CHEMBL623469,A,BAO_0000218,,,1,7767,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5876,,,,,CHEMBL623470,A,BAO_0000218,,,1,7767,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5877,,,,,CHEMBL623471,A,BAO_0000218,,,1,7767,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5878,Heart,,,,CHEMBL623472,A,BAO_0000218,,,1,7767,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5879,Heart,,,,CHEMBL623473,A,BAO_0000218,,,1,7767,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5880,Heart,,,,CHEMBL623474,A,BAO_0000218,,,1,7767,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5881,Kidney,,,,CHEMBL623475,A,BAO_0000218,,,1,7767,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5882,Kidney,,,,CHEMBL623476,A,BAO_0000218,,,1,7767,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5883,Kidney,,,,CHEMBL623477,A,BAO_0000218,,,1,7767,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5884,Intestine,,,,CHEMBL621896,A,BAO_0000218,,,1,7767,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5885,Intestine,,,,CHEMBL621897,A,BAO_0000218,,,1,7767,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5886,Intestine,,,,CHEMBL621898,A,BAO_0000218,,,1,7767,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5887,Liver,,,,CHEMBL621899,A,BAO_0000218,,,1,7767,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5888,Liver,,,,CHEMBL621900,A,BAO_0000218,,,1,7767,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5889,Liver,,,,CHEMBL621901,A,BAO_0000218,,,1,7767,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5890,Lung,,,,CHEMBL621902,A,BAO_0000218,,,1,7767,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5891,Lung,,,,CHEMBL621903,A,BAO_0000218,,,1,7767,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5892,Lung,,,,CHEMBL622587,A,BAO_0000218,,,1,7767,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5893,Muscle tissue,,,,CHEMBL620285,A,BAO_0000218,,,1,7767,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5894,Muscle tissue,,,,CHEMBL875285,A,BAO_0000218,,,1,7767,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5895,Muscle tissue,,,,CHEMBL620286,A,BAO_0000218,,,1,7767,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5896,,,,,CHEMBL620287,A,BAO_0000218,,,1,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5897,,,,,CHEMBL620288,A,BAO_0000218,,,1,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5898,,,,,CHEMBL620289,A,BAO_0000218,,,1,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5899,Intestine,,,,CHEMBL620290,A,BAO_0000218,,,1,7767,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5900,Intestine,,,,CHEMBL620291,A,BAO_0000218,,,1,7767,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5901,Intestine,,,,CHEMBL620292,A,BAO_0000218,,,1,7767,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5902,Spleen,,,,CHEMBL620293,A,BAO_0000218,,,1,7767,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5903,Spleen,,,,CHEMBL620294,A,BAO_0000218,,,1,7767,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5904,Spleen,,,,CHEMBL618614,A,BAO_0000218,,,1,7767,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5905,Stomach,,,,CHEMBL618615,A,BAO_0000218,,,1,7767,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5906,Stomach,,,,CHEMBL618616,A,BAO_0000218,,,1,7767,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
5907,,,,A 172,CHEMBL618617,F,BAO_0000219,,,1,2036,Cytotoxicity against A-172 human tumor cell lines,,Homo sapiens,9606.0,
5908,,,,A 172,CHEMBL618618,F,BAO_0000219,,,1,2357,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,,Homo sapiens,9606.0,
5909,,,,A204,CHEMBL618619,F,BAO_0000219,,,1,1457,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,,Homo sapiens,9606.0,
5910,,,,A2780,CHEMBL618620,F,BAO_0000219,,,1,4379,Tested for antiproliferative activity against A-2780 tumoral cell line,,Homo sapiens,9606.0,
5911,,,,A-375,CHEMBL618621,F,BAO_0000219,,,1,1093,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,,Homo sapiens,9606.0,
5912,,,,A-375,CHEMBL618622,F,BAO_0000219,,,1,12152,Tested in vitro against A-375 cell line human melanoma,,Homo sapiens,9606.0,
5913,,,,A-427,CHEMBL618623,F,BAO_0000219,,,1,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,,Homo sapiens,9606.0,
5914,,,,A-427,CHEMBL618624,F,BAO_0000219,,,1,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,Homo sapiens,9606.0,
5915,,,,A-427,CHEMBL618625,F,BAO_0000219,,,1,16582,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,,Homo sapiens,9606.0,
5916,,,,A-427,CHEMBL618626,F,BAO_0000219,,,1,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,Homo sapiens,9606.0,
5917,,,,A-427,CHEMBL618627,F,BAO_0000219,,,1,10413,Antitumor activity on A-427 lung carcinoma cell lines,,Homo sapiens,9606.0,
5918,,,,A-427,CHEMBL618628,F,BAO_0000219,,,1,6418,Cytotoxic activity against human A-427 lung tumor cell line,,Homo sapiens,9606.0,
5919,,,,A-427,CHEMBL618629,F,BAO_0000219,,,1,17134,In vitro antitumor effects against human A-427 cell lines.,,Homo sapiens,9606.0,
5920,,,,A-427,CHEMBL618630,F,BAO_0000219,,,1,16132,In vitro inhibition of A-427 (human lung cancer) cell growth.,,Homo sapiens,9606.0,
5921,,,,A-427,CHEMBL618631,F,BAO_0000219,,,1,16132,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,,Homo sapiens,9606.0,
5922,,,,A-427,CHEMBL618632,F,BAO_0000219,,,1,16780,Cytotoxic activity of compound against A-427 lung human tumor cell line,,Homo sapiens,9606.0,
5923,,,,A-431,CHEMBL618633,F,BAO_0000219,,,1,4085,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,,Homo sapiens,9606.0,
5924,,,,A498,CHEMBL619315,F,BAO_0000219,,,1,1276,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,,Homo sapiens,9606.0,
5925,,,,A498,CHEMBL619316,F,BAO_0000219,,,1,3498,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,,Homo sapiens,9606.0,
5926,,,,A498,CHEMBL619317,F,BAO_0000219,,,1,1169,Cytotoxicity against human kidney carcinoma A-498cell lines,,Homo sapiens,9606.0,
5927,,,,A498,CHEMBL619318,F,BAO_0000219,,,1,4450,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,,Homo sapiens,9606.0,
5928,,,,A498,CHEMBL619319,F,BAO_0000219,,,1,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,,Homo sapiens,9606.0,
5929,,,,A498,CHEMBL619739,F,BAO_0000219,,,1,4461,Antitumor cytotoxic activity against A-498 cell line was determined,,Homo sapiens,9606.0,
5930,,,,A498,CHEMBL619740,F,BAO_0000219,,,1,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,,Homo sapiens,9606.0,
5931,,,,A498,CHEMBL883158,F,BAO_0000219,,,1,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,,Homo sapiens,9606.0,
5932,,,,A498,CHEMBL884012,F,BAO_0000219,,,1,1457,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,,Homo sapiens,9606.0,
5933,,,,A498,CHEMBL619741,F,BAO_0000219,,,1,3664,In vitro inhibitory activity against A-498 ovarian cancer cell lines,,Homo sapiens,9606.0,
5934,,,,A498,CHEMBL619742,F,BAO_0000219,,,1,15895,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",,Homo sapiens,9606.0,
5935,,,,A549,CHEMBL876610,F,BAO_0000219,,,1,11843,Inhibition of growth lung non-small cell carcinoma A-549 cell line,,Homo sapiens,9606.0,
5936,,,,A549,CHEMBL619743,F,BAO_0000219,,,1,11843,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,,Homo sapiens,9606.0,
5937,,,,A549,CHEMBL619744,F,BAO_0000219,,,1,17705,In vitro antiproliferative activity against human A-549 NSCL cell line,,Homo sapiens,9606.0,
5938,,,,A549,CHEMBL619745,F,BAO_0000219,,,1,17705,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,,Homo sapiens,9606.0,
5939,,,,A549,CHEMBL619746,F,BAO_0000219,,,1,4369,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,,Homo sapiens,9606.0,
5940,,,,A549,CHEMBL619747,F,BAO_0000219,,,1,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,,Homo sapiens,9606.0,
5941,,,,A549,CHEMBL619748,F,BAO_0000219,,,1,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,,Homo sapiens,9606.0,
5942,,,,A549,CHEMBL619749,F,BAO_0000219,,,1,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,,Homo sapiens,9606.0,
5943,,,,A549,CHEMBL619750,F,BAO_0000219,,,1,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,,Homo sapiens,9606.0,
5944,,,,A549,CHEMBL624014,F,BAO_0000219,,,1,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,,Homo sapiens,9606.0,
5945,,,,A549,CHEMBL624015,F,BAO_0000219,,,1,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,,Homo sapiens,9606.0,
5946,,,,A549,CHEMBL885344,F,BAO_0000219,,,1,4787,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,,Homo sapiens,9606.0,
5947,,,,A549,CHEMBL623224,F,BAO_0000219,,,1,4787,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,,Homo sapiens,9606.0,
5948,,,,A549,CHEMBL623225,F,BAO_0000219,,,1,6513,Cytotoxic activity against A-549 cell line,,Homo sapiens,9606.0,
5949,,,,A549,CHEMBL622698,F,BAO_0000219,,,1,6690,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,,Homo sapiens,9606.0,
5950,,,,A549,CHEMBL622699,F,BAO_0000219,,,1,6690,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,,Homo sapiens,9606.0,
5951,,,,A549,CHEMBL622700,F,BAO_0000219,,,1,12263,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",,Homo sapiens,9606.0,
5952,,,,A549,CHEMBL622701,F,BAO_0000219,,,1,1054,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),,Homo sapiens,9606.0,
5953,,,,A549,CHEMBL622702,F,BAO_0000219,,,1,1359,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),,Homo sapiens,9606.0,
5954,,,,A549,CHEMBL622703,F,BAO_0000219,,,1,3547,Cytotoxic activity against human lung carcinoma (A-549) cell line,,Homo sapiens,9606.0,
5955,,,,A549,CHEMBL622704,F,BAO_0000219,,,1,5771,Cytotoxic activity towards A-549 cells,,Homo sapiens,9606.0,
5956,,,,A549,CHEMBL622705,F,BAO_0000219,,,1,14425,"In vitro percent inhibition of A549, lung carcinoma.",,Homo sapiens,9606.0,
5957,,,,A549,CHEMBL622706,F,BAO_0000219,,,1,14425,"In vitro percent inhibition of A549, lung carcinoma",,Homo sapiens,9606.0,
5958,,,,A549,CHEMBL622707,F,BAO_0000219,,,1,14425,"In vitro percent inhibition of A549, lung carcinoma.",,Homo sapiens,9606.0,
5959,,,,A549,CHEMBL622708,F,BAO_0000219,,,1,14425,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",,Homo sapiens,9606.0,
5960,,,,A549,CHEMBL622709,F,BAO_0000219,,,1,5280,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,,Homo sapiens,9606.0,
5961,,,,A549,CHEMBL622710,F,BAO_0000219,,,1,15176,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,,Homo sapiens,9606.0,
5962,,,,A549,CHEMBL622711,F,BAO_0000219,,,1,15300,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,,Homo sapiens,9606.0,
5963,,,,A549,CHEMBL622712,F,BAO_0000218,,,1,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,Homo sapiens,9606.0,
5964,,,,A549,CHEMBL622713,F,BAO_0000218,,,1,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,Homo sapiens,9606.0,
5965,,,,A549,CHEMBL622714,F,BAO_0000218,,,1,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,Homo sapiens,9606.0,
5966,,,,A549,CHEMBL622715,F,BAO_0000218,,,1,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,Homo sapiens,9606.0,
5967,,,,A549,CHEMBL622716,F,BAO_0000218,,,1,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,Homo sapiens,9606.0,
5968,,,,A549,CHEMBL622717,F,BAO_0000219,,,1,17824,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",,Homo sapiens,9606.0,
5969,,,,A549,CHEMBL622718,F,BAO_0000218,,,1,17528,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),,Homo sapiens,9606.0,
5970,,,,A549,CHEMBL622719,F,BAO_0000219,,,1,6870,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,,Homo sapiens,9606.0,
5971,,,,A549,CHEMBL622720,F,BAO_0000219,,,1,6870,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,Homo sapiens,9606.0,
5972,,,,A549,CHEMBL622721,F,BAO_0000219,,,1,6870,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,,Homo sapiens,9606.0,
5973,,,,A549,CHEMBL622722,F,BAO_0000219,,,1,6870,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,Homo sapiens,9606.0,
5974,,,,A549,CHEMBL876030,F,BAO_0000219,,,1,16726,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,Homo sapiens,9606.0,
5975,,,,A549,CHEMBL620206,F,BAO_0000219,,,1,6170,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",,Homo sapiens,9606.0,
5976,,,,A549,CHEMBL620207,F,BAO_0000219,,,1,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,,Homo sapiens,9606.0,
5977,,,,A549,CHEMBL620208,F,BAO_0000219,,,1,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,,Homo sapiens,9606.0,
5978,,,,A549,CHEMBL620209,F,BAO_0000219,,,1,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,,Homo sapiens,9606.0,
5979,,,,A549,CHEMBL620210,F,BAO_0000219,,,1,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,,Homo sapiens,9606.0,
5980,,,,A549,CHEMBL621639,F,BAO_0000219,,,1,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,,Homo sapiens,9606.0,
5981,,,,A549,CHEMBL621640,F,BAO_0000219,,,1,17321,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,,Homo sapiens,9606.0,
5982,,,,A549,CHEMBL621641,F,BAO_0000219,,,1,17528,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,Homo sapiens,9606.0,
5983,,,,A549,CHEMBL621642,F,BAO_0000219,,,1,12888,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,,Homo sapiens,9606.0,
5984,,,,A549,CHEMBL621643,F,BAO_0000219,,,1,4312,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,,Homo sapiens,9606.0,
5985,,,,A549,CHEMBL621644,F,BAO_0000219,,,1,4312,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,,Homo sapiens,9606.0,
5986,,,,A549,CHEMBL621645,F,BAO_0000219,,,1,4312,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,,Homo sapiens,9606.0,
5987,,,,A549,CHEMBL621646,F,BAO_0000219,,,1,17737,In vitro antiproliferative activity against A549 cell line,,Mus musculus,10090.0,
5988,,,,A549,CHEMBL621647,F,BAO_0000219,,,1,6630,Synergism with indomethacin in A549 cells,,,,
5989,,,,A549,CHEMBL621648,F,BAO_0000219,,,1,6630,Synergism with tolmetin in A549 cells,,,,
5990,,,,A549,CHEMBL621649,F,BAO_0000219,,,1,6630,Synergism with sulindac in A549 cells,,,,
5991,,,,A549,CHEMBL621650,F,BAO_0000219,,,1,6630,Antagonism of indomethacin in A549 cells,,,,
5992,,,,A549,CHEMBL621651,F,BAO_0000219,,,1,6630,Antagonism of sulindac in A549 cells,,,,
5993,,,,A549,CHEMBL621652,F,BAO_0000219,,,1,6630,Antagonism of tolmetin in A549 cells,,,,
5994,,,,A549,CHEMBL621653,F,BAO_0000219,,,1,6630,Synergism with indomethacin in A549 cells,,,,
5995,,,,A549,CHEMBL621654,F,BAO_0000219,,,1,6630,Synergism with sulindac in A549 cells,,,,
5996,,,,A549,CHEMBL621655,F,BAO_0000219,,,1,6630,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,,,
5997,,,,,CHEMBL621656,A,BAO_0000218,,,1,16907,Cmax value after 30 mg/kg po dose in Dogs,In vivo,Canis lupus familiaris,9615.0,
5998,,,,,CHEMBL621657,A,BAO_0000218,,,1,5944,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),In vivo,Canis lupus familiaris,9615.0,
5999,,,,,CHEMBL621658,A,BAO_0000218,,,1,5944,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,In vivo,Canis lupus familiaris,9615.0,
6000,,,,,CHEMBL621659,A,BAO_0000218,,,1,5944,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),In vivo,Canis lupus familiaris,9615.0,
6001,,,,,CHEMBL621660,A,BAO_0000218,,,1,5944,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,In vivo,Canis lupus familiaris,9615.0,
6002,,,,,CHEMBL621661,A,BAO_0000218,,,1,2959,Cmax value after administration of 4 mg/Kg oral dose in dog,In vivo,Canis lupus familiaris,9615.0,
6003,,,,,CHEMBL621662,A,BAO_0000218,,,1,6241,Cmax value in dog,In vivo,Canis lupus familiaris,9615.0,
6004,,,,,CHEMBL621663,A,BAO_0000218,,,1,6241,Cmax value in dogs after oral administration at 1 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6005,,,,,CHEMBL621664,A,BAO_0000218,,,1,2652,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,In vivo,Canis lupus familiaris,9615.0,
6006,Plasma,,,,CHEMBL621665,A,BAO_0000218,,,1,1806,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,In vivo,Canis lupus familiaris,9615.0,
6007,Plasma,,,,CHEMBL621666,A,BAO_0000218,,,1,1806,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,In vivo,Canis lupus familiaris,9615.0,
6008,,,,,CHEMBL621667,A,BAO_0000218,,,1,1021,Concentration maxima after oral dosing in dogs,In vivo,Canis lupus familiaris,9615.0,
6009,,,,,CHEMBL876738,A,BAO_0000218,,,1,1021,Concentration maxima after oral dosing in dogs; not available,In vivo,Canis lupus familiaris,9615.0,
6010,,,,,CHEMBL621668,A,BAO_0000218,,,1,1021,Concentration maxima after oral dosing in dogs; not available,In vivo,Canis lupus familiaris,9615.0,
6011,,,,,CHEMBL621669,A,BAO_0000218,,,1,5444,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,In vivo,Canis lupus familiaris,9615.0,
6012,,,,,CHEMBL621670,A,BAO_0000218,,,1,5444,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,In vivo,Canis lupus familiaris,9615.0,
6013,,,,,CHEMBL621671,A,BAO_0000218,,,1,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog,In vivo,Canis lupus familiaris,9615.0,
6014,,,,,CHEMBL622360,A,BAO_0000218,,,1,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,In vivo,Canis lupus familiaris,9615.0,
6015,,,,,CHEMBL622361,A,BAO_0000218,,,1,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,In vivo,Canis lupus familiaris,9615.0,
6016,Plasma,,,,CHEMBL622362,A,BAO_0000218,,,1,5130,Cmax in dog plasma after oral dose (1 mg/kg),In vivo,Canis lupus familiaris,9615.0,
6017,Plasma,,,,CHEMBL622363,A,BAO_0000218,,,1,3249,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6018,Plasma,,,,CHEMBL622364,A,BAO_0000218,,,1,5473,Maximal plasma concentration at a dose of 1 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6019,Plasma,,,,CHEMBL622365,A,BAO_0000218,,,1,5474,Maximal plasma concentration at a dose of 1 mg/kg (oral),In vivo,Canis lupus familiaris,9615.0,
6020,Plasma,,,,CHEMBL622533,A,BAO_0000218,,,1,4657,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,In vivo,Canis lupus familiaris,9615.0,
6021,,,,,CHEMBL622534,A,BAO_0000218,,,1,3031,Maximum concentration of compound in dog was evaluated.,In vivo,Canis lupus familiaris,9615.0,
6022,,,,,CHEMBL622535,A,BAO_0000218,,,1,4527,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,In vivo,Canis lupus familiaris,9615.0,
6023,,,,,CHEMBL876739,A,BAO_0000218,,,1,4186,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,In vivo,Canis lupus familiaris,9615.0,
6024,,,,,CHEMBL622536,A,BAO_0000218,,,1,5007,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),In vivo,Canis lupus familiaris,9615.0,
6025,Plasma,,,,CHEMBL622537,A,BAO_0000218,,,1,3132,Maximum concentration obtained in dog plasma was determined,In vivo,Canis lupus familiaris,9615.0,
6026,,,,,CHEMBL622538,A,BAO_0000218,,,1,5006,Maximum concentration was determined,In vivo,Canis lupus familiaris,9615.0,
6027,,,,,CHEMBL627867,A,BAO_0000218,,,1,4727,Maximum concentration at the dose of 2 mg/kg in dog,In vivo,Canis lupus familiaris,9615.0,
6028,,,,,CHEMBL627868,A,BAO_0000218,,,1,1916,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,In vivo,Canis lupus familiaris,9615.0,
6029,Plasma,,,,CHEMBL627869,A,BAO_0000218,,,1,1918,Maximum concentration was evaluated in dog plasma,In vivo,Canis lupus familiaris,9615.0,
6030,,,,,CHEMBL627870,A,BAO_0000218,,,1,3045,Maximum concentration was evaluated after 75 min after administration in dog,In vivo,Canis lupus familiaris,9615.0,
6031,Plasma,,,,CHEMBL627871,A,BAO_0000218,,,1,9579,Maximum plasma concentration determined in dog after oral administration of 17b,In vivo,Canis lupus familiaris,9615.0,
6032,Plasma,,,,CHEMBL627872,A,BAO_0000218,,,1,9579,Maximum plasma concentration determined in dog after oral administration of 2b,In vivo,Canis lupus familiaris,9615.0,
6033,Plasma,,,,CHEMBL627873,A,BAO_0000218,,,1,933,Maximum plasma concentration in dog,In vivo,Canis lupus familiaris,9615.0,
6034,Plasma,,,,CHEMBL627874,A,BAO_0000218,,,1,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6035,Plasma,,,,CHEMBL627875,A,BAO_0000218,,,1,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6036,Plasma,,,,CHEMBL627876,A,BAO_0000218,,,1,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6037,Plasma,,,,CHEMBL627877,A,BAO_0000218,,,1,17839,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6038,Plasma,,,,CHEMBL627878,A,BAO_0000218,,,1,6348,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,Canis lupus familiaris,9615.0,
6039,Plasma,,,,CHEMBL627879,A,BAO_0000218,,,1,16367,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6040,Plasma,,,,CHEMBL875355,A,BAO_0000218,,,1,1337,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,In vivo,Canis lupus familiaris,9615.0,
6041,Plasma,,,,CHEMBL627880,A,BAO_0000218,,,1,1337,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,In vivo,Canis lupus familiaris,9615.0,
6042,Plasma,,,,CHEMBL627881,A,BAO_0000218,,,1,5199,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,In vivo,Canis lupus familiaris,9615.0,
6043,Plasma,,,,CHEMBL627882,A,BAO_0000218,,,1,17650,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,In vivo,Canis lupus familiaris,9615.0,
6044,Plasma,,,,CHEMBL627883,A,BAO_0000218,,,1,6679,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,In vivo,Canis lupus familiaris,9615.0,
6045,Plasma,,,,CHEMBL628526,A,BAO_0000218,,,1,5356,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,In vivo,Canis lupus familiaris,9615.0,
6046,Plasma,,,,CHEMBL628527,A,BAO_0000218,,,1,5356,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,In vivo,Canis lupus familiaris,9615.0,
6047,Plasma,,,,CHEMBL628528,A,BAO_0000218,,,1,6227,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6048,Plasma,,,,CHEMBL628529,A,BAO_0000218,,,1,6227,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6049,Plasma,,,,CHEMBL628530,A,BAO_0000218,,,1,6227,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6050,Plasma,,,,CHEMBL625243,A,BAO_0000218,,,1,6227,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6051,Plasma,,,,CHEMBL625244,A,BAO_0000218,,,1,3598,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6052,,,,,CHEMBL625245,A,BAO_0000218,,,1,4368,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,In vivo,Canis lupus familiaris,9615.0,
6053,,,,,CHEMBL625246,A,BAO_0000218,,,1,6265,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6054,Stomach,,,,CHEMBL625247,A,BAO_0000218,,,1,7767,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
6055,Urine,,,,CHEMBL625248,A,BAO_0000218,,,1,7767,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,Mus musculus,10090.0,
6056,Urine,,,,CHEMBL625249,A,BAO_0000218,,,1,7767,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,In vivo,Mus musculus,10090.0,
6057,Urine,,,,CHEMBL625250,A,BAO_0000218,,,1,7767,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,In vivo,Mus musculus,10090.0,
6058,,,,,CHEMBL625251,A,BAO_0000218,,,1,17811,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,Mus musculus,10090.0,
6059,,,,,CHEMBL875356,A,BAO_0000218,,,1,17811,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,Mus musculus,10090.0,
6060,,,,,CHEMBL625252,A,BAO_0000218,,,1,17827,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,Mus musculus,10090.0,
6061,Blood,,,,CHEMBL625253,A,BAO_0000218,,,1,17827,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,Mus musculus,10090.0,
6062,,,,,CHEMBL625254,A,BAO_0000218,,,1,17827,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,Mus musculus,10090.0,
6063,,,,,CHEMBL625255,A,BAO_0000218,,,1,17827,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,Mus musculus,10090.0,
6064,,,,,CHEMBL625256,A,BAO_0000218,,,1,17827,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,Mus musculus,10090.0,
6065,Blood,,,,CHEMBL625257,A,BAO_0000218,,,1,17827,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,Mus musculus,10090.0,
6066,Blood,,,,CHEMBL625258,A,BAO_0000218,,,1,17827,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),,Mus musculus,10090.0,
6067,,,,,CHEMBL625259,A,BAO_0000218,,,1,17827,Compound was evaluated for washout rate in mice (Radiolabeled compound),,Mus musculus,10090.0,
6068,,,,,CHEMBL625260,A,BAO_0000218,,,1,17827,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,Mus musculus,10090.0,
6069,,,,,CHEMBL625261,A,BAO_0000218,,,1,17827,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,Mus musculus,10090.0,
6070,,,,,CHEMBL625262,A,BAO_0000218,,,1,17827,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,Mus musculus,10090.0,
6071,,,,,CHEMBL622639,A,BAO_0000218,,,1,17827,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,Mus musculus,10090.0,
6072,,,,,CHEMBL622640,A,BAO_0000218,,,1,17257,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,Mus musculus,10090.0,
6073,,,,,CHEMBL622812,A,BAO_0000218,,,1,17257,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,Mus musculus,10090.0,
6074,,,,,CHEMBL622813,A,BAO_0000218,,,1,17257,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,Mus musculus,10090.0,
6075,,,,,CHEMBL622814,A,BAO_0000218,,,1,17257,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,Mus musculus,10090.0,
6076,,,,,CHEMBL622815,A,BAO_0000218,,,1,17827,Time at maximum activity in mice (Radiolabeled compound),,Mus musculus,10090.0,
6077,,,,,CHEMBL625342,A,BAO_0000218,,,1,3760,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,Mus musculus,10090.0,
6078,,,,,CHEMBL625343,A,BAO_0000218,,,1,3760,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,Mus musculus,10090.0,
6079,,,,,CHEMBL877591,A,BAO_0000218,,,1,17409,Binding towards mouse plasma protein at 10 uM,,Mus musculus,10090.0,
6080,,,,,CHEMBL625344,A,BAO_0000218,,,1,17409,Binding towards mouse plasma protein at 100 uM,,Mus musculus,10090.0,
6081,,,,,CHEMBL625345,A,BAO_0000218,,,1,2675,Bioavailability was evaluated in mice after intravenous administration,In vivo,Mus musculus,10090.0,
6082,,,,,CHEMBL625346,A,BAO_0000218,,,1,2675,Bioavailability was evaluated in mice after oral administration,In vivo,Mus musculus,10090.0,
6083,,,,,CHEMBL625347,A,BAO_0000218,,,1,3132,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,In vivo,Mus musculus,10090.0,
6084,,,,,CHEMBL625348,A,BAO_0000218,,,1,3132,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,In vivo,Mus musculus,10090.0,
6085,,,,,CHEMBL625349,A,BAO_0000218,,,1,16597,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,In vivo,Mus musculus,10090.0,
6086,,,,,CHEMBL625350,A,BAO_0000218,,,1,2862,Oral bioavailability in mouse,In vivo,Mus musculus,10090.0,
6087,,,,,CHEMBL882952,A,BAO_0000218,,,1,17764,Oral bioavailability after intravenous administration in mice at 24 uM/kg,In vivo,Mus musculus,10090.0,
6088,Brain,,,,CHEMBL625351,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6089,Brain,,,,CHEMBL625352,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6090,Brain,,,,CHEMBL877592,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6091,Brain,,,,CHEMBL625353,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6092,Brain,,,,CHEMBL625354,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6093,Brain,,,,CHEMBL626019,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6094,Heart,,,,CHEMBL626020,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6095,Heart,,,,CHEMBL626021,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6096,Heart,,,,CHEMBL626022,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6097,Heart,,,,CHEMBL626192,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6098,,,,A549,CHEMBL626193,F,BAO_0000219,,,1,1276,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),,Homo sapiens,9606.0,
6099,,,,A549,CHEMBL626194,F,BAO_0000219,,,1,3498,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,,Homo sapiens,9606.0,
6100,,,,A549,CHEMBL626195,F,BAO_0000219,,,1,1169,Cytotoxicity against human lung carcinoma A-549 cell lines,,Homo sapiens,9606.0,
6101,,,,A549,CHEMBL626196,F,BAO_0000219,,,1,4450,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,,Homo sapiens,9606.0,
6102,,,,A549,CHEMBL626197,F,BAO_0000219,,,1,358,In vitro cytotoxicity against human lung carcinoma cell line A-549,,Homo sapiens,9606.0,
6103,,,,A549,CHEMBL626198,F,BAO_0000219,,,1,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,,Homo sapiens,9606.0,
6104,,,,A549,CHEMBL626199,F,BAO_0000219,,,1,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,,Homo sapiens,9606.0,
6105,,,,A549,CHEMBL626200,F,BAO_0000219,,,1,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,,Homo sapiens,9606.0,
6106,,,,A549,CHEMBL626201,F,BAO_0000219,,,1,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,,Homo sapiens,9606.0,
6107,,,,A549,CHEMBL626202,F,BAO_0000219,,,1,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,,Homo sapiens,9606.0,
6108,,,,A549,CHEMBL626203,F,BAO_0000219,,,1,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,,Homo sapiens,9606.0,
6109,,,,A549,CHEMBL626204,F,BAO_0000219,,,1,15167,In vitro cytotoxicity against A-549 human lung cancer cells,,Homo sapiens,9606.0,
6110,,,,A549,CHEMBL624701,F,BAO_0000219,,,1,4139,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,,Homo sapiens,9606.0,
6111,,,,A549,CHEMBL624702,F,BAO_0000219,,,1,833,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,,Homo sapiens,9606.0,
6112,,,,A549,CHEMBL624703,F,BAO_0000219,,,1,15718,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,Homo sapiens,9606.0,
6113,,,,A549,CHEMBL624704,F,BAO_0000219,,,1,12373,Tested in vitro for cytotoxicity against A-549 lung cancer cells,,Homo sapiens,9606.0,
6114,,,,A549,CHEMBL624705,F,BAO_0000219,,,1,637,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,,Homo sapiens,9606.0,
6115,,,,A549,CHEMBL624706,F,BAO_0000219,,,1,14867,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,,Homo sapiens,9606.0,
6116,,,,A549,CHEMBL624707,F,BAO_0000219,,,1,4461,Antitumor cytotoxic activity against A-549 cell line was determined,,Homo sapiens,9606.0,
6117,,,,A549,CHEMBL624708,F,BAO_0000219,,,1,5406,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",,Homo sapiens,9606.0,
6118,,,,A549,CHEMBL624709,F,BAO_0000219,,,1,4457,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,Homo sapiens,9606.0,
6119,,,,A549,CHEMBL884107,F,BAO_0000219,,,1,1386,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,Homo sapiens,9606.0,
6120,,,,A549,CHEMBL624710,F,BAO_0000219,,,1,3265,Antitumoral activity was assayed against A-549 cell line,,Homo sapiens,9606.0,
6121,,,,A549,CHEMBL624711,F,BAO_0000219,,,1,2359,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,,Homo sapiens,9606.0,
6122,,,,A549,CHEMBL624712,F,BAO_0000219,,,1,4457,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,Homo sapiens,9606.0,
6123,,,,A549,CHEMBL624713,F,BAO_0000219,,,1,12454,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,Homo sapiens,9606.0,
6124,,,,A549,CHEMBL624714,F,BAO_0000219,,,1,1481,Compound was tested for inhibition of cell growth of A-549 cells,,Homo sapiens,9606.0,
6125,,,,A549,CHEMBL624715,F,BAO_0000219,,,1,1750,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,,Homo sapiens,9606.0,
6126,,,,A549,CHEMBL624716,F,BAO_0000219,,,1,5065,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,,Homo sapiens,9606.0,
6127,,,,A549,CHEMBL619505,F,BAO_0000219,,,1,808,In vitro cytotoxicity against A549-human lung carcinoma cells.,,Homo sapiens,9606.0,
6128,,,,A549,CHEMBL619506,F,BAO_0000219,,,1,16364,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,,Homo sapiens,9606.0,
6129,,,,A549,CHEMBL619507,F,BAO_0000219,,,1,1847,Cytotoxic activity against A-549 cell lines.,,Homo sapiens,9606.0,
6130,,,,A549,CHEMBL619508,F,BAO_0000219,,,1,1747,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,,Homo sapiens,9606.0,
6131,,,,A549,CHEMBL619509,F,BAO_0000219,,,1,1003,Cytotoxicity against human A549 non small cell lung cell lines,,Homo sapiens,9606.0,
6132,,,,A549,CHEMBL619510,F,BAO_0000219,,,1,15313,Inhibition of cell growth in (A-549) lung cell line,,Homo sapiens,9606.0,
6133,,,,A549,CHEMBL619511,F,BAO_0000219,,,1,3122,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,,Homo sapiens,9606.0,
6134,,,,A549,CHEMBL619512,F,BAO_0000219,,,1,16049,In vitro antitumor activity against A-549 tumor cells.,,Homo sapiens,9606.0,
6135,,,,A549,CHEMBL619513,F,BAO_0000219,,,1,17134,In vitro antitumor effects against human A-549 cell lines.,,Homo sapiens,9606.0,
6136,,,,A549,CHEMBL619514,F,BAO_0000219,,,1,6406,In vitro cytotoxic activity of compound against A-549 cell line,,Homo sapiens,9606.0,
6137,,,,A549,CHEMBL619515,F,BAO_0000219,,,1,627,In vitro cytotoxicity against human lung carcinoma A-549 cell line,,Homo sapiens,9606.0,
6138,,,,A549,CHEMBL619516,F,BAO_0000219,,,1,12307,In vitro cytotoxicity against human non-small cell lung carcinoma A549,,Homo sapiens,9606.0,
6139,,,,A549,CHEMBL884005,F,BAO_0000219,,,1,17861,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,,Homo sapiens,9606.0,
6140,,,,A549,CHEMBL619517,F,BAO_0000219,,,1,6682,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,,Homo sapiens,9606.0,
6141,,,,A549,CHEMBL619518,F,BAO_0000219,,,1,6663,Inhibitory concentration of compound against A-549 cell line,,Homo sapiens,9606.0,
6142,,,,A549,CHEMBL619519,F,BAO_0000219,,,1,2454,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,,Homo sapiens,9606.0,
6143,,,,A549,CHEMBL876489,F,BAO_0000219,,,1,14709,cytotoxic activity against leukemia (A-549) cancer cell line,,Homo sapiens,9606.0,
6144,,,,A549,CHEMBL619520,F,BAO_0000219,,,1,15718,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,Homo sapiens,9606.0,
6145,,,,A549,CHEMBL619521,F,BAO_0000219,,,1,15718,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,,Homo sapiens,9606.0,
6146,,,,A549,CHEMBL619522,F,BAO_0000219,,,1,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),,Homo sapiens,9606.0,
6147,,,,A549,CHEMBL619523,F,BAO_0000219,,,1,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),,Homo sapiens,9606.0,
6148,,,,A549,CHEMBL619524,F,BAO_0000219,,,1,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),,Homo sapiens,9606.0,
6149,,,,A549,CHEMBL619525,F,BAO_0000219,,,1,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),,Homo sapiens,9606.0,
6150,,,,A549,CHEMBL619526,F,BAO_0000219,,,1,6630,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,,,
6151,,,,A549,CHEMBL619527,F,BAO_0000219,,,1,16726,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,,Homo sapiens,9606.0,
6152,,,,A549,CHEMBL619528,F,BAO_0000219,,,1,17846,Cytotoxicity against A549 cells; No cytotoxicity,,Homo sapiens,9606.0,
6153,,,,A549,CHEMBL619529,F,BAO_0000219,,,1,3415,Cytotoxicity against human lung carcinoma (A549) cell lines,,Homo sapiens,9606.0,
6154,,,,A549,CHEMBL619530,F,BAO_0000219,,,1,3415,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,,Homo sapiens,9606.0,
6155,,,,A549,CHEMBL876490,F,BAO_0000219,,,1,5609,In vitro anticancer activity against human lung (A549) cell line,,Homo sapiens,9606.0,
6156,,,,A549,CHEMBL619531,F,BAO_0000219,,,1,17206,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,,Homo sapiens,9606.0,
6157,,,,A549,CHEMBL619532,F,BAO_0000219,,,1,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,,Homo sapiens,9606.0,
6158,,,,A549,CHEMBL619533,F,BAO_0000219,,,1,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,,Homo sapiens,9606.0,
6159,,,,A549,CHEMBL619534,F,BAO_0000219,,,1,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,,Homo sapiens,9606.0,
6160,,,,A549,CHEMBL620164,F,BAO_0000219,,,1,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,,Homo sapiens,9606.0,
6161,,,,A549,CHEMBL620165,F,BAO_0000219,,,1,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,Homo sapiens,9606.0,
6162,,,,A549,CHEMBL620166,F,BAO_0000219,,,1,16295,Inhibition of A549 human lung tumor cell proliferation,,Homo sapiens,9606.0,
6163,,,,A549,CHEMBL620167,F,BAO_0000219,,,1,16825,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",,Homo sapiens,9606.0,
6164,,,,A549,CHEMBL620168,F,BAO_0000219,,,1,3439,In vitro cytotoxicity against human tumor cell line A549,,Homo sapiens,9606.0,
6165,,,,A549,CHEMBL620338,F,BAO_0000219,,,1,10870,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,,Homo sapiens,9606.0,
6166,,,,A549,CHEMBL620339,F,BAO_0000219,,,1,4845,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,,Homo sapiens,9606.0,
6167,,,,A549,CHEMBL620340,F,BAO_0000219,,,1,5822,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,,Homo sapiens,9606.0,
6168,,,,A549,CHEMBL620341,F,BAO_0000219,,,1,5822,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,,Homo sapiens,9606.0,
6169,,,,A549,CHEMBL876491,F,BAO_0000219,,,1,5822,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,,Homo sapiens,9606.0,
6170,,,,A549,CHEMBL620342,F,BAO_0000219,,,1,16381,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,Homo sapiens,9606.0,
6171,,,,A549,CHEMBL620343,F,BAO_0000219,,,1,16381,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,Homo sapiens,9606.0,
6172,,,,A549,CHEMBL620344,F,BAO_0000219,,,1,16381,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,Homo sapiens,9606.0,
6173,,,,A549,CHEMBL620345,F,BAO_0000219,,,1,5609,In vitro anticancer activity against human lung (A549) cell line,,Homo sapiens,9606.0,
6174,,,,A549,CHEMBL620346,F,BAO_0000219,,,1,4644,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,,Homo sapiens,9606.0,
6175,,,,A549,CHEMBL620347,F,BAO_0000219,,,1,4644,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,,Homo sapiens,9606.0,
6176,,,,A549,CHEMBL620348,F,BAO_0000219,,,1,4644,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,,Homo sapiens,9606.0,
6177,,,,A549,CHEMBL620349,F,BAO_0000219,,,1,4644,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,,Homo sapiens,9606.0,
6178,,,,A549,CHEMBL618667,F,BAO_0000219,,,1,5822,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,,Homo sapiens,9606.0,
6179,,,,A549,CHEMBL618668,F,BAO_0000219,,,1,3415,Percentage inhibition of human lung carcinoma (A549) cell lines,,Homo sapiens,9606.0,
6180,,,,A549,CHEMBL876031,F,BAO_0000219,,,1,16726,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,,Homo sapiens,9606.0,
6181,,,,A549,CHEMBL618759,F,BAO_0000219,,,1,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",,Homo sapiens,9606.0,
6182,,,,A549,CHEMBL618760,F,BAO_0000219,,,1,17206,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,Homo sapiens,9606.0,
6183,,,,A549,CHEMBL619000,F,BAO_0000219,,,1,17206,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,Homo sapiens,9606.0,
6184,,,,A549,CHEMBL619001,F,BAO_0000219,,,1,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",,Homo sapiens,9606.0,
6185,,,,A549,CHEMBL619002,F,BAO_0000219,,,1,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",,Homo sapiens,9606.0,
6186,,,,A549,CHEMBL619003,F,BAO_0000219,,,1,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",,Homo sapiens,9606.0,
6187,,,,A549,CHEMBL619597,F,BAO_0000219,,,1,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",,Homo sapiens,9606.0,
6188,,,,A549,CHEMBL619598,F,BAO_0000219,,,1,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",,Homo sapiens,9606.0,
6189,,,,A549,CHEMBL619599,F,BAO_0000219,,,1,17206,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,,Homo sapiens,9606.0,
6190,,,,A549,CHEMBL619600,F,BAO_0000219,,,1,17206,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,,Homo sapiens,9606.0,
6191,,,,A549,CHEMBL619601,F,BAO_0000219,,,1,16726,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,Homo sapiens,9606.0,
6192,,,,A549,CHEMBL619602,F,BAO_0000219,,,1,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,,Homo sapiens,9606.0,
6193,,,,A549,CHEMBL619603,F,BAO_0000219,,,1,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,,Homo sapiens,9606.0,
6194,,,,A549,CHEMBL619604,F,BAO_0000219,,,1,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,,Homo sapiens,9606.0,
6195,,,,A549,CHEMBL619605,F,BAO_0000219,,,1,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,,Homo sapiens,9606.0,
6196,,,,,CHEMBL619606,A,BAO_0000218,,,1,6084,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,In vivo,Canis lupus familiaris,9615.0,
6197,,,,,CHEMBL876032,A,BAO_0000218,,,1,6084,Pharmacokinetic activity (Cmax) in dog,In vivo,Canis lupus familiaris,9615.0,
6198,,,,,CHEMBL619607,A,BAO_0000218,,,1,4809,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),In vivo,Canis lupus familiaris,9615.0,
6199,,,,,CHEMBL619608,A,BAO_0000218,,,1,5983,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6200,,,,,CHEMBL619609,A,BAO_0000218,,,1,6251,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6201,Plasma,,,,CHEMBL619610,A,BAO_0000218,,,1,5932,Cmax in dog plasma after 30mg/kg oral dose,In vivo,Canis lupus familiaris,9615.0,
6202,Blood,,,,CHEMBL619611,A,BAO_0000218,,,1,4273,Tested for the peak blood level in dog,In vivo,Canis lupus familiaris,9615.0,
6203,,,,,CHEMBL619612,A,BAO_0000218,,,1,5313,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",In vivo,Canis lupus familiaris,9615.0,
6204,,,,,CHEMBL619613,A,BAO_0000218,,,1,5313,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",In vivo,Canis lupus familiaris,9615.0,
6205,Blood,,,,CHEMBL619614,A,BAO_0000218,,,1,6221,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,In vivo,Canis lupus familiaris,9615.0,
6206,,,,,CHEMBL619615,A,BAO_0000218,,,1,4709,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,Canis lupus familiaris,9615.0,
6207,,,,,CHEMBL619616,A,BAO_0000218,,,1,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,Canis lupus familiaris,9615.0,
6208,Plasma,,,,CHEMBL619617,A,BAO_0000218,,,1,6241,Final plasma concentration in dogs after oral administration at 1 mg/kg,,Canis lupus familiaris,9615.0,
6209,,,,,CHEMBL619618,A,BAO_0000218,,,1,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,Canis lupus familiaris,9615.0,
6210,,,,,CHEMBL876033,A,BAO_0000218,,,1,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,Canis lupus familiaris,9615.0,
6211,,,,,CHEMBL619619,A,BAO_0000218,,,1,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,Canis lupus familiaris,9615.0,
6212,,,,,CHEMBL619620,A,BAO_0000218,,,1,2189,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,Canis lupus familiaris,9615.0,
6213,Urine,,,,CHEMBL619621,A,BAO_0000218,,,1,2189,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,,Canis lupus familiaris,9615.0,
6214,Urine,,,,CHEMBL619622,A,BAO_0000218,,,1,2189,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,,Canis lupus familiaris,9615.0,
6215,Urine,,,,CHEMBL618874,A,BAO_0000218,,,1,2189,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,,Canis lupus familiaris,9615.0,
6216,,,,,CHEMBL618875,A,BAO_0000218,,,1,4257,Absolute bioavailability was evaluated in dog,In vivo,Canis lupus familiaris,9615.0,
6217,,,,,CHEMBL618876,A,BAO_0000218,,,1,6221,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,In vivo,Canis lupus familiaris,9615.0,
6218,,,,,CHEMBL618877,A,BAO_0000218,,,1,6215,Bioavailability after peroral administration (1 mg/kg) was determined in dog,In vivo,Canis lupus familiaris,9615.0,
6219,,,,,CHEMBL618878,A,BAO_0000218,,,1,17267,Bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6220,,,,,CHEMBL618879,A,BAO_0000218,,,1,6621,Bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6221,,,,,CHEMBL618880,A,BAO_0000218,,,1,3854,Bioavailability after intravenous administration in dogs,In vivo,Canis lupus familiaris,9615.0,
6222,,,,,CHEMBL618881,A,BAO_0000218,,,1,3854,Bioavailability after peroral administration in dogs,In vivo,Canis lupus familiaris,9615.0,
6223,,,,,CHEMBL618882,A,BAO_0000218,,,1,5007,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),In vivo,Canis lupus familiaris,9615.0,
6224,,,,,CHEMBL624226,A,BAO_0000218,,,1,4333,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,In vivo,Canis lupus familiaris,9615.0,
6225,Plasma,,,,CHEMBL624227,A,BAO_0000218,,,1,4333,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,In vivo,Canis lupus familiaris,9615.0,
6226,,,,,CHEMBL624228,A,BAO_0000218,,,1,5006,Bioavailability,In vivo,Canis lupus familiaris,9615.0,
6227,,,,,CHEMBL624229,A,BAO_0000218,,,1,5199,Bioavailability,In vivo,Canis lupus familiaris,9615.0,
6228,,,,,CHEMBL624230,A,BAO_0000218,,,1,4368,Bioavailability by intravenous administration of 1.2 mg/kg in dog,In vivo,Canis lupus familiaris,9615.0,
6229,,,,,CHEMBL624231,A,BAO_0000218,,,1,3771,Bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6230,,,,,CHEMBL624232,A,BAO_0000218,,,1,4953,Bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6231,,,,,CHEMBL625127,A,BAO_0000218,,,1,5064,Bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6232,,,,,CHEMBL625128,A,BAO_0000218,,,1,17657,Bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6233,,,,,CHEMBL621675,A,BAO_0000218,,,1,17796,Bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6234,,,,,CHEMBL621676,A,BAO_0000218,,,1,17853,Bioavailability in dog (p.o.) at 2.0 mpk,In vivo,Canis lupus familiaris,9615.0,
6235,,,,,CHEMBL621677,A,BAO_0000218,,,1,4521,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),In vivo,Canis lupus familiaris,9615.0,
6236,,,,,CHEMBL621678,A,BAO_0000218,,,1,4521,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,In vivo,Canis lupus familiaris,9615.0,
6237,,,,,CHEMBL621679,A,BAO_0000218,,,1,5006,Bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6238,,,,,CHEMBL621680,A,BAO_0000218,,,1,16365,Bioavailability was evaluated after oral administration in dog,In vivo,Canis lupus familiaris,9615.0,
6239,,,,,CHEMBL621681,A,BAO_0000218,,,1,1916,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,In vivo,Canis lupus familiaris,9615.0,
6240,,,,,CHEMBL876740,A,BAO_0000218,,,1,1918,Bioavailability was evaluated in dog,In vivo,Canis lupus familiaris,9615.0,
6241,,,,,CHEMBL621682,A,BAO_0000218,,,1,4239,Bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6242,,,,,CHEMBL621683,A,BAO_0000218,,,1,6505,Bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6243,,,,,CHEMBL621684,A,BAO_0000218,,,1,5334,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),In vivo,Canis lupus familiaris,9615.0,
6244,,,,,CHEMBL621685,A,BAO_0000218,,,1,5334,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),In vivo,Canis lupus familiaris,9615.0,
6245,,,,,CHEMBL621686,A,BAO_0000218,,,1,4809,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),In vivo,Canis lupus familiaris,9615.0,
6246,,,,,CHEMBL621687,A,BAO_0000218,,,1,6348,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,Canis lupus familiaris,9615.0,
6247,,,,,CHEMBL621688,A,BAO_0000218,,,1,6005,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6248,,,,,CHEMBL621689,A,BAO_0000218,,,1,17804,Bioavailability of compound in dog was determined after peroral administration,In vivo,Canis lupus familiaris,9615.0,
6249,,,,,CHEMBL621690,A,BAO_0000218,,,1,3184,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6250,,,,,CHEMBL621691,A,BAO_0000218,,,1,1806,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,In vivo,Canis lupus familiaris,9615.0,
6251,,,,,CHEMBL875941,A,BAO_0000218,,,1,1806,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,In vivo,Canis lupus familiaris,9615.0,
6252,,,,,CHEMBL621692,A,BAO_0000218,,,1,1806,Compound was evaluated for oral bioavailability in dogs; 37-38 %,In vivo,Canis lupus familiaris,9615.0,
6253,,,,,CHEMBL621693,A,BAO_0000218,,,1,4839,Bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6254,,,,,CHEMBL621694,A,BAO_0000218,,,1,5017,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),In vivo,Canis lupus familiaris,9615.0,
6255,Heart,,,,CHEMBL621695,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6256,Heart,,,,CHEMBL621696,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6257,Kidney,,,,CHEMBL621697,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6258,Kidney,,,,CHEMBL621698,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6259,Kidney,,,,CHEMBL623420,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6260,Kidney,,,,CHEMBL623421,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6261,Kidney,,,,CHEMBL623422,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6262,Kidney,,,,CHEMBL623423,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6263,Liver,,,,CHEMBL623424,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6264,Liver,,,,CHEMBL623425,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6265,Liver,,,,CHEMBL623426,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6266,Liver,,,,CHEMBL623427,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6267,Liver,,,,CHEMBL623428,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6268,Liver,,,,CHEMBL875947,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6269,Lung,,,,CHEMBL623429,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6270,Lung,,,,CHEMBL623430,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6271,Lung,,,,CHEMBL622588,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6272,Lung,,,,CHEMBL622589,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6273,Lung,,,,CHEMBL622751,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6274,Lung,,,,CHEMBL622752,A,BAO_0000218,,,1,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,Mus musculus,10090.0,
6275,,,,CCRF S-180,CHEMBL622753,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,,Mus musculus,10090.0,
6276,,,,CCRF S-180,CHEMBL622647,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,,Mus musculus,10090.0,
6277,,,,CCRF S-180,CHEMBL875163,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,,Mus musculus,10090.0,
6278,,,,CCRF S-180,CHEMBL622648,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,,Mus musculus,10090.0,
6279,,,,CCRF S-180,CHEMBL622649,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,,Mus musculus,10090.0,
6280,Brain,,,CCRF S-180,CHEMBL622650,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,,Mus musculus,10090.0,
6281,Brain,,,CCRF S-180,CHEMBL622651,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,,Mus musculus,10090.0,
6282,Brain,,,CCRF S-180,CHEMBL622652,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,,Mus musculus,10090.0,
6283,Brain,,,CCRF S-180,CHEMBL622653,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,,Mus musculus,10090.0,
6284,Brain,,,CCRF S-180,CHEMBL622654,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,,Mus musculus,10090.0,
6285,Heart,,,CCRF S-180,CHEMBL622655,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,,Mus musculus,10090.0,
6286,Heart,,,CCRF S-180,CHEMBL622656,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,,Mus musculus,10090.0,
6287,Heart,,,CCRF S-180,CHEMBL622657,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,,Mus musculus,10090.0,
6288,Heart,,,CCRF S-180,CHEMBL622658,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,,Mus musculus,10090.0,
6289,Heart,,,CCRF S-180,CHEMBL622659,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,,Mus musculus,10090.0,
6290,Kidney,,,CCRF S-180,CHEMBL624630,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,,Mus musculus,10090.0,
6291,Kidney,,,CCRF S-180,CHEMBL624631,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,,Mus musculus,10090.0,
6292,Kidney,,,CCRF S-180,CHEMBL624632,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,,Mus musculus,10090.0,
6293,,,,A549,CHEMBL624633,F,BAO_0000219,,,1,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,,Homo sapiens,9606.0,
6294,,,,A549,CHEMBL624634,F,BAO_0000219,,,1,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,,Homo sapiens,9606.0,
6295,,,,A549,CHEMBL624635,F,BAO_0000219,,,1,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),,Homo sapiens,9606.0,
6296,,,,A549,CHEMBL624636,F,BAO_0000219,,,1,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),,Homo sapiens,9606.0,
6297,,,,A549,CHEMBL857055,F,BAO_0000219,,,1,3263,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,Homo sapiens,9606.0,
6298,,,,A549,CHEMBL624637,F,BAO_0000219,,,1,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,,Homo sapiens,9606.0,
6299,,,,A549,CHEMBL624638,F,BAO_0000219,,,1,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,,Homo sapiens,9606.0,
6300,,,,A549,CHEMBL874366,F,BAO_0000219,,,1,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,,Homo sapiens,9606.0,
6301,,,,A549,CHEMBL624639,F,BAO_0000219,,,1,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,,Homo sapiens,9606.0,
6302,,,,A549,CHEMBL624640,F,BAO_0000219,,,1,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,,Homo sapiens,9606.0,
6303,,,,A549,CHEMBL624641,F,BAO_0000219,,,1,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,,Homo sapiens,9606.0,
6304,,,,A549,CHEMBL624642,F,BAO_0000219,,,1,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,,Homo sapiens,9606.0,
6305,,,,A549,CHEMBL624643,F,BAO_0000219,,,1,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,,Homo sapiens,9606.0,
6306,,,,A549,CHEMBL624644,F,BAO_0000219,,,1,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,,Homo sapiens,9606.0,
6307,,,,A549,CHEMBL624645,F,BAO_0000219,,,1,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,,Homo sapiens,9606.0,
6308,,,,A549,CHEMBL619445,F,BAO_0000219,,,1,3983,The compound was evaluated for its cytotoxic potency against A-549 cell line,,Homo sapiens,9606.0,
6309,,,,A549,CHEMBL839886,F,BAO_0000219,,,1,11141,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,,Homo sapiens,9606.0,
6310,,,,A549,CHEMBL619446,F,BAO_0000219,,,1,5076,Cytotoxic activity of compound against A-549 tumor cell line.,,Homo sapiens,9606.0,
6311,,,,A549,CHEMBL619447,F,BAO_0000219,,,1,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,,Homo sapiens,9606.0,
6312,,,,A549,CHEMBL619448,F,BAO_0000219,,,1,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,,Homo sapiens,9606.0,
6313,,,,A549,CHEMBL619449,F,BAO_0000219,,,1,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,,Homo sapiens,9606.0,
6314,,,,A549,CHEMBL619450,F,BAO_0000219,,,1,5076,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,,Homo sapiens,9606.0,
6315,,,,A549,CHEMBL619451,F,BAO_0000219,,,1,4150,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),,Homo sapiens,9606.0,
6316,,,,A549,CHEMBL619452,F,BAO_0000219,,,1,2150,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,,Homo sapiens,9606.0,
6317,,,,A549,CHEMBL619453,F,BAO_0000219,,,1,4644,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,,Homo sapiens,9606.0,
6318,,,,A549,CHEMBL874367,F,BAO_0000219,,,1,263,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,,Homo sapiens,9606.0,
6319,,,,A549,CHEMBL619454,F,BAO_0000219,,,1,11333,Cytotoxic concentration against A-549 tumor cells.,,Homo sapiens,9606.0,
6320,,,,A549,CHEMBL619455,F,BAO_0000219,,,1,11333,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,,Homo sapiens,9606.0,
6321,,,,A549,CHEMBL619456,F,BAO_0000219,,,1,15895,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",,Homo sapiens,9606.0,
6322,,,,,CHEMBL619457,F,BAO_0000218,,,1,16677,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,Acinetobacter baumannii,470.0,
6323,,,,,CHEMBL619458,F,BAO_0000218,,,1,10624,Activity against Acinetobacter calcoaceticus (AC54),,Acinetobacter calcoaceticus,471.0,
6324,,,,,CHEMBL619459,F,BAO_0000218,,,1,16717,In vitro antifungal activity against Aspergillus flavus CM74,,Aspergillus flavus,5059.0,
6325,,,,,CHEMBL619460,F,BAO_0000218,,,1,16717,In vitro antifungal activity against Aspergillus flavus CM74,,Aspergillus flavus,5059.0,
6326,,,,,CHEMBL619461,F,BAO_0000218,,,1,5513,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,Aspergillus fumigatus,746128.0,
6327,,,,,CHEMBL619462,F,BAO_0000218,,,1,15962,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,Aspergillus fumigatus,746128.0,
6328,,,,,CHEMBL620388,F,BAO_0000218,,,1,15962,Antimicrobial activity against Aspergillus fumigatus (MIC),,Aspergillus fumigatus,746128.0,
6329,,,,,CHEMBL620389,F,BAO_0000218,,,1,15962,Antimicrobial activity against Aspergillus fumigatus (MIC),,Aspergillus fumigatus,746128.0,
6330,,,,,CHEMBL620390,F,BAO_0000218,,,1,15962,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,Aspergillus fumigatus,746128.0,
6331,,,,,CHEMBL620391,F,BAO_0000218,,,1,16717,In vitro antifungal activity against Aspergillus fumigatus 48238E,,Aspergillus fumigatus,746128.0,
6332,,,,,CHEMBL621073,F,BAO_0000218,,,1,16717,In vitro antifungal activity against Aspergillus fumigatus 48238E,,Aspergillus fumigatus,746128.0,
6333,,,,,CHEMBL621074,F,BAO_0000218,,,1,8117,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,Actinomyces naeslundii,1655.0,
6334,,,,,CHEMBL621075,F,BAO_0000218,,,1,8117,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,Actinomyces viscosus,1656.0,
6335,,,,,CHEMBL619554,F,BAO_0000218,,,1,15472,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,Acanthocheilonema viteae,6277.0,
6336,,,,,CHEMBL619555,F,BAO_0000218,,,1,15472,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,Acanthocheilonema viteae,6277.0,
6337,,,,,CHEMBL619556,F,BAO_0000218,,,1,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,Aggregatibacter actinomycetemcomitans,714.0,
6338,,,,,CHEMBL619557,F,BAO_0000218,,,1,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,Aggregatibacter actinomycetemcomitans,714.0,
6339,,,,,CHEMBL619558,F,BAO_0000218,,,1,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,Aggregatibacter actinomycetemcomitans,714.0,
6340,,,,A549,CHEMBL619559,F,BAO_0000219,,,1,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,Homo sapiens,9606.0,
6341,,,,A549,CHEMBL619560,F,BAO_0000219,,,1,17206,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,,Homo sapiens,9606.0,
6342,,,,A549,CHEMBL619561,F,BAO_0000219,,,1,16381,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,Homo sapiens,9606.0,
6343,,,,A549,CHEMBL619562,F,BAO_0000219,,,1,16381,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,Homo sapiens,9606.0,
6344,,,,A549,CHEMBL619563,F,BAO_0000219,,,1,16381,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,Homo sapiens,9606.0,
6345,,,,A549,CHEMBL857457,F,BAO_0000219,,,1,16381,GI values against A549 cells (lung cancer),,Homo sapiens,9606.0,
6346,,,,A549,CHEMBL619564,F,BAO_0000219,,,1,17206,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,,Homo sapiens,9606.0,
6347,,,,A549,CHEMBL619565,F,BAO_0000219,,,1,16325,Inhibitory activity against A549 human adenocarcinoma,,Homo sapiens,9606.0,
6348,,,,A549,CHEMBL619566,F,BAO_0000218,,,1,10708,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,,Homo sapiens,9606.0,
6349,,,,A549,CHEMBL619567,F,BAO_0000218,,,1,10708,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,,Homo sapiens,9606.0,
6350,,,,A549,CHEMBL619568,F,BAO_0000219,,,1,17376,Inhibitory activity against A549 lung adenocarcinoma cell line,,Homo sapiens,9606.0,
6351,,,,A549,CHEMBL619569,F,BAO_0000219,,,1,17376,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,,Homo sapiens,9606.0,
6352,,,,A549,CHEMBL619570,F,BAO_0000219,,,1,17488,Cytotoxicity against human A549 lung cells,,Homo sapiens,9606.0,
6353,,,,A549,CHEMBL619571,F,BAO_0000218,,,1,17404,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,,Homo sapiens,9606.0,
6354,,,,A549,CHEMBL619572,F,BAO_0000219,,,1,10958,Growth inhibition of A549 (human lung carcinoma) cell line.,,Homo sapiens,9606.0,
6355,,,,A549,CHEMBL619573,F,BAO_0000219,,,1,17099,Effective dose required for inhibitory activity against A549 human tumor cell line.,,Homo sapiens,9606.0,
6356,,,,A549,CHEMBL619574,F,BAO_0000219,,,1,17099,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,,Homo sapiens,9606.0,
6357,,,,A549,CHEMBL619575,F,BAO_0000219,,,1,4096,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,,Homo sapiens,9606.0,
6358,,,,A549,CHEMBL619576,F,BAO_0000219,,,1,4096,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,,Homo sapiens,9606.0,
6359,,,,A549,CHEMBL619577,F,BAO_0000219,,,1,4096,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,,Homo sapiens,9606.0,
6360,,,,A549,CHEMBL619578,F,BAO_0000219,,,1,2525,In vitro inhibitory activity against A549 tumor cell culture,,Homo sapiens,9606.0,
6361,,,,A549,CHEMBL884009,F,BAO_0000219,,,1,2525,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,,Homo sapiens,9606.0,
6362,,,,A549,CHEMBL619579,F,BAO_0000219,,,1,5302,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),,Homo sapiens,9606.0,
6363,,,,A549,CHEMBL619580,F,BAO_0000219,,,1,16325,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,,Homo sapiens,9606.0,
6364,,,,A549,CHEMBL619581,F,BAO_0000219,,,1,16939,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,,Homo sapiens,9606.0,
6365,,,,A549,CHEMBL619582,F,BAO_0000219,,,1,17229,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,,Homo sapiens,9606.0,
6366,,,,A549,CHEMBL619583,F,BAO_0000219,,,1,17380,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,,Homo sapiens,9606.0,
6367,,,,A549,CHEMBL876502,F,BAO_0000219,,,1,17380,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,,Homo sapiens,9606.0,
6368,,,,A549,CHEMBL619584,F,BAO_0000219,,,1,1903,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,,Homo sapiens,9606.0,
6369,,,,A549,CHEMBL619585,F,BAO_0000219,,,1,3838,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,Homo sapiens,9606.0,
6370,,,,A549,CHEMBL619586,F,BAO_0000219,,,1,14696,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,Homo sapiens,9606.0,
6371,,,,A549,CHEMBL619587,F,BAO_0000219,,,1,3838,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,Homo sapiens,9606.0,
6372,,,,A549,CHEMBL619588,F,BAO_0000219,,,1,1522,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,,Homo sapiens,9606.0,
6373,,,,A549,CHEMBL619589,F,BAO_0000219,,,1,12400,Tested in vitro for cytotoxicity in A549/ATCC cell lines,,Homo sapiens,9606.0,
6374,,,,A549,CHEMBL619590,F,BAO_0000219,,,1,14696,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,Homo sapiens,9606.0,
6375,,,,A549,CHEMBL619591,F,BAO_0000219,,,1,14769,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),,Homo sapiens,9606.0,
6376,,,,A549,CHEMBL619592,F,BAO_0000219,,,1,14696,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,,Homo sapiens,9606.0,
6377,,,,A549,CHEMBL619593,F,BAO_0000219,,,1,1888,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,,Homo sapiens,9606.0,
6378,,,,A549,CHEMBL620217,F,BAO_0000219,,,1,12016,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,,Homo sapiens,9606.0,
6379,,,,A549,CHEMBL620218,F,BAO_0000219,,,1,6058,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,,Homo sapiens,9606.0,
6380,,,,A549,CHEMBL620219,F,BAO_0000219,,,1,17708,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,,Homo sapiens,9606.0,
6381,,,,A549,CHEMBL620220,F,BAO_0000219,,,1,12301,Antitumor activity against A549/ATCC cell line,,Homo sapiens,9606.0,
6382,,,,A549,CHEMBL625141,F,BAO_0000219,,,1,11970,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,,Homo sapiens,9606.0,
6383,,,,A549,CHEMBL625142,F,BAO_0000219,,,1,11818,In vitro cytotoxicity against A549/ATCC cell line.,,Homo sapiens,9606.0,
6384,,,,A549,CHEMBL625143,F,BAO_0000219,,,1,12400,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,,Homo sapiens,9606.0,
6385,,,,A549,CHEMBL625144,F,BAO_0000219,,,1,3381,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,,Homo sapiens,9606.0,
6386,,,,A549,CHEMBL622474,F,BAO_0000219,,,1,17376,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,,Homo sapiens,9606.0,
6387,,,,A549,CHEMBL884104,F,BAO_0000219,,,1,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,,Homo sapiens,9606.0,
6388,,,,,CHEMBL622475,F,BAO_0000219,,,0,2964,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,Homo sapiens,9606.0,
6389,,,,,CHEMBL622476,A,BAO_0000218,,,0,5005,Compound was tested for oral bioavailability in dogs,In vivo,Canis lupus familiaris,9615.0,
6390,,,,,CHEMBL875831,A,BAO_0000218,,,1,6229,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,In vivo,Canis lupus familiaris,9615.0,
6391,,,,,CHEMBL622477,A,BAO_0000218,,,1,6229,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,In vivo,Canis lupus familiaris,9615.0,
6392,,,,,CHEMBL622478,A,BAO_0000218,,,1,5374,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6393,,,,,CHEMBL623172,A,BAO_0000218,,,1,5374,Compound was tested for the oral bioavailability in dog; No availability,In vivo,Canis lupus familiaris,9615.0,
6394,,,,,CHEMBL623173,A,BAO_0000218,,,1,6265,Oral bioavailability in dog (dose 5 mg/kg),In vivo,Canis lupus familiaris,9615.0,
6395,,,,,CHEMBL623174,A,BAO_0000218,,,1,5654,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,In vivo,Canis lupus familiaris,9615.0,
6396,,,,,CHEMBL623175,A,BAO_0000218,,,1,5654,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,In vivo,Canis lupus familiaris,9615.0,
6397,,,,,CHEMBL623340,A,BAO_0000218,,,1,16456,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),In vivo,Canis lupus familiaris,9615.0,
6398,,,,,CHEMBL623341,A,BAO_0000218,,,1,5302,Oral bioavailability in dog (dose 5 mg/kg),In vivo,Canis lupus familiaris,9615.0,
6399,,,,,CHEMBL623342,A,BAO_0000218,,,1,3624,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),In vivo,Canis lupus familiaris,9615.0,
6400,,,,,CHEMBL623343,A,BAO_0000218,,,1,16452,Oral bioavailability of active FTIs in dogs,In vivo,Canis lupus familiaris,9615.0,
6401,,,,,CHEMBL623344,A,BAO_0000218,,,1,5802,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),In vivo,Canis lupus familiaris,9615.0,
6402,,,,,CHEMBL623345,A,BAO_0000218,,,1,3598,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6403,,,,,CHEMBL875832,A,BAO_0000218,,,1,17839,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6404,,,,,CHEMBL623346,A,BAO_0000218,,,1,6762,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6405,,,,,CHEMBL623347,A,BAO_0000218,,,1,6821,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6406,,,,,CHEMBL623348,A,BAO_0000218,,,1,6821,Oral bioavailability of compound was determined in dog; Not tested,In vivo,Canis lupus familiaris,9615.0,
6407,,,,,CHEMBL623349,A,BAO_0000218,,,1,5210,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6408,,,,,CHEMBL623350,A,BAO_0000218,,,1,6227,Oral bioavailability (10 mg/kg) was determined in dog,In vivo,Canis lupus familiaris,9615.0,
6409,,,,,CHEMBL623351,A,BAO_0000218,,,1,761,Oral bioavailability,In vivo,Canis lupus familiaris,9615.0,
6410,,,,,CHEMBL623352,A,BAO_0000218,,,1,761,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),In vivo,Canis lupus familiaris,9615.0,
6411,,,,,CHEMBL623353,A,BAO_0000218,,,1,761,Oral bioavailability administered in solution in rats,In vivo,Canis lupus familiaris,9615.0,
6412,,,,,CHEMBL875833,A,BAO_0000218,,,1,16907,Oral bioavailability after 30 mg/kg po dose in Dogs,In vivo,Canis lupus familiaris,9615.0,
6413,,,,,CHEMBL623354,A,BAO_0000218,,,1,5474,Oral bioavailability at a dose of 1 mg/kg in dogs,In vivo,Canis lupus familiaris,9615.0,
6414,,,,,CHEMBL623355,A,BAO_0000218,,,1,6535,Oral bioavailability in dog (dose 1 mg/kg p.o.),In vivo,Canis lupus familiaris,9615.0,
6415,,,,,CHEMBL623356,A,BAO_0000218,,,1,6535,Oral bioavailability in Dog; ND = not determined,In vivo,Canis lupus familiaris,9615.0,
6416,,,,,CHEMBL623357,A,BAO_0000218,,,1,3352,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6417,,,,,CHEMBL623358,A,BAO_0000218,,,1,6168,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6418,,,,,CHEMBL623359,A,BAO_0000218,,,1,5988,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6419,,,,,CHEMBL623360,A,BAO_0000218,,,1,4942,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6420,,,,,CHEMBL623361,A,BAO_0000218,,,1,4942,Oral bioavailability in dogs; No data,In vivo,Canis lupus familiaris,9615.0,
6421,,,,,CHEMBL623362,A,BAO_0000218,,,1,14541,Oral bioavailability measured in dogs,In vivo,Canis lupus familiaris,9615.0,
6422,,,,,CHEMBL623363,A,BAO_0000218,,,1,4449,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6423,,,,,CHEMBL623364,A,BAO_0000218,,,1,6057,Oral bioavailability was calculated in dog,In vivo,Canis lupus familiaris,9615.0,
6424,,,,,CHEMBL875834,A,BAO_0000218,,,1,5600,Oral bioavailability after 0.3 mg/kg po administration in dog,In vivo,Canis lupus familiaris,9615.0,
6425,,,,,CHEMBL623365,A,BAO_0000218,,,1,5542,Oral bioavailability in dog (i.v. dosing),In vivo,Canis lupus familiaris,9615.0,
6426,,,,,CHEMBL623366,A,BAO_0000218,,,1,5542,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6427,,,,,CHEMBL623367,A,BAO_0000218,,,1,5546,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,In vivo,Canis lupus familiaris,9615.0,
6428,,,,,CHEMBL623368,A,BAO_0000218,,,1,4514,Oral bioavailability in Beagle dogs,In vivo,Canis lupus familiaris,9615.0,
6429,,,,,CHEMBL623369,A,BAO_0000218,,,1,3624,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6430,,,,,CHEMBL623370,A,BAO_0000218,,,1,3854,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6431,,,,,CHEMBL623371,A,BAO_0000218,,,1,5836,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6432,,,,,CHEMBL623372,A,BAO_0000218,,,1,5940,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6433,,,,,CHEMBL621351,A,BAO_0000218,,,1,6168,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6434,,,,,CHEMBL621352,A,BAO_0000218,,,1,6227,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6435,,,,,CHEMBL621353,A,BAO_0000218,,,1,6251,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6436,,,,,CHEMBL621354,A,BAO_0000218,,,1,6448,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6437,,,,,CHEMBL621355,A,BAO_0000218,,,1,6647,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6438,,,,,CHEMBL621356,A,BAO_0000218,,,1,5940,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6439,,,,,CHEMBL621357,A,BAO_0000218,,,1,933,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6440,,,,,CHEMBL621358,A,BAO_0000218,,,1,5210,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6441,,,,,CHEMBL621359,A,BAO_0000218,,,1,6642,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),In vivo,Canis lupus familiaris,9615.0,
6442,,,,,CHEMBL621360,A,BAO_0000218,,,1,6641,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),In vivo,Canis lupus familiaris,9615.0,
6443,,,,,CHEMBL621361,A,BAO_0000218,,,1,6642,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),In vivo,Canis lupus familiaris,9615.0,
6444,,,,,CHEMBL621362,A,BAO_0000218,,,1,5472,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6445,,,,,CHEMBL621363,A,BAO_0000218,,,1,5985,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6446,,,,,CHEMBL621364,A,BAO_0000218,,,1,15660,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6447,,,,,CHEMBL621166,A,BAO_0000218,,,1,5530,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),In vivo,Canis lupus familiaris,9615.0,
6448,,,,,CHEMBL621167,A,BAO_0000218,,,1,5530,Oral bioavailability in dog (dose 1 mg/kg i.v.),In vivo,Canis lupus familiaris,9615.0,
6449,,,,,CHEMBL621168,A,BAO_0000218,,,1,6305,Oral bioavailability (F) in dogs,In vivo,Canis lupus familiaris,9615.0,
6450,,,,,CHEMBL621169,A,BAO_0000218,,,1,5210,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6451,,,,,CHEMBL875950,A,BAO_0000218,,,1,5238,Bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6452,,,,,CHEMBL621170,A,BAO_0000218,,,1,5668,Oral bioavailability in dog (dose 10 mg/kg),In vivo,Canis lupus familiaris,9615.0,
6453,,,,,CHEMBL621171,A,BAO_0000218,,,1,5668,Oral bioavailability after peroral administration at 5 mpk in Dog,In vivo,Canis lupus familiaris,9615.0,
6454,,,,,CHEMBL621172,A,BAO_0000218,,,1,5668,Oral bioavailability in dog (dose 5 mg/kg),In vivo,Canis lupus familiaris,9615.0,
6455,,,,,CHEMBL621173,A,BAO_0000218,,,1,6084,Oral bioavailability in dog (dose 10 mg/kg),In vivo,Canis lupus familiaris,9615.0,
6456,Kidney,,,CCRF S-180,CHEMBL621174,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,,Mus musculus,10090.0,
6457,Kidney,,,CCRF S-180,CHEMBL621175,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,,Mus musculus,10090.0,
6458,Liver,,,CCRF S-180,CHEMBL621176,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,,Mus musculus,10090.0,
6459,Liver,,,CCRF S-180,CHEMBL621177,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,,Mus musculus,10090.0,
6460,Liver,,,CCRF S-180,CHEMBL621178,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,,Mus musculus,10090.0,
6461,Liver,,,CCRF S-180,CHEMBL621179,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,,Mus musculus,10090.0,
6462,Liver,,,CCRF S-180,CHEMBL621180,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,,Mus musculus,10090.0,
6463,Lung,,,CCRF S-180,CHEMBL875951,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,,Mus musculus,10090.0,
6464,Lung,,,CCRF S-180,CHEMBL621181,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,,Mus musculus,10090.0,
6465,Lung,,,CCRF S-180,CHEMBL621182,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,,Mus musculus,10090.0,
6466,Lung,,,CCRF S-180,CHEMBL621183,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,,Mus musculus,10090.0,
6467,Lung,,,CCRF S-180,CHEMBL621184,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,,Mus musculus,10090.0,
6468,,,,CCRF S-180,CHEMBL621185,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,,Mus musculus,10090.0,
6469,,,,CCRF S-180,CHEMBL621186,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,,Mus musculus,10090.0,
6470,,,,CCRF S-180,CHEMBL621187,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,,Mus musculus,10090.0,
6471,,,,CCRF S-180,CHEMBL621188,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,,Mus musculus,10090.0,
6472,,,,CCRF S-180,CHEMBL621189,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,,Mus musculus,10090.0,
6473,Spleen,,,CCRF S-180,CHEMBL621190,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,,Mus musculus,10090.0,
6474,Spleen,,,CCRF S-180,CHEMBL618520,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,,Mus musculus,10090.0,
6475,Spleen,,,CCRF S-180,CHEMBL621739,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,,Mus musculus,10090.0,
6476,Spleen,,,CCRF S-180,CHEMBL621740,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,,Mus musculus,10090.0,
6477,Spleen,,,CCRF S-180,CHEMBL621741,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,,Mus musculus,10090.0,
6478,,,,CCRF S-180,CHEMBL621742,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,,Mus musculus,10090.0,
6479,,,,CCRF S-180,CHEMBL621743,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,,Mus musculus,10090.0,
6480,,,,CCRF S-180,CHEMBL621744,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,,Mus musculus,10090.0,
6481,,,,CCRF S-180,CHEMBL621745,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,,Mus musculus,10090.0,
6482,,,,CCRF S-180,CHEMBL621746,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,,Mus musculus,10090.0,
6483,,,,CCRF S-180,CHEMBL621747,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,,Mus musculus,10090.0,
6484,,,,CCRF S-180,CHEMBL621748,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,,Mus musculus,10090.0,
6485,,,,CCRF S-180,CHEMBL621749,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,,Mus musculus,10090.0,
6486,,,,CCRF S-180,CHEMBL621750,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,,Mus musculus,10090.0,
6487,,,,CCRF S-180,CHEMBL621751,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,,Mus musculus,10090.0,
6488,Heart,,,CCRF S-180,CHEMBL621752,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,,Mus musculus,10090.0,
6489,Heart,,,CCRF S-180,CHEMBL621753,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,,Mus musculus,10090.0,
6490,Heart,,,CCRF S-180,CHEMBL875955,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,,Mus musculus,10090.0,
6491,Heart,,,CCRF S-180,CHEMBL621754,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,,Mus musculus,10090.0,
6492,Heart,,,CCRF S-180,CHEMBL621755,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,,Mus musculus,10090.0,
6493,Liver,,,CCRF S-180,CHEMBL621756,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,,Mus musculus,10090.0,
6494,Liver,,,CCRF S-180,CHEMBL624199,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,,Mus musculus,10090.0,
6495,Liver,,,CCRF S-180,CHEMBL624200,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,,Mus musculus,10090.0,
6496,Liver,,,CCRF S-180,CHEMBL624375,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,,Mus musculus,10090.0,
6497,Liver,,,CCRF S-180,CHEMBL624376,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,,Mus musculus,10090.0,
6498,Lung,,,CCRF S-180,CHEMBL624377,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,,Mus musculus,10090.0,
6499,Lung,,,CCRF S-180,CHEMBL624378,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,,Mus musculus,10090.0,
6500,,,,,CHEMBL857901,F,BAO_0000218,,,1,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,aeinetobacter anitrotap,107673.0,
6501,,,,,CHEMBL875274,F,BAO_0000218,,,1,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,Acinetobacter calcoaceticus subsp. anitratus,107673.0,
6502,,,,,CHEMBL624379,F,BAO_0000218,,,1,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,Acinetobacter calcoaceticus subsp. anitratus,107673.0,
6503,,,,,CHEMBL624380,F,BAO_0000218,,,1,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,aeinetobacter anitrotap,107673.0,
6504,,,,,CHEMBL624381,F,BAO_0000218,,,1,10624,Activity against Acinetobacter calcoaceticus (AC54),,Acinetobacter calcoaceticus,471.0,
6505,,,,,CHEMBL624382,F,BAO_0000218,,,1,17216,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,Anolis carolinensis,28377.0,
6506,,,,,CHEMBL624383,F,BAO_0000218,,,1,17216,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,Anolis carolinensis,28377.0,
6507,,,,,CHEMBL624384,F,BAO_0000218,,,1,9560,Chlorohexidine coefficient for Actinomyces naeslundii 631,,Actinomyces naeslundii,1655.0,
6508,,,,,CHEMBL624385,F,BAO_0000218,,,1,9560,Chlorohexidine coefficient for Actinomyces naeslundii B74,,Actinomyces naeslundii,1655.0,
6509,,,,,CHEMBL624386,F,BAO_0000218,,,1,9560,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,Actinomyces naeslundii,1655.0,
6510,,,,,CHEMBL624387,F,BAO_0000218,,,1,9560,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,Actinomyces naeslundii,1655.0,
6511,,,,,CHEMBL624388,F,BAO_0000218,,,1,9560,Plaque bactericidal index against Actinomyces naeslundii 631,,Actinomyces naeslundii,1655.0,
6512,,,,,CHEMBL624389,F,BAO_0000218,,,1,9560,Plaque bactericidal index against Actinomyces naeslundii N/9,,Actinomyces naeslundii,1655.0,
6513,,,,,CHEMBL624390,F,BAO_0000218,,,1,9560,Plaque bactericidal index against Actinomyces naeslundii B74,,Actinomyces naeslundii,1655.0,
6514,,,,,CHEMBL875275,F,BAO_0000218,,,1,9560,Plaque bactericidal index against Actinomyces naeslundii N/3,,Actinomyces naeslundii,1655.0,
6515,,,,,CHEMBL624391,F,BAO_0000218,,,1,114,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,Artemia salina,85549.0,
6516,,,,,CHEMBL623636,F,BAO_0000218,,,1,114,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,Artemia salina,85549.0,
6517,,,,,CHEMBL623637,F,BAO_0000218,,,1,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,Ascaris suum,6253.0,
6518,,,,,CHEMBL623638,F,BAO_0000218,,,1,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,Ascaris suum,6253.0,
6519,,,,,CHEMBL623639,F,BAO_0000218,,,1,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,Ascaris suum,6253.0,
6520,,,,,CHEMBL623640,F,BAO_0000218,,,1,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,Ascaris suum,6253.0,
6521,,,,,CHEMBL623641,F,BAO_0000218,,,1,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,Ascaris suum,6253.0,
6522,,,,,CHEMBL623642,F,BAO_0000218,,,1,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,Ascaris suum,6253.0,
6523,,,,,CHEMBL623643,F,BAO_0000218,,,1,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,Ascaris suum,6253.0,
6524,,,,,CHEMBL623644,F,BAO_0000218,,,1,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,Ascaris suum,6253.0,
6525,,,,,CHEMBL623645,F,BAO_0000218,,,1,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,Ascaris suum,6253.0,
6526,,,,,CHEMBL623646,F,BAO_0000218,,,1,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,Ascaris suum,6253.0,
6527,,,,,CHEMBL623647,F,BAO_0000218,,,1,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,Ascaris suum,6253.0,
6528,,,,,CHEMBL623648,F,BAO_0000218,,,1,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,Ascaris suum,6253.0,
6529,,,,,CHEMBL623649,F,BAO_0000218,,,1,8117,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,Actinomyces viscosus,1656.0,
6530,,,,,CHEMBL623650,F,BAO_0000218,,,1,8117,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,Actinomyces viscosus,1656.0,
6531,,,,,CHEMBL623651,F,BAO_0000218,,,1,9560,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,Actinomyces viscosus,1656.0,
6532,,,,,CHEMBL623652,F,BAO_0000218,,,1,9560,Chlorohexidine coefficient for Actinomyces viscosus M-100,,Actinomyces viscosus,1656.0,
6533,,,,,CHEMBL623653,F,BAO_0000218,,,1,9560,Chlorohexidine coefficient for Actinomyces viscosus M-626,,Actinomyces viscosus,1656.0,
6534,,,,,CHEMBL623654,F,BAO_0000218,,,1,9560,Chlorohexidine coefficient for Actinomyces viscosus T14V,,Actinomyces viscosus,1656.0,
6535,,,,,CHEMBL623655,F,BAO_0000218,,,1,9560,Plaque bactericidal index against Actinomyces viscosus 8A06,,Actinomyces viscosus,1656.0,
6536,,,,,CHEMBL623656,F,BAO_0000218,,,1,9560,Plaque bactericidal index against Actinomyces viscosus M-100,,Actinomyces viscosus,1656.0,
6537,,,,,CHEMBL623657,F,BAO_0000218,,,1,9560,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,Actinomyces viscosus,1656.0,
6538,,,,,CHEMBL623658,F,BAO_0000218,,,1,9560,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,Actinomyces viscosus,1656.0,
6539,,,,,CHEMBL623659,F,BAO_0000218,,,1,9560,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,Actinomyces viscosus,1656.0,
6540,,,,,CHEMBL623660,F,BAO_0000218,,,1,9560,Plaque bactericidal index against Actinomyces viscosus 626,,Actinomyces viscosus,1656.0,
6541,,,,,CHEMBL623661,F,BAO_0000218,,,1,9560,Plaque bactericidal index against Actinomyces viscosus T14V,,Actinomyces viscosus,1656.0,
6542,,,,,CHEMBL875281,F,BAO_0000218,,,1,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,Acanthocheilonema viteae,6277.0,
6543,,,,,CHEMBL623662,F,BAO_0000218,,,1,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,Acanthocheilonema viteae,6277.0,
6544,,,,,CHEMBL623663,F,BAO_0000218,,,1,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,Acanthocheilonema viteae,6277.0,
6545,,,,,CHEMBL623664,F,BAO_0000218,,,1,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,Acanthocheilonema viteae,6277.0,
6546,,,,,CHEMBL623665,F,BAO_0000218,,,1,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,Acanthocheilonema viteae,6277.0,
6547,,,,A673,CHEMBL621856,F,BAO_0000219,,,1,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,,Homo sapiens,9606.0,
6548,,,,A704,CHEMBL620432,F,BAO_0000219,,,1,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,,Homo sapiens,9606.0,
6549,,,,,CHEMBL620433,F,BAO_0000219,,,0,416,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,Rattus norvegicus,10116.0,
6550,,,,A9,CHEMBL620434,F,BAO_0000219,,,1,14354,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,Mus musculus,10090.0,
6551,,,,A9,CHEMBL620435,F,BAO_0000219,,,1,14354,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,Mus musculus,10090.0,
6552,,,,A9,CHEMBL620436,F,BAO_0000219,,,1,5116,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,,Homo sapiens,9606.0,
6553,,,,A9,CHEMBL876597,F,BAO_0000219,,,1,5116,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,,Homo sapiens,9606.0,
6554,,,,Human ovarian carcinoma cell line,CHEMBL620437,F,BAO_0000219,,,1,15694,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,,Homo sapiens,9606.0,
6555,,,,A9,CHEMBL620438,F,BAO_0000219,,,1,13038,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",,Mus musculus,10090.0,
6556,,,,A9,CHEMBL620439,F,BAO_0000219,,,1,13038,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,,Mus musculus,10090.0,
6557,,,,A9,CHEMBL619657,F,BAO_0000219,,,1,10923,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,,Mus musculus,10090.0,
6558,,,,A9,CHEMBL619658,F,BAO_0000219,,,1,10923,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,,Mus musculus,10090.0,
6559,,,,A9,CHEMBL619659,F,BAO_0000219,,,1,10923,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,,Mus musculus,10090.0,
6560,,,,,CHEMBL619660,F,BAO_0000019,,,8,10923,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,,,
6561,,,,A9,CHEMBL619661,F,BAO_0000219,,,1,10923,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,,Mus musculus,10090.0,
6562,,,,A9,CHEMBL619662,F,BAO_0000219,,,1,10923,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,,Mus musculus,10090.0,
6563,,,,AA6,CHEMBL619663,F,BAO_0000219,,,1,8158,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,,Cricetulus griseus,10029.0,
6564,,,,,CHEMBL619664,F,BAO_0000219,,,0,15494,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,Homo sapiens,9606.0,
6565,,,,,CHEMBL619665,F,BAO_0000219,,,0,15494,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,Homo sapiens,9606.0,
6566,,,,AA5,CHEMBL883244,F,BAO_0000219,,,1,12348,Anti -HIV activity was measured against AA5/HIV-1(IIIB),,Homo sapiens,9606.0,
6567,,,,AA5,CHEMBL884011,F,BAO_0000219,,,1,12348,Cytotoxicity was measured against AA5/HIV-1(IIIB),,Homo sapiens,9606.0,
6568,,,,AA5,CHEMBL619666,F,BAO_0000219,,,1,2726,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,,Homo sapiens,9606.0,
6569,,,,U-937,CHEMBL619667,F,BAO_0000219,,,1,2726,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,,Homo sapiens,9606.0,
6570,,,,UV4,CHEMBL619668,F,BAO_0000219,,,1,10747,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,,Cricetulus griseus,10029.0,
6571,,,,CHO-AA8,CHEMBL619669,F,BAO_0000219,,,1,11005,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,Cricetulus griseus,10029.0,
6572,,,,CHO-AA8,CHEMBL876608,F,BAO_0000219,,,1,12687,Average intracellular compound concentration when the hypoxic SER=1.6,,Cricetulus griseus,10029.0,
6573,,,,CHO-AA8,CHEMBL619670,F,BAO_0000219,,,1,12687,Average intracellular compound concentration when the hypoxic SER=1.6.,,Cricetulus griseus,10029.0,
6574,,,,CHO-AA8,CHEMBL619671,F,BAO_0000219,,,1,12687,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,,Cricetulus griseus,10029.0,
6575,,,,CHO-AA8,CHEMBL619672,F,BAO_0000219,,,1,12687,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,,Cricetulus griseus,10029.0,
6576,,,,CHO-AA8,CHEMBL619673,F,BAO_0000219,,,1,12687,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,,Cricetulus griseus,10029.0,
6577,,,,CHO-AA8,CHEMBL619674,F,BAO_0000219,,,1,13436,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",,Cricetulus griseus,10029.0,
6578,,,,CHO-AA8,CHEMBL619675,F,BAO_0000219,,,1,13435,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",,Cricetulus griseus,10029.0,
6579,,,,CHO-AA8,CHEMBL619676,F,BAO_0000219,,,1,13302,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,,Cricetulus griseus,10029.0,
6580,,,,CHO-AA8,CHEMBL619677,F,BAO_0000219,,,1,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,Cricetulus griseus,10029.0,
6581,,,,CHO-AA8,CHEMBL619678,A,BAO_0000219,,,1,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,Cricetulus griseus,10029.0,
6582,,,,CHO-AA8,CHEMBL619679,A,BAO_0000219,,,1,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,,Cricetulus griseus,10029.0,
6583,,,,CHO-AA8,CHEMBL619680,A,BAO_0000219,,,1,12878,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,,Cricetulus griseus,10029.0,
6584,,,,CHO-AA8,CHEMBL621457,A,BAO_0000219,,,1,12878,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,,Cricetulus griseus,10029.0,
6585,,,,CHO-AA8,CHEMBL876609,F,BAO_0000219,,,1,14367,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,,Cricetulus griseus,10029.0,
6586,,,,CHO-AA8,CHEMBL621458,F,BAO_0000219,,,1,14367,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,,Cricetulus griseus,10029.0,
6587,,,,CHO-AA8,CHEMBL621459,F,BAO_0000219,,,1,12398,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,,hampster,36483.0,
6588,,,,CHO-AA8,CHEMBL621460,F,BAO_0000219,,,1,12878,Aerobic growth inhibition in Chinese hamster cell line AA8,,Cricetulus griseus,10029.0,
6589,,,,CHO-AA8,CHEMBL621461,F,BAO_0000219,,,1,13820,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,,Cricetulus griseus,10029.0,
6590,,,,CHO-AA8,CHEMBL621462,F,BAO_0000219,,,1,13436,Inhibition of growth under aerobic conditions in AA8 cells,,Cricetulus griseus,10029.0,
6591,,,,,CHEMBL621463,A,BAO_0000218,,,1,6084,Oral bioavailability in dog (dose 10 mg/kg),In vivo,Canis lupus familiaris,9615.0,
6592,,,,,CHEMBL621464,A,BAO_0000218,,,1,5711,Oral bioavailability in dog at 10 mg/kg of the compound,In vivo,Canis lupus familiaris,9615.0,
6593,,,,,CHEMBL621465,A,BAO_0000218,,,1,4353,Oral bioavailability in dog (dose 5 uM/kg),In vivo,Canis lupus familiaris,9615.0,
6594,,,,,CHEMBL621466,A,BAO_0000218,,,1,4353,Oral bioavailability in dog (dose 5 uM/kg),In vivo,Canis lupus familiaris,9615.0,
6595,,,,,CHEMBL621467,A,BAO_0000218,,,1,17800,Oral bioavailability in dog (mongrel),In vivo,Canis lupus familiaris,9615.0,
6596,,,,,CHEMBL621468,A,BAO_0000218,,,1,3994,Oral bioavailability in dog (dose 10 mg/kg),In vivo,Canis lupus familiaris,9615.0,
6597,,,,,CHEMBL876734,F,BAO_0000218,,,1,3994,Oral bioavailability in dog (dose 10 mg/kg),In vivo,Canis lupus familiaris,9615.0,
6598,,,,,CHEMBL618476,A,BAO_0000218,,,1,5145,Bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6599,,,,,CHEMBL618477,A,BAO_0000218,,,1,16452,Bioavailability in dog (dose 1 mg/kg i.v.),In vivo,Canis lupus familiaris,9615.0,
6600,,,,,CHEMBL618478,A,BAO_0000218,,,1,16452,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),In vivo,Canis lupus familiaris,9615.0,
6601,,,,,CHEMBL618479,A,BAO_0000218,,,1,5983,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6602,,,,,CHEMBL618480,A,BAO_0000218,,,1,4273,Bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6603,,,,,CHEMBL618481,A,BAO_0000218,,,1,12500,Bioavailability in dog (dose 3-10 mg/kg),In vivo,Canis lupus familiaris,9615.0,
6604,Plasma,,,,CHEMBL618482,A,BAO_0000218,,,1,12500,The compound was tested for bioavailability of compound in plasma of dog; Complete,In vivo,Canis lupus familiaris,9615.0,
6605,,,,,CHEMBL618483,A,BAO_0000218,,,1,3639,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6606,,,,,CHEMBL618484,A,BAO_0000218,,,1,3880,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6607,,,,,CHEMBL618485,A,BAO_0000218,,,1,4838,Bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6608,,,,,CHEMBL618486,A,BAO_0000218,,,1,15600,oral bioavailability was measured in dogs,In vivo,Canis lupus familiaris,9615.0,
6609,,,,,CHEMBL618487,A,BAO_0000218,,,1,17248,Compound was tested for plasma protein binding in dog; Not determined,,Canis lupus familiaris,9615.0,
6610,,,,,CHEMBL618488,A,BAO_0000218,,,1,17248,Compound was tested for plasma protein binding of dog,,Canis lupus familiaris,9615.0,
6611,,,,,CHEMBL876735,A,BAO_0000218,,,1,17248,Compound was tested for plasma protein binding of dog; Not determined,,Canis lupus familiaris,9615.0,
6612,,,,,CHEMBL618489,A,BAO_0000218,,,1,17443,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,Canis lupus familiaris,9615.0,
6613,,,,,CHEMBL618490,A,BAO_0000218,,,1,4186,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,In vivo,Canis lupus familiaris,9615.0,
6614,,,,,CHEMBL618491,A,BAO_0000218,,,1,3749,Half life was determined,,Canis lupus familiaris,9615.0,
6615,,,,,CHEMBL618492,A,BAO_0000218,,,1,3249,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6616,,,,,CHEMBL873354,A,BAO_0000218,,,1,3022,Half life was evaluated in dog,,Canis lupus familiaris,9615.0,
6617,,,,,CHEMBL618493,A,BAO_0000218,,,1,3749,Half life was determined,,Canis lupus familiaris,9615.0,
6618,,,,,CHEMBL618494,A,BAO_0000218,,,1,2517,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,Canis lupus familiaris,9615.0,
6619,Heart,,,,CHEMBL618495,A,BAO_0000218,,,1,2517,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,Canis lupus familiaris,9615.0,
6620,Kidney,,,,CHEMBL618496,A,BAO_0000218,,,1,2517,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,Canis lupus familiaris,9615.0,
6621,Liver,,,,CHEMBL618497,A,BAO_0000218,,,1,2517,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,Canis lupus familiaris,9615.0,
6622,Lung,,,,CHEMBL618498,A,BAO_0000218,,,1,2517,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,Canis lupus familiaris,9615.0,
6623,Spleen,,,,CHEMBL618499,A,BAO_0000218,,,1,2517,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,Canis lupus familiaris,9615.0,
6624,,,,,CHEMBL876736,A,BAO_0000218,,,1,3639,LogP in dog,,Canis lupus familiaris,9615.0,
6625,,,,,CHEMBL618500,A,BAO_0000218,,,1,6227,Partition coefficient (logP),,Canis lupus familiaris,9615.0,
6626,,,,,CHEMBL857831,A,BAO_0000218,,,1,6227,Partition coefficient in dog,,Canis lupus familiaris,9615.0,
6627,,,,,CHEMBL618501,A,BAO_0000218,,,1,17764,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,In vivo,Canis lupus familiaris,9615.0,
6628,,,,,CHEMBL618502,A,BAO_0000218,,,1,4809,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),In vivo,Canis lupus familiaris,9615.0,
6629,,,,,CHEMBL618503,A,BAO_0000218,,,1,5600,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,Canis lupus familiaris,9615.0,
6630,,,,,CHEMBL618504,A,BAO_0000218,,,1,14294,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,Canis lupus familiaris,9615.0,
6631,,,,,CHEMBL618505,A,BAO_0000218,,,1,14294,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,Canis lupus familiaris,9615.0,
6632,,,,,CHEMBL618506,A,BAO_0000218,,,1,14294,Metabolism of compound in dog S9 microsomes; Trace,,Canis lupus familiaris,9615.0,
6633,Liver,,,,CHEMBL618507,A,BAO_0000218,,,1,6251,In vitro metabolic potential in dog liver microsomes,,Canis lupus familiaris,9615.0,
6634,,,,,CHEMBL876737,A,BAO_0000218,,,1,3748,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,In vivo,Canis lupus familiaris,9615.0,
6635,,,,,CHEMBL618508,A,BAO_0000218,,,1,2713,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6636,,,,,CHEMBL618509,A,BAO_0000218,,,1,6512,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6637,,,,,CHEMBL618510,A,BAO_0000218,,,1,6679,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,Canis lupus familiaris,9615.0,
6638,,,,,CHEMBL618511,A,BAO_0000218,,,1,3749,The compound was tested for bioavailability in dogs,In vivo,Canis lupus familiaris,9615.0,
6639,,,,,CHEMBL618512,A,BAO_0000218,,,1,3749,The compound was tested for oral bioavailability in dogs,In vivo,Canis lupus familiaris,9615.0,
6640,,,,,CHEMBL618513,A,BAO_0000218,,,1,6742,Oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
6641,,,,,CHEMBL618514,A,BAO_0000218,,,1,6227,Compound was tested for percent protein binding (PB) in dog,,Canis lupus familiaris,9615.0,
6642,,,,,CHEMBL620052,A,BAO_0000218,,,1,6874,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,Canis lupus familiaris,9615.0,
6643,Plasma,,,,CHEMBL620053,A,BAO_0000218,,,1,2877,Compound was evaluated for plasma clearance.,In vivo,Canis lupus familiaris,9615.0,
6644,Plasma,,,,CHEMBL620054,A,BAO_0000218,,,1,12500,The compound was tested for plasma clearance in dog,In vivo,Canis lupus familiaris,9615.0,
6645,Plasma,,,,CHEMBL620055,A,BAO_0000218,,,1,12500,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,In vivo,Canis lupus familiaris,9615.0,
6646,,,,,CHEMBL620056,A,BAO_0000218,,,1,4709,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,Canis lupus familiaris,9615.0,
6647,Liver,,,,CHEMBL620057,A,BAO_0000218,,,1,5542,In vitro relative rate of metabolism was determined in dog liver microsomes,,Canis lupus familiaris,9615.0,
6648,,,,,CHEMBL618939,A,BAO_0000218,,,1,17594,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,In vivo,Canis lupus familiaris,9615.0,
6649,,,,,CHEMBL618940,A,BAO_0000218,,,1,2652,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,In vivo,Canis lupus familiaris,9615.0,
6650,,,,,CHEMBL618941,A,BAO_0000218,,,1,17764,Half life after intravenous administration in dogs at 1.2 uM/kg,In vivo,Canis lupus familiaris,9615.0,
6651,Lung,,,CCRF S-180,CHEMBL624473,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,,Mus musculus,10090.0,
6652,Lung,,,CCRF S-180,CHEMBL624474,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,,Mus musculus,10090.0,
6653,Lung,,,CCRF S-180,CHEMBL624475,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,,Mus musculus,10090.0,
6654,,,,CCRF S-180,CHEMBL624476,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,,Mus musculus,10090.0,
6655,,,,CCRF S-180,CHEMBL623478,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,,Mus musculus,10090.0,
6656,,,,CCRF S-180,CHEMBL623479,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,,Mus musculus,10090.0,
6657,,,,CCRF S-180,CHEMBL623480,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,,Mus musculus,10090.0,
6658,,,,CCRF S-180,CHEMBL623481,A,BAO_0000218,,,1,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,,Mus musculus,10090.0,
6659,Brain,,,,CHEMBL623482,A,BAO_0000218,,,1,17641,C2 in brain of mice at the oral dose of 50 mg/kg,,Mus musculus,10090.0,
6660,Kidney,,,,CHEMBL623483,A,BAO_0000218,,,1,17641,C2 in kidney of mice at the oral dose of 50 mg/kg,,Mus musculus,10090.0,
6661,Liver,,,,CHEMBL623484,A,BAO_0000218,,,1,17641,C2 in liver of mice at the oral dose of 50 mg/kg,,Mus musculus,10090.0,
6662,Lung,,,,CHEMBL623485,A,BAO_0000218,,,1,17641,C2 in lungs of mice at the oral dose of 50 mg/kg,,Mus musculus,10090.0,
6663,Spleen,,,,CHEMBL623486,A,BAO_0000218,,,1,17641,C2 in spleen of mice at the oral dose of 50 mg/kg,,Mus musculus,10090.0,
6664,,,,,CHEMBL623487,A,BAO_0000218,,,1,17852,Plasma clearance in mouse,In vivo,Mus musculus,10090.0,
6665,,,,,CHEMBL623488,A,BAO_0000218,,,1,17764,Clearance of compound after intravenous administration in mice at 24 uM/kg,In vivo,Mus musculus,10090.0,
6666,,,,,CHEMBL623489,A,BAO_0000218,,,1,17837,Clearance from mouse blood following i.v. administration of 10 mg/kg,In vivo,Mus musculus,10090.0,
6667,,,,,CHEMBL875157,A,BAO_0000218,,,1,2675,Clearance was evaluated in mice after intravenous administration,In vivo,Mus musculus,10090.0,
6668,,,,,CHEMBL623490,A,BAO_0000218,,,1,2675,Clearance was evaluated in mice after oral administration,In vivo,Mus musculus,10090.0,
6669,,,,,CHEMBL623491,A,BAO_0000218,,,1,4239,Pharmacokinetic property (Plasma clearance) was measured in mouse,In vivo,Mus musculus,10090.0,
6670,,,,,CHEMBL623492,A,BAO_0000218,,,1,17753,Plasma clearance of compound was determined at 40 mg/Kg,In vivo,Mus musculus,10090.0,
6671,,,,,CHEMBL623493,A,BAO_0000218,,,1,17753,Plasma clearance of at 24 mg/Kg,In vivo,Mus musculus,10090.0,
6672,,,,,CHEMBL623494,A,BAO_0000218,,,1,17753,Plasma clearance at 24 mg/Kg,In vivo,Mus musculus,10090.0,
6673,,,,,CHEMBL623495,A,BAO_0000218,,,1,17753,Plasma clearance at 5 mg/Kg,In vivo,Mus musculus,10090.0,
6674,,,,,CHEMBL623496,A,BAO_0000218,,,1,5727,Plasma clearance in mice,In vivo,Mus musculus,10090.0,
6675,,,,,CHEMBL623497,A,BAO_0000218,,,1,2862,Plasma clearance value upon iv administration in mouse,In vivo,Mus musculus,10090.0,
6676,Plasma,,,,CHEMBL623498,A,BAO_0000218,,,1,5980,Total plasma clearance in mice,In vivo,Mus musculus,10090.0,
6677,,,,,CHEMBL623499,A,BAO_0000218,,,1,17592,Clearance in mouse,In vivo,Mus musculus,10090.0,
6678,,,,,CHEMBL623500,A,BAO_0000218,,,1,17718,Clearance value was determined,In vivo,Mus musculus,10090.0,
6679,,,,,CHEMBL623501,A,BAO_0000218,,,1,16597,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,In vivo,Mus musculus,10090.0,
6680,,,,,CHEMBL875158,P,BAO_0000100,,,0,17384,Calculated partition coefficient (clogP),,,,
6681,,,,,CHEMBL623502,A,BAO_0000218,,,1,6062,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,In vivo,Mus musculus,10090.0,
6682,,,,,CHEMBL623503,A,BAO_0000218,,,1,17734,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,In vivo,Mus musculus,10090.0,
6683,,,,,CHEMBL623504,A,BAO_0000218,,,1,6348,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,Mus musculus,10090.0,
6684,,,,,CHEMBL623505,A,BAO_0000218,,,1,5969,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,In vivo,Mus musculus,10090.0,
6685,,,,,CHEMBL623506,A,BAO_0000218,,,1,5969,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,In vivo,Mus musculus,10090.0,
6686,,,,,CHEMBL623507,A,BAO_0000218,,,1,5969,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,In vivo,Mus musculus,10090.0,
6687,,,,,CHEMBL623508,A,BAO_0000218,,,1,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,In vivo,Mus musculus,10090.0,
6688,,,,,CHEMBL623509,A,BAO_0000218,,,1,5781,Cmax after oral administration at 30 mg/kg in ICR mouse,In vivo,Mus musculus,10090.0,
6689,,,,,CHEMBL875159,A,BAO_0000218,,,1,17764,Cmax after peroral administration in mice at 2.4 uM/kg,In vivo,Mus musculus,10090.0,
6690,Brain,,,,CHEMBL623510,A,BAO_0000218,,,1,17641,Cmax in brain of mice at the oral dose of 50 mg/kg,In vivo,Mus musculus,10090.0,
6691,Kidney,,,,CHEMBL623511,A,BAO_0000218,,,1,17641,Cmax in kidney of mice at the oral dose of 50 mg/kg,In vivo,Mus musculus,10090.0,
6692,Liver,,,,CHEMBL623512,A,BAO_0000218,,,1,17641,Cmax in liver of mice at the oral dose of 50 mg/kg,In vivo,Mus musculus,10090.0,
6693,Lung,,,,CHEMBL623513,A,BAO_0000218,,,1,17641,Cmax in lungs of mice at the oral dose of 50 mg/kg,In vivo,Mus musculus,10090.0,
6694,,,,,CHEMBL623514,F,BAO_0000218,,,1,17764,Cmax in mice at 18 uM/kg i.p. administration,In vivo,Mus musculus,10090.0,
6695,,,,,CHEMBL622609,F,BAO_0000218,,,1,17764,Cmax in mice at 23 uM/kg i.v. administration,In vivo,Mus musculus,10090.0,
6696,,,,,CHEMBL622610,F,BAO_0000218,,,1,17764,Cmax in mice at 24 uM/kg i.p. administration,In vivo,Mus musculus,10090.0,
6697,,,,,CHEMBL621823,F,BAO_0000218,,,1,17764,Cmax in mice at 25 uM/kg i.p. administration,In vivo,Mus musculus,10090.0,
6698,,,,,CHEMBL621824,F,BAO_0000218,,,1,17764,Cmax in mice at 26 uM/kg i.p. administration,In vivo,Mus musculus,10090.0,
6699,Spleen,,,,CHEMBL621825,A,BAO_0000218,,,1,17641,Cmax in spleen of mice at the oral dose of 50 mg/kg,In vivo,Mus musculus,10090.0,
6700,,,,,CHEMBL621826,A,BAO_0000218,,,1,16597,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,In vivo,Mus musculus,10090.0,
6701,,,,,CHEMBL621827,A,BAO_0000218,,,1,16597,Cmax value at a dose of 10 mg/kg peroral administration in mice.,In vivo,Mus musculus,10090.0,
6702,,,,,CHEMBL621828,A,BAO_0000218,,,1,5727,Cmax value was determined,In vivo,Mus musculus,10090.0,
6703,,,,,CHEMBL621829,A,BAO_0000218,,,1,5951,Cmax value in IRC mice,In vivo,Mus musculus,10090.0,
6704,,,,,CHEMBL621830,A,BAO_0000218,,,1,5506,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,In vivo,Mus musculus,10090.0,
6705,,,,,CHEMBL621831,A,BAO_0000218,,,1,5506,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,In vivo,Mus musculus,10090.0,
6706,Plasma,,,,CHEMBL621832,A,BAO_0000218,,,1,14239,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,In vivo,Mus musculus,10090.0,
6707,Plasma,,,,CHEMBL624579,A,BAO_0000218,,,1,4890,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",In vivo,Mus musculus,10090.0,
6708,,,,,CHEMBL624580,A,BAO_0000218,,,1,429,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,In vivo,Mus musculus,10090.0,
6709,,,,,CHEMBL624581,F,BAO_0000218,,,1,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,Acanthocheilonema viteae,6277.0,
6710,,,,,CHEMBL624582,F,BAO_0000218,,,1,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,Acanthocheilonema viteae,6277.0,
6711,,,,,CHEMBL624583,F,BAO_0000218,,,1,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,Acanthocheilonema viteae,6277.0,
6712,,,,A-375,CHEMBL624584,F,BAO_0000219,,,1,13227,Inhibitory activity against human tumor cell line A0375 melanoma.,,Homo sapiens,9606.0,
6713,,,,,CHEMBL624585,B,BAO_0000249,,,9,4481,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,,Rattus norvegicus,10116.0,Brain membranes
6714,,,,,CHEMBL875165,F,BAO_0000019,,,9,16931,Forskolin-induced cAMP production at human A1 adenosine receptor,,Homo sapiens,9606.0,
6715,,,,CHO,CHEMBL619490,F,BAO_0000219,,,8,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,,,
6716,,,,CHO,CHEMBL619491,F,BAO_0000219,,,8,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,,,
6717,,,,CHO,CHEMBL619492,F,BAO_0000219,,,8,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,,,
6718,,,,CHO,CHEMBL619493,F,BAO_0000219,,,8,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,,,
6719,,,,CHO,CHEMBL619494,F,BAO_0000219,,,8,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,,,
6720,,,,CHO,CHEMBL619495,F,BAO_0000219,,,8,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,,,
6721,,,,CHO,CHEMBL619496,F,BAO_0000219,,,8,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,,,
6722,,,,CHO,CHEMBL619497,F,BAO_0000219,,,9,3850,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,Homo sapiens,9606.0,
6723,,,,CHO,CHEMBL619498,F,BAO_0000219,,,8,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,,,
6724,,,,CHO,CHEMBL619499,F,BAO_0000219,,,8,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,,,
6725,,,,CHO,CHEMBL619500,F,BAO_0000219,,,8,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,,,
6726,,,,CHO,CHEMBL619501,F,BAO_0000219,,,8,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,,,
6727,,,,CHO,CHEMBL619502,F,BAO_0000219,,,8,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,,,
6728,,,,CHO,CHEMBL619503,F,BAO_0000219,,,8,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,,,
6729,,,,CHO,CHEMBL619504,F,BAO_0000219,,,8,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,,,
6730,,,,CHO,CHEMBL621298,F,BAO_0000219,,,8,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,,,
6731,,,,CHO,CHEMBL621299,F,BAO_0000219,,,8,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,,,
6732,,,,CHO,CHEMBL621300,F,BAO_0000219,,,8,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,,,
6733,,,,CHO,CHEMBL621301,F,BAO_0000219,,,8,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,,,
6734,,,,CHO,CHEMBL621302,F,BAO_0000219,,,8,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,,,
6735,,,,A10,CHEMBL621303,F,BAO_0000219,,,1,12680,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,,Oryctolagus cuniculus,9986.0,
6736,,,,A10,CHEMBL621304,F,BAO_0000219,,,0,1313,In vitro potassium channel opening activity in A10 (smooth muscle) cells,,Rattus norvegicus,10116.0,
6737,,,,A10,CHEMBL621305,F,BAO_0000219,,,0,1313,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,,Rattus norvegicus,10116.0,
6738,,,,A10,CHEMBL621306,F,BAO_0000219,,,1,17567,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,,Rattus norvegicus,10116.0,
6739,,,,A10,CHEMBL618444,F,BAO_0000219,,,1,17567,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,,Rattus norvegicus,10116.0,
6740,,,,A10,CHEMBL618445,F,BAO_0000219,,,1,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,,Rattus norvegicus,10116.0,
6741,,,,CHO-AA8,CHEMBL618446,F,BAO_0000219,,,1,13436,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,,Cricetulus griseus,10029.0,
6742,,,,CHO-AA8,CHEMBL618447,F,BAO_0000219,,,1,12687,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,,Cricetulus griseus,10029.0,
6743,,,,CHO-AA8,CHEMBL618448,F,BAO_0000219,,,1,12651,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,,Cricetulus griseus,10029.0,
6744,,,,CHO-AA8,CHEMBL618449,F,BAO_0000219,,,1,13300,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,,Cricetulus griseus,10029.0,
6745,,,,CHO-AA8,CHEMBL618637,F,BAO_0000219,,,1,15296,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,Cricetulus griseus,10029.0,
6746,,,,CHO-AA8,CHEMBL618638,F,BAO_0000219,,,1,15328,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",,Cricetulus griseus,10029.0,
6747,,,,CHO-AA8,CHEMBL618639,F,BAO_0000219,,,1,13302,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),,Cricetulus griseus,10029.0,
6748,,,,CHO-AA8,CHEMBL618640,F,BAO_0000219,,,1,14367,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",,Cricetulus griseus,10029.0,
6749,,,,CHO-AA8,CHEMBL618641,F,BAO_0000219,,,1,17002,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,,Cricetulus griseus,10029.0,
6750,,,,CHO-AA8,CHEMBL618642,F,BAO_0000219,,,1,13436,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,,Cricetulus griseus,10029.0,
6751,,,,CHO-AA8,CHEMBL618643,F,BAO_0000219,,,1,13435,Inhibitory activity against aerobic growth of AA8 cells.,,Cricetulus griseus,10029.0,
6752,,,,CHO-AA8,CHEMBL884013,A,BAO_0000219,,,1,10503,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,Cricetulus griseus,10029.0,
6753,,,,CHO-AA8,CHEMBL622723,F,BAO_0000219,,,1,10503,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,Cricetulus griseus,10029.0,
6754,,,,CHO-AA8,CHEMBL622724,F,BAO_0000219,,,1,10503,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,Cricetulus griseus,10029.0,
6755,,,,CHO-AA8,CHEMBL622725,F,BAO_0000219,,,1,15090,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,,Cricetulus griseus,10029.0,
6756,,,,CHO-AA8,CHEMBL622726,F,BAO_0000219,,,1,10368,Cytotoxicity against AA8 cell line,,Cricetulus griseus,10029.0,
6757,,,,CHO-AA8,CHEMBL622727,F,BAO_0000219,,,1,12651,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),,Cricetulus griseus,10029.0,
6758,,,,CHO-AA8,CHEMBL622728,A,BAO_0000219,,,1,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,Cricetulus griseus,10029.0,
6759,,,,CHO-AA8,CHEMBL622729,F,BAO_0000219,,,1,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,Cricetulus griseus,10029.0,
6760,,,,CHO-AA8,CHEMBL622730,A,BAO_0000219,,,1,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,Cricetulus griseus,10029.0,
6761,,,,CHO-AA8,CHEMBL622731,F,BAO_0000219,,,1,1890,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,,Cricetulus griseus,10029.0,
6762,,,,CHO-AA8,CHEMBL622732,F,BAO_0000219,,,1,10747,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,Cricetulus griseus,10029.0,
6763,,,,CHO-AA8,CHEMBL622733,F,BAO_0000219,,,1,10747,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,Cricetulus griseus,10029.0,
6764,,,,,CHEMBL622734,F,BAO_0000218,,,0,11616,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,Cricetulus griseus,10029.0,
6765,,,,CHO-AA8,CHEMBL622735,F,BAO_0000219,,,1,11616,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,,Cricetulus griseus,10029.0,
6766,,,,CHO-AA8,CHEMBL618746,F,BAO_0000219,,,0,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,,Cricetulus griseus,10029.0,
6767,,,,CHO-AA8,CHEMBL618747,F,BAO_0000219,,,0,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,,Cricetulus griseus,10029.0,
6768,,,,CHO-AA8,CHEMBL620540,F,BAO_0000219,,,0,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,,Cricetulus griseus,10029.0,
6769,,,,CHO-AA8,CHEMBL620541,F,BAO_0000219,,,0,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,,Cricetulus griseus,10029.0,
6770,,,,CHO-AA8,CHEMBL620542,F,BAO_0000219,,,0,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,,Cricetulus griseus,10029.0,
6771,,,,CHO-AA8,CHEMBL620543,F,BAO_0000219,,,0,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,,Cricetulus griseus,10029.0,
6772,,,,CHO-AA8,CHEMBL618832,F,BAO_0000219,,,0,3471,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,,Cricetulus griseus,10029.0,
6773,,,,CHO-AA8,CHEMBL618833,F,BAO_0000219,,,1,11616,Concentration required to reduce AA8 cell survival by 10%,,Cricetulus griseus,10029.0,
6774,,,,CHO-AA8,CHEMBL618834,F,BAO_0000219,,,0,2656,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",,Cricetulus griseus,10029.0,
6775,,,,CHO-AA8,CHEMBL618835,F,BAO_0000219,,,0,10518,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,Cricetulus griseus,10029.0,
6776,,,,CHO-AA8,CHEMBL618836,F,BAO_0000219,,,0,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,Cricetulus griseus,10029.0,
6777,,,,CHO-AA8,CHEMBL618837,F,BAO_0000219,,,0,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,,Cricetulus griseus,10029.0,
6778,,,,CHO-AA8,CHEMBL618838,F,BAO_0000219,,,0,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,,Cricetulus griseus,10029.0,
6779,,,,CHO-AA8,CHEMBL618839,F,BAO_0000219,,,0,16156,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,,Cricetulus griseus,10029.0,
6780,,,,CHO-AA8,CHEMBL618840,F,BAO_0000219,,,0,2656,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,,Cricetulus griseus,10029.0,
6781,,,,,CHEMBL618841,F,BAO_0000019,,,0,11005,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,Cricetulus griseus,10029.0,
6782,,,,CHO-AA8,CHEMBL618842,F,BAO_0000219,,,0,11942,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,,Cricetulus griseus,10029.0,
6783,,,,CHO-AA8,CHEMBL618843,F,BAO_0000219,,,0,2128,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,,Cricetulus griseus,10029.0,
6784,,,,,CHEMBL618844,A,BAO_0000218,,,1,16907,Half life period after 15 mg/kg iv dose in Dogs,In vivo,Canis lupus familiaris,9615.0,
6785,,,,,CHEMBL618845,A,BAO_0000218,,,1,16907,Half life period after 30 mg/kg po dose in Dogs,In vivo,Canis lupus familiaris,9615.0,
6786,,,,,CHEMBL618846,A,BAO_0000218,,,1,9579,Half life was measured after oral 2b administration (tested in 6 dogs),In vivo,Canis lupus familiaris,9615.0,
6787,,,,,CHEMBL618847,A,BAO_0000218,,,1,9579,Half life was measured in dog after oral 17b administration,In vivo,Canis lupus familiaris,9615.0,
6788,,,,,CHEMBL618848,A,BAO_0000218,,,1,9579,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,In vivo,Canis lupus familiaris,9615.0,
6789,,,,,CHEMBL618849,A,BAO_0000218,,,1,9579,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,In vivo,Canis lupus familiaris,9615.0,
6790,,,,,CHEMBL618850,A,BAO_0000218,,,1,16907,Tmax value after 15 mg/kg iv dose in Dogs,In vivo,Canis lupus familiaris,9615.0,
6791,,,,,CHEMBL618851,A,BAO_0000218,,,1,16907,Tmax value after 30 mg/kg po dose in Dogs,In vivo,Canis lupus familiaris,9615.0,
6792,,,,,CHEMBL873815,A,BAO_0000218,,,1,3184,Compound was evaluated for its half life when administered intravenously in dog,In vivo,Canis lupus familiaris,9615.0,
6793,Plasma,,,,CHEMBL618852,A,BAO_0000218,,,1,5017,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),In vivo,Canis lupus familiaris,9615.0,
6794,,,,,CHEMBL618853,A,BAO_0000218,,,1,6821,Elimination Half-life of compound was determined in dog,,Canis lupus familiaris,9615.0,
6795,,,,,CHEMBL618854,A,BAO_0000218,,,1,17839,Half life of compound in dog following oral administration,In vivo,Canis lupus familiaris,9615.0,
6796,,,,,CHEMBL618855,A,BAO_0000218,,,1,17267,Half life of compound was determined in dog,,Canis lupus familiaris,9615.0,
6797,Blood,,,,CHEMBL618856,A,BAO_0000218,,,1,4727,Half life of compound was determined in dog blood,,Canis lupus familiaris,9615.0,
6798,,,,,CHEMBL875827,A,BAO_0000218,,,1,5238,Half life after oral and iv dosing in dogs,In vivo,Canis lupus familiaris,9615.0,
6799,,,,,CHEMBL618857,A,BAO_0000218,,,1,4942,Half life in dogs in hours,,Canis lupus familiaris,9615.0,
6800,,,,,CHEMBL618858,A,BAO_0000218,,,1,6505,Half life on i.v. administration of 2 mg/kg was measured in dog,In vivo,Canis lupus familiaris,9615.0,
6801,,,,,CHEMBL618859,A,BAO_0000218,,,1,5130,t1/2 in dog after oral dose (1 mg/kg),In vivo,Canis lupus familiaris,9615.0,
6802,,,,,CHEMBL618860,A,BAO_0000218,,,1,1475,Half life was evaluated in dog,,Canis lupus familiaris,9615.0,
6803,,,,,CHEMBL618861,A,BAO_0000218,,,1,17804,Half life period of compound was determined after intravenous administration at 2 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6804,,,,,CHEMBL622539,A,BAO_0000218,,,1,17804,Half life period of compound was determined after peroral administration at 2 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6805,,,,,CHEMBL622540,A,BAO_0000218,,,1,6084,Half life period (10 mg/kg) was determined in dog,In vivo,Canis lupus familiaris,9615.0,
6806,,,,,CHEMBL873803,A,BAO_0000218,,,1,6084,Half life period (10 mg/kg) was determined in dog,In vivo,Canis lupus familiaris,9615.0,
6807,,,,,CHEMBL873804,A,BAO_0000218,,,1,5542,Half life period by iv administration in dog at a dose of 0.3 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6808,,,,,CHEMBL624311,A,BAO_0000218,,,1,5542,Half life period by po administration in dog at a dose of 0.3 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6809,,,,,CHEMBL624312,A,BAO_0000218,,,1,6084,Half life period in dog,,Canis lupus familiaris,9615.0,
6810,,,,,CHEMBL624313,A,BAO_0000218,,,1,6241,Half life period in dogs after oral administration at 1 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6811,,,,,CHEMBL624314,A,BAO_0000218,,,1,1916,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,In vivo,Canis lupus familiaris,9615.0,
6812,,,,,CHEMBL624315,A,BAO_0000218,,,1,6621,Half-life of compound was determined in dogs,,Canis lupus familiaris,9615.0,
6813,Plasma,,,,CHEMBL624316,A,BAO_0000218,,,1,1696,Half-life in dog plasma,,Canis lupus familiaris,9615.0,
6814,,,,,CHEMBL624317,A,BAO_0000218,,,1,17800,Half-life in mongrel dogs was determined,,Canis lupus familiaris,9615.0,
6815,,,,,CHEMBL624318,A,BAO_0000218,,,1,17657,Half-life in dog upon oral administration,In vivo,Canis lupus familiaris,9615.0,
6816,,,,,CHEMBL624319,A,BAO_0000218,,,1,17657,Half-life in dog upon oral administration; Unable to calculate,In vivo,Canis lupus familiaris,9615.0,
6817,,,,,CHEMBL624496,A,BAO_0000218,,,1,4239,Half-life was measured in dog,,Canis lupus familiaris,9615.0,
6818,,,,,CHEMBL624497,A,BAO_0000218,,,1,5985,Half-life was measured in dog,,Canis lupus familiaris,9615.0,
6819,,,,,CHEMBL624498,A,BAO_0000218,,,1,9932,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,Canis lupus familiaris,9615.0,
6820,,,,,CHEMBL624499,A,BAO_0000218,,,1,5199,Oral half life was determined,In vivo,Canis lupus familiaris,9615.0,
6821,Plasma,,,,CHEMBL624500,A,BAO_0000218,,,1,5199,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,In vivo,Canis lupus familiaris,9615.0,
6822,Plasma,,,,CHEMBL624501,A,BAO_0000218,,,1,1475,Plasma half life was evaluated,,Canis lupus familiaris,9615.0,
6823,Plasma,,,,CHEMBL623666,A,BAO_0000218,,,1,1475,Plasma half life was evaluated in Dog,,Canis lupus familiaris,9615.0,
6824,Plasma,,,,CHEMBL623667,A,BAO_0000218,,,1,1475,Plasma half life was evaluated in dog,,Canis lupus familiaris,9615.0,
6825,,,,,CHEMBL623668,A,BAO_0000218,,,1,6316,T1/2 (Half-life) was after oral administration at 5 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6826,,,,,CHEMBL623669,A,BAO_0000218,,,1,4883,Tested for the half life value in dog,,Canis lupus familiaris,9615.0,
6827,,,,,CHEMBL623670,A,BAO_0000218,,,1,4727,Maximum time at the dose of 2 mg/kg in dog,In vivo,Canis lupus familiaris,9615.0,
6828,,,,,CHEMBL623671,A,BAO_0000218,,,1,1916,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,In vivo,Canis lupus familiaris,9615.0,
6829,Blood,,,,CHEMBL875945,A,BAO_0000218,,,1,1337,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,In vivo,Canis lupus familiaris,9615.0,
6830,Blood,,,,CHEMBL623672,A,BAO_0000218,,,1,1337,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,In vivo,Canis lupus familiaris,9615.0,
6831,,,,,CHEMBL623673,A,BAO_0000218,,,1,6265,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6832,,,,,CHEMBL623674,A,BAO_0000218,,,1,4809,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),In vivo,Canis lupus familiaris,9615.0,
6833,,,,,CHEMBL623675,A,BAO_0000218,,,1,5983,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,In vivo,Canis lupus familiaris,9615.0,
6834,,,,,CHEMBL872526,A,BAO_0000218,,,1,5313,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,Canis lupus familiaris,9615.0,
6835,,,,,CHEMBL623676,A,BAO_0000218,,,1,5313,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",In vivo,Canis lupus familiaris,9615.0,
6836,Plasma,,,,CHEMBL623677,A,BAO_0000218,,,1,17650,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,In vivo,Canis lupus familiaris,9615.0,
6837,Plasma,,,,CHEMBL623678,A,BAO_0000218,,,1,5199,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,In vivo,Canis lupus familiaris,9615.0,
6838,Plasma,,,,CHEMBL623679,A,BAO_0000218,,,1,933,Time taken for maximum plasma concentration in dog,,Canis lupus familiaris,9615.0,
6839,,,,,CHEMBL623680,A,BAO_0000218,,,1,16367,Time to reach Cmax after oral administration to dogs,In vivo,Canis lupus familiaris,9615.0,
6840,Plasma,,,,CHEMBL623681,A,BAO_0000218,,,1,6348,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,Canis lupus familiaris,9615.0,
6841,,,,,CHEMBL623682,A,BAO_0000218,,,1,6316,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6842,,,,,CHEMBL623683,A,BAO_0000218,,,1,6215,Tmax after peroral administration (1 mg/kg) was determined in dog,In vivo,Canis lupus familiaris,9615.0,
6843,,,,,CHEMBL623684,A,BAO_0000218,,,1,3598,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6844,,,,,CHEMBL622745,A,BAO_0000218,,,1,4527,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,In vivo,Canis lupus familiaris,9615.0,
6845,,,,,CHEMBL622746,A,BAO_0000218,,,1,17764,Tmax after peroral administration in dogs at 2.4 uM/kg,In vivo,Canis lupus familiaris,9615.0,
6846,,,,,CHEMBL622747,A,BAO_0000218,,,1,5969,In vivo Cmax in mice at dose of 100 mg/kg,In vivo,Mus musculus,10090.0,
6847,,,,,CHEMBL622748,A,BAO_0000218,,,1,5969,In vivo Cmax in mice at dose of 50 mg/kg,In vivo,Mus musculus,10090.0,
6848,,,,,CHEMBL622749,A,BAO_0000218,,,1,4573,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,In vivo,Mus musculus,10090.0,
6849,Plasma,,,,CHEMBL622750,A,BAO_0000218,,,1,3277,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),In vivo,Mus musculus,10090.0,
6850,Plasma,,,,CHEMBL623411,A,BAO_0000218,,,1,17734,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,In vivo,Mus musculus,10090.0,
6851,Plasma,,,,CHEMBL875946,A,BAO_0000218,,,1,3132,Maximum concentration obtained in mouse plasma was determined,In vivo,Mus musculus,10090.0,
6852,Plasma,,,,CHEMBL623412,A,BAO_0000218,,,1,3132,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,In vivo,Mus musculus,10090.0,
6853,Plasma,,,,CHEMBL623413,A,BAO_0000218,,,1,6348,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,Mus musculus,10090.0,
6854,Plasma,,,,CHEMBL623414,A,BAO_0000218,,,1,17729,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,In vivo,Mus musculus,10090.0,
6855,Plasma,,,,CHEMBL623415,A,BAO_0000218,,,1,17729,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,In vivo,Mus musculus,10090.0,
6856,Plasma,,,,CHEMBL623416,A,BAO_0000218,,,1,17729,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,In vivo,Mus musculus,10090.0,
6857,Plasma,,,,CHEMBL623417,A,BAO_0000218,,,1,17728,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,In vivo,Mus musculus,10090.0,
6858,Plasma,,,,CHEMBL623418,A,BAO_0000218,,,1,17728,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,In vivo,Mus musculus,10090.0,
6859,Plasma,,,,CHEMBL623419,A,BAO_0000218,,,1,17728,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,In vivo,Mus musculus,10090.0,
6860,,,,,CHEMBL622816,A,BAO_0000218,,,1,4066,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,In vivo,Mus musculus,10090.0,
6861,,,,,CHEMBL623313,A,BAO_0000218,,,1,6178,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,In vivo,Mus musculus,10090.0,
6862,,,,,CHEMBL623314,A,BAO_0000218,,,1,6178,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,In vivo,Mus musculus,10090.0,
6863,,,,,CHEMBL876788,A,BAO_0000218,,,1,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,In vivo,Mus musculus,10090.0,
6864,,,,,CHEMBL623315,A,BAO_0000218,,,1,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,In vivo,Mus musculus,10090.0,
6865,,,,,CHEMBL623316,A,BAO_0000218,,,1,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,In vivo,Mus musculus,10090.0,
6866,,,,,CHEMBL623317,A,BAO_0000218,,,1,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,In vivo,Mus musculus,10090.0,
6868,,,,,CHEMBL623319,A,BAO_0000218,,,1,5961,Cmax in male mice after 2 mg/kg oral dose,In vivo,Mus musculus,10090.0,
6869,,,,,CHEMBL623320,A,BAO_0000218,,,1,6137,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,In vivo,Mus musculus,10090.0,
6870,,,,,CHEMBL623321,A,BAO_0000218,,,1,3802,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,In vivo,Mus musculus,10090.0,
6871,,,,,CHEMBL623322,A,BAO_0000218,,,1,3535,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,Mus musculus,10090.0,
6872,,,,,CHEMBL623323,A,BAO_0000218,,,1,3535,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,Mus musculus,10090.0,
6873,,,,,CHEMBL623324,A,BAO_0000218,,,1,3535,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,Mus musculus,10090.0,
6874,,,,,CHEMBL623325,A,BAO_0000218,,,1,3535,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,Mus musculus,10090.0,
6875,,,,,CHEMBL623326,A,BAO_0000218,,,1,3535,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,Mus musculus,10090.0,
6876,,,,,CHEMBL623327,A,BAO_0000218,,,1,3535,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,Mus musculus,10090.0,
6877,Plasma,,,,CHEMBL623328,A,BAO_0000218,,,1,2862,Maximum concentration in plasma upon oral administration in mouse,,Mus musculus,10090.0,
6878,Plasma,,,,CHEMBL623329,A,BAO_0000218,,,1,2675,Maximum plasma concentration was evaluated in mice after oral administration,,Mus musculus,10090.0,
6879,Plasma,,,,CHEMBL623330,A,BAO_0000218,,,1,2675,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,In vivo,Mus musculus,10090.0,
6880,,,,,CHEMBL876789,A,BAO_0000218,,,1,5399,Dose at which the compound induced fecal excretion in mice,,Mus musculus,10090.0,
6893,,,,A10,CHEMBL623333,F,BAO_0000219,,,1,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,,Rattus norvegicus,10116.0,
6894,,,,A10,CHEMBL623334,F,BAO_0000219,,,1,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,,Rattus norvegicus,10116.0,
6895,,,,A10,CHEMBL627536,F,BAO_0000219,,,1,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,,Rattus norvegicus,10116.0,
6896,,,,A10,CHEMBL627537,F,BAO_0000219,,,1,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,,Rattus norvegicus,10116.0,
6897,,,,A10,CHEMBL627538,F,BAO_0000219,,,1,16361,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),,Rattus norvegicus,10116.0,
6898,,,,A121,CHEMBL884106,F,BAO_0000219,,,1,2288,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,,Homo sapiens,9606.0,
6899,,,,A121,CHEMBL625294,F,BAO_0000219,,,1,10404,Anticancer activity against human ovarian carcinoma A121 cells,,Homo sapiens,9606.0,
6900,,,,A121,CHEMBL625295,F,BAO_0000219,,,1,14790,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,,Homo sapiens,9606.0,
6901,,,,A121,CHEMBL625296,F,BAO_0000219,,,1,14790,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,,Homo sapiens,9606.0,
6902,,,,A121,CHEMBL625297,F,BAO_0000219,,,1,14253,Growth inhibition of human ovarian carcinoma (A121) cell line,,Homo sapiens,9606.0,
6903,,,,A121,CHEMBL625298,F,BAO_0000219,,,1,13617,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,,Homo sapiens,9606.0,
6904,,,,A121,CHEMBL625960,F,BAO_0000219,,,1,1003,Cytotoxicity against human A121 ovarian cells,,Homo sapiens,9606.0,
6905,,,,A121,CHEMBL625961,F,BAO_0000219,,,1,830,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,,Homo sapiens,9606.0,
6906,,,,A121,CHEMBL625962,F,BAO_0000219,,,1,12307,In vitro cytotoxicity against human ovarian carcinoma A21,,Homo sapiens,9606.0,
6907,,,,A121,CHEMBL624717,F,BAO_0000219,,,1,14254,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,,Homo sapiens,9606.0,
6908,,,,A121,CHEMBL624718,F,BAO_0000219,,,1,13370,Inhibitory activity of compound against human A121 ovarian cell line.,,Homo sapiens,9606.0,
6909,,,,A121,CHEMBL624719,F,BAO_0000219,,,1,14790,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,,Homo sapiens,9606.0,
6910,,,,A121,CHEMBL624720,F,BAO_0000219,,,1,3614,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,,Homo sapiens,9606.0,
6911,,,,A 172,CHEMBL624721,F,BAO_0000219,,,1,2664,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,,Homo sapiens,9606.0,
6912,,,,A 172,CHEMBL624722,F,BAO_0000219,,,1,2037,In vitro cytotoxicity against A172 human tumor cell lines.,,Homo sapiens,9606.0,
6913,,,,A 172,CHEMBL877597,F,BAO_0000219,,,1,14539,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,,Homo sapiens,9606.0,
6914,,,,A 172,CHEMBL624723,F,BAO_0000219,,,1,2836,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,,Homo sapiens,9606.0,
6915,,,,A 172,CHEMBL624724,F,BAO_0000219,,,1,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,,Homo sapiens,9606.0,
6916,,,,,CHEMBL624725,B,BAO_0000224,,,4,8975,Association constant against A2 adenosine receptor,,Canis lupus familiaris,9615.0,
6917,,,,A2,CHEMBL624726,F,BAO_0000219,,,1,7645,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,,fish,,
6918,,,,,CHEMBL857535,B,BAO_0000224,,,5,11377,Ratio of Ki for adenosine A2 and A1 receptor binding,,Rattus norvegicus,10116.0,
6919,,,,A204,CHEMBL624727,F,BAO_0000219,,,1,13528,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,,Homo sapiens,9606.0,
6920,,,,A204,CHEMBL624728,F,BAO_0000219,,,1,10160,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,,Homo sapiens,9606.0,
6921,,,,A2058,CHEMBL624729,F,BAO_0000219,,,1,15144,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,,Homo sapiens,9606.0,
6922,,,,A253 cell line,CHEMBL624730,F,BAO_0000219,,,1,13160,Growth inhibition against Human squamous cell line(A 253),,Homo sapiens,9606.0,
6923,,,,A253 cell line,CHEMBL624731,F,BAO_0000219,,,1,12898,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,,Homo sapiens,9606.0,
6924,,,,A253 cell line,CHEMBL624732,F,BAO_0000219,,,1,13069,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,,Homo sapiens,9606.0,
6925,,,,A253 cell line,CHEMBL883245,F,BAO_0000219,,,1,15984,Growth inhibition of A253 cell lines.,,Homo sapiens,9606.0,
6926,,,,A253 cell line,CHEMBL624733,F,BAO_0000219,,,1,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),,Homo sapiens,9606.0,
6927,,,,A253 cell line,CHEMBL624734,F,BAO_0000219,,,1,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,Homo sapiens,9606.0,
6928,,,,A253 cell line,CHEMBL624735,F,BAO_0000219,,,1,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,Homo sapiens,9606.0,
6929,,,,A2780,CHEMBL621780,F,BAO_0000219,,,1,4720,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,,Homo sapiens,9606.0,
6930,,,,A2780,CHEMBL877598,F,BAO_0000219,,,1,16112,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,,Homo sapiens,9606.0,
6931,,,,A2780,CHEMBL621781,F,BAO_0000219,,,1,16597,Cytotoxic activity against A2780 human ovarian carcinoma cell line,,Homo sapiens,9606.0,
6932,,,,A2780,CHEMBL621782,F,BAO_0000219,,,1,16378,Cytotoxicity against human cancer cell lines A2780 (ovarian),,Homo sapiens,9606.0,
6933,,,,A2780,CHEMBL621783,F,BAO_0000219,,,1,16085,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,,Homo sapiens,9606.0,
6934,,,,A2780,CHEMBL621784,F,BAO_0000219,,,1,16317,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,,Homo sapiens,9606.0,
6935,,,,A2780,CHEMBL621785,F,BAO_0000219,,,1,15748,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,Homo sapiens,9606.0,
6936,,,,A2780,CHEMBL621968,F,BAO_0000219,,,1,16597,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,,Homo sapiens,9606.0,
6937,,,,A2780,CHEMBL621969,F,BAO_0000219,,,1,16597,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,,Homo sapiens,9606.0,
6938,,,,A2780,CHEMBL621970,F,BAO_0000219,,,1,16597,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,,Homo sapiens,9606.0,
6939,,,,A2780,CHEMBL621971,F,BAO_0000219,,,1,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,,Homo sapiens,9606.0,
6940,,,,A2780,CHEMBL621972,F,BAO_0000219,,,1,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,,Homo sapiens,9606.0,
6941,,,,A2780,CHEMBL884108,F,BAO_0000219,,,1,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,,Homo sapiens,9606.0,
6942,,,,,CHEMBL623826,F,BAO_0000019,,,0,15296,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,Cricetulus griseus,10029.0,
6943,,,,CHO-AA8,CHEMBL623827,A,BAO_0000219,,,0,10251,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,,Cricetulus griseus,10029.0,
6944,,,,CHO-AA8,CHEMBL623828,F,BAO_0000219,,,0,10251,Evaluated for growth inhibition of AA8 cells under aerobic conditions,,Cricetulus griseus,10029.0,
6945,,,,CHO-AA8,CHEMBL623829,F,BAO_0000219,,,0,10251,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,,Cricetulus griseus,10029.0,
6946,,,,CHO-AA8,CHEMBL623830,F,BAO_0000219,,,0,10251,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),,Cricetulus griseus,10029.0,
6947,,,,,CHEMBL623831,F,BAO_0000019,,,0,11858,Growth inhibition against CHO-derived cell line AA8,,Cricetulus griseus,10029.0,
6948,,,,CHO-AA8,CHEMBL623832,F,BAO_0000219,,,0,11858,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],,Cricetulus griseus,10029.0,
6949,,,,CHO-AA8,CHEMBL623833,F,BAO_0000219,,,1,11616,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,,hampster,36483.0,
6950,,,,CHO-AA8,CHEMBL623834,F,BAO_0000219,,,1,11616,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,,Cricetulus griseus,10029.0,
6951,,,,CHO-AA8,CHEMBL623835,F,BAO_0000219,,,0,10518,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,,Cricetulus griseus,10029.0,
6952,,,,CHO-AA8,CHEMBL623836,F,BAO_0000219,,,0,11396,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,,Cricetulus griseus,10029.0,
6953,,,,CHO-AA8,CHEMBL623837,F,BAO_0000219,,,0,10518,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,,Cricetulus griseus,10029.0,
6954,,,,CHO-AA8,CHEMBL623838,F,BAO_0000219,,,1,11616,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,,Cricetulus griseus,10029.0,
6955,,,,,CHEMBL623839,F,BAO_0000019,,,8,14837,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,,,
6956,,,,,CHEMBL623840,F,BAO_0000019,,,8,14837,Number of binding sites (n) of isolated serum protein AAG,,,,
6957,,,,,CHEMBL623841,B,BAO_0000225,,,3,16037,Association constant for binding to AATT duplex,,,,
6958,,,,ABAE,CHEMBL623842,F,BAO_0000219,,,1,16597,Inhibition of ABAE human fibroblast cell proliferation,,Homo sapiens,9606.0,
6959,,,,AC755,CHEMBL623843,F,BAO_0000218,,,1,8831,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",,Mus musculus,10090.0,
6960,,,,,CHEMBL618669,F,BAO_0000218,,,9,13419,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,Oryctolagus cuniculus,9986.0,
6961,,,,,CHEMBL618670,F,BAO_0000218,,,9,13419,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,In vivo,Oryctolagus cuniculus,9986.0,
6962,,,,,CHEMBL618671,B,BAO_0000357,,,8,15778,Inhibitory activity against angiotensin-converting enzyme (ACE).,,,,
6963,,,,,CHEMBL618672,B,BAO_0000357,,,8,15778,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,,,
6964,,,,ACH-2 cell line,CHEMBL618673,F,BAO_0000219,,,1,12988,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,,Homo sapiens,9606.0,
6965,,,,ACH-2 cell line,CHEMBL618674,F,BAO_0000219,,,1,12988,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),,Homo sapiens,9606.0,
6966,,,,T cell line,CHEMBL618675,F,BAO_0000219,,,0,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,,Human immunodeficiency virus 1,11676.0,
6967,,,,T cell line,CHEMBL618676,F,BAO_0000219,,,0,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),,Human immunodeficiency virus 1,11676.0,
6968,,,,T cell line,CHEMBL618677,F,BAO_0000219,,,0,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),,Human immunodeficiency virus 1,11676.0,
6969,,,,ACHN,CHEMBL618678,F,BAO_0000219,,,1,11843,Inhibition of growth of renal cancer ACHN cell line,,Homo sapiens,9606.0,
6970,,,,ACHN,CHEMBL618679,F,BAO_0000219,,,1,16939,Inhibition of growth of ACHN renal cancer cell line,,Homo sapiens,9606.0,
6971,,,,ACHN,CHEMBL618680,F,BAO_0000219,,,1,4782,Inhibitory concentration required against ACHN renal cancer cell line,,Homo sapiens,9606.0,
6972,,,,ACHN,CHEMBL618681,F,BAO_0000219,,,1,6310,Concentration required to inhibit growth of human renal (ACHN) cell line,,Homo sapiens,9606.0,
6973,,,,ACHN,CHEMBL618682,F,BAO_0000219,,,1,6310,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,,Homo sapiens,9606.0,
6974,,,,ACHN,CHEMBL618683,F,BAO_0000219,,,1,12858,Cytotoxic activity against ACHN Renal cancer cell line,,Homo sapiens,9606.0,
6975,,,,ACHN,CHEMBL618684,F,BAO_0000219,,,1,17380,Cytotoxicity evaluation against ACHN renal cancer cells,,Homo sapiens,9606.0,
6976,,,,ACHN,CHEMBL618685,F,BAO_0000219,,,1,5858,In vitro antitumor activity against human renal ACHN cell line,,Homo sapiens,9606.0,
6977,,,,ACHN,CHEMBL876499,F,BAO_0000219,,,1,3838,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,Homo sapiens,9606.0,
6978,,,,ACHN,CHEMBL618686,F,BAO_0000219,,,1,3838,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,Homo sapiens,9606.0,
6979,,,,ACHN,CHEMBL618687,F,BAO_0000219,,,1,5406,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",,Homo sapiens,9606.0,
6980,,,,ACHN,CHEMBL618688,F,BAO_0000219,,,1,4071,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,Homo sapiens,9606.0,
6981,,,,ACHN,CHEMBL618689,F,BAO_0000219,,,1,4071,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,Homo sapiens,9606.0,
6982,,,,ACHN,CHEMBL618690,F,BAO_0000219,,,1,4071,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,,Homo sapiens,9606.0,
6983,,,,ACHN,CHEMBL618691,F,BAO_0000219,,,1,15002,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,,Homo sapiens,9606.0,
6984,,,,ACHN,CHEMBL619373,F,BAO_0000219,,,1,14769,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,Homo sapiens,9606.0,
6985,,,,ACHN,CHEMBL884008,F,BAO_0000219,,,1,13958,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",,Homo sapiens,9606.0,
6986,,,,ACHN,CHEMBL619374,F,BAO_0000219,,,1,1665,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,,Homo sapiens,9606.0,
6987,,,,ACHN,CHEMBL619375,F,BAO_0000219,,,1,15354,Compound was tested for the growth inhibition of ACHN renal tumor cell line,,Homo sapiens,9606.0,
6988,,,,ACHN,CHEMBL619376,F,BAO_0000219,,,1,15354,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,,Homo sapiens,9606.0,
6989,,,,ACHN,CHEMBL619377,F,BAO_0000219,,,1,13978,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,,Homo sapiens,9606.0,
6990,,,,ACHN,CHEMBL619378,F,BAO_0000219,,,1,6798,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,,Homo sapiens,9606.0,
6991,,,,,CHEMBL872527,A,BAO_0000218,,,1,2959,Tmax value after administration of 4 mg/Kg oral dose in dog,In vivo,Canis lupus familiaris,9615.0,
6992,,,,,CHEMBL876500,A,BAO_0000218,,,1,9932,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,Canis lupus familiaris,9615.0,
6993,,,,,CHEMBL619379,A,BAO_0000218,,,1,5546,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,Canis lupus familiaris,9615.0,
6994,,,,,CHEMBL619538,A,BAO_0000218,,,1,16907,Volume distribution after 15 mg/kg iv dose in Dogs,In vivo,Canis lupus familiaris,9615.0,
6995,,,,,CHEMBL619539,A,BAO_0000218,,,1,16907,Volume distribution after 30 mg/kg po dose in Dogs,In vivo,Canis lupus familiaris,9615.0,
6996,,,,,CHEMBL619540,A,BAO_0000218,,,1,4257,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,In vivo,Canis lupus familiaris,9615.0,
6997,,,,,CHEMBL619541,A,BAO_0000218,,,1,4305,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,In vivo,Canis lupus familiaris,9615.0,
6998,,,,,CHEMBL619542,A,BAO_0000218,,,1,5472,Volume of distribution was evaluated in dog,In vivo,Canis lupus familiaris,9615.0,
6999,,,,,CHEMBL619543,A,BAO_0000218,,,1,6062,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,In vivo,Canis lupus familiaris,9615.0,
7000,,,,,CHEMBL619544,A,BAO_0000218,,,1,3598,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,Canis lupus familiaris,9615.0,
7001,,,,,CHEMBL619545,A,BAO_0000218,,,1,12500,The compound was tested for volume of distribution in dog,In vivo,Canis lupus familiaris,9615.0,
7002,,,,,CHEMBL619546,A,BAO_0000218,,,1,12500,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,In vivo,Canis lupus familiaris,9615.0,
7003,,,,,CHEMBL619547,A,BAO_0000218,,,1,6227,Vd (1 mg/kg) was determined in dog (in vivo),In vivo,Canis lupus familiaris,9615.0,
7004,,,,,CHEMBL619548,A,BAO_0000218,,,1,6227,Vd in dog,In vivo,Canis lupus familiaris,9615.0,
7005,,,,,CHEMBL619549,A,BAO_0000218,,,1,4219,Volume distribution was determined,In vivo,Canis lupus familiaris,9615.0,
7006,,,,,CHEMBL619550,A,BAO_0000218,,,1,1696,Volume of distribution in dog,In vivo,Canis lupus familiaris,9615.0,
7007,,,,,CHEMBL876501,A,BAO_0000218,,,1,5542,Volume of distribution by as 4 fold increase by iv administration in dogs,In vivo,Canis lupus familiaris,9615.0,
7008,,,,,CHEMBL619551,A,BAO_0000218,,,1,5199,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,In vivo,Canis lupus familiaris,9615.0,
7009,,,,,CHEMBL619552,A,BAO_0000218,,,1,6348,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,Canis lupus familiaris,9615.0,
7010,,,,,CHEMBL619553,A,BAO_0000218,,,1,4727,Volume distribution at the dose of 2 mg/kg in dog,In vivo,Canis lupus familiaris,9615.0,
7011,,,,,CHEMBL618722,A,BAO_0000218,,,1,16367,Steady state volume of distribution was determined,In vivo,Canis lupus familiaris,9615.0,
7012,,,,,CHEMBL618723,A,BAO_0000218,,,1,2652,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,In vivo,Canis lupus familiaris,9615.0,
7013,,,,,CHEMBL618724,A,BAO_0000218,,,1,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,In vivo,Canis lupus familiaris,9615.0,
7014,,,,,CHEMBL618725,A,BAO_0000218,,,1,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,In vivo,Canis lupus familiaris,9615.0,
7015,,,,,CHEMBL618726,A,BAO_0000218,,,1,16452,Bioavailability in dog (dose 1 mg/kg i.v.),In vivo,Canis lupus familiaris,9615.0,
7016,,,,,CHEMBL618727,A,BAO_0000218,,,1,5334,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),In vivo,Canis lupus familiaris,9615.0,
7017,,,,,CHEMBL624233,A,BAO_0000218,,,1,4239,Pharmacokinetic property (vdss) was measured in dog,In vivo,Canis lupus familiaris,9615.0,
7018,,,,,CHEMBL624234,A,BAO_0000218,,,1,4709,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,In vivo,Canis lupus familiaris,9615.0,
7019,,,,,CHEMBL624235,A,BAO_0000218,,,1,5600,Vdss was determined after iv 0.1 mg/kg administration in dog,In vivo,Canis lupus familiaris,9615.0,
7020,,,,,CHEMBL624236,A,BAO_0000218,,,1,6057,Volume displacement was calculated in dog,In vivo,Canis lupus familiaris,9615.0,
7021,,,,,CHEMBL624237,A,BAO_0000218,,,1,5654,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,In vivo,Canis lupus familiaris,9615.0,
7022,,,,,CHEMBL624238,A,BAO_0000218,,,1,5505,Volume distribution constant was determined,In vivo,Canis lupus familiaris,9615.0,
7023,,,,,CHEMBL624239,A,BAO_0000218,,,1,4527,Volume distribution at a dose of 1 uM/kg in dog was determined,In vivo,Canis lupus familiaris,9615.0,
7024,,,,,CHEMBL875829,A,BAO_0000218,,,1,4521,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,In vivo,Canis lupus familiaris,9615.0,
7025,,,,,CHEMBL624240,A,BAO_0000218,,,1,4521,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,In vivo,Canis lupus familiaris,9615.0,
7026,,,,,CHEMBL624241,A,BAO_0000218,,,1,15660,Volume distribution (Vdss) was measured in dog,In vivo,Canis lupus familiaris,9615.0,
7027,,,,,CHEMBL624242,A,BAO_0000218,,,1,15660,Volume distribution (Vdss) was measured in dog,In vivo,Canis lupus familiaris,9615.0,
7028,,,,,CHEMBL624243,A,BAO_0000218,,,1,6679,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,Canis lupus familiaris,9615.0,
7029,,,,,CHEMBL624244,A,BAO_0000218,,,1,5145,Volume of distribution in steady state was determined in dog,In vivo,Canis lupus familiaris,9615.0,
7030,,,,,CHEMBL624245,A,BAO_0000218,,,1,6821,Volume of distribution of compound was determined in dog,In vivo,Canis lupus familiaris,9615.0,
7031,,,,,CHEMBL624246,A,BAO_0000218,,,1,4137,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,In vivo,Canis lupus familiaris,9615.0,
7032,,,,,CHEMBL624247,A,BAO_0000218,,,1,5334,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),In vivo,Canis lupus familiaris,9615.0,
7033,,,,,CHEMBL624248,A,BAO_0000218,,,1,15660,Volume of distribution (Vdss) was measured in dog,In vivo,Canis lupus familiaris,9615.0,
7034,,,,,CHEMBL624249,A,BAO_0000218,,,1,6642,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),In vivo,Canis lupus familiaris,9615.0,
7035,,,,,CHEMBL624250,A,BAO_0000218,,,1,6641,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,Canis lupus familiaris,9615.0,
7036,,,,,CHEMBL624251,A,BAO_0000218,,,1,6642,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,Canis lupus familiaris,9615.0,
7037,,,,,CHEMBL624252,A,BAO_0000218,,,1,11659,Maximum rate of depolarization of the upstroke of the action potential,,Canis lupus familiaris,9615.0,
7038,,,,,CHEMBL624253,A,BAO_0000218,,,1,6448,Steady state volume distribution in dog,In vivo,Canis lupus familiaris,9615.0,
7039,,,,,CHEMBL624950,A,BAO_0000218,,,1,5474,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,In vivo,Canis lupus familiaris,9615.0,
7040,,,,,CHEMBL624951,A,BAO_0000218,,,1,1466,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,In vivo,Canis lupus familiaris,9615.0,
7041,,,,,CHEMBL875830,A,BAO_0000218,,,1,6535,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,In vivo,Canis lupus familiaris,9615.0,
7042,,,,,CHEMBL624952,A,BAO_0000218,,,1,6535,Volume distribution in dog after administration of 1 mg/kg iv,In vivo,Canis lupus familiaris,9615.0,
7043,,,,,CHEMBL624953,A,BAO_0000218,,,1,17764,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,In vivo,Canis lupus familiaris,9615.0,
7044,,,,,CHEMBL624954,A,BAO_0000218,,,1,6215,Vss after intravenous administration (0.5 mg/kg) was determined in dog,In vivo,Canis lupus familiaris,9615.0,
7045,,,,,CHEMBL624955,A,BAO_0000218,,,1,6505,Vss on i.v. administration of 2 mg/kg was measured in dog,In vivo,Canis lupus familiaris,9615.0,
7046,,,,,CHEMBL624956,A,BAO_0000218,,,1,3639,Vss was determined,,Canis lupus familiaris,9615.0,
7047,,,,,CHEMBL625129,A,BAO_0000218,,,1,3639,Vss in dog,,Canis lupus familiaris,9615.0,
7048,,,,,CHEMBL625130,A,BAO_0000218,,,1,6062,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,In vivo,Canis lupus familiaris,9615.0,
7049,,,,,CHEMBL625131,A,BAO_0000218,,,1,4942,Volume distribution in dogs,In vivo,Canis lupus familiaris,9615.0,
7050,,,,,CHEMBL625132,A,BAO_0000218,,,1,17796,Volume of distribution in dog,In vivo,Canis lupus familiaris,9615.0,
7051,,,,,CHEMBL872263,A,BAO_0000218,,,1,4883,Tested for the oral bioavailability in dog,In vivo,Canis lupus familiaris,9615.0,
7060,,,,,CHEMBL624336,A,BAO_0000218,,,1,17837,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,In vivo,Mus musculus,10090.0,
7061,,,,,CHEMBL624337,A,BAO_0000218,,,1,17729,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,In vivo,Mus musculus,10090.0,
7062,,,,,CHEMBL624338,A,BAO_0000218,,,1,17729,Bioavailability after peroral administration of 50 mg/kg of dose in mice,In vivo,Mus musculus,10090.0,
7063,,,,,CHEMBL624339,A,BAO_0000218,,,1,4239,Bioavailability was measured in mouse,In vivo,Mus musculus,10090.0,
7064,,,,,CHEMBL624340,A,BAO_0000218,,,1,17592,Bioavailability in mouse,In vivo,Mus musculus,10090.0,
7065,,,,,CHEMBL624341,A,BAO_0000218,,,1,6348,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,Mus musculus,10090.0,
7066,,,,,CHEMBL624342,A,BAO_0000218,,,1,2801,Bioavailability in mouse,In vivo,Mus musculus,10090.0,
7067,,,,,CHEMBL624343,A,BAO_0000218,,,1,2801,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,In vivo,Mus musculus,10090.0,
7068,,,,,CHEMBL624344,A,BAO_0000218,,,1,17718,Oral bioavailability in mouse,In vivo,Mus musculus,10090.0,
7069,,,,,CHEMBL624345,A,BAO_0000218,,,1,5727,Oral availability at 50 mg/kg po in male mice,In vivo,Mus musculus,10090.0,
7070,,,,,CHEMBL624346,A,BAO_0000218,,,1,5302,Oral bioavailability in mouse (dose 10 mg/kg),In vivo,Mus musculus,10090.0,
7071,,,,,CHEMBL624347,A,BAO_0000218,,,1,3598,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,In vivo,Mus musculus,10090.0,
7072,,,,,CHEMBL624348,A,BAO_0000218,,,1,5961,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",In vivo,Mus musculus,10090.0,
7074,,,,,CHEMBL622754,A,BAO_0000218,,,1,6091,Oral bioavailability in mouse,In vivo,Mus musculus,10090.0,
7075,,,,,CHEMBL622755,A,BAO_0000218,,,1,6091,Oral bioavailability in vivo in mice;ND=Not determined,In vivo,Mus musculus,10090.0,
7076,,,,,CHEMBL622756,A,BAO_0000218,,,1,5711,Oral bioavailability in mouse at 10 mg/kg of the compound,In vivo,Mus musculus,10090.0,
7077,,,,,CHEMBL622757,A,BAO_0000218,,,1,17728,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),In vivo,Mus musculus,10090.0,
7078,,,,,CHEMBL622758,A,BAO_0000218,,,1,17728,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),In vivo,Mus musculus,10090.0,
7079,,,,,CHEMBL622759,A,BAO_0000218,,,1,3802,Tested for bioavailability of the compound,In vivo,Mus musculus,10090.0,
7080,,,,,CHEMBL622760,A,BAO_0000218,,,1,3802,Tested for half life at the dose of 10 mg/kg when administered intravenously,In vivo,Mus musculus,10090.0,
7081,Plasma,,,,CHEMBL622761,A,BAO_0000218,,,1,14029,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,,Mus musculus,10090.0,
7082,Plasma,,,,CHEMBL622762,A,BAO_0000218,,,1,14029,The plasma half life of compound was determined on heparin prepared by human plasma. ,,Mus musculus,10090.0,
7083,Plasma,,,,CHEMBL622763,A,BAO_0000218,,,1,14029,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,,Mus musculus,10090.0,
7084,Plasma,,,,CHEMBL622764,A,BAO_0000218,,,1,14029,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,,Mus musculus,10090.0,
7085,Plasma,,,,CHEMBL622765,A,BAO_0000218,,,1,14029,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,,Mus musculus,10090.0,
7086,,,,,CHEMBL622766,F,BAO_0000218,,,1,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,Mus musculus,10090.0,
7087,,,,,CHEMBL622767,A,BAO_0000218,,,1,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,Mus musculus,10090.0,
7088,,,,,CHEMBL622768,A,BAO_0000218,,,1,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,Mus musculus,10090.0,
7089,Blood,,,,CHEMBL875948,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,Mus musculus,10090.0,
7090,Blood,,,,CHEMBL622769,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,Mus musculus,10090.0,
7091,Blood,,,,CHEMBL622770,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,Mus musculus,10090.0,
7092,Blood,,,,CHEMBL622771,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,Mus musculus,10090.0,
7093,Blood,,,,CHEMBL622772,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,Mus musculus,10090.0,
7094,Blood,,,,CHEMBL622773,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,Mus musculus,10090.0,
7095,Blood,,,,CHEMBL622774,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,Mus musculus,10090.0,
7096,Bone,,,,CHEMBL621725,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,Mus musculus,10090.0,
7097,Bone,,,,CHEMBL621726,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,In vivo,Mus musculus,10090.0,
7098,,,,A2780,CHEMBL621727,F,BAO_0000219,,,1,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,,Homo sapiens,9606.0,
7099,,,,A2780,CHEMBL622413,F,BAO_0000219,,,1,3290,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,,Homo sapiens,9606.0,
7100,,,,A2780,CHEMBL622414,F,BAO_0000219,,,1,2859,Compound was evaluated for cytotoxicity against A2780 cell line,,Homo sapiens,9606.0,
7101,,,,A2780,CHEMBL622415,F,BAO_0000219,,,1,15688,Inhibition of A2780 cell clonogenic assay,,Homo sapiens,9606.0,
7102,,,,A2780,CHEMBL884001,F,BAO_0000219,,,1,5642,Cytotoxic effect on ovarian cancer cell line (A2780),,Homo sapiens,9606.0,
7103,,,,A2780,CHEMBL622416,F,BAO_0000219,,,1,6633,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,,Homo sapiens,9606.0,
7104,,,,A2780,CHEMBL622417,F,BAO_0000219,,,1,3906,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",,Homo sapiens,9606.0,
7105,,,,A2780,CHEMBL622590,F,BAO_0000219,,,1,6788,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,,Homo sapiens,9606.0,
7106,,,,A2780,CHEMBL622591,F,BAO_0000219,,,1,17582,Antiproliferative activity against human A2780 cells,,Homo sapiens,9606.0,
7107,,,,A2780,CHEMBL622592,F,BAO_0000219,,,1,17764,Inhibition of human A2780 cell proliferation,,Homo sapiens,9606.0,
7108,,,,A2780,CHEMBL622593,F,BAO_0000219,,,1,17764,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,,Homo sapiens,9606.0,
7109,,,,A2780,CHEMBL622594,F,BAO_0000219,,,1,17764,Inhibition of human A2780 cell proliferation (No data),,Homo sapiens,9606.0,
7110,,,,A2780,CHEMBL622595,F,BAO_0000219,,,1,2815,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,,Homo sapiens,9606.0,
7111,,,,A2780,CHEMBL622596,F,BAO_0000219,,,1,16930,Compound was evaluated against human Ovarian carcinoma cell line A2780,,Homo sapiens,9606.0,
7112,,,,A2780,CHEMBL622597,F,BAO_0000219,,,1,17777,Growth inhibition against A2780 wild-type ovarian cell lines,,Homo sapiens,9606.0,
7113,,,,A2780,CHEMBL622598,F,BAO_0000219,,,1,17777,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,,Homo sapiens,9606.0,
7114,,,,,CHEMBL622599,F,BAO_0000019,,,5,16936,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,Homo sapiens,9606.0,
7115,,,,A2780,CHEMBL622600,F,BAO_0000219,,,1,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,Homo sapiens,9606.0,
7116,,,,A2780,CHEMBL622601,F,BAO_0000219,,,1,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,Homo sapiens,9606.0,
7117,,,,A2780,CHEMBL622602,F,BAO_0000219,,,1,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,Homo sapiens,9606.0,
7118,,,,A2780,CHEMBL622603,F,BAO_0000219,,,1,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,Homo sapiens,9606.0,
7119,,,,A2780,CHEMBL622604,F,BAO_0000219,,,1,15292,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,Homo sapiens,9606.0,
7120,,,,A2780,CHEMBL622605,F,BAO_0000219,,,1,15292,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,Homo sapiens,9606.0,
7121,,,,A2780,CHEMBL622606,F,BAO_0000219,,,1,15069,In vitro inhibition of human ovarian cell line A2780,,Homo sapiens,9606.0,
7122,,,,A2780,CHEMBL619463,F,BAO_0000219,,,1,15069,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",,Homo sapiens,9606.0,
7123,,,,A2780,CHEMBL619464,F,BAO_0000219,,,1,14073,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),,Homo sapiens,9606.0,
7124,,,,A2780,CHEMBL619465,F,BAO_0000219,,,1,14553,Concentration required to inhibit A2780-cell growth by 50%,,Homo sapiens,9606.0,
7125,,,,A2780,CHEMBL619466,F,BAO_0000219,,,1,13040,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,,Homo sapiens,9606.0,
7126,,,,A2780,CHEMBL619467,F,BAO_0000219,,,1,6891,Cytotoxic effect on human ovarian (A2780) cancer cell line,,Homo sapiens,9606.0,
7127,,,,A2780,CHEMBL619468,F,BAO_0000219,,,1,15569,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,,Homo sapiens,9606.0,
7128,,,,A2780,CHEMBL619469,F,BAO_0000219,,,1,14190,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,,Homo sapiens,9606.0,
7129,,,,A2780,CHEMBL619470,F,BAO_0000219,,,1,15014,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,Homo sapiens,9606.0,
7130,,,,A2780,CHEMBL619471,F,BAO_0000219,,,1,15014,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,Homo sapiens,9606.0,
7131,,,,A2780,CHEMBL619472,F,BAO_0000219,,,1,17496,Cytotoxicity against human ovarian carcinoma A2780 cell line,,Homo sapiens,9606.0,
7132,,,,A2780,CHEMBL619473,F,BAO_0000219,,,1,13617,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",,Homo sapiens,9606.0,
7133,,,,A2780,CHEMBL874368,F,BAO_0000219,,,1,13617,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",,Homo sapiens,9606.0,
7134,,,,A2780,CHEMBL884003,F,BAO_0000219,,,1,13617,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",,Homo sapiens,9606.0,
7135,,,,A2780,CHEMBL622690,F,BAO_0000219,,,1,13617,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",,Homo sapiens,9606.0,
7136,,,,A2780,CHEMBL622691,F,BAO_0000219,,,1,17672,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,,Homo sapiens,9606.0,
7137,,,,A2780,CHEMBL622692,F,BAO_0000219,,,1,4544,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,Homo sapiens,9606.0,
7138,,,,A2780,CHEMBL623406,F,BAO_0000219,,,1,4544,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,Homo sapiens,9606.0,
7139,,,,A2780,CHEMBL884004,F,BAO_0000219,,,1,16317,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",,Homo sapiens,9606.0,
7140,,,,A2780,CHEMBL623407,F,BAO_0000219,,,1,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,,Homo sapiens,9606.0,
7141,,,,A2780,CHEMBL623408,F,BAO_0000219,,,1,13978,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,,Homo sapiens,9606.0,
7142,,,,A2780,CHEMBL623409,F,BAO_0000219,,,1,12989,In vitro antitumor activity against A2780 cell line.,,Homo sapiens,9606.0,
7143,,,,A2780,CHEMBL623410,F,BAO_0000219,,,1,5574,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,,Homo sapiens,9606.0,
7144,,,,A2780,CHEMBL623576,F,BAO_0000219,,,1,13528,In vitro cytotoxicity against A2780 human ovarian cancer cell line,,Homo sapiens,9606.0,
7145,,,,ACHN,CHEMBL623577,F,BAO_0000219,,,1,12782,Inhibitory activity against kidney A-CHN tumor cell growth in culture,,Homo sapiens,9606.0,
7146,,,,ACHN,CHEMBL623578,F,BAO_0000219,,,1,14255,The IC50 value was measured on ACHN cell line in renal tumor type.,,Homo sapiens,9606.0,
7147,,,,ACHN,CHEMBL623579,F,BAO_0000219,,,1,16364,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,,Homo sapiens,9606.0,
7148,,,,ACHN,CHEMBL623580,F,BAO_0000219,,,1,17376,In vitro lethal concentration against most sensitive ACHN cell line,,Homo sapiens,9606.0,
7149,,,,ACHN,CHEMBL623581,F,BAO_0000219,,,1,12016,Tested for cytotoxic activity against renal cancer ACHN cell line,,Homo sapiens,9606.0,
7150,,,,ACHN,CHEMBL857456,F,BAO_0000219,,,1,6058,Compound tested for growth inhibition of renal cancer cell line ACHN,,Homo sapiens,9606.0,
7151,,,,ACHN,CHEMBL623582,F,BAO_0000219,,,1,17708,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,,Homo sapiens,9606.0,
7152,,,,ACHN,CHEMBL623583,F,BAO_0000219,,,1,15176,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,,Homo sapiens,9606.0,
7153,,,,ACHN,CHEMBL623584,F,BAO_0000219,,,1,2806,In vitro anticancer activity against ACHN renal cancer cell line,,Homo sapiens,9606.0,
7154,,,,ACHN,CHEMBL623585,F,BAO_0000219,,,1,15300,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,,Homo sapiens,9606.0,
7155,,,,ACHN,CHEMBL623586,F,BAO_0000219,,,1,16364,Percent selectivity was evaluated in renal ACHN cell lines,,Homo sapiens,9606.0,
7156,,,,ACHN,CHEMBL623587,F,BAO_0000219,,,1,13859,In vitro inhibitory activity against renal ACHN cancer cell line,,Homo sapiens,9606.0,
7157,,,,ACHN,CHEMBL875279,F,BAO_0000219,,,1,11970,Tested for cytotoxicity against ACHN cell lines in renal cancer,,Homo sapiens,9606.0,
7158,,,,ACHN,CHEMBL623588,F,BAO_0000219,,,1,2450,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,,Homo sapiens,9606.0,
7159,,,,ACHN,CHEMBL623589,F,BAO_0000219,,,1,12696,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,Homo sapiens,9606.0,
7160,,,,ACHN,CHEMBL623590,F,BAO_0000219,,,1,12400,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,,Homo sapiens,9606.0,
7161,,,,ACHN,CHEMBL623591,F,BAO_0000219,,,1,12888,Cytotoxic effect on renal cancer line ACHN,,Homo sapiens,9606.0,
7162,,,,ACHN,CHEMBL623592,F,BAO_0000219,,,1,3156,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,,Homo sapiens,9606.0,
7163,,,,ACHN,CHEMBL623593,F,BAO_0000219,,,1,3381,In vitro inhibition of Renal Cancer ACHN cell lines,,Homo sapiens,9606.0,
7164,,,,ACHN,CHEMBL623594,F,BAO_0000219,,,1,16747,Antitumor activity against human renal adenocarcinoma ACHN cells,,Homo sapiens,9606.0,
7165,,,,ACHN,CHEMBL621833,F,BAO_0000219,,,1,16748,Antitumor activity against human renal adenocarcinoma ACHN cells.,,Homo sapiens,9606.0,
7166,,,,ACHN,CHEMBL621834,F,BAO_0000219,,,1,12062,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,,Homo sapiens,9606.0,
7167,,,,ACHN,CHEMBL621835,F,BAO_0000219,,,1,14769,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,Homo sapiens,9606.0,
7168,,,,ACHN,CHEMBL621836,F,BAO_0000219,,,1,15895,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",,Homo sapiens,9606.0,
7169,,,,ACHN,CHEMBL621837,F,BAO_0000219,,,1,17376,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,,Homo sapiens,9606.0,
7170,,,,ACHN,CHEMBL875280,F,BAO_0000219,,,1,14882,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,Homo sapiens,9606.0,
7171,,,,ACHN,CHEMBL621838,F,BAO_0000219,,,1,14882,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,,Homo sapiens,9606.0,
7172,,,,ACHN,CHEMBL621839,F,BAO_0000219,,,1,15661,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,,Homo sapiens,9606.0,
7173,,,,,CHEMBL621840,A,BAO_0000019,,,0,9680,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,,,
7174,,,,,CHEMBL621841,F,BAO_0000019,,,8,14579,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,,,
7175,,,,HEL,CHEMBL622979,F,BAO_0000218,,,1,17290,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,,Cytomegalovirus,10358.0,
7176,,,,,CHEMBL876595,F,BAO_0000218,,,1,17290,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,Cytomegalovirus,10358.0,
7177,,,,,CHEMBL620221,B,BAO_0000357,,,8,15891,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,,,
7178,,,,,CHEMBL620222,B,BAO_0000357,,,8,15890,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,,,
7179,,,,ADDP cell line,CHEMBL620506,F,BAO_0000219,,,1,3801,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,,Bos taurus,9913.0,
7180,,,,ADJ/PC6,CHEMBL620507,F,BAO_0000219,,,1,9222,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,,Mus musculus,10090.0,
7181,,,,ADJ/PC6,CHEMBL620508,F,BAO_0000219,,,1,9222,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,,Mus musculus,10090.0,
7182,,,,ADJ/PC6,CHEMBL620509,F,BAO_0000219,,,1,7257,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",,Mus musculus,10090.0,
7183,,,,ADJ/PC6,CHEMBL620510,F,BAO_0000219,,,1,7257,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,,Mus musculus,10090.0,
7184,,,,ADJ/PC6,CHEMBL620511,A,BAO_0000219,,,1,7257,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,,Mus musculus,10090.0,
7185,,,,ADJ/PC6,CHEMBL620512,F,BAO_0000219,,,1,8084,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,,Mus musculus,10090.0,
7186,,,,,CHEMBL620513,F,BAO_0000019,,,0,14943,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,Mus musculus,10090.0,
7187,,,,,CHEMBL620514,F,BAO_0000019,,,0,14943,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,Mus musculus,10090.0,
7188,,,,,CHEMBL620515,F,BAO_0000019,,,0,14943,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,Mus musculus,10090.0,
7189,,,,,CHEMBL620516,A,BAO_0000218,,,0,10524,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),In vivo,Bacillus subtilis,1423.0,
7190,Plasma,,,,CHEMBL620517,A,BAO_0000218,,,1,3546,AUC value in dog after IV administration at a dose of 5 mg/kg,,Canis lupus familiaris,9615.0,
7191,Plasma,,,,CHEMBL620518,A,BAO_0000218,,,1,3546,AUC value in dog after oral administration at a dose of 5 mg/kg,,Canis lupus familiaris,9615.0,
7192,,,,,CHEMBL620519,A,BAO_0000218,,,1,3546,Cmax value in dog after oral administration at a dose of 5 mg/kg,In vivo,Canis lupus familiaris,9615.0,
7193,,,,,CHEMBL621386,A,BAO_0000218,,,1,3546,Bioavailability in dog after oral administration at a dose of 5 mg/kg,In vivo,Canis lupus familiaris,9615.0,
7194,,,,,CHEMBL621387,A,BAO_0000218,,,1,3546,Tmax value in dog after oral administration at a dose of 5 mg/kg,In vivo,Canis lupus familiaris,9615.0,
7195,,,,,CHEMBL621388,A,BAO_0000218,,,1,3184,Compound was evaluated for its clearance when administered intravenously in dog,In vivo,Canis lupus familiaris,9615.0,
7196,,,,,CHEMBL621389,A,BAO_0000218,,,1,16456,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,In vivo,Canis lupus familiaris,9615.0,
7197,,,,,CHEMBL621390,A,BAO_0000218,,,1,4809,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),In vivo,Canis lupus familiaris,9615.0,
7198,,,,,CHEMBL621391,P,BAO_0000100,,,0,4219,Calculated partition coefficient (clogP),,,,
7199,,,,,CHEMBL621392,A,BAO_0000218,,,1,3748,Half life in dog,,Canis lupus familiaris,9615.0,
7200,,,,,CHEMBL621393,A,BAO_0000218,,,1,3132,Time taken for EC90 was determined when tested in dog,,Canis lupus familiaris,9615.0,
7201,,,,,CHEMBL621394,A,BAO_0000218,,,1,4219,Half life (iv) was determined,,Canis lupus familiaris,9615.0,
7202,Liver,,,,CHEMBL621395,A,BAO_0000218,,,1,16907,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,Canis lupus familiaris,9615.0,
7203,,,,,CHEMBL621396,A,BAO_0000218,,,1,6057,Area under the curve was calculated in dog after iv administration,,Canis lupus familiaris,9615.0,
7204,,,,,CHEMBL621397,A,BAO_0000218,,,1,6057,Area under the curve was calculated in dog after peroral administration,,Canis lupus familiaris,9615.0,
7205,,,,,CHEMBL621398,A,BAO_0000218,,,1,17853,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,Canis lupus familiaris,9615.0,
7206,,,,,CHEMBL618818,A,BAO_0000218,,,1,3639,pKa was evaluated in dog,,Canis lupus familiaris,9615.0,
7207,,,,,CHEMBL618819,A,BAO_0000218,,,1,14541,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,Canis lupus familiaris,9615.0,
7208,,,,,CHEMBL618820,A,BAO_0000218,,,1,16456,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,In vivo,Canis lupus familiaris,9615.0,
7209,,,,,CHEMBL873810,A,BAO_0000218,,,1,16456,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,In vivo,Canis lupus familiaris,9615.0,
7210,,,,,CHEMBL876606,A,BAO_0000218,,,1,2652,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,In vivo,Canis lupus familiaris,9615.0,
7211,,,,,CHEMBL618821,A,BAO_0000218,,,1,3624,Compound was evaluated for the half-life (t 1/2) in hours,,Canis lupus familiaris,9615.0,
7212,Blood,,,,CHEMBL618822,A,BAO_0000218,,,1,1337,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,In vivo,Canis lupus familiaris,9615.0,
7213,Blood,,,,CHEMBL618823,A,BAO_0000218,,,1,1337,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,In vivo,Canis lupus familiaris,9615.0,
7214,,,,,CHEMBL618824,A,BAO_0000218,,,1,4709,Half life after intravenous administration of 1 mg/kg in dog,In vivo,Canis lupus familiaris,9615.0,
7215,,,,,CHEMBL618825,A,BAO_0000218,,,1,15660,Half life was measured in dog,,Canis lupus familiaris,9615.0,
7216,,,,,CHEMBL618826,A,BAO_0000218,,,1,5302,Half life period in dog after 5 mg/kg dose,In vivo,Canis lupus familiaris,9615.0,
7217,,,,,CHEMBL618827,A,BAO_0000218,,,1,17791,Half life period was evaluated in dog; 4-4.8,,Canis lupus familiaris,9615.0,
7218,,,,,CHEMBL618828,A,BAO_0000218,,,1,6348,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,Canis lupus familiaris,9615.0,
7219,,,,,CHEMBL618829,A,BAO_0000218,,,1,4257,Half-life was determined in dog after a3 mg/kg of iv dose,In vivo,Canis lupus familiaris,9615.0,
7220,,,,,CHEMBL618830,A,BAO_0000218,,,1,3771,Half-life was determined,,Canis lupus familiaris,9615.0,
7221,,,,,CHEMBL618831,A,BAO_0000218,,,1,6305,Half life in dogs,,Canis lupus familiaris,9615.0,
7222,Plasma,,,,CHEMBL619489,A,BAO_0000218,,,1,13501,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,In vivo,Canis lupus familiaris,9615.0,
7223,,,,,CHEMBL619649,A,BAO_0000218,,,1,17594,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,In vivo,Canis lupus familiaris,9615.0,
7224,,,,,CHEMBL876607,A,BAO_0000218,,,1,3045,Compound was evaluated for the half life period after iv administration in Beagle dog.,In vivo,Canis lupus familiaris,9615.0,
7225,,,,,CHEMBL619650,A,BAO_0000218,,,1,3043,Compound was evaluated for the half life period after oral administration in conscious dog.,In vivo,Canis lupus familiaris,9615.0,
7226,,,,,CHEMBL619651,A,BAO_0000218,,,1,4839,Compound was tested for half life in dog,,Canis lupus familiaris,9615.0,
7227,,,,,CHEMBL619652,A,BAO_0000218,,,1,4839,Compound was tested for its half life in dog,,Canis lupus familiaris,9615.0,
7228,,,,,CHEMBL619653,A,BAO_0000218,,,1,5802,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,In vivo,Canis lupus familiaris,9615.0,
7229,,,,,CHEMBL619654,A,BAO_0000218,,,1,17839,Half life of compound in dog was determined,,Canis lupus familiaris,9615.0,
7230,,,,,CHEMBL619655,A,BAO_0000218,,,1,4219,Half life (iv) was determined,In vivo,Canis lupus familiaris,9615.0,
7231,Blood,,,,CHEMBL619656,A,BAO_0000218,,,1,13966,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),,Canis lupus familiaris,9615.0,
7232,Plasma,,,,CHEMBL873812,A,BAO_0000218,,,1,3994,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,In vivo,Canis lupus familiaris,9615.0,
7233,Plasma,,,,CHEMBL621365,F,BAO_0000218,,,1,3994,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,In vivo,Canis lupus familiaris,9615.0,
7234,,,,,CHEMBL621366,A,BAO_0000218,,,1,4453,Half life in dog,,Canis lupus familiaris,9615.0,
7235,Plasma,,,,CHEMBL621367,A,BAO_0000218,,,1,6535,Half life in dog plasma,,Canis lupus familiaris,9615.0,
7236,Plasma,,,,CHEMBL621368,A,BAO_0000218,,,1,6535,Half life in dog plasma after administration of 0.25 mg/kg iv,In vivo,Canis lupus familiaris,9615.0,
7237,Plasma,,,,CHEMBL621369,A,BAO_0000218,,,1,6535,Half life in dog plasma after administration of 1 mg/kg iv,In vivo,Canis lupus familiaris,9615.0,
7238,Plasma,,,,CHEMBL621370,A,BAO_0000218,,,1,3132,Half life in dog plasma was determined at dose 10 mg/kg,In vivo,Canis lupus familiaris,9615.0,
7239,,,,,CHEMBL621371,A,BAO_0000218,,,1,5374,Half life in dog was determined,,Canis lupus familiaris,9615.0,
7240,,,,,CHEMBL621372,A,BAO_0000218,,,1,5007,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),In vivo,Canis lupus familiaris,9615.0,
7241,Plasma,,,,CHEMBL621373,A,BAO_0000218,,,1,16907,Half life upon exposure to human plasma,,Canis lupus familiaris,9615.0,
7242,,,,,CHEMBL621374,A,BAO_0000218,,,1,6057,Half life was calculated in dog,,Canis lupus familiaris,9615.0,
7243,,,,,CHEMBL621375,A,BAO_0000218,,,1,5006,Half life was determined,,Canis lupus familiaris,9615.0,
7244,,,,,CHEMBL621376,A,BAO_0000218,,,1,5473,Half life was determined,,Canis lupus familiaris,9615.0,
7245,,,,,CHEMBL619624,A,BAO_0000218,,,1,4368,Half life by intravenous administration of 1.2 mg/kg in dog,In vivo,Canis lupus familiaris,9615.0,
7246,,,,,CHEMBL875840,A,BAO_0000218,,,1,6448,Half life in dog,,Canis lupus familiaris,9615.0,
7247,,,,,CHEMBL619625,A,BAO_0000218,,,1,4353,Half life in dog after intra venous administration of the compound,,Canis lupus familiaris,9615.0,
7248,,,,,CHEMBL619626,A,BAO_0000218,,,1,4353,Half life in dog after intra venous administration of the compound; ND means Not determined,,Canis lupus familiaris,9615.0,
7249,,,,,CHEMBL619627,A,BAO_0000218,,,1,4353,Half life in dog after po administration of the compound,In vivo,Canis lupus familiaris,9615.0,
7250,,,,,CHEMBL873817,A,BAO_0000218,,,1,4353,Half life in dog after po administration of the compound; ND means Not determined,In vivo,Canis lupus familiaris,9615.0,
7251,,,,,CHEMBL619628,A,BAO_0000218,,,1,6265,Half life in dog at the single oral dose of 1 mg/kg,In vivo,Canis lupus familiaris,9615.0,
7252,,,,,CHEMBL619629,A,BAO_0000218,,,1,5006,Half life in dogs,,Canis lupus familiaris,9615.0,
7253,,,,,CHEMBL619630,A,BAO_0000218,,,1,5356,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,In vivo,Canis lupus familiaris,9615.0,
7254,,,,,CHEMBL619631,A,BAO_0000218,,,1,405,Half life in rat,,Canis lupus familiaris,9615.0,
7255,,,,,CHEMBL619632,A,BAO_0000218,,,1,6642,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),In vivo,Canis lupus familiaris,9615.0,
7256,Bone,,,,CHEMBL619633,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,Mus musculus,10090.0,
7257,Bone,,,,CHEMBL875841,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,Mus musculus,10090.0,
7258,Bone,,,,CHEMBL619634,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,Mus musculus,10090.0,
7259,Bone,,,,CHEMBL619635,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,Mus musculus,10090.0,
7260,Bone,,,,CHEMBL619636,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,Mus musculus,10090.0,
7261,Gut,,,,CHEMBL619637,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,Mus musculus,10090.0,
7262,Gut,,,,CHEMBL619638,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,Mus musculus,10090.0,
7263,Gut,,,,CHEMBL619639,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,Mus musculus,10090.0,
7264,Gut,,,,CHEMBL619640,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,Mus musculus,10090.0,
7265,Gut,,,,CHEMBL619641,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,Mus musculus,10090.0,
7266,Gut,,,,CHEMBL619642,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,Mus musculus,10090.0,
7267,Gut,,,,CHEMBL619643,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,Mus musculus,10090.0,
7268,Heart,,,,CHEMBL619644,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,Mus musculus,10090.0,
7269,Heart,,,,CHEMBL621112,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,Mus musculus,10090.0,
7270,Heart,,,,CHEMBL621113,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,Mus musculus,10090.0,
7271,Heart,,,,CHEMBL621114,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,Mus musculus,10090.0,
7272,Heart,,,,CHEMBL621115,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,Mus musculus,10090.0,
7273,Heart,,,,CHEMBL621116,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,Mus musculus,10090.0,
7274,Heart,,,,CHEMBL621117,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,Mus musculus,10090.0,
7275,Kidney,,,,CHEMBL621118,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,Mus musculus,10090.0,
7276,Kidney,,,,CHEMBL621119,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,In vivo,Mus musculus,10090.0,
7277,Kidney,,,,CHEMBL621120,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,Mus musculus,10090.0,
7278,Kidney,,,,CHEMBL621757,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,Mus musculus,10090.0,
7279,Kidney,,,,CHEMBL621758,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,Mus musculus,10090.0,
7280,Kidney,,,,CHEMBL621759,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,Mus musculus,10090.0,
7281,Kidney,,,,CHEMBL621760,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,Mus musculus,10090.0,
7282,Liver,,,,CHEMBL621761,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,Mus musculus,10090.0,
7283,Liver,,,,CHEMBL621762,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,Mus musculus,10090.0,
7284,Liver,,,,CHEMBL621763,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,Mus musculus,10090.0,
7285,Liver,,,,CHEMBL624502,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,Mus musculus,10090.0,
7286,Liver,,,,CHEMBL624503,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,Mus musculus,10090.0,
7287,Liver,,,,CHEMBL624504,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,Mus musculus,10090.0,
7288,Liver,,,,CHEMBL624505,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,Mus musculus,10090.0,
7289,Lung,,,,CHEMBL624506,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,Mus musculus,10090.0,
7290,,,,A2780,CHEMBL624507,F,BAO_0000219,,,1,5895,In vitro cytotoxicity against A2780 (human ovarian cancer),,Homo sapiens,9606.0,
7291,,,,A2780,CHEMBL624508,F,BAO_0000219,,,1,6338,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,,Homo sapiens,9606.0,
7292,,,,A2780,CHEMBL624509,F,BAO_0000219,,,1,15163,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,,Homo sapiens,9606.0,
7293,,,,A2780,CHEMBL624510,F,BAO_0000219,,,1,15163,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,,Homo sapiens,9606.0,
7294,,,,A2780,CHEMBL875956,F,BAO_0000219,,,1,15000,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,,Homo sapiens,9606.0,
7295,,,,A2780,CHEMBL839885,F,BAO_0000219,,,1,15000,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,,Homo sapiens,9606.0,
7296,,,,A2780,CHEMBL624511,F,BAO_0000219,,,1,14729,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,,Homo sapiens,9606.0,
7297,,,,A2780,CHEMBL624512,F,BAO_0000219,,,1,17270,In vitro cytotoxicity against A2780 cell line,,Homo sapiens,9606.0,
7298,,,,A2780,CHEMBL624513,F,BAO_0000219,,,1,5685,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,,Homo sapiens,9606.0,
7299,,,,A2780,CHEMBL624514,F,BAO_0000219,,,1,3563,In vitro inhibitory activity against human ovarian cancer A2780 cell line,,Homo sapiens,9606.0,
7300,,,,A2780,CHEMBL618547,F,BAO_0000218,,,1,17753,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,,Homo sapiens,9606.0,
7301,,,,A2780,CHEMBL618548,F,BAO_0000219,,,1,16317,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",,Homo sapiens,9606.0,
7302,,,,A2780,CHEMBL618549,F,BAO_0000219,,,1,16936,Inhibition of tubulin polymerization in analogy of ca.,,Homo sapiens,9606.0,
7303,,,,A2780,CHEMBL618550,F,BAO_0000219,,,1,3801,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,,Homo sapiens,9606.0,
7304,,,,A2780,CHEMBL618551,F,BAO_0000219,,,1,6181,Cytotoxic effect in ovarian cancer cell line (A2780),,Homo sapiens,9606.0,
7305,,,,A2780,CHEMBL618552,F,BAO_0000219,,,1,5318,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,,Homo sapiens,9606.0,
7306,,,,A2780,CHEMBL618553,F,BAO_0000219,,,1,4840,Tested for the cytotoxicity in A2780 ovarian cell line,,Homo sapiens,9606.0,
7307,,,,A2780,CHEMBL618554,F,BAO_0000219,,,1,15748,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,Homo sapiens,9606.0,
7308,,,,A2780,CHEMBL618555,F,BAO_0000219,,,1,15748,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,,Homo sapiens,9606.0,
7309,,,,A2780cisR,CHEMBL618556,F,BAO_0000219,,,1,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,,,
7310,,,,A2780cisR,CHEMBL618557,F,BAO_0000219,,,1,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,,,
7311,,,,A2780cisR,CHEMBL618558,F,BAO_0000219,,,1,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,,,
7312,,,,A2780cisR,CHEMBL618559,F,BAO_0000219,,,1,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,,,
7313,,,,A2780,CHEMBL618560,F,BAO_0000218,,,1,17753,In vivo log of cells killed after administration of compound in A2780 cell line,,Homo sapiens,9606.0,
7314,,,,A2780,CHEMBL618561,F,BAO_0000218,,,1,17753,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,In vivo,Homo sapiens,9606.0,
7315,,,,A2780,CHEMBL618562,F,BAO_0000219,,,1,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,,Homo sapiens,9606.0,
7316,,,,A2780,CHEMBL618563,F,BAO_0000219,,,1,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,,Homo sapiens,9606.0,
7317,,,,A2780,CHEMBL618564,F,BAO_0000219,,,1,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,,Homo sapiens,9606.0,
7318,,,,A2780,CHEMBL618565,F,BAO_0000219,,,1,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,,Homo sapiens,9606.0,
7319,,,,A2780,CHEMBL618566,F,BAO_0000218,,,1,17528,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),,Homo sapiens,9606.0,
7320,,,,A2780,CHEMBL618567,F,BAO_0000219,,,1,6633,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,,Homo sapiens,9606.0,
7321,,,,A2780,CHEMBL618568,F,BAO_0000219,,,1,15000,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,,Homo sapiens,9606.0,
7322,,,,A2780,CHEMBL618569,F,BAO_0000219,,,1,17528,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,Homo sapiens,9606.0,
7323,,,,A2780,CHEMBL621857,F,BAO_0000219,,,1,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,,Homo sapiens,9606.0,
7324,,,,A2780,CHEMBL621858,F,BAO_0000219,,,1,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,,Homo sapiens,9606.0,
7325,,,,A2780,CHEMBL621859,F,BAO_0000219,,,1,16936,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,,Homo sapiens,9606.0,
7326,,,,A2780,CHEMBL621860,F,BAO_0000219,,,1,16936,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",,Homo sapiens,9606.0,
7327,,,,A2780,CHEMBL621861,F,BAO_0000219,,,1,16936,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),,Homo sapiens,9606.0,
7328,,,,A2780,CHEMBL621862,F,BAO_0000219,,,1,16936,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",,Homo sapiens,9606.0,
7329,,,,A2780,CHEMBL621863,F,BAO_0000219,,,1,16936,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,Homo sapiens,9606.0,
7330,,,,A2780,CHEMBL621864,F,BAO_0000219,,,1,16936,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,Homo sapiens,9606.0,
7331,,,,A2780,CHEMBL621865,F,BAO_0000219,,,1,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),,Homo sapiens,9606.0,
7332,,,,A2780,CHEMBL621866,F,BAO_0000219,,,1,17737,In vitro antiproliferative activity against A2780 cell line,,Mus musculus,10090.0,
7333,,,,A2780,CHEMBL621867,F,BAO_0000219,,,1,17764,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,,Mus musculus,10090.0,
7334,,,,A2780,CHEMBL621868,F,BAO_0000219,,,1,3830,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,,Homo sapiens,9606.0,
7335,,,,A2780,CHEMBL875282,F,BAO_0000219,,,1,3829,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,,Homo sapiens,9606.0,
7336,,,,,CHEMBL621869,A,BAO_0000218,,,1,3546,Vc value in dog after IV administration at a dose of 5 mg/kg,,Canis lupus familiaris,9615.0,
7337,,,,,CHEMBL621870,A,BAO_0000218,,,1,3546,Half life period in dog after IV administration at a dose of 5 mg/kg,In vivo,Canis lupus familiaris,9615.0,
7338,,,,,CHEMBL621871,A,BAO_0000019,,,0,5668,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,Cercopithecidae,9527.0,
7339,Plasma,,,,CHEMBL621243,A,BAO_0000218,,,0,3443,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Cercopithecidae,9527.0,
7340,Plasma,,,,CHEMBL621244,A,BAO_0000218,,,0,3443,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Cercopithecidae,9527.0,
7341,,,,,CHEMBL621245,A,BAO_0000218,,,0,4256,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,In vivo,Macaca fascicularis,9541.0,
7342,,,,,CHEMBL621246,A,BAO_0000218,,,0,4256,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,In vivo,Macaca fascicularis,9541.0,
7343,,,,,CHEMBL621247,A,BAO_0000218,,,0,4256,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,In vivo,Macaca fascicularis,9541.0,
7344,,,,,CHEMBL618386,A,BAO_0000218,,,0,4256,Oral Bioavailability in rat,In vivo,Rattus norvegicus,10116.0,
7345,,,,,CHEMBL618387,A,BAO_0000218,,,0,1916,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,Cercopithecidae,9527.0,
7346,,,,,CHEMBL618388,A,BAO_0000218,,,0,5302,Area under curve value in monkey at a dose of 5 mg/kg,,Cercopithecidae,9527.0,
7347,,,,,CHEMBL618389,A,BAO_0000218,,,0,4257,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,Cercopithecidae,9527.0,
7348,,,,,CHEMBL618574,A,BAO_0000019,,,0,5355,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,Cercopithecidae,9527.0,
7349,,,,,CHEMBL618575,A,BAO_0000019,,,0,5355,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,Cercopithecidae,9527.0,
7350,,,,,CHEMBL618576,A,BAO_0000019,,,0,5355,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,Cercopithecidae,9527.0,
7351,,,,,CHEMBL618577,A,BAO_0000218,,,0,6078,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,Cercopithecidae,9527.0,
7352,,,,,CHEMBL876487,A,BAO_0000218,,,0,6078,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,Cercopithecidae,9527.0,
7353,,,,,CHEMBL618578,A,BAO_0000218,,,0,6062,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,Cercopithecidae,9527.0,
7354,,,,,CHEMBL618579,A,BAO_0000218,,,0,2661,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,Cercopithecidae,9527.0,
7355,,,,,CHEMBL618580,A,BAO_0000019,,,0,2661,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,Cercopithecidae,9527.0,
7356,,,,,CHEMBL618581,A,BAO_0000218,,,0,5394,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,Cercopithecidae,9527.0,
7357,,,,,CHEMBL618582,A,BAO_0000218,,,0,4397,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,Cercopithecidae,9527.0,
7358,,,,,CHEMBL618583,A,BAO_0000218,,,0,17509,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,Cercopithecidae,9527.0,
7359,,,,,CHEMBL618584,A,BAO_0000218,,,0,17509,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,Cercopithecidae,9527.0,
7360,,,,,CHEMBL618585,A,BAO_0000218,,,0,6641,Oral AUCN in monkey (dosed at 0.5 mpk iv ),In vivo,Cercopithecidae,9527.0,
7361,,,,,CHEMBL618586,A,BAO_0000218,,,0,5355,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,Cercopithecidae,9527.0,
7362,,,,,CHEMBL618587,A,BAO_0000218,,,0,3443,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,Cercopithecidae,9527.0,
7363,,,,,CHEMBL618588,A,BAO_0000218,,,0,3443,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,Cercopithecidae,9527.0,
7364,,,,,CHEMBL618589,A,BAO_0000019,,,0,17409,Binding towards monkey plasma protein at 10 uM,,Cercopithecidae,9527.0,
7365,,,,,CHEMBL618590,A,BAO_0000019,,,0,17409,Binding towards monkey plasma protein at 100 uM,,Cercopithecidae,9527.0,
7366,,,,,CHEMBL872262,A,BAO_0000218,,,0,1052,Apparent bioavailability in squirrel monkey was determined,In vivo,Cercopithecidae,9527.0,
7367,,,,,CHEMBL618591,A,BAO_0000218,,,0,13501,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,In vivo,Cercopithecidae,9527.0,
7368,,,,,CHEMBL618592,A,BAO_0000218,,,0,17509,Bioavailability in monkey (dose 2 mg/kg),In vivo,monkey,9443.0,
7369,,,,,CHEMBL876488,A,BAO_0000218,,,0,5394,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,In vivo,Cercopithecidae,9527.0,
7370,,,,,CHEMBL618593,A,BAO_0000218,,,0,2661,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,In vivo,Cercopithecidae,9527.0,
7371,,,,,CHEMBL618594,A,BAO_0000218,,,0,11219,Bioavailability in monkey (i.d. dosing),In vivo,monkey,9443.0,
7372,,,,,CHEMBL618595,A,BAO_0000218,,,0,3045,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,In vivo,Cercopithecidae,9527.0,
7373,,,,,CHEMBL621469,A,BAO_0000019,,,0,17796,Clearance of the drug was measured in cynomolgus,,Cercopithecidae,9527.0,
7374,,,,,CHEMBL621470,A,BAO_0000218,,,0,1399,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,In vivo,Cercopithecidae,9527.0,
7375,,,,,CHEMBL621471,A,BAO_0000218,,,0,2661,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,In vivo,Cercopithecidae,9527.0,
7376,Plasma,,,,CHEMBL621472,A,BAO_0000218,,,0,5005,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,In vivo,Macaca mulatta,9544.0,
7377,,,,,CHEMBL621473,A,BAO_0000218,,,0,17267,Plasma clearance in rhesus monkey was determined,In vivo,Cercopithecidae,9527.0,
7378,,,,,CHEMBL621474,A,BAO_0000218,,,0,6535,Plasma clearance in monkey after administration of 1 mg/kg iv,In vivo,Cercopithecidae,9527.0,
7379,,,,,CHEMBL621475,A,BAO_0000218,,,0,5922,Plasma clearance in cynomolgus monkey,In vivo,Cercopithecidae,9527.0,
7380,,,,,CHEMBL621476,A,BAO_0000218,,,0,6221,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,In vivo,Cercopithecidae,9527.0,
7381,,,,,CHEMBL624290,A,BAO_0000218,,,0,5668,Plasma clearance after peroral administration at 10 mpk in Rhesus,In vivo,Cercopithecidae,9527.0,
7382,,,,,CHEMBL624291,A,BAO_0000218,,,0,5355,The total clearance was determined after intravenous administration in cynomolgus monkeys,In vivo,Cercopithecidae,9527.0,
7383,,,,,CHEMBL624292,A,BAO_0000218,,,0,5355,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,In vivo,Cercopithecidae,9527.0,
7384,,,,,CHEMBL624293,A,BAO_0000218,,,0,5355,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,In vivo,Cercopithecidae,9527.0,
7385,,,,,CHEMBL624294,A,BAO_0000218,,,0,4578,Tested for Clearance upon iv administration to african green monkey,In vivo,Cercopithecidae,9527.0,
7386,,,,,CHEMBL624295,A,BAO_0000218,,,0,17592,Clearance in monkey,In vivo,Cercopithecidae,9527.0,
7387,,,,,CHEMBL624296,A,BAO_0000218,,,1,6641,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,Canis lupus familiaris,9615.0,
7388,,,,,CHEMBL624297,A,BAO_0000218,,,1,6642,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,Canis lupus familiaris,9615.0,
7389,,,,,CHEMBL624298,A,BAO_0000218,,,1,16367,Half life was evaluated after intravenous administration to dogs,In vivo,Canis lupus familiaris,9615.0,
7390,,,,,CHEMBL624299,A,BAO_0000218,,,1,5472,Half life was evaluated in dog,,Canis lupus familiaris,9615.0,
7391,,,,,CHEMBL624300,A,BAO_0000218,,,1,5474,Half life was evaluated in dog,,Canis lupus familiaris,9615.0,
7392,,,,,CHEMBL624301,A,BAO_0000218,,,1,5654,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,In vivo,Canis lupus familiaris,9615.0,
7393,,,,,CHEMBL624302,A,BAO_0000218,,,1,6227,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),In vivo,Canis lupus familiaris,9615.0,
7394,,,,,CHEMBL876026,A,BAO_0000218,,,1,6227,Half life period after intravenous administration in dog,In vivo,Canis lupus familiaris,9615.0,
7395,,,,,CHEMBL624303,A,BAO_0000218,,,1,6221,Half life period after oral administration (2.5 mg/kg) in dog was determined,In vivo,Canis lupus familiaris,9615.0,
7396,,,,,CHEMBL624304,A,BAO_0000218,,,1,4527,Half life period at a dose of 1 uM/kg in dog was determined,,Canis lupus familiaris,9615.0,
7397,,,,,CHEMBL624305,A,BAO_0000218,,,1,5668,Half life period was determine after peroral administration at 10 mpk in dog,In vivo,Canis lupus familiaris,9615.0,
7398,,,,,CHEMBL624306,A,BAO_0000218,,,1,5668,Half life period was determine after peroral administration at 5 mpk in dog,In vivo,Canis lupus familiaris,9615.0,
7399,,,,,CHEMBL624307,A,BAO_0000218,,,1,3854,Half life period was determined,,Canis lupus familiaris,9615.0,
7400,,,,,CHEMBL624308,A,BAO_0000218,,,1,5505,Half life period was determined,,Canis lupus familiaris,9615.0,
7401,,,,,CHEMBL624309,A,BAO_0000218,,,1,6251,Half life period by iv administration in dog at a dose of 6 mg/kg,In vivo,Canis lupus familiaris,9615.0,
7402,,,,,CHEMBL624310,A,BAO_0000218,,,1,1918,Half life period was evaluated in dog,,Canis lupus familiaris,9615.0,
7403,,,,,CHEMBL625003,A,BAO_0000218,,,1,5546,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,In vivo,Canis lupus familiaris,9615.0,
7404,,,,,CHEMBL625004,A,BAO_0000218,,,1,4809,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),In vivo,Canis lupus familiaris,9615.0,
7405,,,,,CHEMBL625005,A,BAO_0000218,,,1,6215,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,In vivo,Canis lupus familiaris,9615.0,
7406,,,,,CHEMBL873813,A,BAO_0000218,,,1,4527,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,In vivo,Canis lupus familiaris,9615.0,
7407,,,,,CHEMBL625006,A,BAO_0000218,,,1,17594,Half-life after oral dose of compound at 3 mg/kg in dogs,In vivo,Canis lupus familiaris,9615.0,
7408,,,,,CHEMBL625007,A,BAO_0000218,,,1,17839,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,In vivo,Canis lupus familiaris,9615.0,
7409,,,,,CHEMBL876027,A,BAO_0000218,,,1,17839,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,In vivo,Canis lupus familiaris,9615.0,
7410,,,,,CHEMBL625008,A,BAO_0000218,,,1,17839,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,In vivo,Canis lupus familiaris,9615.0,
7411,,,,,CHEMBL625009,A,BAO_0000218,,,1,17839,Half-life of compound in dog following p.o. administration of 1 mg/kg,In vivo,Canis lupus familiaris,9615.0,
7412,Plasma,,,,CHEMBL625010,A,BAO_0000218,,,1,5210,Half-life of compound in plasma of dog was determined,,Canis lupus familiaris,9615.0,
7413,,,,,CHEMBL625011,A,BAO_0000218,,,1,5210,Half-life of compound was determined in dogs,,Canis lupus familiaris,9615.0,
7414,,,,,CHEMBL621553,A,BAO_0000218,,,1,2959,Half-life after administration of 4 mg/Kg oral dose in dog,In vivo,Canis lupus familiaris,9615.0,
7415,,,,,CHEMBL621554,A,BAO_0000218,,,1,4137,Half-life after intravenous administration of 1 mg/kg/h in dog,In vivo,Canis lupus familiaris,9615.0,
7416,,,,,CHEMBL621555,A,BAO_0000218,,,1,5064,Half-life in Dog,,Canis lupus familiaris,9615.0,
7417,,,,,CHEMBL621556,A,BAO_0000218,,,1,5147,Half-life in Dog,,Canis lupus familiaris,9615.0,
7418,,,,,CHEMBL621557,A,BAO_0000218,,,1,5145,Half-life in dog,,Canis lupus familiaris,9615.0,
7419,,,,,CHEMBL621558,A,BAO_0000218,,,1,6123,Half-life in dog after oral administration at 1 mg/kg,In vivo,Canis lupus familiaris,9615.0,
7420,,,,,CHEMBL621559,A,BAO_0000218,,,1,6123,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,In vivo,Canis lupus familiaris,9615.0,
7421,,,,,CHEMBL621560,A,BAO_0000218,,,1,4333,Half-life in dogs,,Canis lupus familiaris,9615.0,
7422,,,,,CHEMBL876028,A,BAO_0000218,,,1,4333,Half-life in dogs; ND indicates not determined,,Canis lupus familiaris,9615.0,
7423,Plasma,,,,CHEMBL621561,A,BAO_0000218,,,1,12500,Half-life in plasma of dog,,Canis lupus familiaris,9615.0,
7424,Plasma,,,,CHEMBL621562,A,BAO_0000218,,,1,12500,Half-life in plasma of dog at dose of 3-10 mgkg,,Canis lupus familiaris,9615.0,
7425,,,,,CHEMBL621563,A,BAO_0000218,,,1,6005,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,In vivo,Canis lupus familiaris,9615.0,
7426,,,,,CHEMBL621564,A,BAO_0000218,,,1,6062,Half-life was measured in dog after an iv dose of 1 mg/kg,In vivo,Canis lupus familiaris,9615.0,
7427,,,,,CHEMBL621565,A,BAO_0000218,,,1,17650,Half-life was measured in dogs after an oral dose of 10 uM/kg,In vivo,Canis lupus familiaris,9615.0,
7428,,,,,CHEMBL621566,A,BAO_0000218,,,1,5530,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,In vivo,Canis lupus familiaris,9615.0,
7429,,,,,CHEMBL621567,A,BAO_0000218,,,1,5530,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,In vivo,Canis lupus familiaris,9615.0,
7430,,,,,CHEMBL622978,A,BAO_0000218,,,1,5600,Half-life of the compound after 0.3 mg/kg po administration in dog,In vivo,Canis lupus familiaris,9615.0,
7431,,,,,CHEMBL873814,A,BAO_0000218,,,1,6039,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,In vivo,Canis lupus familiaris,9615.0,
7432,,,,,CHEMBL623219,A,BAO_0000218,,,1,6039,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,In vivo,Canis lupus familiaris,9615.0,
7433,,,,,CHEMBL624477,A,BAO_0000218,,,1,6039,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,In vivo,Canis lupus familiaris,9615.0,
7434,,,,,CHEMBL624478,A,BAO_0000218,,,1,6227,t1/2 in dog,,Canis lupus familiaris,9615.0,
7435,,,,,CHEMBL624479,A,BAO_0000218,,,1,14541,Half-life period measured in dogs,,Canis lupus familiaris,9615.0,
7436,,,,,CHEMBL624480,A,BAO_0000218,,,1,4521,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,In vivo,Canis lupus familiaris,9615.0,
7437,,,,,CHEMBL623595,A,BAO_0000218,,,1,4521,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,In vivo,Canis lupus familiaris,9615.0,
7438,,,,,CHEMBL623596,A,BAO_0000218,,,1,6679,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,Canis lupus familiaris,9615.0,
7439,Plasma,,,,CHEMBL623597,A,BAO_0000218,,,1,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",In vitro,Canis lupus familiaris,9615.0,
7440,,,,,CHEMBL623598,A,BAO_0000218,,,1,5444,In vivo half life period was calculated at 1 mg/kg in dog,In vivo,Canis lupus familiaris,9615.0,
7441,,,,,CHEMBL623599,A,BAO_0000218,,,1,5444,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,In vivo,Canis lupus familiaris,9615.0,
7442,,,,,CHEMBL623600,A,BAO_0000218,,,1,17853,Longer half-life in dog (i.v.) at 0.5 mpk,In vivo,Canis lupus familiaris,9615.0,
7443,,,,,CHEMBL623601,A,BAO_0000218,,,1,4353,Oral bioavailability in dog (dose 5 uM/kg),In vivo,Canis lupus familiaris,9615.0,
7444,,,,,CHEMBL623602,A,BAO_0000218,,,1,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,In vivo,Canis lupus familiaris,9615.0,
7445,,,,,CHEMBL623603,A,BAO_0000218,,,1,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,In vivo,Canis lupus familiaris,9615.0,
7446,,,,,CHEMBL623604,A,BAO_0000218,,,1,16452,Bioavailability in dog (dose 1 mg/kg i.v.),In vivo,Canis lupus familiaris,9615.0,
7447,Lung,,,,CHEMBL623605,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,In vivo,Mus musculus,10090.0,
7448,Lung,,,,CHEMBL623606,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,Mus musculus,10090.0,
7449,Lung,,,,CHEMBL623607,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,Mus musculus,10090.0,
7450,Lung,,,,CHEMBL623608,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,Mus musculus,10090.0,
7451,Lung,,,,CHEMBL623609,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,Mus musculus,10090.0,
7452,Lung,,,,CHEMBL623610,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,Mus musculus,10090.0,
7453,Muscle tissue,,,,CHEMBL623611,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,Mus musculus,10090.0,
7454,Muscle tissue,,,,CHEMBL623612,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,In vivo,Mus musculus,10090.0,
7455,Muscle tissue,,,,CHEMBL623613,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,Mus musculus,10090.0,
7456,Muscle tissue,,,,CHEMBL623614,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,Mus musculus,10090.0,
7457,Muscle tissue,,,,CHEMBL623615,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,Mus musculus,10090.0,
7458,Muscle tissue,,,,CHEMBL623616,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,Mus musculus,10090.0,
7459,Muscle tissue,,,,CHEMBL623617,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,Mus musculus,10090.0,
7460,Zone of skin,,,,CHEMBL875944,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,Mus musculus,10090.0,
7461,Zone of skin,,,,CHEMBL623618,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,Mus musculus,10090.0,
7462,Zone of skin,,,,CHEMBL623619,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,Mus musculus,10090.0,
7463,Zone of skin,,,,CHEMBL623620,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,Mus musculus,10090.0,
7464,Zone of skin,,,,CHEMBL623621,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,Mus musculus,10090.0,
7465,Zone of skin,,,,CHEMBL623622,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,Mus musculus,10090.0,
7466,Zone of skin,,,,CHEMBL623623,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,Mus musculus,10090.0,
7467,Spleen,,,,CHEMBL623624,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,Mus musculus,10090.0,
7468,Spleen,,,,CHEMBL618521,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,Mus musculus,10090.0,
7469,Spleen,,,,CHEMBL618522,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,Mus musculus,10090.0,
7470,Spleen,,,,CHEMBL618523,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,Mus musculus,10090.0,
7471,Spleen,,,,CHEMBL618524,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,Mus musculus,10090.0,
7472,Spleen,,,,CHEMBL618525,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,Mus musculus,10090.0,
7473,Spleen,,,,CHEMBL624586,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,Mus musculus,10090.0,
7474,Stomach,,,,CHEMBL624587,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,Mus musculus,10090.0,
7475,Stomach,,,,CHEMBL624588,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,Mus musculus,10090.0,
7476,Stomach,,,,CHEMBL624589,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,Mus musculus,10090.0,
7477,Stomach,,,,CHEMBL624590,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,Mus musculus,10090.0,
7478,Stomach,,,,CHEMBL624591,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,Mus musculus,10090.0,
7479,Stomach,,,,CHEMBL624592,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,Mus musculus,10090.0,
7480,Stomach,,,,CHEMBL624593,A,BAO_0000218,,,1,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,Mus musculus,10090.0,
7481,,,,,CHEMBL624594,A,BAO_0000218,,,1,4689,Oral bioavailability in rat,In vivo,Rattus norvegicus,10116.0,
7482,,,,,CHEMBL624595,A,BAO_0000218,,,1,4950,Tested for the bioavailability in rat,In vivo,Rattus norvegicus,10116.0,
7483,,,,,CHEMBL624596,A,BAO_0000218,,,1,5328,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),In vivo,Rattus norvegicus,10116.0,
7484,,,,,CHEMBL624597,A,BAO_0000218,,,1,406,Bioavailability in rat,In vivo,Rattus norvegicus,10116.0,
7485,,,,,CHEMBL624598,A,BAO_0000218,,,1,12500,Bioavailability in rat,In vivo,Rattus norvegicus,10116.0,
7486,,,,,CHEMBL624599,A,BAO_0000218,,,1,12500,Bioavailability in rat (dose 3-10 mg/kg),In vivo,Rattus norvegicus,10116.0,
7487,,,,,CHEMBL875166,A,BAO_0000218,,,1,5247,Bioavailability in rat,In vivo,Rattus norvegicus,10116.0,
7488,Plasma,,,,CHEMBL624600,A,BAO_0000218,,,1,4186,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,In vivo,Rattus norvegicus,10116.0,
7489,Plasma,,,,CHEMBL624601,A,BAO_0000218,,,1,4186,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,In vivo,Rattus norvegicus,10116.0,
7490,,,,,CHEMBL624602,A,BAO_0000218,,,1,6647,Half life after oral administration was determined in rats at 6 mg/kg,In vivo,Rattus norvegicus,10116.0,
7491,,,,,CHEMBL624603,A,BAO_0000218,,,1,6484,Half life was determined,,Rattus norvegicus,10116.0,
7492,,,,,CHEMBL624604,A,BAO_0000218,,,1,3249,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,In vivo,Rattus norvegicus,10116.0,
7493,Plasma,,,,CHEMBL624605,A,BAO_0000218,,,1,6281,Plasma half life in rat at oral dose 2.8 mg/mk body weight,In vivo,Rattus norvegicus,10116.0,
7494,,,,,CHEMBL624606,A,BAO_0000218,,,1,3307,Half life in rats,,Rattus norvegicus,10116.0,
7495,Blood,,,,CHEMBL624607,A,BAO_0000218,,,1,12058,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,In vivo,Rattus norvegicus,10116.0,
7496,,,,,CHEMBL624608,A,BAO_0000218,,,1,8833,Hill coefficient of the compound,,Rattus norvegicus,10116.0,
7497,Blood,,,,CHEMBL624609,A,BAO_0000218,,,1,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,,Rattus norvegicus,10116.0,
7498,Blood,,,,CHEMBL624610,A,BAO_0000218,,,1,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,,Rattus norvegicus,10116.0,
7499,Blood,,,,CHEMBL624611,A,BAO_0000218,,,1,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,,Rattus norvegicus,10116.0,
7500,Blood,,,,CHEMBL624612,A,BAO_0000218,,,1,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,,Rattus norvegicus,10116.0,
7501,Blood,,,,CHEMBL875167,A,BAO_0000218,,,1,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,,Rattus norvegicus,10116.0,
7502,Blood,,,,CHEMBL624613,A,BAO_0000218,,,1,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,,Rattus norvegicus,10116.0,
7503,Blood,,,,CHEMBL624614,A,BAO_0000218,,,1,3193,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",,Rattus norvegicus,10116.0,
7504,,,,,CHEMBL624392,A,BAO_0000218,,,1,5960,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,Rattus norvegicus,10116.0,
7505,Brain,,,,CHEMBL624393,A,BAO_0000218,,,1,13950,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,In vivo,Rattus norvegicus,10116.0,
7506,Brain,,,,CHEMBL624394,A,BAO_0000218,,,1,13950,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,In vivo,Rattus norvegicus,10116.0,
7507,Brain,,,,CHEMBL624395,A,BAO_0000218,,,1,13950,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,In vivo,Rattus norvegicus,10116.0,
7508,Brain,,,,CHEMBL624396,A,BAO_0000218,,,1,13950,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,In vivo,Rattus norvegicus,10116.0,
7509,Brain,,,,CHEMBL624397,A,BAO_0000218,,,1,13950,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,In vivo,Rattus norvegicus,10116.0,
7510,Thyroid gland,,,,CHEMBL624398,A,BAO_0000218,,,1,13950,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,In vivo,Rattus norvegicus,10116.0,
7511,Thyroid gland,,,,CHEMBL624399,A,BAO_0000218,,,1,13950,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,In vivo,Rattus norvegicus,10116.0,
7512,Thyroid gland,,,,CHEMBL624400,A,BAO_0000218,,,1,13950,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,In vivo,Rattus norvegicus,10116.0,
7513,Thyroid gland,,,,CHEMBL624401,A,BAO_0000218,,,1,13950,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,In vivo,Rattus norvegicus,10116.0,
7514,Thyroid gland,,,,CHEMBL624402,A,BAO_0000218,,,1,13950,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,In vivo,Rattus norvegicus,10116.0,
7515,Blood,,,,CHEMBL624403,A,BAO_0000218,,,1,9866,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,In vivo,Rattus norvegicus,10116.0,
7516,Blood,,,,CHEMBL624404,A,BAO_0000218,,,1,9866,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,In vivo,Rattus norvegicus,10116.0,
7517,Blood,,,,CHEMBL624405,A,BAO_0000218,,,1,9866,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,In vivo,Rattus norvegicus,10116.0,
7518,Bone,,,,CHEMBL624406,A,BAO_0000218,,,1,9866,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,In vivo,Rattus norvegicus,10116.0,
7519,Bone,,,,CHEMBL624407,A,BAO_0000218,,,1,9866,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,In vivo,Rattus norvegicus,10116.0,
7520,Bone,,,,CHEMBL624408,A,BAO_0000218,,,1,9866,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,In vivo,Rattus norvegicus,10116.0,
7521,Heart,,,,CHEMBL618644,A,BAO_0000218,,,1,9866,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,In vivo,Rattus norvegicus,10116.0,
7522,Heart,,,,CHEMBL618645,A,BAO_0000218,,,1,9866,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,In vivo,Rattus norvegicus,10116.0,
7523,Heart,,,,CHEMBL618646,A,BAO_0000218,,,1,9866,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,In vivo,Rattus norvegicus,10116.0,
